1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	6	case	_	_
4	concomitant	concomitant	JJ	_	6	attr	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	administration	administration	NN	_	2	ppmod	_	_
7	on	on	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	steady-state	steady-state	JJ	_	10	attr	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	'	'	``	_	4	p	_	_
4	drug2	drug0	NN	_	1	prn	_	_
5	'	'	''	_	4	p	_	_
6	)	-rrb-	-RRB-	_	4	p	_	_
7	is	be	VBZ	_	0	root	_	_
8	a	a	DT	_	11	det	_	_
9	newly	newly	RB	_	10	adv	_	_
10	introduced	introduce	VBN	_	11	attr	_	_
11	drug3	drug0	NN	_	7	obj	_	_
12	with	with	IN	_	14	case	_	_
13	demonstrated	demonstrate	VBN	_	14	attr	_	_
14	efficacy	efficacy	NN	_	11	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	treatment	treatment	NN	_	14	ppmod	_	_
18	of	of	IN	_	22	case	_	_
19	positive	positive	JJ	_	22	attr	_	_
20	and	and	CC	_	19	cc	_	_
21	negative	negative	JJ	_	19	conj	_	_
22	symptoms	symptom	NNS	_	17	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	schizophrenia	schizophrenia	NN	_	22	ppmod	_	_
25	.	.	.	_	7	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	extensively	extensively	RB	_	4	adv	_	_
4	metabolized	metabolize	VBN	_	0	root	_	_
5	,	,	,	_	4	p	_	_
6	predominantly	predominantly	RB	_	4	adv	_	_
7	by	by	IN	_	10	case	_	_
8	cytochrome	cytochrome	NN	_	10	com	_	_
9	P450	p0	NN	_	10	com	_	_
10	3A4	0a0	NN	_	4	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	Therefore	therefore	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	concurrent	concurrent	JJ	_	4	attr	_	_
4	administration	administration	NN	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drugs	drug	NNS	_	4	ppmod	_	_
7	that	that	WDT	_	8	dep	_	_
8	induce	induce	VBP	_	6	relcl	_	_
9	or	or	CC	_	8	cc	_	_
10	inhibit	inhibit	VBP	_	8	conj	_	_
11	this	this	DT	_	12	det	_	_
12	enzyme	enzyme	NN	_	10	obj	_	_
13	may	may	MD	_	14	modal	_	_
14	affect	affect	VB	_	0	root	_	_
15	drug1	drug0	NN	_	16	com	_	_
16	pharmacokinetics	pharmacokinetics	NNS	_	14	obj	_	_
17	.	.	.	_	14	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	demonstrated	demonstrate	VBD	_	0	root	_	_
4	that	that	IN	_	13	mark	_	_
5	the	the	DT	_	8	det	_	_
6	potent	potent	JJ	_	8	attr	_	_
7	cytochrome	cytochrome	NN	_	8	com	_	_
8	P450	p0	NN	_	10	com	_	_
9	enzyme-inducer	enzyme-inducer	NN	_	10	com	_	_
10	drug1	drug0	NN	_	13	dep	_	_
11	did	do	VBD	_	13	aux	_	_
12	indeed	indeed	RB	_	13	adv	_	_
13	have	have	VB	_	3	comp	_	_
14	a	a	DT	_	16	det	_	_
15	marked	marked	JJ	_	16	attr	_	_
16	effect	effect	NN	_	13	obj	_	_
17	on	on	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	metabolism	metabolism	NN	_	13	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	,	,	,	_	13	p	_	_
23	resulting	result	VBG	_	13	comp	_	_
24	in	in	IN	_	27	case	_	_
25	a	a	DT	_	27	det	_	_
26	5-fold	0-fold	JJ	_	27	attr	_	_
27	increase	increase	NN	_	23	ppmod	_	_
28	in	in	IN	_	29	case	_	_
29	clearance	clearance	NN	_	27	ppmod	_	_
30	when	when	WRB	_	31	adv	_	_
31	administered	administer	VBN	_	13	comp	_	_
32	concomitantly	concomitantly	RB	_	31	adv	_	_
33	to	to	TO	_	34	aux	_	_
34	patients	patient	NNS	_	31	ppmod	_	_
35	with	with	IN	_	37	case	_	_
36	DSM-IV-diagnosed	dsm-iv-diagnosed	JJ	_	37	attr	_	_
37	schizophrenia	schizophrenia	NN	_	34	ppmod	_	_
38	,	,	,	_	37	p	_	_
39	schizoaffective	schizoaffective	JJ	_	40	attr	_	_
40	disorder	disorder	NN	_	37	conj	_	_
41	,	,	,	_	40	p	_	_
42	or	or	CC	_	40	cc	_	_
43	bipolar	bipolar	JJ	_	44	attr	_	_
44	disorder	disorder	NN	_	37	conj	_	_
45	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	dosage	dosage	JJ	_	6	attr	_	_
6	adjustment	adjustment	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	be	be	VB	_	3	advcl	_	_
11	necessary	necessary	JJ	_	10	dep	_	_
12	when	when	WRB	_	17	adv	_	_
13	the	the	DT	_	15	det	_	_
14	two	#crd#	CD	_	15	num	_	_
15	drugs	drug	NNS	_	17	dep	_	_
16	are	be	VBP	_	17	aux	_	_
17	given	give	VBN	_	11	comp	_	_
18	concurrently	concurrently	RB	_	17	adv	_	_
19	and	and	CC	_	10	cc	_	_
20	that	that	IN	_	24	mark	_	_
21	caution	caution	NN	_	24	dep	_	_
22	may	may	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	required	require	VBN	_	10	conj	_	_
25	when	when	WRB	_	26	adv	_	_
26	administering	administer	VBG	_	24	comp	_	_
27	other	other	JJ	_	28	attr	_	_
28	drugs	drug	NNS	_	26	obj	_	_
29	that	that	WDT	_	30	dep	_	_
30	inhibit	inhibit	VBP	_	28	relcl	_	_
31	or	or	CC	_	30	cc	_	_
32	induce	induce	VBP	_	30	conj	_	_
33	cytochromes	cytochrome	NNS	_	32	obj	_	_
34	,	,	,	_	33	p	_	_
35	particularly	particularly	RB	_	33	adv	_	_
36	P450	p0	NN	_	37	com	_	_
37	3A4	0a0	NN	_	33	appo	_	_
38	.	.	.	_	3	p	_	_

1	-LSB-Drug	-lsb-drug	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	14	dep	_	_
3	of	of	IN	_	5	case	_	_
4	erection	erection	NN	_	5	com	_	_
5	disorders	disorder	NNS	_	2	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	patients	patient	NNS	_	2	ppmod	_	_
8	with	with	IN	_	13	case	_	_
9	cardiovascular	cardiovascular	JJ	_	10	attr	_	_
10	disease	disease	NN	_	13	attr	_	_
11	]	-rsb-	-RRB-	_	13	p	_	_
12	Erectile	erectile	JJ	_	13	attr	_	_
13	dysfunction	dysfunction	NN	_	7	ppmod	_	_
14	is	be	VBZ	_	0	root	_	_
15	a	a	DT	_	17	det	_	_
16	frequent	frequent	JJ	_	17	attr	_	_
17	condition	condition	NN	_	14	obj	_	_
18	in	in	IN	_	20	case	_	_
19	cardiovascular	cardiovascular	JJ	_	20	attr	_	_
20	patients	patient	NNS	_	17	ppmod	_	_
21	.	.	.	_	14	p	_	_

1	Since	since	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	arrival	arrival	NN	_	9	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	9	p	_	_
8	patients	patient	NNS	_	9	dep	_	_
9	want	want	VBP	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	know	know	VB	_	9	comp	_	_
12	how	how	WRB	_	16	adv	_	_
13	safe	safe	JJ	_	15	attr	_	_
14	sexual	sexual	JJ	_	15	attr	_	_
15	activity	activity	NN	_	16	dep	_	_
16	is	be	VBZ	_	11	comp	_	_
17	in	in	IN	_	19	case	_	_
18	cardiovascular	cardiovascular	JJ	_	19	attr	_	_
19	disease	disease	NN	_	16	ppmod	_	_
20	in	in	IN	_	21	case	_	_
21	general	general	JJ	_	16	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	during	during	IN	_	24	case	_	_
24	use	use	NN	_	21	conj	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	in	in	IN	_	28	case	_	_
28	particular	particular	JJ	_	26	ppmod	_	_
29	.	.	.	_	9	p	_	_

1	Sexual	sexual	JJ	_	2	attr	_	_
2	intercourse	intercourse	NN	_	7	dep	_	_
3	with	with	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	steady	steady	JJ	_	6	attr	_	_
6	partner	partner	NN	_	2	ppmod	_	_
7	causes	cause	VBZ	_	0	root	_	_
8	no	no	DT	_	11	det	_	_
9	more	more	RBR	_	11	adv	_	_
10	cardiovascular	cardiovascular	JJ	_	11	attr	_	_
11	risk	risk	NN	_	7	obj	_	_
12	than	than	IN	_	15	case	_	_
13	normal	normal	JJ	_	15	attr	_	_
14	daily	daily	JJ	_	15	attr	_	_
15	activities	activity	NNS	_	11	ppmod	_	_
16	such	such	JJ	_	18	adv	_	_
17	as	as	IN	_	18	case	_	_
18	ironing	ironing	NN	_	15	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	2	0	CD	_	21	num	_	_
21	kilometers	kilometer	NNS	_	18	appo	_	_
22	of	of	IN	_	23	case	_	_
23	walking	walking	NN	_	21	ppmod	_	_
24	without	without	IN	_	25	case	_	_
25	climbing	climbing	NN	_	21	ppmod	_	_
26	,	,	,	_	18	p	_	_
27	paperhanging	paperhanging	NN	_	18	appo	_	_
28	,	,	,	_	7	p	_	_
29	playing	play	VBG	_	7	comp	_	_
30	golf	golf	NN	_	29	obj	_	_
31	or	or	CC	_	30	cc	_	_
32	gardening	gardening	NN	_	30	conj	_	_
33	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	relative	relative	JJ	_	3	attr	_	_
3	risk	risk	NN	_	10	dep	_	_
4	of	of	IN	_	6	case	_	_
5	myocardial	myocardial	JJ	_	6	attr	_	_
6	infarction	infarction	NN	_	3	ppmod	_	_
7	during	during	IN	_	9	case	_	_
8	sexual	sexual	JJ	_	9	attr	_	_
9	activity	activity	NN	_	3	ppmod	_	_
10	is	be	VBZ	_	0	root	_	_
11	not	not	RB	_	10	neg	_	_
12	significantly	significantly	RB	_	13	adv	_	_
13	higher	high	JJR	_	10	dep	_	_
14	than	than	IN	_	17	case	_	_
15	for	for	IN	_	17	case	_	_
16	healthy	healthy	JJ	_	17	attr	_	_
17	persons	person	NNS	_	13	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	incidence	incidence	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	cardiovascular	cardiovascular	JJ	_	5	attr	_	_
5	morbidity	morbidity	NN	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	mortality	mortality	NN	_	5	conj	_	_
8	is	be	VBZ	_	0	root	_	_
9	not	not	RB	_	8	neg	_	_
10	higher	high	JJR	_	8	dep	_	_
11	among	among	IN	_	12	case	_	_
12	users	user	NNS	_	10	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	contraindicated	contraindicate	VBN	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	patients	patient	NNS	_	3	ppmod	_	_
6	using	use	VBG	_	5	acl	_	_
7	drug2	drug0	NN	_	6	obj	_	_
8	or	or	CC	_	11	cc	_	_
9	who	who	WP	_	11	dep	_	_
10	may	may	MD	_	11	dep	_	_
11	need	need	VBP	_	5	relcl	_	_
12	to	to	TO	_	13	aux	_	_
13	use	use	VB	_	11	comp	_	_
14	drug3	drug0	NN	_	13	obj	_	_
15	,	,	,	_	11	p	_	_
16	because	because	IN	_	20	mark	_	_
17	the	the	DT	_	18	det	_	_
18	combination	combination	NN	_	20	dep	_	_
19	may	may	MD	_	20	modal	_	_
20	cause	cause	VB	_	11	comp	_	_
21	a	a	DT	_	23	det	_	_
22	sharp	sharp	JJ	_	23	attr	_	_
23	fall	fall	VBP	_	20	obj	_	_
24	of	of	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	blood	blood	NN	_	27	com	_	_
27	pressure	pressure	NN	_	23	ppmod	_	_
28	.	.	.	_	3	p	_	_

1	No	no	DT	_	2	det	_	_
2	interactions	interaction	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	and	and	CC	_	11	cc	_	_
13	drug4	drug0	NN	_	7	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug5	drug0	NN	_	7	conj	_	_
16	.	.	.	_	5	p	_	_

1	Before	before	IN	_	2	case	_	_
2	prescribing	prescribe	VBG	_	19	ppmod	_	_
3	a	a	DT	_	8	det	_	_
4	symptomatic	symptomatic	JJ	_	8	attr	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	pharmaceutical	pharmaceutical	JJ	_	8	attr	_	_
7	)	-rrb-	-RRB-	_	8	p	_	_
8	treatment	treatment	NN	_	2	obj	_	_
9	for	for	IN	_	10	case	_	_
10	patients	patient	NNS	_	8	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	an	an	DT	_	14	det	_	_
13	erection	erection	JJ	_	14	attr	_	_
14	disorder	disorder	NN	_	10	ppmod	_	_
15	,	,	,	_	19	p	_	_
16	attention	attention	NN	_	19	dep	_	_
17	should	should	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	given	give	VBN	_	0	root	_	_
20	tot	tot	NN	_	19	comp	_	_
21	the	the	DT	_	27	det	_	_
22	sexological	sexological	JJ	_	27	attr	_	_
23	,	,	,	_	22	p	_	_
24	psychological	psychological	JJ	_	22	conj	_	_
25	and	and	CC	_	24	cc	_	_
26	medical	medical	JJ	_	22	conj	_	_
27	backgrounds	background	NNS	_	20	obj	_	_
28	of	of	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	disorder	disorder	NN	_	27	ppmod	_	_
31	.	.	.	_	19	p	_	_

1	Secondary	secondary	JJ	_	2	attr	_	_
2	prevention	prevention	NN	_	7	dep	_	_
3	of	of	IN	_	6	case	_	_
4	atherosclerotic	atherosclerotic	JJ	_	6	attr	_	_
5	risk	risk	NN	_	6	com	_	_
6	factors	factor	NNS	_	2	ppmod	_	_
7	is	be	VBZ	_	0	root	_	_
8	also	also	RB	_	7	adv	_	_
9	important	important	JJ	_	7	dep	_	_
10	:	:	:	_	7	p	_	_
11	regulation	regulation	NN	_	7	dep	_	_
12	of	of	IN	_	14	case	_	_
13	blood	blood	NN	_	14	com	_	_
14	pressure	pressure	NN	_	11	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	blood	blood	NN	_	18	com	_	_
17	sugar	sugar	NN	_	18	com	_	_
18	level	level	NN	_	14	conj	_	_
19	,	,	,	_	18	p	_	_
20	hyperlipidaemia	hyperlipidaemia	NN	_	18	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	obesity	obesity	NN	_	18	conj	_	_
23	,	,	,	_	18	p	_	_
24	as	as	RB	_	25	com	_	_
25	well	well	RB	_	18	cc	_	_
26	as	as	IN	_	25	com	_	_
27	a	a	DT	_	28	det	_	_
28	change	change	NN	_	18	conj	_	_
29	of	of	IN	_	30	case	_	_
30	lifestyle	lifestyle	NN	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	30	p	_	_
32	giving	give	VBG	_	30	acl	_	_
33	up	up	IN	_	34	case	_	_
34	smoking	smoking	NN	_	32	ppmod	_	_
35	,	,	,	_	34	p	_	_
36	adapting	adapting	JJ	_	34	attr	_	_
37	of	of	IN	_	38	case	_	_
38	diet	diet	NN	_	36	ppmod	_	_
39	and	and	CC	_	38	cc	_	_
40	more	more	JJR	_	42	attr	_	_
41	physical	physical	JJ	_	42	attr	_	_
42	exertion	exertion	NN	_	38	conj	_	_
43	)	-rrb-	-RRB-	_	30	p	_	_
44	.	.	.	_	7	p	_	_

1	Patients	patient	NNS	_	10	dep	_	_
2	with	with	IN	_	7	case	_	_
3	a	a	DT	_	7	det	_	_
4	very	very	RB	_	5	adv	_	_
5	low	low	JJ	_	7	attr	_	_
6	cardiac	cardiac	JJ	_	7	attr	_	_
7	capacity	capacity	NN	_	1	ppmod	_	_
8	should	should	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	advised	advise	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	refrain	refrain	VB	_	10	comp	_	_
13	from	from	IN	_	14	case	_	_
14	treatment	treatment	NN	_	12	ppmod	_	_
15	of	of	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	erection	erection	JJ	_	18	attr	_	_
18	disorder	disorder	NN	_	14	ppmod	_	_
19	.	.	.	_	10	p	_	_

1	Failure	failure	NN	_	7	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	modify	modify	VB	_	1	acl	_	_
6	drug2	drug0	NN	_	5	obj	_	_
7	induced	induce	VBD	_	0	root	_	_
8	hypertension	hypertension	NN	_	7	obj	_	_
9	in	in	IN	_	10	case	_	_
10	sheep	sheep	NN	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	Studies	study	NNS	_	5	dep	_	_
2	in	in	IN	_	3	case	_	_
3	rats	rat	NNS	_	1	ppmod	_	_
4	have	have	VBP	_	5	aux	_	_
5	shown	show	VBN	_	0	root	_	_
6	that	that	IN	_	9	mark	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	administration	administration	NN	_	9	dep	_	_
9	attenuates	attenuate	VBZ	_	5	comp	_	_
10	certain	certain	JJ	_	11	attr	_	_
11	types	type	NNS	_	9	obj	_	_
12	of	of	IN	_	15	case	_	_
13	drug2	drug0	NN	_	14	advnp	_	_
14	dependent	dependent	JJ	_	15	attr	_	_
15	hypertension	hypertension	NN	_	11	ppmod	_	_
16	,	,	,	_	11	p	_	_
17	including	include	VBG	_	19	adv	_	_
18	drug3	drug0	JJ	_	19	attr	_	_
19	hypertension	hypertension	NN	_	11	ppmod	_	_
20	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	11	dep	_	_
3	of	of	IN	_	5	case	_	_
4	oral	oral	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	on	on	IN	_	9	case	_	_
7	drug2	drug0	NN	_	8	advnp	_	_
8	induced	induce	VBN	_	9	attr	_	_
9	hypertension	hypertension	NN	_	2	ppmod	_	_
10	were	be	VBD	_	11	aux	_	_
11	examined	examine	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	conscious	conscious	JJ	_	14	attr	_	_
14	sheep	sheep	NN	_	11	ppmod	_	_
15	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	blood	blood	NN	_	8	com	_	_
8	pressure	pressure	NN	_	2	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	metabolic	metabolic	JJ	_	11	attr	_	_
11	responses	response	NNS	_	8	conj	_	_
12	to	to	TO	_	13	aux	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	sheep	sheep	NN	_	11	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	Interaction	interaction	NN	_	0	root	_	_
3	between	between	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	or	or	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	in	in	IN	_	11	case	_	_
10	healthy	healthy	JJ	_	11	attr	_	_
11	males	male	NNS	_	2	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	objective	objective	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	determine	determine	VB	_	6	comp	_	_
9	if	if	IN	_	11	mark	_	_
10	there	there	EX	_	11	dep	_	_
11	is	be	VBZ	_	8	comp	_	_
12	a	a	DT	_	14	det	_	_
13	pharmacokinetic	pharmacokinetic	JJ	_	14	attr	_	_
14	interaction	interaction	NN	_	11	obj	_	_
15	when	when	WRB	_	18	adv	_	_
16	drug1	drug0	NN	_	18	dep	_	_
17	is	be	VBZ	_	18	aux	_	_
18	given	give	VBN	_	14	relcl	_	_
19	with	with	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	or	or	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	and	and	CC	_	8	cc	_	_
24	to	to	TO	_	25	aux	_	_
25	determine	determine	VB	_	8	conj	_	_
26	the	the	DT	_	27	det	_	_
27	effects	effect	NNS	_	25	obj	_	_
28	of	of	IN	_	30	case	_	_
29	these	these	DT	_	30	det	_	_
30	drugs	drug	NNS	_	27	ppmod	_	_
31	on	on	IN	_	35	case	_	_
32	the	the	DT	_	35	det	_	_
33	erythromycin	erythromycin	NN	_	35	com	_	_
34	breath	breath	NN	_	35	com	_	_
35	test	test	NN	_	27	ppmod	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	ERMBT	ermbt	NN	_	35	prn	_	_
38	)	-rrb-	-RRB-	_	37	p	_	_
39	.	.	.	_	6	p	_	_

1	Twenty-four	twenty-four	CD	_	4	num	_	_
2	healthy	healthy	JJ	_	4	attr	_	_
3	male	male	JJ	_	4	attr	_	_
4	subjects	subject	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	randomized	randomize	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	one	#crd#	CD	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	two	#crd#	CD	_	11	num	_	_
11	cohorts	cohort	NNS	_	8	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	All	all	DT	_	2	det	_	_
2	subjects	subject	NNS	_	3	dep	_	_
3	received	receive	VBD	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	1,200	0	CD	_	7	num	_	_
7	mg	mg	NN	_	4	prn	_	_
8	twice	twice	RB	_	7	adv	_	_
9	a	a	DT	_	10	det	_	_
10	day	day	NN	_	7	attr	_	_
11	)	-rrb-	-RRB-	_	7	p	_	_
12	for	for	IN	_	14	case	_	_
13	4	0	CD	_	14	num	_	_
14	days	day	NNS	_	3	ppmod	_	_
15	,	,	,	_	3	p	_	_
16	followed	followed	VBN	_	3	comp	_	_
17	by	by	IN	_	21	case	_	_
18	a	a	DT	_	21	det	_	_
19	7-day	0-day	JJ	_	21	attr	_	_
20	washout	washout	NN	_	21	com	_	_
21	period	period	NN	_	16	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	followed	followed	VBN	_	21	acl	_	_
24	by	by	IN	_	26	case	_	_
25	either	either	CC	_	26	cc	_	_
26	drug2	drug0	NN	_	23	ppmod	_	_
27	(	-lrb-	-LRB-	_	29	p	_	_
28	300	0	CD	_	29	num	_	_
29	mg	mg	NN	_	26	prn	_	_
30	once	once	IN	_	32	case	_	_
31	a	a	NN	_	32	com	_	_
32	day	day	NN	_	29	ppmod	_	_
33	-LSB-QD	-lsb-qd	CD	_	32	num	_	_
34	]	-rsb-	-RRB-	_	29	p	_	_
35	)	-rrb-	-RRB-	_	29	p	_	_
36	(	-lrb-	-LRB-	_	37	p	_	_
37	cohort	cohort	NN	_	26	prn	_	_
38	1	0	CD	_	37	num	_	_
39	)	-rrb-	-RRB-	_	37	p	_	_
40	or	or	CC	_	26	cc	_	_
41	drug3	drug0	NN	_	26	conj	_	_
42	(	-lrb-	-LRB-	_	45	p	_	_
43	600	0	CD	_	44	num	_	_
44	mg	mg	NN	_	45	com	_	_
45	QD	qd	NN	_	41	prn	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	(	-lrb-	-LRB-	_	48	p	_	_
48	cohort	cohort	NN	_	41	prn	_	_
49	2	0	CD	_	48	num	_	_
50	)	-rrb-	-RRB-	_	48	p	_	_
51	for	for	IN	_	53	case	_	_
52	14	0	CD	_	53	num	_	_
53	days	day	NNS	_	23	ppmod	_	_
54	.	.	.	_	3	p	_	_

1	Cohort	cohort	NN	_	4	dep	_	_
2	1	0	CD	_	1	num	_	_
3	then	then	RB	_	4	adv	_	_
4	received	receive	VBD	_	0	root	_	_
5	drug1	drug0	NN	_	4	obj	_	_
6	plus	plus	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	for	for	IN	_	10	case	_	_
9	10	0	CD	_	10	num	_	_
10	days	day	NNS	_	5	ppmod	_	_
11	,	,	,	_	4	p	_	_
12	and	and	CC	_	4	cc	_	_
13	cohort	cohort	NN	_	15	dep	_	_
14	2	0	CD	_	13	num	_	_
15	received	receive	VBD	_	4	conj	_	_
16	drug3	drug0	NN	_	15	obj	_	_
17	plus	plus	CC	_	16	cc	_	_
18	drug4	drug0	NN	_	16	conj	_	_
19	for	for	IN	_	21	case	_	_
20	4	0	CD	_	21	num	_	_
21	days	day	NNS	_	15	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	Serial	serial	JJ	_	5	attr	_	_
2	plasma	plasma	NN	_	5	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	urine	urine	NN	_	2	conj	_	_
5	samples	sample	NNS	_	20	dep	_	_
6	for	for	IN	_	7	case	_	_
7	measurement	measurement	NN	_	5	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	drug3	drug0	NN	_	9	conj	_	_
15	and	and	CC	_	5	cc	_	_
16	their	their	PRP$	_	17	poss	_	_
17	drug4	drug0	NNS	_	5	conj	_	_
18	,	,	,	_	17	p	_	_
19	were	be	VBD	_	20	aux	_	_
20	measured	measure	VBN	_	0	root	_	_
21	by	by	IN	_	24	case	_	_
22	high-performance	high-performance	JJ	_	24	attr	_	_
23	liquid	liquid	JJ	_	24	attr	_	_
24	chromatography	chromatography	NN	_	20	ppmod	_	_
25	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	did	do	VBD	_	5	aux	_	_
3	not	not	RB	_	5	neg	_	_
4	significantly	significantly	RB	_	5	adv	_	_
5	affect	affect	VB	_	0	root	_	_
6	drug2	drug0	NN	_	8	attr	_	_
7	's	's	POS	_	8	case	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	5	obj	_	_
9	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	significantly	significantly	RB	_	3	adv	_	_
3	increased	increase	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	area	area	NN	_	3	obj	_	_
6	under	under	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	curve	curve	NN	_	5	ppmod	_	_
9	at	at	IN	_	11	case	_	_
10	steady	steady	JJ	_	11	attr	_	_
11	state	state	NN	_	8	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	AUC	auc	NN	_	5	prn	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	ss	ss	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	)	-rrb-	-RRB-	_	13	p	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	5	ppmod	_	_
20	by	by	IN	_	21	case	_	_
21	2.93-fold	0-fold	NN	_	3	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	the	the	DT	_	24	det	_	_
24	AUC	auc	NN	_	21	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	ss	ss	NN	_	24	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	21	ppmod	_	_
30	by	by	IN	_	31	case	_	_
31	13.3-fold	0-fold	NN	_	21	ppmod	_	_
32	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	significantly	significantly	RB	_	3	adv	_	_
3	decreased	decrease	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	AUC	auc	NN	_	3	obj	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	ss	ss	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	5	ppmod	_	_
11	by	by	IN	_	12	case	_	_
12	82	0	CD	_	3	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	,	,	,	_	3	p	_	_
15	but	but	CC	_	3	cc	_	_
16	drug3	drug0	NN	_	17	dep	_	_
17	had	have	VBD	_	3	conj	_	_
18	no	no	DT	_	19	det	_	_
19	effect	effect	NN	_	17	obj	_	_
20	on	on	IN	_	22	case	_	_
21	drug4	drug0	NN	_	22	com	_	_
22	pharmacokinetics	pharmacokinetics	NNS	_	17	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreased	decrease	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	results	result	NNS	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	ERMBT	ermbt	NN	_	4	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	83	0	CD	_	2	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	15	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	ERMBT	ermbt	NN	_	2	ppmod	_	_
6	after	after	IN	_	8	case	_	_
7	2	0	CD	_	8	num	_	_
8	weeks	week	NNS	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	therapy	therapy	NN	_	10	conj	_	_
14	were	be	VBD	_	15	aux	_	_
15	increased	increase	VBN	_	0	root	_	_
16	187	0	CD	_	15	obj	_	_
17	and	and	CC	_	16	cc	_	_
18	156	0	CD	_	16	conj	_	_
19	%	%	NN	_	16	meta	_	_
20	,	,	,	_	16	p	_	_
21	respectively	respectively	RB	_	16	adv	_	_
22	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	plus	plus	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	was	be	VBD	_	6	aux	_	_
5	well	well	RB	_	6	adv	_	_
6	tolerated	tolerate	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	plus	plus	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	was	be	VBD	_	6	aux	_	_
5	poorly	poorly	RB	_	6	adv	_	_
6	tolerated	tolerate	VBN	_	0	root	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	5	0	CD	_	13	num	_	_
10	of	of	IN	_	12	case	_	_
11	11	0	CD	_	12	num	_	_
12	subjects	subject	NNS	_	9	ppmod	_	_
13	discontinued	discontinue	VBD	_	6	conj	_	_
14	therapy	therapy	NN	_	13	obj	_	_
15	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	markedly	markedly	RB	_	3	adv	_	_
3	increases	increase	VBZ	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	metabolic	metabolic	JJ	_	6	attr	_	_
6	clearance	clearance	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	and	and	CC	_	3	cc	_	_
11	coadministration	coadministration	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	contraindicated	contraindicate	VBN	_	3	conj	_	_
14	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	significantly	significantly	RB	_	3	adv	_	_
3	decreases	decrease	VBZ	_	0	root	_	_
4	clearance	clearance	NN	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	6	conj	_	_
9	,	,	,	_	3	p	_	_
10	and	and	CC	_	3	cc	_	_
11	the	the	DT	_	12	det	_	_
12	combination	combination	NN	_	15	dep	_	_
13	is	be	VBZ	_	15	aux	_	_
14	poorly	poorly	RB	_	15	adv	_	_
15	tolerated	tolerate	VBN	_	3	conj	_	_
16	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibits	inhibit	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	ERMBT	ermbt	NN	_	2	obj	_	_
5	,	,	,	_	2	p	_	_
6	and	and	CC	_	2	cc	_	_
7	drug2	drug0	NN	_	10	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	are	be	VBP	_	2	conj	_	_
11	equipotent	equipotent	JJ	_	12	attr	_	_
12	inducers	inducer	NNS	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	ERMBT	ermbt	NN	_	12	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	-LSB-The	-lsb-the	NN	_	2	com	_	_
2	effect	effect	NN	_	30	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	activity	activity	NN	_	2	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	mixed-function	mixed-function	JJ	_	10	attr	_	_
10	mono-oxidases	mono-oxidases	NNS	_	7	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	liver	liver	NN	_	14	com	_	_
14	microsomes	microsome	NNS	_	7	ppmod	_	_
15	]	-rsb-	-RRB-	_	2	p	_	_
16	The	the	DT	_	17	det	_	_
17	effects	effect	NNS	_	30	dep	_	_
18	of	of	IN	_	28	case	_	_
19	the	the	DT	_	28	det	_	_
20	drug2	drug0	JJ	_	28	attr	_	_
21	--the	--the	NN	_	28	attr	_	_
22	drug	drug	NN	_	28	attr	_	_
23	drug3	drug0	NN	_	28	attr	_	_
24	--on	--on	NN	_	28	attr	_	_
25	hepatic	hepatic	JJ	_	28	attr	_	_
26	microsomal	microsomal	JJ	_	28	attr	_	_
27	monooxygenase	monooxygenase	NN	_	28	com	_	_
28	activities	activity	NNS	_	17	ppmod	_	_
29	were	be	VBD	_	30	aux	_	_
30	studied	study	VBN	_	0	root	_	_
31	.	.	.	_	30	p	_	_

1	The	the	DT	_	2	det	_	_
2	agent	agent	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	found	find	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	produce	produce	VB	_	4	comp	_	_
7	some	some	DT	_	9	det	_	_
8	inhibiting	inhibiting	NN	_	9	com	_	_
9	activity	activity	NN	_	6	obj	_	_
10	against	against	IN	_	14	case	_	_
11	hepatic	hepatic	JJ	_	14	attr	_	_
12	microsomal	microsomal	JJ	_	14	attr	_	_
13	7-ethoxycoumarine	0-ethoxycoumarine	NN	_	14	com	_	_
14	deethylase	deethylase	NN	_	9	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	male	male	JJ	_	18	attr	_	_
17	Wistar	wistar	NN	_	18	com	_	_
18	rats	rat	NNS	_	9	ppmod	_	_
19	in	in	IN	_	24	case	_	_
20	vitro	vitro	FW	_	24	attr	_	_
21	and	and	CC	_	20	cc	_	_
22	in	in	FW	_	23	adv	_	_
23	vivo	vivo	FW	_	20	conj	_	_
24	experiments	experiment	NNS	_	6	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	given	give	VBN	_	11	advcl	_	_
3	in	in	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	dose	dose	NN	_	2	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	50	0	CD	_	8	num	_	_
8	mg/kg	mg/kg	NN	_	5	ppmod	_	_
9	,	,	,	_	11	p	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	produced	produce	VBD	_	0	root	_	_
12	no	no	DT	_	15	det	_	_
13	statistically	statistically	RB	_	14	adv	_	_
14	significant	significant	JJ	_	15	attr	_	_
15	effect	effect	NN	_	11	obj	_	_
16	on	on	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	duration	duration	NN	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	hexanal-induced	hexanal-induced	JJ	_	21	attr	_	_
21	sleep	sleep	NN	_	18	ppmod	_	_
22	in	in	IN	_	23	case	_	_
23	mice	mouse	NNS	_	21	ppmod	_	_
24	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	findings	finding	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	the	the	DT	_	6	det	_	_
6	agent	agent	NN	_	7	dep	_	_
7	has	have	VBZ	_	3	comp	_	_
8	slight	slight	JJ	_	9	attr	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	on	on	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	tested	test	VBN	_	13	attr	_	_
13	activities	activity	NNS	_	7	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	Repeated	repeat	VBN	_	3	attr	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	administration	administration	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	sheep	sheep	NN	_	3	ppmod	_	_
8	:	:	:	_	9	p	_	_
9	interactions	interaction	NNS	_	0	root	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug3	drug0	NN	_	9	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug4	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	drug5	drug0	NN	_	13	conj	_	_
19	.	.	.	_	9	p	_	_

1	Interactions	interaction	NNS	_	29	dep	_	_
2	between	between	IN	_	3	case	_	_
3	treatments	treatment	NNS	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	an	an	DT	_	10	det	_	_
10	drug3	drug0	NN	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	7	p	_	_
13	drug4	drug0	NN	_	5	conj	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	an	an	DT	_	16	det	_	_
16	drug5	drug0	NN	_	13	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	13	p	_	_
19	and	and	CC	_	13	cc	_	_
20	drug6	drug0	NN	_	5	conj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	an	an	DT	_	23	det	_	_
23	inducer	inducer	NN	_	20	prn	_	_
24	of	of	IN	_	26	case	_	_
25	microsomal	microsomal	JJ	_	26	attr	_	_
26	enzymes	enzyme	NNS	_	23	ppmod	_	_
27	)	-rrb-	-RRB-	_	23	p	_	_
28	were	be	VBD	_	29	aux	_	_
29	investigated	investigate	VBN	_	0	root	_	_
30	in	in	IN	_	31	case	_	_
31	sheep	sheep	NN	_	29	ppmod	_	_
32	.	.	.	_	29	p	_	_

1	A	a	DT	_	3	det	_	_
2	daily	daily	JJ	_	3	attr	_	_
3	dose	dose	NN	_	18	dep	_	_
4	of	of	IN	_	6	case	_	_
5	2	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	/kg	/kg	NNS	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	body	body	NN	_	12	com	_	_
12	weight	weight	NN	_	9	ppmod	_	_
13	for	for	IN	_	15	case	_	_
14	6	0	CD	_	15	num	_	_
15	days	day	NNS	_	12	ppmod	_	_
16	did	do	VBD	_	18	aux	_	_
17	not	not	RB	_	18	neg	_	_
18	affect	affect	VB	_	0	root	_	_
19	the	the	DT	_	21	det	_	_
20	plasma	plasma	NN	_	21	com	_	_
21	enzymes	enzyme	NNS	_	18	obj	_	_
22	or	or	CC	_	21	cc	_	_
23	the	the	DT	_	25	det	_	_
24	antiprothrombinemic	antiprothrombinemic	JJ	_	25	attr	_	_
25	effect	effect	NN	_	21	conj	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	25	ppmod	_	_
28	in	in	IN	_	29	case	_	_
29	wethers	wether	NNS	_	27	ppmod	_	_
30	.	.	.	_	18	p	_	_

1	The	the	DT	_	2	det	_	_
2	treatment	treatment	NN	_	28	dep	_	_
3	of	of	IN	_	4	case	_	_
4	ewes	ewe	NNS	_	2	ppmod	_	_
5	with	with	IN	_	11	case	_	_
6	an	an	DT	_	11	det	_	_
7	intravenous	intravenous	JJ	_	11	attr	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	IV	iv	NN	_	11	attr	_	_
10	)	-rrb-	-RRB-	_	11	p	_	_
11	injection	injection	NN	_	2	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	insufficient	insufficient	JJ	_	13	attr	_	_
16	to	to	TO	_	17	aux	_	_
17	produce	produce	VB	_	15	comp	_	_
18	significant	significant	JJ	_	19	attr	_	_
19	inhibition	inhibition	NN	_	17	obj	_	_
20	of	of	IN	_	26	case	_	_
21	erythrocyte	erythrocyte	NN	_	22	com	_	_
22	acetylcholinesterase	acetylcholinesterase	NN	_	26	attr	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	AChE	ache	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	activity	activity	NN	_	19	ppmod	_	_
27	,	,	,	_	13	p	_	_
28	appeared	appear	VBD	_	0	root	_	_
29	to	to	TO	_	30	aux	_	_
30	produce	produce	VB	_	28	comp	_	_
31	additive	additive	JJ	_	32	attr	_	_
32	effects	effect	NNS	_	30	obj	_	_
33	with	with	IN	_	34	case	_	_
34	those	those	DT	_	30	ppmod	_	_
35	produced	produce	VBN	_	34	acl	_	_
36	by	by	IN	_	38	case	_	_
37	subsequent	subsequent	JJ	_	38	attr	_	_
38	treatment	treatment	NN	_	35	ppmod	_	_
39	with	with	IN	_	41	case	_	_
40	4	0	CD	_	41	num	_	_
41	mg	mg	NN	_	38	ppmod	_	_
42	of	of	IN	_	44	case	_	_
43	drug2	drug0	NN	_	44	com	_	_
44	/kg/day	/kg/day	NN	_	41	ppmod	_	_
45	.	.	.	_	28	p	_	_

1	In	in	IN	_	2	case	_	_
2	ewes	ewe	NNS	_	28	ppmod	_	_
3	given	give	VBN	_	2	acl	_	_
4	40	0	CD	_	5	num	_	_
5	mg	mg	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	/kg	/kg	NNS	_	5	ppmod	_	_
9	for	for	IN	_	11	case	_	_
10	5	0	CD	_	11	num	_	_
11	days	day	NNS	_	5	ppmod	_	_
12	intraperitoneally	intraperitoneally	RB	_	3	adv	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	IP	ip	NN	_	3	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	28	p	_	_
17	the	the	DT	_	19	det	_	_
18	anticholinesterase	anticholinesterase	NN	_	19	com	_	_
19	effect	effect	NN	_	28	dep	_	_
20	of	of	IN	_	22	case	_	_
21	4	0	CD	_	22	num	_	_
22	mg	mg	NN	_	19	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	drug2	drug0	NN	_	25	com	_	_
25	/kg	/kg	NNS	_	22	ppmod	_	_
26	was	be	VBD	_	28	aux	_	_
27	significantly	significantly	RB	_	28	adv	_	_
28	reduced	reduce	VBN	_	0	root	_	_
29	and	and	CC	_	28	cc	_	_
30	signs	sign	NNS	_	33	dep	_	_
31	of	of	IN	_	32	case	_	_
32	toxicity	toxicity	NN	_	30	ppmod	_	_
33	were	be	VBD	_	28	conj	_	_
34	not	not	RB	_	33	neg	_	_
35	present	present	JJ	_	33	dep	_	_
36	.	.	.	_	28	p	_	_

1	Treatment	treatment	NN	_	16	dep	_	_
2	with	with	IN	_	4	case	_	_
3	daily	daily	JJ	_	4	attr	_	_
4	doses	dose	NNS	_	1	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	2	0	CD	_	7	num	_	_
7	mg	mg	NN	_	4	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	/kg	/kg	NNS	_	7	ppmod	_	_
11	for	for	IN	_	13	case	_	_
12	6	0	CD	_	13	num	_	_
13	days	day	NNS	_	7	ppmod	_	_
14	did	do	VBD	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	modify	modify	VB	_	0	root	_	_
17	the	the	DT	_	19	det	_	_
18	anticholinesterase	anticholinesterase	NN	_	19	com	_	_
19	effect	effect	NN	_	16	obj	_	_
20	of	of	IN	_	23	case	_	_
21	a	a	DT	_	23	det	_	_
22	2nd	#ord#	JJ	_	23	attr	_	_
23	series	series	NN	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	treatments	treatment	NNS	_	23	ppmod	_	_
26	given	give	VBN	_	25	acl	_	_
27	6	0	CD	_	28	num	_	_
28	weeks	week	NNS	_	29	advnp	_	_
29	later	later	RB	_	26	adv	_	_
30	.	.	.	_	16	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	profile	profile	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	special	special	JJ	_	7	attr	_	_
7	populations	population	NNS	_	2	ppmod	_	_
8	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	8	case	_	_
6	healthy	healthy	JJ	_	8	attr	_	_
7	normal	normal	JJ	_	8	attr	_	_
8	volunteers	volunteer	NNS	_	2	ppmod	_	_
9	has	have	VBZ	_	12	aux	_	_
10	been	be	VBN	_	12	aux	_	_
11	extensively	extensively	RB	_	12	adv	_	_
12	studied	study	VBN	_	0	root	_	_
13	and	and	CC	_	12	cc	_	_
14	is	be	VBZ	_	16	aux	_	_
15	well	well	RB	_	16	adv	_	_
16	described	describe	VBN	_	12	conj	_	_
17	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	characterised	characterise	VBN	_	0	root	_	_
4	by	by	IN	_	8	case	_	_
5	a	a	DT	_	8	det	_	_
6	high	high	JJ	_	8	attr	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	bioavailability	bioavailability	NN	_	3	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	low	low	JJ	_	11	attr	_	_
11	clearance	clearance	NN	_	8	conj	_	_
12	,	,	,	_	11	p	_	_
13	a	a	DT	_	15	det	_	_
14	small	small	JJ	_	15	attr	_	_
15	volume	volume	NN	_	11	appo	_	_
16	of	of	IN	_	17	case	_	_
17	distribution	distribution	NN	_	15	ppmod	_	_
18	,	,	,	_	11	p	_	_
19	and	and	CC	_	11	cc	_	_
20	a	a	DT	_	22	det	_	_
21	7-hour	0-hour	JJ	_	22	attr	_	_
22	half-life	half-life	NN	_	8	conj	_	_
23	.	.	.	_	3	p	_	_

1	It	it	PRP	_	5	dep	_	_
2	is	be	VBZ	_	5	aux	_	_
3	essentially	essentially	RB	_	5	adv	_	_
4	completely	completely	RB	_	5	adv	_	_
5	metabolised	metabolise	VBN	_	10	advcl	_	_
6	,	,	,	_	10	p	_	_
7	therefore	therefore	RB	_	8	adv	_	_
8	little	little	JJ	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	excreted	excrete	VBN	_	0	root	_	_
11	unchanged	unchanged	JJ	_	10	dep	_	_
12	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	is	be	VBZ	_	5	aux	_	_
3	highly	highly	RB	_	5	adv	_	_
4	protein	protein	NN	_	5	dep	_	_
5	bound	bind	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	To	to	TO	_	2	aux	_	_
2	investigate	investigate	VB	_	24	advcl	_	_
3	the	the	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	disease	disease	NN	_	7	com	_	_
7	states	state	NNS	_	4	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	concomitant	concomitant	JJ	_	11	attr	_	_
10	drug	drug	NN	_	11	com	_	_
11	administration	administration	NN	_	7	conj	_	_
12	on	on	IN	_	16	case	_	_
13	a	a	DT	_	14	det	_	_
14	patient	patient	NN	_	16	poss	_	_
15	's	's	POS	_	14	case	_	_
16	response	response	NN	_	4	ppmod	_	_
17	to	to	TO	_	18	aux	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	24	p	_	_
20	additional	additional	JJ	_	22	attr	_	_
21	pharmacokinetic	pharmacokinetic	JJ	_	22	attr	_	_
22	studies	study	NNS	_	24	dep	_	_
23	were	be	VBD	_	24	aux	_	_
24	carried	carry	VBN	_	0	root	_	_
25	out	out	RP	_	24	prt	_	_
26	in	in	IN	_	28	case	_	_
27	special	special	JJ	_	28	attr	_	_
28	populations	population	NNS	_	24	ppmod	_	_
29	.	.	.	_	24	p	_	_

1	Since	since	IN	_	7	mark	_	_
2	drug1	drug0	NN	_	7	dep	_	_
3	has	have	VBZ	_	7	lv	_	_
4	a	a	DT	_	7	det	_	_
5	well-defined	well-defined	JJ	_	7	attr	_	_
6	pharmacokinetic-pharmacodynamic	pharmacokinetic-pharmacodynamic	JJ	_	7	attr	_	_
7	relationship	relationship	NN	_	13	advcl	_	_
8	,	,	,	_	13	p	_	_
9	measurement	measurement	NN	_	13	dep	_	_
10	of	of	IN	_	12	case	_	_
11	pharmacokinetic	pharmacokinetic	JJ	_	12	attr	_	_
12	parameters	parameter	NNS	_	9	ppmod	_	_
13	is	be	VBZ	_	0	root	_	_
14	clinically	clinically	RB	_	15	adv	_	_
15	relevant	relevant	JJ	_	13	dep	_	_
16	.	.	.	_	13	p	_	_

1	Data	datum	NNS	_	6	dep	_	_
2	from	from	IN	_	3	case	_	_
3	studies	study	NNS	_	1	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	date	date	NN	_	3	ppmod	_	_
6	show	show	VBP	_	0	root	_	_
7	that	that	IN	_	20	mark	_	_
8	disease	disease	NN	_	9	com	_	_
9	states	state	NNS	_	20	dep	_	_
10	,	,	,	_	9	p	_	_
11	underlying	underlying	JJ	_	12	attr	_	_
12	conditions	condition	NNS	_	9	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	concomitantly	concomitantly	RB	_	16	adv	_	_
16	administered	administer	VBN	_	19	attr	_	_
17	highly	highly	RB	_	18	adv	_	_
18	protein-bound	protein-bound	JJ	_	19	attr	_	_
19	drugs	drug	NNS	_	9	conj	_	_
20	have	have	VBP	_	6	comp	_	_
21	essentially	essentially	RB	_	23	adv	_	_
22	no	no	DT	_	23	det	_	_
23	effect	effect	NN	_	20	obj	_	_
24	on	on	IN	_	26	case	_	_
25	drug1	drug0	NN	_	26	com	_	_
26	pharmacokinetics	pharmacokinetics	NNS	_	20	ppmod	_	_
27	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	7	dep	_	_
4	can	can	MD	_	7	modal	_	_
5	generally	generally	RB	_	7	adv	_	_
6	be	be	VB	_	7	aux	_	_
7	given	give	VBN	_	0	root	_	_
8	without	without	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	need	need	NN	_	7	ppmod	_	_
11	for	for	IN	_	13	case	_	_
12	dosage	dosage	JJ	_	13	attr	_	_
13	modifications	modification	NNS	_	10	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	special	special	JJ	_	16	attr	_	_
16	populations	population	NNS	_	13	ppmod	_	_
17	such	such	JJ	_	21	adv	_	_
18	as	as	IN	_	21	case	_	_
19	uncompromised	uncompromised	JJ	_	21	attr	_	_
20	elderly	elderly	JJ	_	21	attr	_	_
21	patients	patient	NNS	_	16	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	those	those	DT	_	21	conj	_	_
24	with	with	IN	_	27	case	_	_
25	moderate	moderate	JJ	_	27	attr	_	_
26	renal	renal	JJ	_	27	attr	_	_
27	impairment	impairment	NN	_	23	ppmod	_	_
28	,	,	,	_	23	p	_	_
29	and	and	CC	_	23	cc	_	_
30	patients	patient	NNS	_	21	conj	_	_
31	with	with	IN	_	34	case	_	_
32	stable	stable	JJ	_	34	attr	_	_
33	hepatic	hepatic	JJ	_	34	attr	_	_
34	disease	disease	NN	_	30	ppmod	_	_
35	.	.	.	_	7	p	_	_

1	Enhanced	enhance	VBN	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	clearance	clearance	NN	_	4	dep	_	_
4	secondary	secondary	JJ	_	0	root	_	_
5	to	to	TO	_	7	aux	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	therapy	therapy	NN	_	4	ppmod	_	_
8	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	report	report	NN	_	3	dep	_	_
3	describes	describe	VBZ	_	0	root	_	_
4	two	#crd#	CD	_	5	num	_	_
5	cases	case	NNS	_	3	obj	_	_
6	in	in	IN	_	7	case	_	_
7	which	which	WDT	_	10	ppmod	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	clearance	clearance	NN	_	10	dep	_	_
10	accelerated	accelerate	VBD	_	5	relcl	_	_
11	markedly	markedly	RB	_	10	adv	_	_
12	with	with	IN	_	15	case	_	_
13	concomitant	concomitant	JJ	_	15	attr	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	administration	administration	NN	_	10	ppmod	_	_
16	.	.	.	_	3	p	_	_

1	Maximum	maximum	JJ	_	4	attr	_	_
2	calculated	calculate	VBN	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	clearance	clearance	NN	_	5	dep	_	_
5	ranged	range	VBD	_	0	root	_	_
6	from	from	IN	_	13	case	_	_
7	2	0	CD	_	13	num	_	_
8	1/2	0	CD	_	13	num	_	_
9	to	to	TO	_	8	cc	_	_
10	3	0	CD	_	8	conj	_	_
11	1/2	0	CD	_	13	num	_	_
12	times	time	NNS	_	13	com	_	_
13	baseline	baseline	NN	_	5	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	Onset	onset	NN	_	5	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	interaction	interaction	NN	_	1	ppmod	_	_
5	began	begin	VBD	_	0	root	_	_
6	within	within	IN	_	8	case	_	_
7	five	#crd#	CD	_	8	num	_	_
8	days	day	NNS	_	5	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	beginning	beginning	NN	_	11	advnp	_	_
11	concurrent	concurrent	JJ	_	12	attr	_	_
12	therapy	therapy	NN	_	8	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	With	with	IN	_	3	case	_	_
2	combined	combined	JJ	_	3	attr	_	_
3	use	use	NN	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	clinicians	clinician	NNS	_	7	dep	_	_
6	should	should	MD	_	7	modal	_	_
7	be	be	VB	_	0	root	_	_
8	aware	aware	NN	_	7	obj	_	_
9	,	,	,	_	13	p	_	_
10	when	when	WRB	_	13	adv	_	_
11	drug1	drug0	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	added	add	VBN	_	8	prn	_	_
14	,	,	,	_	13	p	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	potential	potential	NN	_	8	ppmod	_	_
18	for	for	IN	_	19	case	_	_
19	reexacerbation	reexacerbation	NN	_	17	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	pulmonary	pulmonary	JJ	_	22	attr	_	_
22	symptomatology	symptomatology	NN	_	19	ppmod	_	_
23	due	due	IN	_	28	case	_	_
24	to	to	TO	_	28	aux	_	_
25	lowered	lowered	JJ	_	28	attr	_	_
26	serum	serum	NN	_	28	com	_	_
27	drug2	drug0	NN	_	28	com	_	_
28	concentrations	concentration	NNS	_	19	ppmod	_	_
29	.	.	.	_	7	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	activity	activity	NN	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	either	either	CC	_	8	cc	_	_
8	singly	singly	RB	_	3	adv	_	_
9	or	or	CC	_	8	cc	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	8	conj	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	3	p	_	_
15	against	against	IN	_	17	case	_	_
16	Mycobacterium	mycobacterium	NN	_	17	com	_	_
17	ulcerans	ulcerans	NNS	_	3	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	antimicrobial	antimicrobial	JJ	_	3	attr	_	_
3	effect	effect	NN	_	19	dep	_	_
4	of	of	IN	_	6	case	_	_
5	a	a	DT	_	6	det	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	drug2	drug0	NN	_	6	appo	_	_
9	,	,	,	_	6	p	_	_
10	either	either	CC	_	11	cc	_	_
11	alone	alone	RB	_	6	adv	_	_
12	or	or	CC	_	11	cc	_	_
13	in	in	IN	_	14	case	_	_
14	combination	combination	NN	_	11	conj	_	_
15	with	with	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	14	p	_	_
18	was	be	VBD	_	19	aux	_	_
19	evaluated	evaluate	VBN	_	0	root	_	_
20	in	in	FW	_	21	adv	_	_
21	vitro	vitro	FW	_	19	adv	_	_
22	against	against	IN	_	25	case	_	_
23	two	#crd#	CD	_	25	num	_	_
24	type	type	NN	_	25	com	_	_
25	strains	strain	NNS	_	19	ppmod	_	_
26	and	and	CC	_	25	cc	_	_
27	six	#crd#	CD	_	29	num	_	_
28	clinical	clinical	JJ	_	29	attr	_	_
29	isolates	isolate	NNS	_	25	conj	_	_
30	of	of	IN	_	32	case	_	_
31	Mycobacterium	mycobacterium	NN	_	32	com	_	_
32	ulcerans	ulcerans	NNS	_	29	ppmod	_	_
33	.	.	.	_	19	p	_	_

1	Growth	growth	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	M	m	NN	_	1	ppmod	_	_
4	.	.	.	_	1	p	_	_

1	ulcerans	ulcerans	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	measured	measure	VBN	_	0	root	_	_
4	by	by	IN	_	6	case	_	_
5	plate	plate	NN	_	6	com	_	_
6	counts	count	NNS	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	the	the	DT	_	11	det	_	_
9	BACTEC	bactec	NN	_	10	advnp	_	_
10	radiometric	radiometric	JJ	_	11	attr	_	_
11	method	method	NN	_	6	conj	_	_
12	.	.	.	_	3	p	_	_

1	The	the	DT	_	4	det	_	_
2	minimal	minimal	JJ	_	4	attr	_	_
3	inhibitory	inhibitory	JJ	_	4	attr	_	_
4	concentration	concentration	NN	_	0	root	_	_
5	as	as	RB	_	6	com	_	_
6	well	well	RB	_	4	cc	_	_
7	as	as	IN	_	6	com	_	_
8	minimal	minimal	JJ	_	10	attr	_	_
9	bactericidal	bactericidal	JJ	_	10	attr	_	_
10	concentration	concentration	NN	_	4	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	against	against	IN	_	14	case	_	_
14	M	m	NN	_	10	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	ulcerans	ulcerans	NN	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	between	between	IN	_	7	case	_	_
4	0.012	0	CD	_	7	num	_	_
5	and	and	CC	_	4	cc	_	_
6	0.025	0	CD	_	4	conj	_	_
7	mg/l	mg/l	NN	_	2	ppmod	_	_
8	,	,	,	_	2	p	_	_
9	while	while	IN	_	16	mark	_	_
10	corresponding	corresponding	JJ	_	11	attr	_	_
11	values	value	NNS	_	16	dep	_	_
12	for	for	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	were	be	VBD	_	2	comp	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	range	range	NN	_	16	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	0.1-0.8	0	CD	_	22	num	_	_
22	mg/l	mg/l	NN	_	19	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	0.1-0.4	0	CD	_	25	num	_	_
25	mg/l	mg/l	NN	_	22	conj	_	_
26	respectively	respectively	RB	_	22	adv	_	_
27	.	.	.	_	2	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	combined	combine	VBN	_	7	advcl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	drug2	drug0	NN	_	7	dep	_	_
7	exhibited	exhibit	VBD	_	0	root	_	_
8	strong	strong	JJ	_	10	attr	_	_
9	synergistic	synergistic	JJ	_	10	attr	_	_
10	activity	activity	NN	_	7	obj	_	_
11	while	while	IN	_	16	mark	_	_
12	only	only	RB	_	14	adv	_	_
13	additive	additive	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	16	dep	_	_
15	were	be	VBD	_	16	aux	_	_
16	observed	observe	VBN	_	7	comp	_	_
17	with	with	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	combination	combination	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	or	or	CC	_	24	cc	_	_
24	drug4	drug0	NN	_	21	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	and	and	CC	_	21	cc	_	_
27	drug5	drug0	NN	_	21	conj	_	_
28	.	.	.	_	7	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	has	have	VBZ	_	3	comp	_	_
7	a	a	DT	_	9	det	_	_
8	great	great	JJ	_	9	attr	_	_
9	potential	potential	NN	_	6	obj	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	treatment	treatment	NN	_	6	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	M	m	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	ulcerans	ulcerans	NNS	_	2	com	_	_
2	infection	infection	NN	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	Pharmacokinetics	pharmacokinetics	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	.	.	.	_	1	p	_	_

1	Effective	effective	JJ	_	2	attr	_	_
2	use	use	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	therapy	therapy	NN	_	2	ppmod	_	_
7	depends	depend	VBZ	_	0	root	_	_
8	not	not	RB	_	9	com	_	_
9	only	only	RB	_	12	cc	_	_
10	on	on	IN	_	12	case	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	acumen	acumen	NN	_	7	ppmod	_	_
13	but	but	CC	_	12	cc	_	_
14	also	also	RB	_	13	com	_	_
15	on	on	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	availability	availability	NN	_	12	conj	_	_
18	of	of	IN	_	23	case	_	_
19	relevant	relevant	JJ	_	23	attr	_	_
20	pharmacokinetic	pharmacokinetic	JJ	_	23	attr	_	_
21	and	and	CC	_	20	cc	_	_
22	pharmacodynamic	pharmacodynamic	JJ	_	20	conj	_	_
23	data	datum	NNS	_	17	ppmod	_	_
24	.	.	.	_	7	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	information	information	NN	_	3	dep	_	_
3	assists	assist	VBZ	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	development	development	NN	_	3	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	safe	safe	JJ	_	9	attr	_	_
8	dosing	dosing	NN	_	9	com	_	_
9	regimens	regimen	NNS	_	5	ppmod	_	_
10	,	,	,	_	5	p	_	_
11	prediction	prediction	NN	_	5	conj	_	_
12	of	of	IN	_	14	case	_	_
13	abnormal	abnormal	JJ	_	14	attr	_	_
14	handling	handling	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drugs	drug	NNS	_	14	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	states	state	NNS	_	14	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	disease	disease	NN	_	18	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	disorder	disorder	NN	_	20	conj	_	_
23	and	and	CC	_	11	cc	_	_
24	anticipation	anticipation	NN	_	5	conj	_	_
25	of	of	IN	_	27	case	_	_
26	drug	drug	NN	_	27	com	_	_
27	interactions	interaction	NNS	_	24	ppmod	_	_
28	.	.	.	_	3	p	_	_

1	For	for	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	drug1	drug0	NN	_	20	ppmod	_	_
4	now	now	RB	_	5	adv	_	_
5	available	available	JJ	_	3	attr	_	_
6	in	in	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	United	united	JJ	_	9	attr	_	_
9	States	state	NNS	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	drug2	drug0	NN	_	9	prn	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	11	conj	_	_
16	)	-rrb-	-RRB-	_	11	p	_	_
17	,	,	,	_	20	p	_	_
18	these	these	DT	_	19	det	_	_
19	data	datum	NNS	_	20	dep	_	_
20	appeared	appear	VBD	_	0	root	_	_
21	well	well	RB	_	27	adv	_	_
22	after	after	IN	_	27	mark	_	_
23	clinical	clinical	JJ	_	24	attr	_	_
24	patterns	pattern	NNS	_	27	dep	_	_
25	of	of	IN	_	26	case	_	_
26	use	use	NN	_	24	ppmod	_	_
27	evolved	evolve	VBD	_	20	comp	_	_
28	.	.	.	_	20	p	_	_

1	Nonetheless	nonetheless	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	their	their	PRP$	_	4	poss	_	_
4	relevance	relevance	NN	_	5	dep	_	_
5	continues	continue	VBZ	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	be	be	VB	_	8	aux	_	_
8	demonstrated	demonstrate	VBN	_	5	comp	_	_
9	by	by	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	dependence	dependence	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	each	each	DT	_	14	det	_	_
14	agent	agent	NN	_	11	ppmod	_	_
15	on	on	IN	_	19	case	_	_
16	intact	intact	JJ	_	19	attr	_	_
17	liver	liver	NN	_	19	com	_	_
18	blood	blood	NN	_	19	com	_	_
19	flow	flow	NN	_	11	ppmod	_	_
20	and	and	CC	_	8	cc	_	_
21	function	function	VB	_	8	conj	_	_
22	for	for	IN	_	24	case	_	_
23	normal	normal	JJ	_	24	attr	_	_
24	rates	rate	NNS	_	21	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	elimination	elimination	NN	_	24	ppmod	_	_
27	;	;	:	_	5	p	_	_

1	by	by	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	nonlinear	nonlinear	JJ	_	5	attr	_	_
4	kinetic	kinetic	JJ	_	5	attr	_	_
5	characteristics	characteristic	NNS	_	0	root	_	_
6	for	for	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	(	-lrb-	-LRB-	_	17	p	_	_
11	and	and	CC	_	17	cc	_	_
12	probably	probably	RB	_	17	adv	_	_
13	for	for	IN	_	14	case	_	_
14	drug3	drug0	NN	_	17	ppmod	_	_
15	,	,	,	_	17	p	_	_
16	as	as	IN	_	17	case	_	_
17	well	well	NN	_	7	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	and	and	CC	_	5	cc	_	_
20	the	the	DT	_	22	det	_	_
21	derivative	derivative	JJ	_	22	attr	_	_
22	implications	implication	NNS	_	5	conj	_	_
23	for	for	IN	_	27	case	_	_
24	decreased	decrease	VBN	_	27	attr	_	_
25	dosing	dosing	NN	_	27	com	_	_
26	frequency	frequency	NN	_	27	com	_	_
27	requirements	requirement	NNS	_	22	ppmod	_	_
28	;	;	:	_	5	p	_	_

1	and	and	CC	_	3	cc	_	_
2	by	by	IN	_	3	case	_	_
3	observations	observation	NNS	_	0	root	_	_
4	now	now	RB	_	5	adv	_	_
5	appearing	appear	VBG	_	3	acl	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	relation	relation	NN	_	5	ppmod	_	_
9	between	between	IN	_	12	case	_	_
10	plasma	plasma	NN	_	12	com	_	_
11	drug	drug	NN	_	12	com	_	_
12	levels	level	NNS	_	8	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug	drug	NN	_	15	com	_	_
15	effects	effect	NNS	_	12	conj	_	_
16	,	,	,	_	15	p	_	_
17	both	both	CC	_	18	cc	_	_
18	therapeutic	therapeutic	JJ	_	15	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	toxic	toxic	JJ	_	18	conj	_	_
21	.	.	.	_	3	p	_	_

1	Such	such	JJ	_	2	attr	_	_
2	data	datum	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	discussed	discuss	VBN	_	0	root	_	_
5	herein	herein	RB	_	4	adv	_	_
6	,	,	,	_	4	p	_	_
7	with	with	IN	_	8	case	_	_
8	emphasis	emphasis	NN	_	4	ppmod	_	_
9	on	on	IN	_	11	case	_	_
10	those	those	DT	_	11	det	_	_
11	aspects	aspect	NNS	_	8	ppmod	_	_
12	that	that	IN	_	13	case	_	_
13	impact	impact	NN	_	11	ppmod	_	_
14	on	on	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	clinical	clinical	JJ	_	17	attr	_	_
17	use	use	NN	_	13	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	drug1	drug0	NN	_	17	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Herbal	herbal	JJ	_	2	attr	_	_
2	remedies	remedy	NNS	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	nephropathies	nephropathy	NNS	_	2	conj	_	_
5	,	,	,	_	4	p	_	_
6	and	and	CC	_	4	cc	_	_
7	renal	renal	JJ	_	8	attr	_	_
8	disease	disease	NN	_	2	conj	_	_
9	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	use	use	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	herbal	herbal	JJ	_	5	attr	_	_
5	remedies	remedy	NNS	_	2	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	becoming	become	VBG	_	0	root	_	_
8	increasingly	increasingly	RB	_	9	adv	_	_
9	popular	popular	JJ	_	7	dep	_	_
10	in	in	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	United	united	JJ	_	13	attr	_	_
13	States	state	NNS	_	9	ppmod	_	_
14	.	.	.	_	7	p	_	_

1	Research	research	NN	_	3	dep	_	_
2	has	have	VBZ	_	3	aux	_	_
3	shown	show	VBN	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	herbal	herbal	JJ	_	7	attr	_	_
6	remedy	remedy	NN	_	7	com	_	_
7	use	use	NN	_	10	dep	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	associated	associate	VBN	_	3	comp	_	_
11	with	with	IN	_	14	case	_	_
12	acute	acute	JJ	_	14	attr	_	_
13	renal	renal	JJ	_	14	attr	_	_
14	failure	failure	NN	_	10	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	10	ppmod	_	_
3	,	,	,	_	10	p	_	_
4	the	the	DT	_	5	det	_	_
5	use	use	NN	_	10	dep	_	_
6	of	of	IN	_	8	case	_	_
7	herbal	herbal	JJ	_	8	attr	_	_
8	remedies	remedy	NNS	_	5	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	be	be	VB	_	0	root	_	_
11	detrimental	detrimental	JJ	_	10	dep	_	_
12	for	for	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	patient	patient	NN	_	11	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	compromised	compromise	VBN	_	18	attr	_	_
17	renal	renal	JJ	_	18	attr	_	_
18	function	function	NN	_	14	ppmod	_	_
19	.	.	.	_	10	p	_	_

1	Patients	patient	NNS	_	9	dep	_	_
2	with	with	IN	_	4	case	_	_
3	renal	renal	JJ	_	4	attr	_	_
4	insufficiency	insufficiency	NN	_	1	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	renal	renal	JJ	_	7	attr	_	_
7	failure	failure	NN	_	4	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	be	be	VB	_	0	root	_	_
10	at	at	IN	_	11	case	_	_
11	risk	risk	NN	_	9	ppmod	_	_
12	for	for	IN	_	15	case	_	_
13	further	far	JJ	_	15	attr	_	_
14	kidney	kidney	NN	_	15	com	_	_
15	damage	damage	NN	_	11	ppmod	_	_
16	as	as	RB	_	17	com	_	_
17	well	well	RB	_	15	cc	_	_
18	as	as	IN	_	17	com	_	_
19	complications	complication	NNS	_	15	conj	_	_
20	related	related	JJ	_	19	attr	_	_
21	to	to	TO	_	22	aux	_	_
22	interactions	interaction	NNS	_	20	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	herbal	herbal	JJ	_	25	attr	_	_
25	remedies	remedy	NNS	_	22	ppmod	_	_
26	with	with	IN	_	30	case	_	_
27	complex	complex	JJ	_	30	attr	_	_
28	renal	renal	JJ	_	30	attr	_	_
29	therapy	therapy	NN	_	30	com	_	_
30	regimens	regimen	NNS	_	22	ppmod	_	_
31	.	.	.	_	9	p	_	_

1	This	this	DT	_	2	det	_	_
2	article	article	NN	_	4	dep	_	_
3	will	will	MD	_	4	modal	_	_
4	describe	describe	VBP	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	escalating	escalating	JJ	_	7	attr	_	_
7	use	use	NN	_	4	obj	_	_
8	of	of	IN	_	10	case	_	_
9	herbal	herbal	JJ	_	10	attr	_	_
10	therapy	therapy	NN	_	7	ppmod	_	_
11	and	and	CC	_	7	cc	_	_
12	the	the	DT	_	13	det	_	_
13	hazards	hazard	NNS	_	7	conj	_	_
14	of	of	IN	_	15	case	_	_
15	herbal	herbal	NN	_	13	ppmod	_	_
16	remedy	remedy	IN	_	17	case	_	_
17	use	use	NN	_	4	ppmod	_	_
18	among	among	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	their	their	PRP$	_	4	poss	_	_
4	complications	complication	NNS	_	1	conj	_	_
5	.	.	.	_	1	p	_	_

1	Drugs	drug	NNS	_	9	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	suppress	suppress	VBP	_	1	relcl	_	_
4	the	the	DT	_	6	det	_	_
5	immune	immune	JJ	_	6	attr	_	_
6	system	system	NN	_	3	obj	_	_
7	are	be	VBP	_	9	aux	_	_
8	widely	widely	RB	_	9	adv	_	_
9	used	use	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	They	they	PRP	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	part	part	NN	_	2	obj	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	treatment	treatment	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	organ	organ	NN	_	11	com	_	_
11	transplants	transplant	NNS	_	8	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	malignancy	malignancy	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	increasingly	increasingly	RB	_	17	adv	_	_
17	those	those	DT	_	11	conj	_	_
18	with	with	IN	_	19	case	_	_
19	conditions	condition	NNS	_	17	ppmod	_	_
20	such	such	JJ	_	22	adv	_	_
21	as	as	IN	_	22	case	_	_
22	psoriasis	psoriasis	NN	_	19	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	rheumatoid	rheumatoid	NN	_	25	com	_	_
25	arthritis	arthritis	NN	_	22	conj	_	_
26	,	,	,	_	25	p	_	_
27	and	and	CC	_	25	cc	_	_
28	liver	liver	NN	_	22	conj	_	_
29	and	and	CC	_	17	cc	_	_
30	bowel	bowel	NN	_	31	com	_	_
31	disease	disease	NN	_	17	conj	_	_
32	in	in	IN	_	33	case	_	_
33	which	which	WDT	_	35	ppmod	_	_
34	inflammation	inflammation	NN	_	35	dep	_	_
35	is	be	VBZ	_	17	relcl	_	_
36	an	an	DT	_	38	det	_	_
37	aetiological	aetiological	JJ	_	38	attr	_	_
38	factor	factor	NN	_	35	obj	_	_
39	.	.	.	_	2	p	_	_

1	Because	because	IN	_	5	case	_	_
2	of	of	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	broadening	broadening	JJ	_	5	attr	_	_
5	indications	indication	NNS	_	28	ppmod	_	_
6	for	for	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	5	p	_	_
9	and	and	CC	_	5	cc	_	_
10	the	the	DT	_	12	det	_	_
11	prolonged	prolonged	JJ	_	12	attr	_	_
12	survival	survival	NN	_	5	conj	_	_
13	in	in	IN	_	14	case	_	_
14	conditions	condition	NNS	_	12	ppmod	_	_
15	for	for	IN	_	16	case	_	_
16	which	which	WDT	_	20	ppmod	_	_
17	they	they	PRP	_	20	dep	_	_
18	are	be	VBP	_	20	aux	_	_
19	being	be	VBG	_	20	aux	_	_
20	used	use	VBN	_	14	relcl	_	_
21	,	,	,	_	28	p	_	_
22	many	many	JJ	_	23	attr	_	_
23	patients	patient	NNS	_	28	dep	_	_
24	on	on	IN	_	25	case	_	_
25	immunosuppression	immunosuppression	NN	_	23	ppmod	_	_
26	are	be	VBP	_	28	aux	_	_
27	now	now	RB	_	28	adv	_	_
28	cared	care	VBN	_	0	root	_	_
29	for	for	IN	_	32	case	_	_
30	in	in	IN	_	32	case	_	_
31	the	the	DT	_	32	det	_	_
32	community	community	NN	_	28	ppmod	_	_
33	or	or	CC	_	32	cc	_	_
34	seen	see	VBN	_	32	conj	_	_
35	in	in	IN	_	37	case	_	_
36	non-specialist	non-specialist	JJ	_	37	attr	_	_
37	hospitals	hospital	NNS	_	34	ppmod	_	_
38	,	,	,	_	34	p	_	_
39	usually	usually	RB	_	34	adv	_	_
40	in	in	IN	_	42	case	_	_
41	close	close	JJ	_	42	attr	_	_
42	collaboration	collaboration	NN	_	34	ppmod	_	_
43	with	with	IN	_	45	case	_	_
44	a	a	DT	_	45	det	_	_
45	specialist	specialist	NN	_	42	ppmod	_	_
46	.	.	.	_	28	p	_	_

1	This	this	DT	_	2	det	_	_
2	article	article	NN	_	3	dep	_	_
3	looks	look	VBZ	_	0	root	_	_
4	at	at	IN	_	8	case	_	_
5	five	#crd#	CD	_	8	num	_	_
6	commonly	commonly	RB	_	7	adv	_	_
7	used	use	VBN	_	8	attr	_	_
8	drug1	drug0	NN	_	3	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	turn	turn	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	appo	_	_
15	,	,	,	_	12	p	_	_
16	drug4	drug0	NN	_	12	appo	_	_
17	,	,	,	_	12	p	_	_
18	drug5	drug0	NN	_	12	appo	_	_
19	,	,	,	_	12	p	_	_
20	drug6	drug0	NN	_	12	appo	_	_
21	)	-rrb-	-RRB-	_	12	p	_	_
22	,	,	,	_	10	p	_	_
23	discussing	discuss	VBG	_	10	acl	_	_
24	the	the	DT	_	25	det	_	_
25	main	main	JJ	_	23	obj	_	_
26	,	,	,	_	25	p	_	_
27	non-infection	non-infection	NN	_	25	appo	_	_
28	,	,	,	_	25	p	_	_
29	unwanted	unwanted	JJ	_	30	attr	_	_
30	effects	effect	NNS	_	25	appo	_	_
31	,	,	,	_	25	p	_	_
32	ways	way	NNS	_	25	appo	_	_
33	to	to	TO	_	34	aux	_	_
34	avoid	avoid	VB	_	23	comp	_	_
35	them	them	PRP	_	34	obj	_	_
36	and	and	CC	_	10	cc	_	_
37	what	what	WP	_	39	dep	_	_
38	to	to	TO	_	39	aux	_	_
39	do	do	VB	_	10	conj	_	_
40	if	if	IN	_	42	mark	_	_
41	problems	problem	NNS	_	42	dep	_	_
42	arise	arise	VBP	_	39	comp	_	_
43	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	management	management	NN	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	infection	infection	NN	_	2	ppmod	_	_
5	is	be	VBZ	_	6	aux	_	_
6	dealt	deal	VBN	_	0	root	_	_
7	with	with	IN	_	6	case	_	_
8	as	as	IN	_	11	case	_	_
9	a	a	DT	_	11	det	_	_
10	separate	separate	JJ	_	11	attr	_	_
11	section	section	NN	_	6	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	similarly	similarly	RB	_	5	adv	_	_
5	inhibit	inhibit	VBP	_	0	root	_	_
6	and	and	CC	_	5	cc	_	_
7	stimulate	stimulate	VB	_	5	conj	_	_
8	drug3	drug0	NN	_	12	advnp	_	_
9	-	-	CC	_	8	cc	_	_
10	or	or	CC	_	8	cc	_	_
11	drug4	drug0	NN	_	8	conj	_	_
12	-induced	-induced	JJ	_	13	attr	_	_
13	proliferation	proliferation	NN	_	7	obj	_	_
14	of	of	IN	_	16	case	_	_
15	prostatic	prostatic	JJ	_	16	attr	_	_
16	epithelium	epithelium	NN	_	13	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Prostatic	prostatic	JJ	_	2	attr	_	_
2	epithelium	epithelium	NN	_	3	dep	_	_
3	proliferates	proliferate	VBZ	_	0	root	_	_
4	in	in	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	defined	define	VBN	_	7	attr	_	_
7	medium	medium	NN	_	3	ppmod	_	_
8	consisting	consist	VBG	_	7	acl	_	_
9	of	of	IN	_	11	case	_	_
10	basal	basal	JJ	_	11	attr	_	_
11	medium	medium	NN	_	8	ppmod	_	_
12	RPMI1640	rpmi0	CD	_	11	num	_	_
13	containing	contain	VBG	_	11	acl	_	_
14	drug1	drug0	NN	_	13	obj	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	1	0	CD	_	17	num	_	_
17	microgram/ml	microgram/ml	NN	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	,	,	,	_	14	p	_	_
20	drug2	drug0	NN	_	14	conj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	10	0	CD	_	23	num	_	_
23	ng/ml	ng/ml	NN	_	20	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	20	p	_	_
26	and	and	CC	_	20	cc	_	_
27	drug3	drug0	NN	_	14	conj	_	_
28	(	-lrb-	-LRB-	_	30	p	_	_
29	3.7	0	CD	_	30	num	_	_
30	micrograms/ml	micrograms/ml	NN	_	27	prn	_	_
31	or	or	CC	_	30	cc	_	_
32	0.1	0	CD	_	33	num	_	_
33	IU/ml	iu/ml	NN	_	30	conj	_	_
34	)	-rrb-	-RRB-	_	30	p	_	_
35	.	.	.	_	3	p	_	_

1	Although	although	IN	_	6	mark	_	_
2	neither	neither	CC	_	3	cc	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	nor	nor	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	affected	affect	VBD	_	19	advcl	_	_
7	the	the	DT	_	8	det	_	_
8	proliferation	proliferation	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	prostatic	prostatic	JJ	_	11	attr	_	_
11	epithelium	epithelium	NN	_	8	ppmod	_	_
12	in	in	IN	_	15	case	_	_
13	RPMI1640	rpmi0	NN	_	15	com	_	_
14	containing	containing	NN	_	15	com	_	_
15	drug3	drug0	NN	_	8	ppmod	_	_
16	alone	alone	RB	_	15	adv	_	_
17	,	,	,	_	19	p	_	_
18	they	they	PRP	_	19	dep	_	_
19	modify	modify	VB	_	0	root	_	_
20	the	the	DT	_	22	det	_	_
21	mitogenic	mitogenic	JJ	_	22	attr	_	_
22	effect	effect	NN	_	19	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	drug5	drug0	NN	_	24	conj	_	_
27	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	19	dep	_	_
2	at	at	IN	_	7	case	_	_
3	10	0	CD	_	7	num	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	-10	0	CD	_	7	num	_	_
6	)	-rrb-	-RRB-	_	7	p	_	_
7	M	m	NN	_	1	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	at	at	IN	_	18	case	_	_
11	about	about	RB	_	12	adv	_	_
12	3	0	CD	_	18	num	_	_
13	X	x	CC	_	12	cc	_	_
14	10	0	CD	_	12	conj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	-9	0	NN	_	12	num	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	M	m	NN	_	1	ppmod	_	_
19	inhibits	inhibit	VBZ	_	0	root	_	_
20	proliferation	proliferation	NN	_	19	obj	_	_
21	stimulated	stimulate	VBN	_	20	acl	_	_
22	by	by	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	19	p	_	_

1	Higher	high	JJR	_	2	attr	_	_
2	concentrations	concentration	NNS	_	33	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	15	p	_	_
6	10	0	CD	_	15	num	_	_
7	(	-lrb-	-LRB-	_	15	p	_	_
8	-8	0	CD	_	15	num	_	_
9	)	-rrb-	-RRB-	_	15	p	_	_
10	-	-	:	_	15	p	_	_
11	10	0	CD	_	15	num	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	-6	0	CD	_	15	num	_	_
14	)	-rrb-	-RRB-	_	15	p	_	_
15	M	m	NN	_	4	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	or	or	CC	_	4	cc	_	_
18	drug2	drug0	NN	_	4	conj	_	_
19	(	-lrb-	-LRB-	_	31	p	_	_
20	3	0	CD	_	31	num	_	_
21	X	x	CC	_	31	cc	_	_
22	10	0	CD	_	31	num	_	_
23	(	-lrb-	-LRB-	_	31	p	_	_
24	-8	0	CD	_	31	num	_	_
25	)	-rrb-	-RRB-	_	31	p	_	_
26	-	-	:	_	31	p	_	_
27	10	0	CD	_	31	num	_	_
28	(	-lrb-	-LRB-	_	31	p	_	_
29	-7	0	CD	_	31	num	_	_
30	)	-rrb-	-RRB-	_	31	p	_	_
31	M	m	NN	_	18	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	enhance	enhance	VBP	_	0	root	_	_
34	the	the	DT	_	36	det	_	_
35	mitogenic	mitogenic	JJ	_	36	attr	_	_
36	activity	activity	NN	_	33	obj	_	_
37	of	of	IN	_	38	case	_	_
38	drug3	drug0	NN	_	36	ppmod	_	_
39	.	.	.	_	33	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	similar	similar	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	presence	presence	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	However	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	stimulated	stimulate	VBD	_	0	root	_	_
5	,	,	,	_	4	p	_	_
6	but	but	CC	_	4	cc	_	_
7	did	do	VBD	_	10	aux	_	_
8	not	not	RB	_	10	neg	_	_
9	significantly	significantly	RB	_	10	adv	_	_
10	inhibit	inhibit	VB	_	4	conj	_	_
11	,	,	,	_	10	p	_	_
12	proliferation	proliferation	NN	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	presence	presence	NN	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	18	mark	_	_
5	both	both	CC	_	6	cc	_	_
6	drug1	drug0	NN	_	18	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	6	p	_	_
10	and	and	CC	_	6	cc	_	_
11	possibly	possibly	RB	_	10	com	_	_
12	other	other	JJ	_	13	attr	_	_
13	drug3	drug0	NN	_	6	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug4	drug0	NN	_	13	conj	_	_
16	,	,	,	_	13	p	_	_
17	may	may	MD	_	18	modal	_	_
18	regulate	regulate	VB	_	3	comp	_	_
19	the	the	DT	_	20	det	_	_
20	proliferation	proliferation	NN	_	18	obj	_	_
21	of	of	IN	_	23	case	_	_
22	prostate	prostate	NN	_	23	com	_	_
23	epithelium	epithelium	NN	_	20	ppmod	_	_
24	by	by	IN	_	27	case	_	_
25	a	a	DT	_	27	det	_	_
26	dose-dependent	dose-dependent	JJ	_	27	attr	_	_
27	modification	modification	NN	_	18	ppmod	_	_
28	of	of	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	activity	activity	NN	_	27	ppmod	_	_
31	of	of	IN	_	32	case	_	_
32	drug5	drug0	NN	_	30	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	drug6	drug0	NN	_	32	conj	_	_
35	.	.	.	_	3	p	_	_

1	Death	death	NN	_	0	root	_	_
2	in	in	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	users	user	NNS	_	1	ppmod	_	_
5	:	:	:	_	1	p	_	_
6	causes	cause	NNS	_	1	appo	_	_
7	and	and	CC	_	6	cc	_	_
8	rates	rate	NNS	_	6	conj	_	_
9	.	.	.	_	1	p	_	_

1	The	the	DT	_	4	det	_	_
2	world	world	NN	_	4	attr	_	_
3	medical	medical	JJ	_	4	attr	_	_
4	literature	literature	NN	_	5	dep	_	_
5	contains	contain	VBZ	_	0	root	_	_
6	43	0	CD	_	7	num	_	_
7	reports	report	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	deaths	death	NNS	_	7	ppmod	_	_
10	associated	associate	VBN	_	9	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	35-year	0-year	JJ	_	16	attr	_	_
16	period	period	NN	_	5	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	These	these	DT	_	2	dep	_	_
2	included	include	VBD	_	0	root	_	_
3	seven	#crd#	CD	_	5	num	_	_
4	cerebrovascular	cerebrovascular	JJ	_	5	attr	_	_
5	accidents	accident	NNS	_	2	obj	_	_
6	,	,	,	_	5	p	_	_
7	six	#crd#	CD	_	10	num	_	_
8	sudden	sudden	JJ	_	10	attr	_	_
9	cardiac	cardiac	JJ	_	10	attr	_	_
10	deaths	death	NNS	_	5	appo	_	_
11	,	,	,	_	10	p	_	_
12	three	#crd#	CD	_	13	num	_	_
13	cases	case	NNS	_	10	appo	_	_
14	of	of	IN	_	15	case	_	_
15	hyperpyrexia	hyperpyrexia	NN	_	13	ppmod	_	_
16	,	,	,	_	13	p	_	_
17	eight	#crd#	CD	_	18	num	_	_
18	poisonings	poisoning	NNS	_	13	conj	_	_
19	of	of	IN	_	21	case	_	_
20	uncertain	uncertain	JJ	_	21	attr	_	_
21	mechanism	mechanism	NN	_	18	ppmod	_	_
22	and	and	CC	_	18	cc	_	_
23	seven	#crd#	CD	_	24	num	_	_
24	cases	case	NNS	_	13	conj	_	_
25	of	of	IN	_	27	case	_	_
26	medical	medical	JJ	_	27	attr	_	_
27	complications	complication	NNS	_	24	ppmod	_	_
28	of	of	IN	_	30	case	_	_
29	intravenous	intravenous	JJ	_	30	attr	_	_
30	injection	injection	NN	_	27	ppmod	_	_
31	;	;	:	_	2	p	_	_

1	the	the	DT	_	2	det	_	_
2	remainder	remainder	NN	_	3	dep	_	_
3	were	be	VBD	_	0	root	_	_
4	of	of	IN	_	6	case	_	_
5	uncertain	uncertain	JJ	_	6	attr	_	_
6	cause	cause	NN	_	3	ppmod	_	_
7	.	.	.	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	13	ppmod	_	_
3	,	,	,	_	13	p	_	_
4	in	in	IN	_	5	case	_	_
5	Ontario	ontario	NN	_	13	ppmod	_	_
6	alone	alone	RB	_	5	adv	_	_
7	,	,	,	_	13	p	_	_
8	in	in	IN	_	9	case	_	_
9	1972	0	CD	_	13	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	1973	0	CD	_	9	conj	_	_
12	there	there	EX	_	13	dep	_	_
13	were	be	VBD	_	0	root	_	_
14	26	0	CD	_	15	num	_	_
15	deaths	death	NNS	_	13	obj	_	_
16	in	in	IN	_	18	case	_	_
17	drug1	drug0	NN	_	18	com	_	_
18	users	user	NNS	_	15	ppmod	_	_
19	,	,	,	_	15	p	_	_
20	of	of	IN	_	21	case	_	_
21	which	which	WDT	_	23	ppmod	_	_
22	16	0	CD	_	23	num	_	_
23	were	be	VBD	_	15	relcl	_	_
24	due	due	JJ	_	23	dep	_	_
25	to	to	TO	_	26	aux	_	_
26	accident	accident	NN	_	24	ppmod	_	_
27	suicide	suicide	NN	_	26	attr	_	_
28	or	or	CC	_	26	cc	_	_
29	homicide	homicide	NN	_	26	conj	_	_
30	.	.	.	_	13	p	_	_

1	Of	of	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	remaining	remain	VBG	_	4	attr	_	_
4	cases	case	NNS	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	two	#crd#	CD	_	7	num	_	_
7	were	be	VBD	_	0	root	_	_
8	cardiac	cardiac	JJ	_	10	attr	_	_
9	,	,	,	_	10	p	_	_
10	two	#crd#	CD	_	7	obj	_	_
11	hepatic	hepatic	JJ	_	10	attr	_	_
12	and	and	CC	_	7	cc	_	_
13	the	the	DT	_	14	det	_	_
14	rest	rest	NN	_	16	dep	_	_
15	were	be	VBD	_	16	aux	_	_
16	mixed	mix	VBN	_	7	conj	_	_
17	drug	drug	NN	_	18	com	_	_
18	overdose	overdose	NN	_	16	obj	_	_
19	.	.	.	_	7	p	_	_

1	Pulmonary	pulmonary	JJ	_	2	attr	_	_
2	granulomata	granuloma	NN	_	14	dep	_	_
3	,	,	,	_	2	p	_	_
4	subacute	subacute	JJ	_	5	attr	_	_
5	hepatitis	hepatitis	NN	_	2	conj	_	_
6	and	and	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	lesions	lesion	NNS	_	2	conj	_	_
9	resulting	result	VBG	_	2	acl	_	_
10	from	from	IN	_	13	case	_	_
11	intravenous	intravenous	JJ	_	13	attr	_	_
12	drug	drug	NN	_	13	com	_	_
13	use	use	NN	_	9	ppmod	_	_
14	were	be	VBD	_	0	root	_	_
15	common	common	JJ	_	16	attr	_	_
16	findings	finding	NNS	_	14	obj	_	_
17	at	at	IN	_	18	case	_	_
18	autopsy	autopsy	NN	_	14	ppmod	_	_
19	.	.	.	_	14	p	_	_

1	On	on	IN	_	7	case	_	_
2	the	the	DT	_	7	det	_	_
3	basis	basis	NN	_	7	advnp	_	_
4	of	of	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	estimated	estimate	VBN	_	7	attr	_	_
7	number	number	NN	_	23	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	regular	regular	JJ	_	10	attr	_	_
10	users	user	NNS	_	7	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	intravenous	intravenous	JJ	_	13	attr	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	in	in	IN	_	15	case	_	_
15	Ontario	ontario	NN	_	13	ppmod	_	_
16	,	,	,	_	23	p	_	_
17	the	the	DT	_	19	det	_	_
18	mortality	mortality	NN	_	19	com	_	_
19	rate	rate	NN	_	23	dep	_	_
20	in	in	IN	_	22	case	_	_
21	such	such	JJ	_	22	attr	_	_
22	users	user	NNS	_	19	ppmod	_	_
23	is	be	VBZ	_	0	root	_	_
24	at	at	IN	_	26	case	_	_
25	least	least	JJS	_	26	attr	_	_
26	four	#crd#	CD	_	27	num	_	_
27	times	time	NNS	_	23	obj	_	_
28	as	as	RB	_	29	adv	_	_
29	high	high	JJ	_	27	attr	_	_
30	as	as	IN	_	34	case	_	_
31	in	in	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	general	general	JJ	_	34	attr	_	_
34	population	population	NN	_	29	ppmod	_	_
35	of	of	IN	_	38	case	_	_
36	the	the	DT	_	38	det	_	_
37	same	same	JJ	_	38	attr	_	_
38	age	age	NN	_	34	ppmod	_	_
39	,	,	,	_	23	p	_	_
40	and	and	CC	_	23	cc	_	_
41	is	be	VBZ	_	23	conj	_	_
42	comparable	comparable	JJ	_	41	dep	_	_
43	to	to	TO	_	44	aux	_	_
44	that	that	DT	_	42	ppmod	_	_
45	in	in	IN	_	46	case	_	_
46	alcoholics	alcoholic	NNS	_	44	ppmod	_	_
47	and	and	CC	_	46	cc	_	_
48	drug2	drug0	NN	_	49	com	_	_
49	addicts	addict	NNS	_	46	conj	_	_
50	.	.	.	_	23	p	_	_

1	However	however	RB	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	the	the	DT	_	5	det	_	_
4	absolute	absolute	JJ	_	5	attr	_	_
5	number	number	NN	_	10	dep	_	_
6	of	of	IN	_	9	case	_	_
7	drug1	drug0	JJ	_	9	attr	_	_
8	-related	-related	JJ	_	9	attr	_	_
9	deaths	death	NNS	_	5	ppmod	_	_
10	is	be	VBZ	_	0	root	_	_
11	far	far	RB	_	12	adv	_	_
12	greater	great	JJR	_	10	dep	_	_
13	than	than	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	number	number	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	deaths	death	NNS	_	15	ppmod	_	_
18	in	in	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	users	user	NNS	_	19	conj	_	_
23	.	.	.	_	10	p	_	_

1	-LSB-A	-lsb-a	JJ	_	3	attr	_	_
2	pharmacological	pharmacological	JJ	_	3	attr	_	_
3	analysis	analysis	NN	_	22	dep	_	_
4	of	of	IN	_	15	case	_	_
5	the	the	DT	_	6	det	_	_
6	effect	effect	NN	_	15	attr	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	on	on	IN	_	12	case	_	_
10	stimulated	stimulate	VBN	_	12	attr	_	_
11	gastric	gastric	JJ	_	12	attr	_	_
12	secretion	secretion	NN	_	6	ppmod	_	_
13	]	-rsb-	-RRB-	_	6	p	_	_
14	Chronic	chronic	JJ	_	15	attr	_	_
15	experiments	experiment	NNS	_	3	ppmod	_	_
16	on	on	IN	_	17	case	_	_
17	dogs	dog	NNS	_	15	ppmod	_	_
18	with	with	IN	_	20	case	_	_
19	gastric	gastric	JJ	_	20	attr	_	_
20	fistulas	fistula	NNS	_	17	ppmod	_	_
21	were	be	VBD	_	22	aux	_	_
22	carried	carry	VBN	_	0	root	_	_
23	out	out	RP	_	22	prt	_	_
24	to	to	TO	_	25	aux	_	_
25	study	study	VB	_	22	comp	_	_
26	the	the	DT	_	27	det	_	_
27	influence	influence	NN	_	25	obj	_	_
28	of	of	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	and	and	CC	_	29	cc	_	_
31	drug3	drug0	NN	_	29	conj	_	_
32	on	on	IN	_	40	case	_	_
33	drug4	drug0	NN	_	37	advnp	_	_
34	-	-	CC	_	33	cc	_	_
35	and	and	CC	_	33	cc	_	_
36	drug5	drug0	NN	_	33	conj	_	_
37	-induced	-induced	JJ	_	40	attr	_	_
38	gastric	gastric	JJ	_	40	attr	_	_
39	acid	acid	NN	_	40	com	_	_
40	secretion	secretion	NN	_	27	ppmod	_	_
41	.	.	.	_	22	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	established	establish	VBN	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	both	both	DT	_	6	det	_	_
6	angiotensins	angiotensin	NNS	_	7	dep	_	_
7	inhibited	inhibit	VBD	_	3	comp	_	_
8	gastric	gastric	JJ	_	10	attr	_	_
9	acid	acid	NN	_	10	com	_	_
10	secretion	secretion	NN	_	7	obj	_	_
11	stimulated	stimulate	VBN	_	10	acl	_	_
12	by	by	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	but	but	CC	_	13	cc	_	_
15	not	not	RB	_	17	neg	_	_
16	by	by	IN	_	17	case	_	_
17	drug2	drug0	NN	_	13	conj	_	_
18	.	.	.	_	3	p	_	_

1	Comparative	comparative	JJ	_	2	attr	_	_
2	analysis	analysis	NN	_	25	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	stimulation	stimulation	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	inhibition	inhibition	NN	_	7	conj	_	_
10	of	of	IN	_	11	case	_	_
11	cholino-	cholino-	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	adrenoreceptors	adrenoreceptors	NN	_	11	conj	_	_
14	on	on	IN	_	17	case	_	_
15	this	this	DT	_	17	det	_	_
16	inhibitory	inhibitory	JJ	_	17	attr	_	_
17	action	action	NN	_	5	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	suggested	suggest	VBD	_	25	aux	_	_
21	the	the	DT	_	22	det	_	_
22	mediation	mediation	NN	_	25	obj	_	_
23	of	of	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	influence	influence	VB	_	0	root	_	_
26	through	through	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	modulation	modulation	NN	_	25	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	cholinergic	cholinergic	JJ	_	31	attr	_	_
31	reactions	reaction	NNS	_	28	ppmod	_	_
32	of	of	IN	_	34	case	_	_
33	parietal	parietal	JJ	_	34	attr	_	_
34	cells	cell	NNS	_	31	ppmod	_	_
35	in	in	IN	_	37	case	_	_
36	the	the	DT	_	37	det	_	_
37	stomach	stomach	NN	_	34	ppmod	_	_
38	.	.	.	_	25	p	_	_

1	-LSB-Stimulation	-lsb-stimulation	NN	_	22	dep	_	_
2	by	by	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	--an	--an	NN	_	5	com	_	_
5	analog	analog	NN	_	1	ppmod	_	_
6	of	of	IN	_	11	case	_	_
7	the	the	DT	_	11	det	_	_
8	octapeptide	octapeptide	NN	_	11	com	_	_
9	cholecystokinin--of	cholecystokinin--of	NN	_	11	com	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	binding	binding	NN	_	5	ppmod	_	_
12	after	after	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	long-term	long-term	JJ	_	15	attr	_	_
15	administration	administration	NN	_	1	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	]	-rsb-	-RRB-	_	22	p	_	_
19	It	it	PRP	_	22	dep	_	_
20	has	have	VBZ	_	22	aux	_	_
21	been	be	VBN	_	22	aux	_	_
22	established	establish	VBN	_	0	root	_	_
23	in	in	IN	_	24	case	_	_
24	experiments	experiment	NNS	_	22	ppmod	_	_
25	on	on	IN	_	28	case	_	_
26	white	white	JJ	_	28	attr	_	_
27	male	male	JJ	_	28	attr	_	_
28	rats	rat	NNS	_	24	ppmod	_	_
29	that	that	WDT	_	52	dep	_	_
30	prolonged	prolonged	JJ	_	31	attr	_	_
31	administration	administration	NN	_	52	dep	_	_
32	(	-lrb-	-LRB-	_	35	p	_	_
33	twice	twice	RB	_	35	adv	_	_
34	a	a	DT	_	35	det	_	_
35	day	day	NN	_	31	prn	_	_
36	for	for	IN	_	38	case	_	_
37	14	0	CD	_	38	num	_	_
38	days	day	NNS	_	35	ppmod	_	_
39	)	-rrb-	-RRB-	_	35	p	_	_
40	of	of	IN	_	41	case	_	_
41	drug4	drug0	NN	_	31	ppmod	_	_
42	(	-lrb-	-LRB-	_	44	p	_	_
43	0.25	0	CD	_	44	num	_	_
44	mg/kg	mg/kg	NN	_	41	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	and	and	CC	_	41	cc	_	_
47	drug5	drug0	NN	_	41	conj	_	_
48	(	-lrb-	-LRB-	_	50	p	_	_
49	0.25	0	CD	_	50	num	_	_
50	mg/kg	mg/kg	NN	_	41	prn	_	_
51	)	-rrb-	-RRB-	_	50	p	_	_
52	resulted	result	VBD	_	28	relcl	_	_
53	in	in	IN	_	56	case	_	_
54	the	the	DT	_	56	det	_	_
55	reduced	reduce	VBN	_	56	attr	_	_
56	interaction	interaction	NN	_	52	ppmod	_	_
57	between	between	IN	_	58	case	_	_
58	drug6	drug0	NN	_	56	ppmod	_	_
59	and	and	CC	_	58	cc	_	_
60	low	low	JJ	_	63	attr	_	_
61	affinity	affinity	NN	_	63	com	_	_
62	binding	binding	NN	_	63	com	_	_
63	sites	site	NNS	_	58	conj	_	_
64	for	for	IN	_	65	case	_	_
65	drug7	drug0	NN	_	63	ppmod	_	_
66	in	in	IN	_	68	case	_	_
67	subcortical	subcortical	JJ	_	68	attr	_	_
68	structures	structure	NNS	_	65	ppmod	_	_
69	,	,	,	_	52	p	_	_
70	whereas	whereas	IN	_	80	mark	_	_
71	drug8	drug0	NN	_	72	com	_	_
72	binding	binding	NN	_	80	dep	_	_
73	with	with	IN	_	77	case	_	_
74	high	high	JJ	_	77	attr	_	_
75	affinity	affinity	NN	_	77	com	_	_
76	binding	binding	NN	_	77	com	_	_
77	sites	site	NNS	_	72	ppmod	_	_
78	for	for	IN	_	79	case	_	_
79	drug9	drug0	NN	_	77	ppmod	_	_
80	increased	increase	VBD	_	52	comp	_	_
81	both	both	DT	_	80	obj	_	_
82	in	in	IN	_	85	case	_	_
83	the	the	DT	_	85	det	_	_
84	frontal	frontal	JJ	_	85	attr	_	_
85	cortex	cortex	NN	_	81	ppmod	_	_
86	and	and	CC	_	85	cc	_	_
87	subcortical	subcortical	JJ	_	88	attr	_	_
88	structures	structure	NNS	_	85	conj	_	_
89	of	of	IN	_	91	case	_	_
90	the	the	DT	_	91	det	_	_
91	forebrain	forebrain	NN	_	88	ppmod	_	_
92	.	.	.	_	22	p	_	_

1	After	after	IN	_	3	case	_	_
2	prolonged	prolonged	JJ	_	3	attr	_	_
3	administration	administration	NN	_	19	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	the	the	DT	_	8	det	_	_
7	displacing	displacing	JJ	_	8	attr	_	_
8	effect	effect	NN	_	19	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	an	an	DT	_	13	det	_	_
13	analog	analog	NN	_	10	appo	_	_
14	of	of	IN	_	16	case	_	_
15	cholecystokinin	cholecystokinin	NN	_	16	com	_	_
16	octapeptide	octapeptide	NN	_	13	ppmod	_	_
17	,	,	,	_	10	p	_	_
18	was	be	VBD	_	19	aux	_	_
19	replaced	replace	VBN	_	0	root	_	_
20	by	by	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	stimulant	stimulant	JJ	_	23	attr	_	_
23	action	action	NN	_	19	ppmod	_	_
24	on	on	IN	_	26	case	_	_
25	drug3	drug0	NN	_	26	com	_	_
26	binding	binding	NN	_	23	ppmod	_	_
27	.	.	.	_	19	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	assumed	assume	VBN	_	0	root	_	_
4	that	that	IN	_	20	mark	_	_
5	increased	increase	VBN	_	6	attr	_	_
6	interaction	interaction	NN	_	20	dep	_	_
7	between	between	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	high	high	JJ	_	13	attr	_	_
11	affinity	affinity	NN	_	13	com	_	_
12	binding	binding	NN	_	13	com	_	_
13	sites	site	NNS	_	8	conj	_	_
14	for	for	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	on	on	IN	_	17	case	_	_
17	dopamine2-	dopamine0-	NN	_	6	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	serotonin2-receptors	serotonin0-receptors	NN	_	17	conj	_	_
20	underlies	underlie	VBZ	_	3	comp	_	_
21	the	the	DT	_	23	det	_	_
22	antipsychotic	antipsychotic	JJ	_	23	attr	_	_
23	action	action	NN	_	20	obj	_	_
24	of	of	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	after	after	IN	_	29	case	_	_
27	their	their	PRP$	_	29	poss	_	_
28	prolonged	prolonged	JJ	_	29	attr	_	_
29	administration	administration	NN	_	25	ppmod	_	_
30	.	.	.	_	3	p	_	_

1	Cholecystokinin	cholecystokinin	NN	_	2	com	_	_
2	octapeptide	octapeptide	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	necessary	necessary	JJ	_	6	attr	_	_
6	factor	factor	NN	_	3	obj	_	_
7	for	for	IN	_	8	case	_	_
8	realization	realization	NN	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	this	this	DT	_	11	det	_	_
11	action	action	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	in	in	IN	_	7	case	_	_
7	rats	rat	NNS	_	1	ppmod	_	_
8	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	18	dep	_	_
3	of	of	IN	_	6	case	_	_
4	intramuscularly	intramuscularly	RB	_	5	adv	_	_
5	injected	inject	VBN	_	6	attr	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	its	its	PRP$	_	10	poss	_	_
9	N-demethylated	n-demethylated	JJ	_	10	attr	_	_
10	metabolite	metabolite	NN	_	6	conj	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	metabolite	metabolite	NN	_	13	com	_	_
13	I	i	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	2	ppmod	_	_
17	was	be	VBD	_	18	aux	_	_
18	evaluated	evaluate	VBN	_	0	root	_	_
19	in	in	IN	_	20	case	_	_
20	rats	rat	NNS	_	18	ppmod	_	_
21	.	.	.	_	18	p	_	_

1	Five	#crd#	CD	_	9	num	_	_
2	,	,	,	_	1	p	_	_
3	10	0	CD	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	20	0	CD	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	or	or	CC	_	5	cc	_	_
8	50	0	CD	_	1	conj	_	_
9	mg/kg	mg/kg	NN	_	25	dep	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	alone	alone	RB	_	9	adv	_	_
13	or	or	CC	_	9	cc	_	_
14	20	0	CD	_	20	num	_	_
15	,	,	,	_	14	p	_	_
16	50	0	CD	_	14	conj	_	_
17	,	,	,	_	16	p	_	_
18	or	or	CC	_	16	cc	_	_
19	100	0	CD	_	14	conj	_	_
20	mg/kg	mg/kg	NN	_	9	conj	_	_
21	of	of	IN	_	23	case	_	_
22	metabolite	metabolite	NN	_	23	com	_	_
23	I	i	NN	_	20	ppmod	_	_
24	alone	alone	RB	_	20	adv	_	_
25	produced	produce	VBD	_	0	root	_	_
26	less	less	JJR	_	28	attr	_	_
27	than	than	IN	_	26	com	_	_
28	10	0	CD	_	29	num	_	_
29	minutes	minute	NNS	_	25	obj	_	_
30	of	of	IN	_	31	case	_	_
31	hypnosis	hypnosis	NN	_	29	ppmod	_	_
32	.	.	.	_	25	p	_	_

1	However	however	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	drug1	drug0	NN	_	5	attr	_	_
4	anesthetic	anesthetic	JJ	_	5	attr	_	_
5	requirement	requirement	NN	_	12	dep	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	i.e.	i.e.	FW	_	9	ppmod	_	_
8	,	,	,	_	9	p	_	_
9	MAC	mac	NN	_	5	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	was	be	VBD	_	12	aux	_	_
12	depressed	depress	VBN	_	0	root	_	_
13	in	in	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	dose-dependent	dose-dependent	JJ	_	16	attr	_	_
16	fashion	fashion	NN	_	12	ppmod	_	_
17	as	as	IN	_	18	case	_	_
18	much	much	JJ	_	12	ppmod	_	_
19	as	as	IN	_	20	case	_	_
20	56	0	CD	_	18	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	1-2	0	CD	_	23	num	_	_
23	hours	hour	NNS	_	20	appo	_	_
24	and	and	CC	_	20	cc	_	_
25	as	as	RB	_	28	adv	_	_
26	much	much	JJ	_	28	attr	_	_
27	as	as	IN	_	28	case	_	_
28	14	0	CD	_	20	conj	_	_
29	%	%	NN	_	28	meta	_	_
30	5-6	0	CD	_	31	num	_	_
31	hours	hour	NNS	_	28	appo	_	_
32	after	after	IN	_	33	case	_	_
33	injection	injection	NN	_	31	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	drug2	drug0	NN	_	33	ppmod	_	_
36	,	,	,	_	35	p	_	_
37	50	0	CD	_	38	num	_	_
38	mg/kg	mg/kg	NN	_	35	appo	_	_
39	,	,	,	_	35	p	_	_
40	im	im	NN	_	35	appo	_	_
41	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	reduction	reduction	NN	_	6	dep	_	_
3	in	in	IN	_	4	case	_	_
4	MAC	mac	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	correlated	correlate	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	brain	brain	NN	_	9	com	_	_
9	levels	level	NNS	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	metabolite	metabolite	NN	_	14	com	_	_
14	I	i	NN	_	11	conj	_	_
15	,	,	,	_	6	p	_	_
16	suggesting	suggest	VBG	_	6	comp	_	_
17	a	a	DT	_	23	det	_	_
18	drug2	drug0	NN	_	23	attr	_	_
19	:	:	:	_	23	p	_	_
20	metabolite	metabolite	NN	_	23	com	_	_
21	I	i	NN	_	23	com	_	_
22	potency	potency	NN	_	23	com	_	_
23	ration	ration	NN	_	16	obj	_	_
24	of	of	IN	_	25	case	_	_
25	3:1	0	NN	_	23	ppmod	_	_
26	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	half-life	half-life	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	plasma	plasma	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	brain	brain	NN	_	6	conj	_	_
9	was	be	VBD	_	0	root	_	_
10	longer	long	JJR	_	9	dep	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	presence	presence	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	than	than	IN	_	20	case	_	_
17	when	when	WRB	_	20	adv	_	_
18	drug3	drug0	NN	_	20	dep	_	_
19	was	be	VBD	_	20	aux	_	_
20	given	give	VBN	_	10	ppmod	_	_
21	alone	alone	RB	_	20	adv	_	_
22	.	.	.	_	9	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	concluded	conclude	VBN	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	is	be	VBZ	_	3	advcl	_	_
7	not	not	RB	_	6	neg	_	_
8	a	a	DT	_	10	det	_	_
9	short-acting	short-acting	JJ	_	10	attr	_	_
10	drug	drug	NN	_	6	obj	_	_
11	and	and	CC	_	6	cc	_	_
12	that	that	IN	_	19	mark	_	_
13	concomitant	concomitant	JJ	_	14	attr	_	_
14	use	use	NN	_	19	dep	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	would	would	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	expected	expect	VBN	_	6	conj	_	_
20	to	to	TO	_	21	aux	_	_
21	prolong	prolong	VB	_	19	comp	_	_
22	further	far	RB	_	21	adv	_	_
23	the	the	DT	_	24	det	_	_
24	duration	duration	NN	_	21	obj	_	_
25	of	of	IN	_	27	case	_	_
26	its	its	PRP$	_	27	poss	_	_
27	action	action	NN	_	24	ppmod	_	_
28	on	on	IN	_	32	case	_	_
29	the	the	DT	_	32	det	_	_
30	central	central	JJ	_	32	attr	_	_
31	nervous	nervous	JJ	_	32	attr	_	_
32	system	system	NN	_	24	ppmod	_	_
33	.	.	.	_	3	p	_	_

1	In	in	FW	_	2	adv	_	_
2	vitro	vitro	FW	_	3	attr	_	_
3	interaction	interaction	NN	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	in	in	IN	_	10	case	_	_
9	placental	placental	JJ	_	10	attr	_	_
10	vessels	vessel	NNS	_	3	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	12	dep	_	_
3	of	of	IN	_	7	case	_	_
4	drug1	drug0	JJ	_	7	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	synthetic	synthetic	JJ	_	4	conj	_	_
7	drug2	drug0	NN	_	2	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	placental	placental	JJ	_	10	attr	_	_
10	vessels	vessel	NNS	_	2	ppmod	_	_
11	was	be	VBD	_	12	aux	_	_
12	studied	study	VBN	_	0	root	_	_
13	in	in	FW	_	14	adv	_	_
14	vitro	vitro	FW	_	12	adv	_	_
15	.	.	.	_	12	p	_	_

1	Resistance	resistance	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	measured	measure	VBN	_	0	root	_	_
4	near	near	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	placental	placental	JJ	_	7	attr	_	_
7	margin	margin	NN	_	3	ppmod	_	_
8	after	after	IN	_	11	case	_	_
9	spontaneous	spontaneous	JJ	_	11	attr	_	_
10	term	term	NN	_	11	com	_	_
11	delivery	delivery	NN	_	7	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	In	in	IN	_	3	case	_	_
2	seven	#crd#	CD	_	3	num	_	_
3	experiments	experiment	NNS	_	10	ppmod	_	_
4	reactions	reaction	NNS	_	10	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	were	be	VBD	_	10	aux	_	_
10	drug3	drug0	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	produced	produce	VBD	_	0	root	_	_
3	significantly	significantly	RB	_	4	adv	_	_
4	increased	increase	VBN	_	5	attr	_	_
5	vasoconstriction	vasoconstriction	NN	_	2	obj	_	_
6	after	after	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	single	single	JJ	_	9	attr	_	_
9	administration	administration	NN	_	2	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	In	in	IN	_	3	case	_	_
2	eight	#crd#	CD	_	3	num	_	_
3	experiments	experiment	NNS	_	7	ppmod	_	_
4	the	the	DT	_	6	det	_	_
5	perfusion	perfusion	NN	_	6	com	_	_
6	medium	medium	NN	_	7	dep	_	_
7	contained	contain	VBD	_	0	root	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	.	.	.	_	7	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	change	change	NN	_	2	obj	_	_
5	after	after	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	single	single	JJ	_	8	attr	_	_
8	dose	dose	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	reaction	reaction	NN	_	5	dep	_	_
3	after	after	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	remained	remain	VBD	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	same	same	JJ	_	5	obj	_	_
8	in	in	IN	_	10	case	_	_
9	both	both	DT	_	10	det	_	_
10	groups	group	NNS	_	5	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	experiments	experiment	NNS	_	10	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	thus	thus	RB	_	2	adv	_	_
4	an	an	DT	_	6	det	_	_
5	enhancement	enhancement	NN	_	6	com	_	_
6	effect	effect	NN	_	2	obj	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	thus	thus	RB	_	2	adv	_	_
4	an	an	DT	_	6	det	_	_
5	enhancement	enhancement	NN	_	6	com	_	_
6	effect	effect	NN	_	2	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	upon	upon	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	reaction	reaction	NN	_	6	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	placental	placental	JJ	_	14	attr	_	_
14	vessels	vessel	NNS	_	11	ppmod	_	_
15	to	to	TO	_	16	aux	_	_
16	drug2	drug0	NN	_	11	ppmod	_	_
17	in	in	FW	_	18	adv	_	_
18	vitro	vitro	FW	_	11	attr	_	_
19	.	.	.	_	2	p	_	_

1	Note	note	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	dissolution	dissolution	NN	_	1	appo	_	_
4	of	of	IN	_	6	case	_	_
5	aerosol	aerosol	NN	_	6	com	_	_
6	particles	particle	NNS	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	drug2	drug0	NN	_	3	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	a	a	DT	_	14	det	_	_
13	model	model	JJ	_	14	attr	_	_
14	drug3	drug0	NN	_	10	appo	_	_
15	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	23	dep	_	_
3	of	of	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	extract	extract	NN	_	2	ppmod	_	_
7	from	from	IN	_	9	case	_	_
8	bovine	bovine	JJ	_	9	attr	_	_
9	lung	lung	NN	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	appo	_	_
12	,	,	,	_	9	p	_	_
13	on	on	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	dissolution	dissolution	NN	_	16	com	_	_
16	rate	rate	NN	_	2	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	aerosol	aerosol	NN	_	19	com	_	_
19	particles	particle	NNS	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	was	be	VBD	_	23	aux	_	_
23	determined	determine	VBN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	Aerosol	aerosol	NN	_	2	com	_	_
2	particles	particle	NNS	_	6	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	6	aux	_	_
6	generated	generate	VBN	_	0	root	_	_
7	from	from	IN	_	10	case	_	_
8	an	an	DT	_	10	det	_	_
9	drug2	drug0	JJ	_	10	attr	_	_
10	solution	solution	NN	_	6	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	dried	dry	VBN	_	6	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	collected	collect	VBN	_	6	conj	_	_
16	by	by	IN	_	19	case	_	_
17	a	a	DT	_	19	det	_	_
18	cascade	cascade	NN	_	19	com	_	_
19	impactor	impactor	NN	_	15	ppmod	_	_
20	for	for	IN	_	21	case	_	_
21	characterization	characterization	NN	_	19	ppmod	_	_
22	or	or	CC	_	19	cc	_	_
23	by	by	IN	_	26	case	_	_
24	a	a	DT	_	26	det	_	_
25	liquid	liquid	JJ	_	26	attr	_	_
26	impinger	impinger	NN	_	19	conj	_	_
27	for	for	IN	_	29	case	_	_
28	dissolution	dissolution	NN	_	29	com	_	_
29	experiments	experiment	NNS	_	26	ppmod	_	_
30	.	.	.	_	6	p	_	_

1	Powder	powder	NN	_	3	com	_	_
2	x-ray	x-ray	NN	_	3	com	_	_
3	diffraction	diffraction	NN	_	18	dep	_	_
4	,	,	,	_	3	p	_	_
5	differential	differential	JJ	_	7	attr	_	_
6	scanning	scanning	NN	_	7	com	_	_
7	calorimetry	calorimetry	NN	_	3	conj	_	_
8	,	,	,	_	7	p	_	_
9	differential	differential	JJ	_	11	attr	_	_
10	thermal	thermal	JJ	_	11	attr	_	_
11	analysis	analysis	NN	_	3	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	scanning	scanning	NN	_	16	com	_	_
15	electron	electron	NN	_	16	com	_	_
16	microscopy	microscopy	NN	_	3	conj	_	_
17	were	be	VBD	_	18	aux	_	_
18	used	use	VBN	_	0	root	_	_
19	to	to	TO	_	20	aux	_	_
20	characterize	characterize	VB	_	18	comp	_	_
21	the	the	DT	_	23	det	_	_
22	aerosol	aerosol	NN	_	23	com	_	_
23	particles	particle	NNS	_	20	obj	_	_
24	and	and	CC	_	20	cc	_	_
25	starting	start	VBG	_	20	conj	_	_
26	material	material	NN	_	25	obj	_	_
27	.	.	.	_	18	p	_	_

1	No	no	DT	_	2	det	_	_
2	change	change	NN	_	6	dep	_	_
3	in	in	IN	_	4	case	_	_
4	phase	phase	NN	_	2	ppmod	_	_
5	was	be	VBD	_	6	aux	_	_
6	detected	detect	VBN	_	0	root	_	_
7	,	,	,	_	6	p	_	_
8	although	although	IN	_	12	mark	_	_
9	the	the	DT	_	11	det	_	_
10	aerosol	aerosol	NN	_	11	com	_	_
11	particles	particle	NNS	_	12	dep	_	_
12	appeared	appear	VBD	_	6	comp	_	_
13	to	to	TO	_	14	aux	_	_
14	contain	contain	VB	_	12	comp	_	_
15	residual	residual	JJ	_	16	attr	_	_
16	drug1	drug0	NN	_	14	obj	_	_
17	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	dissolution	dissolution	NN	_	3	com	_	_
3	rate	rate	NN	_	10	dep	_	_
4	of	of	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	aerosol	aerosol	NN	_	7	com	_	_
7	particles	particle	NNS	_	3	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	saline	saline	NN	_	3	ppmod	_	_
10	was	be	VBD	_	0	root	_	_
11	low	low	JJ	_	10	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	variable	variable	JJ	_	11	conj	_	_
14	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	increased	increase	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	extent	extent	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	dissolution	dissolution	NN	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	14	case	_	_
10	proportion	proportion	NN	_	14	advnp	_	_
11	to	to	TO	_	14	aux	_	_
12	the	the	DT	_	14	det	_	_
13	added	add	VBN	_	14	attr	_	_
14	concentration	concentration	NN	_	2	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	which	which	WDT	_	19	dep	_	_
17	was	be	VBD	_	19	aux	_	_
18	also	also	RB	_	19	adv	_	_
19	verified	verify	VBN	_	14	relcl	_	_
20	by	by	IN	_	23	case	_	_
21	equilibrium	equilibrium	NN	_	23	com	_	_
22	solubilization	solubilization	NN	_	23	com	_	_
23	studies	study	NNS	_	19	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	increased	increase	VBD	_	0	root	_	_
4	rate	rate	NN	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	dissolution	dissolution	NN	_	4	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	in	in	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	manner	manner	NN	_	3	ppmod	_	_
11	similar	similar	JJ	_	10	attr	_	_
12	to	to	TO	_	13	aux	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	Analysis	analysis	NN	_	9	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	concentration	concentration	NN	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	following	follow	VBG	_	8	adv	_	_
8	ultracentrifugation	ultracentrifugation	NN	_	6	ppmod	_	_
9	indicated	indicate	VBD	_	0	root	_	_
10	that	that	IN	_	12	mark	_	_
11	there	there	EX	_	12	dep	_	_
12	is	be	VBZ	_	9	comp	_	_
13	rapid	rapid	JJ	_	14	attr	_	_
14	equilibration	equilibration	NN	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	between	between	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	drug3	drug0	NN	_	14	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	aqueous	aqueous	JJ	_	22	attr	_	_
22	phase	phase	NN	_	19	conj	_	_
23	.	.	.	_	9	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	show	show	VBP	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	has	have	VBZ	_	3	comp	_	_
7	the	the	DT	_	8	det	_	_
8	potential	potential	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	enhancing	enhance	VBG	_	8	ppmod	_	_
11	the	the	DT	_	12	det	_	_
12	rate	rate	NN	_	10	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	extent	extent	NN	_	12	conj	_	_
15	of	of	IN	_	16	case	_	_
16	dissolution	dissolution	NN	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drugs	drug	NNS	_	16	ppmod	_	_
19	administered	administer	VBN	_	18	acl	_	_
20	to	to	TO	_	22	aux	_	_
21	the	the	DT	_	22	det	_	_
22	lung	lung	NN	_	19	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	Anaesthesia	anaesthesia	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	the	the	DT	_	5	det	_	_
4	epileptic	epileptic	JJ	_	5	attr	_	_
5	pateint	pateint	NN	_	1	conj	_	_
6	.	.	.	_	1	p	_	_

1	A	a	DT	_	2	det	_	_
2	review	review	NN	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	A	a	DT	_	2	det	_	_
2	review	review	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	presented	present	VBN	_	0	root	_	_
5	of	of	IN	_	6	case	_	_
6	some	some	DT	_	4	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	problems	problem	NNS	_	6	ppmod	_	_
10	that	that	WDT	_	12	dep	_	_
11	may	may	MD	_	12	modal	_	_
12	arise	arise	VB	_	9	relcl	_	_
13	in	in	IN	_	14	case	_	_
14	association	association	NN	_	12	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	anaesthesia	anaesthesia	NN	_	14	ppmod	_	_
17	for	for	IN	_	19	case	_	_
18	epileptic	epileptic	JJ	_	19	attr	_	_
19	patients	patient	NNS	_	14	ppmod	_	_
20	.	.	.	_	4	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	possibility	possibility	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	precipitating	precipitate	VBG	_	4	ppmod	_	_
7	anticonvulsant	anticonvulsant	JJ	_	9	attr	_	_
8	drug	drug	NN	_	9	com	_	_
9	toxicity	toxicity	NN	_	6	obj	_	_
10	.	.	.	_	2	p	_	_

1	Numerous	numerous	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	interactions	interaction	NNS	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	possible	possible	JJ	_	4	dep	_	_
6	with	with	IN	_	8	case	_	_
7	some	some	DT	_	8	det	_	_
8	drug1	drug0	NNS	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	such	such	JJ	_	12	adv	_	_
11	as	as	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	12	p	_	_
16	which	which	WDT	_	17	dep	_	_
17	affect	affect	VBP	_	12	relcl	_	_
18	hepatic	hepatic	JJ	_	21	attr	_	_
19	microsomal	microsomal	JJ	_	21	attr	_	_
20	enzyme	enzyme	NN	_	21	com	_	_
21	systems	system	NNS	_	17	obj	_	_
22	.	.	.	_	4	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	risk	risk	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	convulsions	convulsion	NNS	_	4	ppmod	_	_
7	occurring	occur	VBG	_	6	acl	_	_
8	in	in	IN	_	10	case	_	_
9	susceptible	susceptible	JJ	_	10	attr	_	_
10	patients	patient	NNS	_	7	ppmod	_	_
11	following	follow	VBG	_	13	adv	_	_
12	the	the	DT	_	13	det	_	_
13	use	use	NN	_	4	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	new	new	JJ	_	17	attr	_	_
17	drug1	drug0	NN	_	13	ppmod	_	_
18	which	which	WDT	_	19	dep	_	_
19	are	be	VBP	_	17	relcl	_	_
20	capable	capable	JJ	_	19	dep	_	_
21	of	of	IN	_	22	case	_	_
22	inducing	induce	VBG	_	20	ppmod	_	_
23	CNS	cns	NN	_	24	com	_	_
24	excitability	excitability	NN	_	22	obj	_	_
25	.	.	.	_	2	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	development	development	NN	_	1	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	spontaneous	spontaneous	JJ	_	11	attr	_	_
11	motility	motility	NN	_	8	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	chick	chick	NN	_	14	com	_	_
14	embryos	embryo	NNS	_	11	ppmod	_	_
15	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	study	study	NN	_	5	ppmod	_	_
4	we	we	PRP	_	5	dep	_	_
5	investigated	investigate	VBD	_	0	root	_	_
6	whether	whether	IN	_	9	mark	_	_
7	also	also	RB	_	9	adv	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	fulfils	fulfils	NNS	_	5	comp	_	_
10	the	the	DT	_	11	det	_	_
11	function	function	NN	_	9	obj	_	_
12	as	as	IN	_	13	case	_	_
13	co-activator	co-activator	NN	_	11	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	glutamatergic	glutamatergic	JJ	_	16	attr	_	_
16	activation	activation	NN	_	11	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	NMDA	nmda	JJ	_	19	attr	_	_
19	receptors	receptor	NNS	_	16	ppmod	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	neuronal	neuronal	JJ	_	23	attr	_	_
23	apparatus	apparatus	NN	_	16	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	spontaneous	spontaneous	JJ	_	26	attr	_	_
26	motility	motility	NN	_	23	ppmod	_	_
27	in	in	IN	_	29	case	_	_
28	chick	chick	NN	_	29	com	_	_
29	embryos	embryo	NNS	_	23	ppmod	_	_
30	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	successive	successive	JJ	_	3	attr	_	_
3	application	application	NN	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	3	p	_	_
7	5	0	CD	_	12	num	_	_
8	or	or	CC	_	7	cc	_	_
9	10	0	CD	_	7	conj	_	_
10	mg/kg	mg/kg	NN	_	12	com	_	_
11	egg	egg	NN	_	12	com	_	_
12	weight	weight	NN	_	3	appo	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	e.w.	e.w.	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_

1	and	and	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	15	0	CD	_	6	num	_	_
5	mg/kg	mg/kg	NN	_	6	com	_	_
6	e.w.	e.w.	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	successive	successive	JJ	_	3	attr	_	_
3	application	application	NN	_	29	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	14	p	_	_
7	5	0	CD	_	12	num	_	_
8	or	or	CC	_	7	cc	_	_
9	10	0	CD	_	7	conj	_	_
10	mg/kg	mg/kg	NN	_	12	com	_	_
11	egg	egg	NN	_	12	com	_	_
12	weight	weight	NN	_	14	dep	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	e.w.	e.w.	NN	_	5	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	and	and	CC	_	5	cc	_	_
17	drug2	drug0	NN	_	5	conj	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	15	0	CD	_	21	num	_	_
20	mg/kg	mg/kg	NN	_	21	com	_	_
21	e.w.	e.w.	NN	_	17	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	in	in	IN	_	27	case	_	_
24	a	a	DT	_	27	det	_	_
25	10	0	CD	_	26	num	_	_
26	min	min	NN	_	27	com	_	_
27	interval	interval	NN	_	3	ppmod	_	_
28	significantly	significantly	RB	_	29	adv	_	_
29	increased	increase	VBD	_	0	root	_	_
30	the	the	DT	_	31	det	_	_
31	activation	activation	NN	_	29	obj	_	_
32	of	of	IN	_	34	case	_	_
33	spontaneous	spontaneous	JJ	_	34	attr	_	_
34	motility	motility	NN	_	31	ppmod	_	_
35	of	of	IN	_	38	case	_	_
36	17-day-old	0-day-old	JJ	_	38	attr	_	_
37	chick	chick	NN	_	38	com	_	_
38	embryos	embryo	NNS	_	34	ppmod	_	_
39	in	in	IN	_	40	case	_	_
40	comparison	comparison	NN	_	29	ppmod	_	_
41	with	with	IN	_	43	case	_	_
42	the	the	DT	_	43	det	_	_
43	effect	effect	NN	_	40	ppmod	_	_
44	of	of	IN	_	45	case	_	_
45	drug3	drug0	NN	_	43	ppmod	_	_
46	alone	alone	RB	_	45	adv	_	_
47	.	.	.	_	29	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	did	do	VBD	_	5	aux	_	_
4	not	not	RB	_	5	neg	_	_
5	depend	depend	VB	_	0	root	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	order	order	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	application	application	NN	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	drugs	drug	NNS	_	10	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	13-day-old	0-day-old	JJ	_	3	attr	_	_
3	embryos	embryo	NNS	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	was	be	VBD	_	0	root	_	_
7	ineffective	ineffective	JJ	_	6	dep	_	_
8	in	in	IN	_	10	case	_	_
9	both	both	DT	_	10	det	_	_
10	doses	dose	NNS	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	concluded	conclude	VBN	_	0	root	_	_
4	from	from	IN	_	6	case	_	_
5	these	these	DT	_	6	det	_	_
6	results	result	NNS	_	3	ppmod	_	_
7	that	that	IN	_	13	mark	_	_
8	the	the	DT	_	10	det	_	_
9	modulatory	modulatory	JJ	_	10	attr	_	_
10	effect	effect	NN	_	13	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	is	be	VBZ	_	3	comp	_	_
14	evidently	evidently	RB	_	13	adv	_	_
15	a	a	DT	_	18	det	_	_
16	later	late	JJ	_	18	attr	_	_
17	developmental	developmental	JJ	_	18	attr	_	_
18	acquisition	acquisition	NN	_	13	obj	_	_
19	(	-lrb-	-LRB-	_	13	p	_	_
20	after	after	IN	_	21	case	_	_
21	day	day	NN	_	13	ppmod	_	_
22	15	0	CD	_	21	num	_	_
23	of	of	IN	_	24	case	_	_
24	incubation	incubation	NN	_	21	ppmod	_	_
25	)	-rrb-	-RRB-	_	13	p	_	_
26	in	in	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	embryogenesis	embryogenesis	NN	_	13	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	NMDA-ergic	nmda-ergic	JJ	_	31	attr	_	_
31	activation	activation	NN	_	28	ppmod	_	_
32	of	of	IN	_	34	case	_	_
33	spontaneous	spontaneous	JJ	_	34	attr	_	_
34	motility	motility	NN	_	31	ppmod	_	_
35	in	in	IN	_	37	case	_	_
36	chick	chick	NN	_	37	com	_	_
37	embryos	embryo	NNS	_	31	ppmod	_	_
38	similarly	similarly	RB	_	41	adv	_	_
39	as	as	IN	_	41	case	_	_
40	glycinergic	glycinergic	JJ	_	41	attr	_	_
41	inhibition	inhibition	NN	_	13	ppmod	_	_
42	.	.	.	_	3	p	_	_

1	Acute	acute	JJ	_	2	attr	_	_
2	effect	effect	NN	_	0	root	_	_
3	of	of	IN	_	5	case	_	_
4	different	different	JJ	_	5	attr	_	_
5	drug1	drug0	NNS	_	2	ppmod	_	_
6	on	on	IN	_	7	case	_	_
7	glycemia	glycemia	NN	_	2	ppmod	_	_
8	in	in	IN	_	12	case	_	_
9	diabetic	diabetic	JJ	_	12	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	non-diabetic	non-diabetic	JJ	_	9	conj	_	_
12	rats	rat	NNS	_	7	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	Diabetic	diabetic	JJ	_	2	attr	_	_
2	patients	patient	NNS	_	8	dep	_	_
3	have	have	VBP	_	8	lv	_	_
4	a	a	DT	_	8	det	_	_
5	20	0	CD	_	7	num	_	_
6	%	%	NN	_	5	meta	_	_
7	higher	high	JJR	_	8	attr	_	_
8	risk	risk	NN	_	0	root	_	_
9	of	of	IN	_	10	case	_	_
10	depression	depression	NN	_	8	ppmod	_	_
11	than	than	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	general	general	JJ	_	14	attr	_	_
14	population	population	NN	_	8	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	Treatment	treatment	NN	_	6	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	can	can	MD	_	6	modal	_	_
5	directly	directly	RB	_	6	adv	_	_
6	interfere	interfere	VB	_	0	root	_	_
7	with	with	IN	_	10	case	_	_
8	blood	blood	NN	_	10	com	_	_
9	glucose	glucose	NN	_	10	com	_	_
10	levels	level	NNS	_	6	ppmod	_	_
11	or	or	CC	_	6	cc	_	_
12	may	may	MD	_	13	modal	_	_
13	interact	interact	VB	_	6	conj	_	_
14	with	with	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	treatment	treatment	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	depression	depression	NN	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	diabetic	diabetic	JJ	_	7	attr	_	_
7	patients	patient	NNS	_	2	ppmod	_	_
8	must	must	MD	_	9	modal	_	_
9	take	take	VB	_	0	root	_	_
10	into	into	IN	_	11	mark	_	_
11	account	account	VBP	_	9	comp	_	_
12	variations	variation	NNS	_	11	obj	_	_
13	of	of	IN	_	15	case	_	_
14	glycemic	glycemic	JJ	_	15	attr	_	_
15	levels	level	NNS	_	12	ppmod	_	_
16	at	at	IN	_	18	case	_	_
17	different	different	JJ	_	18	attr	_	_
18	times	time	NNS	_	11	ppmod	_	_
19	and	and	CC	_	9	cc	_	_
20	a	a	DT	_	21	det	_	_
21	comparison	comparison	NN	_	26	dep	_	_
22	of	of	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	available	available	JJ	_	25	attr	_	_
25	drug1	drug0	NN	_	21	ppmod	_	_
26	is	be	VBZ	_	9	conj	_	_
27	important	important	JJ	_	26	dep	_	_
28	.	.	.	_	9	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	6	ppmod	_	_
5	we	we	PRP	_	6	dep	_	_
6	evaluated	evaluate	VBD	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	interference	interference	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	blood	blood	NN	_	14	com	_	_
13	glucose	glucose	NN	_	14	com	_	_
14	levels	level	NNS	_	8	ppmod	_	_
15	of	of	IN	_	19	case	_	_
16	diabetic	diabetic	JJ	_	19	attr	_	_
17	and	and	CC	_	16	cc	_	_
18	non-diabetic	non-diabetic	JJ	_	16	conj	_	_
19	rats	rat	NNS	_	14	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	In	in	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	first	#ord#	JJ	_	4	attr	_	_
4	experiment	experiment	NN	_	11	ppmod	_	_
5	,	,	,	_	11	p	_	_
6	male	male	JJ	_	9	attr	_	_
7	adult	adult	JJ	_	9	attr	_	_
8	Wistar	wistar	NN	_	9	com	_	_
9	rats	rat	NNS	_	11	dep	_	_
10	were	be	VBD	_	11	aux	_	_
11	fasted	fast	VBN	_	0	root	_	_
12	for	for	IN	_	14	case	_	_
13	12	0	CD	_	14	num	_	_
14	h	h	NN	_	11	ppmod	_	_
15	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	32	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	5	0	CD	_	4	num	_	_
4	mg/kg	mg/kg	NN	_	1	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	,	,	,	_	1	p	_	_
7	drug2	drug0	NN	_	1	conj	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	30	0	CD	_	10	num	_	_
10	mg/kg	mg/kg	NN	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	7	p	_	_
13	drug3	drug0	NN	_	1	conj	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	0.25	0	CD	_	16	num	_	_
16	mg/kg	mg/kg	NN	_	13	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	,	,	,	_	13	p	_	_
19	drug4	drug0	JJ	_	24	attr	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	20	0	CD	_	22	num	_	_
22	mg/kg	mg/kg	NN	_	19	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	drug5	drug0	NN	_	1	conj	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	30	0	CD	_	27	num	_	_
27	mg/kg	mg/kg	NN	_	24	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	or	or	CC	_	24	cc	_	_
30	vehicle	vehicle	NN	_	1	conj	_	_
31	was	be	VBD	_	32	aux	_	_
32	administered	administer	VBN	_	0	root	_	_
33	.	.	.	_	32	p	_	_

1	After	after	IN	_	3	case	_	_
2	30	0	CD	_	3	num	_	_
3	min	min	NN	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	fasting	fasting	JJ	_	6	attr	_	_
6	glycemia	glycemia	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	measured	measure	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	An	an	DT	_	4	det	_	_
2	oral	oral	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	overload	overload	NN	_	15	dep	_	_
5	of	of	IN	_	7	case	_	_
6	1	0	CD	_	7	num	_	_
7	ml	ml	NN	_	4	ppmod	_	_
8	of	of	IN	_	13	case	_	_
9	a	a	DT	_	13	det	_	_
10	50	0	CD	_	13	num	_	_
11	%	%	NN	_	10	meta	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	solution	solution	NN	_	7	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	given	give	VBN	_	0	root	_	_
16	to	to	TO	_	17	aux	_	_
17	rats	rat	NNS	_	15	ppmod	_	_
18	and	and	CC	_	15	cc	_	_
19	blood	blood	NN	_	20	com	_	_
20	glucose	glucose	NN	_	22	dep	_	_
21	was	be	VBD	_	22	aux	_	_
22	determined	determine	VBN	_	15	conj	_	_
23	after	after	IN	_	29	case	_	_
24	30	0	CD	_	29	num	_	_
25	,	,	,	_	24	p	_	_
26	60	0	CD	_	24	conj	_	_
27	and	and	CC	_	26	cc	_	_
28	90	0	CD	_	24	conj	_	_
29	min	min	NN	_	22	ppmod	_	_
30	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	did	do	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	change	change	VB	_	0	root	_	_
7	fasting	fasting	NN	_	6	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	overload	overload	NN	_	10	com	_	_
10	glycemia	glycemia	NN	_	7	conj	_	_
11	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	increased	increase	VBD	_	0	root	_	_
5	blood	blood	NN	_	6	com	_	_
6	drug3	drug0	NN	_	4	obj	_	_
7	at	at	IN	_	9	case	_	_
8	different	different	JJ	_	9	attr	_	_
9	times	time	NNS	_	4	ppmod	_	_
10	after	after	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	glucose	glucose	NN	_	13	com	_	_
13	overload	overload	NN	_	9	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	neutralized	neutralize	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	increase	increase	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	glycemia	glycemia	NN	_	4	ppmod	_	_
7	induced	induce	VBN	_	4	acl	_	_
8	by	by	IN	_	11	case	_	_
9	oral	oral	JJ	_	11	attr	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	overload	overload	NN	_	7	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	second	#ord#	JJ	_	4	attr	_	_
4	experiment	experiment	NN	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	non-diabetic	non-diabetic	JJ	_	10	attr	_	_
7	and	and	CC	_	10	cc	_	_
8	streptozotocin-induced	streptozotocin-induced	JJ	_	10	attr	_	_
9	diabetic	diabetic	JJ	_	10	attr	_	_
10	rats	rat	NNS	_	12	dep	_	_
11	were	be	VBD	_	12	aux	_	_
12	fasted	fast	VBN	_	0	root	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	the	the	DT	_	17	det	_	_
16	same	same	JJ	_	17	attr	_	_
17	procedures	procedure	NNS	_	19	dep	_	_
18	were	be	VBD	_	19	aux	_	_
19	followed	followed	VBN	_	12	conj	_	_
20	for	for	IN	_	21	case	_	_
21	estimation	estimation	NN	_	19	ppmod	_	_
22	of	of	IN	_	26	case	_	_
23	drug1	drug0	NN	_	26	attr	_	_
24	tolerance	tolerance	NN	_	26	attr	_	_
25	30	0	CD	_	26	num	_	_
26	min	min	NN	_	21	ppmod	_	_
27	after	after	IN	_	29	case	_	_
28	drug2	drug0	NN	_	29	com	_	_
29	overload	overload	NN	_	26	ppmod	_	_
30	.	.	.	_	12	p	_	_

1	Again	again	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	neutralized	neutralize	VBD	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	increase	increase	NN	_	4	obj	_	_
7	in	in	IN	_	8	case	_	_
8	glycemia	glycemia	NN	_	6	ppmod	_	_
9	after	after	IN	_	11	case	_	_
10	drug2	drug0	NN	_	11	com	_	_
11	overload	overload	NN	_	6	ppmod	_	_
12	both	both	CC	_	11	cc	_	_
13	in	in	IN	_	17	case	_	_
14	diabetic	diabetic	JJ	_	17	attr	_	_
15	and	and	CC	_	14	cc	_	_
16	non-diabetic	non-diabetic	JJ	_	14	conj	_	_
17	rats	rat	NNS	_	11	conj	_	_
18	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	raise	raise	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	question	question	NN	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	whether	whether	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	is	be	VBZ	_	5	ppmod	_	_
10	the	the	DT	_	12	det	_	_
11	best	good	JJS	_	12	attr	_	_
12	choice	choice	NN	_	9	obj	_	_
13	for	for	IN	_	15	case	_	_
14	prolonged	prolonged	JJ	_	15	attr	_	_
15	use	use	NN	_	12	ppmod	_	_
16	for	for	IN	_	18	case	_	_
17	diabetic	diabetic	JJ	_	18	attr	_	_
18	individuals	individual	NNS	_	15	ppmod	_	_
19	,	,	,	_	9	p	_	_
20	because	because	IN	_	24	case	_	_
21	of	of	IN	_	24	case	_	_
22	its	its	PRP$	_	24	poss	_	_
23	antihyperglycemic	antihyperglycemic	JJ	_	24	attr	_	_
24	effects	effect	NNS	_	9	ppmod	_	_
25	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	would	would	MD	_	3	modal	_	_
3	be	be	VB	_	0	root	_	_
4	useful	useful	JJ	_	3	dep	_	_
5	in	in	IN	_	6	case	_	_
6	cases	case	NNS	_	4	ppmod	_	_
7	with	with	IN	_	9	case	_	_
8	potential	potential	JJ	_	9	attr	_	_
9	risk	risk	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	hypoglycemia	hypoglycemia	NN	_	9	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	promotes	promote	VBZ	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	translocation	translocation	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	phosphatidate	phosphatidate	NN	_	7	com	_	_
7	phosphohydrolase	phosphohydrolase	NN	_	4	ppmod	_	_
8	from	from	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	cytosol	cytosol	NN	_	4	ppmod	_	_
11	to	to	TO	_	14	aux	_	_
12	the	the	DT	_	14	det	_	_
13	microsomal	microsomal	JJ	_	14	attr	_	_
14	fraction	fraction	NN	_	4	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	rat	rat	NN	_	17	com	_	_
17	liver	liver	NN	_	14	ppmod	_	_
18	and	and	CC	_	2	cc	_	_
19	it	it	PRP	_	20	dep	_	_
20	enhances	enhance	VBZ	_	2	conj	_	_
21	the	the	DT	_	22	det	_	_
22	effects	effect	NNS	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	oleate	oleate	NN	_	22	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	this	this	DT	_	27	det	_	_
27	respect	respect	NN	_	22	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	0.5-2	0	NN	_	4	num	_	_
4	mM	mm	NN	_	1	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	promoted	promote	VBD	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	translocation	translocation	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	phosphatidate	phosphatidate	NN	_	11	com	_	_
11	phosphohydrolase	phosphohydrolase	NN	_	8	ppmod	_	_
12	from	from	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	soluble	soluble	JJ	_	8	ppmod	_	_
15	to	to	TO	_	18	aux	_	_
16	the	the	DT	_	18	det	_	_
17	microsomal	microsomal	JJ	_	18	attr	_	_
18	fraction	fraction	NN	_	8	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	a	a	DT	_	22	det	_	_
21	cell-free	cell-free	JJ	_	22	attr	_	_
22	system	system	NN	_	6	ppmod	_	_
23	derived	derive	VBN	_	22	acl	_	_
24	from	from	IN	_	26	case	_	_
25	rat	rat	NN	_	26	com	_	_
26	liver	liver	NN	_	23	ppmod	_	_
27	.	.	.	_	6	p	_	_

1	By	by	IN	_	2	case	_	_
2	contrast	contrast	NN	_	15	ppmod	_	_
3	,	,	,	_	15	p	_	_
4	drug1	drug0	NN	_	15	dep	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	1	0	CD	_	7	num	_	_
7	mM	mm	NN	_	4	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	and	and	CC	_	4	cc	_	_
10	drug2	drug0	NN	_	4	conj	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	1	0	CD	_	13	num	_	_
13	mM	mm	NN	_	10	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	had	have	VBD	_	0	root	_	_
16	no	no	DT	_	18	det	_	_
17	significant	significant	JJ	_	18	attr	_	_
18	effect	effect	NN	_	15	obj	_	_
19	on	on	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	translocation	translocation	NN	_	15	ppmod	_	_
22	when	when	WRB	_	23	adv	_	_
23	added	add	VBN	_	21	relcl	_	_
24	alone	alone	RB	_	23	adv	_	_
25	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	and	and	CC	_	1	cc	_	_
4	to	to	TO	_	7	aux	_	_
5	a	a	DT	_	7	det	_	_
6	lesser	less	JJR	_	7	attr	_	_
7	extent	extent	NN	_	1	ppmod	_	_
8	,	,	,	_	1	p	_	_
9	drug2	drug0	NN	_	1	conj	_	_
10	,	,	,	_	9	p	_	_
11	enhanced	enhance	VBD	_	0	root	_	_
12	the	the	DT	_	14	det	_	_
13	translocating	translocating	NN	_	14	com	_	_
14	action	action	NN	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	oleate	oleate	NN	_	14	ppmod	_	_
17	and	and	CC	_	11	cc	_	_
18	increased	increase	VBD	_	11	conj	_	_
19	its	its	PRP$	_	20	poss	_	_
20	effectiveness	effectiveness	NN	_	18	obj	_	_
21	in	in	IN	_	22	case	_	_
22	transferring	transfer	VBG	_	20	ppmod	_	_
23	the	the	DT	_	24	det	_	_
24	phosphohydrolase	phosphohydrolase	NN	_	22	obj	_	_
25	from	from	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	soluble	soluble	JJ	_	24	ppmod	_	_
28	to	to	TO	_	31	aux	_	_
29	the	the	DT	_	31	det	_	_
30	microsomal	microsomal	JJ	_	31	attr	_	_
31	fraction	fraction	NN	_	24	ppmod	_	_
32	.	.	.	_	11	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	proposed	propose	VBN	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	the	the	DT	_	6	det	_	_
6	phosphohydrolase	phosphohydrolase	NN	_	7	dep	_	_
7	becomes	become	VBZ	_	3	advcl	_	_
8	metabolically	metabolically	RB	_	9	adv	_	_
9	active	active	JJ	_	7	dep	_	_
10	when	when	WRB	_	12	adv	_	_
11	it	it	PRP	_	12	dep	_	_
12	combines	combine	VBZ	_	7	comp	_	_
13	with	with	IN	_	14	case	_	_
14	membranes	membrane	NNS	_	12	ppmod	_	_
15	and	and	CC	_	7	cc	_	_
16	that	that	IN	_	19	mark	_	_
17	polyamines	polyamines	NNS	_	19	dep	_	_
18	might	might	MD	_	19	modal	_	_
19	help	help	VB	_	7	conj	_	_
20	to	to	TO	_	21	aux	_	_
21	regulate	regulate	VB	_	19	comp	_	_
22	this	this	DT	_	23	det	_	_
23	interaction	interaction	NN	_	21	obj	_	_
24	.	.	.	_	3	p	_	_

1	This	this	DT	_	3	dep	_	_
2	could	could	MD	_	3	modal	_	_
3	facilitate	facilitate	VB	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	action	action	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	fatty	fatty	JJ	_	8	attr	_	_
8	acids	acid	NNS	_	5	ppmod	_	_
9	and	and	CC	_	3	cc	_	_
10	enable	enable	VB	_	3	conj	_	_
11	cells	cell	NNS	_	10	obj	_	_
12	to	to	TO	_	13	aux	_	_
13	increase	increase	VB	_	3	comp	_	_
14	their	their	PRP$	_	15	poss	_	_
15	capacity	capacity	NN	_	13	obj	_	_
16	for	for	IN	_	18	case	_	_
17	triacylglycerol	triacylglycerol	NN	_	18	com	_	_
18	synthesis	synthesis	NN	_	15	ppmod	_	_
19	to	to	TO	_	20	aux	_	_
20	match	match	VBP	_	15	acl	_	_
21	an	an	DT	_	23	det	_	_
22	increased	increase	VBN	_	23	attr	_	_
23	availability	availability	NN	_	20	obj	_	_
24	of	of	IN	_	26	case	_	_
25	fatty	fatty	JJ	_	26	attr	_	_
26	acids	acid	NNS	_	23	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	of	of	IN	_	8	case	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	anesthesia	anesthesia	NN	_	4	conj	_	_
9	on	on	IN	_	11	case	_	_
10	drug3	drug0	NN	_	11	com	_	_
11	tolerance	tolerance	NN	_	2	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	dogs	dog	NNS	_	11	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	In	in	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	comparison	comparison	NN	_	22	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	tolerance	tolerance	NN	_	3	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	dogs	dog	NNS	_	6	ppmod	_	_
9	anesthetized	anesthetize	VBN	_	8	acl	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	drug4	drug0	NN	_	11	conj	_	_
17	,	,	,	_	22	p	_	_
18	the	the	DT	_	19	det	_	_
19	dosage	dosage	NN	_	22	dep	_	_
20	of	of	IN	_	21	case	_	_
21	drug5	drug0	NN	_	19	ppmod	_	_
22	needed	need	VBD	_	0	root	_	_
23	to	to	TO	_	24	aux	_	_
24	cause	cause	VB	_	22	comp	_	_
25	ventricular	ventricular	JJ	_	26	attr	_	_
26	tachycardia	tachycardia	NN	_	24	obj	_	_
27	was	be	VBD	_	26	acl	_	_
28	significantly	significantly	RB	_	29	adv	_	_
29	higher	high	JJR	_	27	dep	_	_
30	,	,	,	_	27	p	_	_
31	as	as	IN	_	32	mark	_	_
32	was	be	VBD	_	27	comp	_	_
33	the	the	DT	_	34	det	_	_
34	LD50	ld0	NN	_	32	obj	_	_
35	of	of	IN	_	36	case	_	_
36	drug6	drug0	NN	_	34	ppmod	_	_
37	,	,	,	_	27	p	_	_
38	with	with	IN	_	39	case	_	_
39	drug7	drug0	NN	_	27	ppmod	_	_
40	or	or	CC	_	39	cc	_	_
41	drug8	drug0	NN	_	39	conj	_	_
42	than	than	IN	_	44	case	_	_
43	with	with	IN	_	44	case	_	_
44	drug9	drug0	NN	_	24	ppmod	_	_
45	.	.	.	_	22	p	_	_

1	Ventricular	ventricular	JJ	_	2	attr	_	_
2	tachycardia	tachycardia	NN	_	8	dep	_	_
3	induced	induce	VBN	_	2	acl	_	_
4	by	by	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	was	be	VBD	_	8	aux	_	_
7	generally	generally	RB	_	8	adv	_	_
8	converted	convert	VBN	_	0	root	_	_
9	to	to	TO	_	11	aux	_	_
10	sinus	sinus	NN	_	11	com	_	_
11	rhythm	rhythm	NN	_	8	ppmod	_	_
12	following	follow	VBG	_	13	adv	_	_
13	administration	administration	NN	_	8	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	drug3	drug0	NN	_	15	conj	_	_
18	,	,	,	_	17	p	_	_
19	or	or	CC	_	17	cc	_	_
20	drug4	drug0	NN	_	15	conj	_	_
21	but	but	CC	_	13	cc	_	_
22	not	not	RB	_	24	neg	_	_
23	after	after	IN	_	24	case	_	_
24	administration	administration	NN	_	13	conj	_	_
25	of	of	IN	_	26	case	_	_
26	drug5	drug0	NN	_	24	ppmod	_	_
27	alone	alone	RB	_	26	adv	_	_
28	or	or	CC	_	27	cc	_	_
29	after	after	IN	_	30	case	_	_
30	drug6	drug0	NN	_	27	conj	_	_
31	.	.	.	_	8	p	_	_

1	Excretion	excretion	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	thioethers	thioethers	NNS	_	1	ppmod	_	_
4	in	in	IN	_	5	case	_	_
5	urine	urine	NN	_	1	ppmod	_	_
6	after	after	IN	_	7	case	_	_
7	exposure	exposure	NN	_	1	ppmod	_	_
8	to	to	TO	_	10	aux	_	_
9	electrophilic	electrophilic	JJ	_	10	attr	_	_
10	chemicals	chemical	NNS	_	7	ppmod	_	_
11	.	.	.	_	1	p	_	_

1	Electrophilic	electrophilic	JJ	_	5	attr	_	_
2	agents--a	agents--a	NN	_	5	attr	_	_
3	class	class	NN	_	5	attr	_	_
4	of	of	IN	_	5	case	_	_
5	chemicals	chemical	NNS	_	12	dep	_	_
6	that	that	WDT	_	7	dep	_	_
7	includes	include	VBZ	_	5	relcl	_	_
8	most	most	RBS	_	9	adv	_	_
9	genotoxic	genotoxic	JJ	_	10	attr	_	_
10	compounds--can	compounds--can	NN	_	7	obj	_	_
11	be	be	VB	_	12	aux	_	_
12	inactivated	inactivate	VBN	_	0	root	_	_
13	by	by	IN	_	14	case	_	_
14	reaction	reaction	NN	_	12	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	glutathione	glutathione	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	other	other	JJ	_	20	attr	_	_
19	SH-bearing	sh-bearing	JJ	_	20	attr	_	_
20	molecules	molecule	NNS	_	16	conj	_	_
21	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	conjugates	conjugate	NNS	_	6	dep	_	_
3	so	so	RB	_	4	adv	_	_
4	formed	form	VBN	_	2	acl	_	_
5	often	often	RB	_	6	adv	_	_
6	appear	appear	VBP	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	urine	urine	NN	_	6	ppmod	_	_
10	as	as	IN	_	12	case	_	_
11	mercapturic	mercapturic	JJ	_	12	attr	_	_
12	acids	acid	NNS	_	6	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	other	other	JJ	_	16	attr	_	_
15	thioether	thioether	NN	_	16	com	_	_
16	products	product	NNS	_	12	conj	_	_
17	.	.	.	_	6	p	_	_

1	This	this	DT	_	2	det	_	_
2	paper	paper	NN	_	4	dep	_	_
3	critically	critically	RB	_	4	adv	_	_
4	reviews	review	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	suitability	suitability	NN	_	4	obj	_	_
7	of	of	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	urinary	urinary	JJ	_	11	attr	_	_
10	thioether	thioether	NN	_	11	com	_	_
11	assay	assay	NN	_	6	ppmod	_	_
12	as	as	IN	_	14	case	_	_
13	a	a	DT	_	14	det	_	_
14	method	method	NN	_	4	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	detection	detection	NN	_	14	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	exposure	exposure	NN	_	17	ppmod	_	_
20	to	to	TO	_	22	aux	_	_
21	electrophilic	electrophilic	JJ	_	22	attr	_	_
22	agents	agent	NNS	_	19	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	their	their	PRP$	_	25	poss	_	_
25	precursors	precursor	NNS	_	22	conj	_	_
26	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	practice	practice	NN	_	11	ppmod	_	_
3	,	,	,	_	11	p	_	_
4	the	the	DT	_	6	det	_	_
5	greatest	great	JJS	_	6	attr	_	_
6	value	value	NN	_	11	dep	_	_
7	of	of	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	thioether	thioether	NN	_	10	com	_	_
10	assay	assay	NN	_	6	ppmod	_	_
11	appears	appear	VBZ	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	lie	lie	VBP	_	11	comp	_	_
14	in	in	IN	_	17	case	_	_
15	its	its	PRP$	_	17	poss	_	_
16	signal	signal	NN	_	17	com	_	_
17	function	function	NN	_	13	ppmod	_	_
18	.	.	.	_	11	p	_	_

1	This	this	DT	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	demonstrated	demonstrate	VBN	_	0	root	_	_
4	for	for	IN	_	6	case	_	_
5	cigarette	cigarette	JJ	_	6	attr	_	_
6	smokers	smoker	NNS	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	industrial	industrial	JJ	_	9	attr	_	_
9	workers	worker	NNS	_	6	conj	_	_
10	involved	involve	VBN	_	6	acl	_	_
11	in	in	IN	_	14	case	_	_
12	chemical	chemical	JJ	_	14	attr	_	_
13	waste	waste	NN	_	14	com	_	_
14	incineration	incineration	NN	_	10	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Whenever	whenever	RB	_	6	adv	_	_
2	increased	increase	VBN	_	4	attr	_	_
3	thioether	thioether	NN	_	4	com	_	_
4	excretion	excretion	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	observed	observe	VBN	_	9	advcl	_	_
7	,	,	,	_	9	p	_	_
8	it	it	PRP	_	9	dep	_	_
9	is	be	VBZ	_	0	root	_	_
10	likely	likely	JJ	_	9	dep	_	_
11	to	to	TO	_	12	aux	_	_
12	be	be	VB	_	10	comp	_	_
13	due	due	JJ	_	12	dep	_	_
14	to	to	TO	_	15	aux	_	_
15	exposure	exposure	NN	_	13	ppmod	_	_
16	to	to	TO	_	21	aux	_	_
17	one	#crd#	CD	_	21	num	_	_
18	or	or	CC	_	17	cc	_	_
19	more	more	JJR	_	17	conj	_	_
20	suspect	suspect	NN	_	21	com	_	_
21	compounds	compound	NNS	_	15	ppmod	_	_
22	.	.	.	_	9	p	_	_

1	However	however	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	when	when	WRB	_	7	adv	_	_
4	the	the	DT	_	6	det	_	_
5	thioether	thioether	NN	_	6	com	_	_
6	concentration	concentration	NN	_	7	dep	_	_
7	ranges	range	VBZ	_	19	advcl	_	_
8	within	within	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	limits	limit	NNS	_	7	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	normal	normal	JJ	_	14	attr	_	_
14	value	value	NN	_	10	ppmod	_	_
15	,	,	,	_	19	p	_	_
16	one	#crd#	PRP	_	19	dep	_	_
17	must	must	MD	_	19	modal	_	_
18	not	not	RB	_	19	neg	_	_
19	conclude	conclude	VB	_	0	root	_	_
20	that	that	IN	_	22	mark	_	_
21	there	there	EX	_	22	dep	_	_
22	is	be	VBZ	_	19	comp	_	_
23	no	no	DT	_	22	obj	_	_
24	,	,	,	_	23	p	_	_
25	or	or	CC	_	23	cc	_	_
26	negligible	negligible	JJ	_	23	conj	_	_
27	,	,	,	_	23	p	_	_
28	exposure	exposure	NN	_	23	appo	_	_
29	.	.	.	_	19	p	_	_

1	More	more	RBR	_	2	adv	_	_
2	specific	specific	JJ	_	3	attr	_	_
3	applications	application	NNS	_	12	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	assay	assay	NN	_	3	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	thio	thio	NN	_	9	com	_	_
9	compounds	compound	NNS	_	6	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	urine	urine	NN	_	3	ppmod	_	_
12	allow	allow	VBP	_	0	root	_	_
13	development	development	NN	_	12	obj	_	_
14	of	of	IN	_	16	case	_	_
15	selective	selective	JJ	_	16	attr	_	_
16	methods	method	NNS	_	13	ppmod	_	_
17	that	that	WDT	_	19	dep	_	_
18	may	may	MD	_	19	modal	_	_
19	be	be	VB	_	16	relcl	_	_
20	useful	useful	JJ	_	19	dep	_	_
21	for	for	IN	_	23	case	_	_
22	biological	biological	JJ	_	23	attr	_	_
23	monitoring	monitoring	NN	_	20	ppmod	_	_
24	.	.	.	_	12	p	_	_

1	Rhabdomyolysis	rhabdomyolysis	NN	_	2	dep	_	_
2	secondary	secondary	JJ	_	0	root	_	_
3	to	to	TO	_	6	aux	_	_
4	a	a	DT	_	6	det	_	_
5	drug	drug	NN	_	6	com	_	_
6	interaction	interaction	NN	_	2	ppmod	_	_
7	between	between	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	.	.	.	_	2	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	To	to	TO	_	4	aux	_	_
4	report	report	VBP	_	1	acl	_	_
5	a	a	DT	_	6	det	_	_
6	case	case	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	rhabdomyolysis	rhabdomyolysis	NN	_	6	ppmod	_	_
9	resulting	result	VBG	_	8	acl	_	_
10	from	from	IN	_	12	case	_	_
11	concomitant	concomitant	JJ	_	12	attr	_	_
12	use	use	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	.	.	.	_	1	p	_	_

1	CASE	case	NN	_	2	com	_	_
2	SUMMARY	summary	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	A	a	DT	_	7	det	_	_
5	64-year-old	0-year-old	JJ	_	7	attr	_	_
6	African-American	african-american	NN	_	7	com	_	_
7	man	man	NN	_	9	dep	_	_
8	was	be	VBD	_	9	aux	_	_
9	admitted	admit	VBN	_	2	acl	_	_
10	to	to	TO	_	12	aux	_	_
11	the	the	DT	_	12	det	_	_
12	hospital	hospital	NN	_	9	ppmod	_	_
13	for	for	IN	_	16	case	_	_
14	worsening	worsening	JJ	_	16	attr	_	_
15	renal	renal	JJ	_	16	attr	_	_
16	failure	failure	NN	_	9	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	elevated	elevated	JJ	_	20	attr	_	_
19	creatine	creatine	NN	_	20	com	_	_
20	phosphokinase	phosphokinase	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	diffuse	diffuse	JJ	_	24	attr	_	_
23	muscle	muscle	NN	_	24	com	_	_
24	pain	pain	NN	_	16	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	severe	severe	JJ	_	29	attr	_	_
28	muscle	muscle	NN	_	29	com	_	_
29	weakness	weakness	NN	_	16	conj	_	_
30	.	.	.	_	2	p	_	_

1	About	about	IN	_	3	case	_	_
2	three	#crd#	CD	_	3	num	_	_
3	weeks	week	NNS	_	11	ppmod	_	_
4	prior	prior	JJ	_	3	attr	_	_
5	to	to	TO	_	6	aux	_	_
6	admission	admission	NN	_	4	ppmod	_	_
7	,	,	,	_	11	p	_	_
8	the	the	DT	_	9	det	_	_
9	patient	patient	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	started	start	VBN	_	0	root	_	_
12	on	on	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	for	for	IN	_	15	case	_	_
15	sinusitis	sinusitis	NN	_	13	ppmod	_	_
16	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	patient	patient	NN	_	5	dep	_	_
3	had	have	VBD	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	receiving	receive	VBG	_	0	root	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	for	for	IN	_	10	case	_	_
8	approximately	approximately	RB	_	9	adv	_	_
9	six	#crd#	CD	_	10	num	_	_
10	months	month	NNS	_	6	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	He	he	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	treated	treat	VBN	_	0	root	_	_
4	aggressively	aggressively	RB	_	3	adv	_	_
5	with	with	IN	_	7	case	_	_
6	intravenous	intravenous	JJ	_	7	attr	_	_
7	hydration	hydration	NN	_	3	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug1	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	hemodialysis	hemodialysis	NN	_	7	conj	_	_
13	.	.	.	_	3	p	_	_

1	A	a	DT	_	3	det	_	_
2	muscle	muscle	NN	_	3	com	_	_
3	biopsy	biopsy	NN	_	4	dep	_	_
4	revealed	reveal	VBD	_	0	root	_	_
5	necrotizing	necrotizing	JJ	_	6	attr	_	_
6	myopathy	myopathy	NN	_	4	obj	_	_
7	secondary	secondary	JJ	_	6	attr	_	_
8	to	to	TO	_	10	aux	_	_
9	a	a	DT	_	10	det	_	_
10	toxin	toxin	NN	_	7	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	patient	patient	NN	_	3	dep	_	_
3	continued	continue	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	receive	receive	VBP	_	3	comp	_	_
6	intermittent	intermittent	JJ	_	7	attr	_	_
7	hemodialysis	hemodialysis	NN	_	5	obj	_	_
8	until	until	IN	_	10	case	_	_
9	his	his	NN	_	10	com	_	_
10	death	death	NN	_	5	ppmod	_	_
11	from	from	IN	_	13	case	_	_
12	infectious	infectious	JJ	_	13	attr	_	_
13	complications	complication	NNS	_	10	ppmod	_	_
14	that	that	WDT	_	15	dep	_	_
15	occurred	occur	VBD	_	13	relcl	_	_
16	three	#crd#	CD	_	17	num	_	_
17	months	month	NNS	_	15	obj	_	_
18	after	after	IN	_	19	case	_	_
19	admission	admission	NN	_	15	ppmod	_	_
20	.	.	.	_	3	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	several	several	JJ	_	4	attr	_	_
4	factors	factor	NNS	_	2	obj	_	_
5	that	that	WDT	_	10	dep	_	_
6	could	could	MD	_	10	modal	_	_
7	have	have	VBP	_	10	lv	_	_
8	increased	increase	VBN	_	10	attr	_	_
9	his	his	NN	_	10	com	_	_
10	risk	risk	NN	_	4	relcl	_	_
11	for	for	IN	_	12	case	_	_
12	developing	develop	VBG	_	10	ppmod	_	_
13	rhabdomyolysis	rhabdomyolysis	NN	_	12	obj	_	_
14	,	,	,	_	13	p	_	_
15	including	include	VBG	_	18	adv	_	_
16	chronic	chronic	JJ	_	18	attr	_	_
17	renal	renal	JJ	_	18	attr	_	_
18	failure	failure	NN	_	13	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	DISCUSSION	discussion	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	a	a	DT	_	7	det	_	_
6	potent	potent	JJ	_	7	attr	_	_
7	inhibitor	inhibitor	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	CYP3A4	cyp0a0	NN	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	the	the	DT	_	13	det	_	_
12	major	major	JJ	_	13	attr	_	_
13	enzyme	enzyme	NN	_	7	appo	_	_
14	responsible	responsible	JJ	_	13	attr	_	_
15	for	for	IN	_	17	case	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	metabolism	metabolism	NN	_	14	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	other	other	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	5	conj	_	_
9	have	have	VBP	_	0	root	_	_
10	resulted	result	VBD	_	9	comp	_	_
11	in	in	IN	_	13	case	_	_
12	previous	previous	JJ	_	13	attr	_	_
13	reports	report	NNS	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	rhabdomyolysis	rhabdomyolysis	NN	_	13	ppmod	_	_
16	.	.	.	_	9	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	factors	factor	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	increase	increase	VB	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	risk	risk	NN	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	this	this	DT	_	10	det	_	_
9	drug	drug	NN	_	10	com	_	_
10	interaction	interaction	NN	_	6	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	including	include	VBG	_	14	adv	_	_
13	the	the	DT	_	14	det	_	_
14	administration	administration	NN	_	6	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	other	other	JJ	_	17	attr	_	_
17	medications	medication	NNS	_	14	ppmod	_	_
18	that	that	WDT	_	20	dep	_	_
19	are	be	VBP	_	20	aux	_	_
20	associated	associate	VBN	_	17	relcl	_	_
21	with	with	IN	_	22	case	_	_
22	myopathy	myopathy	NN	_	20	ppmod	_	_
23	,	,	,	_	20	p	_	_
24	underlying	underlie	VBG	_	20	comp	_	_
25	renal	renal	JJ	_	26	attr	_	_
26	insufficiency	insufficiency	NN	_	24	obj	_	_
27	,	,	,	_	14	p	_	_
28	and	and	CC	_	14	cc	_	_
29	administration	administration	NN	_	14	conj	_	_
30	of	of	IN	_	32	case	_	_
31	high	high	JJ	_	32	attr	_	_
32	doses	dose	NNS	_	29	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug1	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	4	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	inhibit	inhibit	VBP	_	1	acl	_	_
5	the	the	DT	_	6	det	_	_
6	metabolism	metabolism	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NNS	_	6	ppmod	_	_
9	that	that	WDT	_	11	dep	_	_
10	are	be	VBP	_	11	aux	_	_
11	metabolized	metabolize	VBN	_	8	relcl	_	_
12	by	by	IN	_	13	case	_	_
13	CYP3A4	cyp0a0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	i.e.	i.e.	FW	_	17	ppmod	_	_
16	,	,	,	_	17	p	_	_
17	drug3	drug0	NN	_	11	prn	_	_
18	,	,	,	_	17	p	_	_
19	drug4	drug0	NN	_	17	appo	_	_
20	,	,	,	_	17	p	_	_
21	drug5	drug0	NN	_	17	appo	_	_
22	,	,	,	_	17	p	_	_
23	drug6	drug0	NN	_	17	appo	_	_
24	)	-rrb-	-RRB-	_	17	p	_	_
25	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	result	result	VB	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	myopathy	myopathy	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	rhabdomyolysis	rhabdomyolysis	NN	_	6	conj	_	_
9	,	,	,	_	4	p	_	_
10	particularly	particularly	RB	_	12	adv	_	_
11	in	in	IN	_	12	case	_	_
12	patients	patient	NNS	_	4	ppmod	_	_
13	with	with	IN	_	15	case	_	_
14	renal	renal	JJ	_	15	attr	_	_
15	insufficiency	insufficiency	NN	_	12	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	those	those	DT	_	15	conj	_	_
18	who	who	WP	_	22	dep	_	_
19	are	be	VBP	_	22	aux	_	_
20	concurrently	concurrently	RB	_	22	adv	_	_
21	taking	take	VBG	_	22	lv	_	_
22	medications	medication	NNS	_	17	relcl	_	_
23	associated	associate	VBN	_	22	acl	_	_
24	with	with	IN	_	25	case	_	_
25	myopathy	myopathy	NN	_	23	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	Optimal	optimal	JJ	_	2	attr	_	_
2	designs	design	NNS	_	0	root	_	_
3	for	for	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	individual	individual	NN	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	joint	joint	NN	_	12	attr	_	_
8	exposure	exposure	NN	_	12	attr	_	_
9	general	general	JJ	_	12	attr	_	_
10	logistic	logistic	JJ	_	12	attr	_	_
11	regression	regression	NN	_	12	com	_	_
12	models	model	NNS	_	5	conj	_	_
13	.	.	.	_	2	p	_	_

1	Interest	interest	NN	_	7	dep	_	_
2	in	in	IN	_	4	case	_	_
3	administering	administer	VBG	_	4	attr	_	_
4	compounds	compound	NNS	_	1	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	combination	combination	NN	_	1	ppmod	_	_
7	lies	lie	VBZ	_	0	root	_	_
8	both	both	CC	_	10	cc	_	_
9	in	in	IN	_	10	case	_	_
10	enhancing	enhance	VBG	_	7	ppmod	_	_
11	efficacious	efficacious	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	10	obj	_	_
13	and	and	CC	_	10	cc	_	_
14	in	in	IN	_	15	case	_	_
15	limiting	limit	VBG	_	10	conj	_	_
16	adverse	adverse	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	15	obj	_	_
18	.	.	.	_	7	p	_	_

1	Although	although	IN	_	6	mark	_	_
2	much	much	JJ	_	4	attr	_	_
3	statistical	statistical	JJ	_	4	attr	_	_
4	work	work	NN	_	6	dep	_	_
5	has	have	VBZ	_	6	aux	_	_
6	focused	focus	VBN	_	21	advcl	_	_
7	on	on	IN	_	8	case	_	_
8	developing	develop	VBG	_	6	ppmod	_	_
9	mathematical	mathematical	JJ	_	10	attr	_	_
10	functions	function	NNS	_	8	obj	_	_
11	to	to	TO	_	12	aux	_	_
12	model	model	VB	_	8	comp	_	_
13	the	the	DT	_	16	det	_	_
14	joint	joint	NN	_	16	attr	_	_
15	dose-response	dose-response	JJ	_	16	attr	_	_
16	curves	curve	NNS	_	12	obj	_	_
17	,	,	,	_	21	p	_	_
18	relatively	relatively	RB	_	19	adv	_	_
19	little	little	JJ	_	20	attr	_	_
20	work	work	NN	_	21	dep	_	_
21	exists	exist	VBZ	_	0	root	_	_
22	in	in	IN	_	26	case	_	_
23	regard	regard	NN	_	26	advnp	_	_
24	to	to	TO	_	26	aux	_	_
25	designing	designing	JJ	_	26	attr	_	_
26	experiments	experiment	NNS	_	21	ppmod	_	_
27	for	for	IN	_	28	case	_	_
28	assessing	assess	VBG	_	21	ppmod	_	_
29	joint	joint	NN	_	30	com	_	_
30	action	action	NN	_	28	obj	_	_
31	.	.	.	_	21	p	_	_

1	A	a	DT	_	2	det	_	_
2	variety	variety	NN	_	18	dep	_	_
3	of	of	IN	_	6	case	_	_
4	parametric	parametric	JJ	_	6	attr	_	_
5	dose-response	dose-response	JJ	_	6	attr	_	_
6	models	model	NNS	_	2	ppmod	_	_
7	based	base	VBN	_	6	acl	_	_
8	on	on	IN	_	15	case	_	_
9	either	either	CC	_	15	cc	_	_
10	the	the	DT	_	15	det	_	_
11	normal	normal	JJ	_	15	attr	_	_
12	or	or	CC	_	11	cc	_	_
13	logistic	logistic	JJ	_	11	conj	_	_
14	probability	probability	NN	_	15	com	_	_
15	distribution	distribution	NN	_	7	ppmod	_	_
16	have	have	VBP	_	18	aux	_	_
17	been	be	VBN	_	18	aux	_	_
18	proposed	propose	VBN	_	0	root	_	_
19	in	in	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	literature	literature	NN	_	18	ppmod	_	_
22	.	.	.	_	18	p	_	_

1	These	these	DT	_	2	det	_	_
2	models	model	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	typically	typically	RB	_	3	adv	_	_
5	nonlinear	nonlinear	JJ	_	3	dep	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	parameters	parameter	NNS	_	3	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	and	and	CC	_	3	cc	_	_
11	as	as	IN	_	12	case	_	_
12	such	such	JJ	_	22	ppmod	_	_
13	,	,	,	_	22	p	_	_
14	a	a	DT	_	19	det	_	_
15	nonlinear	nonlinear	JJ	_	19	attr	_	_
16	weighted	weighted	JJ	_	19	attr	_	_
17	least	least	RBS	_	18	adv	_	_
18	squares	squares	JJ	_	19	attr	_	_
19	approach	approach	NN	_	22	dep	_	_
20	can	can	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	employed	employ	VBN	_	3	conj	_	_
23	for	for	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	purpose	purpose	NN	_	22	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	designing	designing	JJ	_	28	attr	_	_
28	experiments	experiment	NNS	_	25	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	approach	approach	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	applicable	applicable	JJ	_	3	dep	_	_
5	across	across	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	wide	wide	JJ	_	8	attr	_	_
8	variety	variety	NN	_	4	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	settings	setting	NNS	_	8	ppmod	_	_
11	commonly	commonly	RB	_	12	adv	_	_
12	associated	associate	VBN	_	10	acl	_	_
13	with	with	IN	_	16	case	_	_
14	joint	joint	NN	_	16	com	_	_
15	action	action	NN	_	16	com	_	_
16	data	datum	NNS	_	12	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	including	include	VBG	_	22	adv	_	_
19	continuous	continuous	JJ	_	22	attr	_	_
20	and	and	CC	_	19	cc	_	_
21	discrete	discrete	JJ	_	19	conj	_	_
22	responses	response	NNS	_	16	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	alternative	alternative	NN	_	26	com	_	_
25	error	error	NN	_	26	com	_	_
26	structures	structure	NNS	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	nonzero	nonzero	JJ	_	31	attr	_	_
30	background	background	NN	_	31	com	_	_
31	response	response	NN	_	22	conj	_	_
32	.	.	.	_	3	p	_	_

1	Further	far	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	designs	design	NNS	_	6	dep	_	_
4	can	can	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	expressed	express	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	terms	term	NNS	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	proportionate	proportionate	JJ	_	11	attr	_	_
11	responses	response	NNS	_	8	ppmod	_	_
12	associated	associate	VBN	_	11	acl	_	_
13	with	with	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	individual	individual	JJ	_	16	attr	_	_
16	compounds	compound	NNS	_	12	ppmod	_	_
17	rather	rather	RB	_	16	cc	_	_
18	than	than	IN	_	17	com	_	_
19	dose	dose	NN	_	20	com	_	_
20	levels	level	NNS	_	16	conj	_	_
21	,	,	,	_	6	p	_	_
22	thereby	thereby	RB	_	23	adv	_	_
23	providing	provide	VBG	_	6	comp	_	_
24	for	for	IN	_	25	case	_	_
25	results	result	NNS	_	23	ppmod	_	_
26	that	that	WDT	_	27	dep	_	_
27	are	be	VBP	_	25	relcl	_	_
28	applicable	applicable	JJ	_	27	dep	_	_
29	across	across	IN	_	30	case	_	_
30	compounds	compound	NNS	_	28	ppmod	_	_
31	.	.	.	_	6	p	_	_

1	As	as	IN	_	3	case	_	_
2	a	a	DT	_	3	det	_	_
3	precursor	precursor	NN	_	26	ppmod	_	_
4	to	to	TO	_	6	aux	_	_
5	this	this	DT	_	6	det	_	_
6	effort	effort	NN	_	3	ppmod	_	_
7	,	,	,	_	26	p	_	_
8	optimal	optimal	JJ	_	12	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	minimal	minimal	JJ	_	8	conj	_	_
11	experimental	experimental	JJ	_	12	attr	_	_
12	designs	design	NNS	_	26	dep	_	_
13	for	for	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	case	case	NN	_	12	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	which	which	WDT	_	22	ppmod	_	_
18	a	a	DT	_	20	det	_	_
19	single	single	JJ	_	20	attr	_	_
20	compound	compound	NN	_	22	dep	_	_
21	is	be	VBZ	_	22	aux	_	_
22	administered	administer	VBN	_	15	relcl	_	_
23	have	have	VBP	_	26	aux	_	_
24	also	also	RB	_	26	adv	_	_
25	been	be	VBN	_	26	aux	_	_
26	developed	develop	VBN	_	0	root	_	_
27	.	.	.	_	26	p	_	_

1	Although	although	IN	_	11	mark	_	_
2	the	the	DT	_	4	det	_	_
3	proposed	proposed	JJ	_	4	attr	_	_
4	methodology	methodology	NN	_	11	dep	_	_
5	for	for	IN	_	6	case	_	_
6	deriving	derive	VBG	_	4	ppmod	_	_
7	experimental	experimental	JJ	_	8	attr	_	_
8	designs	design	NNS	_	6	obj	_	_
9	can	can	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	applied	apply	VBN	_	21	advcl	_	_
12	to	to	TO	_	16	aux	_	_
13	any	any	DT	_	16	det	_	_
14	nonlinear	nonlinear	JJ	_	16	attr	_	_
15	regression	regression	NN	_	16	com	_	_
16	model	model	NN	_	11	ppmod	_	_
17	,	,	,	_	21	p	_	_
18	primary	primary	JJ	_	19	attr	_	_
19	focus	focus	NN	_	21	dep	_	_
20	is	be	VBZ	_	21	aux	_	_
21	given	give	VBN	_	0	root	_	_
22	to	to	TO	_	33	aux	_	_
23	the	the	DT	_	33	det	_	_
24	additive	additive	JJ	_	33	attr	_	_
25	and	and	CC	_	24	cc	_	_
26	nonadditive	nonadditive	JJ	_	24	conj	_	_
27	independent	independent	JJ	_	29	attr	_	_
28	joint	joint	NN	_	29	com	_	_
29	action	action	NN	_	26	advnp	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	IJA	ija	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	models	model	NNS	_	21	ppmod	_	_
34	for	for	IN	_	35	case	_	_
35	individual	individual	NN	_	33	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	combined	combined	JJ	_	38	attr	_	_
38	exposures	exposure	NNS	_	35	conj	_	_
39	proposed	propose	VBN	_	33	acl	_	_
40	by	by	IN	_	41	case	_	_
41	Barton	barton	NNP	_	39	ppmod	_	_
42	,	,	,	_	41	p	_	_
43	Braunberg	braunberg	NNP	_	41	conj	_	_
44	,	,	,	_	43	p	_	_
45	and	and	CC	_	43	cc	_	_
46	Friedman	friedman	NN	_	41	conj	_	_
47	(	-lrb-	-LRB-	_	46	p	_	_
48	1	0	CD	_	46	num	_	_
49	)	-rrb-	-RRB-	_	46	p	_	_
50	.	.	.	_	21	p	_	_

1	-LSB-The	-lsb-the	JJ	_	3	attr	_	_
2	GABA-ergic	gaba-ergic	JJ	_	3	attr	_	_
3	system	system	NN	_	11	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	brain	brain	NN	_	6	com	_	_
6	edema	edema	NN	_	3	conj	_	_
7	]	-rsb-	-RRB-	_	6	p	_	_
8	It	it	PRP	_	6	appo	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	shown	show	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	rats	rat	NNS	_	11	ppmod	_	_
14	with	with	IN	_	19	case	_	_
15	experimental	experimental	JJ	_	19	attr	_	_
16	toxic	toxic	JJ	_	19	attr	_	_
17	and	and	CC	_	16	cc	_	_
18	traumatic	traumatic	JJ	_	16	conj	_	_
19	edemas	edema	NNS	_	13	ppmod	_	_
20	that	that	IN	_	26	mark	_	_
21	drug1	drug0	NN	_	26	dep	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	1	0	CD	_	24	num	_	_
24	mg/kg	mg/kg	NN	_	21	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	removes	remove	VBZ	_	11	comp	_	_
27	the	the	DT	_	29	det	_	_
28	antiedematous	antiedematous	JJ	_	29	attr	_	_
29	action	action	NN	_	26	obj	_	_
30	of	of	IN	_	31	case	_	_
31	drug2	drug0	NN	_	29	ppmod	_	_
32	,	,	,	_	31	p	_	_
33	drug3	drug0	NN	_	31	conj	_	_
34	,	,	,	_	33	p	_	_
35	drug4	drug0	NN	_	31	conj	_	_
36	and	and	CC	_	35	cc	_	_
37	drug5	drug0	NN	_	31	conj	_	_
38	and	and	CC	_	26	cc	_	_
39	reduces	reduce	VBZ	_	26	conj	_	_
40	the	the	DT	_	41	det	_	_
41	action	action	NN	_	39	obj	_	_
42	of	of	IN	_	43	case	_	_
43	drug6	drug0	NN	_	41	ppmod	_	_
44	.	.	.	_	11	p	_	_

1	When	when	WRB	_	7	adv	_	_
2	the	the	DT	_	3	det	_	_
3	dose	dose	NN	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	minimized	minimize	VBN	_	16	advcl	_	_
8	to	to	TO	_	10	aux	_	_
9	0.5	0	CD	_	10	num	_	_
10	mg/kg	mg/kg	NN	_	7	ppmod	_	_
11	such	such	PDT	_	13	det	_	_
12	an	an	DT	_	13	det	_	_
13	effect	effect	NN	_	16	dep	_	_
14	is	be	VBZ	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	observed	observe	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	Prolonged	prolonged	JJ	_	3	attr	_	_
2	daily	daily	JJ	_	3	attr	_	_
3	administration	administration	NN	_	12	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	a	a	DT	_	8	det	_	_
8	dose	dose	NN	_	3	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	1	0	CD	_	11	num	_	_
11	mg/kg	mg/kg	NN	_	8	ppmod	_	_
12	results	result	VBZ	_	0	root	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	development	development	NN	_	12	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	brain	brain	NN	_	18	com	_	_
18	edema	edema	NN	_	15	ppmod	_	_
19	.	.	.	_	12	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	recommended	recommend	VBN	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	GABA-positive	gaba-positive	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	8	dep	_	_
7	be	be	VB	_	8	aux	_	_
8	included	include	VBN	_	3	comp	_	_
9	into	into	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	complex	complex	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	treatment	treatment	NN	_	14	com	_	_
14	measures	measure	NNS	_	11	ppmod	_	_
15	for	for	IN	_	16	case	_	_
16	edema	edema	NN	_	14	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	New	new	JJ	_	3	attr	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	therapies	therapy	NNS	_	0	root	_	_
4	for	for	IN	_	8	case	_	_
5	type	type	NN	_	8	attr	_	_
6	2	0	CD	_	8	num	_	_
7	diabetes	diabetes	NN	_	8	com	_	_
8	mellitus	mellitus	NN	_	3	ppmod	_	_
9	:	:	:	_	3	p	_	_
10	The	the	DT	_	11	det	_	_
11	drug1	drug0	NN	_	3	appo	_	_
12	or	or	CC	_	11	cc	_	_
13	insulin	insulin	NN	_	14	com	_	_
14	sensitizers	sensitizer	NNS	_	11	conj	_	_
15	.	.	.	_	3	p	_	_

1	Type	type	NN	_	4	attr	_	_
2	2	0	CD	_	4	num	_	_
3	diabetes	diabetes	NN	_	4	com	_	_
4	mellitus	mellitus	NN	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	a	a	DT	_	8	det	_	_
7	growing	grow	VBG	_	8	attr	_	_
8	problem	problem	NN	_	5	obj	_	_
9	not	not	RB	_	10	com	_	_
10	only	only	RB	_	14	cc	_	_
11	in	in	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	United	united	JJ	_	14	attr	_	_
14	States	state	NNS	_	8	ppmod	_	_
15	but	but	CC	_	14	cc	_	_
16	also	also	RB	_	15	com	_	_
17	across	across	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	world	world	NN	_	14	conj	_	_
20	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	now	now	RB	_	2	adv	_	_
4	strong	strong	JJ	_	5	attr	_	_
5	evidence	evidence	NN	_	2	obj	_	_
6	that	that	IN	_	14	mark	_	_
7	intensive	intensive	JJ	_	8	attr	_	_
8	control	control	NN	_	14	dep	_	_
9	of	of	IN	_	11	case	_	_
10	blood	blood	NN	_	11	com	_	_
11	glucose	glucose	NN	_	8	ppmod	_	_
12	can	can	MD	_	14	modal	_	_
13	significantly	significantly	RB	_	14	adv	_	_
14	reduce	reduce	VB	_	5	acl	_	_
15	and	and	CC	_	14	cc	_	_
16	retard	retard	VB	_	14	conj	_	_
17	the	the	DT	_	19	det	_	_
18	microvascular	microvascular	JJ	_	19	attr	_	_
19	complications	complication	NNS	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	retinopathy	retinopathy	NN	_	19	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	nephropathy	nephropathy	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	neuropathy	neuropathy	NN	_	21	conj	_	_
27	.	.	.	_	2	p	_	_

1	Ultimately	ultimately	RB	_	12	adv	_	_
2	however	however	RB	_	12	adv	_	_
3	,	,	,	_	12	p	_	_
4	up	up	RB	_	6	adv	_	_
5	to	to	TO	_	6	attr	_	_
6	80	0	CD	_	12	num	_	_
7	%	%	NN	_	6	meta	_	_
8	of	of	IN	_	11	case	_	_
9	type	type	NN	_	11	attr	_	_
10	2	0	CD	_	11	num	_	_
11	diabetics	diabetics	NN	_	6	ppmod	_	_
12	die	die	VBP	_	0	root	_	_
13	from	from	IN	_	16	case	_	_
14	macrovascular	macrovascular	JJ	_	16	attr	_	_
15	cardiovascular	cardiovascular	JJ	_	16	attr	_	_
16	disease	disease	NN	_	12	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	This	this	DT	_	3	det	_	_
2	increased	increase	VBN	_	3	attr	_	_
3	incidence	incidence	NN	_	9	dep	_	_
4	of	of	IN	_	6	case	_	_
5	atherosclerotic	atherosclerotic	JJ	_	6	attr	_	_
6	disease	disease	NN	_	3	ppmod	_	_
7	is	be	VBZ	_	9	aux	_	_
8	intricately	intricately	RB	_	9	adv	_	_
9	associated	associate	VBN	_	0	root	_	_
10	with	with	IN	_	12	case	_	_
11	insulin	insulin	NN	_	12	com	_	_
12	resistance	resistance	NN	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	which	which	WDT	_	15	dep	_	_
15	is	be	VBZ	_	12	relcl	_	_
16	a	a	DT	_	19	det	_	_
17	major	major	JJ	_	19	attr	_	_
18	pathophysiologic	pathophysiologic	JJ	_	19	attr	_	_
19	abnormality	abnormality	NN	_	15	obj	_	_
20	in	in	IN	_	23	case	_	_
21	type	type	NN	_	23	attr	_	_
22	2	0	CD	_	23	num	_	_
23	diabetes	diabetes	NNS	_	19	ppmod	_	_
24	.	.	.	_	9	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	strong	strong	JJ	_	4	attr	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	that	that	IN	_	9	mark	_	_
6	insulin	insulin	NN	_	7	com	_	_
7	resistance	resistance	NN	_	9	dep	_	_
8	is	be	VBZ	_	9	aux	_	_
9	involved	involve	VBN	_	4	acl	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	development	development	NN	_	9	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	not	not	RB	_	15	com	_	_
15	only	only	RB	_	16	cc	_	_
16	hyperglycemia	hyperglycemia	NN	_	12	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	but	but	CC	_	16	cc	_	_
19	also	also	RB	_	18	com	_	_
20	dyslipidemia	dyslipidemia	NN	_	16	conj	_	_
21	,	,	,	_	20	p	_	_
22	hypertension	hypertension	NN	_	16	conj	_	_
23	,	,	,	_	22	p	_	_
24	hypercoagulation	hypercoagulation	NN	_	16	conj	_	_
25	,	,	,	_	24	p	_	_
26	vasculopathy	vasculopathy	NN	_	16	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	ultimately	ultimately	RB	_	32	adv	_	_
30	atherosclerotic	atherosclerotic	JJ	_	32	attr	_	_
31	cardiovascular	cardiovascular	JJ	_	32	attr	_	_
32	disease	disease	NN	_	16	conj	_	_
33	.	.	.	_	2	p	_	_

1	This	this	DT	_	2	det	_	_
2	cluster	cluster	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	metabolic	metabolic	JJ	_	5	attr	_	_
5	abnormalities	abnormality	NNS	_	2	ppmod	_	_
6	has	have	VBZ	_	8	aux	_	_
7	been	be	VBN	_	8	aux	_	_
8	termed	term	VBN	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	insulin	insulin	NN	_	11	com	_	_
11	resistance	resistance	NN	_	8	obj	_	_
12	or	or	CC	_	11	cc	_	_
13	cardiovascular	cardiovascular	JJ	_	15	attr	_	_
14	dysmetabolic	dysmetabolic	JJ	_	15	attr	_	_
15	syndrome	syndrome	NN	_	11	conj	_	_
16	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NN	_	16	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	drug2	drug0	NN	_	2	prn	_	_
5	and	and	CC	_	4	cc	_	_
6	drug3	drug0	NN	_	4	conj	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	,	,	,	_	2	p	_	_
9	a	a	DT	_	11	det	_	_
10	new	new	JJ	_	11	attr	_	_
11	class	class	NN	_	2	appo	_	_
12	of	of	IN	_	14	case	_	_
13	oral	oral	JJ	_	14	attr	_	_
14	drug4	drug0	NN	_	11	ppmod	_	_
15	,	,	,	_	2	p	_	_
16	are	be	VBP	_	0	root	_	_
17	&quot	&quot	JJ	_	16	dep	_	_
18	;	;	:	_	16	p	_	_
19	insulin	insulin	NN	_	20	com	_	_
20	sensitizers&quot	sensitizers&quot	NN	_	16	dep	_	_
21	;	;	:	_	16	p	_	_

1	and	and	CC	_	2	cc	_	_
2	exert	exert	VBP	_	0	root	_	_
3	direct	direct	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	mechanisms	mechanism	NNS	_	2	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	insulin	insulin	NN	_	10	com	_	_
10	resistance	resistance	NN	_	7	ppmod	_	_
11	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	not	not	RB	_	4	com	_	_
4	only	only	RB	_	5	cc	_	_
5	improve	improve	VB	_	0	root	_	_
6	insulin	insulin	NN	_	7	com	_	_
7	sensitivity	sensitivity	NN	_	5	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	glycemic	glycemic	JJ	_	10	attr	_	_
10	control	control	NN	_	7	conj	_	_
11	with	with	IN	_	14	case	_	_
12	reduced	reduce	VBN	_	14	attr	_	_
13	insulin	insulin	NN	_	14	com	_	_
14	requirements	requirement	NNS	_	5	ppmod	_	_
15	,	,	,	_	5	p	_	_
16	but	but	CC	_	5	cc	_	_
17	also	also	RB	_	16	com	_	_
18	have	have	VBP	_	5	conj	_	_
19	potentially	potentially	RB	_	21	adv	_	_
20	favorable	favorable	JJ	_	21	attr	_	_
21	effects	effect	NNS	_	18	obj	_	_
22	on	on	IN	_	24	case	_	_
23	other	other	JJ	_	24	attr	_	_
24	components	component	NNS	_	21	ppmod	_	_
25	of	of	IN	_	29	case	_	_
26	the	the	DT	_	29	det	_	_
27	cardiovascular	cardiovascular	JJ	_	29	attr	_	_
28	dysmetabolic	dysmetabolic	JJ	_	29	attr	_	_
29	syndrome	syndrome	NN	_	24	ppmod	_	_
30	.	.	.	_	5	p	_	_

1	Long-term	long-term	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	needed	need	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	determine	determine	VB	_	4	comp	_	_
7	whether	whether	IN	_	15	mark	_	_
8	the	the	DT	_	10	det	_	_
9	insulin-sensitizing	insulin-sensitizing	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	15	dep	_	_
11	of	of	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	can	can	MD	_	15	modal	_	_
15	prevent	prevent	VB	_	6	comp	_	_
16	or	or	CC	_	15	cc	_	_
17	delay	delay	VBP	_	15	conj	_	_
18	premature	premature	JJ	_	21	attr	_	_
19	atherosclerotic	atherosclerotic	JJ	_	21	attr	_	_
20	cardiovascular	cardiovascular	JJ	_	21	attr	_	_
21	disease	disease	NN	_	17	obj	_	_
22	,	,	,	_	21	p	_	_
23	morbidity	morbidity	NN	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	death	death	NN	_	21	conj	_	_
27	.	.	.	_	4	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	apparent	apparent	JJ	_	7	attr	_	_
7	volume	volume	NN	_	1	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	distribution	distribution	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	elimination	elimination	NN	_	9	conj	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	9	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	According	accord	VBG	_	0	root	_	_
2	to	to	TO	_	3	aux	_	_
3	Gibaldi	gibaldi	NNP	_	1	ppmod	_	_
4	et	et	FW	_	3	attr	_	_
5	al	al	FW	_	3	attr	_	_
6	.	.	.	_	1	p	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	1968	0	CD	_	20	num	_	_
3	,	,	,	_	2	p	_	_
4	1970	0	CD	_	2	appo	_	_
5	)	-rrb-	-RRB-	_	2	p	_	_
6	,	,	,	_	20	p	_	_
7	the	the	DT	_	10	det	_	_
8	higher	high	JJR	_	10	attr	_	_
9	serum	serum	NN	_	10	com	_	_
10	concentrations	concentration	NNS	_	20	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	reached	reach	VBN	_	12	acl	_	_
16	after	after	IN	_	17	case	_	_
17	administration	administration	NN	_	15	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	are	be	VBP	_	0	root	_	_
21	due	due	JJ	_	20	dep	_	_
22	not	not	RB	_	23	com	_	_
23	only	only	RB	_	27	cc	_	_
24	to	to	TO	_	27	aux	_	_
25	slower	slow	JJR	_	27	attr	_	_
26	renal	renal	JJ	_	27	attr	_	_
27	elimination	elimination	NN	_	21	ppmod	_	_
28	but	but	CC	_	27	cc	_	_
29	also	also	RB	_	28	com	_	_
30	to	to	TO	_	33	aux	_	_
31	an	an	DT	_	33	det	_	_
32	altered	altered	JJ	_	33	attr	_	_
33	distribution	distribution	NN	_	27	conj	_	_
34	in	in	IN	_	36	case	_	_
35	the	the	DT	_	36	det	_	_
36	body	body	NN	_	33	ppmod	_	_
37	.	.	.	_	20	p	_	_

1	To	to	TO	_	2	aux	_	_
2	determine	determine	VB	_	22	advcl	_	_
3	whether	whether	IN	_	5	mark	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	has	have	VBZ	_	2	comp	_	_
6	a	a	DT	_	8	det	_	_
7	direct	direct	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	obj	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	distribution	distribution	NN	_	5	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	22	p	_	_
15	the	the	DT	_	16	det	_	_
16	elimination	elimination	NN	_	22	dep	_	_
17	and	and	CC	_	16	cc	_	_
18	distribution	distribution	NN	_	16	conj	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	16	ppmod	_	_
21	was	be	VBD	_	22	aux	_	_
22	studied	study	VBN	_	0	root	_	_
23	in	in	IN	_	25	case	_	_
24	six	#crd#	CD	_	25	num	_	_
25	patients	patient	NNS	_	22	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	five	#crd#	CD	_	25	appo	_	_
28	lacking	lack	VBG	_	27	acl	_	_
29	kidney	kidney	NN	_	30	com	_	_
30	function	function	NN	_	28	obj	_	_
31	and	and	CC	_	27	cc	_	_
32	one	#crd#	CD	_	27	conj	_	_
33	with	with	IN	_	38	case	_	_
34	a	a	DT	_	38	det	_	_
35	partially	partially	RB	_	36	adv	_	_
36	impaired	impaired	JJ	_	38	attr	_	_
37	renal	renal	JJ	_	38	attr	_	_
38	function	function	NN	_	32	ppmod	_	_
39	,	,	,	_	25	p	_	_
40	in	in	IN	_	42	case	_	_
41	the	the	DT	_	42	det	_	_
42	presence	presence	NN	_	22	ppmod	_	_
43	or	or	CC	_	42	cc	_	_
44	absence	absence	NN	_	42	conj	_	_
45	of	of	IN	_	46	case	_	_
46	drug4	drug0	NN	_	42	ppmod	_	_
47	.	.	.	_	22	p	_	_

1	No	no	DT	_	3	det	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	difference	difference	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	found	find	VBN	_	0	root	_	_
6	between	between	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	mean	mean	JJ	_	9	attr	_	_
9	values	value	NNS	_	5	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	volume	volume	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	distribution	distribution	NN	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	with	with	IN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	without	without	IN	_	20	case	_	_
20	drug2	drug0	NN	_	17	conj	_	_
21	(	-lrb-	-LRB-	_	25	p	_	_
22	13.0	0	CD	_	25	num	_	_
23	and	and	CC	_	22	cc	_	_
24	12.6	0	CD	_	22	conj	_	_
25	liters	liter	NNS	_	20	prn	_	_
26	,	,	,	_	25	p	_	_
27	respectively	respectively	RB	_	25	adv	_	_
28	)	-rrb-	-RRB-	_	25	p	_	_
29	.	.	.	_	5	p	_	_

1	Thus	thus	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	the	the	DT	_	4	det	_	_
4	hypothesis	hypothesis	NN	_	0	root	_	_
5	of	of	IN	_	6	case	_	_
6	Gibaldi	gibaldi	NNP	_	4	ppmod	_	_
7	et	et	FW	_	6	attr	_	_
8	al	al	FW	_	6	attr	_	_
9	.	.	.	_	4	p	_	_

1	could	could	MD	_	4	modal	_	_
2	not	not	RB	_	4	neg	_	_
3	be	be	VB	_	4	aux	_	_
4	confirmed	confirm	VBN	_	0	root	_	_
5	for	for	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	lacking	lack	VBG	_	8	acl	_	_
10	kidney	kidney	NN	_	11	com	_	_
11	function	function	NN	_	9	obj	_	_
12	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	spite	spite	NN	_	19	ppmod	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	absence	absence	NN	_	2	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	kidney	kidney	NN	_	8	com	_	_
8	function	function	NN	_	5	ppmod	_	_
9	,	,	,	_	19	p	_	_
10	the	the	DT	_	11	det	_	_
11	value	value	NN	_	19	dep	_	_
12	of	of	IN	_	16	case	_	_
13	the	the	DT	_	16	det	_	_
14	elimination	elimination	NN	_	16	com	_	_
15	rate	rate	NN	_	16	com	_	_
16	constant	constant	NN	_	11	ppmod	_	_
17	was	be	VBD	_	19	aux	_	_
18	significantly	significantly	RB	_	19	adv	_	_
19	decreased	decrease	VBN	_	0	root	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	presence	presence	NN	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	29	p	_	_
26	from	from	IN	_	29	case	_	_
27	0.326	0	CD	_	29	num	_	_
28	to	to	TO	_	29	attr	_	_
29	0.263/h	0/h	CD	_	24	num	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	.	.	.	_	19	p	_	_

1	This	this	DT	_	4	dep	_	_
2	might	might	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	explained	explain	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	blockade	blockade	NN	_	4	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	elimination	elimination	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	by	by	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	liver	liver	NN	_	12	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Stereoselective	stereoselective	JJ	_	3	attr	_	_
2	behavioral	behavioral	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	7	case	_	_
7	pigeons	pigeon	NNS	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	squirrel	squirrel	NN	_	10	com	_	_
10	monkeys	monkey	NNS	_	7	conj	_	_
11	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	behavioral	behavioral	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	13	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	stereoisomers	stereoisomers	NNS	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	drug2	drug0	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	were	be	VBD	_	13	aux	_	_
13	compared	compare	VBN	_	0	root	_	_
14	with	with	IN	_	15	case	_	_
15	those	those	DT	_	13	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	drug4	drug0	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	in	in	IN	_	22	case	_	_
22	pigeons	pigeon	NNS	_	17	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	squirrel	squirrel	NN	_	25	com	_	_
25	monkeys	monkey	NNS	_	22	conj	_	_
26	responding	respond	VBG	_	22	acl	_	_
27	under	under	IN	_	36	case	_	_
28	a	a	DT	_	36	det	_	_
29	multiple	multiple	JJ	_	36	attr	_	_
30	fixed-interval	fixed-interval	JJ	_	36	attr	_	_
31	fixed-ratio	fixed-ratio	NN	_	36	attr	_	_
32	(	-lrb-	-LRB-	_	36	p	_	_
33	FI	fi	NN	_	36	attr	_	_
34	FR	fr	NN	_	36	attr	_	_
35	)	-rrb-	-RRB-	_	36	p	_	_
36	schedule	schedule	NN	_	26	ppmod	_	_
37	of	of	IN	_	39	case	_	_
38	food	food	NN	_	39	com	_	_
39	presentation	presentation	NN	_	36	ppmod	_	_
40	.	.	.	_	13	p	_	_

1	Intermediate	intermediate	JJ	_	2	attr	_	_
2	doses	dose	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	produced	produce	VBD	_	0	root	_	_
8	transient	transient	JJ	_	9	attr	_	_
9	increases	increase	NNS	_	7	obj	_	_
10	in	in	IN	_	11	case	_	_
11	FI	fi	NN	_	9	ppmod	_	_
12	responding	respond	VBG	_	11	acl	_	_
13	in	in	IN	_	14	case	_	_
14	monkeys	monkey	NNS	_	12	ppmod	_	_
15	and	and	CC	_	9	cc	_	_
16	sustained	sustained	JJ	_	17	attr	_	_
17	increases	increase	NNS	_	9	conj	_	_
18	in	in	IN	_	19	case	_	_
19	FI	fi	NN	_	17	ppmod	_	_
20	responding	respond	VBG	_	19	acl	_	_
21	in	in	IN	_	22	case	_	_
22	pigeons	pigeon	NNS	_	20	ppmod	_	_
23	;	;	:	_	7	p	_	_

1	higher	high	JJR	_	2	attr	_	_
2	doses	dose	NNS	_	3	dep	_	_
3	decreased	decrease	VBD	_	0	root	_	_
4	FI	fi	NN	_	3	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	FR	fr	NN	_	4	conj	_	_
7	responding	respond	VBG	_	4	acl	_	_
8	in	in	IN	_	10	case	_	_
9	both	both	DT	_	10	det	_	_
10	species	species	NNS	_	7	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	In	in	IN	_	5	case	_	_
2	contrast	contrast	NN	_	5	advnp	_	_
3	to	to	TO	_	5	aux	_	_
4	its	its	PRP$	_	5	poss	_	_
5	enantiomer	enantiomer	NN	_	8	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	failed	fail	VBD	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	increase	increase	VB	_	8	comp	_	_
11	FI	fi	NN	_	10	obj	_	_
12	responding	respond	VBG	_	11	acl	_	_
13	significantly	significantly	RB	_	12	adv	_	_
14	in	in	IN	_	16	case	_	_
15	either	either	DT	_	16	det	_	_
16	species	species	NNS	_	12	ppmod	_	_
17	;	;	:	_	8	p	_	_

1	at	at	IN	_	3	case	_	_
2	high	high	JJ	_	3	attr	_	_
3	doses	dose	NNS	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	decreased	decrease	VBD	_	0	root	_	_
7	FI	fi	NN	_	6	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	FR	fr	NN	_	7	conj	_	_
10	responding	respond	VBG	_	7	acl	_	_
11	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	monkeys	monkey	NNS	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	was	be	VBD	_	0	root	_	_
6	about	about	RB	_	7	adv	_	_
7	10	0	CD	_	8	num	_	_
8	times	time	NNS	_	5	obj	_	_
9	more	more	RBR	_	10	adv	_	_
10	potent	potent	JJ	_	8	attr	_	_
11	than	than	IN	_	12	case	_	_
12	drug2	drug0	NN	_	5	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	decreasing	decrease	VBG	_	5	ppmod	_	_
15	responding	respond	VBG	_	14	obj	_	_
16	,	,	,	_	5	p	_	_
17	whereas	whereas	IN	_	21	mark	_	_
18	in	in	IN	_	19	case	_	_
19	pigeons	pigeon	NNS	_	21	ppmod	_	_
20	drug3	drug0	NN	_	21	dep	_	_
21	was	be	VBD	_	5	comp	_	_
22	about	about	RB	_	23	adv	_	_
23	equipotent	equipotent	JJ	_	21	dep	_	_
24	with	with	IN	_	25	case	_	_
25	drug4	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	both	both	DT	_	3	det	_	_
3	species	species	NNS	_	11	ppmod	_	_
4	,	,	,	_	11	p	_	_
5	drug1	drug0	NN	_	11	dep	_	_
6	,	,	,	_	5	p	_	_
7	but	but	CC	_	5	cc	_	_
8	not	not	RB	_	7	com	_	_
9	drug2	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	antagonized	antagonize	VBD	_	0	root	_	_
12	the	the	DT	_	14	det	_	_
13	rate-decreasing	rate-decreasing	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug3	drug0	NN	_	14	ppmod	_	_
17	on	on	IN	_	18	case	_	_
18	FI	fi	NN	_	14	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	FR	fr	NN	_	18	conj	_	_
21	responding	respond	VBG	_	18	acl	_	_
22	.	.	.	_	11	p	_	_

1	In	in	IN	_	2	case	_	_
2	monkeys	monkey	NNS	_	16	ppmod	_	_
3	,	,	,	_	16	p	_	_
4	the	the	DT	_	5	det	_	_
5	effects	effect	NNS	_	16	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	but	but	CC	_	7	cc	_	_
10	not	not	RB	_	9	com	_	_
11	drug2	drug0	NN	_	7	conj	_	_
12	or	or	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	,	,	,	_	11	p	_	_
15	were	be	VBD	_	16	aux	_	_
16	antagonized	antagonize	VBN	_	0	root	_	_
17	by	by	IN	_	18	case	_	_
18	drug4	drug0	NN	_	16	ppmod	_	_
19	;	;	:	_	16	p	_	_

1	the	the	DT	_	2	det	_	_
2	doses	dose	NNS	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	required	require	VBN	_	4	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	antagonize	antagonize	VB	_	5	comp	_	_
8	the	the	DT	_	9	det	_	_
9	effects	effect	NNS	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	were	be	VBD	_	0	root	_	_
13	more	more	JJR	_	15	attr	_	_
14	than	than	IN	_	13	com	_	_
15	100	0	CD	_	16	num	_	_
16	times	time	NNS	_	17	advnp	_	_
17	higher	high	JJR	_	12	dep	_	_
18	than	than	IN	_	19	case	_	_
19	those	those	DT	_	17	ppmod	_	_
20	required	require	VBN	_	19	acl	_	_
21	to	to	TO	_	22	aux	_	_
22	antagonize	antagonize	VB	_	20	comp	_	_
23	the	the	DT	_	24	det	_	_
24	effects	effect	NNS	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	12	p	_	_

1	In	in	IN	_	2	case	_	_
2	pigeons	pigeon	NNS	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	drug1	drug0	NN	_	8	dep	_	_
5	did	do	VBD	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	systematically	systematically	RB	_	8	adv	_	_
8	alter	alter	VB	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	effects	effect	NNS	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	or	or	CC	_	14	cc	_	_
16	drug4	drug0	NN	_	12	conj	_	_
17	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduced	reduce	VBD	_	0	root	_	_
3	or	or	CC	_	2	cc	_	_
4	eliminated	eliminate	VBD	_	2	conj	_	_
5	the	the	DT	_	6	det	_	_
6	increases	increase	NNS	_	4	obj	_	_
7	in	in	IN	_	8	case	_	_
8	FI	fi	NN	_	6	ppmod	_	_
9	responding	respond	VBG	_	8	attr	_	_
10	produced	produce	VBN	_	8	acl	_	_
11	by	by	IN	_	13	case	_	_
12	intermediate	intermediate	JJ	_	13	attr	_	_
13	doses	dose	NNS	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	either	either	CC	_	16	cc	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	in	in	IN	_	20	case	_	_
20	pigeons	pigeon	NNS	_	10	ppmod	_	_
21	,	,	,	_	4	p	_	_
22	but	but	CC	_	4	cc	_	_
23	did	do	VBD	_	25	aux	_	_
24	not	not	RB	_	25	neg	_	_
25	antagonize	antagonize	VB	_	2	conj	_	_
26	the	the	DT	_	27	det	_	_
27	decreases	decrease	NNS	_	25	obj	_	_
28	in	in	IN	_	29	case	_	_
29	FI	fi	NN	_	27	ppmod	_	_
30	or	or	CC	_	29	cc	_	_
31	FR	fr	NN	_	29	conj	_	_
32	responding	respond	VBG	_	33	aux	_	_
33	produced	produce	VBN	_	29	acl	_	_
34	by	by	IN	_	36	case	_	_
35	high	high	JJ	_	36	attr	_	_
36	doses	dose	NNS	_	33	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	PCP	pcp	NN	_	36	ppmod	_	_
39	or	or	CC	_	38	cc	_	_
40	either	either	DT	_	41	det	_	_
41	stereoisomer	stereoisomer	NN	_	38	conj	_	_
42	of	of	IN	_	43	case	_	_
43	drug4	drug0	NN	_	41	ppmod	_	_
44	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	demonstrate	demonstrate	VBP	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	high	high	JJ	_	6	attr	_	_
6	degree	degree	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	stereoselectivity	stereoselectivity	NN	_	6	ppmod	_	_
9	in	in	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	behavioral	behavioral	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	6	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	levorotatory	levorotatory	JJ	_	3	attr	_	_
3	isomer	isomer	NN	_	4	dep	_	_
4	had	have	VBD	_	0	root	_	_
5	opioid-antagonist	opioid-antagonist	JJ	_	9	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	non-opioid	non-opioid	JJ	_	5	conj	_	_
8	agonist	agonist	NN	_	9	com	_	_
9	effects	effect	NNS	_	4	obj	_	_
10	in	in	IN	_	11	case	_	_
11	pigeons	pigeon	NNS	_	9	ppmod	_	_
12	and	and	CC	_	9	cc	_	_
13	mixed	mixed	JJ	_	16	attr	_	_
14	opioid	opioid	JJ	_	16	attr	_	_
15	agonist-antagonist	agonist-antagonist	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	9	conj	_	_
17	in	in	IN	_	18	case	_	_
18	monkeys	monkey	NNS	_	16	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	dextrorotatory	dextrorotatory	JJ	_	3	attr	_	_
3	isomer	isomer	NN	_	10	dep	_	_
4	,	,	,	_	3	p	_	_
5	on	on	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	other	other	JJ	_	8	attr	_	_
8	hand	hand	NN	_	3	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	had	have	VBD	_	0	root	_	_
11	effects	effect	NNS	_	10	obj	_	_
12	similar	similar	JJ	_	11	attr	_	_
13	to	to	TO	_	14	aux	_	_
14	those	those	DT	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	both	both	DT	_	19	det	_	_
19	species	species	NNS	_	10	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	Cancer	cancer	NN	_	0	root	_	_
2	in	in	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	elderly	elderly	JJ	_	1	ppmod	_	_
5	:	:	:	_	1	p	_	_
6	basic	basic	JJ	_	7	attr	_	_
7	science	science	NNP	_	1	appo	_	_
8	and	and	CC	_	7	cc	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	aspects	aspect	NNS	_	7	conj	_	_
11	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	incidence	incidence	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	cancer	cancer	NN	_	2	ppmod	_	_
5	increases	increase	VBZ	_	0	root	_	_
6	progressively	progressively	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	age	age	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	Rearrangements	rearrangement	NNS	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	genomes	genome	NNS	_	1	ppmod	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	found	find	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	accompany	accompany	VBP	_	6	comp	_	_
9	cellular	cellular	JJ	_	10	attr	_	_
10	aging	aging	NN	_	8	obj	_	_
11	.	.	.	_	6	p	_	_

1	These	these	DT	_	2	det	_	_
2	factors	factor	NNS	_	17	dep	_	_
3	,	,	,	_	2	p	_	_
4	in	in	IN	_	5	case	_	_
5	concert	concert	NN	_	2	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	age-dependent	age-dependent	JJ	_	8	attr	_	_
8	alterations	alteration	NNS	_	5	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	immune	immune	JJ	_	11	attr	_	_
11	function	function	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	host	host	NN	_	14	com	_	_
14	defense	defense	NN	_	11	conj	_	_
15	,	,	,	_	2	p	_	_
16	may	may	MD	_	17	modal	_	_
17	help	help	VB	_	0	root	_	_
18	to	to	TO	_	19	aux	_	_
19	explain	explain	VB	_	17	comp	_	_
20	the	the	DT	_	22	det	_	_
21	increased	increase	VBN	_	22	attr	_	_
22	risk	risk	NN	_	19	obj	_	_
23	of	of	IN	_	25	case	_	_
24	malignant	malignant	JJ	_	25	attr	_	_
25	disease	disease	NN	_	22	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	aged	aged	JJ	_	28	attr	_	_
28	persons	person	NNS	_	22	ppmod	_	_
29	.	.	.	_	17	p	_	_

1	The	the	DT	_	3	det	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	presentation	presentation	NN	_	11	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	natural	natural	JJ	_	6	attr	_	_
6	history	history	NN	_	3	conj	_	_
7	of	of	IN	_	8	case	_	_
8	neoplasia	neoplasia	NN	_	3	ppmod	_	_
9	are	be	VBP	_	11	aux	_	_
10	also	also	RB	_	11	adv	_	_
11	affected	affect	VBN	_	0	root	_	_
12	by	by	IN	_	13	case	_	_
13	aging	aging	NN	_	11	ppmod	_	_
14	.	.	.	_	11	p	_	_

1	This	this	DT	_	2	det	_	_
2	conference	conference	NN	_	3	dep	_	_
3	reviews	review	VBZ	_	0	root	_	_
4	recent	recent	JJ	_	5	attr	_	_
5	developments	development	NNS	_	3	obj	_	_
6	in	in	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	areas	area	NNS	_	5	ppmod	_	_
9	,	,	,	_	3	p	_	_
10	examines	examine	VBZ	_	3	conj	_	_
11	the	the	DT	_	12	det	_	_
12	effects	effect	NNS	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	drug	drug	NN	_	15	com	_	_
15	use	use	NN	_	12	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	elderly	elderly	JJ	_	12	ppmod	_	_
19	and	and	CC	_	12	cc	_	_
20	implications	implication	NNS	_	12	conj	_	_
21	for	for	IN	_	22	case	_	_
22	management	management	NN	_	20	ppmod	_	_
23	,	,	,	_	10	p	_	_
24	and	and	CC	_	10	cc	_	_
25	discusses	discuss	VBZ	_	3	conj	_	_
26	current	current	JJ	_	27	attr	_	_
27	information	information	NN	_	25	obj	_	_
28	on	on	IN	_	32	case	_	_
29	how	how	WRB	_	32	adv	_	_
30	age	age	NN	_	32	dep	_	_
31	may	may	MD	_	32	modal	_	_
32	influence	influence	VB	_	27	ppmod	_	_
33	the	the	DT	_	34	det	_	_
34	response	response	NN	_	32	obj	_	_
35	of	of	IN	_	36	case	_	_
36	cancer	cancer	NN	_	34	ppmod	_	_
37	to	to	TO	_	38	aux	_	_
38	therapy	therapy	NN	_	34	ppmod	_	_
39	.	.	.	_	3	p	_	_

1	Prescribing	prescribing	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Keys	key	NNS	_	3	dep	_	_
2	to	to	TO	_	3	aux	_	_
3	maximizing	maximizing	VB	_	0	root	_	_
4	benefit	benefit	NN	_	3	obj	_	_
5	while	while	IN	_	6	case	_	_
6	avoiding	avoid	VBG	_	3	ppmod	_	_
7	adverse	adverse	JJ	_	9	attr	_	_
8	drug	drug	NN	_	9	com	_	_
9	effects	effect	NNS	_	6	obj	_	_
10	.	.	.	_	3	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	prescribing	prescribe	VBG	_	9	advcl	_	_
3	for	for	IN	_	5	case	_	_
4	older	old	JJR	_	5	attr	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	,	,	,	_	9	p	_	_
7	some	some	DT	_	8	det	_	_
8	physicians	physician	NNS	_	9	dep	_	_
9	are	be	VBP	_	0	root	_	_
10	overly	overly	RB	_	11	adv	_	_
11	cautious	cautious	JJ	_	9	dep	_	_
12	,	,	,	_	9	p	_	_
13	and	and	CC	_	9	cc	_	_
14	this	this	DT	_	15	det	_	_
15	strategy	strategy	NN	_	17	dep	_	_
16	can	can	MD	_	17	modal	_	_
17	result	result	VB	_	9	conj	_	_
18	in	in	IN	_	24	case	_	_
19	a	a	DT	_	24	det	_	_
20	less	less	JJR	_	22	adv	_	_
21	than	than	IN	_	22	case	_	_
22	optimal	optimal	JJ	_	24	attr	_	_
23	treatment	treatment	NN	_	24	com	_	_
24	outcome	outcome	NN	_	17	ppmod	_	_
25	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	reluctance	reluctance	NN	_	6	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	treat	treat	VB	_	2	acl	_	_
5	aggressively	aggressively	RB	_	4	adv	_	_
6	is	be	VBZ	_	0	root	_	_
7	understandable	understandable	JJ	_	6	dep	_	_
8	because	because	IN	_	12	mark	_	_
9	the	the	DT	_	11	det	_	_
10	geriatric	geriatric	JJ	_	11	attr	_	_
11	population	population	NN	_	12	dep	_	_
12	is	be	VBZ	_	6	comp	_	_
13	susceptible	susceptible	JJ	_	12	dep	_	_
14	to	to	TO	_	17	aux	_	_
15	adverse	adverse	JJ	_	17	attr	_	_
16	drug	drug	NN	_	17	com	_	_
17	reactions	reaction	NNS	_	13	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	key	key	JJ	_	6	dep	_	_
3	to	to	TO	_	5	aux	_	_
4	maximizing	maximizing	JJ	_	5	attr	_	_
5	therapy	therapy	NN	_	2	ppmod	_	_
6	lies	lie	VBZ	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	individualizing	individualizing	JJ	_	6	ppmod	_	_
9	it	it	PRP	_	6	comp	_	_
10	as	as	RB	_	11	com	_	_
11	much	much	RB	_	13	cc	_	_
12	as	as	IN	_	11	com	_	_
13	possible	possible	JJ	_	9	dep	_	_
14	.	.	.	_	6	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	a	a	DT	_	4	det	_	_
4	number	number	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	steps	step	NNS	_	7	com	_	_
7	physicians	physician	NNS	_	4	ppmod	_	_
8	can	can	MD	_	9	modal	_	_
9	take	take	VB	_	2	comp	_	_
10	to	to	TO	_	11	aux	_	_
11	ensure	ensure	VB	_	9	comp	_	_
12	that	that	IN	_	17	mark	_	_
13	their	their	PRP$	_	14	poss	_	_
14	patients	patient	NNS	_	17	dep	_	_
15	are	be	VBP	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	being	be	VBG	_	11	comp	_	_
18	undertreated	undertreated	JJ	_	17	dep	_	_
19	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	steps	step	NNS	_	3	dep	_	_
3	include	include	VBP	_	0	root	_	_
4	regular	regular	JJ	_	5	attr	_	_
5	reevaluations	reevaluation	NNS	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	dosages	dosage	NNS	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	drug	drug	NN	_	11	com	_	_
11	concentrations	concentration	NNS	_	7	conj	_	_
12	,	,	,	_	5	p	_	_
13	recognition	recognition	NN	_	5	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	understanding	understanding	NN	_	13	conj	_	_
16	of	of	IN	_	19	case	_	_
17	drug	drug	NN	_	19	com	_	_
18	side	side	NN	_	19	com	_	_
19	effects	effect	NNS	_	13	ppmod	_	_
20	,	,	,	_	13	p	_	_
21	and	and	CC	_	13	cc	_	_
22	avoidance	avoidance	NN	_	5	conj	_	_
23	of	of	IN	_	25	case	_	_
24	certain	certain	JJ	_	25	attr	_	_
25	agents	agent	NNS	_	22	ppmod	_	_
26	.	.	.	_	3	p	_	_

1	Close	close	JJ	_	2	attr	_	_
2	monitoring	monitoring	NN	_	3	dep	_	_
3	allows	allow	VBZ	_	0	root	_	_
4	physicians	physician	NNS	_	6	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	minimize	minimize	VB	_	3	comp	_	_
7	risks	risk	NNS	_	6	obj	_	_
8	,	,	,	_	6	p	_	_
9	maximize	maximize	VB	_	6	conj	_	_
10	benefits	benefit	NNS	_	9	obj	_	_
11	,	,	,	_	9	p	_	_
12	and	and	CC	_	9	cc	_	_
13	get	get	VB	_	6	conj	_	_
14	the	the	DT	_	15	det	_	_
15	most	most	JJS	_	13	obj	_	_
16	out	out	RP	_	22	prt	_	_
17	of	of	IN	_	22	case	_	_
18	what	what	WP	_	22	dep	_	_
19	modern	modern	JJ	_	20	attr	_	_
20	medications	medication	NNS	_	22	dep	_	_
21	can	can	MD	_	22	modal	_	_
22	do	do	VBP	_	15	ppmod	_	_
23	to	to	TO	_	24	aux	_	_
24	help	help	VB	_	22	comp	_	_
25	older	old	JJR	_	26	attr	_	_
26	patients	patient	NNS	_	24	obj	_	_
27	.	.	.	_	3	p	_	_

1	Determinants	determinant	NNS	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	cellular	cellular	JJ	_	4	attr	_	_
4	sensitivity	sensitivity	NN	_	1	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	.	.	.	_	1	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	now	now	RB	_	2	adv	_	_
4	clear	clear	JJ	_	2	dep	_	_
5	that	that	IN	_	9	mark	_	_
6	topoisomerase	topoisomerase	NN	_	8	com	_	_
7	activity	activity	NN	_	8	com	_	_
8	level	level	NN	_	9	dep	_	_
9	is	be	VBZ	_	2	comp	_	_
10	an	an	DT	_	12	det	_	_
11	important	important	JJ	_	12	attr	_	_
12	determinant	determinant	NN	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	sensitivity	sensitivity	NN	_	12	ppmod	_	_
15	to	to	TO	_	17	aux	_	_
16	topo	topo	NN	_	17	com	_	_
17	drugs	drug	NNS	_	14	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	regulation	regulation	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	topoisomerases	topoisomerases	NNS	_	2	ppmod	_	_
5	is	be	VBZ	_	0	root	_	_
6	no	no	DT	_	7	det	_	_
7	doubt	doubt	NN	_	5	obj	_	_
8	complex	complex	JJ	_	7	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	multifaceted	multifaceted	JJ	_	8	conj	_	_
11	and	and	CC	_	5	cc	_	_
12	is	be	VBZ	_	14	aux	_	_
13	probably	probably	RB	_	14	adv	_	_
14	accomplished	accomplish	VBN	_	5	conj	_	_
15	through	through	IN	_	16	case	_	_
16	redundancy	redundancy	NN	_	14	ppmod	_	_
17	at	at	IN	_	20	case	_	_
18	many	many	JJ	_	20	attr	_	_
19	control	control	JJ	_	20	attr	_	_
20	levels	level	NNS	_	14	ppmod	_	_
21	.	.	.	_	5	p	_	_

1	The	the	DT	_	4	det	_	_
2	mechanism	mechanism	NN	_	4	attr	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	s	s	NNS	_	15	dep	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	of	of	IN	_	10	case	_	_
7	altered	altered	JJ	_	10	attr	_	_
8	topo	topo	NN	_	10	com	_	_
9	I	i	NN	_	10	com	_	_
10	expression	expression	NN	_	4	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	certain	certain	JJ	_	14	attr	_	_
13	tumor	tumor	NN	_	14	com	_	_
14	types	type	NNS	_	10	ppmod	_	_
15	is	be	VBZ	_	0	root	_	_
16	unknown	unknown	JJ	_	15	dep	_	_
17	,	,	,	_	15	p	_	_
18	but	but	CC	_	15	cc	_	_
19	may	may	MD	_	20	modal	_	_
20	be	be	VB	_	15	conj	_	_
21	related	related	JJ	_	20	dep	_	_
22	to	to	TO	_	25	aux	_	_
23	the	the	DT	_	25	det	_	_
24	central	central	JJ	_	25	attr	_	_
25	importance	importance	NN	_	21	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	topoisomerases	topoisomerases	NNS	_	25	ppmod	_	_
28	in	in	IN	_	29	case	_	_
29	proliferating	proliferate	VBG	_	25	ppmod	_	_
30	cell	cell	NN	_	31	com	_	_
31	functions	function	NNS	_	29	obj	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	transcription	transcription	NN	_	31	prn	_	_
34	,	,	,	_	33	p	_	_
35	replication	replication	NN	_	33	conj	_	_
36	,	,	,	_	35	p	_	_
37	etc.	etc.	NN	_	33	conj	_	_
38	)	-rrb-	-RRB-	_	33	p	_	_
39	,	,	,	_	31	p	_	_
40	and	and	CC	_	31	cc	_	_
41	the	the	DT	_	45	det	_	_
42	aberrant	aberrant	JJ	_	45	attr	_	_
43	and	and	CC	_	42	cc	_	_
44	chronic	chronic	JJ	_	42	conj	_	_
45	activation	activation	NN	_	31	conj	_	_
46	of	of	IN	_	48	case	_	_
47	these	these	DT	_	48	det	_	_
48	functions	function	NNS	_	45	ppmod	_	_
49	as	as	IN	_	51	case	_	_
50	a	a	DT	_	51	det	_	_
51	result	result	NN	_	29	ppmod	_	_
52	of	of	IN	_	55	case	_	_
53	specific	specific	JJ	_	55	attr	_	_
54	tumorigenic	tumorigenic	JJ	_	55	attr	_	_
55	alterations	alteration	NNS	_	51	ppmod	_	_
56	.	.	.	_	15	p	_	_

1	Small	small	JJ	_	2	attr	_	_
2	differences	difference	NNS	_	8	dep	_	_
3	in	in	IN	_	4	case	_	_
4	sensitivity	sensitivity	NN	_	2	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	chemotherapy	chemotherapy	NN	_	4	ppmod	_	_
7	can	can	MD	_	8	modal	_	_
8	have	have	VB	_	0	root	_	_
9	a	a	DT	_	11	det	_	_
10	dramatic	dramatic	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	on	on	IN	_	14	case	_	_
13	cure	cure	NN	_	14	com	_	_
14	rates	rate	NNS	_	11	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	and	and	CC	_	8	cc	_	_
17	therefore	therefore	RB	_	23	adv	_	_
18	subtle	subtle	JJ	_	21	attr	_	_
19	cell	cell	NN	_	20	advnp	_	_
20	type-specific	type-specific	JJ	_	21	attr	_	_
21	differences	difference	NNS	_	23	dep	_	_
22	may	may	MD	_	23	modal	_	_
23	be	be	VB	_	8	conj	_	_
24	important	important	JJ	_	25	attr	_	_
25	determinants	determinant	NNS	_	23	obj	_	_
26	of	of	IN	_	28	case	_	_
27	drug	drug	NN	_	28	com	_	_
28	sensitivity	sensitivity	NN	_	25	ppmod	_	_
29	.	.	.	_	8	p	_	_

1	Whether	whether	IN	_	9	mark	_	_
2	abnormal	abnormal	JJ	_	4	attr	_	_
3	topoisomerase	topoisomerase	NN	_	4	com	_	_
4	quantity	quantity	NN	_	9	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	specific	specific	JJ	_	7	attr	_	_
7	activity	activity	NN	_	4	conj	_	_
8	are	be	VBP	_	9	aux	_	_
9	associated	associate	VBN	_	23	advcl	_	_
10	with	with	IN	_	11	case	_	_
11	resistance	resistance	NN	_	9	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	sensitivity	sensitivity	NN	_	11	conj	_	_
14	to	to	TO	_	16	aux	_	_
15	topoisomerase-targeted	topoisomerase-targeted	JJ	_	16	attr	_	_
16	chemotherapy	chemotherapy	NN	_	11	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	clinic	clinic	NN	_	11	ppmod	_	_
20	is	be	VBZ	_	23	aux	_	_
21	now	now	RB	_	23	adv	_	_
22	being	be	VBG	_	23	aux	_	_
23	studied	study	VBN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	Determinants	determinant	NNS	_	26	dep	_	_
2	downstream	downstream	JJ	_	1	attr	_	_
3	of	of	IN	_	6	case	_	_
4	cleavable	cleavable	NN	_	6	com	_	_
5	complex	complex	NN	_	6	com	_	_
6	formation	formation	NN	_	2	ppmod	_	_
7	that	that	WDT	_	8	dep	_	_
8	affect	affect	VBP	_	1	relcl	_	_
9	the	the	DT	_	10	det	_	_
10	sensitivity	sensitivity	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	tumor	tumor	NN	_	10	ppmod	_	_
13	versus	versus	CC	_	12	cc	_	_
14	normal	normal	JJ	_	15	attr	_	_
15	cells	cell	NNS	_	12	conj	_	_
16	to	to	TO	_	18	aux	_	_
17	topo	topo	NN	_	18	com	_	_
18	drugs	drug	NNS	_	10	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	particular	particular	JJ	_	8	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	DNA-damaging	dna-damaging	JJ	_	23	attr	_	_
23	agents	agent	NNS	_	20	conj	_	_
24	in	in	IN	_	25	case	_	_
25	general	general	JJ	_	20	ppmod	_	_
26	are	be	VBP	_	0	root	_	_
27	little	little	JJ	_	26	obj	_	_
28	known	know	VBN	_	27	acl	_	_
29	.	.	.	_	26	p	_	_

1	The	the	DT	_	2	det	_	_
2	goal	goal	NN	_	20	dep	_	_
3	of	of	IN	_	8	case	_	_
4	enhancing	enhancing	JJ	_	8	attr	_	_
5	selective	selective	JJ	_	8	attr	_	_
6	tumor	tumor	NN	_	8	com	_	_
7	cell	cell	NN	_	8	com	_	_
8	killing	killing	NN	_	2	ppmod	_	_
9	relative	relative	JJ	_	8	attr	_	_
10	to	to	TO	_	13	aux	_	_
11	the	the	DT	_	13	det	_	_
12	normal	normal	JJ	_	13	attr	_	_
13	cells	cell	NNS	_	9	ppmod	_	_
14	that	that	WDT	_	15	dep	_	_
15	are	be	VBP	_	13	relcl	_	_
16	dose	dose	NN	_	17	advnp	_	_
17	limiting	limit	VBG	_	15	dep	_	_
18	may	may	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	achieved	achieve	VBN	_	0	root	_	_
21	either	either	CC	_	23	cc	_	_
22	by	by	IN	_	23	case	_	_
23	overcoming	overcome	VBG	_	20	ppmod	_	_
24	tumor	tumor	NN	_	26	com	_	_
25	cell	cell	NN	_	26	com	_	_
26	resistance	resistance	NN	_	23	obj	_	_
27	or	or	CC	_	23	cc	_	_
28	by	by	IN	_	29	case	_	_
29	protecting	protect	VBG	_	23	conj	_	_
30	normal	normal	JJ	_	31	attr	_	_
31	cells	cell	NNS	_	29	obj	_	_
32	.	.	.	_	20	p	_	_

1	Both	both	DT	_	6	dep	_	_
2	of	of	IN	_	4	case	_	_
3	these	these	DT	_	4	det	_	_
4	strategies	strategy	NNS	_	1	ppmod	_	_
5	will	will	MD	_	6	modal	_	_
6	become	become	VB	_	0	root	_	_
7	more	more	RBR	_	8	adv	_	_
8	feasible	feasible	JJ	_	6	dep	_	_
9	as	as	IN	_	21	mark	_	_
10	specific	specific	JJ	_	12	attr	_	_
11	molecular	molecular	JJ	_	12	attr	_	_
12	differences	difference	NNS	_	21	dep	_	_
13	between	between	IN	_	14	case	_	_
14	tumor	tumor	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	normal	normal	JJ	_	17	attr	_	_
17	cells	cell	NNS	_	14	conj	_	_
18	are	be	VBP	_	21	aux	_	_
19	being	be	VBG	_	21	aux	_	_
20	rapidly	rapidly	RB	_	21	adv	_	_
21	identified	identify	VBN	_	6	comp	_	_
22	and	and	CC	_	21	cc	_	_
23	new	new	JJ	_	25	attr	_	_
24	combination	combination	NN	_	25	com	_	_
25	therapies	therapy	NNS	_	34	dep	_	_
26	that	that	WDT	_	27	dep	_	_
27	take	take	VBP	_	25	relcl	_	_
28	advantage	advantage	NN	_	27	obj	_	_
29	of	of	IN	_	31	case	_	_
30	these	these	DT	_	31	det	_	_
31	differences	difference	NNS	_	28	ppmod	_	_
32	are	be	VBP	_	34	aux	_	_
33	being	be	VBG	_	34	aux	_	_
34	designed	design	VBN	_	21	conj	_	_
35	and	and	CC	_	34	cc	_	_
36	tested	test	VBN	_	34	conj	_	_
37	.	.	.	_	6	p	_	_

1	Interactions	interaction	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	in	in	IN	_	7	case	_	_
7	absorption	absorption	NN	_	1	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	retention	retention	NN	_	7	conj	_	_
10	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	36	dep	_	_
3	of	of	IN	_	6	case	_	_
4	supplementary	supplementary	JJ	_	6	attr	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	as	as	RB	_	11	com	_	_
11	well	well	RB	_	8	cc	_	_
12	as	as	IN	_	11	com	_	_
13	the	the	DT	_	14	det	_	_
14	interaction	interaction	NN	_	6	conj	_	_
15	between	between	IN	_	16	case	_	_
16	both	both	DT	_	14	ppmod	_	_
17	at	at	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	absorption	absorption	NN	_	20	com	_	_
20	site	site	NN	_	16	ppmod	_	_
21	,	,	,	_	14	p	_	_
22	fecal	fecal	JJ	_	25	attr	_	_
23	and	and	CC	_	25	cc	_	_
24	urinary	urinary	JJ	_	25	attr	_	_
25	excretion	excretion	NN	_	6	conj	_	_
26	as	as	RB	_	27	com	_	_
27	well	well	RB	_	25	cc	_	_
28	as	as	IN	_	27	com	_	_
29	the	the	DT	_	30	det	_	_
30	retention	retention	NN	_	6	conj	_	_
31	of	of	IN	_	34	case	_	_
32	these	these	DT	_	34	det	_	_
33	trace	trace	NN	_	34	com	_	_
34	elements	element	NNS	_	30	ppmod	_	_
35	were	be	VBD	_	36	aux	_	_
36	determined	determine	VBN	_	0	root	_	_
37	by	by	IN	_	38	case	_	_
38	using	use	VBG	_	36	ppmod	_	_
39	four	#crd#	CD	_	40	num	_	_
40	diets	diet	NNS	_	38	obj	_	_
41	containing	contain	VBG	_	40	acl	_	_
42	either	either	CC	_	46	cc	_	_
43	9	0	CD	_	46	num	_	_
44	or	or	CC	_	43	cc	_	_
45	63	0	CD	_	43	conj	_	_
46	micrograms/kg	micrograms/kg	NNS	_	41	obj	_	_
47	of	of	IN	_	48	case	_	_
48	drug3	drug0	NN	_	46	ppmod	_	_
49	and	and	CC	_	46	cc	_	_
50	48	0	CD	_	53	num	_	_
51	or	or	CC	_	50	cc	_	_
52	446	0	CD	_	50	conj	_	_
53	mg/kg	mg/kg	NN	_	46	conj	_	_
54	of	of	IN	_	55	case	_	_
55	drug4	drug0	NN	_	53	ppmod	_	_
56	over	over	IN	_	58	case	_	_
57	a	a	DT	_	58	det	_	_
58	period	period	NN	_	41	ppmod	_	_
59	of	of	IN	_	61	case	_	_
60	19	0	CD	_	61	num	_	_
61	days	day	NNS	_	58	ppmod	_	_
62	in	in	IN	_	64	case	_	_
63	a	a	DT	_	64	det	_	_
64	total	total	NN	_	61	ppmod	_	_
65	of	of	IN	_	67	case	_	_
66	24	0	CD	_	67	num	_	_
67	rats	rat	NNS	_	64	ppmod	_	_
68	.	.	.	_	36	p	_	_

1	Retention	retention	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	calculated	calculate	VBN	_	0	root	_	_
4	by	by	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	balance	balance	NN	_	7	com	_	_
7	technique	technique	NN	_	3	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	by	by	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	comparative	comparative	JJ	_	13	attr	_	_
12	slaughter	slaughter	NN	_	13	com	_	_
13	technique	technique	NN	_	7	conj	_	_
14	.	.	.	_	3	p	_	_

1	After	after	IN	_	3	case	_	_
2	one	#crd#	CD	_	3	num	_	_
3	day	day	NN	_	16	ppmod	_	_
4	,	,	,	_	16	p	_	_
5	fecal	fecal	NN	_	16	dep	_	_
6	as	as	RB	_	7	com	_	_
7	well	well	RB	_	5	cc	_	_
8	as	as	IN	_	7	com	_	_
9	urinary	urinary	JJ	_	10	attr	_	_
10	excretion	excretion	NN	_	5	conj	_	_
11	of	of	IN	_	13	case	_	_
12	both	both	DT	_	13	det	_	_
13	elements	element	NNS	_	10	ppmod	_	_
14	had	have	VBD	_	16	aux	_	_
15	already	already	RB	_	16	adv	_	_
16	responded	respond	VBD	_	0	root	_	_
17	to	to	TO	_	20	aux	_	_
18	the	the	DT	_	20	det	_	_
19	dietary	dietary	JJ	_	20	attr	_	_
20	treatments	treatment	NNS	_	16	ppmod	_	_
21	,	,	,	_	16	p	_	_
22	with	with	IN	_	26	case	_	_
23	constant	constant	NN	_	24	com	_	_
24	values	value	NNS	_	26	dep	_	_
25	being	be	VBG	_	26	aux	_	_
26	reached	reach	VBN	_	16	ppmod	_	_
27	after	after	IN	_	30	case	_	_
28	approximately	approximately	RB	_	29	adv	_	_
29	three	#crd#	CD	_	30	num	_	_
30	days	day	NNS	_	26	ppmod	_	_
31	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	excretion	excretion	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	enhanced	enhance	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	supplementary	supplementary	JJ	_	7	attr	_	_
7	drug2	drug0	NN	_	4	ppmod	_	_
8	;	;	:	_	4	p	_	_

1	fecal	fecal	JJ	_	2	attr	_	_
2	excretion	excretion	NN	_	7	dep	_	_
3	,	,	,	_	7	p	_	_
4	too	too	RB	_	7	adv	_	_
5	,	,	,	_	7	p	_	_
6	was	be	VBD	_	7	aux	_	_
7	increased	increase	VBN	_	0	root	_	_
8	by	by	IN	_	10	case	_	_
9	supplementary	supplementary	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	7	ppmod	_	_
11	;	;	:	_	7	p	_	_

1	whereas	whereas	IN	_	5	case	_	_
2	urinary	urinary	JJ	_	3	attr	_	_
3	excretion	excretion	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	decreased	decrease	VBN	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	both	both	DT	_	8	det	_	_
8	cases	case	NNS	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	Additional	additional	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	significantly	significantly	RB	_	4	adv	_	_
4	inhibited	inhibit	VBD	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	absorption	absorption	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	13	case	_	_
10	both	both	DT	_	13	det	_	_
11	dietary	dietary	JJ	_	13	attr	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	treatments	treatment	NNS	_	6	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	lower	low	JJR	_	3	attr	_	_
3	rate	rate	NN	_	22	dep	_	_
4	of	of	IN	_	5	case	_	_
5	absorption	absorption	NN	_	3	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	groups	group	NNS	_	5	ppmod	_	_
9	receiving	receive	VBG	_	8	acl	_	_
10	446	0	CD	_	11	num	_	_
11	mg	mg	NN	_	9	obj	_	_
12	drug1	drug0	NN	_	11	appo	_	_
13	instead	instead	RB	_	11	cc	_	_
14	of	of	IN	_	13	com	_	_
15	48	0	CD	_	16	num	_	_
16	mg	mg	NN	_	11	conj	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	per	per	IN	_	21	case	_	_
20	kg	kg	CD	_	21	num	_	_
21	diet	diet	NN	_	16	ppmod	_	_
22	resulted	result	VBD	_	0	root	_	_
23	in	in	IN	_	27	case	_	_
24	a	a	DT	_	27	det	_	_
25	decreased	decrease	VBN	_	27	attr	_	_
26	renal	renal	JJ	_	27	attr	_	_
27	excretion	excretion	NN	_	22	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	drug3	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	22	p	_	_

1	Consequently	consequently	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	the	the	DT	_	4	det	_	_
4	effect	effect	NN	_	12	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	retention	retention	NN	_	4	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	was	be	VBD	_	0	root	_	_
13	lower	low	JJR	_	12	dep	_	_
14	than	than	IN	_	16	case	_	_
15	on	on	IN	_	16	case	_	_
16	absorption	absorption	NN	_	13	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	This	this	DT	_	2	dep	_	_
2	suggests	suggest	VBZ	_	0	root	_	_
3	that	that	IN	_	10	mark	_	_
4	interactions	interaction	NNS	_	10	dep	_	_
5	between	between	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	two	#crd#	CD	_	8	num	_	_
8	elements	element	NNS	_	4	ppmod	_	_
9	only	only	RB	_	10	adv	_	_
10	take	take	VBP	_	2	comp	_	_
11	place	place	NN	_	10	obj	_	_
12	at	at	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	site	site	NN	_	10	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	absorption	absorption	NN	_	14	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	Because	because	IN	_	7	case	_	_
2	of	of	IN	_	7	case	_	_
3	the	the	DT	_	7	det	_	_
4	low	low	JJ	_	7	attr	_	_
5	dietary	dietary	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	concentration	concentration	NN	_	27	ppmod	_	_
8	as	as	IN	_	9	mark	_	_
9	compared	compare	VBN	_	7	acl	_	_
10	to	to	TO	_	13	aux	_	_
11	the	the	DT	_	13	det	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	contents	content	NNS	_	9	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	diets	diet	NNS	_	13	ppmod	_	_
17	,	,	,	_	27	p	_	_
18	no	no	DT	_	19	det	_	_
19	effect	effect	NN	_	27	dep	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	on	on	IN	_	24	case	_	_
23	drug4	drug0	NN	_	24	com	_	_
24	absorption	absorption	NN	_	19	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	excretion	excretion	NN	_	24	conj	_	_
27	occurred	occur	VBD	_	0	root	_	_
28	.	.	.	_	27	p	_	_

1	Differences	difference	NNS	_	7	dep	_	_
2	in	in	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	balance	balance	NN	_	1	ppmod	_	_
5	were	be	VBD	_	7	aux	_	_
6	only	only	RB	_	7	adv	_	_
7	observed	observe	VBN	_	0	root	_	_
8	between	between	IN	_	11	case	_	_
9	both	both	DT	_	11	det	_	_
10	dietary	dietary	JJ	_	11	attr	_	_
11	concentrations	concentration	NNS	_	7	ppmod	_	_
12	,	,	,	_	7	p	_	_
13	showing	show	VBG	_	7	comp	_	_
14	a	a	DT	_	21	det	_	_
15	higher	high	JJR	_	16	adv	_	_
16	absolute	absolute	JJ	_	21	attr	_	_
17	but	but	CC	_	16	cc	_	_
18	a	a	DT	_	20	det	_	_
19	lower	low	RBR	_	20	adv	_	_
20	relative	relative	JJ	_	16	conj	_	_
21	absorption	absorption	NN	_	13	obj	_	_
22	as	as	RB	_	23	com	_	_
23	well	well	RB	_	21	cc	_	_
24	as	as	IN	_	23	com	_	_
25	retention	retention	NN	_	21	conj	_	_
26	in	in	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	groups	group	NNS	_	13	ppmod	_	_
29	fed	feed	VBN	_	28	acl	_	_
30	further	far	JJ	_	31	attr	_	_
31	drug2	drug0	NN	_	29	obj	_	_
32	.	.	.	_	7	p	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	ABSTRACT	abstract	NN	_	7	prn	_	_
35	TRUNCATED	truncate	VBN	_	34	acl	_	_
36	AT	at	IN	_	38	case	_	_
37	250	0	CD	_	38	num	_	_
38	WORDS	word	NNS	_	35	ppmod	_	_
39	)	-rrb-	-RRB-	_	34	p	_	_

1	-LSB-Importance	-lsb-importance	NN	_	6	dep	_	_
2	of	of	IN	_	5	case	_	_
3	pharmacogenetics	pharmacogenetics	NNS	_	5	attr	_	_
4	]	-rsb-	-RRB-	_	5	p	_	_
5	Pharmacogenetics	pharmacogenetics	NNS	_	1	ppmod	_	_
6	deals	deal	VBZ	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	differences	difference	NNS	_	6	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	effect	effect	NN	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drugs	drug	NNS	_	11	ppmod	_	_
14	caused	cause	VBN	_	13	acl	_	_
15	by	by	IN	_	17	case	_	_
16	genetic	genetic	JJ	_	17	attr	_	_
17	variation	variation	NN	_	14	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	Differences	difference	NNS	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	occur	occur	VB	_	0	root	_	_
4	in	in	IN	_	6	case	_	_
5	therapeutic	therapeutic	JJ	_	6	attr	_	_
6	effect	effect	NN	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	in	in	IN	_	10	case	_	_
9	adverse	adverse	JJ	_	10	attr	_	_
10	events	event	NNS	_	6	conj	_	_
11	.	.	.	_	3	p	_	_

1	Genetic	genetic	JJ	_	2	attr	_	_
2	variation	variation	NN	_	6	dep	_	_
3	in	in	IN	_	4	case	_	_
4	metabolism	metabolism	NN	_	2	ppmod	_	_
5	may	may	MD	_	6	modal	_	_
6	result	result	VB	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	high	high	JJ	_	9	attr	_	_
9	concentrations	concentration	NNS	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drugs	drug	NNS	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	an	an	DT	_	15	det	_	_
14	increased	increase	VBN	_	15	attr	_	_
15	risk	risk	NN	_	11	conj	_	_
16	of	of	IN	_	18	case	_	_
17	adverse	adverse	JJ	_	18	attr	_	_
18	effects	effect	NNS	_	15	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	slow	slow	JJ	_	21	attr	_	_
21	metabolizers	metabolizers	NNS	_	15	ppmod	_	_
22	,	,	,	_	21	p	_	_
23	which	which	WDT	_	24	dep	_	_
24	is	be	VBZ	_	21	relcl	_	_
25	important	important	JJ	_	24	dep	_	_
26	when	when	WRB	_	27	adv	_	_
27	using	use	VBG	_	24	comp	_	_
28	for	for	IN	_	29	case	_	_
29	example	example	NN	_	27	ppmod	_	_
30	drug1	drug0	NN	_	27	obj	_	_
31	or	or	CC	_	30	cc	_	_
32	chemotherapy	chemotherapy	NN	_	30	conj	_	_
33	.	.	.	_	6	p	_	_

1	Genetic	genetic	JJ	_	2	attr	_	_
2	variation	variation	NN	_	4	dep	_	_
3	also	also	RB	_	4	adv	_	_
4	occurs	occur	VBZ	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	proteins	protein	NNS	_	4	ppmod	_	_
7	interacting	interact	VBG	_	6	acl	_	_
8	with	with	IN	_	9	case	_	_
9	drugs	drug	NNS	_	7	ppmod	_	_
10	,	,	,	_	4	p	_	_
11	which	which	WDT	_	13	dep	_	_
12	may	may	MD	_	13	modal	_	_
13	change	change	VB	_	4	comp	_	_
14	the	the	DT	_	15	det	_	_
15	effect	effect	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	e.g.	e.g.	FW	_	15	ppmod	_	_

1	asthma	asthma	NN	_	2	com	_	_
2	drugs	drug	NNS	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	drug1	drug0	NN	_	2	conj	_	_
5	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	selection	selection	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	their	their	PRP$	_	7	poss	_	_
7	dosages	dosage	NNS	_	4	conj	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	improved	improve	VBN	_	0	root	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	the	the	DT	_	14	det	_	_
14	number	number	NN	_	18	dep	_	_
15	of	of	IN	_	17	case	_	_
16	adverse	adverse	JJ	_	17	attr	_	_
17	effects	effect	NNS	_	14	ppmod	_	_
18	reduced	reduce	VBD	_	10	conj	_	_
19	by	by	IN	_	21	case	_	_
20	pharmacogenetic	pharmacogenetic	JJ	_	21	attr	_	_
21	investigations	investigation	NNS	_	18	ppmod	_	_
22	.	.	.	_	10	p	_	_

1	However	however	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	be	be	VB	_	0	root	_	_
6	important	important	JJ	_	5	dep	_	_
7	also	also	RB	_	9	adv	_	_
8	in	in	IN	_	9	case	_	_
9	case	case	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	medical	medical	JJ	_	12	attr	_	_
12	examinations	examination	NNS	_	9	ppmod	_	_
13	for	for	IN	_	14	case	_	_
14	insurances	insurance	NNS	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	job	job	NN	_	17	com	_	_
17	appointments	appointment	NNS	_	14	conj	_	_
18	,	,	,	_	5	p	_	_
19	since	since	IN	_	23	mark	_	_
20	some	some	DT	_	21	det	_	_
21	patients	patient	NNS	_	23	dep	_	_
22	may	may	MD	_	23	modal	_	_
23	turn	turn	NN	_	5	comp	_	_
24	out	out	RP	_	23	prt	_	_
25	to	to	TO	_	26	aux	_	_
26	need	need	VBP	_	23	comp	_	_
27	expensive	expensive	JJ	_	28	attr	_	_
28	drugs	drug	NNS	_	26	obj	_	_
29	or	or	CC	_	26	cc	_	_
30	to	to	TO	_	31	aux	_	_
31	be	be	VB	_	26	conj	_	_
32	susceptible	susceptible	JJ	_	31	dep	_	_
33	to	to	TO	_	36	aux	_	_
34	a	a	DT	_	36	det	_	_
35	certain	certain	JJ	_	36	attr	_	_
36	disease	disease	NN	_	32	ppmod	_	_
37	.	.	.	_	5	p	_	_

1	Therefore	therefore	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	4	det	_	_
4	use	use	NN	_	11	dep	_	_
5	of	of	IN	_	7	case	_	_
6	genetic	genetic	JJ	_	7	attr	_	_
7	data	datum	NNS	_	4	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	these	these	DT	_	10	det	_	_
10	instances	instance	NNS	_	4	ppmod	_	_
11	has	have	VBZ	_	0	root	_	_
12	to	to	TO	_	14	aux	_	_
13	be	be	VB	_	14	aux	_	_
14	regulated	regulate	VBN	_	11	comp	_	_
15	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	overdose	overdose	NN	_	3	dep	_	_
3	recognized	recognize	VBN	_	0	root	_	_
4	by	by	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	assay	assay	NN	_	3	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	Altered	altered	JJ	_	3	attr	_	_
2	mental	mental	JJ	_	3	attr	_	_
3	status	status	NN	_	7	dep	_	_
4	in	in	IN	_	6	case	_	_
5	an	an	DT	_	6	det	_	_
6	adolescent	adolescent	JJ	_	3	ppmod	_	_
7	presents	present	VBZ	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	diagnostic	diagnostic	JJ	_	10	attr	_	_
10	challenge	challenge	NN	_	7	obj	_	_
11	,	,	,	_	7	p	_	_
12	and	and	CC	_	7	cc	_	_
13	the	the	DT	_	14	det	_	_
14	clinician	clinician	NN	_	15	dep	_	_
15	depends	depend	VBZ	_	7	conj	_	_
16	on	on	IN	_	18	case	_	_
17	clinical	clinical	JJ	_	18	attr	_	_
18	evaluation	evaluation	NN	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	laboratory	laboratory	NN	_	21	com	_	_
21	studies	study	NNS	_	18	conj	_	_
22	to	to	TO	_	23	aux	_	_
23	determine	determine	VB	_	15	comp	_	_
24	therapy	therapy	NN	_	23	obj	_	_
25	and	and	CC	_	24	cc	_	_
26	prognosis	prognosis	NN	_	24	conj	_	_
27	.	.	.	_	7	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	report	report	VBP	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	case	case	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	an	an	DT	_	7	det	_	_
7	adolescent	adolescent	JJ	_	4	ppmod	_	_
8	with	with	IN	_	10	case	_	_
9	altered	altered	JJ	_	10	attr	_	_
10	consciousness	consciousness	NNS	_	7	ppmod	_	_
11	caused	cause	VBN	_	10	acl	_	_
12	by	by	IN	_	14	case	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	overdose	overdose	NN	_	11	ppmod	_	_
15	with	with	IN	_	19	case	_	_
16	a	a	DT	_	19	det	_	_
17	positive	positive	JJ	_	19	attr	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	level	level	NN	_	14	ppmod	_	_
20	to	to	TO	_	21	aux	_	_
21	alert	alert	VB	_	19	acl	_	_
22	clinicians	clinician	NNS	_	21	obj	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	cross-reactivity	cross-reactivity	NN	_	21	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	with	with	IN	_	31	case	_	_
29	a	a	DT	_	31	det	_	_
30	toxicology	toxicology	JJ	_	31	attr	_	_
31	screen	screen	NN	_	25	ppmod	_	_
32	for	for	IN	_	33	case	_	_
33	drug4	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Treatment	treatment	NN	_	2	com	_	_
2	plans	plan	NNS	_	9	dep	_	_
3	for	for	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	taking	take	VBG	_	4	acl	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	can	can	MD	_	9	modal	_	_
8	become	become	VB	_	9	aux	_	_
9	complicated	complicate	VBN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	predispose	predispose	VBP	_	0	root	_	_
3	a	a	DT	_	4	det	_	_
4	patient	patient	NN	_	2	obj	_	_
5	to	to	TO	_	7	aux	_	_
6	bleeding	bleeding	JJ	_	7	attr	_	_
7	problems	problem	NNS	_	2	ppmod	_	_
8	.	.	.	_	2	p	_	_

1	Many	many	JJ	_	2	attr	_	_
2	drugs	drug	NNS	_	8	dep	_	_
3	used	use	VBN	_	2	acl	_	_
4	in	in	IN	_	5	case	_	_
5	dentistry	dentistry	NN	_	3	ppmod	_	_
6	cannot	cannot	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	taken	take	VBN	_	0	root	_	_
9	concomitantly	concomitantly	RB	_	8	adv	_	_
10	with	with	IN	_	12	case	_	_
11	these	these	DT	_	12	det	_	_
12	medications	medication	NNS	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	Acute	acute	JJ	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	administration	administration	NN	_	6	dep	_	_
4	does	do	VBZ	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	affect	affect	VB	_	0	root	_	_
7	subjective	subjective	JJ	_	8	attr	_	_
8	responses	response	NNS	_	6	obj	_	_
9	to	to	TO	_	10	aux	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	humans	human	NNS	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	RATIONALE	rationale	NN	_	6	dep	_	_
2	:	:	:	_	1	p	_	_
3	Stress	stress	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug1	drug0	NN	_	1	conj	_	_
6	facilitate	facilitate	VBP	_	0	root	_	_
7	and	and	CC	_	6	cc	_	_
8	reinstate	reinstate	VB	_	6	conj	_	_
9	psychostimulant	psychostimulant	JJ	_	10	attr	_	_
10	self-administration	self-administration	NN	_	8	obj	_	_
11	in	in	IN	_	12	case	_	_
12	rodents	rodent	NNS	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	However	however	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	21	dep	_	_
5	of	of	IN	_	6	case	_	_
6	stress	stress	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug1	drug0	NN	_	6	conj	_	_
9	on	on	IN	_	14	case	_	_
10	the	the	DT	_	14	det	_	_
11	subjective	subjective	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	behavioral	behavioral	JJ	_	11	conj	_	_
14	effects	effect	NNS	_	4	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	have	have	VBP	_	21	aux	_	_
18	not	not	RB	_	21	neg	_	_
19	been	be	VBN	_	21	aux	_	_
20	well	well	RB	_	21	adv	_	_
21	studied	study	VBN	_	0	root	_	_
22	in	in	IN	_	23	case	_	_
23	humans	human	NNS	_	21	ppmod	_	_
24	.	.	.	_	21	p	_	_

1	OBJECTIVES	objective	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	To	to	TO	_	4	aux	_	_
4	examine	examine	VB	_	1	acl	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	acute	acute	JJ	_	10	attr	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	pretreatment	pretreatment	NN	_	6	ppmod	_	_
11	on	on	IN	_	16	case	_	_
12	the	the	DT	_	16	det	_	_
13	subjective	subjective	JJ	_	16	attr	_	_
14	and	and	CC	_	13	cc	_	_
15	behavioral	behavioral	JJ	_	13	conj	_	_
16	effects	effect	NNS	_	6	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	15	dep	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	100	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	and	and	CC	_	3	cc	_	_
9	drug2	drug0	NN	_	3	conj	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	20	0	CD	_	12	num	_	_
12	mg	mg	NN	_	9	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	were	be	VBD	_	15	aux	_	_
15	administered	administer	VBN	_	1	acl	_	_
16	orally	orally	RB	_	15	adv	_	_
17	to	to	TO	_	23	aux	_	_
18	16	0	CD	_	23	num	_	_
19	healthy	healthy	JJ	_	23	attr	_	_
20	male	male	JJ	_	23	attr	_	_
21	and	and	CC	_	20	cc	_	_
22	female	female	JJ	_	20	conj	_	_
23	volunteers	volunteer	NNS	_	15	ppmod	_	_
24	in	in	IN	_	33	case	_	_
25	a	a	DT	_	33	det	_	_
26	four-session	four-session	JJ	_	30	adv	_	_
27	,	,	,	_	30	p	_	_
28	placebo-controlled	placebo-controlled	JJ	_	30	adv	_	_
29	,	,	,	_	30	p	_	_
30	within-subject	within-subject	JJ	_	33	attr	_	_
31	,	,	,	_	33	p	_	_
32	crossover	crossover	NN	_	33	com	_	_
33	design	design	NN	_	23	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	To	to	TO	_	2	aux	_	_
2	prevent	prevent	VB	_	7	advcl	_	_
3	stomach	stomach	NN	_	4	com	_	_
4	irritation	irritation	NN	_	2	obj	_	_
5	,	,	,	_	7	p	_	_
6	subjects	subject	NNS	_	7	dep	_	_
7	received	receive	VBD	_	0	root	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	before	before	IN	_	12	case	_	_
10	each	each	DT	_	12	det	_	_
11	experimental	experimental	JJ	_	12	attr	_	_
12	session	session	NN	_	7	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	Dependent	dependent	JJ	_	2	attr	_	_
2	measures	measure	NNS	_	3	dep	_	_
3	included	include	VBD	_	0	root	_	_
4	self-reported	self-reported	JJ	_	5	attr	_	_
5	mood	mood	NN	_	3	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	subjective	subjective	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	5	conj	_	_
9	(	-lrb-	-LRB-	_	13	p	_	_
10	Addiction	addiction	NN	_	13	com	_	_
11	Research	research	NN	_	13	com	_	_
12	Center	center	NN	_	13	com	_	_
13	inventory	inventory	NN	_	5	prn	_	_
14	,	,	,	_	13	p	_	_
15	the	the	DT	_	16	det	_	_
16	profile	profile	NN	_	13	conj	_	_
17	of	of	IN	_	19	case	_	_
18	mood	mood	NN	_	19	com	_	_
19	states	state	NNS	_	16	ppmod	_	_
20	,	,	,	_	16	p	_	_
21	and	and	CC	_	16	cc	_	_
22	a	a	DT	_	23	det	_	_
23	series	series	NN	_	13	conj	_	_
24	of	of	IN	_	27	case	_	_
25	visual	visual	JJ	_	27	attr	_	_
26	analogue	analogue	NN	_	27	com	_	_
27	scales	scale	NNS	_	23	ppmod	_	_
28	)	-rrb-	-RRB-	_	13	p	_	_
29	,	,	,	_	5	p	_	_
30	vital	vital	JJ	_	31	attr	_	_
31	signs	sign	NNS	_	5	conj	_	_
32	,	,	,	_	31	p	_	_
33	salivary	salivary	JJ	_	34	attr	_	_
34	cortisol	cortisol	NN	_	5	conj	_	_
35	,	,	,	_	34	p	_	_
36	and	and	CC	_	34	cc	_	_
37	psychomotor	psychomotor	JJ	_	38	attr	_	_
38	performance	performance	NN	_	5	conj	_	_
39	.	.	.	_	3	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	elevated	elevate	VBD	_	1	acl	_	_
5	salivary	salivary	JJ	_	7	attr	_	_
6	cortisol	cortisol	NN	_	7	com	_	_
7	levels	level	NNS	_	4	obj	_	_
8	,	,	,	_	4	p	_	_
9	produced	produce	VBD	_	4	conj	_	_
10	modest	modest	JJ	_	11	attr	_	_
11	dysphoria	dysphoria	NN	_	9	obj	_	_
12	,	,	,	_	9	p	_	_
13	and	and	CC	_	9	cc	_	_
14	reduced	reduce	VBD	_	4	conj	_	_
15	subjects	subject	NNS	_	17	attr	_	_
16	'	'	POS	_	17	case	_	_
17	reports	report	NNS	_	14	obj	_	_
18	of	of	IN	_	21	case	_	_
19	wanting	wanting	JJ	_	21	attr	_	_
20	more	more	JJR	_	21	attr	_	_
21	drug	drug	NN	_	17	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	pretreatment	pretreatment	NN	_	7	dep	_	_
5	did	do	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	affect	affect	VB	_	0	root	_	_
8	any	any	DT	_	7	obj	_	_
9	of	of	IN	_	17	case	_	_
10	the	the	DT	_	17	det	_	_
11	physiological	physiological	JJ	_	17	attr	_	_
12	,	,	,	_	11	p	_	_
13	behavioral	behavioral	JJ	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	or	or	CC	_	13	cc	_	_
16	subjective	subjective	JJ	_	11	conj	_	_
17	effects	effect	NNS	_	8	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	.	.	.	_	7	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	In	in	IN	_	4	case	_	_
4	contrast	contrast	NN	_	16	ppmod	_	_
5	to	to	TO	_	7	aux	_	_
6	the	the	DT	_	7	det	_	_
7	effects	effect	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	rodent	rodent	JJ	_	12	attr	_	_
12	studies	study	NNS	_	7	ppmod	_	_
13	,	,	,	_	16	p	_	_
14	these	these	DT	_	15	det	_	_
15	results	result	NNS	_	16	dep	_	_
16	indicate	indicate	VBP	_	1	acl	_	_
17	that	that	IN	_	25	mark	_	_
18	an	an	DT	_	20	det	_	_
19	acute	acute	JJ	_	20	attr	_	_
20	increase	increase	NN	_	25	dep	_	_
21	in	in	IN	_	22	case	_	_
22	cortisol	cortisol	NN	_	20	ppmod	_	_
23	does	do	VBZ	_	25	aux	_	_
24	not	not	RB	_	25	neg	_	_
25	enhance	enhance	VB	_	16	comp	_	_
26	the	the	DT	_	28	det	_	_
27	psychostimulant	psychostimulant	JJ	_	28	attr	_	_
28	effects	effect	NNS	_	25	obj	_	_
29	of	of	IN	_	30	case	_	_
30	drug2	drug0	NN	_	28	ppmod	_	_
31	in	in	IN	_	32	case	_	_
32	humans	human	NNS	_	28	ppmod	_	_
33	.	.	.	_	1	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	7	case	_	_
5	drug2	drug0	JJ	_	7	attr	_	_
6	-induced	-induced	JJ	_	7	attr	_	_
7	changes	change	NNS	_	1	ppmod	_	_
8	in	in	IN	_	11	case	_	_
9	steroid	steroid	NN	_	11	com	_	_
10	hormone	hormone	NN	_	11	com	_	_
11	levels	level	NNS	_	7	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	lethality	lethality	NN	_	11	conj	_	_
14	in	in	IN	_	16	case	_	_
15	male	male	JJ	_	16	attr	_	_
16	rats	rat	NNS	_	13	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	examined	examine	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	exogenous	exogenous	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	changes	change	NNS	_	4	ppmod	_	_
11	in	in	IN	_	15	case	_	_
12	serum	serum	NN	_	15	com	_	_
13	steroid	steroid	NN	_	15	com	_	_
14	hormone	hormone	NN	_	15	com	_	_
15	levels	level	NNS	_	10	ppmod	_	_
16	induced	induce	VBN	_	15	acl	_	_
17	by	by	IN	_	20	case	_	_
18	a	a	DT	_	20	det	_	_
19	nonlethal	nonlethal	JJ	_	20	attr	_	_
20	dose	dose	NN	_	16	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	Escherichia	escherichia	FW	_	23	adv	_	_
23	coli	coli	FW	_	24	attr	_	_
24	drug2	drug0	NN	_	20	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	male	male	JJ	_	27	attr	_	_
27	rats	rat	NNS	_	24	ppmod	_	_
28	and	and	CC	_	10	cc	_	_
29	the	the	DT	_	30	det	_	_
30	deaths	death	NNS	_	10	conj	_	_
31	due	due	JJ	_	30	attr	_	_
32	to	to	TO	_	36	aux	_	_
33	nonlethal	nonlethal	JJ	_	36	attr	_	_
34	and	and	CC	_	33	cc	_	_
35	lethal	lethal	JJ	_	33	conj	_	_
36	doses	dose	NNS	_	31	ppmod	_	_
37	of	of	IN	_	38	case	_	_
38	drug3	drug0	NN	_	36	ppmod	_	_
39	.	.	.	_	2	p	_	_

1	Injection	injection	NN	_	12	dep	_	_
2	of	of	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	attr	_	_
4	5	0	CD	_	5	num	_	_
5	min	min	NN	_	1	ppmod	_	_
6	before	before	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	nonlethal	nonlethal	JJ	_	9	attr	_	_
9	dose	dose	NN	_	5	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	changed	change	VBD	_	0	root	_	_
13	the	the	DT	_	18	det	_	_
14	serum	serum	NN	_	18	com	_	_
15	sex	sex	NN	_	18	com	_	_
16	steroid	steroid	NN	_	18	com	_	_
17	hormone	hormone	NN	_	18	com	_	_
18	response	response	NN	_	12	obj	_	_
19	of	of	IN	_	21	case	_	_
20	male	male	JJ	_	21	attr	_	_
21	rats	rat	NNS	_	18	ppmod	_	_
22	to	to	TO	_	23	aux	_	_
23	drug3	drug0	NN	_	18	ppmod	_	_
24	.	.	.	_	12	p	_	_

1	The	the	DT	_	4	det	_	_
2	serum	serum	NN	_	4	com	_	_
3	estrogen	estrogen	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	11	dep	_	_
5	of	of	IN	_	10	case	_	_
6	drug1	drug0	NN	_	10	attr	_	_
7	+	+	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	-treated	-treated	JJ	_	10	attr	_	_
10	rats	rat	NNS	_	4	ppmod	_	_
11	decreased	decrease	VBD	_	0	root	_	_
12	by	by	IN	_	13	case	_	_
13	50	0	CD	_	11	ppmod	_	_
14	%	%	NN	_	13	meta	_	_
15	,	,	,	_	11	p	_	_
16	while	while	IN	_	23	mark	_	_
17	those	those	DT	_	23	dep	_	_
18	of	of	IN	_	22	case	_	_
19	the	the	DT	_	22	det	_	_
20	drug3	drug0	CD	_	22	num	_	_
21	-treated	-treated	JJ	_	22	attr	_	_
22	rats	rat	NNS	_	17	ppmod	_	_
23	increased	increase	VBD	_	11	comp	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	2-	0-	CD	_	23	num	_	_
26	to	to	TO	_	25	attr	_	_
27	5-fold	0-fold	JJ	_	25	attr	_	_
28	)	-rrb-	-RRB-	_	25	p	_	_
29	.	.	.	_	11	p	_	_

1	The	the	DT	_	4	det	_	_
2	serum	serum	NN	_	4	com	_	_
3	androgen	androgen	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	13	dep	_	_
5	of	of	IN	_	10	case	_	_
6	drug1	drug0	NN	_	10	attr	_	_
7	+	+	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	-treated	-treated	JJ	_	10	attr	_	_
10	rats	rat	NNS	_	4	ppmod	_	_
11	did	do	VBD	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	change	change	VB	_	0	root	_	_
14	significantly	significantly	RB	_	13	adv	_	_
15	,	,	,	_	13	p	_	_
16	while	while	IN	_	22	mark	_	_
17	those	those	DT	_	22	dep	_	_
18	of	of	IN	_	21	case	_	_
19	drug3	drug0	NN	_	21	attr	_	_
20	-treated	-treated	JJ	_	21	attr	_	_
21	rats	rat	NNS	_	17	ppmod	_	_
22	dropped	drop	VBD	_	13	comp	_	_
23	to	to	TO	_	24	aux	_	_
24	30-40	0	CD	_	22	ppmod	_	_
25	%	%	NN	_	24	meta	_	_

1	0.001	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Exogenous	exogenous	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	also	also	RB	_	4	adv	_	_
4	appeared	appear	VBD	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	influence	influence	VB	_	4	comp	_	_
7	the	the	DT	_	8	det	_	_
8	percentage	percentage	NN	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	drug2	drug0	JJ	_	12	attr	_	_
11	-induced	-induced	JJ	_	12	attr	_	_
12	deaths	death	NNS	_	8	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	dose-dependent	dose-dependent	JJ	_	16	attr	_	_
16	manner	manner	NN	_	6	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	reduced	reduce	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	number	number	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	deaths	death	NNS	_	4	ppmod	_	_
7	induced	induce	VBN	_	6	acl	_	_
8	by	by	IN	_	14	case	_	_
9	nonlethal	nonlethal	JJ	_	14	attr	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	2	0	CD	_	12	num	_	_
12	mg/kg	mg/kg	NN	_	14	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	dose	dose	NN	_	7	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	but	but	CC	_	2	cc	_	_
18	increased	increase	VBD	_	2	conj	_	_
19	the	the	DT	_	20	det	_	_
20	number	number	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	deaths	death	NNS	_	20	ppmod	_	_
23	induced	induce	VBN	_	22	acl	_	_
24	by	by	IN	_	28	case	_	_
25	a	a	DT	_	28	det	_	_
26	highly	highly	RB	_	27	adv	_	_
27	lethal	lethal	JJ	_	28	attr	_	_
28	dose	dose	NN	_	23	ppmod	_	_
29	(	-lrb-	-LRB-	_	31	p	_	_
30	8	0	CD	_	31	num	_	_
31	mg/kg	mg/kg	NN	_	28	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	16	dep	_	_
3	,	,	,	_	16	p	_	_
4	together	together	RB	_	8	adv	_	_
5	with	with	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	known	known	JJ	_	8	attr	_	_
8	relationships	relationship	NNS	_	16	ppmod	_	_
9	between	between	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	the	the	DT	_	14	det	_	_
13	immune	immune	JJ	_	14	attr	_	_
14	response	response	NN	_	10	conj	_	_
15	,	,	,	_	16	p	_	_
16	suggest	suggest	VBP	_	0	root	_	_
17	that	that	IN	_	19	mark	_	_
18	drug2	drug0	NNS	_	19	dep	_	_
19	affect	affect	VBP	_	16	comp	_	_
20	the	the	DT	_	21	det	_	_
21	course	course	NN	_	19	obj	_	_
22	of	of	IN	_	24	case	_	_
23	septic	septic	JJ	_	24	attr	_	_
24	shock	shock	NN	_	21	ppmod	_	_
25	in	in	IN	_	28	case	_	_
26	a	a	DT	_	28	det	_	_
27	complex	complex	JJ	_	28	attr	_	_
28	fashion	fashion	NN	_	19	ppmod	_	_
29	and	and	CC	_	19	cc	_	_
30	may	may	MD	_	31	modal	_	_
31	have	have	VB	_	19	conj	_	_
32	either	either	CC	_	33	cc	_	_
33	protective	protective	JJ	_	36	attr	_	_
34	or	or	CC	_	33	cc	_	_
35	deleterious	deleterious	JJ	_	33	conj	_	_
36	effect	effect	NN	_	31	obj	_	_
37	.	.	.	_	16	p	_	_

1	Studies	study	NNS	_	0	root	_	_
2	on	on	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	mechanism	mechanism	NN	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	action	action	NN	_	4	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	:	:	:	_	1	p	_	_
10	effect	effect	NN	_	1	appo	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	on	on	IN	_	14	case	_	_
14	respiration	respiration	NN	_	10	ppmod	_	_
15	and	and	CC	_	10	cc	_	_
16	cell	cell	NN	_	17	com	_	_
17	permeability	permeability	NN	_	10	conj	_	_
18	of	of	IN	_	20	case	_	_
19	Candida	candida	NN	_	20	com	_	_
20	albicans	albicans	NNS	_	17	ppmod	_	_
21	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	,	,	,	_	2	p	_	_
4	drug2	drug0	NN	_	2	appo	_	_
5	,	,	,	_	2	p	_	_
6	inhibits	inhibit	VBZ	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	growth	growth	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	several	several	JJ	_	11	attr	_	_
11	species	species	NNS	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	Candida	candida	NN	_	11	ppmod	_	_
14	.	.	.	_	6	p	_	_

1	Candida	candida	NN	_	2	com	_	_
2	albicans	albicans	NNS	_	12	dep	_	_
3	,	,	,	_	2	p	_	_
4	one	#crd#	CD	_	2	appo	_	_
5	of	of	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	pathogenic	pathogenic	JJ	_	8	attr	_	_
8	species	species	NNS	_	4	ppmod	_	_
9	,	,	,	_	2	p	_	_
10	was	be	VBD	_	12	aux	_	_
11	totally	totally	RB	_	12	adv	_	_
12	inhibited	inhibit	VBN	_	0	root	_	_
13	at	at	IN	_	15	case	_	_
14	a	a	DT	_	15	det	_	_
15	concentration	concentration	NN	_	12	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	approximately	approximately	RB	_	18	adv	_	_
18	10	0	CD	_	19	num	_	_
19	mug/ml	mug/ml	NN	_	15	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	Endogenous	endogenous	JJ	_	2	attr	_	_
2	respiration	respiration	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	unaffected	unaffected	VBN	_	0	root	_	_
5	by	by	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	drug	drug	NN	_	4	ppmod	_	_
8	at	at	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	concentration	concentration	NN	_	7	ppmod	_	_
11	as	as	RB	_	12	adv	_	_
12	high	high	JJ	_	10	attr	_	_
13	as	as	IN	_	15	case	_	_
14	100	0	CD	_	15	num	_	_
15	mug/ml	mug/ml	NN	_	12	ppmod	_	_
16	,	,	,	_	4	p	_	_
17	whereas	whereas	IN	_	20	mark	_	_
18	exogenous	exogenous	JJ	_	19	attr	_	_
19	respiration	respiration	NN	_	20	dep	_	_
20	was	be	VBD	_	4	comp	_	_
21	markedly	markedly	RB	_	22	adv	_	_
22	sensitive	sensitive	JJ	_	20	dep	_	_
23	and	and	CC	_	22	cc	_	_
24	inhibited	inhibit	VBN	_	22	conj	_	_
25	to	to	TO	_	27	aux	_	_
26	an	an	DT	_	27	det	_	_
27	extent	extent	NN	_	24	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	85	0	CD	_	27	ppmod	_	_
30	%	%	NN	_	29	meta	_	_
31	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	permeability	permeability	NN	_	8	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	cell	cell	NN	_	6	com	_	_
6	membrane	membrane	NN	_	2	ppmod	_	_
7	was	be	VBD	_	8	aux	_	_
8	changed	change	VBN	_	0	root	_	_
9	as	as	IN	_	10	mark	_	_
10	evidenced	evidence	VBN	_	8	comp	_	_
11	by	by	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	leakage	leakage	NN	_	10	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	260-nm	0-nm	JJ	_	17	attr	_	_
16	absorbing	absorbing	JJ	_	17	attr	_	_
17	materials	material	NNS	_	13	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	amino	amino	NN	_	20	com	_	_
20	acids	acid	NNS	_	17	conj	_	_
21	,	,	,	_	20	p	_	_
22	proteins	protein	NNS	_	17	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	inorganic	inorganic	JJ	_	26	attr	_	_
26	cations	cation	NNS	_	17	conj	_	_
27	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	6	dep	_	_
3	we	we	PRP	_	4	advnp	_	_
4	present	present	JJ	_	2	attr	_	_
5	clearly	clearly	RB	_	6	adv	_	_
6	show	show	VBP	_	0	root	_	_
7	that	that	IN	_	10	mark	_	_
8	the	the	DT	_	9	det	_	_
9	drug	drug	NN	_	10	dep	_	_
10	alters	alter	VBZ	_	6	comp	_	_
11	the	the	DT	_	13	det	_	_
12	cellular	cellular	JJ	_	13	attr	_	_
13	permeability	permeability	NN	_	10	obj	_	_
14	,	,	,	_	10	p	_	_
15	and	and	CC	_	10	cc	_	_
16	thus	thus	RB	_	20	adv	_	_
17	the	the	DT	_	19	det	_	_
18	exogenous	exogenous	JJ	_	19	attr	_	_
19	respiration	respiration	NN	_	20	dep	_	_
20	becomes	become	VBZ	_	10	conj	_	_
21	sensitive	sensitive	JJ	_	20	dep	_	_
22	to	to	TO	_	24	aux	_	_
23	the	the	DT	_	24	det	_	_
24	drug	drug	NN	_	21	ppmod	_	_
25	.	.	.	_	6	p	_	_

1	Interferon	interferon	NN	_	2	com	_	_
2	induction	induction	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	tool	tool	NN	_	2	appo	_	_
5	for	for	IN	_	6	case	_	_
6	establishing	establish	VBG	_	4	ppmod	_	_
7	interactions	interaction	NNS	_	6	obj	_	_
8	among	among	IN	_	9	case	_	_
9	homopolyribonucleotides	homopolyribonucleotides	NNS	_	7	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	Hitherto	hitherto	RB	_	2	adv	_	_
2	unrecognized	unrecognized	JJ	_	3	attr	_	_
3	interactions	interaction	NNS	_	10	dep	_	_
4	between	between	IN	_	5	case	_	_
5	homopolyribonucleotides	homopolyribonucleotides	NNS	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	complexes	complex	NNS	_	5	conj	_	_
8	thereof	thereof	RB	_	10	adv	_	_
9	are	be	VBP	_	10	aux	_	_
10	suggested	suggest	VBN	_	0	root	_	_
11	by	by	IN	_	14	case	_	_
12	interferon	interferon	NN	_	14	com	_	_
13	induction	induction	NN	_	14	com	_	_
14	data	datum	NNS	_	10	ppmod	_	_
15	obtained	obtain	VBN	_	14	acl	_	_
16	in	in	IN	_	21	case	_	_
17	a	a	DT	_	21	det	_	_
18	highly	highly	RB	_	19	adv	_	_
19	sensitive	sensitive	JJ	_	21	attr	_	_
20	assay	assay	NN	_	21	com	_	_
21	system	system	NN	_	15	ppmod	_	_
22	of	of	IN	_	27	case	_	_
23	primary	primary	JJ	_	27	attr	_	_
24	rabbit	rabbit	NN	_	27	com	_	_
25	kidney	kidney	NN	_	27	com	_	_
26	cell	cell	NN	_	27	com	_	_
27	cultures	culture	NNS	_	21	ppmod	_	_
28	superinduced	superinduced	VBN	_	27	acl	_	_
29	by	by	IN	_	31	case	_	_
30	metabolic	metabolic	JJ	_	31	attr	_	_
31	inhibitors	inhibitor	NNS	_	28	ppmod	_	_
32	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	5	p	_	_
3	a	a	DT	_	5	det	_	_
4	therapeutic	therapeutic	JJ	_	5	attr	_	_
5	update	update	NN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Since	since	IN	_	5	case	_	_
4	its	its	PRP$	_	5	poss	_	_
5	approval	approval	NN	_	20	ppmod	_	_
6	by	by	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	US	us	PRP	_	5	ppmod	_	_
9	Food	food	NN	_	8	appo	_	_
10	and	and	CC	_	9	cc	_	_
11	Drug	drug	NN	_	12	com	_	_
12	Administration	administration	NN	_	9	conj	_	_
13	in	in	IN	_	14	case	_	_
14	March	march	NNP	_	5	ppmod	_	_
15	1998	0	CD	_	14	num	_	_
16	,	,	,	_	20	p	_	_
17	drug1	drug0	NN	_	20	dep	_	_
18	has	have	VBZ	_	20	aux	_	_
19	been	be	VBN	_	20	aux	_	_
20	used	use	VBN	_	1	acl	_	_
21	by	by	IN	_	22	case	_	_
22	millions	#crd#	NNS	_	20	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	men	man	NNS	_	22	ppmod	_	_
25	for	for	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	treatment	treatment	NN	_	20	ppmod	_	_
28	of	of	IN	_	30	case	_	_
29	erectile	erectile	JJ	_	30	attr	_	_
30	dysfunction	dysfunction	NN	_	27	ppmod	_	_
31	.	.	.	_	1	p	_	_

1	Recent	recent	JJ	_	2	attr	_	_
2	studies	study	NNS	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	consensus	consensus	NN	_	5	com	_	_
5	reports	report	NNS	_	2	conj	_	_
6	have	have	VBP	_	7	aux	_	_
7	expanded	expand	VBN	_	0	root	_	_
8	our	our	PRP$	_	9	poss	_	_
9	understanding	understanding	NN	_	7	obj	_	_
10	of	of	IN	_	12	case	_	_
11	its	its	PRP$	_	12	poss	_	_
12	efficacy	efficacy	NN	_	9	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	safety	safety	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	contraindications	contraindication	NNS	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	drug	drug	NN	_	20	com	_	_
20	interactions	interaction	NNS	_	12	conj	_	_
21	.	.	.	_	7	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	This	this	DT	_	4	det	_	_
4	paper	paper	NN	_	5	dep	_	_
5	reviews	review	VBZ	_	1	acl	_	_
6	recent	recent	JJ	_	7	attr	_	_
7	studies	study	NNS	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	efficacy	efficacy	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	its	its	PRP$	_	16	poss	_	_
15	adverse	adverse	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	12	conj	_	_
17	and	and	CC	_	16	cc	_	_
18	drug	drug	NN	_	19	com	_	_
19	interactions	interaction	NNS	_	16	conj	_	_
20	,	,	,	_	16	p	_	_
21	and	and	CC	_	16	cc	_	_
22	socioeconomic	socioeconomic	JJ	_	23	attr	_	_
23	factors	factor	NNS	_	12	conj	_	_
24	involved	involve	VBN	_	23	acl	_	_
25	in	in	IN	_	27	case	_	_
26	its	its	PRP$	_	27	poss	_	_
27	use	use	NN	_	24	ppmod	_	_
28	,	,	,	_	5	p	_	_
29	with	with	IN	_	31	case	_	_
30	a	a	DT	_	31	det	_	_
31	focus	focus	NN	_	5	ppmod	_	_
32	on	on	IN	_	35	case	_	_
33	specific	specific	JJ	_	35	attr	_	_
34	patient	patient	NN	_	35	com	_	_
35	populations	population	NNS	_	31	ppmod	_	_
36	(	-lrb-	-LRB-	_	38	p	_	_
37	prostate	prostate	NN	_	38	com	_	_
38	cancer	cancer	NN	_	35	prn	_	_
39	,	,	,	_	38	p	_	_
40	diabetes	diabetes	NN	_	41	com	_	_
41	mellitus	mellitus	NN	_	38	appo	_	_
42	,	,	,	_	38	p	_	_
43	ischemic	ischemic	JJ	_	45	attr	_	_
44	heart	heart	NN	_	45	com	_	_
45	disease	disease	NN	_	38	appo	_	_
46	,	,	,	_	38	p	_	_
47	spinal	spinal	JJ	_	49	attr	_	_
48	cord	cord	NN	_	49	com	_	_
49	injuries	injuries	NN	_	38	appo	_	_
50	,	,	,	_	38	p	_	_
51	neurologic	neurologic	JJ	_	52	attr	_	_
52	disorders	disorder	NNS	_	38	appo	_	_
53	)	-rrb-	-RRB-	_	38	p	_	_
54	.	.	.	_	1	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	4	attr	_	_
4	studies	study	NNS	_	27	dep	_	_
5	,	,	,	_	4	p	_	_
6	case	case	NN	_	7	com	_	_
7	reports	report	NNS	_	4	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	commentaries	commentary	NNS	_	4	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	editorials	editorial	NNS	_	10	conj	_	_
13	concerning	concern	VBG	_	4	acl	_	_
14	drug1	drug0	NN	_	13	obj	_	_
15	published	publish	VBN	_	14	acl	_	_
16	in	in	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	international	international	NNP	_	19	com	_	_
19	literature	literature	NN	_	15	ppmod	_	_
20	between	between	IN	_	21	case	_	_
21	January	january	NNP	_	19	ppmod	_	_
22	1999	0	CD	_	21	num	_	_
23	and	and	CC	_	21	cc	_	_
24	August	august	NNP	_	21	conj	_	_
25	2000	0	CD	_	24	num	_	_
26	were	be	VBD	_	27	aux	_	_
27	identified	identify	VBN	_	1	acl	_	_
28	through	through	IN	_	29	case	_	_
29	searches	search	NNS	_	27	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	MEDLINE	medline	NN	_	29	ppmod	_	_
32	,	,	,	_	31	p	_	_
33	PREMEDLINE	premedline	NN	_	31	conj	_	_
34	,	,	,	_	33	p	_	_
35	and	and	CC	_	33	cc	_	_
36	International	international	NNP	_	38	attr	_	_
37	Pharmaceutical	pharmaceutical	JJ	_	38	attr	_	_
38	Abstracts	abstracts	NN	_	31	conj	_	_
39	,	,	,	_	27	p	_	_
40	using	use	VBG	_	27	comp	_	_
41	the	the	DT	_	42	det	_	_
42	terms	term	NNS	_	40	obj	_	_
43	drug2	drug0	NN	_	42	attr	_	_
44	,	,	,	_	43	p	_	_
45	drug3	drug0	NN	_	43	conj	_	_
46	,	,	,	_	45	p	_	_
47	and	and	CC	_	45	cc	_	_
48	erectile	erectile	JJ	_	49	attr	_	_
49	dysfunction	dysfunction	NN	_	43	conj	_	_
50	.	.	.	_	1	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	has	have	VBZ	_	5	aux	_	_
5	demonstrated	demonstrate	VBN	_	1	acl	_	_
6	effectiveness	effectiveness	NN	_	5	obj	_	_
7	in	in	IN	_	8	case	_	_
8	men	man	NNS	_	6	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	erectile	erectile	JJ	_	11	attr	_	_
11	dysfunction	dysfunction	NN	_	8	ppmod	_	_
12	associated	associate	VBN	_	11	acl	_	_
13	with	with	IN	_	14	case	_	_
14	prostatectomy	prostatectomy	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	radiation	radiation	NN	_	17	com	_	_
17	therapy	therapy	NN	_	14	conj	_	_
18	,	,	,	_	17	p	_	_
19	diabetes	diabetes	NN	_	20	com	_	_
20	mellitus	mellitus	NN	_	14	conj	_	_
21	,	,	,	_	20	p	_	_
22	certain	certain	JJ	_	24	attr	_	_
23	neurologic	neurologic	JJ	_	24	attr	_	_
24	disorders	disorder	NNS	_	14	conj	_	_
25	,	,	,	_	24	p	_	_
26	and	and	CC	_	24	cc	_	_
27	drug	drug	NN	_	28	com	_	_
28	therapy	therapy	NN	_	14	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	eg	eg	NN	_	28	prn	_	_
31	,	,	,	_	30	p	_	_
32	drug2	drug0	NN	_	30	appo	_	_
33	[	-lsb-	-LRB-	_	34	p	_	_
34	drug3	drug0	NN	_	32	prn	_	_
35	]	-rsb-	-RRB-	_	34	p	_	_
36	)	-rrb-	-RRB-	_	30	p	_	_
37	.	.	.	_	1	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	been	be	VBN	_	0	root	_	_
5	as	as	RB	_	6	adv	_	_
6	effective	effective	JJ	_	4	dep	_	_
7	in	in	IN	_	8	case	_	_
8	women	woman	NNS	_	6	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	sexual	sexual	JJ	_	11	attr	_	_
11	dysfunction	dysfunction	NN	_	8	ppmod	_	_
12	,	,	,	_	6	p	_	_
13	with	with	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	exception	exception	NN	_	6	ppmod	_	_
16	of	of	IN	_	20	case	_	_
17	drug1	drug0	NN	_	20	attr	_	_
18	-associated	-associated	JJ	_	20	attr	_	_
19	sexual	sexual	JJ	_	20	attr	_	_
20	dysfunction	dysfunction	NN	_	15	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Some	some	DT	_	2	det	_	_
2	disorders	disorder	NNS	_	16	dep	_	_
3	unrelated	unrelated	JJ	_	2	attr	_	_
4	to	to	TO	_	6	aux	_	_
5	sexual	sexual	JJ	_	6	attr	_	_
6	dysfunction	dysfunction	NN	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	eg	eg	NN	_	6	prn	_	_
9	,	,	,	_	8	p	_	_
10	esophageal	esophageal	JJ	_	12	attr	_	_
11	motility	motility	NN	_	12	com	_	_
12	dysfunction	dysfunction	NN	_	8	appo	_	_
13	)	-rrb-	-RRB-	_	8	p	_	_
14	may	may	MD	_	16	modal	_	_
15	also	also	RB	_	16	adv	_	_
16	respond	respond	VB	_	0	root	_	_
17	to	to	TO	_	18	aux	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	16	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	general	general	JJ	_	4	attr	_	_
4	population	population	NN	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	considered	consider	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	have	have	VB	_	8	comp	_	_
11	an	an	DT	_	14	det	_	_
12	acceptable	acceptable	JJ	_	14	attr	_	_
13	tolerability	tolerability	NN	_	14	com	_	_
14	profile	profile	NN	_	10	obj	_	_
15	;	;	:	_	8	p	_	_

1	however	however	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	patients	patient	NNS	_	15	dep	_	_
4	with	with	IN	_	9	case	_	_
5	moderate	moderate	JJ	_	7	adv	_	_
6	to	to	TO	_	7	adv	_	_
7	severe	severe	JJ	_	9	attr	_	_
8	cardiovascular	cardiovascular	JJ	_	9	attr	_	_
9	disease	disease	NN	_	3	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	those	those	DT	_	9	conj	_	_
12	taking	take	VBG	_	11	acl	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	therapy	therapy	NN	_	12	obj	_	_
15	are	be	VBP	_	0	root	_	_
16	at	at	IN	_	18	case	_	_
17	increased	increase	VBN	_	18	attr	_	_
18	risk	risk	NN	_	15	ppmod	_	_
19	for	for	IN	_	24	case	_	_
20	potentially	potentially	RB	_	21	adv	_	_
21	serious	serious	JJ	_	22	adv	_	_
22	cardiovascular	cardiovascular	JJ	_	24	attr	_	_
23	adverse	adverse	JJ	_	24	attr	_	_
24	effects	effect	NNS	_	18	ppmod	_	_
25	with	with	IN	_	27	case	_	_
26	drug2	drug0	NN	_	27	com	_	_
27	therapy	therapy	NN	_	24	ppmod	_	_
28	.	.	.	_	15	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	20	ppmod	_	_
3	,	,	,	_	20	p	_	_
4	patients	patient	NNS	_	20	dep	_	_
5	taking	take	VBG	_	4	acl	_	_
6	drugs	drug	NNS	_	5	obj	_	_
7	that	that	WDT	_	8	dep	_	_
8	inhibit	inhibit	VBP	_	6	relcl	_	_
9	the	the	DT	_	12	det	_	_
10	cytochrome	cytochrome	NN	_	12	com	_	_
11	P450	p0	NN	_	12	com	_	_
12	3A4	0a0	NN	_	13	com	_	_
13	isozyme	isozyme	NN	_	8	obj	_	_
14	,	,	,	_	13	p	_	_
15	which	which	WDT	_	16	dep	_	_
16	metabolizes	metabolize	VBZ	_	13	relcl	_	_
17	drug1	drug0	NN	_	16	obj	_	_
18	,	,	,	_	13	p	_	_
19	may	may	MD	_	20	modal	_	_
20	experience	experience	VBP	_	0	root	_	_
21	increased	increase	VBN	_	23	attr	_	_
22	drug	drug	NN	_	23	com	_	_
23	concentrations	concentration	NNS	_	20	obj	_	_
24	and	and	CC	_	23	cc	_	_
25	possible	possible	JJ	_	26	attr	_	_
26	toxicity	toxicity	NN	_	23	conj	_	_
27	from	from	IN	_	29	case	_	_
28	normal	normal	JJ	_	29	attr	_	_
29	doses	dose	NNS	_	20	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	drug2	drug0	NN	_	29	ppmod	_	_
32	.	.	.	_	20	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	an	an	DT	_	8	det	_	_
6	effective	effective	JJ	_	8	attr	_	_
7	first-line	first-line	NN	_	8	com	_	_
8	therapy	therapy	NN	_	4	obj	_	_
9	for	for	IN	_	11	case	_	_
10	erectile	erectile	JJ	_	11	attr	_	_
11	dysfunction	dysfunction	NN	_	8	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	men	man	NNS	_	11	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	decision	decision	NN	_	8	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	prescribe	prescribe	VB	_	2	acl	_	_
5	this	this	DT	_	6	det	_	_
6	agent	agent	NN	_	4	obj	_	_
7	should	should	MD	_	8	modal	_	_
8	include	include	VB	_	0	root	_	_
9	such	such	JJ	_	10	attr	_	_
10	considerations	consideration	NNS	_	8	obj	_	_
11	as	as	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	cost-risk-benefit	cost-risk-benefit	JJ	_	14	attr	_	_
14	balance	balance	NN	_	10	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	patient	patient	NN	_	17	com	_	_
17	access	access	NN	_	14	conj	_	_
18	,	,	,	_	17	p	_	_
19	drug	drug	NN	_	21	com	_	_
20	distribution	distribution	NN	_	21	com	_	_
21	pathways	pathway	NNS	_	14	conj	_	_
22	,	,	,	_	21	p	_	_
23	and	and	CC	_	21	cc	_	_
24	prescription	prescription	NN	_	26	com	_	_
25	drug	drug	NN	_	26	com	_	_
26	coverage	coverage	NN	_	14	conj	_	_
27	.	.	.	_	8	p	_	_

1	Tumor	tumor	NN	_	2	com	_	_
2	phenotype	phenotype	NN	_	0	root	_	_
3	and	and	CC	_	2	cc	_	_
4	susceptibility	susceptibility	NN	_	2	conj	_	_
5	to	to	TO	_	6	aux	_	_
6	progression	progression	NN	_	4	ppmod	_	_
7	as	as	IN	_	9	case	_	_
8	an	an	DT	_	9	det	_	_
9	expression	expression	NN	_	2	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	subpopulations	subpopulation	NNS	_	9	ppmod	_	_
12	of	of	IN	_	15	case	_	_
13	initiated	initiated	JJ	_	15	attr	_	_
14	murine	murine	JJ	_	15	attr	_	_
15	cells	cell	NNS	_	11	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	Currently	currently	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	it	it	PRP	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	conceived	conceive	VBN	_	0	root	_	_
6	that	that	IN	_	16	mark	_	_
7	a	a	DT	_	8	det	_	_
8	number	number	NN	_	16	dep	_	_
9	of	of	IN	_	10	case	_	_
10	events	event	NNS	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	or	or	CC	_	10	cc	_	_
13	hits	hit	NNS	_	10	conj	_	_
14	,	,	,	_	13	p	_	_
15	are	be	VBP	_	16	aux	_	_
16	required	require	VBN	_	5	comp	_	_
17	for	for	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	induction	induction	NN	_	16	ppmod	_	_
20	of	of	IN	_	21	case	_	_
21	tumors	tumor	NNS	_	19	ppmod	_	_
22	by	by	IN	_	24	case	_	_
23	chemical	chemical	JJ	_	24	attr	_	_
24	agents	agent	NNS	_	19	ppmod	_	_
25	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	first	#ord#	JJ	_	3	attr	_	_
3	phase	phase	NN	_	11	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	sequence	sequence	NN	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	initiation	initiation	NN	_	6	appo	_	_
9	,	,	,	_	6	p	_	_
10	is	be	VBZ	_	11	aux	_	_
11	considered	consider	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	result	result	VB	_	11	comp	_	_
14	from	from	IN	_	18	case	_	_
15	at	at	IN	_	17	case	_	_
16	least	least	JJS	_	17	attr	_	_
17	one	#crd#	CD	_	18	num	_	_
18	event	event	NN	_	13	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	genetic	genetic	JJ	_	22	attr	_	_
22	apparatus	apparatus	NN	_	13	ppmod	_	_
23	.	.	.	_	11	p	_	_

1	Analyses	analysis	NNS	_	11	dep	_	_
2	of	of	IN	_	4	case	_	_
3	this	this	DT	_	4	det	_	_
4	sequence	sequence	NN	_	1	ppmod	_	_
5	,	,	,	_	11	p	_	_
6	however	however	RB	_	11	adv	_	_
7	,	,	,	_	11	p	_	_
8	usually	usually	RB	_	11	adv	_	_
9	give	give	VBP	_	11	lv	_	_
10	little	little	JJ	_	11	attr	_	_
11	consideration	consideration	NN	_	0	root	_	_
12	to	to	TO	_	14	aux	_	_
13	the	the	DT	_	14	det	_	_
14	nature	nature	NN	_	11	ppmod	_	_
15	of	of	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	target	target	NN	_	18	com	_	_
18	cell	cell	NN	_	14	ppmod	_	_
19	or	or	CC	_	14	cc	_	_
20	to	to	TO	_	22	aux	_	_
21	the	the	DT	_	22	det	_	_
22	characteristics	characteristic	NNS	_	14	conj	_	_
23	of	of	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	resultant	resultant	JJ	_	26	attr	_	_
26	tumors	tumor	NNS	_	22	ppmod	_	_
27	.	.	.	_	11	p	_	_

1	Vesselinovitch	vesselinovitch	NNP	_	0	root	_	_
2	et	et	FW	_	1	attr	_	_
3	al	al	FW	_	1	attr	_	_
4	.	.	.	_	1	p	_	_

1	(	-lrb-	-LRB-	_	3	p	_	_
2	Cancer	cancer	NN	_	3	com	_	_
3	Res.	res.	NNP	_	12	prn	_	_
4	,	,	,	_	3	p	_	_
5	38	0	CD	_	3	appo	_	_
6	:	:	:	_	3	p	_	_
7	2003-2010	0	CD	_	3	appo	_	_
8	,	,	,	_	3	p	_	_
9	1978	0	CD	_	3	appo	_	_
10	)	-rrb-	-RRB-	_	3	p	_	_
11	have	have	VBP	_	12	aux	_	_
12	reported	report	VBN	_	0	root	_	_
13	that	that	IN	_	22	mark	_	_
14	a	a	DT	_	18	det	_	_
15	single	single	JJ	_	17	adv	_	_
16	,	,	,	_	17	p	_	_
17	small	small	JJ	_	18	attr	_	_
18	pulse	pulse	NN	_	22	dep	_	_
19	of	of	IN	_	20	case	_	_
20	carcinogen	carcinogen	NN	_	18	ppmod	_	_
21	can	can	MD	_	22	modal	_	_
22	induce	induce	VB	_	12	comp	_	_
23	early	early	JJ	_	27	attr	_	_
24	and	and	CC	_	23	cc	_	_
25	numerous	numerous	JJ	_	23	conj	_	_
26	liver	liver	NN	_	27	com	_	_
27	tumors	tumor	NNS	_	22	obj	_	_
28	when	when	WRB	_	29	adv	_	_
29	administered	administer	VBN	_	22	comp	_	_
30	neonatally	neonatally	RB	_	29	adv	_	_
31	to	to	TO	_	32	aux	_	_
32	mice	mouse	NNS	_	29	ppmod	_	_
33	with	with	IN	_	36	case	_	_
34	a	a	DT	_	36	det	_	_
35	genetic	genetic	JJ	_	36	attr	_	_
36	predisposition	predisposition	NN	_	32	ppmod	_	_
37	to	to	TO	_	38	aux	_	_
38	hepatotumorigenesis	hepatotumorigenesis	NN	_	36	ppmod	_	_
39	.	.	.	_	12	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	current	current	JJ	_	4	attr	_	_
4	study	study	NN	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	the	the	DT	_	9	det	_	_
7	nonpredisposed	nonpredisposed	JJ	_	9	attr	_	_
8	strain	strain	NN	_	9	com	_	_
9	C57BL/6N	c0bl/0n	NN	_	12	dep	_	_
10	was	be	VBD	_	12	aux	_	_
11	also	also	RB	_	12	adv	_	_
12	shown	show	VBN	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	be	be	VB	_	12	comp	_	_
15	highly	highly	RB	_	16	adv	_	_
16	susceptible	susceptible	JJ	_	14	dep	_	_
17	to	to	TO	_	18	aux	_	_
18	diethylnitrosamine	diethylnitrosamine	NN	_	16	ppmod	_	_
19	during	during	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	neonatal	neonatal	JJ	_	22	attr	_	_
22	period	period	NN	_	14	ppmod	_	_
23	.	.	.	_	12	p	_	_

1	C57BL/6N	c0bl/0n	NN	_	2	dep	_	_
2	demonstrated	demonstrate	VBD	_	0	root	_	_
3	large	large	JJ	_	4	attr	_	_
4	numbers	number	NNS	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	two	#crd#	CD	_	4	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	three	#crd#	CD	_	10	num	_	_
10	types	type	NNS	_	6	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	liver	liver	NN	_	13	com	_	_
13	tumors	tumor	NNS	_	10	ppmod	_	_
14	seen	see	VBN	_	13	acl	_	_
15	in	in	IN	_	16	case	_	_
16	livers	liver	NNS	_	14	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	genetically	genetically	RB	_	19	adv	_	_
19	predisposed	predispose	VBN	_	20	attr	_	_
20	mice	mouse	NNS	_	16	ppmod	_	_
21	,	,	,	_	4	p	_	_
22	one	#crd#	CD	_	25	num	_	_
23	of	of	IN	_	24	case	_	_
24	which	which	WDT	_	22	ppmod	_	_
25	required	require	VBD	_	4	relcl	_	_
26	the	the	DT	_	28	det	_	_
27	additional	additional	JJ	_	28	attr	_	_
28	stimulus	stimulus	NN	_	25	obj	_	_
29	of	of	IN	_	31	case	_	_
30	dietary	dietary	NN	_	31	com	_	_
31	drug1	drug0	NN	_	28	ppmod	_	_
32	for	for	IN	_	33	case	_	_
33	growth	growth	NN	_	28	ppmod	_	_
34	.	.	.	_	2	p	_	_

1	Tumors	tumor	NNS	_	7	dep	_	_
2	of	of	IN	_	5	case	_	_
3	more	more	RBR	_	4	adv	_	_
4	malignant	malignant	JJ	_	5	attr	_	_
5	phenotype	phenotype	NN	_	1	ppmod	_	_
6	were	be	VBD	_	7	aux	_	_
7	demonstrated	demonstrate	VBN	_	0	root	_	_
8	only	only	RB	_	12	adv	_	_
9	in	in	IN	_	12	case	_	_
10	genetically	genetically	RB	_	11	adv	_	_
11	predisposed	predispose	VBN	_	12	attr	_	_
12	mice	mouse	NNS	_	7	ppmod	_	_
13	(	-lrb-	-LRB-	_	17	p	_	_
14	C57BL/6N	c0bl/0n	NN	_	17	com	_	_
15	X	x	NN	_	17	com	_	_
16	C3H/HeN	c0h/hen	NN	_	17	com	_	_
17	F1	f0	NN	_	12	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	that	that	WDT	_	20	dep	_	_
20	received	receive	VBD	_	12	relcl	_	_
21	one	#crd#	CD	_	22	num	_	_
22	dose	dose	NN	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	carcinogen	carcinogen	NN	_	22	ppmod	_	_
25	.	.	.	_	7	p	_	_

1	These	these	DT	_	2	det	_	_
2	findings	finding	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	20	mark	_	_
5	the	the	DT	_	6	det	_	_
6	phenotype	phenotype	NN	_	20	dep	_	_
7	of	of	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	tumor	tumor	NN	_	6	ppmod	_	_
10	that	that	WDT	_	11	dep	_	_
11	results	result	VBZ	_	9	relcl	_	_
12	from	from	IN	_	14	case	_	_
13	a	a	DT	_	14	det	_	_
14	pulse	pulse	NN	_	11	ppmod	_	_
15	of	of	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	chemical	chemical	JJ	_	18	attr	_	_
18	carcinogen	carcinogen	NN	_	14	ppmod	_	_
19	may	may	MD	_	20	modal	_	_
20	depend	depend	VB	_	3	comp	_	_
21	upon	upon	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	target	target	NN	_	24	com	_	_
24	cell	cell	NN	_	20	ppmod	_	_
25	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	initiated	initiated	JJ	_	3	attr	_	_
3	cells	cell	NNS	_	10	dep	_	_
4	that	that	WDT	_	5	dep	_	_
5	result	result	VBP	_	3	relcl	_	_
6	from	from	IN	_	8	case	_	_
7	this	this	DT	_	8	det	_	_
8	hit	hit	NN	_	5	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	vary	vary	VB	_	0	root	_	_
11	from	from	IN	_	12	case	_	_
12	those	those	DT	_	10	ppmod	_	_
13	that	that	WDT	_	14	dep	_	_
14	demonstrate	demonstrate	VBP	_	12	relcl	_	_
15	very	very	RB	_	16	adv	_	_
16	little	little	JJ	_	17	attr	_	_
17	progression	progression	NN	_	14	obj	_	_
18	in	in	IN	_	20	case	_	_
19	cell	cell	NN	_	20	com	_	_
20	type	type	NN	_	17	ppmod	_	_
21	and	and	CC	_	14	cc	_	_
22	may	may	MD	_	26	modal	_	_
23	or	or	CC	_	26	cc	_	_
24	may	may	MD	_	26	modal	_	_
25	not	not	RB	_	26	neg	_	_
26	require	require	VB	_	14	conj	_	_
27	exogenous	exogenous	JJ	_	28	attr	_	_
28	enhancement	enhancement	NN	_	26	obj	_	_
29	of	of	IN	_	30	case	_	_
30	growth	growth	NN	_	28	ppmod	_	_
31	to	to	TO	_	32	aux	_	_
32	those	those	DT	_	28	ppmod	_	_
33	that	that	WDT	_	35	dep	_	_
34	can	can	MD	_	35	modal	_	_
35	progress	progress	VB	_	32	relcl	_	_
36	very	very	RB	_	37	com	_	_
37	rapidly	rapidly	RB	_	35	adv	_	_
38	to	to	TO	_	41	aux	_	_
39	fully	fully	RB	_	40	adv	_	_
40	malignant	malignant	JJ	_	41	attr	_	_
41	behavior	behavior	NN	_	35	ppmod	_	_
42	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	latter	latter	JJ	_	4	dep	_	_
3	might	might	MD	_	4	modal	_	_
4	arise	arise	VB	_	0	root	_	_
5	from	from	IN	_	7	case	_	_
6	a	a	DT	_	7	det	_	_
7	hit	hit	NN	_	4	ppmod	_	_
8	in	in	IN	_	12	case	_	_
9	a	a	DT	_	12	det	_	_
10	genetically	genetically	RB	_	11	adv	_	_
11	initiated	initiate	VBN	_	12	attr	_	_
12	cell	cell	NN	_	7	ppmod	_	_
13	,	,	,	_	7	p	_	_
14	the	the	DT	_	15	det	_	_
15	result	result	NN	_	18	dep	_	_
16	of	of	IN	_	17	case	_	_
17	which	which	WDT	_	15	ppmod	_	_
18	is	be	VBZ	_	7	relcl	_	_
19	a	a	DT	_	22	det	_	_
20	more	more	RBR	_	21	adv	_	_
21	rapid	rapid	JJ	_	22	attr	_	_
22	progression	progression	NN	_	18	obj	_	_
23	in	in	IN	_	25	case	_	_
24	tumor	tumor	NN	_	25	com	_	_
25	type	type	NN	_	22	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	Effects	effect	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	upon	upon	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	metabolism	metabolism	NN	_	1	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	chylomicron-like	chylomicron-like	JJ	_	9	attr	_	_
9	emulsions	emulsion	NNS	_	6	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	patients	patient	NNS	_	6	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	coronary	coronary	JJ	_	15	attr	_	_
14	artery	artery	NN	_	15	com	_	_
15	disease	disease	NN	_	11	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	Slow	slow	JJ	_	4	attr	_	_
2	chylomicron	chylomicron	NN	_	4	com	_	_
3	intravascular	intravascular	NN	_	4	com	_	_
4	catabolism	catabolism	NN	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	11	case	_	_
9	coronary	coronary	JJ	_	11	attr	_	_
10	artery	artery	NN	_	11	com	_	_
11	disease	disease	NN	_	7	ppmod	_	_
12	and	and	CC	_	7	cc	_	_
13	screening	screening	NN	_	22	dep	_	_
14	for	for	IN	_	15	case	_	_
15	drugs	drug	NNS	_	13	ppmod	_	_
16	that	that	WDT	_	18	dep	_	_
17	can	can	MD	_	18	modal	_	_
18	speed-up	speed-up	VB	_	15	relcl	_	_
19	this	this	DT	_	20	det	_	_
20	process	process	NN	_	18	obj	_	_
21	can	can	MD	_	22	modal	_	_
22	be	be	VB	_	7	conj	_	_
23	important	important	JJ	_	22	dep	_	_
24	.	.	.	_	7	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	study	study	NN	_	13	ppmod	_	_
4	,	,	,	_	13	p	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	13	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	upon	upon	IN	_	11	case	_	_
10	chylomicron	chylomicron	NN	_	11	com	_	_
11	metabolism	metabolism	NN	_	6	ppmod	_	_
12	was	be	VBD	_	13	aux	_	_
13	tested	test	VBN	_	0	root	_	_
14	by	by	IN	_	15	case	_	_
15	determination	determination	NN	_	13	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	plasma	plasma	NN	_	19	com	_	_
19	kinetics	kinetics	NNS	_	15	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	a	a	DT	_	24	det	_	_
22	chylomicron-like	chylomicron-like	JJ	_	24	attr	_	_
23	emulsion	emulsion	NN	_	24	com	_	_
24	model	model	NN	_	19	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	12	0	CD	_	27	num	_	_
27	patients	patient	NNS	_	24	ppmod	_	_
28	with	with	IN	_	31	case	_	_
29	coronary	coronary	JJ	_	31	attr	_	_
30	artery	artery	NN	_	31	com	_	_
31	disease	disease	NN	_	27	ppmod	_	_
32	,	,	,	_	27	p	_	_
33	aged	aged	JJ	_	35	attr	_	_
34	59+/-11	0+/-0	CD	_	35	num	_	_
35	years	year	NNS	_	27	appo	_	_
36	,	,	,	_	27	p	_	_
37	(	-lrb-	-LRB-	_	39	p	_	_
38	total	total	JJ	_	39	attr	_	_
39	cholesterol	cholesterol	NN	_	27	prn	_	_
40	:	:	:	_	39	p	_	_
41	240+/-41	0+/-0	CD	_	42	num	_	_
42	mg/dl	mg/dl	NN	_	39	appo	_	_
43	;	;	:	_	39	p	_	_
44	triglycerides	triglyceride	NNS	_	39	appo	_	_
45	:	:	:	_	39	p	_	_
46	188+/-42	0+/-0	CD	_	47	num	_	_
47	mg/dl	mg/dl	NN	_	39	appo	_	_
48	)	-rrb-	-RRB-	_	39	p	_	_
49	submitted	submit	VBN	_	27	acl	_	_
50	to	to	TO	_	59	aux	_	_
51	a	a	DT	_	59	det	_	_
52	randomized	randomized	JJ	_	58	adv	_	_
53	,	,	,	_	58	p	_	_
54	crossover	crossover	JJ	_	58	adv	_	_
55	,	,	,	_	58	p	_	_
56	double-blind	double-blind	JJ	_	58	adv	_	_
57	,	,	,	_	58	p	_	_
58	placebo-controlled	placebo-controlled	JJ	_	59	attr	_	_
59	study	study	NN	_	49	ppmod	_	_
60	with	with	IN	_	61	case	_	_
61	administration	administration	NN	_	59	ppmod	_	_
62	of	of	IN	_	64	case	_	_
63	1	0	CD	_	64	num	_	_
64	g	g	NN	_	61	ppmod	_	_
65	per	per	IN	_	67	case	_	_
66	day	day	NN	_	67	com	_	_
67	drug2	drug0	NN	_	64	ppmod	_	_
68	or	or	CC	_	61	cc	_	_
69	placebo	placebo	NN	_	61	conj	_	_
70	for	for	IN	_	71	case	_	_
71	1-month	0-month	NN	_	69	ppmod	_	_
72	.	.	.	_	13	p	_	_

1	A	a	DT	_	4	det	_	_
2	1-month	0-month	JJ	_	4	attr	_	_
3	washout	washout	NN	_	4	com	_	_
4	period	period	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	inserted	insert	VBN	_	0	root	_	_
7	between	between	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	treatment	treatment	NN	_	10	com	_	_
10	periods	period	NNS	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	Patients	patient	NNS	_	4	dep	_	_
2	were	be	VBD	_	4	aux	_	_
3	intravenously	intravenously	RB	_	4	adv	_	_
4	injected	inject	VBN	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	chylomicron-like	chylomicron-like	JJ	_	7	attr	_	_
7	emulsion	emulsion	NN	_	4	obj	_	_
8	doubly	doubly	RB	_	9	adv	_	_
9	labeled	label	VBN	_	7	acl	_	_
10	with	with	IN	_	12	case	_	_
11	14C-cholesteryl	0c-cholesteryl	JJ	_	12	attr	_	_
12	oleate	oleate	NN	_	9	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	3H-triolein	0h-triolein	NN	_	12	conj	_	_
15	at	at	IN	_	16	case	_	_
16	baseline	baseline	NN	_	9	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	after	after	IN	_	19	case	_	_
19	treatments	treatment	NNS	_	16	conj	_	_
20	.	.	.	_	4	p	_	_

1	After	after	IN	_	3	case	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	treatment	treatment	NN	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	there	there	EX	_	6	dep	_	_
6	was	be	VBD	_	0	root	_	_
7	decrease	decrease	NN	_	6	obj	_	_
8	of	of	IN	_	10	case	_	_
9	total	total	JJ	_	10	attr	_	_
10	cholesterol	cholesterol	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	triglyceride	triglyceride	NN	_	14	com	_	_
13	plasma	plasma	NN	_	14	com	_	_
14	levels	level	NNS	_	10	conj	_	_
15	and	and	CC	_	7	cc	_	_
16	a	a	DT	_	17	det	_	_
17	trend	trend	NN	_	7	conj	_	_
18	to	to	TO	_	19	aux	_	_
19	increase	increase	VB	_	17	acl	_	_
20	high-density	high-density	JJ	_	22	attr	_	_
21	lipoprotein	lipoprotein	NN	_	22	com	_	_
22	cholesterol	cholesterol	NN	_	24	com	_	_
23	plasma	plasma	NN	_	24	com	_	_
24	levels	level	NNS	_	19	obj	_	_
25	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	elicited	elicit	VBD	_	0	root	_	_
3	62	0	CD	_	5	num	_	_
4	%	%	NN	_	3	meta	_	_
5	enhancement	enhancement	NN	_	2	obj	_	_
6	of	of	IN	_	10	case	_	_
7	post-	post-	NN	_	10	attr	_	_
8	drug2	drug0	NN	_	10	attr	_	_
9	lipolytic	lipolytic	JJ	_	10	attr	_	_
10	activity	activity	NN	_	5	ppmod	_	_
11	and	and	CC	_	5	cc	_	_
12	100	0	CD	_	14	num	_	_
13	%	%	NN	_	12	meta	_	_
14	increase	increase	NN	_	5	conj	_	_
15	of	of	IN	_	19	case	_	_
16	3H-triglyceride	0h-triglyceride	JJ	_	19	attr	_	_
17	fractional	fractional	JJ	_	19	attr	_	_
18	clearance	clearance	NN	_	19	com	_	_
19	rate	rate	NN	_	14	ppmod	_	_
20	compared	compare	VBN	_	23	adv	_	_
21	with	with	IN	_	23	case	_	_
22	placebo	placebo	NN	_	23	com	_	_
23	treatment	treatment	NN	_	2	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	14C-cholesterol	0c-cholesterol	JJ	_	5	attr	_	_
2	ester	ester	NN	_	5	attr	_	_
3	fractional	fractional	JJ	_	5	attr	_	_
4	clearance	clearance	NN	_	5	com	_	_
5	rate	rate	NN	_	6	dep	_	_
6	was	be	VBD	_	0	root	_	_
7	260	0	CD	_	9	num	_	_
8	%	%	NN	_	7	meta	_	_
9	greater	great	JJR	_	6	dep	_	_
10	after	after	IN	_	11	case	_	_
11	drug1	drug0	NN	_	6	ppmod	_	_
12	than	than	IN	_	14	case	_	_
13	after	after	IN	_	14	case	_	_
14	placebo	placebo	NN	_	6	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Therefore	therefore	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	a	a	DT	_	5	det	_	_
4	potent	potent	JJ	_	5	attr	_	_
5	effect	effect	NN	_	16	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	on	on	IN	_	11	case	_	_
9	both	both	CC	_	11	cc	_	_
10	chylomicron	chylomicron	NN	_	11	com	_	_
11	lipolysis	lipolysis	NN	_	5	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	remnant	remnant	JJ	_	14	attr	_	_
14	removal	removal	NN	_	11	conj	_	_
15	was	be	VBD	_	16	aux	_	_
16	achieved	achieve	VBN	_	0	root	_	_
17	,	,	,	_	16	p	_	_
18	indicating	indicate	VBG	_	16	comp	_	_
19	that	that	IN	_	24	mark	_	_
20	this	this	DT	_	21	det	_	_
21	drug	drug	NN	_	24	dep	_	_
22	can	can	MD	_	24	modal	_	_
23	be	be	VB	_	24	aux	_	_
24	used	use	VBN	_	18	comp	_	_
25	to	to	TO	_	26	aux	_	_
26	improve	improve	VB	_	24	comp	_	_
27	this	this	DT	_	28	det	_	_
28	metabolism	metabolism	NN	_	26	obj	_	_
29	in	in	IN	_	32	case	_	_
30	future	future	JJ	_	32	attr	_	_
31	prospective	prospective	JJ	_	32	attr	_	_
32	studies	study	NNS	_	28	ppmod	_	_
33	.	.	.	_	16	p	_	_

1	Selective	selective	JJ	_	2	attr	_	_
2	survival	survival	NN	_	0	root	_	_
3	in	in	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	of	of	IN	_	10	case	_	_
8	Pseudomonas	pseudomonas	FW	_	10	attr	_	_
9	aeruginosa	aeruginosa	FW	_	10	attr	_	_
10	serotype	serotype	NN	_	4	ppmod	_	_
11	O11	o0	CD	_	10	num	_	_
12	from	from	IN	_	14	case	_	_
13	drug	drug	NN	_	14	com	_	_
14	addicts	addict	NNS	_	4	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	growth	growth	NN	_	0	root	_	_
3	of	of	IN	_	5	case	_	_
4	Pseudomonas	pseudomonas	FW	_	5	attr	_	_
5	aeruginosa	aeruginosa	FW	_	2	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	particularly	particularly	RB	_	9	adv	_	_
8	serotype	serotype	NN	_	9	com	_	_
9	O11	o0	NN	_	5	appo	_	_
10	,	,	,	_	5	p	_	_
11	in	in	IN	_	12	case	_	_
12	drug1	drug0	NN	_	2	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_

1	was	be	VBD	_	2	aux	_	_
2	evaluated	evaluate	VBN	_	0	root	_	_
3	as	as	IN	_	6	case	_	_
4	a	a	DT	_	6	det	_	_
5	possible	possible	JJ	_	6	attr	_	_
6	explanation	explanation	NN	_	2	ppmod	_	_
7	for	for	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	association	association	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	deep-seated	deep-seated	JJ	_	12	attr	_	_
12	infection	infection	NN	_	9	ppmod	_	_
13	with	with	IN	_	15	case	_	_
14	this	this	DT	_	15	det	_	_
15	organism	organism	NN	_	12	ppmod	_	_
16	and	and	CC	_	6	cc	_	_
17	abuse	abuse	NN	_	6	conj	_	_
18	of	of	IN	_	20	case	_	_
19	these	these	DT	_	20	det	_	_
20	drugs	drug	NNS	_	17	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	mean	mean	JJ	_	3	attr	_	_
3	reduction	reduction	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	growth	growth	NN	_	3	ppmod	_	_
6	caused	cause	VBN	_	5	acl	_	_
7	by	by	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	drugs	drug	NNS	_	6	ppmod	_	_
10	was	be	VBD	_	0	root	_	_
11	1,000-fold	0-fold	RB	_	12	adv	_	_
12	greater	great	JJR	_	10	dep	_	_
13	for	for	IN	_	16	case	_	_
14	49	0	CD	_	16	num	_	_
15	Pseudomonas	pseudomonas	FW	_	16	attr	_	_
16	strains	strain	NNS	_	12	ppmod	_	_
17	from	from	IN	_	19	case	_	_
18	normal	normal	JJ	_	19	attr	_	_
19	subjects	subject	NNS	_	16	ppmod	_	_
20	than	than	IN	_	23	case	_	_
21	for	for	IN	_	23	case	_	_
22	32	0	CD	_	23	num	_	_
23	strains	strain	NNS	_	12	ppmod	_	_
24	from	from	IN	_	26	case	_	_
25	drug	drug	NN	_	26	com	_	_
26	addicts	addict	NNS	_	23	ppmod	_	_
27	(	-lrb-	-LRB-	_	31	p	_	_
28	4.2	0	CD	_	31	num	_	_
29	vs.	vs.	CC	_	28	cc	_	_
30	1.3	0	CD	_	28	conj	_	_
31	logs	log	NNS	_	26	prn	_	_
32	of	of	IN	_	33	case	_	_
33	reduction	reduction	NN	_	31	ppmod	_	_
34	at	at	IN	_	36	case	_	_
35	2	0	CD	_	36	num	_	_
36	hr	hr	NN	_	31	ppmod	_	_
37	,	,	,	_	31	p	_	_
38	P	p	NN	_	31	appo	_	_
39	less	less	JJR	_	38	attr	_	_
40	than	than	IN	_	41	case	_	_
41	.0005	0	NN	_	39	ppmod	_	_
42	)	-rrb-	-RRB-	_	31	p	_	_
43	.	.	.	_	10	p	_	_

1	A	a	DT	_	4	det	_	_
2	common	common	JJ	_	4	attr	_	_
3	phenotypic	phenotypic	JJ	_	4	attr	_	_
4	subset	subset	NN	_	13	dep	_	_
5	of	of	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	serotype	serotype	NN	_	9	com	_	_
8	O11	o0	NN	_	9	com	_	_
9	strains	strain	NNS	_	4	ppmod	_	_
10	from	from	IN	_	12	case	_	_
11	drug	drug	NN	_	12	com	_	_
12	addicts	addict	NNS	_	9	ppmod	_	_
13	was	be	VBD	_	0	root	_	_
14	especially	especially	RB	_	15	adv	_	_
15	resistant	resistant	JJ	_	13	dep	_	_
16	to	to	TO	_	19	aux	_	_
17	the	the	DT	_	19	det	_	_
18	inhibitory	inhibitory	JJ	_	19	attr	_	_
19	effects	effect	NNS	_	15	ppmod	_	_
20	.	.	.	_	13	p	_	_

1	Twelve	#crd#	CD	_	2	num	_	_
2	strains	strain	NNS	_	26	dep	_	_
3	of	of	IN	_	5	case	_	_
4	Staphylococcus	staphylococcus	FW	_	5	attr	_	_
5	aureus	aureus	FW	_	2	ppmod	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	a	a	DT	_	9	det	_	_
8	frequent	frequent	JJ	_	9	attr	_	_
9	cause	cause	NN	_	5	prn	_	_
10	of	of	IN	_	11	case	_	_
11	infection	infection	NN	_	9	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	drug1	drug0	NN	_	9	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	but	but	CC	_	13	cc	_	_
16	not	not	RB	_	18	neg	_	_
17	in	in	IN	_	18	case	_	_
18	drug2	drug0	NN	_	13	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug3	drug0	NN	_	18	conj	_	_
21	,	,	,	_	9	p	_	_
22	addicts	addict	NNS	_	9	appo	_	_
23	)	-rrb-	-RRB-	_	9	p	_	_
24	were	be	VBD	_	26	aux	_	_
25	completely	completely	RB	_	26	adv	_	_
26	inhibited	inhibit	VBN	_	0	root	_	_
27	by	by	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	drug	drug	NN	_	30	com	_	_
30	combination	combination	NN	_	26	ppmod	_	_
31	.	.	.	_	26	p	_	_

1	Dose-response	dose-response	JJ	_	2	attr	_	_
2	curves	curve	NNS	_	18	dep	_	_
3	(	-lrb-	-LRB-	_	2	p	_	_
4	derived	derive	VBN	_	2	acl	_	_
5	from	from	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	results	result	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	using	use	VBG	_	7	ppmod	_	_
10	the	the	DT	_	11	det	_	_
11	tablets	tablet	NNS	_	9	obj	_	_
12	as	as	RB	_	13	com	_	_
13	well	well	RB	_	11	cc	_	_
14	as	as	IN	_	13	com	_	_
15	pure	pure	JJ	_	16	attr	_	_
16	powders	powder	NNS	_	11	conj	_	_
17	)	-rrb-	-RRB-	_	2	p	_	_
18	showed	show	VBD	_	0	root	_	_
19	that	that	IN	_	21	mark	_	_
20	drug1	drug0	NN	_	21	dep	_	_
21	was	be	VBD	_	18	comp	_	_
22	responsible	responsible	JJ	_	21	dep	_	_
23	for	for	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	inhibitory	inhibitory	JJ	_	26	attr	_	_
26	activity	activity	NN	_	22	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	which	which	WDT	_	31	dep	_	_
29	was	be	VBD	_	31	aux	_	_
30	partially	partially	RB	_	31	adv	_	_
31	antagonized	antagonize	VBN	_	26	relcl	_	_
32	by	by	IN	_	33	case	_	_
33	drug2	drug0	NN	_	31	ppmod	_	_
34	.	.	.	_	18	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	conclude	conclude	VBP	_	0	root	_	_
3	that	that	IN	_	5	mark	_	_
4	an	an	DT	_	5	det	_	_
5	ability	ability	NN	_	2	comp	_	_
6	of	of	IN	_	8	case	_	_
7	some	some	DT	_	8	det	_	_
8	P	p	NN	_	5	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	aeruginosa	aeruginosa	FW	_	3	attr	_	_
2	serotype	serotype	NN	_	3	com	_	_
3	O11	o0	NN	_	4	dep	_	_
4	strains	strain	VBZ	_	0	root	_	_
5	,	,	,	_	8	p	_	_
6	but	but	CC	_	8	cc	_	_
7	not	not	RB	_	6	com	_	_
8	S	s	NN	_	4	dep	_	_
9	.	.	.	_	4	p	_	_

1	aureus	aureus	FW	_	10	adv	_	_
2	,	,	,	_	10	p	_	_
3	to	to	TO	_	4	aux	_	_
4	survive	survive	VB	_	10	advcl	_	_
5	in	in	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	may	may	MD	_	10	modal	_	_
10	explain	explain	VB	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	part	part	NN	_	10	ppmod	_	_
13	a	a	DT	_	14	det	_	_
14	shift	shift	NN	_	10	obj	_	_
15	from	from	IN	_	16	case	_	_
16	S	s	NNS	_	14	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	aureus	aureus	FW	_	0	root	_	_
2	to	to	TO	_	3	aux	_	_
3	P	p	NN	_	1	ppmod	_	_
4	.	.	.	_	1	p	_	_

1	aeruginosa	aeruginosa	FW	_	0	root	_	_
2	as	as	IN	_	4	case	_	_
3	common	common	JJ	_	4	attr	_	_
4	pathogens	pathogen	NNS	_	1	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	drug	drug	NN	_	7	com	_	_
7	addicts	addict	NNS	_	4	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	areas	area	NNS	_	1	ppmod	_	_
10	where	where	WRB	_	18	adv	_	_
11	abuse	abuse	NN	_	18	dep	_	_
12	of	of	IN	_	14	case	_	_
13	this	this	DT	_	14	det	_	_
14	combination	combination	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drugs	drug	NNS	_	14	ppmod	_	_
17	has	have	VBZ	_	18	aux	_	_
18	increased	increase	VBN	_	9	relcl	_	_
19	.	.	.	_	1	p	_	_

1	Influence	influence	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	coadministration	coadministration	NN	_	1	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	on	on	IN	_	8	case	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	QTc	qtc	NN	_	11	com	_	_
11	intervals	interval	NNS	_	8	conj	_	_
12	in	in	IN	_	14	case	_	_
13	healthy	healthy	JJ	_	14	attr	_	_
14	volunteers	volunteer	NNS	_	8	ppmod	_	_
15	.	.	.	_	1	p	_	_

1	STUDY	study	NN	_	2	com	_	_
2	OBJECTIVE	objective	NN	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	To	to	TO	_	5	aux	_	_
5	evaluate	evaluate	VB	_	2	acl	_	_
6	the	the	DT	_	7	det	_	_
7	effect	effect	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	on	on	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	pharmacokinetics	pharmacokinetics	NNS	_	7	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	cardiovascular	cardiovascular	JJ	_	15	attr	_	_
15	safety	safety	NN	_	12	conj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	12	ppmod	_	_
18	at	at	IN	_	20	case	_	_
19	steady	steady	JJ	_	20	attr	_	_
20	state	state	NN	_	12	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	healthy	healthy	JJ	_	23	attr	_	_
23	men	man	NNS	_	20	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	DESIGN	design	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Open-label	open-label	JJ	_	7	adv	_	_
4	,	,	,	_	7	p	_	_
5	three-phase	three-phase	JJ	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	sequential	sequential	JJ	_	8	attr	_	_
8	study	study	NN	_	1	appo	_	_
9	.	.	.	_	1	p	_	_

1	SETTING	setting	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Clinical	clinical	JJ	_	5	attr	_	_
4	research	research	NN	_	5	com	_	_
5	center	center	NN	_	1	appo	_	_
6	.	.	.	_	1	p	_	_

1	SUBJECTS	subject	NNS	_	6	dep	_	_
2	:	:	:	_	6	p	_	_
3	Twelve	#crd#	CD	_	6	num	_	_
4	healthy	healthy	JJ	_	6	attr	_	_
5	male	male	JJ	_	6	attr	_	_
6	volunteers	volunteer	NNS	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	INTERVENTIONS	interventions	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Each	each	DT	_	4	det	_	_
4	subject	subject	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	treated	treat	VBN	_	1	acl	_	_
7	according	accord	VBG	_	11	adv	_	_
8	to	to	TO	_	11	aux	_	_
9	the	the	DT	_	11	det	_	_
10	following	following	JJ	_	11	attr	_	_
11	sequence	sequence	NN	_	6	ppmod	_	_
12	:	:	:	_	1	p	_	_
13	baseline	baseline	NN	_	1	appo	_	_
14	;	;	:	_	1	p	_	_

1	phase	phase	NN	_	0	root	_	_
2	1	0	CD	_	1	num	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	days	day	NNS	_	1	prn	_	_
5	1-6	0	CD	_	4	num	_	_
6	)	-rrb-	-RRB-	_	4	p	_	_
7	:	:	:	_	1	p	_	_
8	drug1	drug0	NN	_	12	attr	_	_
9	10	0	CD	_	12	num	_	_
10	mg	mg	NN	_	12	attr	_	_
11	4	0	CD	_	12	num	_	_
12	times/day	times/day	NN	_	1	appo	_	_
13	;	;	:	_	1	p	_	_

1	washout	washout	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	days	day	NNS	_	1	prn	_	_
4	7-13	0	CD	_	3	num	_	_
5	)	-rrb-	-RRB-	_	3	p	_	_
6	;	;	:	_	1	p	_	_

1	phase	phase	NN	_	0	root	_	_
2	2	0	CD	_	1	num	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	days	day	NNS	_	1	prn	_	_
5	14-44	0	CD	_	4	num	_	_
6	)	-rrb-	-RRB-	_	4	p	_	_
7	:	:	:	_	1	p	_	_
8	drug1	drug0	NN	_	10	attr	_	_
9	20	0	CD	_	10	num	_	_
10	mg/day	mg/day	NN	_	1	appo	_	_
11	;	;	:	_	1	p	_	_

1	and	and	CC	_	2	cc	_	_
2	phase	phase	NN	_	0	root	_	_
3	3	0	CD	_	2	num	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	days	day	NNS	_	2	prn	_	_
6	45-52	0	CD	_	5	num	_	_
7	)	-rrb-	-RRB-	_	5	p	_	_
8	:	:	:	_	2	p	_	_
9	drug1	drug0	NN	_	11	attr	_	_
10	10	0	CD	_	11	num	_	_
11	mg	mg	NN	_	2	appo	_	_
12	4	0	CD	_	11	num	_	_
13	times/day	times/day	JJ	_	11	attr	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	days	day	NNS	_	13	prn	_	_
16	45-51	0	CD	_	15	num	_	_
17	)	-rrb-	-RRB-	_	15	p	_	_
18	plus	plus	CC	_	11	cc	_	_
19	drug2	drug0	NN	_	21	attr	_	_
20	20	0	CD	_	21	num	_	_
21	mg/day	mg/day	NN	_	11	conj	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	days	day	NNS	_	11	prn	_	_
24	45-52	0	CD	_	23	num	_	_
25	)	-rrb-	-RRB-	_	23	p	_	_
26	.	.	.	_	2	p	_	_

1	MEASUREMENTS	measurement	NNS	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	MAIN	main	JJ	_	4	attr	_	_
4	RESULTS	result	NNS	_	1	conj	_	_
5	:	:	:	_	1	p	_	_
6	Blood	blood	NN	_	7	com	_	_
7	samples	sample	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	drawn	draw	VBN	_	1	acl	_	_
10	and	and	CC	_	9	cc	_	_
11	12-lead	0-lead	NN	_	12	com	_	_
12	electrocardiograms	electrocardiogram	NNS	_	13	dep	_	_
13	performed	performed	VBN	_	9	conj	_	_
14	at	at	IN	_	17	case	_	_
15	specified	specify	VBN	_	17	attr	_	_
16	time	time	NN	_	17	com	_	_
17	points	point	NNS	_	13	ppmod	_	_
18	after	after	IN	_	22	case	_	_
19	the	the	DT	_	22	det	_	_
20	last	last	JJ	_	22	attr	_	_
21	morning	morning	NN	_	22	com	_	_
22	dose	dose	NN	_	17	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	in	in	IN	_	26	case	_	_
26	phases	phase	NNS	_	22	ppmod	_	_
27	1	0	CD	_	26	num	_	_
28	and	and	CC	_	27	cc	_	_
29	3	0	CD	_	27	conj	_	_
30	.	.	.	_	1	p	_	_

1	Blood	blood	NN	_	2	com	_	_
2	samples	sample	NNS	_	5	dep	_	_
3	also	also	RB	_	5	adv	_	_
4	were	be	VBD	_	5	aux	_	_
5	taken	take	VBN	_	0	root	_	_
6	before	before	IN	_	8	case	_	_
7	morning	morning	NN	_	8	com	_	_
8	doses	dose	NNS	_	5	ppmod	_	_
9	on	on	IN	_	17	case	_	_
10	the	the	DT	_	17	det	_	_
11	3rd	#ord#	CD	_	17	num	_	_
12	,	,	,	_	11	p	_	_
13	4th	#ord#	CD	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	5th	#ord#	CD	_	11	conj	_	_
17	days	day	NNS	_	8	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	phases	phase	NNS	_	17	ppmod	_	_
20	1	0	CD	_	19	num	_	_
21	and	and	CC	_	20	cc	_	_
22	3	0	CD	_	20	conj	_	_
23	.	.	.	_	5	p	_	_

1	Electrocardiograms	electrocardiogram	NNS	_	3	dep	_	_
2	were	be	VBD	_	3	aux	_	_
3	done	do	VBN	_	0	root	_	_
4	at	at	IN	_	5	case	_	_
5	baseline	baseline	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	on	on	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	last	last	JJ	_	10	attr	_	_
10	day	day	NN	_	5	conj	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	washout	washout	NN	_	14	com	_	_
14	period	period	NN	_	10	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	phase	phase	NN	_	14	conj	_	_
17	2	0	CD	_	16	num	_	_
18	.	.	.	_	3	p	_	_

1	Coadministration	coadministration	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	significantly	significantly	RB	_	5	adv	_	_
5	decreased	decrease	VBD	_	0	root	_	_
6	drug2	drug0	NN	_	8	com	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	5	obj	_	_
9	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	6	det	_	_
4	clinically	clinically	RB	_	5	adv	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	changes	change	NNS	_	2	obj	_	_
7	in	in	IN	_	10	case	_	_
8	corrected	corrected	JJ	_	10	attr	_	_
9	QT	qt	VBG	_	10	attr	_	_
10	intervals	interval	NNS	_	2	ppmod	_	_
11	during	during	IN	_	12	case	_	_
12	administration	administration	NN	_	10	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	alone	alone	RB	_	12	adv	_	_
16	or	or	CC	_	15	cc	_	_
17	with	with	IN	_	18	case	_	_
18	drug2	drug0	NN	_	15	conj	_	_
19	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	was	be	VBD	_	4	aux	_	_
3	well	well	RB	_	4	adv	_	_
4	tolerated	tolerate	VBN	_	0	root	_	_
5	when	when	WRB	_	6	adv	_	_
6	administered	administer	VBN	_	4	comp	_	_
7	alone	alone	RB	_	6	adv	_	_
8	or	or	CC	_	7	cc	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	7	conj	_	_
11	.	.	.	_	4	p	_	_

1	CONCLUSION	conclusion	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	can	can	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	administered	administer	VBN	_	1	acl	_	_
7	safely	safely	RB	_	6	adv	_	_
8	to	to	TO	_	9	aux	_	_
9	patients	patient	NNS	_	6	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	low	low	JJ	_	13	attr	_	_
12	therapeutic	therapeutic	JJ	_	13	attr	_	_
13	dosages	dosage	NNS	_	10	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	Activity	activity	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	alone	alone	RB	_	1	adv	_	_
5	and	and	CC	_	4	cc	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	4	conj	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	9	conj	_	_
12	against	against	IN	_	14	case	_	_
13	Cryptosporidium	cryptosporidium	FW	_	14	attr	_	_
14	parvum	parvum	FW	_	9	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	cell	cell	NN	_	17	com	_	_
17	culture	culture	NN	_	9	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	The	the	DT	_	5	det	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	5	attr	_	_
4	anti-cryptosporidial	anti-cryptosporidial	JJ	_	5	attr	_	_
5	activity	activity	NN	_	17	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	alone	alone	RB	_	5	adv	_	_
9	and	and	CC	_	8	cc	_	_
10	in	in	IN	_	11	case	_	_
11	combination	combination	NN	_	8	conj	_	_
12	with	with	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	was	be	VBD	_	17	aux	_	_
17	investigated	investigate	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	showed	show	VBD	_	0	root	_	_
3	moderate	moderate	JJ	_	4	attr	_	_
4	activity	activity	NN	_	2	obj	_	_
5	,	,	,	_	4	p	_	_
6	which	which	WDT	_	7	dep	_	_
7	increased	increase	VBD	_	4	relcl	_	_
8	with	with	IN	_	9	case	_	_
9	increasing	increase	VBG	_	7	ppmod	_	_
10	concentration	concentration	NN	_	9	obj	_	_
11	to	to	TO	_	14	aux	_	_
12	55.7	0	CD	_	14	num	_	_
13	%	%	NN	_	12	meta	_	_
14	suppression	suppression	NN	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	growth	growth	NN	_	14	ppmod	_	_
17	at	at	IN	_	19	case	_	_
18	20	0	CD	_	19	num	_	_
19	microM	microm	NN	_	14	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	Moreover	moreover	RB	_	6	adv	_	_
2	,	,	,	_	6	p	_	_
3	its	its	PRP$	_	4	poss	_	_
4	activity	activity	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	enhanced	enhance	VBN	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	it	it	PRP	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	combined	combine	VBN	_	6	comp	_	_
11	with	with	IN	_	13	case	_	_
12	either	either	CC	_	13	cc	_	_
13	drug1	drug0	NN	_	10	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	with	with	IN	_	20	case	_	_
17	90	0	CD	_	20	num	_	_
18	%	%	NN	_	17	meta	_	_
19	parasite	parasite	NN	_	20	com	_	_
20	reduction	reduction	NN	_	10	ppmod	_	_
21	at	at	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	highest	high	JJS	_	24	attr	_	_
24	concentration	concentration	NN	_	20	ppmod	_	_
25	tested	test	VBN	_	24	acl	_	_
26	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	be	be	VB	_	0	root	_	_
4	active	active	JJ	_	3	dep	_	_
5	in	in	IN	_	6	case	_	_
6	inhibiting	inhibit	VBG	_	3	ppmod	_	_
7	Cryptosporidium	cryptosporidium	NN	_	9	com	_	_
8	parvum	parvum	NN	_	9	com	_	_
9	growth	growth	NN	_	6	obj	_	_
10	in	in	FW	_	11	adv	_	_
11	vitro	vitro	FW	_	6	adv	_	_
12	upon	upon	IN	_	13	case	_	_
13	combination	combination	NN	_	6	ppmod	_	_
14	with	with	IN	_	16	case	_	_
15	either	either	CC	_	16	cc	_	_
16	drug2	drug0	NN	_	13	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	.	.	.	_	3	p	_	_

1	Modification	modification	NN	_	6	dep	_	_
2	of	of	IN	_	5	case	_	_
3	surface	surface	NN	_	5	com	_	_
4	histidine	histidine	NN	_	5	com	_	_
5	residues	residue	NNS	_	1	ppmod	_	_
6	abolishes	abolish	VBZ	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	cytotoxic	cytotoxic	JJ	_	9	attr	_	_
9	activity	activity	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	displays	display	VBZ	_	0	root	_	_
3	both	both	CC	_	4	cc	_	_
4	cytotoxic	cytotoxic	JJ	_	7	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	enterotoxic	enterotoxic	JJ	_	4	conj	_	_
7	activities	activity	NNS	_	2	obj	_	_
8	.	.	.	_	2	p	_	_

1	It	it	PRP	_	5	dep	_	_
2	has	have	VBZ	_	5	aux	_	_
3	recently	recently	RB	_	5	adv	_	_
4	been	be	VBN	_	5	aux	_	_
5	demonstrated	demonstrate	VBN	_	0	root	_	_
6	that	that	IN	_	8	mark	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	exerts	exert	VBZ	_	5	comp	_	_
9	its	its	PRP$	_	11	poss	_	_
10	cytotoxic	cytotoxic	JJ	_	11	attr	_	_
11	effect	effect	NN	_	8	obj	_	_
12	by	by	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	glucosylation	glucosylation	NN	_	8	ppmod	_	_
15	of	of	IN	_	19	case	_	_
16	the	the	DT	_	19	det	_	_
17	small	small	JJ	_	19	attr	_	_
18	GTP-binding	gtp-binding	JJ	_	19	attr	_	_
19	proteins	protein	NNS	_	14	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	Rho	rho	NN	_	23	com	_	_
23	family	family	NN	_	19	ppmod	_	_
24	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	8	dep	_	_
2	,	,	,	_	1	p	_	_
3	at	at	IN	_	4	case	_	_
4	pH	ph	NN	_	1	ppmod	_	_
5	7.0	0	CD	_	4	num	_	_
6	,	,	,	_	1	p	_	_
7	was	be	VBD	_	8	aux	_	_
8	used	use	VBN	_	0	root	_	_
9	to	to	TO	_	11	aux	_	_
10	chemically	chemically	RB	_	11	adv	_	_
11	modify	modify	VB	_	8	comp	_	_
12	exposed	expose	VBN	_	14	attr	_	_
13	histidine	histidine	NN	_	14	com	_	_
14	residues	residue	NNS	_	11	obj	_	_
15	on	on	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	Modification	modification	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	abolished	abolish	VBD	_	0	root	_	_
7	both	both	CC	_	10	cc	_	_
8	its	its	PRP$	_	10	poss	_	_
9	cytotoxic	cytotoxic	JJ	_	10	attr	_	_
10	activity	activity	NN	_	6	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	the	the	DT	_	13	det	_	_
13	ability	ability	NN	_	10	conj	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	toxin	toxin	NN	_	13	ppmod	_	_
17	to	to	TO	_	18	aux	_	_
18	bind	bind	VB	_	13	acl	_	_
19	Zn-Sepharose	zn-sepharose	NN	_	20	com	_	_
20	gel	gel	NN	_	18	obj	_	_
21	.	.	.	_	6	p	_	_

1	Treatment	treatment	NN	_	13	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	12	case	_	_
5	[	-lsb-	-LRB-	_	9	p	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	14	0	CD	_	9	num	_	_
8	)	-rrb-	-RRB-	_	9	p	_	_
9	C	c	NN	_	12	attr	_	_
10	]	-rsb-	-RRB-	_	9	p	_	_
11	-	-	:	_	9	p	_	_
12	drug2	drug0	NN	_	1	ppmod	_	_
13	revealed	reveal	VBD	_	0	root	_	_
14	concentration	concentration	NN	_	15	advnp	_	_
15	dependent	dependent	JJ	_	16	attr	_	_
16	labelling	labelling	NN	_	13	obj	_	_
17	of	of	IN	_	19	case	_	_
18	histidine	histidine	NN	_	19	com	_	_
19	residues	residue	NNS	_	16	ppmod	_	_
20	on	on	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	toxin	toxin	NN	_	23	com	_	_
23	molecules	molecule	NNS	_	16	ppmod	_	_
24	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	could	could	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	reversed	reverse	VBN	_	0	root	_	_
8	by	by	IN	_	10	case	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	treatment	treatment	NN	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	10	dep	_	_
3	suggest	suggest	VBP	_	10	aux	_	_
4	the	the	DT	_	7	det	_	_
5	modified	modified	JJ	_	7	attr	_	_
6	histidine	histidine	NN	_	7	com	_	_
7	residues	residue	NNS	_	10	obj	_	_
8	on	on	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	are	be	VBP	_	0	root	_	_
11	critical	critical	JJ	_	10	dep	_	_
12	to	to	TO	_	15	aux	_	_
13	its	its	PRP$	_	15	poss	_	_
14	cytotoxic	cytotoxic	JJ	_	15	attr	_	_
15	activity	activity	NN	_	11	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	Histidine	histidine	NN	_	2	com	_	_
2	modification	modification	NN	_	3	dep	_	_
3	had	have	VBD	_	0	root	_	_
4	no	no	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	on	on	IN	_	11	case	_	_
7	the	the	DT	_	11	det	_	_
8	glucosyl	glucosyl	NN	_	11	com	_	_
9	transferase	transferase	NN	_	11	com	_	_
10	enzyme	enzyme	NN	_	11	com	_	_
11	activity	activity	NN	_	3	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	However	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	modification	modification	NN	_	4	dep	_	_
4	abolished	abolish	VBD	_	0	root	_	_
5	the	the	DT	_	9	det	_	_
6	'	'	``	_	9	p	_	_
7	cold	cold	JJ	_	9	attr	_	_
8	'	'	''	_	9	p	_	_
9	binding	binding	NN	_	4	obj	_	_
10	of	of	IN	_	11	case	_	_
11	toxin	toxin	NN	_	9	ppmod	_	_
12	to	to	TO	_	14	aux	_	_
13	bovine	bovine	JJ	_	14	attr	_	_
14	thyroglobulin	thyroglobulin	NN	_	9	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	an	an	DT	_	17	det	_	_
17	ELISA	elisa	NN	_	4	ppmod	_	_
18	and	and	CC	_	4	cc	_	_
19	reduced	reduce	VBD	_	4	conj	_	_
20	ligand	ligand	NN	_	22	com	_	_
21	binding	binding	NN	_	22	com	_	_
22	activity	activity	NN	_	19	obj	_	_
23	in	in	IN	_	28	case	_	_
24	a	a	DT	_	28	det	_	_
25	rabbit	rabbit	NN	_	28	com	_	_
26	erythrocyte	erythrocyte	NN	_	28	com	_	_
27	haemagglutination	haemagglutination	NN	_	28	com	_	_
28	assay	assay	NN	_	19	ppmod	_	_
29	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	the	the	DT	_	7	det	_	_
6	histidine	histidine	NN	_	7	com	_	_
7	residues	residue	NNS	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	be	be	VB	_	3	comp	_	_
10	crucial	crucial	JJ	_	9	dep	_	_
11	to	to	TO	_	14	aux	_	_
12	the	the	DT	_	14	det	_	_
13	receptor-binding	receptor-binding	JJ	_	14	attr	_	_
14	activity	activity	NN	_	10	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	Exposed	expose	VBN	_	2	attr	_	_
2	histidines	histidine	NNS	_	5	dep	_	_
3	on	on	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	are	be	VBP	_	0	root	_	_
6	available	available	JJ	_	5	dep	_	_
7	for	for	IN	_	9	case	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	chelation	chelation	NN	_	6	ppmod	_	_
10	,	,	,	_	5	p	_	_
11	and	and	CC	_	5	cc	_	_
12	these	these	DT	_	15	dep	_	_
13	have	have	VBP	_	15	aux	_	_
14	been	be	VBN	_	15	aux	_	_
15	exploited	exploit	VBN	_	5	conj	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	development	development	NN	_	15	ppmod	_	_
19	of	of	IN	_	23	case	_	_
20	a	a	DT	_	23	det	_	_
21	novel	novel	JJ	_	23	attr	_	_
22	purification	purification	NN	_	23	com	_	_
23	protocol	protocol	NN	_	18	ppmod	_	_
24	for	for	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	using	use	VBG	_	15	comp	_	_
27	drug4	drug0	NN	_	29	attr	_	_
28	-chelating	-chelating	JJ	_	29	attr	_	_
29	chromatography	chromatography	NN	_	26	obj	_	_
30	.	.	.	_	5	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	in	in	IN	_	7	case	_	_
7	vitro	vitro	FW	_	1	ppmod	_	_
8	.	.	.	_	1	p	_	_

1	The	the	DT	_	4	det	_	_
2	minimal	minimal	JJ	_	4	attr	_	_
3	inhibitory	inhibitory	JJ	_	4	attr	_	_
4	concentrations	concentration	NNS	_	14	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	alone	alone	RB	_	6	adv	_	_
10	and	and	CC	_	9	cc	_	_
11	in	in	IN	_	12	case	_	_
12	combinations	combination	NNS	_	9	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	determined	determine	VBN	_	0	root	_	_
15	by	by	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	microdilution	microdilution	JJ	_	18	attr	_	_
18	method	method	NN	_	14	ppmod	_	_
19	for	for	IN	_	28	case	_	_
20	163	0	CD	_	28	num	_	_
21	aerobic	aerobic	JJ	_	28	attr	_	_
22	,	,	,	_	21	p	_	_
23	facultative	facultative	JJ	_	21	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	anaerobic	anaerobic	JJ	_	21	conj	_	_
27	clinical	clinical	JJ	_	28	attr	_	_
28	isolates	isolate	NNS	_	18	ppmod	_	_
29	.	.	.	_	14	p	_	_

1	All	all	DT	_	3	det	_	_
2	77	0	JJ	_	3	num	_	_
3	strains	strain	NNS	_	26	dep	_	_
4	of	of	IN	_	6	case	_	_
5	Staphylococcus	staphylococcus	FW	_	6	attr	_	_
6	aureus	aureus	FW	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	Diplococcus	diplococcus	FW	_	9	attr	_	_
9	pneumoniae	pneumoniae	FW	_	6	conj	_	_
10	,	,	,	_	9	p	_	_
11	Streptococcus	streptococcus	FW	_	12	attr	_	_
12	pyogenes	pyogenes	FW	_	6	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	anaerobic	anaerobic	JJ	_	16	attr	_	_
16	bacteria	bacteria	NNS	_	6	conj	_	_
17	(	-lrb-	-LRB-	_	3	p	_	_
18	except	except	IN	_	21	case	_	_
19	for	for	IN	_	21	case	_	_
20	three	#crd#	CD	_	21	num	_	_
21	strains	strain	NNS	_	3	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	Clostridium	clostridium	NN	_	21	ppmod	_	_
24	)	-rrb-	-RRB-	_	3	p	_	_
25	were	be	VBD	_	26	aux	_	_
26	inhibited	inhibit	VBN	_	0	root	_	_
27	by	by	IN	_	29	case	_	_
28	1.6	0	CD	_	29	num	_	_
29	mug	mug	NN	_	26	ppmod	_	_
30	or	or	CC	_	31	cc	_	_
31	less	less	JJR	_	29	num	_	_
32	of	of	IN	_	33	case	_	_
33	drug1	drug0	NN	_	29	ppmod	_	_
34	per	per	IN	_	35	case	_	_
35	ml	ml	NN	_	29	ppmod	_	_
36	.	.	.	_	26	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	interfere	interfere	VB	_	0	root	_	_
5	with	with	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	activity	activity	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	within	within	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	range	range	NN	_	4	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	concentrations	concentration	NNS	_	12	ppmod	_	_
15	tested	test	VBN	_	14	acl	_	_
16	(	-lrb-	-LRB-	_	20	p	_	_
17	0.1	0	CD	_	20	num	_	_
18	to	to	TO	_	17	cc	_	_
19	100	0	CD	_	17	conj	_	_
20	mug/ml	mug/ml	NN	_	14	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	;	;	:	_	4	p	_	_

1	for	for	IN	_	3	case	_	_
2	some	some	DT	_	3	det	_	_
3	strains	strain	NNS	_	5	ppmod	_	_
4	combinations	combination	NNS	_	5	dep	_	_
5	were	be	VBD	_	0	root	_	_
6	synergistic	synergistic	JJ	_	5	dep	_	_
7	.	.	.	_	5	p	_	_

1	Sixty-two	sixty-two	NN	_	15	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	94	0	CD	_	1	num	_	_
4	%	%	NN	_	3	meta	_	_
5	)	-rrb-	-RRB-	_	3	p	_	_
6	of	of	IN	_	8	case	_	_
7	66	0	CD	_	8	num	_	_
8	strains	strain	NNS	_	1	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	Enterobacteriaceae	enterobacteriaceae	FW	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	Pseudomonas	pseudomonas	FW	_	13	attr	_	_
13	aeruginosa	aeruginosa	FW	_	10	conj	_	_
14	were	be	VBD	_	15	aux	_	_
15	inhibited	inhibit	VBN	_	0	root	_	_
16	by	by	IN	_	18	case	_	_
17	6.2	0	CD	_	18	num	_	_
18	mug	mug	NN	_	15	ppmod	_	_
19	or	or	CC	_	20	cc	_	_
20	less	less	JJR	_	18	num	_	_
21	of	of	IN	_	22	case	_	_
22	drug1	drug0	NN	_	18	ppmod	_	_
23	per	per	IN	_	24	case	_	_
24	ml	ml	NN	_	18	ppmod	_	_
25	.	.	.	_	15	p	_	_

1	Combinations	combination	NNS	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	were	be	VBD	_	0	root	_	_
7	indifferent	indifferent	JJ	_	6	dep	_	_
8	for	for	IN	_	10	case	_	_
9	29	0	CD	_	10	num	_	_
10	strains	strain	NNS	_	7	ppmod	_	_
11	and	and	CC	_	7	cc	_	_
12	synergistic	synergistic	JJ	_	7	conj	_	_
13	for	for	IN	_	15	case	_	_
14	33	0	CD	_	15	num	_	_
15	strains	strain	NNS	_	12	ppmod	_	_
16	.	.	.	_	6	p	_	_

1	All	all	DT	_	3	det	_	_
2	20	0	CD	_	3	num	_	_
3	strains	strain	NNS	_	24	dep	_	_
4	of	of	IN	_	5	case	_	_
5	enterococcus	enterococcus	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	three	#crd#	CD	_	8	num	_	_
8	strains	strain	NNS	_	3	conj	_	_
9	of	of	IN	_	10	case	_	_
10	Clostridium	clostridium	NN	_	8	ppmod	_	_
11	,	,	,	_	8	p	_	_
12	three	#crd#	CD	_	13	num	_	_
13	strains	strain	NNS	_	3	conj	_	_
14	of	of	IN	_	16	case	_	_
15	Escherichia	escherichia	FW	_	16	attr	_	_
16	coli	coli	FW	_	13	ppmod	_	_
17	,	,	,	_	13	p	_	_
18	and	and	CC	_	13	cc	_	_
19	one	#crd#	CD	_	20	num	_	_
20	strain	strain	NN	_	3	conj	_	_
21	of	of	IN	_	23	case	_	_
22	Proteus	proteus	NN	_	23	com	_	_
23	rettgeri	rettgeri	NN	_	20	ppmod	_	_
24	were	be	VBD	_	0	root	_	_
25	resistant	resistant	JJ	_	24	dep	_	_
26	to	to	TO	_	28	aux	_	_
27	both	both	CC	_	28	cc	_	_
28	drug1	drug0	NN	_	25	ppmod	_	_
29	(	-lrb-	-LRB-	_	32	p	_	_
30	minimal	minimal	JJ	_	32	attr	_	_
31	inhibitory	inhibitory	JJ	_	32	attr	_	_
32	concentration	concentration	NN	_	28	prn	_	_
33	greater	great	JJR	_	32	attr	_	_
34	than	than	IN	_	36	case	_	_
35	3.1	0	CD	_	36	num	_	_
36	mug/ml	mug/ml	NN	_	33	ppmod	_	_
37	)	-rrb-	-RRB-	_	32	p	_	_
38	and	and	CC	_	28	cc	_	_
39	drug2	drug0	NN	_	28	conj	_	_
40	(	-lrb-	-LRB-	_	43	p	_	_
41	minimal	minimal	JJ	_	43	attr	_	_
42	inhibitory	inhibitory	JJ	_	43	attr	_	_
43	concentration	concentration	NN	_	39	prn	_	_
44	greater	great	JJR	_	43	attr	_	_
45	than	than	IN	_	47	case	_	_
46	6.2	0	CD	_	47	num	_	_
47	mug/ml	mug/ml	NN	_	44	ppmod	_	_
48	)	-rrb-	-RRB-	_	43	p	_	_
49	.	.	.	_	24	p	_	_

1	Combinations	combination	NNS	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	were	be	VBD	_	0	root	_	_
7	indifferent	indifferent	JJ	_	6	dep	_	_
8	for	for	IN	_	9	case	_	_
9	16	0	CD	_	7	ppmod	_	_
10	and	and	CC	_	7	cc	_	_
11	synergistic	synergistic	JJ	_	7	conj	_	_
12	for	for	IN	_	13	case	_	_
13	11	0	CD	_	11	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	resistant	resistant	JJ	_	17	attr	_	_
17	strains	strain	NNS	_	13	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	Except	except	IN	_	5	case	_	_
2	for	for	IN	_	5	case	_	_
3	drug1	drug0	NN	_	5	attr	_	_
4	-sensitive	-sensitive	JJ	_	5	attr	_	_
5	isolates	isolate	NNS	_	10	ppmod	_	_
6	,	,	,	_	10	p	_	_
7	synergy	synergy	NN	_	10	dep	_	_
8	was	be	VBD	_	10	aux	_	_
9	usually	usually	RB	_	10	adv	_	_
10	observed	observe	VBN	_	0	root	_	_
11	only	only	RB	_	10	adv	_	_
12	at	at	IN	_	13	case	_	_
13	concentrations	concentration	NNS	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	one	#crd#	CD	_	13	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	both	both	DT	_	18	attr	_	_
18	drugs	drug	NNS	_	15	conj	_	_
19	which	which	WDT	_	20	dep	_	_
20	are	be	VBP	_	18	relcl	_	_
21	not	not	RB	_	20	neg	_	_
22	readily	readily	RB	_	20	adv	_	_
23	obtainable	obtainable	JJ	_	20	dep	_	_
24	in	in	FW	_	25	adv	_	_
25	vivo	vivo	FW	_	23	adv	_	_
26	.	.	.	_	10	p	_	_

1	Antagonism	antagonism	NN	_	4	dep	_	_
2	was	be	VBD	_	4	aux	_	_
3	never	never	RB	_	4	neg	_	_
4	observed	observe	VBN	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	the	the	DT	_	5	det	_	_
4	common	common	JJ	_	5	attr	_	_
5	cold	cold	NN	_	1	conj	_	_
6	.	.	.	_	1	p	_	_

1	Evaluation	evaluation	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	its	its	PRP$	_	4	poss	_	_
4	efficacy	efficacy	NN	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	toxicity	toxicity	NN	_	4	conj	_	_
7	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	reviewed	review	VBN	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	clinical	clinical	JJ	_	5	attr	_	_
5	data	datum	NNS	_	2	obj	_	_
6	relating	relate	VBG	_	5	acl	_	_
7	to	to	TO	_	9	aux	_	_
8	the	the	DT	_	9	det	_	_
9	efficacy	efficacy	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	safety	safety	NN	_	9	conj	_	_
12	of	of	IN	_	14	case	_	_
13	pharmacologic	pharmacologic	JJ	_	14	attr	_	_
14	doses	dose	NNS	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	prevention	prevention	NN	_	9	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	treatment	treatment	NN	_	19	conj	_	_
22	of	of	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	common	common	JJ	_	25	attr	_	_
25	cold	cold	NN	_	19	ppmod	_	_
26	.	.	.	_	2	p	_	_

1	Although	although	IN	_	5	mark	_	_
2	one	#crd#	CD	_	3	num	_	_
3	study	study	NN	_	5	dep	_	_
4	tentatively	tentatively	RB	_	5	adv	_	_
5	supports	support	VBZ	_	26	advcl	_	_
6	the	the	DT	_	7	det	_	_
7	hypothesis	hypothesis	NN	_	5	obj	_	_
8	that	that	IN	_	14	mark	_	_
9	such	such	JJ	_	10	attr	_	_
10	doses	dose	NNS	_	14	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	may	may	MD	_	14	modal	_	_
14	be	be	VB	_	7	acl	_	_
15	efficacious	efficacious	JJ	_	14	dep	_	_
16	,	,	,	_	26	p	_	_
17	a	a	DT	_	19	det	_	_
18	second	#ord#	JJ	_	19	attr	_	_
19	study	study	NN	_	26	dep	_	_
20	by	by	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	same	same	JJ	_	23	attr	_	_
23	group	group	NN	_	19	ppmod	_	_
24	did	do	VBD	_	26	aux	_	_
25	not	not	RB	_	26	neg	_	_
26	confirm	confirm	VB	_	0	root	_	_
27	the	the	DT	_	29	det	_	_
28	significant	significant	JJ	_	29	attr	_	_
29	findings	finding	NNS	_	26	obj	_	_
30	,	,	,	_	26	p	_	_
31	and	and	CC	_	26	cc	_	_
32	no	no	DT	_	36	det	_	_
33	clear	clear	JJ	_	35	adv	_	_
34	,	,	,	_	35	p	_	_
35	reproducible	reproducible	JJ	_	36	attr	_	_
36	pattern	pattern	NN	_	40	dep	_	_
37	of	of	IN	_	38	case	_	_
38	efficacy	efficacy	NN	_	36	ppmod	_	_
39	has	have	VBZ	_	40	aux	_	_
40	emerged	emerge	VBN	_	26	conj	_	_
41	from	from	IN	_	43	case	_	_
42	the	the	DT	_	43	det	_	_
43	review	review	NN	_	40	ppmod	_	_
44	of	of	IN	_	47	case	_	_
45	all	all	PDT	_	47	det	_	_
46	the	the	DT	_	47	det	_	_
47	evidence	evidence	NN	_	43	ppmod	_	_
48	.	.	.	_	26	p	_	_

1	Similarly	similarly	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	currently	currently	RB	_	4	adv	_	_
6	little	little	JJ	_	8	attr	_	_
7	adequate	adequate	JJ	_	8	attr	_	_
8	evidence	evidence	NN	_	4	obj	_	_
9	on	on	IN	_	12	case	_	_
10	either	either	CC	_	12	cc	_	_
11	the	the	DT	_	12	det	_	_
12	presence	presence	NN	_	8	ppmod	_	_
13	or	or	CC	_	12	cc	_	_
14	the	the	DT	_	15	det	_	_
15	absence	absence	NN	_	12	conj	_	_
16	of	of	IN	_	19	case	_	_
17	serious	serious	JJ	_	19	attr	_	_
18	adverse	adverse	JJ	_	19	attr	_	_
19	reactions	reaction	NNS	_	15	ppmod	_	_
20	to	to	TO	_	22	aux	_	_
21	such	such	JJ	_	22	attr	_	_
22	doses	dose	NNS	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	4	p	_	_
26	although	although	IN	_	32	mark	_	_
27	many	many	JJ	_	29	attr	_	_
28	such	such	JJ	_	29	attr	_	_
29	reactions	reaction	NNS	_	32	dep	_	_
30	have	have	VBP	_	32	aux	_	_
31	been	be	VBN	_	32	aux	_	_
32	hypothesized	hypothesize	VBN	_	4	comp	_	_
33	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	unrestricted	unrestricted	JJ	_	3	attr	_	_
3	use	use	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	for	for	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	purposes	purpose	NNS	_	3	ppmod	_	_
9	cannot	cannot	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	advocated	advocate	VBN	_	0	root	_	_
12	on	on	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	basis	basis	NN	_	11	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	evidence	evidence	NN	_	14	ppmod	_	_
18	currently	currently	RB	_	19	adv	_	_
19	available	available	JJ	_	17	attr	_	_
20	.	.	.	_	11	p	_	_

1	Effects	effect	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	in	in	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	light/dark	light/dark	NN	_	7	com	_	_
7	test	test	NN	_	1	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	mice	mouse	NNS	_	7	ppmod	_	_
10	and	and	CC	_	1	cc	_	_
11	the	the	DT	_	12	det	_	_
12	contribution	contribution	NN	_	1	conj	_	_
13	of	of	IN	_	15	case	_	_
14	adenosine	adenosine	NN	_	15	com	_	_
15	receptors	receptor	NNS	_	12	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	investigated	investigate	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	2	obj	_	_
5	of	of	IN	_	8	case	_	_
6	adenosine	adenosine	NN	_	8	com	_	_
7	receptor	receptor	NN	_	8	com	_	_
8	antagonists	antagonist	NNS	_	4	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	drug1	drug0	NN	_	8	appo	_	_
11	,	,	,	_	10	p	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug4	drug0	NN	_	10	conj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	drug5	drug0	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	8	p	_	_
22	in	in	IN	_	25	case	_	_
23	a	a	DT	_	25	det	_	_
24	light/dark	light/dark	NN	_	25	com	_	_
25	test	test	NN	_	4	ppmod	_	_
26	in	in	IN	_	27	case	_	_
27	mice	mouse	NNS	_	2	ppmod	_	_
28	.	.	.	_	2	p	_	_

1	All	all	DT	_	2	det	_	_
2	antagonists	antagonist	NNS	_	3	dep	_	_
3	decreased	decrease	VBD	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	time	time	NN	_	6	com	_	_
6	spent	spent	NN	_	3	obj	_	_
7	in	in	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	light	light	JJ	_	10	attr	_	_
10	zone	zone	NN	_	6	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	this	this	DT	_	13	det	_	_
13	test	test	NN	_	10	ppmod	_	_
14	,	,	,	_	6	p	_	_
15	which	which	WDT	_	16	dep	_	_
16	suggested	suggest	VBD	_	6	relcl	_	_
17	that	that	IN	_	20	mark	_	_
18	these	these	DT	_	19	det	_	_
19	compounds	compound	NNS	_	20	dep	_	_
20	have	have	VBP	_	16	comp	_	_
21	anxiogenic	anxiogenic	JJ	_	22	attr	_	_
22	effects	effect	NNS	_	20	obj	_	_
23	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	anxiogenic	anxiogenic	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	7	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	were	be	VBD	_	7	aux	_	_
7	reduced	reduce	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	pretreatment	pretreatment	NN	_	7	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	an	an	DT	_	15	det	_	_
14	A2-selective	a0-selective	JJ	_	15	attr	_	_
15	agonist	agonist	NN	_	11	appo	_	_
16	,	,	,	_	11	p	_	_
17	but	but	CC	_	9	cc	_	_
18	not	not	RB	_	20	neg	_	_
19	by	by	IN	_	20	case	_	_
20	drug3	drug0	NN	_	9	conj	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	drug4	drug0	NN	_	20	prn	_	_
23	)	-rrb-	-RRB-	_	22	p	_	_
24	,	,	,	_	20	p	_	_
25	an	an	DT	_	27	det	_	_
26	A1-selective	a0-selective	JJ	_	27	attr	_	_
27	agonist	agonist	NN	_	20	appo	_	_
28	.	.	.	_	7	p	_	_

1	However	however	RB	_	15	adv	_	_
2	,	,	,	_	15	p	_	_
3	the	the	DT	_	4	det	_	_
4	antagonism	antagonism	NN	_	15	dep	_	_
5	of	of	IN	_	10	case	_	_
6	the	the	DT	_	10	det	_	_
7	drug1	drug0	NN	_	10	attr	_	_
8	-induced	-induced	JJ	_	10	attr	_	_
9	anxiogenic	anxiogenic	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	4	ppmod	_	_
11	by	by	IN	_	12	case	_	_
12	drug2	drug0	NN	_	4	ppmod	_	_
13	was	be	VBD	_	15	aux	_	_
14	only	only	RB	_	15	adv	_	_
15	observed	observe	VBN	_	0	root	_	_
16	in	in	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	time	time	NN	_	19	com	_	_
19	spent	spent	NN	_	15	ppmod	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	light	light	JJ	_	23	attr	_	_
23	zone	zone	NN	_	19	ppmod	_	_
24	,	,	,	_	15	p	_	_
25	and	and	CC	_	15	cc	_	_
26	drug3	drug0	NN	_	29	attr	_	_
27	-induced	-induced	JJ	_	29	attr	_	_
28	anxiogenic	anxiogenic	JJ	_	29	attr	_	_
29	effects	effect	NNS	_	32	dep	_	_
30	were	be	VBD	_	32	aux	_	_
31	neither	neither	RB	_	32	neg	_	_
32	reversed	reverse	VBN	_	15	conj	_	_
33	by	by	IN	_	34	case	_	_
34	drug4	drug0	NN	_	32	ppmod	_	_
35	nor	nor	CC	_	34	cc	_	_
36	by	by	IN	_	37	case	_	_
37	drug5	drug0	NN	_	34	conj	_	_
38	.	.	.	_	15	p	_	_

1	Finally	finally	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	it	it	PRP	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	notable	notable	JJ	_	4	dep	_	_
6	that	that	IN	_	13	mark	_	_
7	xanthine-derived	xanthine-derived	JJ	_	9	attr	_	_
8	adenosine	adenosine	NN	_	9	com	_	_
9	antagonists	antagonist	NNS	_	13	dep	_	_
10	tested	test	VBN	_	9	acl	_	_
11	here	here	RB	_	10	adv	_	_
12	commonly	commonly	RB	_	13	adv	_	_
13	showed	show	VBD	_	4	comp	_	_
14	anxiogenic	anxiogenic	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	13	obj	_	_
16	in	in	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	light/dark	light/dark	NN	_	19	com	_	_
19	test	test	NN	_	13	ppmod	_	_
20	in	in	IN	_	21	case	_	_
21	mice	mouse	NNS	_	13	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	suggested	suggest	VBN	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	there	there	EX	_	6	dep	_	_
6	is	be	VBZ	_	3	comp	_	_
7	a	a	DT	_	9	det	_	_
8	minor	minor	JJ	_	9	attr	_	_
9	contribution	contribution	NN	_	6	obj	_	_
10	of	of	IN	_	12	case	_	_
11	adenosine	adenosine	NN	_	12	com	_	_
12	receptors	receptor	NNS	_	9	ppmod	_	_
13	to	to	TO	_	15	aux	_	_
14	these	these	DT	_	15	det	_	_
15	effects	effect	NNS	_	9	ppmod	_	_
16	,	,	,	_	6	p	_	_
17	although	although	IN	_	23	mark	_	_
18	drug1	drug0	NN	_	19	advnp	_	_
19	-induced	-induced	JJ	_	20	adv	_	_
20	anxiogenic	anxiogenic	JJ	_	21	attr	_	_
21	effects	effect	NNS	_	23	dep	_	_
22	were	be	VBD	_	23	aux	_	_
23	antagonized	antagonize	VBN	_	6	comp	_	_
24	by	by	IN	_	28	case	_	_
25	an	an	DT	_	28	det	_	_
26	A2	a0	NN	_	28	com	_	_
27	receptor	receptor	NN	_	28	com	_	_
28	agonist	agonist	NN	_	23	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	Restoration	restoration	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	susceptibility	susceptibility	NN	_	1	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	Enterococcus	enterococcus	NN	_	7	com	_	_
7	faecalis	faecalis	NN	_	4	ppmod	_	_
8	by	by	IN	_	12	case	_	_
9	antiresistance	antiresistance	NN	_	12	com	_	_
10	determinant	determinant	NN	_	12	com	_	_
11	gene	gene	NN	_	12	com	_	_
12	transfer	transfer	NN	_	1	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	assessed	assess	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	ability	ability	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	gene	gene	NN	_	7	com	_	_
7	transfer	transfer	NN	_	4	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	reverse	reverse	VB	_	4	acl	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	resistance	resistance	NN	_	9	obj	_	_
12	in	in	IN	_	20	case	_	_
13	class	class	NN	_	18	advnp	_	_
14	A	a	NN	_	18	advnp	_	_
15	(	-lrb-	-LRB-	_	18	p	_	_
16	VanA	vana	NN	_	18	advnp	_	_
17	)	-rrb-	-RRB-	_	18	p	_	_
18	glycopeptide-resistant	glycopeptide-resistant	JJ	_	20	attr	_	_
19	Enterococcus	enterococcus	NN	_	20	com	_	_
20	faecalis	faecalis	NN	_	9	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	Recombinant	recombinant	JJ	_	3	attr	_	_
2	shuttle	shuttle	NN	_	3	com	_	_
3	vectors	vector	NNS	_	12	dep	_	_
4	containing	contain	VBG	_	3	acl	_	_
5	a	a	DT	_	10	det	_	_
6	vanH	vanh	NN	_	10	attr	_	_
7	promoter-vanA	promoter-vana	NN	_	10	attr	_	_
8	antisense	antisense	JJ	_	10	attr	_	_
9	gene	gene	NN	_	10	com	_	_
10	cassette	cassette	NN	_	4	obj	_	_
11	fully	fully	RB	_	12	adv	_	_
12	restored	restore	VBD	_	0	root	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	susceptibility	susceptibility	NN	_	12	obj	_	_
15	through	through	IN	_	22	case	_	_
16	a	a	DT	_	21	det	_	_
17	combined	combined	JJ	_	21	attr	_	_
18	transcriptional	transcriptional	JJ	_	21	attr	_	_
19	activator	activator	NN	_	21	com	_	_
20	binding	binding	NN	_	21	com	_	_
21	domain	domain	NN	_	22	com	_	_
22	decoy	decoy	NN	_	12	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	inducible	inducible	JJ	_	27	attr	_	_
25	vanA	vana	NN	_	27	attr	_	_
26	antisense	antisense	JJ	_	27	attr	_	_
27	RNA	rna	NN	_	28	com	_	_
28	effect	effect	NN	_	22	conj	_	_
29	.	.	.	_	12	p	_	_

1	Induction	induction	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	apoptosis	apoptosis	NN	_	1	ppmod	_	_
4	in	in	IN	_	7	case	_	_
5	breast	breast	NN	_	7	com	_	_
6	cancer	cancer	NN	_	7	com	_	_
7	cells	cell	NNS	_	1	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	response	response	NN	_	7	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	.	.	.	_	1	p	_	_

1	1	0	CD	_	5	num	_	_
2	,	,	,	_	5	p	_	_
3	drug1	drug0	NN	_	5	attr	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	14	dep	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	,	,	,	_	5	p	_	_
8	the	the	DT	_	10	det	_	_
9	active	active	JJ	_	10	attr	_	_
10	metabolite	metabolite	NN	_	5	appo	_	_
11	of	of	IN	_	12	case	_	_
12	drug3	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	5	p	_	_
14	is	be	VBZ	_	0	root	_	_
15	a	a	DT	_	17	det	_	_
16	potent	potent	JJ	_	17	attr	_	_
17	inhibitor	inhibitor	NN	_	14	obj	_	_
18	of	of	IN	_	22	case	_	_
19	breast	breast	NN	_	22	com	_	_
20	cancer	cancer	NN	_	22	com	_	_
21	cell	cell	NN	_	22	com	_	_
22	growth	growth	NN	_	17	ppmod	_	_
23	both	both	CC	_	25	cc	_	_
24	in	in	FW	_	25	adv	_	_
25	vivo	vivo	FW	_	14	adv	_	_
26	and	and	CC	_	25	cc	_	_
27	in	in	FW	_	28	adv	_	_
28	vitro	vitro	FW	_	25	conj	_	_
29	.	.	.	_	14	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	shown	show	VBN	_	0	root	_	_
4	that	that	IN	_	12	mark	_	_
5	MCF-7	mcf-0	NN	_	6	com	_	_
6	cells	cell	NNS	_	12	dep	_	_
7	treated	treat	VBN	_	6	acl	_	_
8	with	with	IN	_	11	case	_	_
9	100	0	CD	_	10	num	_	_
10	nM	nm	NN	_	11	com	_	_
11	drug1	drug0	NN	_	7	ppmod	_	_
12	exhibit	exhibit	VBP	_	3	comp	_	_
13	characteristic	characteristic	JJ	_	15	attr	_	_
14	apoptotic	apoptotic	JJ	_	15	attr	_	_
15	morphology	morphology	NN	_	12	obj	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	pyknotic	pyknotic	JJ	_	18	attr	_	_
18	nuclei	nucleus	NNS	_	15	prn	_	_
19	,	,	,	_	18	p	_	_
20	chromatin	chromatin	NN	_	18	appo	_	_
21	and	and	CC	_	20	cc	_	_
22	cytoplasmic	cytoplasmic	JJ	_	23	attr	_	_
23	condensation	condensation	NN	_	20	conj	_	_
24	,	,	,	_	18	p	_	_
25	nuclear	nuclear	JJ	_	28	attr	_	_
26	matrix	matrix	NN	_	28	com	_	_
27	protein	protein	NN	_	28	com	_	_
28	reorganization	reorganization	NN	_	18	appo	_	_
29	)	-rrb-	-RRB-	_	18	p	_	_
30	within	within	IN	_	32	case	_	_
31	48	0	CD	_	32	num	_	_
32	h	h	NN	_	12	ppmod	_	_
33	.	.	.	_	3	p	_	_

1	In	in	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	experiments	experiment	NNS	_	8	ppmod	_	_
4	reported	report	VBN	_	3	acl	_	_
5	here	here	RB	_	4	adv	_	_
6	,	,	,	_	8	p	_	_
7	we	we	PRP	_	8	dep	_	_
8	examined	examine	VBD	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	interactions	interaction	NNS	_	8	obj	_	_
11	between	between	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	the	the	DT	_	16	det	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	drug3	drug0	NN	_	12	conj	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	drug4	drug0	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	,	,	,	_	12	p	_	_
21	which	which	WDT	_	23	dep	_	_
22	also	also	RB	_	23	adv	_	_
23	induces	induce	VBZ	_	12	relcl	_	_
24	apoptosis	apoptosis	NN	_	23	obj	_	_
25	in	in	IN	_	27	case	_	_
26	MCF-7	mcf-0	NN	_	27	com	_	_
27	cells	cell	NNS	_	23	ppmod	_	_
28	.	.	.	_	8	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	potentiates	potentiate	VBZ	_	3	comp	_	_
8	the	the	DT	_	9	det	_	_
9	reduction	reduction	NN	_	7	obj	_	_
10	in	in	IN	_	12	case	_	_
11	cell	cell	NN	_	12	com	_	_
12	number	number	NN	_	9	ppmod	_	_
13	induced	induce	VBN	_	12	acl	_	_
14	by	by	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	alone	alone	RB	_	15	adv	_	_
17	.	.	.	_	3	p	_	_

1	Combined	combined	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	7	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	enhances	enhance	VBZ	_	0	root	_	_
8	the	the	DT	_	9	det	_	_
9	degree	degree	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	apoptosis	apoptosis	NN	_	9	ppmod	_	_
12	assessed	assess	VBN	_	11	acl	_	_
13	using	use	VBG	_	12	comp	_	_
14	morphological	morphological	JJ	_	15	attr	_	_
15	markers	marker	NNS	_	13	obj	_	_
16	that	that	WDT	_	17	dep	_	_
17	identify	identify	VBP	_	15	relcl	_	_
18	chromatin	chromatin	NN	_	17	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	nuclear	nuclear	JJ	_	23	attr	_	_
21	matrix	matrix	NN	_	23	com	_	_
22	protein	protein	NN	_	23	com	_	_
23	condensation	condensation	NN	_	18	conj	_	_
24	.	.	.	_	7	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	have	have	VBP	_	3	aux	_	_
3	selected	select	VBN	_	0	root	_	_
4	a	a	DT	_	5	det	_	_
5	subclone	subclone	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	MCF-7	mcf-0	NN	_	8	com	_	_
8	cells	cell	NNS	_	5	ppmod	_	_
9	resistant	resistant	JJ	_	8	attr	_	_
10	to	to	TO	_	11	aux	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	MCF-7D3Res	mcf-0d0res	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	cells	cell	NNS	_	3	dep	_	_
3	express	express	VBP	_	0	root	_	_
4	the	the	DT	_	7	det	_	_
5	vitamin	vitamin	NN	_	7	com	_	_
6	D	d	NN	_	7	com	_	_
7	receptor	receptor	NN	_	3	obj	_	_
8	and	and	CC	_	3	cc	_	_
9	exhibit	exhibit	VBP	_	3	conj	_	_
10	doubling	double	VBG	_	11	attr	_	_
11	times	time	NNS	_	9	obj	_	_
12	comparable	comparable	JJ	_	11	attr	_	_
13	to	to	TO	_	17	aux	_	_
14	the	the	DT	_	17	det	_	_
15	parental	parental	JJ	_	17	attr	_	_
16	MCF-7	mcf-0	NN	_	17	com	_	_
17	cells	cell	NNS	_	12	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	even	even	RB	_	20	com	_	_
20	when	when	WRB	_	21	adv	_	_
21	grown	grow	VBN	_	17	relcl	_	_
22	in	in	IN	_	25	case	_	_
23	100	0	CD	_	24	num	_	_
24	mM	mm	NN	_	25	com	_	_
25	drug1	drug0	NN	_	21	ppmod	_	_
26	.	.	.	_	3	p	_	_

1	Treatment	treatment	NN	_	11	dep	_	_
2	of	of	IN	_	8	case	_	_
3	both	both	CC	_	4	cc	_	_
4	parental	parental	JJ	_	8	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	resistant	resistant	JJ	_	4	conj	_	_
7	MCF-7	mcf-0	NN	_	8	com	_	_
8	cells	cell	NNS	_	1	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	drug1	drug0	NN	_	1	ppmod	_	_
11	induces	induce	VBZ	_	0	root	_	_
12	apoptosis	apoptosis	NN	_	11	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	clusterin	clusterin	NN	_	12	conj	_	_
15	.	.	.	_	11	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	emphasize	emphasize	VBP	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	apoptosis	apoptosis	NN	_	8	dep	_	_
6	can	can	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	induced	induce	VBN	_	3	comp	_	_
9	in	in	IN	_	11	case	_	_
10	MCF-7	mcf-0	NN	_	11	com	_	_
11	cells	cell	NNS	_	8	ppmod	_	_
12	either	either	CC	_	11	cc	_	_
13	by	by	IN	_	14	case	_	_
14	activation	activation	NN	_	11	conj	_	_
15	of	of	IN	_	18	case	_	_
16	drug1	drug0	NN	_	18	attr	_	_
17	-mediated	-mediated	JJ	_	18	attr	_	_
18	signalling	signalling	NN	_	14	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	disruption	disruption	NN	_	24	attr	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	-dependent	-dependent	JJ	_	24	attr	_	_
24	signalling	signalling	NN	_	18	conj	_	_
25	.	.	.	_	3	p	_	_

1	Cholinergic	cholinergic	JJ	_	2	attr	_	_
2	role	role	NN	_	0	root	_	_
3	in	in	IN	_	6	case	_	_
4	drug1	drug0	NN	_	6	attr	_	_
5	's	's	POS	_	6	case	_	_
6	effects	effect	NNS	_	2	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	evoked	evoke	VBN	_	9	attr	_	_
9	potentials	potential	NNS	_	2	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	visual	visual	JJ	_	12	attr	_	_
12	cortex	cortex	NN	_	9	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	albino	albino	JJ	_	16	attr	_	_
16	rat	rat	NN	_	12	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	Photic	photic	JJ	_	3	attr	_	_
2	evoked	evoke	VBN	_	3	attr	_	_
3	potentials	potential	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	recorded	record	VBN	_	0	root	_	_
6	from	from	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	visual	visual	JJ	_	9	attr	_	_
9	cortex	cortex	NN	_	5	ppmod	_	_
10	of	of	IN	_	14	case	_	_
11	chronically	chronically	RB	_	12	adv	_	_
12	implanted	implant	VBN	_	14	attr	_	_
13	albino	albino	NN	_	14	com	_	_
14	rats	rat	NNS	_	9	ppmod	_	_
15	.	.	.	_	5	p	_	_

1	Since	since	IN	_	6	mark	_	_
2	photic	photic	JJ	_	5	attr	_	_
3	evoked	evoke	VBN	_	5	attr	_	_
4	potential	potential	JJ	_	5	attr	_	_
5	components	component	NNS	_	6	dep	_	_
6	are	be	VBP	_	28	advcl	_	_
7	representations	representation	NNS	_	6	obj	_	_
8	of	of	IN	_	10	case	_	_
9	neural	neural	JJ	_	10	attr	_	_
10	pathways	pathway	NNS	_	7	ppmod	_	_
11	which	which	WDT	_	13	dep	_	_
12	are	be	VBP	_	13	aux	_	_
13	activated	activate	VBN	_	7	relcl	_	_
14	during	during	IN	_	16	case	_	_
15	photic	photic	JJ	_	16	attr	_	_
16	stimulation	stimulation	NN	_	13	ppmod	_	_
17	,	,	,	_	28	p	_	_
18	study	study	NN	_	28	dep	_	_
19	of	of	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	effects	effect	NNS	_	18	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug1	drug0	NN	_	21	ppmod	_	_
24	on	on	IN	_	26	case	_	_
25	these	these	DT	_	26	det	_	_
26	components	component	NNS	_	21	ppmod	_	_
27	may	may	MD	_	28	modal	_	_
28	help	help	VB	_	0	root	_	_
29	to	to	TO	_	30	aux	_	_
30	trace	trace	VB	_	28	comp	_	_
31	pathways	pathway	NNS	_	30	obj	_	_
32	which	which	WDT	_	34	dep	_	_
33	are	be	VBP	_	34	aux	_	_
34	affected	affect	VBN	_	31	relcl	_	_
35	by	by	IN	_	36	case	_	_
36	drug2	drug0	NN	_	34	ppmod	_	_
37	.	.	.	_	28	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	evoked	evoke	VBN	_	7	attr	_	_
7	potentials	potential	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	recorded	record	VBN	_	0	root	_	_
10	at	at	IN	_	17	case	_	_
11	5	0	CD	_	17	num	_	_
12	,	,	,	_	11	p	_	_
13	20	0	CD	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	40	0	CD	_	11	conj	_	_
17	min	min	NN	_	9	ppmod	_	_
18	following	follow	VBG	_	20	adv	_	_
19	IP	ip	JJ	_	20	attr	_	_
20	injections	injection	NNS	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	saline	saline	NN	_	20	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	drug1	drug0	NN	_	22	conj	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	2.0	0	CD	_	27	num	_	_
27	g/kg	g/kg	NN	_	24	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	,	,	,	_	24	p	_	_
30	drug2	drug0	NN	_	22	conj	_	_
31	(	-lrb-	-LRB-	_	33	p	_	_
32	0.6	0	CD	_	33	num	_	_
33	mg/kg	mg/kg	NN	_	30	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	or	or	CC	_	30	cc	_	_
36	drug3	drug0	NN	_	22	conj	_	_
37	(	-lrb-	-LRB-	_	39	p	_	_
38	15.0	0	CD	_	39	num	_	_
39	mg/kg	mg/kg	NN	_	36	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	on	on	IN	_	43	case	_	_
42	separate	separate	JJ	_	43	attr	_	_
43	days	day	NNS	_	9	ppmod	_	_
44	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	depressed	depress	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	amplitudes	amplitude	NNS	_	2	obj	_	_
5	of	of	IN	_	9	case	_	_
6	most	most	JJS	_	9	attr	_	_
7	evoked	evoke	VBN	_	9	attr	_	_
8	potential	potential	JJ	_	9	attr	_	_
9	components	component	NNS	_	4	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	comparison	comparison	NN	_	4	ppmod	_	_
12	to	to	TO	_	14	aux	_	_
13	saline	saline	NN	_	14	com	_	_
14	administration	administration	NN	_	11	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	Component	component	NN	_	2	com	_	_
2	P2	p0	NN	_	7	dep	_	_
3	,	,	,	_	7	p	_	_
4	however	however	RB	_	7	adv	_	_
5	,	,	,	_	7	p	_	_
6	was	be	VBD	_	7	aux	_	_
7	increased	increase	VBN	_	0	root	_	_
8	in	in	IN	_	9	case	_	_
9	amplitude	amplitude	NN	_	7	ppmod	_	_
10	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	briefly	briefly	RB	_	3	adv	_	_
3	reduced	reduce	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	amplitude	amplitude	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	most	most	JJ	_	8	attr	_	_
8	components	component	NNS	_	5	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	including	include	VBG	_	11	adv	_	_
11	P2	p0	NN	_	8	ppmod	_	_
12	.	.	.	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	increased	increase	VBD	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	amplitudes	amplitude	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	components	component	NNS	_	7	ppmod	_	_
10	P1	p0	NN	_	9	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	P2	p0	NN	_	10	conj	_	_
13	,	,	,	_	5	p	_	_
14	while	while	IN	_	15	mark	_	_
15	decreasing	decrease	VBG	_	5	comp	_	_
16	components	component	NNS	_	15	obj	_	_
17	N1	n0	NNP	_	19	attr	_	_
18	,	,	,	_	19	p	_	_
19	N2	n0	NNP	_	16	attr	_	_
20	and	and	CC	_	19	cc	_	_
21	N3	n0	NNP	_	19	conj	_	_
22	for	for	IN	_	24	case	_	_
23	varying	vary	VBG	_	24	attr	_	_
24	durations	duration	NNS	_	16	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	time	time	NN	_	24	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	pretreatment	pretreatment	NN	_	3	dep	_	_
3	augmented	augment	VBD	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	depressant	depressant	JJ	_	6	attr	_	_
6	effect	effect	NN	_	3	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	on	on	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	early	early	JJ	_	12	attr	_	_
12	components	component	NNS	_	6	ppmod	_	_
13	P1	p0	NN	_	12	attr	_	_
14	and	and	CC	_	13	cc	_	_
15	N1	n0	NN	_	13	conj	_	_
16	,	,	,	_	3	p	_	_
17	while	while	IN	_	18	mark	_	_
18	attenuating	attenuate	VBG	_	3	comp	_	_
19	drug3	drug0	NN	_	21	poss	_	_
20	's	's	POS	_	19	case	_	_
21	influence	influence	NN	_	18	obj	_	_
22	on	on	IN	_	23	case	_	_
23	components	component	NNS	_	21	ppmod	_	_
24	P2	p0	NN	_	23	attr	_	_
25	and	and	CC	_	24	cc	_	_
26	P3	p0	NN	_	24	conj	_	_
27	.	.	.	_	3	p	_	_

1	Pretreatment	pretreatment	NN	_	6	dep	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	likewise	likewise	RB	_	6	adv	_	_
5	further	far	RB	_	6	adv	_	_
6	reduced	reduce	VBD	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	amplitudes	amplitude	NNS	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	components	component	NNS	_	8	ppmod	_	_
11	P1	p0	NN	_	10	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	N1	n0	NN	_	11	conj	_	_
14	,	,	,	_	6	p	_	_
15	and	and	CC	_	6	cc	_	_
16	produced	produce	VBD	_	6	conj	_	_
17	a	a	DT	_	19	det	_	_
18	similar	similar	JJ	_	19	attr	_	_
19	effect	effect	NN	_	16	obj	_	_
20	on	on	IN	_	22	case	_	_
21	component	component	NN	_	22	com	_	_
22	N3	n0	NN	_	19	ppmod	_	_
23	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	either	either	CC	_	4	cc	_	_
4	alone	alone	RB	_	1	adv	_	_
5	or	or	CC	_	4	cc	_	_
6	in	in	IN	_	7	case	_	_
7	combination	combination	NN	_	4	conj	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	produced	produce	VBD	_	0	root	_	_
12	approximately	approximately	RB	_	15	adv	_	_
13	the	the	DT	_	15	det	_	_
14	same	same	JJ	_	15	attr	_	_
15	degree	degree	NN	_	11	obj	_	_
16	of	of	IN	_	17	case	_	_
17	enhancement	enhancement	NN	_	15	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	component	component	NN	_	20	com	_	_
20	P2	p0	NN	_	17	ppmod	_	_
21	.	.	.	_	11	p	_	_

1	In	in	IN	_	2	case	_	_
2	comparison	comparison	NN	_	10	ppmod	_	_
3	to	to	TO	_	5	aux	_	_
4	saline	saline	NN	_	5	com	_	_
5	values	value	NNS	_	2	ppmod	_	_
6	,	,	,	_	10	p	_	_
7	all	all	DT	_	9	det	_	_
8	three	#crd#	CD	_	9	num	_	_
9	agents	agent	NNS	_	10	dep	_	_
10	produced	produce	VBD	_	0	root	_	_
11	reliable	reliable	JJ	_	12	attr	_	_
12	increases	increase	NNS	_	10	obj	_	_
13	in	in	IN	_	15	case	_	_
14	peak	peak	JJ	_	15	attr	_	_
15	latency	latency	NN	_	12	ppmod	_	_
16	for	for	IN	_	17	case	_	_
17	most	most	JJS	_	15	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	components	component	NNS	_	17	ppmod	_	_
21	,	,	,	_	10	p	_	_
22	with	with	IN	_	24	case	_	_
23	only	only	JJ	_	24	attr	_	_
24	N3	n0	NN	_	10	ppmod	_	_
25	showing	show	VBG	_	24	acl	_	_
26	no	no	DT	_	27	det	_	_
27	effects	effect	NNS	_	25	obj	_	_
28	.	.	.	_	10	p	_	_

1	The	the	DT	_	3	det	_	_
2	amplitude	amplitude	JJ	_	3	attr	_	_
3	data	datum	NNS	_	7	dep	_	_
4	from	from	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	study	study	NN	_	3	ppmod	_	_
7	suggest	suggest	VBP	_	0	root	_	_
8	that	that	IN	_	16	mark	_	_
9	drug1	drug0	NN	_	11	poss	_	_
10	's	's	POS	_	9	case	_	_
11	augmentation	augmentation	NN	_	16	dep	_	_
12	of	of	IN	_	14	case	_	_
13	component	component	NN	_	14	com	_	_
14	P2	p0	NN	_	11	ppmod	_	_
15	may	may	MD	_	16	modal	_	_
16	result	result	VB	_	7	comp	_	_
17	,	,	,	_	16	p	_	_
18	at	at	IN	_	19	case	_	_
19	least	least	JJS	_	21	adv	_	_
20	in	in	IN	_	21	case	_	_
21	part	part	NN	_	16	ppmod	_	_
22	,	,	,	_	16	p	_	_
23	from	from	IN	_	24	case	_	_
24	alterations	alteration	NNS	_	16	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	cholinergic	cholinergic	JJ	_	27	attr	_	_
27	functions	function	NNS	_	24	ppmod	_	_
28	.	.	.	_	7	p	_	_

1	Increased	increase	VBN	_	0	root	_	_
2	hepatotoxicity	hepatotoxicity	NN	_	1	obj	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	by	by	IN	_	7	case	_	_
6	concomitant	concomitant	JJ	_	7	attr	_	_
7	administration	administration	NN	_	1	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	rat	rat	NN	_	7	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	Since	since	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	is	be	VBZ	_	5	aux	_	_
4	frequently	frequently	RB	_	5	adv	_	_
5	co-administered	co-administered	VBN	_	10	advcl	_	_
6	with	with	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	10	p	_	_
9	it	it	PRP	_	10	dep	_	_
10	is	be	VBZ	_	0	root	_	_
11	of	of	IN	_	13	case	_	_
12	clinical	clinical	JJ	_	13	attr	_	_
13	interest	interest	NN	_	10	ppmod	_	_
14	to	to	TO	_	15	aux	_	_
15	study	study	VB	_	10	comp	_	_
16	the	the	DT	_	17	det	_	_
17	effect	effect	NN	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	on	on	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	hepatotoxicity	hepatotoxicity	NN	_	17	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NNS	_	22	ppmod	_	_
25	.	.	.	_	10	p	_	_

1	In	in	IN	_	4	case	_	_
2	male	male	JJ	_	4	attr	_	_
3	Sprague-Dawley	sprague-dawley	NN	_	4	com	_	_
4	rats	rat	NNS	_	11	ppmod	_	_
5	fasted	fast	VBN	_	4	acl	_	_
6	for	for	IN	_	8	case	_	_
7	18	0	CD	_	8	num	_	_
8	h	h	NN	_	5	ppmod	_	_
9	,	,	,	_	11	p	_	_
10	concomitant	concomitant	JJ	_	11	attr	_	_
11	administration	administration	NN	_	0	root	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	0.1	0	CD	_	16	num	_	_
16	g/kg	g/kg	NN	_	11	prn	_	_
17	,	,	,	_	16	p	_	_
18	i.p.	i.p.	RB	_	16	adv	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_

1	as	as	IN	_	2	case	_	_
2	judged	judge	VBN	_	0	root	_	_
3	by	by	IN	_	7	case	_	_
4	increased	increase	VBN	_	7	attr	_	_
5	serum	serum	NN	_	7	com	_	_
6	enzyme	enzyme	NN	_	7	com	_	_
7	activities	activity	NNS	_	2	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	increased	increase	VBN	_	10	attr	_	_
10	incidence	incidence	NN	_	7	conj	_	_
11	of	of	IN	_	13	case	_	_
12	hepatic	hepatic	JJ	_	13	attr	_	_
13	necrosis	necrosis	NN	_	10	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	Careful	careful	JJ	_	2	attr	_	_
2	observations	observation	NNS	_	6	dep	_	_
3	on	on	IN	_	4	case	_	_
4	hepatotoxicity	hepatotoxicity	NN	_	2	ppmod	_	_
5	are	be	VBP	_	6	aux	_	_
6	suggested	suggest	VBN	_	0	root	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	is	be	VBZ	_	10	aux	_	_
10	prescribed	prescribe	VBN	_	6	comp	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	Dual	dual	JJ	_	2	attr	_	_
2	effect	effect	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	9	case	_	_
6	the	the	DT	_	9	det	_	_
7	drug2	drug0	NN	_	8	advnp	_	_
8	-induced	-induced	JJ	_	9	attr	_	_
9	contraction	contraction	NN	_	2	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	norepinephrine	norepinephrine	NN	_	12	com	_	_
12	release	release	NN	_	9	conj	_	_
13	in	in	IN	_	17	case	_	_
14	the	the	DT	_	17	det	_	_
15	guinea-pig	guinea-pig	JJ	_	17	attr	_	_
16	vas	vas	NN	_	17	com	_	_
17	deferens	deferens	NNS	_	9	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	16	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	,	,	,	_	1	p	_	_
6	C129H223N3O54	c0h0n0o0	NN	_	1	appo	_	_
7	,	,	,	_	1	p	_	_
8	isolated	isolate	VBN	_	1	acl	_	_
9	from	from	IN	_	11	case	_	_
10	marine	marine	JJ	_	11	attr	_	_
11	coelenterates	coelenterate	NNS	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	Palythoa	palythoa	NN	_	14	com	_	_
14	tuberculosa	tuberculosa	NN	_	11	ppmod	_	_
15	,	,	,	_	1	p	_	_
16	caused	cause	VBD	_	0	root	_	_
17	a	a	DT	_	20	det	_	_
18	first	#ord#	JJ	_	20	attr	_	_
19	rapid	rapid	JJ	_	20	attr	_	_
20	contraction	contraction	NN	_	16	obj	_	_
21	followed	followed	VBN	_	20	acl	_	_
22	by	by	IN	_	26	case	_	_
23	the	the	DT	_	26	det	_	_
24	slow	slow	JJ	_	26	attr	_	_
25	phasic	phasic	NN	_	26	com	_	_
26	contraction	contraction	NN	_	21	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	guinea-pig	guinea-pig	JJ	_	30	attr	_	_
29	vas	vas	NN	_	30	com	_	_
30	deferens	deferens	NNS	_	26	ppmod	_	_
31	.	.	.	_	16	p	_	_

1	In	in	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	presence	presence	NN	_	5	advnp	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	22	ppmod	_	_
6	(	-lrb-	-LRB-	_	11	p	_	_
7	10	0	CD	_	11	num	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	-5	0	CD	_	11	num	_	_
10	)	-rrb-	-RRB-	_	11	p	_	_
11	M	m	NN	_	5	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	,	,	,	_	22	p	_	_
14	drug2	drug0	NN	_	22	dep	_	_
15	(	-lrb-	-LRB-	_	20	p	_	_
16	10	0	CD	_	20	num	_	_
17	(	-lrb-	-LRB-	_	20	p	_	_
18	-8	0	CD	_	20	num	_	_
19	)	-rrb-	-RRB-	_	20	p	_	_
20	M	m	NN	_	14	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	failed	fail	VBD	_	0	root	_	_
23	to	to	TO	_	24	aux	_	_
24	cause	cause	VB	_	22	comp	_	_
25	the	the	DT	_	27	det	_	_
26	first	#ord#	JJ	_	27	attr	_	_
27	contraction	contraction	NN	_	24	obj	_	_
28	;	;	:	_	22	p	_	_

1	however	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	the	the	DT	_	5	det	_	_
4	second	#ord#	JJ	_	5	attr	_	_
5	contraction	contraction	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	potentiated	potentiate	VBN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	In	in	IN	_	5	case	_	_
2	the	the	DT	_	5	det	_	_
3	presence	presence	NN	_	5	advnp	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	18	ppmod	_	_
6	(	-lrb-	-LRB-	_	11	p	_	_
7	10	0	CD	_	11	num	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	-6	0	CD	_	11	num	_	_
10	)	-rrb-	-RRB-	_	11	p	_	_
11	M	m	NN	_	5	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	,	,	,	_	18	p	_	_
14	the	the	DT	_	16	det	_	_
15	second	#ord#	JJ	_	16	attr	_	_
16	contraction	contraction	NN	_	18	dep	_	_
17	was	be	VBD	_	18	aux	_	_
18	inhibited	inhibit	VBN	_	0	root	_	_
19	selectively	selectively	RB	_	18	adv	_	_
20	.	.	.	_	18	p	_	_

1	When	when	WRB	_	4	adv	_	_
2	drug1	drug0	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	applied	apply	VBN	_	23	advcl	_	_
5	to	to	TO	_	7	aux	_	_
6	the	the	DT	_	7	det	_	_
7	muscle	muscle	NN	_	4	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	presence	presence	NN	_	4	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	23	p	_	_
14	both	both	CC	_	15	cc	_	_
15	first	#ord#	JJ	_	19	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	second	#ord#	JJ	_	15	conj	_	_
18	contractile	contractile	JJ	_	19	attr	_	_
19	responses	response	NNS	_	23	dep	_	_
20	to	to	TO	_	21	aux	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	were	be	VBD	_	23	aux	_	_
23	abolished	abolish	VBN	_	0	root	_	_
24	.	.	.	_	23	p	_	_

1	When	when	WRB	_	5	adv	_	_
2	the	the	DT	_	3	det	_	_
3	muscle	muscle	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	exposed	expose	VBN	_	19	advcl	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	potassium-depleted	potassium-depleted	JJ	_	9	attr	_	_
9	solution	solution	NN	_	5	ppmod	_	_
10	,	,	,	_	19	p	_	_
11	the	the	DT	_	14	det	_	_
12	first	#ord#	JJ	_	14	attr	_	_
13	contractile	contractile	JJ	_	14	attr	_	_
14	response	response	NN	_	19	dep	_	_
15	to	to	TO	_	16	aux	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	was	be	VBD	_	19	aux	_	_
18	rather	rather	RB	_	19	adv	_	_
19	potentiated	potentiate	VBN	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	caused	cause	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	release	release	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	norepinephrine	norepinephrine	NN	_	4	ppmod	_	_
7	from	from	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	muscle	muscle	NN	_	4	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	Exposure	exposure	NN	_	15	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	muscle	muscle	NN	_	1	ppmod	_	_
5	to	to	TO	_	6	aux	_	_
6	drug1	drug0	NN	_	1	ppmod	_	_
7	(	-lrb-	-LRB-	_	12	p	_	_
8	10	0	CD	_	12	num	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	-5	0	CD	_	12	num	_	_
11	)	-rrb-	-RRB-	_	12	p	_	_
12	M	m	NN	_	6	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	markedly	markedly	RB	_	15	adv	_	_
15	increased	increase	VBD	_	0	root	_	_
16	the	the	DT	_	19	det	_	_
17	drug2	drug0	JJ	_	19	attr	_	_
18	-induced	-induced	JJ	_	19	attr	_	_
19	release	release	NN	_	15	obj	_	_
20	.	.	.	_	15	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	indicated	indicate	VBN	_	0	root	_	_
4	that	that	IN	_	13	mark	_	_
5	the	the	DT	_	10	det	_	_
6	first	#ord#	JJ	_	10	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	second	#ord#	JJ	_	6	conj	_	_
9	contractile	contractile	JJ	_	10	attr	_	_
10	responses	response	NNS	_	13	dep	_	_
11	to	to	TO	_	12	aux	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	have	have	VBP	_	3	comp	_	_
14	entirely	entirely	RB	_	15	adv	_	_
15	different	different	JJ	_	16	attr	_	_
16	properties	property	NNS	_	13	obj	_	_
17	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	second	#ord#	JJ	_	3	attr	_	_
3	response	response	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	due	due	JJ	_	4	dep	_	_
6	to	to	TO	_	8	aux	_	_
7	a	a	DT	_	8	det	_	_
8	release	release	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	norepinephrine	norepinephrine	NN	_	8	ppmod	_	_
11	from	from	IN	_	12	case	_	_
12	nerves	nerve	NNS	_	8	ppmod	_	_
13	and	and	CC	_	4	cc	_	_
14	was	be	VBD	_	15	aux	_	_
15	potentiated	potentiate	VBN	_	4	conj	_	_
16	by	by	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	through	through	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	increase	increase	NN	_	15	ppmod	_	_
21	in	in	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	norepinephrine	norepinephrine	NN	_	24	com	_	_
24	release	release	NN	_	20	ppmod	_	_
25	,	,	,	_	15	p	_	_
26	whereas	whereas	IN	_	30	mark	_	_
27	the	the	DT	_	29	det	_	_
28	first	#ord#	JJ	_	29	attr	_	_
29	response	response	NN	_	30	dep	_	_
30	was	be	VBD	_	15	comp	_	_
31	not	not	RB	_	30	neg	_	_
32	due	due	JJ	_	30	dep	_	_
33	to	to	TO	_	36	aux	_	_
34	the	the	DT	_	36	det	_	_
35	norepinephrine	norepinephrine	NN	_	36	com	_	_
36	release	release	NN	_	32	ppmod	_	_
37	but	but	CC	_	36	cc	_	_
38	presumably	presumably	RB	_	42	adv	_	_
39	to	to	TO	_	42	aux	_	_
40	a	a	DT	_	42	det	_	_
41	direct	direct	JJ	_	42	attr	_	_
42	action	action	NN	_	36	conj	_	_
43	on	on	IN	_	46	case	_	_
44	smooth	smooth	JJ	_	46	attr	_	_
45	muscle	muscle	NN	_	46	com	_	_
46	cell	cell	NN	_	42	ppmod	_	_
47	and	and	CC	_	30	cc	_	_
48	was	be	VBD	_	49	aux	_	_
49	inhibited	inhibit	VBN	_	30	conj	_	_
50	by	by	IN	_	51	case	_	_
51	drug2	drug0	NN	_	49	ppmod	_	_
52	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	action	action	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	discussed	discuss	VBN	_	0	root	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	relation	relation	NN	_	9	ppmod	_	_
13	with	with	IN	_	14	case	_	_
14	Na	na	NN	_	12	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	K-ATPase	k-atpase	NN	_	14	appo	_	_
17	.	.	.	_	9	p	_	_

1	Analgesic	analgesic	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	literature	literature	NN	_	3	dep	_	_
3	provides	provide	VBZ	_	0	root	_	_
4	considerable	considerable	JJ	_	5	attr	_	_
5	evidence	evidence	NN	_	3	obj	_	_
6	indicating	indicate	VBG	_	5	acl	_	_
7	that	that	IN	_	17	mark	_	_
8	several	several	JJ	_	17	dep	_	_
9	,	,	,	_	8	p	_	_
10	but	but	CC	_	8	cc	_	_
11	not	not	RB	_	10	com	_	_
12	all	all	DT	_	13	det	_	_
13	drug1	drug0	JJ	_	8	conj	_	_
14	,	,	,	_	13	p	_	_
15	are	be	VBP	_	17	aux	_	_
16	indeed	indeed	RB	_	17	adv	_	_
17	drug2	drug0	VBN	_	6	comp	_	_
18	and	and	CC	_	17	cc	_	_
19	some	some	DT	_	21	dep	_	_
20	are	be	VBP	_	21	aux	_	_
21	drug3	drug0	VBN	_	17	conj	_	_
22	as	as	IN	_	23	case	_	_
23	well	well	NN	_	21	ppmod	_	_
24	.	.	.	_	3	p	_	_

1	Those	those	DT	_	7	dep	_	_
2	for	for	IN	_	3	case	_	_
3	which	which	WDT	_	6	ppmod	_	_
4	effectiveness	effectiveness	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	reported	report	VBN	_	1	relcl	_	_
7	includes	include	VBZ	_	0	root	_	_
8	drug1	drug0	NN	_	7	obj	_	_
9	,	,	,	_	8	p	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	,	,	,	_	10	p	_	_
12	drug3	drug0	NN	_	8	conj	_	_
13	,	,	,	_	12	p	_	_
14	drug4	drug0	NN	_	8	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug5	drug0	NN	_	8	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug6	drug0	NN	_	8	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug7	drug0	NN	_	8	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	drug8	drug0	NN	_	8	conj	_	_
24	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	proposed	proposed	JJ	_	3	attr	_	_
3	mechanisms	mechanism	NNS	_	10	dep	_	_
4	of	of	IN	_	6	case	_	_
5	analgesic	analgesic	JJ	_	6	attr	_	_
6	action	action	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	are	be	VBP	_	10	aux	_	_
10	reviewed	review	VBN	_	0	root	_	_
11	and	and	CC	_	10	cc	_	_
12	discussed	discuss	VBN	_	10	conj	_	_
13	.	.	.	_	10	p	_	_

1	The	the	DT	_	2	det	_	_
2	literature	literature	NN	_	3	dep	_	_
3	suggests	suggest	VBZ	_	0	root	_	_
4	that	that	IN	_	11	mark	_	_
5	more	more	JJR	_	7	attr	_	_
6	than	than	IN	_	5	com	_	_
7	one	#crd#	CD	_	8	num	_	_
8	mechanism	mechanism	NN	_	11	dep	_	_
9	of	of	IN	_	10	case	_	_
10	action	action	NN	_	8	ppmod	_	_
11	exists	exist	VBZ	_	3	comp	_	_
12	for	for	IN	_	13	case	_	_
13	them	them	PRP	_	11	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	considerable	considerable	JJ	_	4	attr	_	_
4	evidence	evidence	NN	_	2	obj	_	_
5	suggesting	suggest	VBG	_	4	acl	_	_
6	that	that	IN	_	13	mark	_	_
7	histaminergic	histaminergic	JJ	_	11	attr	_	_
8	and	and	CC	_	7	cc	_	_
9	serotoninergic	serotoninergic	JJ	_	7	conj	_	_
10	central	central	JJ	_	11	attr	_	_
11	pathways	pathway	NNS	_	13	dep	_	_
12	are	be	VBP	_	13	aux	_	_
13	involved	involve	VBN	_	5	advcl	_	_
14	in	in	IN	_	15	case	_	_
15	nociception	nociception	NN	_	13	ppmod	_	_
16	and	and	CC	_	13	cc	_	_
17	that	that	IN	_	21	mark	_	_
18	drug1	drug0	NN	_	19	com	_	_
19	drugs	drug	NNS	_	21	dep	_	_
20	can	can	MD	_	21	modal	_	_
21	modulate	modulate	VB	_	13	conj	_	_
22	their	their	PRP$	_	23	poss	_	_
23	responses	response	NNS	_	21	obj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	1	0	CD	_	2	num	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	evidence	evidence	NN	_	20	dep	_	_
3	for	for	IN	_	5	case	_	_
4	a	a	DT	_	5	det	_	_
5	role	role	NN	_	2	ppmod	_	_
6	for	for	IN	_	7	case	_	_
7	norepinephrine	norepinephrine	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	dopamine	dopamine	NN	_	7	conj	_	_
10	and	and	CC	_	5	cc	_	_
11	the	the	DT	_	12	det	_	_
12	effects	effect	NNS	_	5	conj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	on	on	IN	_	16	case	_	_
16	them	them	PRP	_	12	ppmod	_	_
17	are	be	VBP	_	20	aux	_	_
18	less	less	RBR	_	19	com	_	_
19	well	well	RB	_	20	adv	_	_
20	established	establish	VBN	_	0	root	_	_
21	.	.	.	_	20	p	_	_

1	Still	still	RB	_	6	adv	_	_
2	other	other	JJ	_	3	attr	_	_
3	pathways	pathway	NNS	_	6	dep	_	_
4	have	have	VBP	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	proposed	propose	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	A	a	DT	_	3	det	_	_
2	greater	great	JJR	_	3	attr	_	_
3	understanding	understanding	NN	_	8	dep	_	_
4	of	of	IN	_	6	case	_	_
5	pain	pain	JJ	_	6	attr	_	_
6	mechanisms	mechanism	NNS	_	3	ppmod	_	_
7	will	will	MD	_	8	modal	_	_
8	aid	aid	VB	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	elucidating	elucidate	VBG	_	8	ppmod	_	_
11	the	the	DT	_	12	det	_	_
12	role	role	NN	_	10	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	analgesia	analgesia	NN	_	12	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	11	case	_	_
5	voltage-dependent	voltage-dependent	JJ	_	6	attr	_	_
6	Ca	ca	NN	_	11	attr	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	2+	0+	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	channel	channel	NN	_	11	com	_	_
11	subtypes	subtype	NNS	_	1	ppmod	_	_
12	in	in	IN	_	15	case	_	_
13	bovine	bovine	JJ	_	15	attr	_	_
14	chromaffin	chromaffin	NN	_	15	com	_	_
15	cells	cell	NNS	_	11	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	previous	previous	JJ	_	3	attr	_	_
3	reports	report	NNS	_	6	ppmod	_	_
4	we	we	PRP	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	shown	show	VBN	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	inhibit	inhibit	VBP	_	6	comp	_	_
10	high	high	JJ	_	13	attr	_	_
11	threshold	threshold	NN	_	13	attr	_	_
12	voltage-dependent	voltage-dependent	JJ	_	13	attr	_	_
13	Ca	ca	NN	_	17	attr	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	2+	0+	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	channels	channel	NNS	_	9	obj	_	_
18	in	in	IN	_	20	case	_	_
19	neuronal	neuronal	JJ	_	20	attr	_	_
20	cells	cell	NNS	_	17	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	these	these	DT	_	4	det	_	_
4	studies	study	NNS	_	7	dep	_	_
5	did	do	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	show	show	VB	_	0	root	_	_
8	whether	whether	IN	_	18	mark	_	_
9	drug1	drug0	NN	_	11	attr	_	_
10	-induced	-induced	JJ	_	11	attr	_	_
11	inhibition	inhibition	NN	_	18	dep	_	_
12	of	of	IN	_	17	case	_	_
13	Ca	ca	NN	_	17	attr	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	2+	0+	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	currents	current	NNS	_	11	ppmod	_	_
18	discriminates	discriminate	VBZ	_	7	comp	_	_
19	among	among	IN	_	27	case	_	_
20	the	the	DT	_	22	det	_	_
21	various	various	JJ	_	22	attr	_	_
22	Ca	ca	NN	_	27	attr	_	_
23	(	-lrb-	-LRB-	_	24	p	_	_
24	2+	0+	NN	_	22	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	channel	channel	NN	_	27	com	_	_
27	subtypes	subtype	NNS	_	18	ppmod	_	_
28	,	,	,	_	7	p	_	_
29	although	although	IN	_	32	mark	_	_
30	it	it	PRP	_	32	dep	_	_
31	is	be	VBZ	_	32	aux	_	_
32	known	know	VBN	_	7	comp	_	_
33	that	that	IN	_	35	mark	_	_
34	there	there	EX	_	35	dep	_	_
35	are	be	VBP	_	32	comp	_	_
36	at	at	IN	_	38	case	_	_
37	least	least	JJS	_	38	attr	_	_
38	five	#crd#	CD	_	45	num	_	_
39	different	different	JJ	_	45	attr	_	_
40	Ca	ca	NN	_	45	attr	_	_
41	(	-lrb-	-LRB-	_	42	p	_	_
42	2+	0+	NN	_	40	prn	_	_
43	)	-rrb-	-RRB-	_	42	p	_	_
44	channel	channel	NN	_	45	com	_	_
45	subtypes	subtype	NNS	_	35	obj	_	_
46	in	in	IN	_	48	case	_	_
47	neuronal	neuronal	JJ	_	48	attr	_	_
48	cells	cell	NNS	_	45	ppmod	_	_
49	.	.	.	_	7	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	study	study	NN	_	5	ppmod	_	_
4	we	we	PRP	_	5	dep	_	_
5	investigated	investigate	VBD	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	effect	effect	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	on	on	IN	_	19	case	_	_
11	high	high	JJ	_	14	attr	_	_
12	threshold	threshold	NN	_	14	attr	_	_
13	voltage-dependent	voltage-dependent	JJ	_	14	attr	_	_
14	Ca	ca	NN	_	19	attr	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	2+	0+	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	channel	channel	NN	_	19	com	_	_
19	subtypes	subtype	NNS	_	7	ppmod	_	_
20	using	use	VBG	_	5	comp	_	_
21	their	their	PRP$	_	23	poss	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	drug3	drug0	NN	_	20	obj	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	L-type	l-type	NN	_	23	prn	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	,	,	,	_	23	p	_	_
28	drug4	drug0	NN	_	23	conj	_	_
29	(	-lrb-	-LRB-	_	30	p	_	_
30	N-type	n-type	NN	_	28	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	,	,	,	_	28	p	_	_
33	or	or	CC	_	28	cc	_	_
34	drug5	drug0	NN	_	23	conj	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	P-type	p-type	NN	_	34	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	in	in	IN	_	41	case	_	_
39	bovine	bovine	JJ	_	41	attr	_	_
40	chromaffin	chromaffin	NN	_	41	com	_	_
41	cells	cell	NNS	_	20	ppmod	_	_
42	.	.	.	_	5	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	could	could	MD	_	3	modal	_	_
3	observe	observe	VB	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	inhibited	inhibit	VBD	_	3	comp	_	_
7	high	high	JJ	_	10	attr	_	_
8	threshold	threshold	NN	_	10	attr	_	_
9	voltage-dependent	voltage-dependent	JJ	_	10	attr	_	_
10	Ca	ca	NN	_	14	attr	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	2+	0+	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	currents	current	NNS	_	6	obj	_	_
15	in	in	IN	_	18	case	_	_
16	a	a	DT	_	18	det	_	_
17	dose-dependent	dose-dependent	JJ	_	18	attr	_	_
18	manner	manner	NN	_	6	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	IC	ic	NN	_	6	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	50	0	CD	_	2	num	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	was	be	VBD	_	0	root	_	_
7	about	about	IN	_	9	case	_	_
8	120	0	CD	_	9	num	_	_
9	microgram/ml	microgram/ml	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	effect	effect	NN	_	2	obj	_	_
5	on	on	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	response	response	NN	_	2	ppmod	_	_
8	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	are	be	VBP	_	8	aux	_	_
7	negatively	negatively	RB	_	8	adv	_	_
8	coupled	couple	VBN	_	3	comp	_	_
9	to	to	TO	_	11	aux	_	_
10	three	#crd#	CD	_	11	num	_	_
11	types	type	NNS	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	calcium	calcium	NN	_	14	com	_	_
14	channels	channel	NNS	_	11	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	bovine	bovine	JJ	_	18	attr	_	_
17	chromaffin	chromaffin	NN	_	18	com	_	_
18	cell	cell	NN	_	14	ppmod	_	_
19	,	,	,	_	14	p	_	_
20	including	include	VBG	_	27	adv	_	_
21	an	an	DT	_	27	det	_	_
22	drug2	drug0	NN	_	27	attr	_	_
23	-sensitive	-sensitive	JJ	_	27	attr	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	N-type	n-type	NN	_	27	attr	_	_
26	)	-rrb-	-RRB-	_	27	p	_	_
27	channel	channel	NN	_	14	ppmod	_	_
28	,	,	,	_	27	p	_	_
29	an	an	DT	_	35	det	_	_
30	drug3	drug0	NN	_	35	attr	_	_
31	-sensitive	-sensitive	JJ	_	35	attr	_	_
32	(	-lrb-	-LRB-	_	35	p	_	_
33	P-type	p-type	NN	_	35	attr	_	_
34	)	-rrb-	-RRB-	_	35	p	_	_
35	channel	channel	NN	_	27	conj	_	_
36	and	and	CC	_	35	cc	_	_
37	drug4	drug0	NN	_	27	conj	_	_
38	/	/	:	_	27	p	_	_
39	drug5	drug0	NN	_	27	appo	_	_
40	/	/	:	_	27	p	_	_
41	drug6	drug0	NN	_	42	advnp	_	_
42	-resistant	-resistant	JJ	_	47	attr	_	_
43	(	-lrb-	-LRB-	_	45	p	_	_
44	presumptive	presumptive	JJ	_	45	attr	_	_
45	Q-type	q-type	NN	_	42	prn	_	_
46	)	-rrb-	-RRB-	_	45	p	_	_
47	channel	channel	NN	_	27	appo	_	_
48	.	.	.	_	3	p	_	_

1	Thus	thus	RB	_	20	adv	_	_
2	,	,	,	_	20	p	_	_
3	the	the	DT	_	5	det	_	_
4	selective	selective	JJ	_	5	attr	_	_
5	regulation	regulation	NN	_	20	dep	_	_
6	of	of	IN	_	12	case	_	_
7	voltage-dependent	voltage-dependent	JJ	_	8	attr	_	_
8	Ca	ca	NN	_	12	attr	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	2+	0+	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	subtypes	subtype	NNS	_	5	ppmod	_	_
13	by	by	IN	_	14	case	_	_
14	drug1	drug0	NN	_	5	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	bovine	bovine	JJ	_	18	attr	_	_
17	chromaffin	chromaffin	NN	_	18	com	_	_
18	cell	cell	NN	_	5	ppmod	_	_
19	could	could	MD	_	20	modal	_	_
20	be	be	VB	_	0	root	_	_
21	the	the	DT	_	23	det	_	_
22	cellular	cellular	JJ	_	23	attr	_	_
23	basis	basis	NN	_	20	obj	_	_
24	of	of	IN	_	26	case	_	_
25	antistress	antistress	JJ	_	26	attr	_	_
26	effects	effect	NNS	_	23	ppmod	_	_
27	induced	induce	VBN	_	26	acl	_	_
28	by	by	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	20	p	_	_

1	A	a	DT	_	3	det	_	_
2	proposed	proposed	JJ	_	3	attr	_	_
3	mechanism	mechanism	NN	_	0	root	_	_
4	for	for	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	potentiation	potentiation	NN	_	3	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	cAMP-mediated	camp-mediated	JJ	_	10	attr	_	_
9	acid	acid	NN	_	10	com	_	_
10	secretion	secretion	NN	_	6	ppmod	_	_
11	by	by	IN	_	12	case	_	_
12	drug1	drug0	NN	_	6	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Acid	acid	NN	_	2	com	_	_
2	secretion	secretion	NN	_	9	dep	_	_
3	in	in	IN	_	7	case	_	_
4	isolated	isolate	VBN	_	7	attr	_	_
5	rabbit	rabbit	JJ	_	7	attr	_	_
6	gastric	gastric	JJ	_	7	attr	_	_
7	glands	gland	NNS	_	2	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	monitored	monitor	VBN	_	0	root	_	_
10	by	by	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	accumulation	accumulation	NN	_	9	ppmod	_	_
13	of	of	IN	_	20	case	_	_
14	[	-lsb-	-LRB-	_	20	p	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	14	0	CD	_	20	num	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	C	c	NN	_	20	attr	_	_
19	]	-rsb-	-RRB-	_	20	p	_	_
20	drug1	drug0	NN	_	12	ppmod	_	_
21	.	.	.	_	9	p	_	_

1	Stimulation	stimulation	NN	_	8	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	glands	gland	NNS	_	1	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	1	ppmod	_	_
7	synergistically	synergistically	RB	_	8	adv	_	_
8	augmented	augment	VBD	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	response	response	NN	_	8	obj	_	_
11	to	to	TO	_	13	aux	_	_
12	dibutyryl	dibutyryl	NN	_	13	com	_	_
13	cAMP	camp	NN	_	10	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	augmentation	augmentation	NN	_	3	dep	_	_
3	persisted	persist	VBD	_	0	root	_	_
4	even	even	RB	_	8	adv	_	_
5	after	after	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	was	be	VBD	_	8	aux	_	_
8	washed	wash	VBN	_	3	comp	_	_
9	out	out	RP	_	8	prt	_	_
10	and	and	CC	_	8	cc	_	_
11	was	be	VBD	_	8	conj	_	_
12	resistant	resistant	JJ	_	11	dep	_	_
13	to	to	TO	_	16	aux	_	_
14	chelated	chelate	VBN	_	16	attr	_	_
15	extracellular	extracellular	JJ	_	16	attr	_	_
16	Ca	ca	NN	_	12	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	2+	0+	NN	_	16	prn	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	and	and	CC	_	16	cc	_	_
21	to	to	TO	_	22	aux	_	_
22	inhibitors	inhibitor	NNS	_	16	conj	_	_
23	of	of	IN	_	27	case	_	_
24	either	either	CC	_	27	cc	_	_
25	protein	protein	NN	_	27	com	_	_
26	kinase	kinase	NN	_	27	com	_	_
27	C	c	NN	_	22	ppmod	_	_
28	or	or	CC	_	27	cc	_	_
29	calmodulin	calmodulin	NN	_	30	com	_	_
30	kinase	kinase	NN	_	27	conj	_	_
31	II	ii	CD	_	30	num	_	_
32	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	at	at	IN	_	4	case	_	_
3	10	0	CD	_	4	num	_	_
4	microM	microm	NN	_	1	ppmod	_	_
5	preferentially	preferentially	RB	_	6	adv	_	_
6	blocked	block	VBD	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	secretory	secretory	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	9	cc	_	_
13	its	its	PRP$	_	14	poss	_	_
14	synergism	synergism	NN	_	9	conj	_	_
15	with	with	IN	_	16	case	_	_
16	cAMP	camp	NN	_	14	ppmod	_	_
17	,	,	,	_	6	p	_	_
18	whereas	whereas	IN	_	20	mark	_	_
19	it	it	PRP	_	20	dep	_	_
20	had	have	VBD	_	6	comp	_	_
21	no	no	DT	_	22	det	_	_
22	effect	effect	NN	_	20	obj	_	_
23	on	on	IN	_	24	case	_	_
24	histamine-	histamine-	NN	_	20	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	cAMP-stimulated	camp-stimulated	JJ	_	28	attr	_	_
27	acid	acid	NN	_	28	com	_	_
28	secretion	secretion	NN	_	24	conj	_	_
29	within	within	IN	_	31	case	_	_
30	15	0	CD	_	31	num	_	_
31	min	min	NN	_	20	ppmod	_	_
32	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibited	inhibit	VBD	_	0	root	_	_
3	the	the	DT	_	22	det	_	_
4	drug2	drug0	JJ	_	22	attr	_	_
5	-stimulated	-stimulated	JJ	_	11	attr	_	_
6	intracellular	intracellular	JJ	_	11	attr	_	_
7	Ca	ca	NN	_	11	attr	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	2+	0+	NN	_	11	attr	_	_
10	)	-rrb-	-RRB-	_	11	p	_	_
11	concentration	concentration	NN	_	22	attr	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	-LSB-Ca	-lsb-ca	NN	_	11	prn	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	2+	0+	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	]	-rsb-	-RRB-	_	15	p	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	i	i	NN	_	13	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	)	-rrb-	-RRB-	_	13	p	_	_
22	increase	increase	NN	_	2	obj	_	_
23	due	due	IN	_	25	case	_	_
24	to	to	TO	_	25	aux	_	_
25	release	release	NN	_	22	ppmod	_	_
26	from	from	IN	_	32	case	_	_
27	the	the	DT	_	32	det	_	_
28	Ca	ca	NN	_	32	attr	_	_
29	(	-lrb-	-LRB-	_	32	p	_	_
30	2+	0+	NN	_	32	attr	_	_
31	)	-rrb-	-RRB-	_	32	p	_	_
32	store	store	NN	_	25	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	Treatment	treatment	NN	_	7	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	glands	gland	NNS	_	1	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	1	ppmod	_	_
7	redistributed	redistribute	VBD	_	0	root	_	_
8	type	type	NN	_	12	attr	_	_
9	3	0	CD	_	12	num	_	_
10	inositol	inositol	NN	_	12	com	_	_
11	1,4,5-trisphosphate	0-trisphosphate	NN	_	12	com	_	_
12	receptor	receptor	NN	_	7	obj	_	_
13	(	-lrb-	-LRB-	_	16	p	_	_
14	the	the	DT	_	16	det	_	_
15	major	major	JJ	_	16	attr	_	_
16	subtype	subtype	NN	_	12	prn	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	parietal	parietal	JJ	_	20	attr	_	_
20	cell	cell	NN	_	16	ppmod	_	_
21	)	-rrb-	-RRB-	_	16	p	_	_
22	from	from	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	fraction	fraction	NN	_	7	ppmod	_	_
25	containing	contain	VBG	_	24	acl	_	_
26	membranes	membrane	NNS	_	25	obj	_	_
27	of	of	IN	_	29	case	_	_
28	large	large	JJ	_	29	attr	_	_
29	size	size	NN	_	26	ppmod	_	_
30	to	to	TO	_	33	aux	_	_
31	the	the	DT	_	33	det	_	_
32	microsomal	microsomal	JJ	_	33	attr	_	_
33	fraction	fraction	NN	_	29	ppmod	_	_
34	,	,	,	_	7	p	_	_
35	suggesting	suggest	VBG	_	7	comp	_	_
36	a	a	DT	_	37	det	_	_
37	dissociation	dissociation	NN	_	35	obj	_	_
38	of	of	IN	_	40	case	_	_
39	the	the	DT	_	40	det	_	_
40	store	store	NN	_	37	ppmod	_	_
41	from	from	IN	_	44	case	_	_
42	the	the	DT	_	44	det	_	_
43	plasma	plasma	NN	_	44	com	_	_
44	membrane	membrane	NN	_	37	ppmod	_	_
45	.	.	.	_	7	p	_	_

1	These	these	DT	_	2	det	_	_
2	findings	finding	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	14	mark	_	_
5	intracellular	intracellular	JJ	_	6	attr	_	_
6	Ca	ca	NN	_	10	attr	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	2+	0+	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	release	release	NN	_	14	dep	_	_
11	by	by	IN	_	13	case	_	_
12	cholinergic	cholinergic	JJ	_	13	attr	_	_
13	stimulation	stimulation	NN	_	10	ppmod	_	_
14	is	be	VBZ	_	3	advcl	_	_
15	critical	critical	JJ	_	14	dep	_	_
16	for	for	IN	_	17	case	_	_
17	determining	determine	VBG	_	15	ppmod	_	_
18	synergism	synergism	NN	_	17	obj	_	_
19	with	with	IN	_	20	case	_	_
20	cAMP	camp	NN	_	18	ppmod	_	_
21	in	in	IN	_	24	case	_	_
22	parietal	parietal	JJ	_	24	attr	_	_
23	cell	cell	NN	_	24	com	_	_
24	activation	activation	NN	_	18	ppmod	_	_
25	and	and	CC	_	14	cc	_	_
26	that	that	IN	_	40	mark	_	_
27	functional	functional	JJ	_	28	attr	_	_
28	coupling	coupling	NN	_	40	dep	_	_
29	between	between	IN	_	35	case	_	_
30	the	the	DT	_	31	det	_	_
31	Ca	ca	NN	_	35	attr	_	_
32	(	-lrb-	-LRB-	_	33	p	_	_
33	2+	0+	NN	_	31	prn	_	_
34	)	-rrb-	-RRB-	_	33	p	_	_
35	store	store	NN	_	28	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	the	the	DT	_	38	det	_	_
38	receptor	receptor	NN	_	35	conj	_	_
39	is	be	VBZ	_	40	aux	_	_
40	maintained	maintain	VBN	_	14	conj	_	_
41	by	by	IN	_	43	case	_	_
42	actin	actin	NN	_	43	com	_	_
43	microfilaments	microfilaments	NNS	_	40	ppmod	_	_
44	.	.	.	_	3	p	_	_

1	Phenytoin	phenytoin	NN	_	2	com	_	_
2	intoxication	intoxication	NN	_	3	dep	_	_
3	induced	induce	VBN	_	0	root	_	_
4	by	by	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	.	.	.	_	3	p	_	_

1	A	a	DT	_	2	det	_	_
2	patient	patient	NN	_	5	dep	_	_
3	had	have	VBD	_	5	lv	_	_
4	phenytoin	phenytoin	NN	_	5	com	_	_
5	intoxication	intoxication	NN	_	0	root	_	_
6	after	after	IN	_	7	case	_	_
7	administration	administration	NN	_	5	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	a	a	DT	_	15	det	_	_
12	selective	selective	JJ	_	15	attr	_	_
13	serotonin	serotonin	NN	_	15	com	_	_
14	reuptake	reuptake	NN	_	15	com	_	_
15	inhibitor	inhibitor	NN	_	9	appo	_	_
16	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	serum	serum	NN	_	3	com	_	_
3	concentration	concentration	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	increased	increase	VBD	_	0	root	_	_
7	dramatically	dramatically	RB	_	6	adv	_	_
8	from	from	IN	_	12	case	_	_
9	16.6	0	CD	_	12	num	_	_
10	to	to	TO	_	9	cc	_	_
11	49.1	0	CD	_	9	conj	_	_
12	microg/mL	microg/ml	NN	_	6	ppmod	_	_
13	when	when	WRB	_	16	adv	_	_
14	drug2	drug0	NN	_	16	dep	_	_
15	was	be	VBD	_	16	aux	_	_
16	coadministered	coadministered	VBN	_	6	comp	_	_
17	,	,	,	_	6	p	_	_
18	although	although	IN	_	29	mark	_	_
19	the	the	DT	_	21	det	_	_
20	daily	daily	JJ	_	21	attr	_	_
21	dosage	dosage	NN	_	29	dep	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	other	other	JJ	_	26	attr	_	_
26	drug4	drug0	NNS	_	23	conj	_	_
27	had	have	VBD	_	29	aux	_	_
28	not	not	RB	_	29	neg	_	_
29	changed	change	VBN	_	6	comp	_	_
30	.	.	.	_	6	p	_	_

1	During	during	IN	_	2	case	_	_
2	drug1	drug0	NN	_	17	ppmod	_	_
3	and	and	CC	_	2	cc	_	_
4	fluvoxamine	fluvoxamine	NN	_	5	com	_	_
5	treatment	treatment	NN	_	2	conj	_	_
6	,	,	,	_	17	p	_	_
7	ataxia	ataxia	NN	_	17	dep	_	_
8	,	,	,	_	7	p	_	_
9	a	a	DT	_	12	det	_	_
10	typical	typical	JJ	_	12	attr	_	_
11	side	side	JJ	_	12	attr	_	_
12	effect	effect	NN	_	7	appo	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	7	p	_	_
16	was	be	VBD	_	17	aux	_	_
17	observed	observe	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	The	the	DT	_	2	det	_	_
2	genotypes	genotype	NNS	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	2C19	0c0	NN	_	4	conj	_	_
7	,	,	,	_	4	p	_	_
8	the	the	DT	_	9	det	_	_
9	enzymes	enzyme	NNS	_	4	appo	_	_
10	responsible	responsible	JJ	_	9	attr	_	_
11	for	for	IN	_	13	case	_	_
12	phenytoin	phenytoin	NN	_	13	com	_	_
13	metabolism	metabolism	NN	_	10	ppmod	_	_
14	,	,	,	_	4	p	_	_
15	were	be	VBD	_	0	root	_	_
16	homozygous	homozygous	JJ	_	15	dep	_	_
17	for	for	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	wild-type	wild-type	JJ	_	20	attr	_	_
20	alleles	allele	NNS	_	16	ppmod	_	_
21	(	-lrb-	-LRB-	_	25	p	_	_
22	drug2	drug0	NN	_	25	com	_	_
23	*	*	NN	_	25	com	_	_
24	1/	0/	NN	_	25	com	_	_
25	*	*	NN	_	20	prn	_	_
26	1	0	CD	_	25	num	_	_
27	and	and	CC	_	25	cc	_	_
28	2C19	0c0	NN	_	31	com	_	_
29	*	*	NN	_	31	com	_	_
30	1/	0/	NN	_	31	com	_	_
31	*	*	NN	_	25	conj	_	_
32	1	0	CD	_	31	num	_	_
33	)	-rrb-	-RRB-	_	25	p	_	_
34	.	.	.	_	15	p	_	_

1	The	the	DT	_	2	det	_	_
2	interaction	interaction	NN	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	a	a	DT	_	6	det	_	_
6	result	result	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	inhibition	inhibition	NN	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	both	both	CC	_	11	cc	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	2C19	0c0	NN	_	11	conj	_	_
14	by	by	IN	_	15	case	_	_
15	drug2	drug0	NN	_	8	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	evaluation	evaluation	NN	_	0	root	_	_
3	of	of	IN	_	8	case	_	_
4	the	the	DT	_	8	det	_	_
5	drug1	drug0	NN	_	8	attr	_	_
6	-	-	:	_	8	p	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	interaction	interaction	NN	_	2	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	raise	raise	VB	_	3	comp	_	_
6	serum	serum	NN	_	8	com	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	levels	level	NNS	_	5	obj	_	_
9	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	designed	design	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	evaluate	evaluate	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	pharmacokinetic	pharmacokinetic	JJ	_	9	attr	_	_
9	basis	basis	NN	_	6	obj	_	_
10	of	of	IN	_	12	case	_	_
11	this	this	DT	_	12	det	_	_
12	interaction	interaction	NN	_	9	ppmod	_	_
13	in	in	IN	_	16	case	_	_
14	10	0	CD	_	16	num	_	_
15	normal	normal	JJ	_	16	attr	_	_
16	subjects	subject	NNS	_	9	ppmod	_	_
17	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	variables	variable	NNS	_	7	dep	_	_
4	for	for	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	were	be	VBD	_	7	aux	_	_
7	determined	determine	VBN	_	0	root	_	_
8	after	after	IN	_	13	case	_	_
9	a	a	DT	_	13	det	_	_
10	1.0	0	CD	_	11	num	_	_
11	mg	mg	NN	_	13	attr	_	_
12	intravenous	intravenous	JJ	_	13	attr	_	_
13	dose	dose	NN	_	7	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	each	each	DT	_	18	det	_	_
18	subject	subject	NN	_	7	ppmod	_	_
19	,	,	,	_	7	p	_	_
20	before	before	IN	_	7	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	after	after	IN	_	24	case	_	_
23	oral	oral	JJ	_	24	attr	_	_
24	drug3	drug0	NN	_	20	conj	_	_
25	,	,	,	_	24	p	_	_
26	400	0	CD	_	27	num	_	_
27	mg	mg	NN	_	24	appo	_	_
28	daily	daily	JJ	_	27	attr	_	_
29	for	for	IN	_	31	case	_	_
30	3	0	CD	_	31	num	_	_
31	weeks	week	NNS	_	28	ppmod	_	_
32	.	.	.	_	7	p	_	_

1	During	during	IN	_	3	case	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	administration	administration	NN	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	systemic	systemic	JJ	_	6	attr	_	_
6	clearance	clearance	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	reduced	reduce	VBN	_	0	root	_	_
11	from	from	IN	_	15	case	_	_
12	234	0	CD	_	15	num	_	_
13	+/-	+/-	CC	_	12	cc	_	_
14	72	0	CD	_	12	conj	_	_
15	ml/min	ml/min	NN	_	10	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	mean	mean	NN	_	15	prn	_	_
18	+/-	+/-	CC	_	17	cc	_	_
19	standard	standard	JJ	_	20	attr	_	_
20	deviation	deviation	NN	_	17	conj	_	_
21	)	-rrb-	-RRB-	_	17	p	_	_
22	to	to	TO	_	26	aux	_	_
23	172	0	CD	_	26	num	_	_
24	+/-	+/-	CC	_	23	cc	_	_
25	33	0	CD	_	23	conj	_	_
26	ml/min	ml/min	NN	_	10	ppmod	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	p	p	NN	_	26	prn	_	_
29	less	less	JJR	_	28	attr	_	_
30	than	than	IN	_	31	case	_	_
31	0.01	0	CD	_	29	ppmod	_	_
32	)	-rrb-	-RRB-	_	28	p	_	_
33	.	.	.	_	10	p	_	_

1	This	this	DT	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	due	due	JJ	_	2	dep	_	_
4	to	to	TO	_	5	aux	_	_
5	reductions	reduction	NNS	_	3	ppmod	_	_
6	in	in	IN	_	9	case	_	_
7	both	both	DT	_	9	det	_	_
8	renal	renal	JJ	_	9	attr	_	_
9	clearance	clearance	NN	_	5	ppmod	_	_
10	(	-lrb-	-LRB-	_	19	p	_	_
11	from	from	IN	_	19	case	_	_
12	105	0	CD	_	19	num	_	_
13	+/-	+/-	CC	_	12	cc	_	_
14	39	0	CD	_	12	conj	_	_
15	to	to	TO	_	14	cc	_	_
16	84	0	CD	_	12	conj	_	_
17	+/-	+/-	CC	_	16	cc	_	_
18	15	0	CD	_	12	conj	_	_
19	ml/min	ml/min	NN	_	9	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	p	p	NN	_	9	prn	_	_
23	less	less	JJR	_	25	attr	_	_
24	than	than	IN	_	23	com	_	_
25	0.05	0	CD	_	22	num	_	_
26	)	-rrb-	-RRB-	_	22	p	_	_
27	and	and	CC	_	9	cc	_	_
28	nonrenal	nonrenal	JJ	_	29	attr	_	_
29	clearance	clearance	NN	_	9	conj	_	_
30	(	-lrb-	-LRB-	_	39	p	_	_
31	from	from	IN	_	39	case	_	_
32	130	0	CD	_	39	num	_	_
33	+/-	+/-	CC	_	32	cc	_	_
34	38	0	CD	_	32	conj	_	_
35	to	to	TO	_	34	cc	_	_
36	88	0	CD	_	32	conj	_	_
37	+/-	+/-	CC	_	36	cc	_	_
38	20	0	CD	_	32	conj	_	_
39	ml/min	ml/min	NN	_	29	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	(	-lrb-	-LRB-	_	42	p	_	_
42	p	p	NN	_	29	prn	_	_
43	less	less	JJR	_	45	attr	_	_
44	than	than	IN	_	43	com	_	_
45	0.01	0	CD	_	42	num	_	_
46	)	-rrb-	-RRB-	_	42	p	_	_
47	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	half-life	half-life	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	elimination	elimination	NN	_	2	ppmod	_	_
5	was	be	VBD	_	0	root	_	_
6	prolonged	prolonged	JJ	_	5	dep	_	_
7	from	from	IN	_	15	case	_	_
8	34	0	CD	_	15	num	_	_
9	+/-	+/-	CC	_	8	cc	_	_
10	13	0	CD	_	8	conj	_	_
11	to	to	TO	_	10	cc	_	_
12	40	0	CD	_	8	conj	_	_
13	+/-	+/-	CC	_	12	cc	_	_
14	16	0	CD	_	8	conj	_	_
15	hours	hour	NNS	_	5	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	p	p	NN	_	5	prn	_	_
18	less	less	JJR	_	17	attr	_	_
19	than	than	IN	_	20	case	_	_
20	0.05	0	CD	_	18	ppmod	_	_
21	)	-rrb-	-RRB-	_	17	p	_	_
22	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	volume	volume	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	distribution	distribution	NN	_	2	ppmod	_	_
5	was	be	VBD	_	8	aux	_	_
6	not	not	RB	_	8	neg	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	changed	change	VBN	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	caused	cause	VBD	_	0	root	_	_
3	a	a	DT	_	7	det	_	_
4	three-	three-	CD	_	6	num	_	_
5	to	to	TO	_	6	adv	_	_
6	fivefold	fivefold	JJ	_	7	attr	_	_
7	increase	increase	NN	_	2	obj	_	_
8	in	in	IN	_	12	case	_	_
9	serum	serum	NN	_	11	com	_	_
10	reverse	reverse	NN	_	11	com	_	_
11	triiodothyronine	triiodothyronine	NN	_	12	com	_	_
12	levels	level	NNS	_	7	ppmod	_	_
13	,	,	,	_	2	p	_	_
14	but	but	CC	_	2	cc	_	_
15	changes	change	NNS	_	19	dep	_	_
16	in	in	IN	_	18	case	_	_
17	thyroid	thyroid	NN	_	18	com	_	_
18	function	function	NN	_	15	ppmod	_	_
19	were	be	VBD	_	2	conj	_	_
20	not	not	RB	_	19	neg	_	_
21	quantitatively	quantitatively	RB	_	22	adv	_	_
22	related	related	JJ	_	19	dep	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	changes	change	NNS	_	22	ppmod	_	_
26	in	in	IN	_	28	case	_	_
27	drug2	drug0	NN	_	28	com	_	_
28	pharmacokinetics	pharmacokinetics	NNS	_	25	ppmod	_	_
29	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	alterations	alteration	NNS	_	9	dep	_	_
3	in	in	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
6	produced	produce	VBN	_	5	acl	_	_
7	by	by	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	explain	explain	VBP	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	increase	increase	NN	_	9	obj	_	_
12	in	in	IN	_	15	case	_	_
13	serum	serum	NN	_	15	com	_	_
14	drug3	drug0	NN	_	15	com	_	_
15	level	level	NN	_	11	ppmod	_	_
16	that	that	WDT	_	19	dep	_	_
17	has	have	VBZ	_	19	aux	_	_
18	been	be	VBN	_	19	aux	_	_
19	observed	observe	VBN	_	11	relcl	_	_
20	when	when	WRB	_	26	adv	_	_
21	this	this	DT	_	23	det	_	_
22	drug	drug	NN	_	23	com	_	_
23	combination	combination	NN	_	26	dep	_	_
24	has	have	VBZ	_	26	aux	_	_
25	been	be	VBN	_	26	aux	_	_
26	used	use	VBN	_	19	comp	_	_
27	clinically	clinically	RB	_	26	adv	_	_
28	.	.	.	_	9	p	_	_

1	Activation	activation	NN	_	0	root	_	_
2	of	of	IN	_	7	case	_	_
3	an	an	DT	_	7	det	_	_
4	effector	effector	NN	_	7	attr	_	_
5	immediate-early	immediate-early	JJ	_	7	attr	_	_
6	gene	gene	NN	_	7	com	_	_
7	arc	arc	NN	_	1	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	drug1	drug0	NN	_	1	ppmod	_	_
10	.	.	.	_	1	p	_	_

1	As	as	IN	_	8	mark	_	_
2	immediate-early	immediate-early	JJ	_	3	attr	_	_
3	genes	gene	NNS	_	8	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	IEGs	iegs	NNS	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	are	be	VBP	_	8	aux	_	_
8	thought	think	VBN	_	30	advcl	_	_
9	to	to	TO	_	10	aux	_	_
10	play	play	VB	_	8	comp	_	_
11	a	a	DT	_	13	det	_	_
12	critical	critical	JJ	_	13	attr	_	_
13	role	role	NN	_	10	obj	_	_
14	in	in	IN	_	15	case	_	_
15	mediating	mediate	VBG	_	10	ppmod	_	_
16	stimulus-induced	stimulus-induced	JJ	_	18	attr	_	_
17	neural	neural	JJ	_	18	attr	_	_
18	plasticity	plasticity	NN	_	15	obj	_	_
19	,	,	,	_	30	p	_	_
20	IEG	ieg	JJ	_	21	attr	_	_
21	response	response	NN	_	30	dep	_	_
22	induced	induce	VBN	_	21	acl	_	_
23	by	by	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	drug2	drug0	NN	_	24	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	has	have	VBZ	_	30	aux	_	_
29	been	be	VBN	_	30	aux	_	_
30	characterized	characterize	VBN	_	0	root	_	_
31	to	to	TO	_	32	aux	_	_
32	define	define	VB	_	30	comp	_	_
33	the	the	DT	_	34	det	_	_
34	changes	change	NNS	_	32	obj	_	_
35	in	in	IN	_	37	case	_	_
36	gene	gene	NN	_	37	com	_	_
37	expression	expression	NN	_	34	ppmod	_	_
38	that	that	WDT	_	40	dep	_	_
39	may	may	MD	_	40	modal	_	_
40	underlie	underlie	VB	_	34	relcl	_	_
41	its	its	PRP$	_	44	poss	_	_
42	long-lasting	long-lasting	JJ	_	43	adv	_	_
43	behavioral	behavioral	JJ	_	44	attr	_	_
44	effects	effect	NNS	_	40	obj	_	_
45	.	.	.	_	30	p	_	_

1	Although	although	IN	_	10	mark	_	_
2	activation	activation	NN	_	10	dep	_	_
3	of	of	IN	_	7	case	_	_
4	several	several	JJ	_	7	attr	_	_
5	transcription	transcription	NN	_	7	com	_	_
6	factor	factor	NN	_	7	com	_	_
7	IEGs	iegs	NNS	_	2	ppmod	_	_
8	has	have	VBZ	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	described	describe	VBN	_	14	advcl	_	_
11	,	,	,	_	14	p	_	_
12	little	little	JJ	_	14	dep	_	_
13	is	be	VBZ	_	14	aux	_	_
14	known	know	VBN	_	0	root	_	_
15	about	about	IN	_	17	case	_	_
16	effector	effector	NN	_	17	com	_	_
17	IEGs	iegs	NNS	_	14	ppmod	_	_
18	.	.	.	_	14	p	_	_

1	Here	here	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	we	we	PRP	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	examined	examine	VBN	_	0	root	_	_
6	whether	whether	IN	_	9	mark	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	administration	administration	NN	_	9	dep	_	_
9	affects	affect	VBZ	_	5	comp	_	_
10	expression	expression	NN	_	9	obj	_	_
11	of	of	IN	_	15	case	_	_
12	an	an	DT	_	15	det	_	_
13	effector	effector	NN	_	15	com	_	_
14	IEG	ieg	NN	_	15	com	_	_
15	arc	arc	NN	_	10	ppmod	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	activity-regulated	activity-regulated	JJ	_	19	adv	_	_
18	,	,	,	_	19	p	_	_
19	cytoskeleton-associated	cytoskeleton-associated	JJ	_	15	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	that	that	WDT	_	22	dep	_	_
22	encodes	encode	VBZ	_	15	relcl	_	_
23	a	a	DT	_	24	det	_	_
24	protein	protein	NN	_	22	obj	_	_
25	with	with	IN	_	26	case	_	_
26	homology	homology	NN	_	24	ppmod	_	_
27	to	to	TO	_	28	aux	_	_
28	spectrin	spectrin	NN	_	26	ppmod	_	_
29	.	.	.	_	5	p	_	_

1	Using	use	VBG	_	7	advcl	_	_
2	in	in	FW	_	3	adv	_	_
3	situ	situ	FW	_	4	attr	_	_
4	hybridization	hybridization	NN	_	1	obj	_	_
5	,	,	,	_	7	p	_	_
6	we	we	PRP	_	7	dep	_	_
7	observed	observe	VBD	_	0	root	_	_
8	that	that	IN	_	10	mark	_	_
9	drug1	drug0	NN	_	10	dep	_	_
10	caused	cause	VBD	_	7	comp	_	_
11	a	a	DT	_	16	det	_	_
12	rapid	rapid	JJ	_	16	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	transient	transient	JJ	_	12	conj	_	_
15	dose-dependent	dose-dependent	JJ	_	16	attr	_	_
16	increase	increase	NN	_	10	obj	_	_
17	in	in	IN	_	20	case	_	_
18	arc	arc	NN	_	20	com	_	_
19	mRNA	mrna	NN	_	20	com	_	_
20	level	level	NN	_	16	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	striatum	striatum	NN	_	20	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	cortex	cortex	NN	_	23	conj	_	_
26	that	that	WDT	_	28	dep	_	_
27	was	be	VBD	_	28	aux	_	_
28	abolished	abolish	VBN	_	16	relcl	_	_
29	by	by	IN	_	30	case	_	_
30	pretreatment	pretreatment	NN	_	28	ppmod	_	_
31	with	with	IN	_	37	case	_	_
32	the	the	DT	_	37	det	_	_
33	specific	specific	JJ	_	37	attr	_	_
34	dopamine	dopamine	NN	_	37	com	_	_
35	D1	d0	NN	_	37	com	_	_
36	receptor	receptor	NN	_	37	com	_	_
37	antagonist	antagonist	NN	_	30	ppmod	_	_
38	drug2	drug0	CD	_	37	num	_	_
39	but	but	CC	_	30	cc	_	_
40	not	not	RB	_	44	neg	_	_
41	by	by	IN	_	44	case	_	_
42	an	an	DT	_	44	det	_	_
43	drug3	drug0	NN	_	44	com	_	_
44	drug4	drug0	NN	_	30	conj	_	_
45	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	induced	induce	VBD	_	0	root	_	_
3	arc	arc	NN	_	4	com	_	_
4	mRNA	mrna	NN	_	2	obj	_	_
5	in	in	IN	_	6	case	_	_
6	layers	layer	NNS	_	2	ppmod	_	_
7	IV	iv	CD	_	6	num	_	_
8	and	and	CC	_	7	cc	_	_
9	VI	vi	LS	_	12	attr	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	cortex	cortex	NN	_	7	conj	_	_
13	which	which	WDT	_	15	det	_	_
14	dopamine	dopamine	NN	_	15	com	_	_
15	receptor	receptor	NN	_	17	dep	_	_
16	are	be	VBP	_	17	aux	_	_
17	localized	localize	VBN	_	6	relcl	_	_
18	to	to	TO	_	17	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	8	mark	_	_
5	D1	d0	NN	_	6	com	_	_
6	receptors	receptor	NNS	_	8	dep	_	_
7	are	be	VBP	_	8	aux	_	_
8	coupled	couple	VBN	_	3	comp	_	_
9	to	to	TO	_	10	aux	_	_
10	activation	activation	NN	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	arc	arc	NN	_	13	com	_	_
13	gene	gene	NN	_	10	ppmod	_	_
14	,	,	,	_	10	p	_	_
15	which	which	WDT	_	18	dep	_	_
16	may	may	MD	_	18	modal	_	_
17	be	be	VB	_	18	aux	_	_
18	involved	involve	VBN	_	10	relcl	_	_
19	in	in	IN	_	23	case	_	_
20	functional	functional	JJ	_	23	attr	_	_
21	or	or	CC	_	20	cc	_	_
22	structural	structural	JJ	_	20	conj	_	_
23	alterations	alteration	NNS	_	18	ppmod	_	_
24	underlying	underlie	VBG	_	23	acl	_	_
25	neural	neural	JJ	_	26	attr	_	_
26	plasticity	plasticity	NN	_	24	obj	_	_
27	triggered	trigger	VBN	_	26	acl	_	_
28	by	by	IN	_	29	case	_	_
29	drug1	drug0	NN	_	27	ppmod	_	_
30	.	.	.	_	3	p	_	_

1	Differential	differential	JJ	_	2	attr	_	_
2	actions	action	NNS	_	0	root	_	_
3	of	of	IN	_	5	case	_	_
4	intrathecal	intrathecal	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	on	on	IN	_	7	case	_	_
7	blocking	block	VBG	_	2	ppmod	_	_
8	the	the	DT	_	10	det	_	_
9	tail-flick	tail-flick	NN	_	10	com	_	_
10	inhibition	inhibition	NN	_	7	obj	_	_
11	induced	induce	VBN	_	10	acl	_	_
12	by	by	IN	_	14	case	_	_
13	intraventricular	intraventricular	JJ	_	14	attr	_	_
14	drug2	drug0	NN	_	11	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug3	drug0	NN	_	14	conj	_	_
17	in	in	IN	_	18	case	_	_
18	rats	rat	NNS	_	14	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	it	it	PRP	_	8	dep	_	_
7	is	be	VBZ	_	8	aux	_	_
8	proposed	propose	VBN	_	0	root	_	_
9	that	that	IN	_	17	mark	_	_
10	the	the	DT	_	11	det	_	_
11	drug1	drug0	NN	_	17	dep	_	_
12	applied	apply	VBN	_	11	acl	_	_
13	to	to	TO	_	16	aux	_	_
14	supraspinal	supraspinal	JJ	_	16	attr	_	_
15	brain	brain	NN	_	16	com	_	_
16	sites	site	NNS	_	12	ppmod	_	_
17	produced	produce	VBD	_	8	comp	_	_
18	their	their	PRP$	_	20	poss	_	_
19	analgesic	analgesic	JJ	_	20	attr	_	_
20	effects	effect	NNS	_	17	obj	_	_
21	by	by	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	activation	activation	NN	_	17	ppmod	_	_
24	of	of	IN	_	29	case	_	_
25	different	different	JJ	_	29	attr	_	_
26	descending	descending	NN	_	29	attr	_	_
27	pain	pain	NN	_	29	attr	_	_
28	inhibitory	inhibitory	JJ	_	29	attr	_	_
29	systems	system	NNS	_	23	ppmod	_	_
30	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	blockade	blockade	NN	_	25	dep	_	_
3	of	of	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	spinal	spinal	JJ	_	7	attr	_	_
6	endorphinergic	endorphinergic	JJ	_	7	attr	_	_
7	system	system	NN	_	2	ppmod	_	_
8	by	by	IN	_	10	case	_	_
9	intrathecal	intrathecal	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	2	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	production	production	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	tail-flick	tail-flick	NN	_	16	com	_	_
16	inhibition	inhibition	NN	_	13	ppmod	_	_
17	induced	induce	VBN	_	13	acl	_	_
18	by	by	IN	_	20	case	_	_
19	intraventricular	intraventricular	JJ	_	20	attr	_	_
20	drug2	drug0	NN	_	17	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	was	be	VBD	_	25	aux	_	_
24	then	then	RB	_	25	adv	_	_
25	studied	study	VBN	_	0	root	_	_
26	.	.	.	_	25	p	_	_

1	Intraventricular	intraventricular	JJ	_	2	attr	_	_
2	injection	injection	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	produced	produce	VBD	_	0	root	_	_
8	an	an	DT	_	9	det	_	_
9	inhibition	inhibition	NN	_	7	obj	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	tail-flick	tail-flick	NN	_	13	com	_	_
13	response	response	NN	_	9	ppmod	_	_
14	to	to	TO	_	17	aux	_	_
15	the	the	DT	_	17	det	_	_
16	heat	heat	NN	_	17	com	_	_
17	stimulus	stimulus	NN	_	13	ppmod	_	_
18	in	in	IN	_	19	case	_	_
19	rats	rat	NNS	_	13	ppmod	_	_
20	.	.	.	_	7	p	_	_

1	Intrathecal	intrathecal	JJ	_	2	attr	_	_
2	injection	injection	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	at	at	IN	_	6	case	_	_
6	doses	dose	NNS	_	2	ppmod	_	_
7	of	of	IN	_	11	case	_	_
8	0.4	0	CD	_	11	num	_	_
9	to	to	TO	_	8	cc	_	_
10	40	0	CD	_	8	conj	_	_
11	micrograms	microgram	NNS	_	6	ppmod	_	_
12	caused	cause	VBD	_	0	root	_	_
13	a	a	DT	_	15	det	_	_
14	dose-related	dose-related	JJ	_	15	attr	_	_
15	blockade	blockade	NN	_	12	obj	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	inhibition	inhibition	NN	_	15	ppmod	_	_
19	of	of	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	tail-flick	tail-flick	NN	_	22	com	_	_
22	response	response	NN	_	18	ppmod	_	_
23	induced	induce	VBN	_	22	acl	_	_
24	by	by	IN	_	26	case	_	_
25	intraventricular	intraventricular	JJ	_	26	attr	_	_
26	injection	injection	NN	_	23	ppmod	_	_
27	of	of	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	,	,	,	_	12	p	_	_
30	and	and	CC	_	12	cc	_	_
31	a	a	DT	_	33	det	_	_
32	high	high	JJ	_	33	attr	_	_
33	dose	dose	NN	_	41	dep	_	_
34	of	of	IN	_	35	case	_	_
35	drug3	drug0	NN	_	33	ppmod	_	_
36	(	-lrb-	-LRB-	_	38	p	_	_
37	40	0	CD	_	38	num	_	_
38	micrograms	microgram	NNS	_	35	prn	_	_
39	)	-rrb-	-RRB-	_	38	p	_	_
40	completely	completely	RB	_	41	adv	_	_
41	blocked	block	VBD	_	12	conj	_	_
42	the	the	DT	_	44	det	_	_
43	tail-flick	tail-flick	NN	_	44	com	_	_
44	inhibition	inhibition	NN	_	41	obj	_	_
45	induced	induce	VBN	_	44	acl	_	_
46	by	by	IN	_	48	case	_	_
47	intraventricular	intraventricular	JJ	_	48	attr	_	_
48	drug4	drug0	NNS	_	45	ppmod	_	_
49	(	-lrb-	-LRB-	_	51	p	_	_
50	16	0	CD	_	51	num	_	_
51	micrograms	microgram	NNS	_	48	prn	_	_
52	)	-rrb-	-RRB-	_	51	p	_	_
53	.	.	.	_	12	p	_	_

1	On	on	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	other	other	JJ	_	4	attr	_	_
4	hand	hand	NN	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	intrathecal	intrathecal	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	12	dep	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	12-120	0	CD	_	10	num	_	_
10	micrograms	microgram	NNS	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	had	have	VBD	_	0	root	_	_
13	only	only	RB	_	17	adv	_	_
14	a	a	DT	_	17	det	_	_
15	very	very	RB	_	16	adv	_	_
16	weak	weak	JJ	_	17	attr	_	_
17	effect	effect	NN	_	12	obj	_	_
18	on	on	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	tail-flick	tail-flick	NN	_	21	com	_	_
21	inhibition	inhibition	NN	_	12	ppmod	_	_
22	induced	induce	VBN	_	21	acl	_	_
23	by	by	IN	_	25	case	_	_
24	intraventricular	intraventricular	JJ	_	25	attr	_	_
25	drug2	drug0	NN	_	22	ppmod	_	_
26	(	-lrb-	-LRB-	_	28	p	_	_
27	40	0	CD	_	28	num	_	_
28	micrograms	microgram	NNS	_	25	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	.	.	.	_	12	p	_	_

1	Intraventricular	intraventricular	JJ	_	2	attr	_	_
2	injection	injection	NN	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	at	at	IN	_	6	case	_	_
6	doses	dose	NNS	_	2	ppmod	_	_
7	of	of	IN	_	11	case	_	_
8	1.2	0	CD	_	11	num	_	_
9	to	to	TO	_	8	cc	_	_
10	12	0	CD	_	8	conj	_	_
11	micrograms	microgram	NNS	_	6	ppmod	_	_
12	equally	equally	RB	_	13	adv	_	_
13	antagonized	antagonize	VBD	_	0	root	_	_
14	in	in	IN	_	17	case	_	_
15	a	a	DT	_	17	det	_	_
16	dose-dependent	dose-dependent	JJ	_	17	attr	_	_
17	manner	manner	NN	_	13	ppmod	_	_
18	the	the	DT	_	20	det	_	_
19	tail-flick	tail-flick	NN	_	20	com	_	_
20	inhibition	inhibition	NN	_	13	obj	_	_
21	induced	induce	VBN	_	20	acl	_	_
22	by	by	IN	_	24	case	_	_
23	intraventricular	intraventricular	JJ	_	24	attr	_	_
24	drug2	drug0	NN	_	21	ppmod	_	_
25	and	and	CC	_	24	cc	_	_
26	drug3	drug0	NN	_	24	conj	_	_
27	.	.	.	_	13	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	12	mark	_	_
5	a	a	DT	_	10	det	_	_
6	spinal	spinal	JJ	_	10	attr	_	_
7	drug1	drug0	NN	_	10	attr	_	_
8	-sensitive	-sensitive	JJ	_	10	attr	_	_
9	endorphinergic	endorphinergic	NN	_	10	com	_	_
10	system	system	NN	_	12	dep	_	_
11	is	be	VBZ	_	12	aux	_	_
12	involved	involve	VBN	_	3	comp	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	production	production	NN	_	12	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	but	but	CC	_	17	cc	_	_
19	not	not	RB	_	18	com	_	_
20	drug3	drug0	NN	_	23	attr	_	_
21	-induced	-induced	JJ	_	23	attr	_	_
22	tail-flick	tail-flick	NN	_	23	com	_	_
23	inhibition	inhibition	NN	_	17	conj	_	_
24	,	,	,	_	3	p	_	_
25	and	and	CC	_	3	cc	_	_
26	suggest	suggest	VBP	_	3	conj	_	_
27	that	that	IN	_	32	mark	_	_
28	intraventricular	intraventricular	JJ	_	29	attr	_	_
29	drug4	drug0	NN	_	32	dep	_	_
30	and	and	CC	_	29	cc	_	_
31	drug5	drug0	NN	_	29	conj	_	_
32	elicit	elicit	VBP	_	26	comp	_	_
33	their	their	PRP$	_	35	poss	_	_
34	pharmacological	pharmacological	JJ	_	35	attr	_	_
35	actions	action	NNS	_	32	obj	_	_
36	via	via	IN	_	38	case	_	_
37	the	the	DT	_	38	det	_	_
38	activation	activation	NN	_	32	ppmod	_	_
39	of	of	IN	_	44	case	_	_
40	different	different	JJ	_	44	attr	_	_
41	descending	descending	NN	_	44	attr	_	_
42	pain	pain	NN	_	44	attr	_	_
43	inhibitory	inhibitory	JJ	_	44	attr	_	_
44	systems	system	NNS	_	38	ppmod	_	_
45	;	;	:	_	3	p	_	_

1	descending	descending	JJ	_	5	attr	_	_
2	epsilon	epsilon	NN	_	5	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	mu	mu	NN	_	2	conj	_	_
5	systems	system	NNS	_	14	dep	_	_
6	for	for	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	14	p	_	_
11	respectively	respectively	RB	_	14	adv	_	_
12	,	,	,	_	14	p	_	_
13	are	be	VBP	_	14	aux	_	_
14	proposed	propose	VBN	_	0	root	_	_
15	.	.	.	_	14	p	_	_

1	Pharmacological	pharmacological	JJ	_	2	attr	_	_
2	treatment	treatment	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	depression	depression	NN	_	2	ppmod	_	_
5	:	:	:	_	2	p	_	_
6	the	the	DT	_	7	det	_	_
7	role	role	NN	_	2	appo	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	Depression	depression	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	reaching	reach	VBG	_	0	root	_	_
4	epidemic	epidemic	JJ	_	5	attr	_	_
5	proportions	proportion	NNS	_	3	obj	_	_
6	in	in	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	western	western	NN	_	9	com	_	_
9	world	world	NN	_	5	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	With	with	IN	_	4	case	_	_
2	each	each	DT	_	4	det	_	_
3	successive	successive	JJ	_	4	attr	_	_
4	generation	generation	NN	_	5	ppmod	_	_
5	more	more	JJR	_	6	attr	_	_
6	people	people	NN	_	11	dep	_	_
7	are	be	VBP	_	11	aux	_	_
8	becoming	become	VBG	_	11	aux	_	_
9	more	more	RBR	_	10	com	_	_
10	severely	severely	RB	_	11	adv	_	_
11	depressed	depress	VBN	_	0	root	_	_
12	at	at	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	younger	young	JJR	_	15	attr	_	_
15	age	age	NN	_	11	ppmod	_	_
16	.	.	.	_	11	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	How	how	WRB	_	6	adv	_	_
5	to	to	TO	_	6	aux	_	_
6	identify	identify	VB	_	2	acl	_	_
7	them	them	PRP	_	6	obj	_	_
8	.	.	.	_	2	p	_	_

1	Interactions	interaction	NNS	_	7	dep	_	_
2	between	between	IN	_	4	case	_	_
3	theraputic	theraputic	JJ	_	4	attr	_	_
4	agents	agent	NNS	_	1	ppmod	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	recognized	recognize	VBN	_	0	root	_	_
8	as	as	IN	_	25	mark	_	_
9	increasingly	increasingly	RB	_	10	adv	_	_
10	important	important	JJ	_	11	attr	_	_
11	causes	cause	NNS	_	25	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug	drug	NN	_	11	ppmod	_	_
14	at	at	IN	_	18	case	_	_
15	their	their	PRP$	_	18	poss	_	_
16	usual	usual	JJ	_	18	attr	_	_
17	recommended	recommend	VBN	_	18	attr	_	_
18	dose	dose	NN	_	11	ppmod	_	_
19	may	may	MD	_	25	modal	_	_
20	,	,	,	_	25	p	_	_
21	under	under	IN	_	23	case	_	_
22	certain	certain	JJ	_	23	attr	_	_
23	conditions	condition	NNS	_	25	ppmod	_	_
24	,	,	,	_	25	p	_	_
25	produce	produce	VB	_	7	comp	_	_
26	toxicity	toxicity	NN	_	25	obj	_	_
27	of	of	IN	_	29	case	_	_
28	life-endangering	life-endangering	JJ	_	29	attr	_	_
29	proportions	proportion	NNS	_	26	ppmod	_	_
30	.	.	.	_	7	p	_	_

1	While	while	IN	_	10	mark	_	_
2	the	the	DT	_	3	det	_	_
3	recognition	recognition	NN	_	10	dep	_	_
4	of	of	IN	_	6	case	_	_
5	drug	drug	NN	_	6	com	_	_
6	toxicity	toxicity	NN	_	3	ppmod	_	_
7	resulting	result	VBG	_	6	acl	_	_
8	from	from	IN	_	9	case	_	_
9	interactions	interaction	NNS	_	7	ppmod	_	_
10	is	be	VBZ	_	18	advcl	_	_
11	of	of	IN	_	12	case	_	_
12	importance	importance	NN	_	10	ppmod	_	_
13	to	to	TO	_	15	aux	_	_
14	all	all	DT	_	15	det	_	_
15	physciains	physciains	NNS	_	10	ppmod	_	_
16	,	,	,	_	18	p	_	_
17	it	it	PRP	_	18	dep	_	_
18	is	be	VBZ	_	0	root	_	_
19	especially	especially	RB	_	24	adv	_	_
20	so	so	RB	_	24	adv	_	_
21	for	for	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	clinician	clinician	NN	_	24	ppmod	_	_
24	responsible	responsible	JJ	_	18	dep	_	_
25	for	for	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	welfare	welfare	NN	_	24	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	those	those	DT	_	27	ppmod	_	_
30	in	in	IN	_	33	case	_	_
31	the	the	DT	_	33	det	_	_
32	aerospace	aerospace	NN	_	33	com	_	_
33	environment	environment	NN	_	29	ppmod	_	_
34	.	.	.	_	18	p	_	_

1	This	this	DT	_	2	det	_	_
2	paper	paper	NN	_	3	dep	_	_
3	attempts	attempt	VBZ	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	provide	provide	VB	_	3	comp	_	_
6	a	a	DT	_	7	det	_	_
7	basis	basis	NN	_	5	obj	_	_
8	for	for	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	understanding	understanding	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	identifications	identification	NNS	_	10	conj	_	_
13	of	of	IN	_	16	case	_	_
14	important	important	JJ	_	16	attr	_	_
15	drug	drug	NN	_	16	com	_	_
16	interactions	interaction	NNS	_	10	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	Guidelines	guideline	NNS	_	3	dep	_	_
2	are	be	VBP	_	3	aux	_	_
3	provided	provided	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	assist	assist	VBP	_	3	comp	_	_
6	the	the	DT	_	7	det	_	_
7	clinician	clinician	NN	_	5	obj	_	_
8	in	in	IN	_	11	case	_	_
9	his	his	NN	_	11	attr	_	_
10	logical	logical	JJ	_	11	attr	_	_
11	approach	approach	NN	_	7	ppmod	_	_
12	to	to	TO	_	14	aux	_	_
13	the	the	DT	_	14	det	_	_
14	identification	identification	NN	_	7	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	drug	drug	NN	_	17	com	_	_
17	interactions	interaction	NNS	_	14	ppmod	_	_
18	when	when	WRB	_	23	adv	_	_
19	serious	serious	JJ	_	21	attr	_	_
20	drug	drug	NN	_	21	com	_	_
21	toxicity	toxicity	NN	_	23	dep	_	_
22	is	be	VBZ	_	23	aux	_	_
23	encountered	encounter	VBN	_	17	relcl	_	_
24	in	in	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	pateint	pateint	NN	_	23	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	Only	only	RB	_	12	adv	_	_
2	with	with	IN	_	3	case	_	_
3	knowledge	knowledge	NN	_	12	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	interaction	interaction	NN	_	3	ppmod	_	_
7	can	can	MD	_	12	modal	_	_
8	the	the	DT	_	10	det	_	_
9	therapeutic	therapeutic	JJ	_	10	attr	_	_
10	regimen	regimen	NNS	_	12	obj	_	_
11	be	be	VB	_	12	aux	_	_
12	altered	alter	VBN	_	0	root	_	_
13	so	so	RB	_	12	adv	_	_
14	as	as	IN	_	16	mark	_	_
15	to	to	TO	_	16	aux	_	_
16	provide	provide	VBP	_	12	comp	_	_
17	therapeutic	therapeutic	JJ	_	18	attr	_	_
18	levels	level	NNS	_	16	obj	_	_
19	of	of	IN	_	21	case	_	_
20	necessary	necessary	JJ	_	21	attr	_	_
21	drugs	drug	NNS	_	18	ppmod	_	_
22	while	while	IN	_	23	case	_	_
23	avoiding	avoid	VBG	_	16	ppmod	_	_
24	toxicity	toxicity	NN	_	23	obj	_	_
25	.	.	.	_	12	p	_	_

1	Changes	change	NNS	_	5	dep	_	_
2	in	in	IN	_	4	case	_	_
3	urinary	urinary	JJ	_	4	attr	_	_
4	homocysteine	homocysteine	NN	_	1	ppmod	_	_
5	following	follow	VBG	_	0	root	_	_
6	drug1	drug0	NN	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	administration	administration	NN	_	5	obj	_	_
10	to	to	TO	_	11	aux	_	_
11	rats	rat	NNS	_	9	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	present	present	JJ	_	3	attr	_	_
3	work	work	NN	_	4	dep	_	_
4	involved	involve	VBD	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	administration	administration	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	both	both	CC	_	9	cc	_	_
9	drug1	drug0	NN	_	6	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	to	to	TO	_	13	aux	_	_
13	groups	group	NNS	_	6	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	rats	rat	NNS	_	13	ppmod	_	_
16	,	,	,	_	4	p	_	_
17	followed	followed	VBN	_	4	comp	_	_
18	by	by	IN	_	19	case	_	_
19	determination	determination	NN	_	17	ppmod	_	_
20	of	of	IN	_	24	case	_	_
21	the	the	DT	_	24	det	_	_
22	homocysteine	homocysteine	NN	_	24	com	_	_
23	excretion	excretion	NN	_	24	com	_	_
24	rate	rate	NN	_	19	ppmod	_	_
25	in	in	IN	_	26	case	_	_
26	urine	urine	NN	_	24	ppmod	_	_
27	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	a	a	DT	_	8	det	_	_
6	statistically	statistically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	8	attr	_	_
8	difference	difference	NN	_	9	dep	_	_
9	exists	exist	VBZ	_	3	comp	_	_
10	between	between	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	excreted	excreted	JJ	_	13	attr	_	_
13	levels	level	NNS	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	homocysteine	homocysteine	NN	_	13	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	urine	urine	NN	_	13	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	both	both	CC	_	21	cc	_	_
21	control	control	JJ	_	18	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	drug1	drug0	JJ	_	25	attr	_	_
24	-treated	-treated	JJ	_	25	attr	_	_
25	rats	rat	NNS	_	21	conj	_	_
26	and	and	CC	_	13	cc	_	_
27	the	the	DT	_	28	det	_	_
28	levels	level	NNS	_	13	conj	_	_
29	shown	show	VBN	_	28	acl	_	_
30	by	by	IN	_	31	case	_	_
31	rats	rat	NNS	_	29	ppmod	_	_
32	treated	treat	VBN	_	31	acl	_	_
33	with	with	IN	_	34	case	_	_
34	drug2	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	implications	implication	NNS	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	these	these	DT	_	5	det	_	_
5	results	result	NNS	_	2	ppmod	_	_
6	are	be	VBP	_	7	aux	_	_
7	discussed	discuss	VBN	_	0	root	_	_
8	,	,	,	_	7	p	_	_
9	especially	especially	RB	_	11	adv	_	_
10	with	with	IN	_	11	case	_	_
11	respect	respect	NN	_	7	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	observations	observation	NNS	_	11	ppmod	_	_
14	which	which	WDT	_	15	dep	_	_
15	indicate	indicate	VBP	_	13	relcl	_	_
16	that	that	IN	_	19	mark	_	_
17	homocysteine	homocysteine	NN	_	19	dep	_	_
18	may	may	MD	_	19	modal	_	_
19	be	be	VB	_	15	comp	_	_
20	a	a	DT	_	22	det	_	_
21	precipitating	precipitate	VBG	_	22	attr	_	_
22	factor	factor	NN	_	19	obj	_	_
23	in	in	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	development	development	NN	_	19	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	thrombosis	thrombosis	NN	_	25	ppmod	_	_
28	.	.	.	_	7	p	_	_

1	Also	also	RB	_	2	adv	_	_
2	included	include	VBN	_	6	advcl	_	_
3	in	in	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	paper	paper	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	0	root	_	_
7	a	a	DT	_	8	det	_	_
8	study	study	NN	_	6	obj	_	_
9	which	which	WDT	_	10	dep	_	_
10	confirms	confirm	VBZ	_	8	relcl	_	_
11	the	the	DT	_	12	det	_	_
12	identity	identity	NN	_	10	obj	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	HPLC	hplc	NN	_	16	com	_	_
16	peak	peak	NN	_	12	ppmod	_	_
17	as	as	IN	_	18	case	_	_
18	being	be	VBG	_	10	ppmod	_	_
19	homocysteine	homocysteine	NN	_	18	obj	_	_
20	by	by	IN	_	21	case	_	_
21	forming	form	VBG	_	18	ppmod	_	_
22	a	a	DT	_	24	det	_	_
23	radioactive	radioactive	JJ	_	24	attr	_	_
24	derivative	derivative	NN	_	21	obj	_	_
25	of	of	IN	_	30	case	_	_
26	this	this	DT	_	30	det	_	_
27	particular	particular	JJ	_	30	attr	_	_
28	sulphydryl-containing	sulphydryl-containing	JJ	_	30	attr	_	_
29	amino	amino	NN	_	30	com	_	_
30	acid	acid	NN	_	24	ppmod	_	_
31	,	,	,	_	21	p	_	_
32	and	and	CC	_	21	cc	_	_
33	then	then	RB	_	34	adv	_	_
34	analysing	analyse	VBG	_	21	conj	_	_
35	the	the	DT	_	37	det	_	_
36	resulting	result	VBG	_	37	attr	_	_
37	mixture	mixture	NN	_	34	obj	_	_
38	by	by	IN	_	39	case	_	_
39	TLC	tlc	NN	_	34	ppmod	_	_
40	.	.	.	_	6	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	on	on	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	antinociceptive	antinociceptive	JJ	_	9	attr	_	_
9	effect	effect	NN	_	1	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	drug4	drug0	NN	_	11	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	drug5	drug0	NN	_	11	conj	_	_
16	in	in	IN	_	17	case	_	_
17	mice	mouse	NNS	_	11	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	influence	influence	NN	_	29	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	on	on	IN	_	9	case	_	_
8	antinociceptive	antinociceptive	JJ	_	9	attr	_	_
9	effect	effect	NN	_	2	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug3	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	10	0	CD	_	14	num	_	_
14	mg/kg	mg/kg	NN	_	11	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	11	p	_	_
17	drug4	drug0	NN	_	11	conj	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	500	0	CD	_	20	num	_	_
20	mg/kg	mg/kg	NN	_	17	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	and	and	CC	_	17	cc	_	_
23	drug5	drug0	NN	_	11	conj	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	10	0	CD	_	26	num	_	_
26	mg/kg	mg/kg	NN	_	23	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	was	be	VBD	_	29	aux	_	_
29	investigated	investigate	VBN	_	0	root	_	_
30	in	in	IN	_	33	case	_	_
31	a	a	DT	_	33	det	_	_
32	mouse	mouse	NN	_	33	com	_	_
33	model	model	NN	_	29	ppmod	_	_
34	using	use	VBG	_	33	acl	_	_
35	the	the	DT	_	36	det	_	_
36	tail-flick	tail-flick	NN	_	34	obj	_	_
37	and	and	CC	_	36	cc	_	_
38	hot-plate	hot-plate	NN	_	39	com	_	_
39	tests	test	NNS	_	36	conj	_	_
40	.	.	.	_	29	p	_	_

1	All	all	DT	_	2	det	_	_
2	drugs	drug	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	injected	inject	VBN	_	0	root	_	_
5	intraperitoneally	intraperitoneally	RB	_	4	adv	_	_
6	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	were	be	VBD	_	3	aux	_	_
3	administered	administer	VBN	_	0	root	_	_
4	to	to	TO	_	7	aux	_	_
5	mice	mouse	NNS	_	7	attr	_	_
6	30	0	CD	_	7	num	_	_
7	min	min	NN	_	3	ppmod	_	_
8	before	before	IN	_	9	case	_	_
9	applying	apply	VBG	_	3	ppmod	_	_
10	the	the	DT	_	11	det	_	_
11	drug2	drug0	NN	_	9	obj	_	_
12	.	.	.	_	3	p	_	_

1	Measurement	measurement	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	nociception	nociception	NN	_	1	ppmod	_	_
4	was	be	VBD	_	5	aux	_	_
5	performed	performed	VBN	_	0	root	_	_
6	within	within	IN	_	8	case	_	_
7	2	0	CD	_	8	num	_	_
8	h	h	NN	_	5	ppmod	_	_
9	after	after	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	administration	administration	NN	_	8	ppmod	_	_
12	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	at	at	IN	_	3	case	_	_
3	doses	dose	NNS	_	1	ppmod	_	_
4	of	of	IN	_	6	case	_	_
5	0.25	0	CD	_	6	num	_	_
6	mg/kg	mg/kg	NN	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	2.5	0	CD	_	9	num	_	_
9	mg/kg	mg/kg	NN	_	6	conj	_	_
10	injected	inject	VBN	_	6	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	was	be	VBD	_	14	aux	_	_
14	found	find	VBN	_	0	root	_	_
15	to	to	TO	_	16	aux	_	_
16	decrease	decrease	VB	_	14	comp	_	_
17	the	the	DT	_	19	det	_	_
18	antinociceptive	antinociceptive	JJ	_	19	attr	_	_
19	effect	effect	NN	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	Similarly	similarly	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	decreased	decrease	VBD	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	antinociceptive	antinociceptive	JJ	_	7	attr	_	_
7	effect	effect	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	(	-lrb-	-LRB-	_	15	p	_	_
11	only	only	RB	_	15	adv	_	_
12	in	in	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	tail-flick	tail-flick	NN	_	15	com	_	_
15	test	test	NN	_	9	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	and	and	CC	_	9	cc	_	_
18	drug3	drug0	NN	_	9	conj	_	_
19	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	used	use	VBN	_	1	acl	_	_
3	at	at	IN	_	4	case	_	_
4	doses	dose	NNS	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	1.25	0	CD	_	7	num	_	_
7	mg/kg	mg/kg	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	2.5	0	CD	_	10	num	_	_
10	mg/kg	mg/kg	NN	_	7	conj	_	_
11	decreased	decrease	VBD	_	0	root	_	_
12	the	the	DT	_	14	det	_	_
13	antinociceptive	antinociceptive	JJ	_	14	attr	_	_
14	effect	effect	NN	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	(	-lrb-	-LRB-	_	24	p	_	_
20	only	only	RB	_	24	adv	_	_
21	in	in	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	tail-flick	tail-flick	NN	_	24	com	_	_
24	test	test	NN	_	18	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	and	and	CC	_	18	cc	_	_
27	drug4	drug0	NN	_	16	conj	_	_
28	.	.	.	_	11	p	_	_

1	-LSB-The	-lsb-the	NN	_	2	com	_	_
2	effect	effect	NN	_	27	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	renal	renal	JJ	_	8	attr	_	_
8	excretion	excretion	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	in	in	IN	_	14	case	_	_
14	dogs	dog	NNS	_	8	ppmod	_	_
15	]	-rsb-	-RRB-	_	2	p	_	_
16	The	the	DT	_	18	det	_	_
17	intravenous	intravenous	JJ	_	18	attr	_	_
18	injection	injection	NN	_	27	dep	_	_
19	of	of	IN	_	20	case	_	_
20	drug4	drug0	NN	_	18	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	a	a	DT	_	23	det	_	_
23	dose	dose	NN	_	18	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	20	0	CD	_	26	num	_	_
26	mg/kg	mg/kg	NN	_	23	ppmod	_	_
27	enhanced	enhance	VBD	_	0	root	_	_
28	drug5	drug0	NN	_	27	obj	_	_
29	and	and	CC	_	28	cc	_	_
30	drug6	drug0	NN	_	31	com	_	_
31	excretion	excretion	NN	_	28	conj	_	_
32	in	in	IN	_	35	case	_	_
33	chronic	chronic	JJ	_	35	attr	_	_
34	canine	canine	NN	_	35	com	_	_
35	experiments	experiment	NNS	_	27	ppmod	_	_
36	.	.	.	_	27	p	_	_

1	The	the	DT	_	6	det	_	_
2	higher	high	JJR	_	6	attr	_	_
3	drug1	drug0	NN	_	6	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	excretion	excretion	NN	_	7	dep	_	_
7	was	be	VBD	_	0	root	_	_
8	due	due	JJ	_	7	dep	_	_
9	to	to	TO	_	14	aux	_	_
10	their	their	PRP$	_	14	poss	_	_
11	increased	increase	VBN	_	14	attr	_	_
12	renal	renal	JJ	_	14	attr	_	_
13	tubular	tubular	JJ	_	14	attr	_	_
14	secretion	secretion	NN	_	8	ppmod	_	_
15	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	dogs	dog	NNS	_	5	ppmod	_	_
3	,	,	,	_	5	p	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	unchanged	unchanged	JJ	_	0	root	_	_
6	the	the	DT	_	7	det	_	_
7	secretion	secretion	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	a	a	DT	_	13	det	_	_
12	test	test	NN	_	13	com	_	_
13	agent	agent	NN	_	9	appo	_	_
14	for	for	IN	_	16	case	_	_
15	anionic	anionic	JJ	_	16	attr	_	_
16	transport	transport	NN	_	13	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	Possible	possible	JJ	_	3	attr	_	_
2	extrarenal	extrarenal	JJ	_	3	attr	_	_
3	mechanisms	mechanism	NNS	_	15	dep	_	_
4	of	of	IN	_	5	case	_	_
5	action	action	NN	_	3	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	on	on	IN	_	9	case	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	12	com	_	_
12	transport	transport	NN	_	9	conj	_	_
13	were	be	VBD	_	15	aux	_	_
14	also	also	RB	_	15	adv	_	_
15	examined	examine	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Differential	differential	JJ	_	2	attr	_	_
2	regulation	regulation	NN	_	0	root	_	_
3	of	of	IN	_	5	case	_	_
4	tyrosine	tyrosine	NN	_	5	com	_	_
5	phosphorylation	phosphorylation	NN	_	2	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	tumor	tumor	NN	_	8	com	_	_
8	cells	cell	NNS	_	2	ppmod	_	_
9	by	by	IN	_	10	case	_	_
10	drug1	drug0	NN	_	2	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	a	a	DT	_	14	det	_	_
13	homodimeric	homodimeric	JJ	_	14	attr	_	_
14	disintegrin	disintegrin	NN	_	10	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	monomeric	monomeric	JJ	_	18	attr	_	_
18	disintegrins	disintegrins	NNS	_	10	conj	_	_
19	drug2	drug0	NN	_	18	attr	_	_
20	and	and	CC	_	19	cc	_	_
21	drug3	drug0	NN	_	19	conj	_	_
22	.	.	.	_	2	p	_	_

1	The	the	DT	_	4	det	_	_
2	homodimeric	homodimeric	JJ	_	4	attr	_	_
3	disintegrin	disintegrin	NN	_	4	com	_	_
4	drug1	drug0	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	compared	compare	VBN	_	0	root	_	_
7	directly	directly	RB	_	6	adv	_	_
8	to	to	TO	_	11	aux	_	_
9	the	the	DT	_	11	det	_	_
10	monomeric	monomeric	JJ	_	11	attr	_	_
11	disintegrins	disintegrins	NNS	_	6	ppmod	_	_
12	drug2	drug0	NN	_	11	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	for	for	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	ability	ability	NN	_	11	ppmod	_	_
18	to	to	TO	_	19	aux	_	_
19	affect	affect	VB	_	17	acl	_	_
20	protein	protein	NN	_	22	com	_	_
21	tyrosine	tyrosine	NN	_	22	com	_	_
22	phosphorylation	phosphorylation	NN	_	19	obj	_	_
23	in	in	IN	_	25	case	_	_
24	tumor	tumor	NN	_	25	com	_	_
25	cells	cell	NNS	_	22	ppmod	_	_
26	.	.	.	_	6	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	observed	observe	VBN	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	had	have	VBD	_	3	comp	_	_
7	a	a	DT	_	9	det	_	_
8	dramatic	dramatic	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	on	on	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	tyrosine	tyrosine	NN	_	14	com	_	_
13	phosphorylation	phosphorylation	NN	_	14	com	_	_
14	status	status	NN	_	6	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	several	several	JJ	_	17	attr	_	_
17	proteins	protein	NNS	_	14	ppmod	_	_
18	in	in	IN	_	23	case	_	_
19	T24	t0	NN	_	23	attr	_	_
20	human	human	JJ	_	23	attr	_	_
21	bladder	bladder	NN	_	23	com	_	_
22	cancer	cancer	NN	_	23	com	_	_
23	cells	cell	NNS	_	17	ppmod	_	_
24	,	,	,	_	17	p	_	_
25	including	include	VBG	_	27	adv	_	_
26	robust	robust	JJ	_	27	attr	_	_
27	induction	induction	NN	_	17	ppmod	_	_
28	of	of	IN	_	29	case	_	_
29	phosphorylation	phosphorylation	NN	_	27	ppmod	_	_
30	of	of	IN	_	31	case	_	_
31	proteins	protein	NNS	_	29	ppmod	_	_
32	in	in	IN	_	34	case	_	_
33	the	the	DT	_	34	det	_	_
34	range	range	NN	_	27	ppmod	_	_
35	of	of	IN	_	37	case	_	_
36	120-140	0	CD	_	37	num	_	_
37	kDa	kda	NN	_	34	ppmod	_	_
38	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	alone	alone	RB	_	3	adv	_	_
3	had	have	VBD	_	0	root	_	_
4	no	no	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	on	on	IN	_	8	case	_	_
7	tyrosine	tyrosine	NN	_	8	com	_	_
8	phosphorylation	phosphorylation	NN	_	3	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	T24	t0	NN	_	11	com	_	_
11	cells	cell	NNS	_	8	ppmod	_	_
12	,	,	,	_	3	p	_	_
13	but	but	CC	_	3	cc	_	_
14	dose-dependently	dose-dependently	RB	_	15	adv	_	_
15	inhibits	inhibit	VBZ	_	3	conj	_	_
16	the	the	DT	_	17	det	_	_
17	effects	effect	NNS	_	15	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	when	when	WRB	_	23	adv	_	_
21	both	both	DT	_	23	dep	_	_
22	are	be	VBP	_	23	aux	_	_
23	added	add	VBN	_	15	comp	_	_
24	simultaneously	simultaneously	RB	_	23	adv	_	_
25	.	.	.	_	3	p	_	_

1	Among	among	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	proteins	protein	NNS	_	21	ppmod	_	_
4	that	that	WDT	_	5	dep	_	_
5	undergo	undergo	VBP	_	3	relcl	_	_
6	tyrosine	tyrosine	NN	_	7	com	_	_
7	phosphorylation	phosphorylation	NN	_	5	obj	_	_
8	in	in	IN	_	12	case	_	_
9	response	response	NN	_	12	advnp	_	_
10	to	to	TO	_	12	aux	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	treatment	treatment	NN	_	5	ppmod	_	_
13	is	be	VBZ	_	12	acl	_	_
14	CAS	cas	NN	_	13	obj	_	_
15	,	,	,	_	21	p	_	_
16	a	a	DT	_	20	det	_	_
17	130	0	CD	_	18	num	_	_
18	kDa	kda	NN	_	20	com	_	_
19	adapter	adapter	NN	_	20	com	_	_
20	protein	protein	NN	_	21	dep	_	_
21	involved	involve	VBN	_	0	root	_	_
22	in	in	IN	_	24	case	_	_
23	integrin	integrin	NN	_	24	com	_	_
24	signaling	signaling	NN	_	21	ppmod	_	_
25	.	.	.	_	21	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	alone	alone	RB	_	1	adv	_	_
3	was	be	VBD	_	4	aux	_	_
4	found	find	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	have	have	VB	_	4	comp	_	_
7	no	no	DT	_	8	det	_	_
8	effect	effect	NN	_	6	obj	_	_
9	on	on	IN	_	10	case	_	_
10	CAS	ca	NNS	_	6	ppmod	_	_
11	,	,	,	_	4	p	_	_
12	but	but	CC	_	4	cc	_	_
13	can	can	MD	_	15	modal	_	_
14	completely	completely	RB	_	15	adv	_	_
15	block	block	VB	_	4	conj	_	_
16	drug2	drug0	NN	_	18	attr	_	_
17	-induced	-induced	JJ	_	18	attr	_	_
18	phosphorylation	phosphorylation	NN	_	15	obj	_	_
19	of	of	IN	_	21	case	_	_
20	this	this	DT	_	21	det	_	_
21	protein	protein	NN	_	18	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	MDA-MB-435	mda-mb-0	NN	_	24	com	_	_
24	cells	cell	NNS	_	18	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	observations	observation	NNS	_	4	dep	_	_
3	strongly	strongly	RB	_	4	adv	_	_
4	suggest	suggest	VBP	_	0	root	_	_
5	that	that	IN	_	12	mark	_	_
6	the	the	DT	_	8	det	_	_
7	homodimeric	homodimeric	JJ	_	8	attr	_	_
8	structure	structure	NN	_	12	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	functionally	functionally	RB	_	12	adv	_	_
12	distinguishes	distinguish	VBZ	_	4	comp	_	_
13	it	it	PRP	_	12	obj	_	_
14	from	from	IN	_	17	case	_	_
15	other	other	JJ	_	17	attr	_	_
16	monomeric	monomeric	JJ	_	17	attr	_	_
17	members	member	NNS	_	12	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	disintegrin	disintegrin	NN	_	21	com	_	_
21	family	family	NN	_	17	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	Toxicity	toxicity	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	cadmium	cadmium	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug1	drug0	NN	_	3	conj	_	_
6	to	to	TO	_	7	aux	_	_
7	miracidia	miracidia	NN	_	1	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	Schistosoma	schistosoma	NN	_	10	com	_	_
10	mansoni	mansoni	NNS	_	7	ppmod	_	_
11	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	specific	specific	JJ	_	3	attr	_	_
3	objectives	objective	NNS	_	7	dep	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	study	study	NN	_	3	ppmod	_	_
7	were	be	VBD	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	elucidate	elucidate	VB	_	7	comp	_	_
10	metal	metal	JJ	_	11	attr	_	_
11	toxicity	toxicity	NN	_	9	obj	_	_
12	to	to	TO	_	22	aux	_	_
13	hatching	hatching	NN	_	22	dat	_	_
14	,	,	,	_	13	p	_	_
15	survival	survival	NN	_	13	conj	_	_
16	and	and	CC	_	15	cc	_	_
17	avoidance	avoidance	NN	_	18	com	_	_
18	behaviour	behaviour	NN	_	13	conj	_	_
19	of	of	IN	_	21	case	_	_
20	Schistosoma	schistosoma	NN	_	21	com	_	_
21	mansoni	mansoni	NNS	_	13	ppmod	_	_
22	miracidia	miracidia	NN	_	11	ppmod	_	_
23	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	toxicity	toxicity	NN	_	20	dep	_	_
3	of	of	IN	_	4	case	_	_
4	cadmium	cadmium	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug1	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	cadmium/zinc	cadmium/zinc	NN	_	10	com	_	_
10	mixtures	mixture	NNS	_	4	conj	_	_
11	at	at	IN	_	12	case	_	_
12	concentrations	concentration	NNS	_	2	ppmod	_	_
13	ranging	range	VBG	_	12	acl	_	_
14	from	from	IN	_	18	case	_	_
15	10000	0	CD	_	18	num	_	_
16	to	to	TO	_	15	cc	_	_
17	10	0	CD	_	15	conj	_	_
18	microg/l	microg/l	NN	_	13	ppmod	_	_
19	was	be	VBD	_	20	aux	_	_
20	investigated	investigate	VBN	_	0	root	_	_
21	.	.	.	_	20	p	_	_

1	Metal	metal	JJ	_	4	attr	_	_
2	mixture	mixture	NN	_	4	com	_	_
3	toxicity	toxicity	NN	_	4	com	_	_
4	investigation	investigation	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	undertaken	undertake	VBN	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	equal	equal	JJ	_	9	attr	_	_
9	concentrations	concentration	NNS	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	metals	metal	NNS	_	9	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	hatching	hatching	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	miracidia	miracidia	NN	_	2	ppmod	_	_
5	from	from	IN	_	6	case	_	_
6	eggs	egg	NNS	_	2	ppmod	_	_
7	was	be	VBD	_	8	aux	_	_
8	inhibited	inhibit	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	concentrations	concentration	NNS	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	1000-10000	0	CD	_	13	num	_	_
13	microg/l	microg/l	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	single	single	JJ	_	16	attr	_	_
16	metals	metal	NNS	_	13	ppmod	_	_
17	.	.	.	_	8	p	_	_

1	Metal	metal	JJ	_	2	attr	_	_
2	mixtures	mixture	NNS	_	3	dep	_	_
3	had	have	VBD	_	0	root	_	_
4	no	no	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	on	on	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	hatching	hatching	NN	_	3	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	Survival	survival	NN	_	5	dep	_	_
2	of	of	IN	_	3	case	_	_
3	miracidia	miracidia	NN	_	1	ppmod	_	_
4	was	be	VBD	_	5	aux	_	_
5	reduced	reduce	VBN	_	0	root	_	_
6	by	by	IN	_	7	case	_	_
7	increasing	increase	VBG	_	5	ppmod	_	_
8	metal	metal	JJ	_	9	attr	_	_
9	concentration	concentration	NN	_	7	obj	_	_
10	except	except	IN	_	12	case	_	_
11	at	at	IN	_	12	case	_	_
12	concentrations	concentration	NNS	_	7	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	10	0	CD	_	15	num	_	_
15	microg/l	microg/l	NN	_	12	ppmod	_	_
16	for	for	IN	_	19	case	_	_
17	single	single	JJ	_	19	attr	_	_
18	metal	metal	JJ	_	19	attr	_	_
19	toxicity	toxicity	NN	_	15	ppmod	_	_
20	where	where	WRB	_	23	adv	_	_
21	survival	survival	NN	_	23	dep	_	_
22	was	be	VBD	_	23	aux	_	_
23	increased	increase	VBN	_	19	relcl	_	_
24	above	above	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	control	control	NN	_	23	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	Miracidia	miracidia	NN	_	2	dep	_	_
2	demonstrated	demonstrate	VBD	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	rapid	rapid	JJ	_	6	attr	_	_
5	avoidance	avoidance	NN	_	6	com	_	_
6	behaviour	behaviour	NN	_	2	obj	_	_
7	when	when	WRB	_	9	adv	_	_
8	briefly	briefly	RB	_	9	adv	_	_
9	exposed	expose	VBN	_	6	relcl	_	_
10	to	to	TO	_	12	aux	_	_
11	heavy	heavy	JJ	_	12	attr	_	_
12	metals	metal	NNS	_	9	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanisms	mechanism	NNS	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	metal	metal	JJ	_	5	attr	_	_
5	toxicity	toxicity	NN	_	2	ppmod	_	_
6	to	to	TO	_	7	aux	_	_
7	miracidia	miracidia	NN	_	5	ppmod	_	_
8	are	be	VBP	_	10	aux	_	_
9	briefly	briefly	RB	_	10	adv	_	_
10	discussed	discuss	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	Drug-lab	drug-lab	NN	_	2	com	_	_
2	interactions	interaction	NNS	_	0	root	_	_
3	:	:	:	_	2	p	_	_
4	implications	implication	NNS	_	2	appo	_	_
5	for	for	IN	_	7	case	_	_
6	nutrition	nutrition	NN	_	7	com	_	_
7	support	support	NN	_	4	ppmod	_	_
8	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	interference	interference	NN	_	0	root	_	_
3	with	with	IN	_	6	case	_	_
4	urine	urine	NN	_	6	com	_	_
5	ketone	ketone	NN	_	6	com	_	_
6	test	test	NN	_	2	ppmod	_	_
7	.	.	.	_	2	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	important	important	JJ	_	2	dep	_	_
4	that	that	IN	_	8	mark	_	_
5	health	health	NN	_	7	com	_	_
6	care	care	NN	_	7	com	_	_
7	professionals	professional	NNS	_	8	dep	_	_
8	be	be	VB	_	2	comp	_	_
9	aware	aware	NN	_	8	obj	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	potential	potential	NN	_	9	ppmod	_	_
13	for	for	IN	_	14	case	_	_
14	medications	medication	NNS	_	12	ppmod	_	_
15	to	to	TO	_	16	aux	_	_
16	interfere	interfere	VB	_	12	acl	_	_
17	with	with	IN	_	20	case	_	_
18	clinical	clinical	JJ	_	20	attr	_	_
19	laboratory	laboratory	NN	_	20	com	_	_
20	tests	test	NNS	_	16	ppmod	_	_
21	.	.	.	_	2	p	_	_

1	Medications	medication	NNS	_	3	dep	_	_
2	can	can	MD	_	3	modal	_	_
3	cause	cause	VB	_	0	root	_	_
4	in	in	FW	_	5	adv	_	_
5	vivo	vivo	FW	_	6	attr	_	_
6	effects	effect	NNS	_	3	obj	_	_
7	when	when	WRB	_	16	adv	_	_
8	the	the	DT	_	9	det	_	_
9	concentration	concentration	NN	_	16	dep	_	_
10	or	or	CC	_	9	cc	_	_
11	activity	activity	NN	_	9	conj	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	analyte	analyte	NN	_	9	ppmod	_	_
15	is	be	VBZ	_	16	aux	_	_
16	altered	alter	VBN	_	3	comp	_	_
17	before	before	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	analysis	analysis	NN	_	16	ppmod	_	_
20	and	and	CC	_	16	cc	_	_
21	therefore	therefore	RB	_	25	adv	_	_
22	the	the	DT	_	24	det	_	_
23	assay	assay	NN	_	24	com	_	_
24	result	result	NN	_	25	dep	_	_
25	is	be	VBZ	_	16	conj	_	_
26	true	true	JJ	_	25	dep	_	_
27	and	and	CC	_	26	cc	_	_
28	accurate	accurate	JJ	_	26	conj	_	_
29	.	.	.	_	3	p	_	_

1	An	an	DT	_	4	det	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	4	attr	_	_
4	effect	effect	NN	_	5	dep	_	_
5	occurs	occur	VBZ	_	0	root	_	_
6	when	when	WRB	_	9	adv	_	_
7	the	the	DT	_	8	det	_	_
8	medication	medication	NN	_	9	dep	_	_
9	interferes	interfere	VBZ	_	5	comp	_	_
10	with	with	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	assay	assay	NN	_	9	ppmod	_	_
13	,	,	,	_	9	p	_	_
14	and	and	CC	_	9	cc	_	_
15	the	the	DT	_	16	det	_	_
16	result	result	NN	_	17	dep	_	_
17	is	be	VBZ	_	9	conj	_	_
18	erroneous	erroneous	NN	_	17	obj	_	_
19	and	and	CC	_	17	cc	_	_
20	cannot	cannot	MD	_	22	modal	_	_
21	be	be	VB	_	22	aux	_	_
22	interpreted	interpret	VBN	_	17	conj	_	_
23	.	.	.	_	5	p	_	_

1	This	this	DT	_	2	det	_	_
2	report	report	NN	_	3	dep	_	_
3	describes	describe	VBZ	_	0	root	_	_
4	a	a	DT	_	7	det	_	_
5	recently	recently	RB	_	6	adv	_	_
6	identified	identify	VBN	_	7	attr	_	_
7	case	case	NN	_	3	obj	_	_
8	of	of	IN	_	9	case	_	_
9	interference	interference	NN	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	with	with	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	urine	urine	NN	_	15	com	_	_
15	test	test	NN	_	9	ppmod	_	_
16	for	for	IN	_	17	case	_	_
17	ketones	ketone	NNS	_	7	ppmod	_	_
18	and	and	CC	_	3	cc	_	_
19	demonstrates	demonstrate	VBZ	_	3	conj	_	_
20	the	the	DT	_	21	det	_	_
21	importance	importance	NN	_	19	obj	_	_
22	of	of	IN	_	26	case	_	_
23	a	a	DT	_	26	det	_	_
24	thorough	thorough	JJ	_	26	attr	_	_
25	medication	medication	NN	_	26	com	_	_
26	review	review	NN	_	21	ppmod	_	_
27	in	in	IN	_	28	case	_	_
28	evaluating	evaluate	VBG	_	21	ppmod	_	_
29	abnormal	abnormal	JJ	_	31	attr	_	_
30	laboratory	laboratory	NN	_	31	com	_	_
31	tests	test	NNS	_	28	obj	_	_
32	.	.	.	_	3	p	_	_

1	-LSB-Pharmacologic	-lsb-pharmacologic	JJ	_	2	attr	_	_
2	interactions	interaction	NNS	_	0	root	_	_
3	in	in	IN	_	5	case	_	_
4	chronic	chronic	JJ	_	5	attr	_	_
5	treatments	treatment	NNS	_	2	ppmod	_	_
6	:	:	:	_	2	p	_	_
7	corrective	corrective	JJ	_	8	attr	_	_
8	measures	measure	NNS	_	2	appo	_	_
9	for	for	IN	_	11	case	_	_
10	its	its	PRP$	_	11	poss	_	_
11	prevention	prevention	NN	_	8	ppmod	_	_
12	in	in	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	basic	basic	JJ	_	15	attr	_	_
15	area	area	NN	_	11	ppmod	_	_
16	of	of	IN	_	20	case	_	_
17	rural	rural	JJ	_	20	attr	_	_
18	health	health	NN	_	20	attr	_	_
19	]	-rsb-	-RRB-	_	20	p	_	_
20	OBJECTIVES	objective	NNS	_	15	ppmod	_	_
21	:	:	:	_	2	p	_	_
22	To	to	TO	_	23	aux	_	_
23	identify	identify	VB	_	2	acl	_	_
24	the	the	DT	_	26	det	_	_
25	pharmacological	pharmacological	JJ	_	26	attr	_	_
26	interactions	interaction	NNS	_	23	obj	_	_
27	of	of	IN	_	29	case	_	_
28	clinical	clinical	JJ	_	29	attr	_	_
29	relevance	relevance	NN	_	26	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	PICR	picr	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	in	in	IN	_	37	case	_	_
34	the	the	DT	_	37	det	_	_
35	medication	medication	NN	_	37	com	_	_
36	authorization	authorization	NN	_	37	com	_	_
37	cards	card	NNS	_	26	ppmod	_	_
38	(	-lrb-	-LRB-	_	39	p	_	_
39	MAC	mac	NN	_	37	prn	_	_
40	)	-rrb-	-RRB-	_	39	p	_	_
41	of	of	IN	_	42	case	_	_
42	the	the	DT	_	37	ppmod	_	_
43	chronically	chronically	RB	_	44	adv	_	_
44	ill	ill	JJ	_	42	attr	_	_
45	and	and	CC	_	23	cc	_	_
46	to	to	TO	_	47	aux	_	_
47	establish	establish	VB	_	23	conj	_	_
48	strategies	strategy	NNS	_	47	obj	_	_
49	to	to	TO	_	50	aux	_	_
50	minimise	minimise	VB	_	47	comp	_	_
51	their	their	PRP$	_	52	poss	_	_
52	appearance	appearance	NN	_	50	obj	_	_
53	.	.	.	_	2	p	_	_

1	DESIGN	design	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Cross-sectional	cross-sectional	JJ	_	5	attr	_	_
4	descriptive	descriptive	JJ	_	5	attr	_	_
5	study	study	NN	_	1	appo	_	_
6	.	.	.	_	1	p	_	_

1	SETTING	setting	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Rural	rural	JJ	_	6	attr	_	_
4	primary	primary	JJ	_	6	attr	_	_
5	care	care	NN	_	6	com	_	_
6	centre	centre	NN	_	1	appo	_	_
7	.	.	.	_	1	p	_	_

1	PATIENTS	patient	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Random	random	JJ	_	4	attr	_	_
4	sample	sample	NN	_	1	appo	_	_
5	of	of	IN	_	7	case	_	_
6	626	0	CD	_	7	num	_	_
7	MAC	mac	NN	_	4	ppmod	_	_
8	out	out	IN	_	11	case	_	_
9	of	of	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	total	total	NN	_	4	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	1306	0	NN	_	11	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	MEASUREMENTS	measurement	NNS	_	0	root	_	_
2	AND	and	CC	_	1	cc	_	_
3	MAIN	main	JJ	_	4	attr	_	_
4	RESULTS	result	NNS	_	1	conj	_	_
5	:	:	:	_	1	p	_	_
6	In	in	IN	_	7	case	_	_
7	December	december	NNP	_	13	ppmod	_	_
8	1998	0	CD	_	7	num	_	_
9	,	,	,	_	13	p	_	_
10	the	the	DT	_	11	det	_	_
11	following	following	NN	_	13	dep	_	_
12	was	be	VBD	_	13	aux	_	_
13	gathered	gather	VBN	_	47	advcl	_	_
14	for	for	IN	_	16	case	_	_
15	every	every	DT	_	16	det	_	_
16	MAC	mac	NN	_	13	ppmod	_	_
17	with	with	IN	_	22	case	_	_
18	more	more	JJR	_	20	attr	_	_
19	than	than	IN	_	18	com	_	_
20	one	#crd#	CD	_	22	num	_	_
21	drug	drug	NN	_	22	com	_	_
22	treatment	treatment	NN	_	16	ppmod	_	_
23	:	:	:	_	47	p	_	_
24	age	age	NN	_	47	dep	_	_
25	,	,	,	_	24	p	_	_
26	sex	sex	NN	_	24	appo	_	_
27	,	,	,	_	24	p	_	_
28	number	number	NN	_	24	appo	_	_
29	of	of	IN	_	30	case	_	_
30	drugs	drug	NNS	_	28	ppmod	_	_
31	,	,	,	_	30	p	_	_
32	intrinsic	intrinsic	JJ	_	33	attr	_	_
33	value	value	NN	_	30	conj	_	_
34	,	,	,	_	33	p	_	_
35	drugs	drug	NNS	_	30	conj	_	_
36	prescribed	prescribe	VBN	_	35	acl	_	_
37	,	,	,	_	35	p	_	_
38	daily	daily	JJ	_	39	attr	_	_
39	dose	dose	NN	_	30	conj	_	_
40	and	and	CC	_	39	cc	_	_
41	pharmacological	pharmacological	JJ	_	42	attr	_	_
42	interactions	interaction	NNS	_	30	conj	_	_
43	(	-lrb-	-LRB-	_	44	p	_	_
44	PI	pi	NN	_	42	prn	_	_
45	)	-rrb-	-RRB-	_	44	p	_	_
46	,	,	,	_	24	p	_	_
47	classified	classify	VBN	_	1	acl	_	_
48	(	-lrb-	-LRB-	_	49	p	_	_
49	using	use	VBG	_	47	prn	_	_
50	the	the	DT	_	51	det	_	_
51	scale	scale	NN	_	49	obj	_	_
52	of	of	IN	_	53	case	_	_
53	Hansten	hansten	NNP	_	51	ppmod	_	_
54	1996	0	CD	_	53	num	_	_
55	)	-rrb-	-RRB-	_	49	p	_	_
56	into	into	IN	_	57	case	_	_
57	light	light	JJ	_	47	ppmod	_	_
58	and	and	CC	_	57	cc	_	_
59	clinically	clinically	RB	_	60	adv	_	_
60	relevant	relevant	JJ	_	57	conj	_	_
61	.	.	.	_	1	p	_	_

1	Statistical	statistical	JJ	_	2	attr	_	_
2	analysis	analysis	NN	_	4	dep	_	_
3	:	:	:	_	4	p	_	_
4	Mantel-Haenszel	mantel-haenszel	NN	_	0	root	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	alpha	alpha	NN	_	4	prn	_	_
7	=	=	JJ	_	6	attr	_	_
8	0.05	0	CD	_	6	num	_	_
9	)	-rrb-	-RRB-	_	6	p	_	_
10	.	.	.	_	4	p	_	_

1	Patients	patient	NNS	_	4	poss	_	_
2	'	'	POS	_	1	case	_	_
3	mean	mean	NN	_	4	com	_	_
4	age	age	NN	_	5	dep	_	_
5	was	be	VBD	_	0	root	_	_
6	69.1	0	CD	_	5	obj	_	_
7	(	-lrb-	-LRB-	_	10	p	_	_
8	95	0	CD	_	10	num	_	_
9	%	%	NN	_	8	meta	_	_
10	CI	ci	NN	_	6	prn	_	_
11	,	,	,	_	10	p	_	_
12	+/-	+/-	CC	_	10	cc	_	_
13	1.2	0	CD	_	10	conj	_	_
14	)	-rrb-	-RRB-	_	10	p	_	_
15	.	.	.	_	5	p	_	_

1	Mean	mean	NN	_	2	com	_	_
2	number	number	NN	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drugs	drug	NNS	_	2	ppmod	_	_
5	per	per	IN	_	6	case	_	_
6	MAC	mac	NN	_	2	ppmod	_	_
7	was	be	VBD	_	0	root	_	_
8	4	0	CD	_	7	obj	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	95	0	CD	_	12	num	_	_
11	%	%	NN	_	12	meta	_	_
12	CI	ci	CD	_	8	num	_	_
13	,	,	,	_	12	p	_	_
14	+/-	+/-	CC	_	12	cc	_	_
15	0.2	0	CD	_	12	conj	_	_
16	)	-rrb-	-RRB-	_	12	p	_	_
17	.	.	.	_	7	p	_	_

1	341	0	NN	_	5	num	_	_
2	PI	pi	NN	_	5	attr	_	_
3	affecting	affect	VBG	_	5	attr	_	_
4	197	0	CD	_	5	num	_	_
5	patients	patient	NNS	_	18	dep	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	31.5	0	CD	_	5	num	_	_
8	%	%	NN	_	7	meta	_	_
9	,	,	,	_	7	p	_	_
10	95	0	CD	_	12	num	_	_
11	%	%	NN	_	10	meta	_	_
12	CI	ci	NN	_	7	conj	_	_
13	,	,	,	_	12	p	_	_
14	+/-	+/-	CC	_	12	cc	_	_
15	3.6	0	CD	_	7	conj	_	_
16	)	-rrb-	-RRB-	_	7	p	_	_
17	were	be	VBD	_	18	aux	_	_
18	identified	identify	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	24.9	0	CD	_	14	num	_	_
2	%	%	NN	_	1	meta	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	95	0	CD	_	6	num	_	_
5	%	%	NN	_	6	meta	_	_
6	CI	ci	CD	_	1	num	_	_
7	,	,	,	_	6	p	_	_
8	+/-	+/-	CC	_	6	cc	_	_
9	4.5	0	CD	_	6	conj	_	_
10	)	-rrb-	-RRB-	_	6	p	_	_
11	were	be	VBD	_	14	aux	_	_
12	PICR	picr	NN	_	14	obj	_	_
13	,	,	,	_	14	p	_	_
14	detected	detect	VBN	_	0	root	_	_
15	in	in	IN	_	16	case	_	_
16	11.7	0	CD	_	14	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	95	0	CD	_	21	num	_	_
20	%	%	NN	_	21	meta	_	_
21	CI	ci	CD	_	16	num	_	_
22	,	,	,	_	21	p	_	_
23	+/-	+/-	CC	_	21	cc	_	_
24	2.5	0	CD	_	21	conj	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	of	of	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	MAC	mac	NN	_	16	ppmod	_	_
29	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	existence	existence	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	PI	pi	NN	_	2	ppmod	_	_
5	was	be	VBD	_	0	root	_	_
6	related	related	JJ	_	5	dep	_	_
7	to	to	TO	_	9	aux	_	_
8	the	the	DT	_	9	det	_	_
9	number	number	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drugs	drug	NNS	_	9	ppmod	_	_
12	prescribed	prescribe	VBN	_	11	acl	_	_
13	to	to	TO	_	15	aux	_	_
14	each	each	DT	_	15	det	_	_
15	patient	patient	NN	_	6	ppmod	_	_
16	(	-lrb-	-LRB-	_	20	p	_	_
17	p	p	NN	_	20	attr	_	_
18	&lt	&lt	CD	_	20	num	_	_
19	;	;	:	_	20	p	_	_
20	0.01	0	CD	_	6	num	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	.	.	.	_	5	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	26	0	CD	_	4	num	_	_
4	PI	pi	NN	_	2	obj	_	_
5	with	with	IN	_	6	case	_	_
6	drugs	drug	NNS	_	2	ppmod	_	_
7	of	of	IN	_	10	case	_	_
8	low	low	JJ	_	10	attr	_	_
9	intrinsic	intrinsic	JJ	_	10	attr	_	_
10	value	value	NN	_	6	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	7.6	0	CD	_	2	num	_	_
13	%	%	NN	_	12	meta	_	_
14	;	;	:	_	12	p	_	_
15	95	0	CD	_	17	num	_	_
16	%	%	NN	_	17	meta	_	_
17	CI	ci	CD	_	12	conj	_	_
18	,	,	,	_	17	p	_	_
19	+/-	+/-	CC	_	17	cc	_	_
20	2.8	0	CD	_	12	conj	_	_
21	)	-rrb-	-RRB-	_	12	p	_	_
22	.	.	.	_	2	p	_	_

1	74.1	0	CD	_	17	num	_	_
2	%	%	NN	_	1	meta	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	95	0	CD	_	6	num	_	_
5	%	%	NN	_	4	meta	_	_
6	CI	ci	NN	_	1	prn	_	_
7	,	,	,	_	6	p	_	_
8	+/-	+/-	CC	_	6	cc	_	_
9	9.3	0	CD	_	6	conj	_	_
10	)	-rrb-	-RRB-	_	6	p	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	total	total	JJ	_	14	attr	_	_
14	PICR	picr	NN	_	1	ppmod	_	_
15	could	could	MD	_	17	modal	_	_
16	be	be	VB	_	17	aux	_	_
17	avoided	avoid	VBN	_	0	root	_	_
18	by	by	IN	_	20	case	_	_
19	simple	simple	JJ	_	20	attr	_	_
20	recommendations	recommendation	NNS	_	17	ppmod	_	_
21	;	;	:	_	17	p	_	_

1	and	and	CC	_	4	cc	_	_
2	the	the	DT	_	4	det	_	_
3	remaining	remain	VBG	_	4	attr	_	_
4	25.9	0	CD	_	0	root	_	_
5	%	%	NN	_	4	meta	_	_
6	(	-lrb-	-LRB-	_	9	p	_	_
7	95	0	CD	_	9	num	_	_
8	%	%	NN	_	7	meta	_	_
9	CI	ci	NN	_	4	prn	_	_
10	,	,	,	_	9	p	_	_
11	+/-	+/-	CC	_	9	cc	_	_
12	9.3	0	CD	_	9	conj	_	_
13	)	-rrb-	-RRB-	_	9	p	_	_
14	by	by	IN	_	15	case	_	_
15	monitoring	monitoring	NN	_	4	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	follow-up	follow-up	NN	_	15	conj	_	_
18	of	of	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	.	.	.	_	4	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	It	it	PRP	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	important	important	JJ	_	4	dep	_	_
6	to	to	TO	_	7	aux	_	_
7	identify	identify	VB	_	4	comp	_	_
8	the	the	DT	_	9	det	_	_
9	medications	medication	NNS	_	7	obj	_	_
10	most	most	RBS	_	11	com	_	_
11	commonly	commonly	RB	_	12	adv	_	_
12	involved	involve	VBN	_	9	acl	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	PICR	picr	NN	_	12	ppmod	_	_
16	so	so	RB	_	17	com	_	_
17	as	as	RB	_	19	adv	_	_
18	to	to	TO	_	19	aux	_	_
19	establish	establish	VB	_	15	advcl	_	_
20	corrective	corrective	JJ	_	21	attr	_	_
21	measures	measure	NNS	_	19	obj	_	_
22	to	to	TO	_	23	aux	_	_
23	minimise	minimise	VB	_	19	comp	_	_
24	the	the	DT	_	25	det	_	_
25	risks	risk	NNS	_	23	obj	_	_
26	arising	arise	VBG	_	25	acl	_	_
27	from	from	IN	_	29	case	_	_
28	multiple	multiple	JJ	_	29	attr	_	_
29	medication	medication	NN	_	26	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	Four	#crd#	CD	_	3	num	_	_
2	educational	educational	JJ	_	3	attr	_	_
3	messages	message	NNS	_	4	dep	_	_
4	advise	advise	VBP	_	0	root	_	_
5	on	on	IN	_	7	case	_	_
6	over	over	IN	_	7	case	_	_
7	60	0	CD	_	4	ppmod	_	_
8	%	%	NN	_	7	meta	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	PICR	picr	NNS	_	7	ppmod	_	_
12	detected	detect	VBN	_	11	acl	_	_
13	.	.	.	_	4	p	_	_

1	Neurochemical	neurochemical	NN	_	5	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	functional	functional	JJ	_	4	attr	_	_
4	consequences	consequence	NNS	_	1	conj	_	_
5	following	follow	VBG	_	0	root	_	_
6	drug1	drug0	NN	_	5	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug2	drug0	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	and	and	CC	_	6	cc	_	_
11	drug3	drug0	NN	_	6	conj	_	_
12	.	.	.	_	5	p	_	_

1	The	the	DT	_	5	det	_	_
2	neurochemical	neurochemical	JJ	_	5	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	functional	functional	JJ	_	2	conj	_	_
5	consequences	consequence	NNS	_	13	dep	_	_
6	following	follow	VBG	_	5	acl	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	administration	administration	NN	_	6	obj	_	_
9	to	to	TO	_	11	aux	_	_
10	the	the	DT	_	11	det	_	_
11	rat	rat	NN	_	8	ppmod	_	_
12	were	be	VBD	_	13	aux	_	_
13	evaluated	evaluate	VBN	_	0	root	_	_
14	and	and	CC	_	13	cc	_	_
15	compared	compare	VBN	_	13	conj	_	_
16	to	to	TO	_	18	aux	_	_
17	similar	similar	JJ	_	18	attr	_	_
18	effects	effect	NNS	_	15	ppmod	_	_
19	following	follow	VBG	_	21	adv	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	administration	administration	NN	_	15	ppmod	_	_
22	.	.	.	_	13	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	observed	observe	VBN	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	induced	induce	VBD	_	3	comp	_	_
7	long	long	JJ	_	9	attr	_	_
8	lasting	lasting	NN	_	9	com	_	_
9	depletions	depletion	NNS	_	6	obj	_	_
10	of	of	IN	_	13	case	_	_
11	striatal	striatal	JJ	_	12	attr	_	_
12	dopamine	dopamine	NN	_	13	com	_	_
13	concentrations	concentration	NNS	_	9	ppmod	_	_
14	and	and	CC	_	6	cc	_	_
15	this	this	DT	_	17	det	_	_
16	neurotoxic	neurotoxic	JJ	_	17	attr	_	_
17	effect	effect	NN	_	20	dep	_	_
18	could	could	MD	_	20	modal	_	_
19	be	be	VB	_	20	aux	_	_
20	prevented	prevent	VBN	_	6	conj	_	_
21	by	by	IN	_	23	case	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	pretreatment	pretreatment	NN	_	20	ppmod	_	_
24	.	.	.	_	3	p	_	_

1	The	the	DT	_	5	det	_	_
2	drug1	drug0	NN	_	5	attr	_	_
3	-induced	-induced	JJ	_	5	attr	_	_
4	neuronal	neuronal	JJ	_	5	attr	_	_
5	damage	damage	NN	_	6	dep	_	_
6	produced	produce	VBD	_	0	root	_	_
7	a	a	DT	_	8	det	_	_
8	tolerance	tolerance	NN	_	6	obj	_	_
9	to	to	TO	_	12	aux	_	_
10	the	the	DT	_	12	det	_	_
11	disruptive	disruptive	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	a	a	DT	_	17	det	_	_
17	supersensitivity	supersensitivity	NN	_	14	conj	_	_
18	to	to	TO	_	21	aux	_	_
19	the	the	DT	_	21	det	_	_
20	disruptive	disruptive	JJ	_	21	attr	_	_
21	effects	effect	NNS	_	17	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug3	drug0	NN	_	21	ppmod	_	_
24	in	in	IN	_	25	case	_	_
25	rats	rat	NNS	_	21	ppmod	_	_
26	responding	respond	VBG	_	25	acl	_	_
27	in	in	IN	_	31	case	_	_
28	a	a	DT	_	31	det	_	_
29	schedule	schedule	JJ	_	31	attr	_	_
30	controlled	controlled	JJ	_	31	attr	_	_
31	paradigm	paradigm	NN	_	26	ppmod	_	_
32	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	,	,	,	_	1	p	_	_
3	like	like	IN	_	4	case	_	_
4	drug2	drug0	NN	_	1	ppmod	_	_
5	,	,	,	_	1	p	_	_
6	produced	produce	VBD	_	0	root	_	_
7	depletions	depletion	NNS	_	6	obj	_	_
8	of	of	IN	_	10	case	_	_
9	striatal	striatal	JJ	_	10	attr	_	_
10	dopamine	dopamine	NN	_	7	ppmod	_	_
11	but	but	CC	_	6	cc	_	_
12	these	these	DT	_	13	det	_	_
13	actions	action	NNS	_	15	dep	_	_
14	were	be	VBD	_	15	aux	_	_
15	potentiated	potentiate	VBN	_	6	conj	_	_
16	by	by	IN	_	18	case	_	_
17	drug3	drug0	NN	_	18	com	_	_
18	pretreatment	pretreatment	NN	_	15	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	These	these	DT	_	2	det	_	_
2	observations	observation	NNS	_	4	dep	_	_
3	are	be	VBP	_	4	aux	_	_
4	discussed	discuss	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	reference	reference	NN	_	4	ppmod	_	_
7	to	to	TO	_	10	aux	_	_
8	possible	possible	JJ	_	10	attr	_	_
9	deleterious	deleterious	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	6	ppmod	_	_
11	following	follow	VBG	_	13	adv	_	_
12	the	the	DT	_	13	det	_	_
13	administration	administration	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	patients	patient	NNS	_	13	ppmod	_	_
18	with	with	IN	_	21	case	_	_
19	Parkinson	parkinson	NN	_	21	poss	_	_
20	's	's	POS	_	19	case	_	_
21	Disease	disease	NN	_	17	ppmod	_	_
22	.	.	.	_	4	p	_	_

1	Responses	response	NNS	_	0	root	_	_
2	to	to	TO	_	3	aux	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	perfused	perfused	JJ	_	7	attr	_	_
7	pancreas	pancreas	NN	_	3	ppmod	_	_
8	of	of	IN	_	13	case	_	_
9	the	the	DT	_	13	det	_	_
10	genetically	genetically	RB	_	11	adv	_	_
11	diabetic	diabetic	JJ	_	13	attr	_	_
12	Chinese	chinese	NN	_	13	com	_	_
13	hamster	hamster	NN	_	7	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	Nonketotic	nonketotic	JJ	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	genetically	genetically	RB	_	4	adv	_	_
4	diabetic	diabetic	JJ	_	6	attr	_	_
5	Cinese	cinese	NN	_	6	com	_	_
6	hamsters	hamster	NNS	_	7	dep	_	_
7	show	show	VBP	_	0	root	_	_
8	subnormal	subnormal	JJ	_	11	attr	_	_
9	pancreatic	pancreatic	JJ	_	11	attr	_	_
10	insulin	insulin	NN	_	11	com	_	_
11	release	release	NN	_	7	obj	_	_
12	and	and	CC	_	11	cc	_	_
13	impaired	impaired	JJ	_	14	attr	_	_
14	suppression	suppression	NN	_	11	conj	_	_
15	of	of	IN	_	16	case	_	_
16	glucagon	glucagon	NN	_	14	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	response	response	NN	_	7	ppmod	_	_
19	to	to	TO	_	20	aux	_	_
20	glucose	glucose	NN	_	18	ppmod	_	_
21	.	.	.	_	7	p	_	_

1	To	to	TO	_	2	aux	_	_
2	study	study	VB	_	16	advcl	_	_
3	the	the	DT	_	5	det	_	_
4	pancreatic	pancreatic	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	2	obj	_	_
6	of	of	IN	_	8	case	_	_
7	other	other	JJ	_	8	attr	_	_
8	agents	agent	NNS	_	5	ppmod	_	_
9	,	,	,	_	16	p	_	_
10	dynamic	dynamic	JJ	_	11	attr	_	_
11	insulin	insulin	NN	_	16	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	glucagon	glucagon	NN	_	14	com	_	_
14	release	release	NN	_	11	conj	_	_
15	was	be	VBD	_	16	aux	_	_
16	measured	measure	VBN	_	0	root	_	_
17	from	from	IN	_	22	case	_	_
18	the	the	DT	_	22	det	_	_
19	in	in	FW	_	20	adv	_	_
20	vitro	vitro	FW	_	21	adv	_	_
21	perfused	perfuse	VBN	_	22	attr	_	_
22	pancreases	pancreas	NNS	_	16	ppmod	_	_
23	of	of	IN	_	28	case	_	_
24	normal	normal	JJ	_	28	attr	_	_
25	and	and	CC	_	24	cc	_	_
26	diabetic	diabetic	JJ	_	24	conj	_	_
27	Chinese	chinese	JJ	_	28	attr	_	_
28	hamsters	hamster	NNS	_	22	ppmod	_	_
29	in	in	IN	_	33	case	_	_
30	response	response	NN	_	33	advnp	_	_
31	to	to	TO	_	33	aux	_	_
32	various	various	JJ	_	33	attr	_	_
33	combinations	combination	NNS	_	16	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	drug1	drug0	NN	_	33	ppmod	_	_
36	(	-lrb-	-LRB-	_	35	p	_	_
37	20mM	0mm	CD	_	35	num	_	_
38	)	-rrb-	-RRB-	_	35	p	_	_
39	,	,	,	_	35	p	_	_
40	drug2	drug0	NN	_	35	conj	_	_
41	(	-lrb-	-LRB-	_	45	p	_	_
42	100	0	CD	_	45	num	_	_
43	or	or	CC	_	42	cc	_	_
44	150	0	CD	_	42	conj	_	_
45	mg.	mg.	NN	_	40	prn	_	_
46	per	per	IN	_	48	case	_	_
47	100	0	CD	_	48	num	_	_
48	ml.	ml.	NN	_	45	ppmod	_	_
49	)	-rrb-	-RRB-	_	45	p	_	_
50	,	,	,	_	40	p	_	_
51	and	and	CC	_	40	cc	_	_
52	drug3	drug0	NN	_	35	conj	_	_
53	(	-lrb-	-LRB-	_	55	p	_	_
54	10	0	CD	_	55	num	_	_
55	mM	mm	NN	_	52	prn	_	_
56	)	-rrb-	-RRB-	_	55	p	_	_
57	.	.	.	_	16	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	alone	alone	RB	_	3	adv	_	_
3	caused	cause	VBD	_	0	root	_	_
4	identical	identical	JJ	_	8	attr	_	_
5	insulin	insulin	NN	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	glucagon	glucagon	NN	_	5	conj	_	_
8	release	release	NN	_	3	obj	_	_
9	in	in	IN	_	10	case	_	_
10	diabetics	diabetic	NNS	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	normals	normal	NNS	_	10	conj	_	_
13	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	alone	alone	RB	_	1	adv	_	_
4	and	and	CC	_	3	cc	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	presence	presence	NN	_	3	conj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	caused	cause	VBD	_	0	root	_	_
12	subnormal	subnormal	JJ	_	14	attr	_	_
13	insulin	insulin	NN	_	14	com	_	_
14	release	release	NN	_	11	obj	_	_
15	and	and	CC	_	14	cc	_	_
16	less	less	RBR	_	17	adv	_	_
17	suppression	suppression	NN	_	14	conj	_	_
18	of	of	IN	_	20	case	_	_
19	glucagon	glucagon	NN	_	20	com	_	_
20	release	release	NN	_	17	ppmod	_	_
21	in	in	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	diabectics	diabectics	NNS	_	11	ppmod	_	_
24	than	than	IN	_	27	case	_	_
25	in	in	IN	_	27	case	_	_
26	the	the	DT	_	27	det	_	_
27	normals	normal	NNS	_	11	ppmod	_	_
28	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	in	in	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	presence	presence	NN	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	1	p	_	_
11	caused	cause	VBD	_	0	root	_	_
12	excessive	excessive	JJ	_	14	attr	_	_
13	glucagon	glucagon	NN	_	14	com	_	_
14	release	release	NN	_	11	obj	_	_
15	but	but	CC	_	14	cc	_	_
16	nearly	nearly	RB	_	15	com	_	_
17	normal	normal	JJ	_	19	attr	_	_
18	insulin	insulin	NN	_	19	com	_	_
19	release	release	NN	_	14	conj	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	diabetics	diabetic	NNS	_	11	ppmod	_	_
23	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	in	in	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	absence	absence	NN	_	1	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	or	or	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	,	,	,	_	1	p	_	_
11	caused	cause	VBD	_	0	root	_	_
12	excessive	excessive	JJ	_	14	attr	_	_
13	glucagon	glucagon	NN	_	14	com	_	_
14	release	release	NN	_	11	obj	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	diabetics	diabetic	NNS	_	14	ppmod	_	_
18	and	and	CC	_	14	cc	_	_
19	undetectable	undetectable	JJ	_	21	attr	_	_
20	insulin	insulin	NN	_	21	com	_	_
21	release	release	NN	_	14	conj	_	_
22	in	in	IN	_	24	case	_	_
23	either	either	CC	_	24	cc	_	_
24	diabetics	diabetic	NNS	_	11	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	normals	normal	NNS	_	24	conj	_	_
27	.	.	.	_	11	p	_	_

1	Pancreatic	pancreatic	JJ	_	2	attr	_	_
2	content	content	NN	_	7	dep	_	_
3	after	after	IN	_	4	case	_	_
4	perfusion	perfusion	NN	_	2	ppmod	_	_
5	did	do	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	correlate	correlate	VB	_	0	root	_	_
8	with	with	IN	_	9	case	_	_
9	release	release	NN	_	7	ppmod	_	_
10	during	during	IN	_	11	case	_	_
11	perfusion	perfusion	NN	_	7	ppmod	_	_
12	.	.	.	_	7	p	_	_

1	Infusion	infusion	NN	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	alone	alone	RB	_	6	adv	_	_
5	markedly	markedly	RB	_	6	adv	_	_
6	decreased	decrease	VBD	_	0	root	_	_
7	the	the	DT	_	8	det	_	_
8	amount	amount	NN	_	6	obj	_	_
9	of	of	IN	_	12	case	_	_
10	extractable	extractable	JJ	_	12	attr	_	_
11	pancreatic	pancreatic	JJ	_	12	attr	_	_
12	insulin	insulin	NN	_	8	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	glucagon	glucagon	NN	_	12	conj	_	_
15	.	.	.	_	6	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	14	mark	_	_
5	the	the	DT	_	8	det	_	_
6	pancreatic	pancreatic	JJ	_	8	attr	_	_
7	alpha	alpha	NN	_	8	com	_	_
8	cell	cell	NN	_	14	dep	_	_
9	of	of	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	diabetic	diabetic	JJ	_	13	attr	_	_
12	Chinese	chinese	NN	_	13	com	_	_
13	hamster	hamster	NN	_	8	ppmod	_	_
14	responds	respond	VBZ	_	3	comp	_	_
15	excessively	excessively	RB	_	14	adv	_	_
16	to	to	TO	_	17	aux	_	_
17	drug1	drug0	NN	_	14	ppmod	_	_
18	,	,	,	_	14	p	_	_
19	as	as	IN	_	21	mark	_	_
20	is	be	VBZ	_	21	aux	_	_
21	seen	see	VBN	_	14	comp	_	_
22	in	in	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	human	human	JJ	_	25	attr	_	_
25	diabetic	diabetic	NN	_	21	ppmod	_	_
26	.	.	.	_	3	p	_	_

1	This	this	DT	_	2	det	_	_
2	defect	defect	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	not	not	RB	_	3	neg	_	_
5	related	related	JJ	_	3	dep	_	_
6	to	to	TO	_	9	aux	_	_
7	acute	acute	JJ	_	9	attr	_	_
8	insulin	insulin	NN	_	9	com	_	_
9	release	release	NN	_	5	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	the	the	DT	_	12	det	_	_
12	presence	presence	NN	_	9	conj	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Further	far	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	these	these	DT	_	4	det	_	_
4	results	result	NNS	_	5	dep	_	_
5	confirm	confirm	VBP	_	0	root	_	_
6	that	that	IN	_	16	mark	_	_
7	the	the	DT	_	15	det	_	_
8	diabetic	diabetic	JJ	_	15	attr	_	_
9	Chinese	chinese	JJ	_	15	attr	_	_
10	hamster	hamster	NN	_	12	attr	_	_
11	's	's	POS	_	12	case	_	_
12	alpha	alpha	NN	_	15	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	beta	beta	NN	_	12	conj	_	_
15	cells	cell	NNS	_	16	dep	_	_
16	respond	respond	VBP	_	5	comp	_	_
17	normally	normally	RB	_	16	adv	_	_
18	to	to	TO	_	19	aux	_	_
19	drug1	drug0	NN	_	16	ppmod	_	_
20	,	,	,	_	16	p	_	_
21	but	but	CC	_	16	cc	_	_
22	are	be	VBP	_	16	conj	_	_
23	relatively	relatively	RB	_	24	adv	_	_
24	insensitive	insensitive	JJ	_	22	dep	_	_
25	to	to	TO	_	26	aux	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	5	p	_	_

1	Interference	interference	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	biocytin	biocytin	NN	_	1	ppmod	_	_
4	with	with	IN	_	7	case	_	_
5	drug1	drug0	JJ	_	7	attr	_	_
6	-evoked	-evoked	JJ	_	7	attr	_	_
7	hyperpolarization	hyperpolarization	NN	_	1	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	membrane	membrane	NN	_	10	com	_	_
10	properties	property	NNS	_	7	conj	_	_
11	of	of	IN	_	16	case	_	_
12	rat	rat	NN	_	16	attr	_	_
13	spinal	spinal	JJ	_	16	attr	_	_
14	substantia	substantia	NN	_	16	com	_	_
15	gelatinosa	gelatinosa	NN	_	16	com	_	_
16	neurons	neuron	NNS	_	7	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	our	our	PRP$	_	3	poss	_	_
3	laboratory	laboratory	NN	_	23	ppmod	_	_
4	,	,	,	_	23	p	_	_
5	preliminary	preliminary	JJ	_	10	attr	_	_
6	whole-cell	whole-cell	JJ	_	8	adv	_	_
7	,	,	,	_	8	p	_	_
8	tight	tight	JJ	_	10	attr	_	_
9	seal	seal	NN	_	10	com	_	_
10	recordings	recording	NNS	_	23	dep	_	_
11	of	of	IN	_	16	case	_	_
12	rat	rat	NN	_	16	attr	_	_
13	spinal	spinal	JJ	_	16	attr	_	_
14	substantia	substantia	NN	_	16	com	_	_
15	gelatinosa	gelatinosa	NN	_	16	com	_	_
16	neurons	neuron	NNS	_	10	ppmod	_	_
17	including	include	VBG	_	18	adv	_	_
18	biocytin	biocytin	NN	_	16	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	patch	patch	JJ	_	22	attr	_	_
22	pipette	pipette	NN	_	18	ppmod	_	_
23	yielded	yield	VBD	_	0	root	_	_
24	a	a	DT	_	27	det	_	_
25	significantly	significantly	RB	_	26	adv	_	_
26	smaller	small	JJR	_	27	attr	_	_
27	proportion	proportion	NN	_	23	obj	_	_
28	of	of	IN	_	29	case	_	_
29	neurons	neuron	NNS	_	27	ppmod	_	_
30	hyperpolarized	hyperpolarized	VBN	_	29	acl	_	_
31	by	by	IN	_	32	case	_	_
32	drug1	drug0	NN	_	30	ppmod	_	_
33	compared	compare	VBN	_	35	adv	_	_
34	with	with	IN	_	35	case	_	_
35	recordings	recording	NNS	_	30	ppmod	_	_
36	without	without	IN	_	37	case	_	_
37	biocytin	biocytin	NN	_	35	ppmod	_	_
38	.	.	.	_	23	p	_	_

1	Therefore	therefore	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	we	we	PRP	_	4	dep	_	_
4	investigated	investigate	VBD	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	biocytin	biocytin	NN	_	9	com	_	_
9	inclusion	inclusion	NN	_	6	ppmod	_	_
10	on	on	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	responses	response	NNS	_	6	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	other	other	JJ	_	16	attr	_	_
15	membrane	membrane	NN	_	16	com	_	_
16	properties	property	NNS	_	12	conj	_	_
17	during	during	IN	_	22	case	_	_
18	whole-cell	whole-cell	JJ	_	20	adv	_	_
19	,	,	,	_	20	p	_	_
20	tight	tight	JJ	_	22	attr	_	_
21	seal	seal	NN	_	22	com	_	_
22	recordings	recording	NNS	_	4	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	these	these	DT	_	25	det	_	_
25	neurons	neuron	NNS	_	22	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	percentage	percentage	NN	_	15	dep	_	_
3	of	of	IN	_	4	case	_	_
4	neurons	neuron	NNS	_	2	ppmod	_	_
5	hyperpolarized	hyperpolarized	VBN	_	4	acl	_	_
6	by	by	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug3	drug0	NN	_	7	conj	_	_
13	was	be	VBD	_	15	aux	_	_
14	significantly	significantly	RB	_	15	adv	_	_
15	reduced	reduce	VBN	_	0	root	_	_
16	when	when	WRB	_	17	adv	_	_
17	1	0	CD	_	15	comp	_	_
18	%	%	NN	_	17	meta	_	_
19	but	but	CC	_	17	cc	_	_
20	not	not	RB	_	21	neg	_	_
21	&lt	&lt	VBN	_	17	conj	_	_
22	;	;	:	_	15	p	_	_

1	or	or	CC	_	6	cc	_	_
2	=0.2	0	CD	_	4	num	_	_
3	%	%	NN	_	2	meta	_	_
4	biocytin	biocytin	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	included	include	VBN	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	recording	recording	JJ	_	10	attr	_	_
10	pipette	pipette	NN	_	6	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	compared	compare	VBN	_	14	adv	_	_
13	with	with	IN	_	14	case	_	_
14	neurons	neuron	NNS	_	6	ppmod	_	_
15	recorded	record	VBN	_	14	acl	_	_
16	without	without	IN	_	17	case	_	_
17	biocytin	biocytin	NN	_	15	ppmod	_	_
18	.	.	.	_	6	p	_	_

1	However	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	a	a	DT	_	6	det	_	_
4	significantly	significantly	RB	_	5	adv	_	_
5	higher	high	JJR	_	6	attr	_	_
6	proportion	proportion	NN	_	9	dep	_	_
7	of	of	IN	_	8	case	_	_
8	neurons	neuron	NNS	_	6	ppmod	_	_
9	fired	fire	VBD	_	0	root	_	_
10	spontaneous	spontaneous	JJ	_	12	attr	_	_
11	action	action	NN	_	12	com	_	_
12	potentials	potential	NNS	_	9	obj	_	_
13	with	with	IN	_	19	case	_	_
14	either	either	DT	_	19	det	_	_
15	0.05-0.2	0	CD	_	19	num	_	_
16	or	or	CC	_	15	cc	_	_
17	1	0	CD	_	15	conj	_	_
18	%	%	NN	_	15	meta	_	_
19	biocytin	biocytin	NN	_	9	ppmod	_	_
20	compared	compare	VBN	_	23	adv	_	_
21	to	to	TO	_	23	aux	_	_
22	no	no	DT	_	23	det	_	_
23	biocytin	biocytin	NN	_	9	ppmod	_	_
24	.	.	.	_	9	p	_	_

1	Resting	resting	JJ	_	3	attr	_	_
2	membrane	membrane	NN	_	3	com	_	_
3	potential	potential	NN	_	19	dep	_	_
4	,	,	,	_	3	p	_	_
5	input	input	NN	_	6	com	_	_
6	impedance	impedance	NN	_	3	conj	_	_
7	and	and	CC	_	6	cc	_	_
8	the	the	DT	_	9	det	_	_
9	proportion	proportion	NN	_	3	conj	_	_
10	of	of	IN	_	11	case	_	_
11	neurons	neuron	NNS	_	9	ppmod	_	_
12	displaying	display	VBG	_	11	acl	_	_
13	transient	transient	JJ	_	15	attr	_	_
14	outward	outward	NN	_	15	com	_	_
15	rectification	rectification	NN	_	12	obj	_	_
16	were	be	VBD	_	19	aux	_	_
17	each	each	DT	_	19	det	_	_
18	significantly	significantly	RB	_	19	adv	_	_
19	altered	alter	VBN	_	0	root	_	_
20	for	for	IN	_	21	case	_	_
21	neurons	neuron	NNS	_	19	ppmod	_	_
22	recorded	record	VBN	_	21	acl	_	_
23	with	with	IN	_	24	case	_	_
24	1	0	CD	_	22	ppmod	_	_
25	%	%	NN	_	24	meta	_	_
26	but	but	CC	_	24	cc	_	_
27	not	not	RB	_	26	com	_	_
28	0.05-0.2	0	CD	_	24	conj	_	_
29	%	%	NN	_	28	meta	_	_
30	biocytin	biocytin	NN	_	28	appo	_	_
31	.	.	.	_	19	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	4	dep	_	_
3	may	may	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	due	due	JJ	_	4	dep	_	_
6	to	to	TO	_	10	aux	_	_
7	a	a	DT	_	10	det	_	_
8	relatively	relatively	RB	_	9	adv	_	_
9	specific	specific	JJ	_	10	attr	_	_
10	blockade	blockade	NN	_	5	ppmod	_	_
11	of	of	IN	_	15	case	_	_
12	diverse	diverse	JJ	_	15	attr	_	_
13	potassium	potassium	NN	_	15	com	_	_
14	channel	channel	NN	_	15	com	_	_
15	types	type	NNS	_	10	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Because	because	IN	_	6	mark	_	_
2	efficient	efficient	JJ	_	3	attr	_	_
3	labeling	labeling	NN	_	6	dep	_	_
4	can	can	MD	_	6	modal	_	_
5	be	be	VB	_	6	aux	_	_
6	achieved	achieve	VBN	_	18	advcl	_	_
7	with	with	IN	_	10	case	_	_
8	0.1	0	CD	_	10	num	_	_
9	%	%	NN	_	8	meta	_	_
10	biocytin	biocytin	NN	_	6	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	whole-cell	whole-cell	JJ	_	13	attr	_	_
13	recording	recording	NN	_	6	ppmod	_	_
14	,	,	,	_	18	p	_	_
15	higher	high	JJR	_	16	attr	_	_
16	concentrations	concentration	NNS	_	18	dep	_	_
17	are	be	VBP	_	18	aux	_	_
18	contraindicated	contraindicate	VBN	_	0	root	_	_
19	.	.	.	_	18	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	5	p	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	5	attr	_	_
5	evaluation	evaluation	NN	_	0	root	_	_
6	of	of	IN	_	10	case	_	_
7	its	its	PRP$	_	10	poss	_	_
8	permeation	permeation	NN	_	10	com	_	_
9	enhancing	enhancing	NN	_	10	com	_	_
10	effect	effect	NN	_	5	ppmod	_	_
11	on	on	IN	_	13	case	_	_
12	peptide	peptide	NN	_	13	com	_	_
13	drugs	drug	NNS	_	10	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	purpose	purpose	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	evaluate	evaluate	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	effect	effect	NN	_	8	obj	_	_
11	of	of	IN	_	21	case	_	_
12	drug1	drug0	NN	_	21	attr	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	drug2	drug0	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	and	and	CC	_	12	cc	_	_
17	drug3	drug0	NN	_	12	conj	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	drug4	drug0	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	conjugates	conjugate	NNS	_	10	ppmod	_	_
22	on	on	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	intestinal	intestinal	JJ	_	25	attr	_	_
25	permeation	permeation	NN	_	10	ppmod	_	_
26	of	of	IN	_	27	case	_	_
27	drug5	drug0	NN	_	25	ppmod	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	drug6	drug0	NN	_	27	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	and	and	CC	_	27	cc	_	_
32	model	model	JJ	_	34	attr	_	_
33	peptide	peptide	NN	_	34	com	_	_
34	drugs	drug	NNS	_	27	conj	_	_
35	,	,	,	_	34	p	_	_
36	drug7	drug0	NN	_	34	appo	_	_
37	and	and	CC	_	36	cc	_	_
38	drug8	drug0	NN	_	36	conj	_	_
39	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	was	be	VBD	_	4	aux	_	_
3	covalently	covalently	RB	_	4	adv	_	_
4	linked	link	VBN	_	0	root	_	_
5	to	to	TO	_	8	aux	_	_
6	carbodiimide	carbodiimide	NN	_	8	attr	_	_
7	activated	activated	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	4	ppmod	_	_
9	.	.	.	_	4	p	_	_

1	Iodometric	iodometric	JJ	_	2	attr	_	_
2	titration	titration	NN	_	8	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	polymer	polymer	NN	_	6	com	_	_
6	conjugates	conjugate	NNS	_	2	ppmod	_	_
7	was	be	VBD	_	8	aux	_	_
8	used	use	VBN	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	determine	determine	VB	_	8	comp	_	_
11	the	the	DT	_	12	det	_	_
12	extent	extent	NN	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	immobilised	immobilised	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	12	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	Permeation	permeation	NN	_	2	com	_	_
2	studies	study	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	performed	performed	VBN	_	0	root	_	_
5	on	on	IN	_	10	case	_	_
6	guinea	guinea	NN	_	7	com	_	_
7	pig	pig	NN	_	10	attr	_	_
8	small	small	JJ	_	10	attr	_	_
9	intestinal	intestinal	JJ	_	10	attr	_	_
10	mucosa	mucosa	NN	_	4	ppmod	_	_
11	mounted	mount	VBN	_	10	acl	_	_
12	in	in	IN	_	14	case	_	_
13	Ussing-type	ussing-type	JJ	_	14	attr	_	_
14	chamber	chamber	NN	_	11	ppmod	_	_
15	.	.	.	_	4	p	_	_

1	Unmodified	unmodified	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	9	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	1	0	CD	_	6	num	_	_
5	%	%	NN	_	6	meta	_	_
6	m/v	m/v	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	significantly	significantly	RB	_	9	adv	_	_
9	improved	improve	VBD	_	0	root	_	_
10	the	the	DT	_	12	det	_	_
11	transport	transport	NN	_	12	com	_	_
12	ratio	ratio	NN	_	9	obj	_	_
13	(	-lrb-	-LRB-	_	20	p	_	_
14	R=	r=	NN	_	20	attr	_	_
15	P	p	NN	_	20	attr	_	_
16	(	-lrb-	-LRB-	_	20	p	_	_
17	app	app	NN	_	20	attr	_	_
18	)	-rrb-	-RRB-	_	20	p	_	_
19	polymer/	polymer/	NN	_	20	com	_	_
20	P	p	NN	_	12	prn	_	_
21	(	-lrb-	-LRB-	_	20	p	_	_
22	app	app	CD	_	20	num	_	_
23	)	-rrb-	-RRB-	_	20	p	_	_
24	control	control	NN	_	20	appo	_	_
25	)	-rrb-	-RRB-	_	20	p	_	_
26	of	of	IN	_	27	case	_	_
27	drug2	drug0	NN	_	12	ppmod	_	_
28	to	to	TO	_	36	aux	_	_
29	1.3	0	CD	_	36	num	_	_
30	and	and	CC	_	29	cc	_	_
31	1	0	CD	_	29	conj	_	_
32	%	%	NN	_	29	meta	_	_
33	(	-lrb-	-LRB-	_	34	p	_	_
34	m/v	m/v	NN	_	29	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	drug3	drug0	NN	_	12	ppmod	_	_
37	conjugated	conjugate	VBN	_	36	acl	_	_
38	with	with	IN	_	41	case	_	_
39	drug4	drug0	NN	_	41	dep	_	_
40	further	far	RB	_	41	adv	_	_
41	enhanced	enhance	VBD	_	37	ppmod	_	_
42	the	the	DT	_	43	det	_	_
43	permeation	permeation	NN	_	41	obj	_	_
44	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	conjugation	conjugation	NN	_	13	dep	_	_
3	at	at	IN	_	8	case	_	_
4	3.6	0	CD	_	8	num	_	_
5	,	,	,	_	8	p	_	_
6	5.3	0	CD	_	8	num	_	_
7	and	and	CC	_	8	cc	_	_
8	7.3	0	CD	_	2	ppmod	_	_
9	%	%	NN	_	8	meta	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	m/m	m/m	NN	_	8	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	resulted	result	VBD	_	0	root	_	_
14	in	in	IN	_	15	case	_	_
15	R-values	r-values	NN	_	13	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	1.4	0	CD	_	15	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	1.7	0	CD	_	17	conj	_	_
20	and	and	CC	_	19	cc	_	_
21	1.8	0	CD	_	17	conj	_	_
22	,	,	,	_	13	p	_	_
23	respectively	respectively	RB	_	13	adv	_	_
24	.	.	.	_	13	p	_	_

1	Decreasing	decrease	VBG	_	31	advcl	_	_
2	the	the	DT	_	3	det	_	_
3	concentration	concentration	NN	_	1	obj	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	exhibiting	exhibit	VBG	_	5	acl	_	_
8	7.3	0	CD	_	7	obj	_	_
9	%	%	NN	_	8	meta	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	m/m	m/m	NN	_	8	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	of	of	IN	_	15	case	_	_
14	immobilised	immobilised	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	8	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	CMC-Cys7.3	cmc-cys0	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	from	from	IN	_	20	case	_	_
20	1	0	CD	_	26	ppmod	_	_
21	%	%	NN	_	20	meta	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	m/v	m/v	NN	_	20	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	to	to	TO	_	26	aux	_	_
26	0.5	0	CD	_	7	ppmod	_	_
27	%	%	NN	_	26	meta	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	m/v	m/v	NN	_	26	prn	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	decreased	decrease	VBD	_	0	root	_	_
32	the	the	DT	_	33	det	_	_
33	R-value	r-value	NN	_	31	obj	_	_
34	of	of	IN	_	35	case	_	_
35	drug3	drug0	NN	_	33	ppmod	_	_
36	from	from	IN	_	39	case	_	_
37	1.8	0	CD	_	39	num	_	_
38	to	to	TO	_	39	attr	_	_
39	1.2	0	CD	_	31	ppmod	_	_
40	.	.	.	_	31	p	_	_

1	drug1	drug0	CD	_	3	num	_	_
2	at	at	IN	_	3	case	_	_
3	1	0	CD	_	14	num	_	_
4	%	%	NN	_	3	meta	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	m/v	m/v	NN	_	3	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	presence	presence	NN	_	3	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	free	free	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	had	have	VBD	_	0	root	_	_
15	no	no	DT	_	17	det	_	_
16	significant	significant	JJ	_	17	attr	_	_
17	effect	effect	NN	_	14	obj	_	_
18	on	on	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	R-value	r-value	NN	_	14	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	compared	compare	VBN	_	25	adv	_	_
24	to	to	TO	_	25	aux	_	_
25	drug4	drug0	NN	_	20	ppmod	_	_
26	alone	alone	RB	_	25	adv	_	_
27	.	.	.	_	14	p	_	_

1	Formulation	formulation	NN	_	19	dep	_	_
2	of	of	IN	_	5	case	_	_
3	fluorescence	fluorescence	NN	_	5	attr	_	_
4	labelled	labelled	JJ	_	5	attr	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	in	in	IN	_	10	case	_	_
9	unconjugated	unconjugated	JJ	_	10	attr	_	_
10	drug3	drug0	NN	_	1	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	1	0	CD	_	14	num	_	_
13	%	%	NN	_	14	meta	_	_
14	m/v	m/v	NN	_	10	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	did	do	VBD	_	19	aux	_	_
17	not	not	RB	_	19	neg	_	_
18	significantly	significantly	RB	_	19	adv	_	_
19	improve	improve	VB	_	40	advcl	_	_
20	the	the	DT	_	21	det	_	_
21	permeation	permeation	NN	_	19	obj	_	_
22	,	,	,	_	40	p	_	_
23	however	however	RB	_	40	adv	_	_
24	in	in	IN	_	34	case	_	_
25	the	the	DT	_	34	det	_	_
26	presence	presence	NN	_	34	advnp	_	_
27	of	of	IN	_	34	case	_	_
28	1	0	CD	_	34	num	_	_
29	%	%	NN	_	28	meta	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	m/v	m/v	NN	_	28	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	drug4	drug0	NN	_	34	com	_	_
34	7.3	0	NN	_	40	ppmod	_	_
35	a	a	DT	_	38	det	_	_
36	significantly	significantly	RB	_	37	adv	_	_
37	improved	improve	VBN	_	38	attr	_	_
38	permeation	permeation	NN	_	40	dep	_	_
39	was	be	VBD	_	40	aux	_	_
40	observed	observe	VBN	_	0	root	_	_
41	(	-lrb-	-LRB-	_	42	p	_	_
42	R=	r=	NNP	_	40	prn	_	_
43	1.3	0	CD	_	42	num	_	_
44	)	-rrb-	-RRB-	_	42	p	_	_
45	.	.	.	_	40	p	_	_

1	Conjugation	conjugation	NN	_	8	dep	_	_
2	at	at	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	drug2	drug0	NN	_	6	com	_	_
6	moieties	moiety	NNS	_	1	ppmod	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	improves	improve	VBZ	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	intestinal	intestinal	JJ	_	11	attr	_	_
11	permeation	permeation	NN	_	8	dat	_	_
12	of	of	IN	_	16	case	_	_
13	the	the	DT	_	16	det	_	_
14	hydrophilic	hydrophilic	JJ	_	16	attr	_	_
15	molecule	molecule	NN	_	16	com	_	_
16	drug3	drug0	NN	_	11	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	the	the	DT	_	21	det	_	_
19	model	model	NN	_	21	com	_	_
20	peptide	peptide	NN	_	21	com	_	_
21	drugs	drug	NNS	_	16	conj	_	_
22	drug4	drug0	NN	_	21	appo	_	_
23	and	and	CC	_	22	cc	_	_
24	drug5	drug0	NN	_	22	conj	_	_
25	in	in	FW	_	26	adv	_	_
26	vitro	vitro	FW	_	8	adv	_	_
27	,	,	,	_	8	p	_	_
28	therefore	therefore	RB	_	8	adv	_	_
29	this	this	DT	_	32	det	_	_
30	conjugated	conjugate	VBN	_	32	attr	_	_
31	system	system	NN	_	32	com	_	_
32	maybe	maybe	NN	_	8	obj	_	_
33	useful	useful	JJ	_	32	attr	_	_
34	for	for	IN	_	36	case	_	_
35	peroral	peroral	JJ	_	36	attr	_	_
36	administration	administration	NN	_	33	ppmod	_	_
37	of	of	IN	_	39	case	_	_
38	peptide	peptide	NN	_	39	com	_	_
39	drugs	drug	NNS	_	36	ppmod	_	_
40	in	in	IN	_	42	case	_	_
41	the	the	DT	_	42	det	_	_
42	future	future	JJ	_	36	ppmod	_	_
43	.	.	.	_	8	p	_	_

1	Effects	effect	NNS	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	low	low	JJ	_	4	attr	_	_
4	temperatures	temperature	NNS	_	1	ppmod	_	_
5	on	on	IN	_	6	case	_	_
6	microtubules	microtubule	NNS	_	1	ppmod	_	_
7	in	in	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	non-myelinated	non-myelinated	JJ	_	10	attr	_	_
10	axons	axon	NNS	_	6	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	post-ganglionic	post-ganglionic	JJ	_	14	attr	_	_
13	sympathetic	sympathetic	JJ	_	14	attr	_	_
14	nerves	nerve	NNS	_	10	ppmod	_	_
15	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	16	dep	_	_
3	of	of	IN	_	5	case	_	_
4	temperature	temperature	NN	_	5	com	_	_
5	changes	change	NNS	_	2	ppmod	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	number	number	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	microtubules	microtubule	NNS	_	8	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	non-myelinated	non-myelinated	JJ	_	13	attr	_	_
13	axons	axon	NNS	_	10	ppmod	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	studied	study	VBN	_	0	root	_	_
17	in	in	IN	_	23	case	_	_
18	cat	cat	NN	_	23	attr	_	_
19	inferior	inferior	NN	_	23	attr	_	_
20	mesenteric	mesenteric	JJ	_	23	attr	_	_
21	ganglion/hypogastric	ganglion/hypogastric	JJ	_	23	attr	_	_
22	nerve	nerve	NN	_	23	com	_	_
23	preparations	preparation	NNS	_	16	ppmod	_	_
24	incubated	incubate	VBN	_	23	acl	_	_
25	at	at	IN	_	27	case	_	_
26	various	various	JJ	_	27	attr	_	_
27	temperatures	temperature	NNS	_	24	ppmod	_	_
28	in	in	IN	_	34	case	_	_
29	Eagles	eagles	NN	_	34	attr	_	_
30	minimal	minimal	JJ	_	34	attr	_	_
31	essential	essential	JJ	_	34	attr	_	_
32	tissue	tissue	NN	_	34	com	_	_
33	culture	culture	NN	_	34	com	_	_
34	medium	medium	NN	_	24	ppmod	_	_
35	in	in	FW	_	36	adv	_	_
36	vitro	vitro	FW	_	34	adv	_	_
37	.	.	.	_	16	p	_	_

1	At	at	IN	_	4	case	_	_
2	37	0	CD	_	4	num	_	_
3	degrees	degree	NNS	_	4	com	_	_
4	C	c	NN	_	8	ppmod	_	_
5	the	the	DT	_	7	det	_	_
6	non-myelinated	non-myelinated	JJ	_	7	attr	_	_
7	axons	axon	NNS	_	8	dep	_	_
8	contained	contain	VBD	_	0	root	_	_
9	28.4	0	CD	_	8	obj	_	_
10	plus	plus	JJ	_	9	attr	_	_
11	or	or	CC	_	10	cc	_	_
12	minus	minus	JJ	_	10	conj	_	_
13	0.8	0	CD	_	14	num	_	_
14	S.E.M.	s.e.m.	NNP	_	9	attr	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	54	0	CD	_	4	num	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	microtubules	microtubule	NNS	_	0	root	_	_
5	per	per	IN	_	6	case	_	_
6	axon	axon	NN	_	4	ppmod	_	_
7	.	.	.	_	4	p	_	_

1	After	after	IN	_	2	case	_	_
2	incubation	incubation	NN	_	12	ppmod	_	_
3	at	at	IN	_	6	case	_	_
4	0	0	CD	_	6	num	_	_
5	degrees	degree	NNS	_	6	com	_	_
6	C	c	NN	_	2	ppmod	_	_
7	for	for	IN	_	9	case	_	_
8	4	0	CD	_	9	num	_	_
9	h	h	NN	_	2	ppmod	_	_
10	this	this	DT	_	11	det	_	_
11	number	number	NN	_	12	dep	_	_
12	fell	fall	VBP	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	2.3	0	CD	_	12	ppmod	_	_
15	plus	plus	JJ	_	14	attr	_	_
16	or	or	CC	_	14	cc	_	_
17	minus	minus	JJ	_	19	attr	_	_
18	0.1	0	CD	_	19	num	_	_
19	S.E.M.	s.e.m.	NN	_	14	conj	_	_

1	(	-lrb-	-LRB-	_	2	p	_	_
2	41	0	CD	_	5	num	_	_
3	)	-rrb-	-RRB-	_	2	p	_	_
4	but	but	CC	_	5	cc	_	_
5	returned	return	VBD	_	0	root	_	_
6	to	to	TO	_	8	aux	_	_
7	normal	normal	JJ	_	8	attr	_	_
8	levels	level	NNS	_	5	ppmod	_	_
9	when	when	WRB	_	13	adv	_	_
10	the	the	DT	_	11	det	_	_
11	nerves	nerve	NNS	_	13	dep	_	_
12	were	be	VBD	_	13	aux	_	_
13	rewarmed	rewarm	VBN	_	5	comp	_	_
14	.	.	.	_	5	p	_	_

1	This	this	DT	_	2	det	_	_
2	loss	loss	NN	_	14	dep	_	_
3	of	of	IN	_	4	case	_	_
4	microtubules	microtubule	NNS	_	2	ppmod	_	_
5	on	on	IN	_	6	case	_	_
6	cooling	cool	VBG	_	2	ppmod	_	_
7	the	the	DT	_	8	det	_	_
8	nerves	nerve	NNS	_	6	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	their	their	PRP$	_	11	poss	_	_
11	reappearance	reappearance	NN	_	8	conj	_	_
12	on	on	IN	_	13	case	_	_
13	rewarming	rewarming	NN	_	11	ppmod	_	_
14	was	be	VBD	_	0	root	_	_
15	a	a	DT	_	17	det	_	_
16	rapid	rapid	JJ	_	17	attr	_	_
17	process	process	NN	_	14	obj	_	_
18	;	;	:	_	14	p	_	_

1	it	it	PRP	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	independent	independent	JJ	_	2	dep	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	influence	influence	NN	_	3	ppmod	_	_
7	of	of	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	nueronal	nueronal	JJ	_	11	attr	_	_
10	cell	cell	NN	_	11	com	_	_
11	body	body	NN	_	6	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	of	of	IN	_	15	case	_	_
14	protein	protein	NN	_	15	com	_	_
15	synthesis	synthesis	NN	_	6	conj	_	_
16	within	within	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	axon	axon	NN	_	15	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	preservation	preservation	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	microtubules	microtubule	NNS	_	2	ppmod	_	_
6	was	be	VBD	_	7	aux	_	_
7	improved	improve	VBN	_	0	root	_	_
8	when	when	WRB	_	10	adv	_	_
9	D2O	d0o	NN	_	10	dep	_	_
10	was	be	VBD	_	7	comp	_	_
11	present	present	JJ	_	10	dep	_	_
12	in	in	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	incubation	incubation	NN	_	15	com	_	_
15	medium	medium	NN	_	11	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	Reformed	reformed	JJ	_	2	attr	_	_
2	microtubules	microtubule	NNS	_	3	dep	_	_
3	appeared	appear	VBD	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	function	function	VB	_	3	comp	_	_
6	normally	normally	RB	_	5	adv	_	_
7	with	with	IN	_	8	case	_	_
8	respect	respect	NN	_	5	ppmod	_	_
9	to	to	TO	_	12	aux	_	_
10	their	their	PRP$	_	12	poss	_	_
11	possible	possible	JJ	_	12	attr	_	_
12	role	role	NN	_	8	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	transport	transport	NN	_	12	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	noradrenaline	noradrenaline	NN	_	19	com	_	_
18	storage	storage	NN	_	19	com	_	_
19	vesicles	vesicle	NNS	_	15	ppmod	_	_
20	along	along	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	axons	axon	NNS	_	15	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NN	_	9	dep	_	_
3	for	for	IN	_	6	case	_	_
4	urinary	urinary	JJ	_	6	attr	_	_
5	tract	tract	NN	_	6	com	_	_
6	infections	infection	NNS	_	2	ppmod	_	_
7	:	:	:	_	9	p	_	_
8	a	a	DT	_	9	det	_	_
9	review	review	NN	_	0	root	_	_
10	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	a	a	DT	_	7	det	_	_
5	rapidly	rapidly	RB	_	6	adv	_	_
6	growing	grow	VBG	_	7	attr	_	_
7	class	class	NN	_	3	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	broad	broad	JJ	_	13	attr	_	_
13	spectrum	spectrum	NN	_	7	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	activity	activity	NN	_	13	ppmod	_	_
16	against	against	IN	_	22	case	_	_
17	gram-negative	gram-negative	JJ	_	22	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	some	some	DT	_	20	det	_	_
20	gram-positive	gram-positive	JJ	_	17	conj	_	_
21	aerobic	aerobic	JJ	_	22	attr	_	_
22	bacteria	bacteria	NNS	_	15	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	19	dep	_	_
3	,	,	,	_	2	p	_	_
4	including	include	VBG	_	5	adv	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug3	drug0	NN	_	5	conj	_	_
10	,	,	,	_	9	p	_	_
11	drug4	drug0	NN	_	5	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	drug5	drug0	NN	_	5	conj	_	_
15	,	,	,	_	2	p	_	_
16	have	have	VBP	_	19	aux	_	_
17	been	be	VBN	_	19	aux	_	_
18	extensively	extensively	RB	_	19	adv	_	_
19	studied	study	VBN	_	0	root	_	_
20	and	and	CC	_	19	cc	_	_
21	have	have	VBP	_	22	aux	_	_
22	demonstrated	demonstrate	VBN	_	19	conj	_	_
23	efficacy	efficacy	NN	_	22	obj	_	_
24	and	and	CC	_	23	cc	_	_
25	safety	safety	NN	_	26	com	_	_
26	profiles	profile	NNS	_	23	conj	_	_
27	comparable	comparable	JJ	_	23	attr	_	_
28	to	to	TO	_	29	aux	_	_
29	those	those	DT	_	27	ppmod	_	_
30	of	of	IN	_	33	case	_	_
31	other	other	JJ	_	33	attr	_	_
32	traditional	traditional	JJ	_	33	attr	_	_
33	agents	agent	NNS	_	29	ppmod	_	_
34	for	for	IN	_	36	case	_	_
35	the	the	DT	_	36	det	_	_
36	treatment	treatment	NN	_	33	ppmod	_	_
37	of	of	IN	_	43	case	_	_
38	complicated	complicated	JJ	_	43	attr	_	_
39	or	or	CC	_	43	cc	_	_
40	uncomplicated	uncomplicated	JJ	_	43	attr	_	_
41	urinary	urinary	JJ	_	43	attr	_	_
42	tract	tract	NN	_	43	com	_	_
43	infections	infection	NNS	_	36	ppmod	_	_
44	and	and	CC	_	43	cc	_	_
45	prostatitis	prostatitis	NN	_	43	conj	_	_
46	.	.	.	_	19	p	_	_

1	Advantages	advantage	NNS	_	8	dep	_	_
2	offered	offer	VBN	_	1	acl	_	_
3	by	by	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	class	class	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	include	include	VBP	_	0	root	_	_
9	optimal	optimal	JJ	_	10	attr	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	8	obj	_	_
11	,	,	,	_	10	p	_	_
12	effectiveness	effectiveness	NN	_	10	conj	_	_
13	against	against	IN	_	15	case	_	_
14	multidrug-resistant	multidrug-resistant	JJ	_	15	attr	_	_
15	organisms	organism	NNS	_	12	ppmod	_	_
16	,	,	,	_	12	p	_	_
17	and	and	CC	_	12	cc	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	administration	administration	NN	_	10	conj	_	_
20	even	even	RB	_	21	com	_	_
21	when	when	WRB	_	26	adv	_	_
22	parenteral	parenteral	JJ	_	23	attr	_	_
23	drug2	drug0	NN	_	26	dep	_	_
24	are	be	VBP	_	26	aux	_	_
25	generally	generally	RB	_	26	adv	_	_
26	used	use	VBN	_	8	comp	_	_
27	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	6	dep	_	_
3	are	be	VBP	_	6	aux	_	_
4	also	also	RB	_	6	adv	_	_
5	extensively	extensively	RB	_	6	adv	_	_
6	used	use	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	urologic	urologic	JJ	_	9	attr	_	_
9	surgery	surgery	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	If	if	IN	_	2	mark	_	_
2	taken	take	VBN	_	14	advcl	_	_
3	1	0	CD	_	4	num	_	_
4	hour	hour	NN	_	6	dat	_	_
5	before	before	IN	_	6	case	_	_
6	drug1	drug0	NN	_	2	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	drug2	drug0	NN	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	,	,	,	_	14	p	_	_
11	drug3	drug0	NN	_	14	dep	_	_
12	does	do	VBZ	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	affect	affect	VB	_	0	root	_	_
15	drug4	drug0	NN	_	16	com	_	_
16	exposure	exposure	NN	_	14	obj	_	_
17	,	,	,	_	14	p	_	_
18	despite	despite	IN	_	21	case	_	_
19	persistent	persistent	JJ	_	21	attr	_	_
20	buffering	buffer	VBG	_	21	attr	_	_
21	effects	effect	NNS	_	14	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	Concurrent	concurrent	JJ	_	2	attr	_	_
2	administration	administration	NN	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	significantly	significantly	RB	_	8	adv	_	_
8	reduces	reduce	VBZ	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	level	level	NN	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	exposure	exposure	NN	_	10	ppmod	_	_
13	to	to	TO	_	14	aux	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	8	p	_	_
16	but	but	CC	_	8	cc	_	_
17	it	it	PRP	_	18	dep	_	_
18	is	be	VBZ	_	8	conj	_	_
19	unclear	unclear	JJ	_	18	dep	_	_
20	how	how	WRB	_	28	adv	_	_
21	soon	soon	RB	_	28	adv	_	_
22	after	after	IN	_	24	case	_	_
23	drug4	drug0	NN	_	24	com	_	_
24	administration	administration	NN	_	28	ppmod	_	_
25	drug5	drug0	NN	_	28	dep	_	_
26	may	may	MD	_	28	modal	_	_
27	be	be	VB	_	28	aux	_	_
28	given	give	VBN	_	18	comp	_	_
29	safely	safely	RB	_	28	adv	_	_
30	.	.	.	_	8	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	compared	compare	VBD	_	0	root	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	pharmacokinetics	pharmacokinetics	NNS	_	2	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	gastric	gastric	JJ	_	7	attr	_	_
7	pH	ph	NN	_	4	conj	_	_
8	in	in	IN	_	13	case	_	_
9	12	0	CD	_	13	num	_	_
10	human	human	JJ	_	13	attr	_	_
11	immunodeficiency	immunodeficiency	NN	_	13	attr	_	_
12	virus-positive	virus-positive	JJ	_	13	attr	_	_
13	patients	patient	NNS	_	2	ppmod	_	_
14	by	by	IN	_	15	case	_	_
15	use	use	NN	_	2	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	800	0	CD	_	18	num	_	_
18	mg	mg	NN	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	alone	alone	RB	_	20	adv	_	_
22	versus	versus	CC	_	18	cc	_	_
23	800	0	CD	_	24	num	_	_
24	mg	mg	NN	_	18	conj	_	_
25	of	of	IN	_	26	case	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	administered	administer	VBN	_	18	acl	_	_
28	1	0	CD	_	29	num	_	_
29	h	h	NN	_	32	dat	_	_
30	after	after	IN	_	32	case	_	_
31	drug4	drug0	NN	_	32	com	_	_
32	administration	administration	NN	_	27	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	Median	median	NN	_	3	attr	_	_
2	gastric	gastric	JJ	_	3	attr	_	_
3	pH	ph	NN	_	4	dep	_	_
4	was	be	VBD	_	0	root	_	_
5	significantly	significantly	RB	_	6	adv	_	_
6	higher	high	JJR	_	4	dep	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	taken	take	VBN	_	4	comp	_	_
11	after	after	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	administration	administration	NN	_	10	ppmod	_	_
14	;	;	:	_	4	p	_	_

1	however	however	RB	_	26	adv	_	_
2	,	,	,	_	26	p	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	difference	difference	NN	_	26	dep	_	_
6	in	in	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	maximum	maximum	JJ	_	9	attr	_	_
9	concentration	concentration	NN	_	5	ppmod	_	_
10	in	in	IN	_	11	case	_	_
11	plasma	plasma	NN	_	9	ppmod	_	_
12	or	or	CC	_	9	cc	_	_
13	the	the	DT	_	14	det	_	_
14	area	area	NN	_	9	conj	_	_
15	under	under	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	concentration-time	concentration-time	JJ	_	18	attr	_	_
18	curve	curve	NN	_	14	ppmod	_	_
19	from	from	IN	_	20	case	_	_
20	time	time	NN	_	18	ppmod	_	_
21	zero	#crd#	CD	_	20	num	_	_
22	to	to	TO	_	24	aux	_	_
23	8	0	CD	_	24	num	_	_
24	h	h	NN	_	18	ppmod	_	_
25	was	be	VBD	_	26	aux	_	_
26	observed	observe	VBN	_	0	root	_	_
27	.	.	.	_	26	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	may	may	MD	_	4	modal	_	_
3	be	be	VB	_	4	aux	_	_
4	taken	take	VBN	_	0	root	_	_
5	with	with	IN	_	10	case	_	_
6	a	a	DT	_	10	det	_	_
7	light	light	NN	_	10	attr	_	_
8	meal	meal	NN	_	10	attr	_	_
9	1	0	CD	_	10	num	_	_
10	h	h	NN	_	4	ppmod	_	_
11	following	follow	VBG	_	13	adv	_	_
12	the	the	DT	_	13	det	_	_
13	administration	administration	NN	_	10	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	400	0	CD	_	16	num	_	_
16	mg	mg	NN	_	13	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	Progestin-only	progestin-only	JJ	_	3	attr	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	contraception	contraception	NN	_	7	dep	_	_
4	:	:	:	_	7	p	_	_
5	a	a	DT	_	7	det	_	_
6	comprehensive	comprehensive	JJ	_	7	attr	_	_
7	review	review	NN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	mark	_	_
4	provide	provide	VB	_	25	advcl	_	_
5	information	information	NN	_	4	obj	_	_
6	for	for	IN	_	11	case	_	_
7	the	the	DT	_	11	det	_	_
8	appropriate	appropriate	JJ	_	11	attr	_	_
9	package	package	NN	_	11	com	_	_
10	insert	insert	NN	_	11	com	_	_
11	labeling	labeling	NN	_	5	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug2	drug0	NN	_	13	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	US	us	PRP	_	4	ppmod	_	_
20	,	,	,	_	25	p	_	_
21	a	a	DT	_	23	det	_	_
22	comprehensive	comprehensive	JJ	_	23	attr	_	_
23	review	review	NN	_	25	dep	_	_
24	was	be	VBD	_	25	aux	_	_
25	made	make	VBN	_	0	root	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	(	-lrb-	-LRB-	_	30	p	_	_
29	0.075	0	CD	_	30	num	_	_
30	mg	mg	NN	_	27	prn	_	_
31	)	-rrb-	-RRB-	_	30	p	_	_
32	and	and	CC	_	27	cc	_	_
33	drug4	drug0	NN	_	27	conj	_	_
34	(	-lrb-	-LRB-	_	36	p	_	_
35	0.35	0	CD	_	36	num	_	_
36	mg	mg	NN	_	33	prn	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	,	,	,	_	25	p	_	_
39	with	with	IN	_	42	case	_	_
40	the	the	DT	_	42	det	_	_
41	clinical	clinical	JJ	_	42	attr	_	_
42	differences	difference	NNS	_	25	ppmod	_	_
43	indicated	indicate	VBN	_	42	acl	_	_
44	where	where	WRB	_	45	adv	_	_
45	applicable	applicable	JJ	_	43	comp	_	_
46	.	.	.	_	25	p	_	_

1	The	the	DT	_	2	det	_	_
2	goal	goal	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	review	review	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	cite	cite	VBP	_	6	comp	_	_
9	primary	primary	JJ	_	10	attr	_	_
10	sources	source	NNS	_	8	obj	_	_
11	for	for	IN	_	14	case	_	_
12	virtually	virtually	RB	_	14	adv	_	_
13	all	all	DT	_	12	det	_	_
14	research	research	NN	_	10	ppmod	_	_
15	specific	specific	JJ	_	10	attr	_	_
16	to	to	TO	_	17	aux	_	_
17	POPs	pop	NNS	_	15	ppmod	_	_
18	since	since	IN	_	19	case	_	_
19	1975	0	NN	_	17	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	Conclusions	conclusion	NNS	_	12	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	the	the	DT	_	4	det	_	_
4	types	type	NNS	_	1	conj	_	_
5	of	of	IN	_	6	case	_	_
6	studies	study	NNS	_	4	ppmod	_	_
7	which	which	WDT	_	8	dep	_	_
8	support	support	VBP	_	6	relcl	_	_
9	these	these	DT	_	10	det	_	_
10	conclusions	conclusion	NNS	_	8	obj	_	_
11	are	be	VBP	_	12	aux	_	_
12	given	give	VBN	_	0	root	_	_
13	for	for	IN	_	16	case	_	_
14	each	each	DT	_	16	det	_	_
15	major	major	JJ	_	16	attr	_	_
16	section	section	NN	_	12	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	introductory	introductory	JJ	_	3	attr	_	_
3	chapter	chapter	NN	_	4	dep	_	_
4	discusses	discuss	VBZ	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	advantages	advantage	NNS	_	4	obj	_	_
7	and	and	CC	_	6	cc	_	_
8	disadvantages	disadvantage	NNS	_	6	conj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	6	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	the	the	DT	_	13	det	_	_
13	magnitude	magnitude	NN	_	10	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	prevalence	prevalence	NN	_	13	conj	_	_
16	of	of	IN	_	18	case	_	_
17	their	their	PRP$	_	18	poss	_	_
18	use	use	NN	_	13	ppmod	_	_
19	.	.	.	_	4	p	_	_

1	Future	future	JJ	_	2	attr	_	_
2	trends	trend	NNS	_	5	dep	_	_
3	are	be	VBP	_	5	aux	_	_
4	also	also	RB	_	5	adv	_	_
5	predicted	predict	VBN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	Chapter	chapter	NN	_	3	dep	_	_
2	2	0	CD	_	1	num	_	_
3	considers	consider	VBZ	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	mode	mode	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	action	action	NN	_	5	ppmod	_	_
8	,	,	,	_	3	p	_	_
9	including	include	VBG	_	3	comp	_	_
10	ovulation	ovulation	NN	_	11	com	_	_
11	prevention	prevention	NN	_	9	obj	_	_
12	;	;	:	_	3	p	_	_

1	suppression	suppression	NN	_	0	root	_	_
2	of	of	IN	_	5	case	_	_
3	midcycle	midcycle	NN	_	5	com	_	_
4	gonadotropin	gonadotropin	NN	_	5	com	_	_
5	peaks	peak	NNS	_	1	ppmod	_	_
6	;	;	:	_	1	p	_	_

1	changes	change	NNS	_	0	root	_	_
2	in	in	IN	_	4	case	_	_
3	cervical	cervical	JJ	_	4	attr	_	_
4	mucus	mucus	NNS	_	1	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	the	the	DT	_	7	det	_	_
7	endometrium	endometrium	NN	_	4	conj	_	_
8	,	,	,	_	7	p	_	_
9	and	and	CC	_	7	cc	_	_
10	the	the	DT	_	12	det	_	_
11	fallopian	fallopian	NN	_	12	com	_	_
12	tubes	tube	NNS	_	4	conj	_	_
13	;	;	:	_	1	p	_	_

1	and	and	CC	_	3	cc	_	_
2	clinical	clinical	JJ	_	3	attr	_	_
3	implications	implication	NNS	_	0	root	_	_
4	.	.	.	_	3	p	_	_

1	Chapter	chapter	NN	_	3	dep	_	_
2	3	0	CD	_	1	num	_	_
3	covers	cover	VBZ	_	0	root	_	_
4	pharmacology	pharmacology	NN	_	3	obj	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	4	prn	_	_
7	,	,	,	_	6	p	_	_
8	pharmacodynamics	pharmacodynamics	NNS	_	6	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	potency	potency	NN	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	implications	implication	NNS	_	6	conj	_	_
15	)	-rrb-	-RRB-	_	6	p	_	_
16	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	next	next	JJ	_	3	attr	_	_
3	chapter	chapter	NN	_	4	dep	_	_
4	presents	present	VBZ	_	0	root	_	_
5	information	information	NN	_	4	obj	_	_
6	on	on	IN	_	7	case	_	_
7	efficacy	efficacy	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	pregnancy	pregnancy	NN	_	10	com	_	_
10	outcomes	outcome	NNS	_	7	conj	_	_
11	in	in	IN	_	12	case	_	_
12	terms	term	NNS	_	7	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	pregnancy	pregnancy	NN	_	15	com	_	_
15	rates	rate	NNS	_	12	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	compliance	compliance	NN	_	15	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	efficacy	efficacy	NN	_	17	conj	_	_
20	,	,	,	_	17	p	_	_
21	ectopic	ectopic	JJ	_	22	attr	_	_
22	pregnancies	pregnancy	NNS	_	15	conj	_	_
23	,	,	,	_	22	p	_	_
24	the	the	DT	_	25	det	_	_
25	outcome	outcome	NN	_	15	conj	_	_
26	of	of	IN	_	27	case	_	_
27	pregnancies	pregnancy	NNS	_	25	ppmod	_	_
28	conceived	conceive	VBN	_	27	acl	_	_
29	while	while	IN	_	30	case	_	_
30	using	use	VBG	_	28	ppmod	_	_
31	drug1	drug0	NN	_	30	obj	_	_
32	,	,	,	_	25	p	_	_
33	and	and	CC	_	25	cc	_	_
34	fertility	fertility	NN	_	15	conj	_	_
35	following	follow	VBG	_	36	adv	_	_
36	discontinuation	discontinuation	NN	_	34	ppmod	_	_
37	.	.	.	_	4	p	_	_

1	Chapter	chapter	NN	_	3	dep	_	_
2	5	0	CD	_	1	num	_	_
3	focuses	focus	VBZ	_	0	root	_	_
4	on	on	IN	_	6	case	_	_
5	metabolic	metabolic	JJ	_	6	attr	_	_
6	effects	effect	NNS	_	3	ppmod	_	_
7	,	,	,	_	6	p	_	_
8	specifically	specifically	RB	_	6	adv	_	_
9	lipid	lipid	NN	_	10	com	_	_
10	metabolism	metabolism	NN	_	6	appo	_	_
11	,	,	,	_	10	p	_	_
12	carbohydrate	carbohydrate	NN	_	13	com	_	_
13	metabolism	metabolism	NN	_	10	conj	_	_
14	and	and	CC	_	13	cc	_	_
15	diabetes	diabetes	NN	_	10	conj	_	_
16	,	,	,	_	15	p	_	_
17	coagulation	coagulation	NN	_	18	com	_	_
18	factors	factor	NNS	_	15	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	blood	blood	NN	_	22	com	_	_
22	pressure	pressure	NN	_	15	conj	_	_
23	.	.	.	_	3	p	_	_

1	Cardiovascular	cardiovascular	JJ	_	2	attr	_	_
2	disease	disease	NN	_	4	dep	_	_
3	is	be	VBZ	_	4	aux	_	_
4	considered	consider	VBN	_	0	root	_	_
5	in	in	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	next	next	JJ	_	8	attr	_	_
8	chapter	chapter	NN	_	4	ppmod	_	_
9	,	,	,	_	4	p	_	_
10	and	and	CC	_	4	cc	_	_
11	chapter	chapter	NN	_	13	dep	_	_
12	7	0	CD	_	11	num	_	_
13	presents	present	VBZ	_	4	conj	_	_
14	findings	finding	NNS	_	13	obj	_	_
15	on	on	IN	_	22	case	_	_
16	endometrial	endometrial	JJ	_	20	adv	_	_
17	,	,	,	_	20	p	_	_
18	ovarian	ovarian	JJ	_	20	adv	_	_
19	,	,	,	_	20	p	_	_
20	cervical	cervical	JJ	_	22	attr	_	_
21	,	,	,	_	22	p	_	_
22	breast	breast	NN	_	14	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	other	other	JJ	_	26	attr	_	_
26	cancers	cancer	NNS	_	22	conj	_	_
27	.	.	.	_	4	p	_	_

1	A	a	DT	_	2	det	_	_
2	host	host	NN	_	8	dep	_	_
3	of	of	IN	_	6	case	_	_
4	other	other	JJ	_	6	attr	_	_
5	medical	medical	JJ	_	6	attr	_	_
6	considerations	consideration	NNS	_	2	ppmod	_	_
7	are	be	VBP	_	8	aux	_	_
8	discussed	discuss	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	chapter	chapter	NN	_	8	ppmod	_	_
11	8	0	CD	_	10	num	_	_
12	,	,	,	_	8	p	_	_
13	including	include	VBG	_	16	adv	_	_
14	persistent	persistent	JJ	_	16	attr	_	_
15	ovarian	ovarian	JJ	_	16	attr	_	_
16	follicles	follicle	NNS	_	8	ppmod	_	_
17	;	;	:	_	8	p	_	_

1	reproductive	reproductive	JJ	_	3	attr	_	_
2	tract	tract	NN	_	3	com	_	_
3	infections	infection	NNS	_	0	root	_	_
4	;	;	:	_	3	p	_	_

1	abnormal	abnormal	JJ	_	3	attr	_	_
2	vaginal	vaginal	JJ	_	3	attr	_	_
3	bleeding	bleeding	JJ	_	0	root	_	_
4	;	;	:	_	3	p	_	_

1	uterine	uterine	NN	_	2	com	_	_
2	fibroids	fibroid	NNS	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	gestational	gestational	JJ	_	3	attr	_	_
2	trophoblastic	trophoblastic	JJ	_	3	attr	_	_
3	disease	disease	NN	_	0	root	_	_
4	;	;	:	_	3	p	_	_

1	benign	benign	JJ	_	3	attr	_	_
2	breast	breast	NN	_	3	com	_	_
3	disease	disease	NN	_	0	root	_	_
4	;	;	:	_	3	p	_	_

1	diseases	disease	NNS	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	liver	liver	NN	_	1	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	gallbladder	gallbladder	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	bowel	bowel	NN	_	4	conj	_	_
10	;	;	:	_	1	p	_	_

1	endocrine	endocrine	JJ	_	2	attr	_	_
2	dysfunction	dysfunction	NN	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	epilepsy	epilepsy	NN	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	bone	bone	NN	_	2	com	_	_
2	density	density	NN	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	sickle	sickle	JJ	_	3	attr	_	_
2	cell	cell	NN	_	3	com	_	_
3	disease	disease	NN	_	0	root	_	_
4	;	;	:	_	3	p	_	_

1	ocular	ocular	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	0	root	_	_
3	;	;	:	_	2	p	_	_

1	surgery	surgery	NN	_	0	root	_	_
2	;	;	:	_	1	p	_	_

1	and	and	CC	_	2	cc	_	_
2	overdose	overdose	NN	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	The	the	DT	_	4	det	_	_
2	last	last	JJ	_	4	attr	_	_
3	4	0	CD	_	4	num	_	_
4	chapters	chapter	NNS	_	5	dep	_	_
5	cover	cover	VBP	_	0	root	_	_
6	interactions	interaction	NNS	_	5	obj	_	_
7	with	with	IN	_	8	case	_	_
8	drugs	drug	NNS	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	laboratory	laboratory	NN	_	11	com	_	_
11	tests	test	NNS	_	8	conj	_	_
12	,	,	,	_	6	p	_	_
13	common	common	JJ	_	15	attr	_	_
14	side	side	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	6	conj	_	_
16	,	,	,	_	15	p	_	_
17	breast	breast	NN	_	18	com	_	_
18	feeding	feeding	NN	_	6	conj	_	_
19	,	,	,	_	18	p	_	_
20	and	and	CC	_	18	cc	_	_
21	effective	effective	JJ	_	22	attr	_	_
22	use	use	NN	_	6	conj	_	_
23	of	of	IN	_	24	case	_	_
24	drug1	drug0	NN	_	22	ppmod	_	_
25	.	.	.	_	5	p	_	_

1	Information	information	NN	_	21	dep	_	_
2	on	on	IN	_	3	case	_	_
3	precautions	precaution	NNS	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	contraindications	contraindication	NNS	_	3	conj	_	_
6	,	,	,	_	5	p	_	_
7	indications	indication	NNS	_	3	conj	_	_
8	,	,	,	_	7	p	_	_
9	use	use	NN	_	10	com	_	_
10	instructions	instruction	NNS	_	3	conj	_	_
11	,	,	,	_	10	p	_	_
12	and	and	CC	_	10	cc	_	_
13	instructions	instruction	NNS	_	3	conj	_	_
14	for	for	IN	_	16	case	_	_
15	appropriate	appropriate	JJ	_	16	attr	_	_
16	actions	action	NNS	_	3	ppmod	_	_
17	after	after	IN	_	18	case	_	_
18	missing	miss	VBG	_	16	ppmod	_	_
19	a	a	DT	_	20	det	_	_
20	pill	pill	NN	_	18	obj	_	_
21	is	be	VBZ	_	0	root	_	_
22	appended	appended	JJ	_	21	dep	_	_
23	.	.	.	_	21	p	_	_

1	Hypothermia	hypothermia	NN	_	0	root	_	_
2	as	as	IN	_	4	case	_	_
3	an	an	DT	_	4	det	_	_
4	index	index	NN	_	1	ppmod	_	_
5	of	of	IN	_	10	case	_	_
6	the	the	DT	_	10	det	_	_
7	drug1	drug0	NN	_	10	attr	_	_
8	-	-	:	_	10	p	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	reaction	reaction	NN	_	4	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	rat	rat	NN	_	10	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	Decreased	decrease	VBN	_	3	attr	_	_
2	core	core	NN	_	3	com	_	_
3	temperature	temperature	NN	_	8	dep	_	_
4	in	in	IN	_	6	case	_	_
5	female	female	JJ	_	6	attr	_	_
6	rats	rat	NNS	_	3	ppmod	_	_
7	was	be	VBD	_	8	aux	_	_
8	investigated	investigate	VBN	_	0	root	_	_
9	as	as	IN	_	12	case	_	_
10	one	#crd#	CD	_	12	num	_	_
11	possible	possible	JJ	_	12	attr	_	_
12	index	index	NN	_	8	ppmod	_	_
13	of	of	IN	_	18	case	_	_
14	the	the	DT	_	18	det	_	_
15	drug1	drug0	NN	_	18	attr	_	_
16	-	-	:	_	18	p	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	reaction	reaction	NN	_	12	ppmod	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	DER	der	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	.	.	.	_	8	p	_	_

1	Core	core	NN	_	2	com	_	_
2	temperature	temperature	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	decreased	decrease	VBN	_	0	root	_	_
5	in	in	IN	_	6	case	_	_
6	rats	rat	NNS	_	4	ppmod	_	_
7	in	in	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	dose-dependent	dose-dependent	JJ	_	10	attr	_	_
10	manner	manner	NN	_	4	ppmod	_	_
11	when	when	WRB	_	14	adv	_	_
12	drug1	drug0	NN	_	14	dep	_	_
13	was	be	VBD	_	14	aux	_	_
14	administered	administer	VBN	_	4	comp	_	_
15	to	to	TO	_	16	aux	_	_
16	rats	rat	NNS	_	14	ppmod	_	_
17	treated	treat	VBN	_	16	acl	_	_
18	with	with	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	8	0	CD	_	21	num	_	_
21	hours	hour	NNS	_	25	dat	_	_
22	before	before	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	drug3	drug0	NN	_	25	com	_	_
25	challenge	challenge	NN	_	17	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	The	the	DT	_	2	det	_	_
2	decrease	decrease	NN	_	5	dep	_	_
3	in	in	IN	_	4	case	_	_
4	temperature	temperature	NN	_	2	ppmod	_	_
5	began	begin	VBD	_	0	root	_	_
6	within	within	IN	_	8	case	_	_
7	20	0	CD	_	8	num	_	_
8	minutes	minute	NNS	_	5	ppmod	_	_
9	after	after	IN	_	11	case	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	administration	administration	NN	_	8	ppmod	_	_
12	,	,	,	_	5	p	_	_
13	reaching	reach	VBG	_	5	comp	_	_
14	a	a	DT	_	16	det	_	_
15	maximal	maximal	JJ	_	16	attr	_	_
16	decrease	decrease	NN	_	13	obj	_	_
17	between	between	IN	_	21	case	_	_
18	60	0	CD	_	21	num	_	_
19	and	and	CC	_	18	cc	_	_
20	120	0	CD	_	18	conj	_	_
21	minutes	minute	NNS	_	16	ppmod	_	_
22	post	post	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	.	.	.	_	5	p	_	_

1	The	the	DT	_	3	det	_	_
2	core	core	NN	_	3	com	_	_
3	temperature	temperature	NN	_	4	dep	_	_
4	returned	return	VBD	_	0	root	_	_
5	to	to	TO	_	8	aux	_	_
6	normal	normal	JJ	_	8	attr	_	_
7	300	0	CD	_	8	num	_	_
8	minutes	minute	NNS	_	4	ppmod	_	_
9	after	after	IN	_	10	case	_	_
10	drug1	drug0	NN	_	4	ppmod	_	_
11	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	blood	blood	NN	_	3	com	_	_
3	pressure	pressure	NN	_	8	dep	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	carotid	carotid	NN	_	6	com	_	_
6	cannulation	cannulation	NN	_	3	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	decreased	decrease	VBD	_	0	root	_	_
9	along	along	IN	_	13	case	_	_
10	with	with	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	core	core	NN	_	13	com	_	_
13	temperature	temperature	NN	_	8	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	Maximal	maximal	JJ	_	2	attr	_	_
2	hypotension	hypotension	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	found	find	VBN	_	0	root	_	_
5	120	0	CD	_	6	num	_	_
6	minutes	minute	NNS	_	8	dat	_	_
7	post	post	IN	_	8	case	_	_
8	drug1	drug0	NN	_	4	ppmod	_	_
9	,	,	,	_	4	p	_	_
10	and	and	CC	_	4	cc	_	_
11	returned	return	VBD	_	4	conj	_	_
12	to	to	TO	_	15	aux	_	_
13	normal	normal	JJ	_	15	attr	_	_
14	300	0	CD	_	15	num	_	_
15	minutes	minute	NNS	_	11	ppmod	_	_
16	after	after	IN	_	17	case	_	_
17	drug2	drug0	NN	_	11	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	Heart	heart	NN	_	2	com	_	_
2	rate	rate	NN	_	3	dep	_	_
3	increased	increase	VBD	_	0	root	_	_
4	initially	initially	RB	_	3	adv	_	_
5	and	and	CC	_	3	cc	_	_
6	returned	return	VBD	_	3	conj	_	_
7	to	to	TO	_	10	aux	_	_
8	normal	normal	JJ	_	10	attr	_	_
9	40	0	CD	_	10	num	_	_
10	minutes	minute	NNS	_	6	ppmod	_	_
11	after	after	IN	_	13	case	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	challenge	challenge	NN	_	6	ppmod	_	_
14	.	.	.	_	3	p	_	_

1	Intestinal	intestinal	JJ	_	2	attr	_	_
2	absorption	absorption	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	chick	chick	NN	_	2	ppmod	_	_
8	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	intestinal	intestinal	JJ	_	3	attr	_	_
3	absorption	absorption	NN	_	11	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	drug2	drug0	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	investigated	investigate	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	chick	chick	NN	_	11	ppmod	_	_
15	by	by	IN	_	16	case	_	_
16	means	mean	NNS	_	11	ppmod	_	_
17	of	of	IN	_	24	case	_	_
18	the	the	DT	_	23	det	_	_
19	in	in	FW	_	20	adv	_	_
20	situ	situ	FW	_	23	attr	_	_
21	ligated	ligate	VBN	_	23	attr	_	_
22	duodenal	duodenal	JJ	_	23	attr	_	_
23	loop	loop	NN	_	24	com	_	_
24	technique	technique	NN	_	16	ppmod	_	_
25	.	.	.	_	11	p	_	_

1	By	by	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	procedure	procedure	NN	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	it	it	PRP	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	observed	observe	VBN	_	0	root	_	_
8	that	that	IN	_	15	mark	_	_
9	drug1	drug0	NN	_	15	dep	_	_
10	is	be	VBZ	_	15	aux	_	_
11	rapidly	rapidly	RB	_	15	adv	_	_
12	and	and	CC	_	11	cc	_	_
13	essentially	essentially	RB	_	14	com	_	_
14	completely	completely	RB	_	11	conj	_	_
15	absorbed	absorb	VBN	_	7	comp	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	80-95	0	CD	_	15	num	_	_
18	%	%	NN	_	17	meta	_	_
19	)	-rrb-	-RRB-	_	17	p	_	_
20	from	from	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	lumen	lumen	NN	_	15	ppmod	_	_
23	at	at	IN	_	25	case	_	_
24	drug2	drug0	JJ	_	25	attr	_	_
25	concentrations	concentration	NNS	_	15	ppmod	_	_
26	up	up	RB	_	28	adv	_	_
27	to	to	TO	_	28	attr	_	_
28	5	0	CD	_	29	num	_	_
29	mM	mm	NN	_	25	attr	_	_
30	,	,	,	_	15	p	_	_
31	declining	decline	VBG	_	15	comp	_	_
32	to	to	TO	_	36	aux	_	_
33	about	about	RB	_	34	adv	_	_
34	50	0	CD	_	36	num	_	_
35	%	%	NN	_	34	meta	_	_
36	absorption	absorption	NN	_	31	ppmod	_	_
37	at	at	IN	_	39	case	_	_
38	50	0	CD	_	39	num	_	_
39	mM	mm	NN	_	31	ppmod	_	_
40	.	.	.	_	7	p	_	_

1	Transfer	transfer	NN	_	18	dep	_	_
2	from	from	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	intestinal	intestinal	JJ	_	5	attr	_	_
5	lumen	lumen	NN	_	1	ppmod	_	_
6	to	to	TO	_	9	aux	_	_
7	the	the	DT	_	9	det	_	_
8	mucosal	mucosal	JJ	_	9	attr	_	_
9	cells	cell	NNS	_	1	ppmod	_	_
10	at	at	IN	_	13	case	_	_
11	low	low	JJ	_	13	attr	_	_
12	drug1	drug0	NN	_	13	com	_	_
13	concentration	concentration	NN	_	1	ppmod	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	0.1	0	CD	_	16	num	_	_
16	mM	mm	NN	_	13	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	is	be	VBZ	_	0	root	_	_
19	rapid	rapid	JJ	_	18	dep	_	_
20	,	,	,	_	18	p	_	_
21	while	while	IN	_	30	mark	_	_
22	transfer	transfer	NN	_	30	dep	_	_
23	from	from	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	mucosal	mucosal	JJ	_	26	attr	_	_
26	cells	cell	NNS	_	22	ppmod	_	_
27	to	to	TO	_	29	aux	_	_
28	the	the	DT	_	29	det	_	_
29	body	body	NN	_	22	ppmod	_	_
30	occurs	occur	VBZ	_	18	comp	_	_
31	more	more	RBR	_	32	com	_	_
32	slowly	slowly	RB	_	30	adv	_	_
33	.	.	.	_	18	p	_	_

1	At	at	IN	_	4	case	_	_
2	stable	stable	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	concentrations	concentration	NNS	_	16	ppmod	_	_
5	greater	great	JJR	_	4	attr	_	_
6	than	than	IN	_	8	case	_	_
7	1	0	CD	_	8	num	_	_
8	mM	mm	NN	_	5	ppmod	_	_
9	,	,	,	_	16	p	_	_
10	fractional	fractional	JJ	_	13	attr	_	_
11	mucosal	mucosal	JJ	_	13	attr	_	_
12	cell	cell	NN	_	13	com	_	_
13	accumulation	accumulation	NN	_	16	dep	_	_
14	of	of	IN	_	15	case	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	remains	remain	VBZ	_	0	root	_	_
17	constant	constant	JJ	_	16	dep	_	_
18	,	,	,	_	16	p	_	_
19	while	while	IN	_	25	mark	_	_
20	fractional	fractional	JJ	_	21	attr	_	_
21	transfer	transfer	NN	_	25	dep	_	_
22	to	to	TO	_	24	aux	_	_
23	the	the	DT	_	24	det	_	_
24	body	body	NN	_	21	ppmod	_	_
25	declines	decline	VBZ	_	16	comp	_	_
26	.	.	.	_	16	p	_	_

1	However	however	RB	_	14	adv	_	_
2	,	,	,	_	14	p	_	_
3	total	total	JJ	_	5	attr	_	_
4	mucosal	mucosal	JJ	_	5	attr	_	_
5	accumulation	accumulation	NN	_	14	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	5	cc	_	_
9	that	that	DT	_	5	conj	_	_
10	transferred	transfer	VBN	_	9	acl	_	_
11	to	to	TO	_	13	aux	_	_
12	the	the	DT	_	13	det	_	_
13	body	body	NN	_	10	ppmod	_	_
14	increase	increase	VBP	_	0	root	_	_
15	in	in	IN	_	19	case	_	_
16	a	a	DT	_	19	det	_	_
17	linear	linear	JJ	_	19	attr	_	_
18	logarithmic	logarithmic	JJ	_	19	attr	_	_
19	fashion	fashion	NN	_	14	ppmod	_	_
20	from	from	IN	_	21	case	_	_
21	0.05	0	CD	_	19	ppmod	_	_
22	to	to	TO	_	25	aux	_	_
23	5	0	CD	_	24	num	_	_
24	mm	mm	NN	_	25	com	_	_
25	drug2	drug0	NN	_	19	ppmod	_	_
26	.	.	.	_	14	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	readily	readily	RB	_	7	adv	_	_
7	penetrates	penetrate	VBZ	_	3	comp	_	_
8	both	both	CC	_	13	cc	_	_
9	the	the	DT	_	13	det	_	_
10	mucosal	mucosal	JJ	_	13	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	serosal	serosal	JJ	_	10	conj	_	_
13	surfaces	surface	NNS	_	7	obj	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	epithelial	epithelial	JJ	_	17	attr	_	_
17	membrane	membrane	NN	_	13	ppmod	_	_
18	.	.	.	_	3	p	_	_

1	Furthermore	furthermore	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	drug1	drug0	NN	_	8	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	do	do	VBP	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	appear	appear	VB	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	share	share	VB	_	8	comp	_	_
11	a	a	DT	_	14	det	_	_
12	common	common	JJ	_	14	attr	_	_
13	transport	transport	NN	_	14	com	_	_
14	pathway	pathway	NN	_	10	obj	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	duodenum	duodenum	NN	_	14	ppmod	_	_
18	and	and	CC	_	8	cc	_	_
19	no	no	DT	_	20	det	_	_
20	evidence	evidence	NN	_	22	dep	_	_
21	was	be	VBD	_	22	aux	_	_
22	obtained	obtain	VBN	_	8	conj	_	_
23	for	for	IN	_	25	case	_	_
24	any	any	DT	_	25	det	_	_
25	interaction	interaction	NN	_	22	ppmod	_	_
26	between	between	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	two	#crd#	CD	_	25	ppmod	_	_
29	at	at	IN	_	31	case	_	_
30	this	this	DT	_	31	det	_	_
31	level	level	NN	_	25	ppmod	_	_
32	.	.	.	_	8	p	_	_

1	drug1	drug0	JJ	_	2	attr	_	_
2	administration	administration	NN	_	6	dep	_	_
3	to	to	TO	_	5	aux	_	_
4	rachitic	rachitic	JJ	_	5	attr	_	_
5	chicks	chick	NNS	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	effective	effective	JJ	_	6	dep	_	_
8	in	in	IN	_	10	case	_	_
9	significantly	significantly	RB	_	10	adv	_	_
10	elevating	elevate	VBG	_	6	ppmod	_	_
11	duodenal	duodenal	JJ	_	13	attr	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	absorption	absorption	NN	_	10	obj	_	_
14	,	,	,	_	13	p	_	_
15	acting	act	VBG	_	13	acl	_	_
16	primarily	primarily	RB	_	15	adv	_	_
17	to	to	TO	_	18	aux	_	_
18	enhance	enhance	VB	_	15	comp	_	_
19	serosal	serosal	JJ	_	20	attr	_	_
20	transport	transport	NN	_	18	obj	_	_
21	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	an	an	DT	_	5	det	_	_
4	updated	updated	JJ	_	5	attr	_	_
5	review	review	NN	_	1	appo	_	_
6	of	of	IN	_	8	case	_	_
7	its	its	PRP$	_	8	poss	_	_
8	use	use	NN	_	5	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	management	management	NN	_	5	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	schizophrenia	schizophrenia	NN	_	11	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	4	det	_	_
4	drug2	drug0	NN	_	1	appo	_	_
5	,	,	,	_	1	p	_	_
6	is	be	VBZ	_	0	root	_	_
7	a	a	DT	_	8	det	_	_
8	drug3	drug0	NN	_	6	obj	_	_
9	which	which	WDT	_	10	dep	_	_
10	has	have	VBZ	_	8	relcl	_	_
11	proven	proven	JJ	_	12	attr	_	_
12	efficacy	efficacy	NN	_	10	obj	_	_
13	against	against	IN	_	18	case	_	_
14	the	the	DT	_	18	det	_	_
15	positive	positive	JJ	_	18	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	negative	negative	JJ	_	15	conj	_	_
18	symptoms	symptom	NNS	_	12	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	schizophrenia	schizophrenia	NN	_	18	ppmod	_	_
21	.	.	.	_	6	p	_	_

1	Compared	compare	VBN	_	3	adv	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	it	it	PRP	_	6	dep	_	_
6	has	have	VBZ	_	0	root	_	_
7	greater	great	JJR	_	8	attr	_	_
8	affinity	affinity	NN	_	6	obj	_	_
9	for	for	IN	_	11	case	_	_
10	serotonin	serotonin	NN	_	11	com	_	_
11	5-HT2A	0-ht0a	NN	_	8	ppmod	_	_
12	than	than	IN	_	16	case	_	_
13	for	for	IN	_	16	case	_	_
14	dopamine	dopamine	NN	_	16	com	_	_
15	D2	d0	NN	_	16	com	_	_
16	receptors	receptor	NNS	_	8	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	In	in	IN	_	6	case	_	_
2	large	large	JJ	_	5	adv	_	_
3	,	,	,	_	5	p	_	_
4	well	well	RB	_	5	adv	_	_
5	controlled	control	VBN	_	6	attr	_	_
6	trials	trial	NNS	_	20	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	6	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	schizophrenia	schizophrenia	NN	_	8	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	related	related	JJ	_	13	attr	_	_
13	psychoses	psychosis	NNS	_	10	conj	_	_
14	,	,	,	_	20	p	_	_
15	drug1	drug0	NN	_	19	attr	_	_
16	5	0	CD	_	19	num	_	_
17	to	to	TO	_	19	attr	_	_
18	20	0	CD	_	19	num	_	_
19	mg/day	mg/day	NN	_	20	dep	_	_
20	was	be	VBD	_	0	root	_	_
21	significantly	significantly	RB	_	22	adv	_	_
22	superior	superior	JJ	_	20	dep	_	_
23	to	to	TO	_	28	aux	_	_
24	drug2	drug0	NN	_	28	attr	_	_
25	5	0	CD	_	28	num	_	_
26	to	to	TO	_	28	attr	_	_
27	20	0	CD	_	28	num	_	_
28	mg/day	mg/day	NN	_	22	ppmod	_	_
29	in	in	IN	_	31	case	_	_
30	overall	overall	JJ	_	31	attr	_	_
31	improvements	improvement	NNS	_	28	ppmod	_	_
32	in	in	IN	_	35	case	_	_
33	psychopathology	psychopathology	NN	_	35	attr	_	_
34	rating	rating	JJ	_	35	attr	_	_
35	scales	scale	NNS	_	31	ppmod	_	_
36	and	and	CC	_	35	cc	_	_
37	in	in	IN	_	39	case	_	_
38	the	the	DT	_	39	det	_	_
39	treatment	treatment	NN	_	35	conj	_	_
40	of	of	IN	_	44	case	_	_
41	depressive	depressive	JJ	_	44	attr	_	_
42	and	and	CC	_	44	cc	_	_
43	negative	negative	JJ	_	44	attr	_	_
44	symptoms	symptom	NNS	_	39	ppmod	_	_
45	,	,	,	_	20	p	_	_
46	and	and	CC	_	20	cc	_	_
47	was	be	VBD	_	20	conj	_	_
48	comparable	comparable	JJ	_	47	dep	_	_
49	in	in	IN	_	50	case	_	_
50	effects	effect	NNS	_	48	ppmod	_	_
51	on	on	IN	_	54	case	_	_
52	positive	positive	JJ	_	54	attr	_	_
53	psychotic	psychotic	JJ	_	54	attr	_	_
54	symptoms	symptom	NNS	_	50	ppmod	_	_
55	.	.	.	_	20	p	_	_

1	The	the	DT	_	3	det	_	_
2	1-year	0-year	JJ	_	3	attr	_	_
3	risk	risk	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	relapse	relapse	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	rehospitalisation	rehospitalisation	NN	_	5	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	was	be	VBD	_	0	root	_	_
10	significantly	significantly	RB	_	11	adv	_	_
11	lower	low	JJR	_	9	dep	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	than	than	IN	_	17	case	_	_
15	with	with	IN	_	17	case	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	treatment	treatment	NN	_	11	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	In	in	IN	_	6	case	_	_
2	the	the	DT	_	6	det	_	_
3	first	#ord#	JJ	_	6	attr	_	_
4	double-blind	double-blind	JJ	_	6	attr	_	_
5	comparative	comparative	JJ	_	6	attr	_	_
6	study	study	NN	_	20	ppmod	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	28-week	0-week	JJ	_	6	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	6	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	,	,	,	_	20	p	_	_
15	drug3	drug0	NN	_	19	attr	_	_
16	10	0	CD	_	19	num	_	_
17	to	to	TO	_	19	attr	_	_
18	20	0	CD	_	19	num	_	_
19	mg/day	mg/day	NN	_	20	dep	_	_
20	proved	prove	VBD	_	0	root	_	_
21	to	to	TO	_	22	aux	_	_
22	be	be	VB	_	20	comp	_	_
23	significantly	significantly	RB	_	22	adv	_	_
24	more	more	RBR	_	25	adv	_	_
25	effective	effective	JJ	_	22	dep	_	_
26	than	than	IN	_	31	case	_	_
27	drug4	drug0	NN	_	31	attr	_	_
28	4	0	CD	_	31	num	_	_
29	to	to	TO	_	31	attr	_	_
30	12	0	CD	_	31	num	_	_
31	mg/day	mg/day	NN	_	25	ppmod	_	_
32	in	in	IN	_	34	case	_	_
33	the	the	DT	_	34	det	_	_
34	treatment	treatment	NN	_	25	ppmod	_	_
35	of	of	IN	_	39	case	_	_
36	negative	negative	JJ	_	39	attr	_	_
37	and	and	CC	_	39	cc	_	_
38	depressive	depressive	JJ	_	39	attr	_	_
39	symptoms	symptom	NNS	_	34	ppmod	_	_
40	but	but	CC	_	34	cc	_	_
41	not	not	RB	_	45	neg	_	_
42	on	on	IN	_	45	case	_	_
43	overall	overall	JJ	_	44	attr	_	_
44	psychopathology	psychopathology	NN	_	45	com	_	_
45	symptoms	symptom	NNS	_	34	conj	_	_
46	.	.	.	_	20	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	17	ppmod	_	_
3	,	,	,	_	17	p	_	_
4	preliminary	preliminary	JJ	_	5	attr	_	_
5	results	result	NNS	_	17	dep	_	_
6	from	from	IN	_	10	case	_	_
7	an	an	DT	_	10	det	_	_
8	8-week	0-week	JJ	_	10	attr	_	_
9	controlled	controlled	JJ	_	10	attr	_	_
10	study	study	NN	_	5	ppmod	_	_
11	suggested	suggest	VBD	_	17	aux	_	_
12	drug1	drug0	NN	_	16	attr	_	_
13	2	0	CD	_	16	num	_	_
14	to	to	TO	_	16	attr	_	_
15	6	0	CD	_	16	num	_	_
16	mg/day	mg/day	NN	_	17	obj	_	_
17	was	be	VBD	_	0	root	_	_
18	superior	superior	JJ	_	17	dep	_	_
19	to	to	TO	_	20	aux	_	_
20	drug2	drug0	NN	_	18	ppmod	_	_
21	5	0	CD	_	20	num	_	_
22	to	to	TO	_	24	aux	_	_
23	20	0	CD	_	24	num	_	_
24	mg/day	mg/day	NN	_	18	ppmod	_	_
25	against	against	IN	_	29	case	_	_
26	positive	positive	JJ	_	29	attr	_	_
27	and	and	CC	_	26	cc	_	_
28	anxiety/depressive	anxiety/depressive	JJ	_	26	conj	_	_
29	symptoms	symptom	NNS	_	24	ppmod	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	p	p	NN	_	29	prn	_	_
32	&lt	&lt	CD	_	31	num	_	_
33	;	;	:	_	31	p	_	_
34	0.05	0	CD	_	31	num	_	_
35	)	-rrb-	-RRB-	_	31	p	_	_
36	,	,	,	_	17	p	_	_
37	although	although	IN	_	46	mark	_	_
38	consistent	consistent	JJ	_	46	comp	_	_
39	with	with	IN	_	42	case	_	_
40	the	the	DT	_	42	det	_	_
41	first	#ord#	JJ	_	42	attr	_	_
42	study	study	NN	_	38	ppmod	_	_
43	,	,	,	_	46	p	_	_
44	both	both	DT	_	45	det	_	_
45	agents	agent	NNS	_	46	dep	_	_
46	demonstrated	demonstrate	VBD	_	17	comp	_	_
47	similar	similar	JJ	_	48	attr	_	_
48	efficacy	efficacy	NN	_	46	obj	_	_
49	on	on	IN	_	50	case	_	_
50	measures	measure	NNS	_	46	ppmod	_	_
51	of	of	IN	_	53	case	_	_
52	overall	overall	JJ	_	53	attr	_	_
53	psychopathology	psychopathology	NN	_	50	ppmod	_	_
54	.	.	.	_	17	p	_	_

1	Improvements	improvement	NNS	_	21	dep	_	_
2	in	in	IN	_	5	case	_	_
3	general	general	JJ	_	5	attr	_	_
4	cognitive	cognitive	JJ	_	5	attr	_	_
5	function	function	NN	_	1	ppmod	_	_
6	seen	see	VBN	_	5	acl	_	_
7	with	with	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	treatment	treatment	NN	_	6	ppmod	_	_
10	in	in	IN	_	14	case	_	_
11	a	a	DT	_	14	det	_	_
12	1-year	0-year	JJ	_	14	attr	_	_
13	controlled	controlled	JJ	_	14	attr	_	_
14	study	study	NN	_	6	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	with	with	IN	_	19	case	_	_
18	early-phase	early-phase	JJ	_	19	attr	_	_
19	schizophrenia	schizophrenia	NNS	_	16	ppmod	_	_
20	,	,	,	_	1	p	_	_
21	were	be	VBD	_	0	root	_	_
22	significantly	significantly	RB	_	23	adv	_	_
23	greater	great	JJR	_	21	dep	_	_
24	than	than	IN	_	25	case	_	_
25	changes	change	NNS	_	23	ppmod	_	_
26	seen	see	VBN	_	25	acl	_	_
27	with	with	IN	_	29	case	_	_
28	either	either	CC	_	29	cc	_	_
29	drug2	drug0	NN	_	26	ppmod	_	_
30	or	or	CC	_	29	cc	_	_
31	drug3	drug0	NN	_	29	conj	_	_
32	.	.	.	_	21	p	_	_

1	However	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	preliminary	preliminary	JJ	_	4	attr	_	_
4	results	result	NNS	_	9	dep	_	_
5	from	from	IN	_	8	case	_	_
6	an	an	DT	_	8	det	_	_
7	8-week	0-week	JJ	_	8	attr	_	_
8	trial	trial	NN	_	4	ppmod	_	_
9	showed	show	VBD	_	0	root	_	_
10	comparable	comparable	JJ	_	13	attr	_	_
11	cognitive	cognitive	JJ	_	13	attr	_	_
12	enhancing	enhancing	NN	_	13	com	_	_
13	effects	effect	NNS	_	9	obj	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	treatment	treatment	NN	_	15	conj	_	_
19	in	in	IN	_	20	case	_	_
20	patients	patient	NNS	_	13	ppmod	_	_
21	with	with	IN	_	22	case	_	_
22	schizophrenia	schizophrenia	NN	_	20	ppmod	_	_
23	or	or	CC	_	22	cc	_	_
24	schizoaffective	schizoaffective	JJ	_	25	attr	_	_
25	disorder	disorder	NN	_	22	conj	_	_
26	.	.	.	_	9	p	_	_

1	Several	several	JJ	_	2	attr	_	_
2	studies	study	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	has	have	VBZ	_	7	lv	_	_
7	benefits	benefit	NNS	_	3	comp	_	_
8	against	against	IN	_	9	case	_	_
9	symptoms	symptom	NNS	_	7	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	aggression	aggression	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	agitation	agitation	NN	_	11	conj	_	_
14	,	,	,	_	7	p	_	_
15	while	while	IN	_	19	mark	_	_
16	other	other	JJ	_	17	attr	_	_
17	studies	study	NNS	_	19	dep	_	_
18	strongly	strongly	RB	_	19	adv	_	_
19	support	support	VBP	_	7	comp	_	_
20	the	the	DT	_	21	det	_	_
21	effectiveness	effectiveness	NN	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	in	in	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	treatment	treatment	NN	_	21	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	depressive	depressive	JJ	_	29	attr	_	_
29	symptomatology	symptomatology	NN	_	26	ppmod	_	_
30	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	associated	associate	VBN	_	0	root	_	_
4	with	with	IN	_	8	case	_	_
5	significantly	significantly	RB	_	6	adv	_	_
6	fewer	few	JJR	_	8	attr	_	_
7	extrapyramidal	extrapyramidal	NN	_	8	com	_	_
8	symptoms	symptom	NNS	_	3	ppmod	_	_
9	than	than	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug3	drug0	NN	_	10	conj	_	_
13	.	.	.	_	3	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	drug1	drug0	NN	_	7	dep	_	_
5	is	be	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	associated	associate	VBN	_	0	root	_	_
8	with	with	IN	_	10	case	_	_
9	a	a	DT	_	10	det	_	_
10	risk	risk	NN	_	7	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	agranulocytosis	agranulocytosis	NN	_	10	ppmod	_	_
13	as	as	IN	_	14	mark	_	_
14	seen	see	VBN	_	7	comp	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	clinically	clinically	RB	_	19	adv	_	_
19	significant	significant	JJ	_	20	attr	_	_
20	hyperprolactinaemia	hyperprolactinaemia	NN	_	16	conj	_	_
21	as	as	IN	_	22	mark	_	_
22	seen	see	VBN	_	20	acl	_	_
23	with	with	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	or	or	CC	_	24	cc	_	_
26	prolongation	prolongation	NN	_	24	conj	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	QT	qt	JJ	_	30	attr	_	_
30	interval	interval	NN	_	26	ppmod	_	_
31	.	.	.	_	7	p	_	_

1	The	the	DT	_	5	det	_	_
2	most	most	RBS	_	3	adv	_	_
3	common	common	JJ	_	5	attr	_	_
4	adverse	adverse	JJ	_	5	attr	_	_
5	effects	effect	NNS	_	9	dep	_	_
6	reported	report	VBN	_	5	acl	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	are	be	VBP	_	0	root	_	_
10	bodyweight	bodyweight	NN	_	11	com	_	_
11	gain	gain	NN	_	9	obj	_	_
12	,	,	,	_	11	p	_	_
13	somnolence	somnolence	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	dizziness	dizziness	NN	_	11	conj	_	_
16	,	,	,	_	15	p	_	_
17	anticholinergic	anticholinergic	JJ	_	18	attr	_	_
18	effects	effect	NNS	_	11	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	constipation	constipation	NN	_	18	prn	_	_
21	and	and	CC	_	20	cc	_	_
22	dry	dry	NN	_	23	com	_	_
23	mouth	mouth	NN	_	20	conj	_	_
24	)	-rrb-	-RRB-	_	20	p	_	_
25	and	and	CC	_	18	cc	_	_
26	transient	transient	JJ	_	30	attr	_	_
27	asymptomatic	asymptomatic	JJ	_	30	attr	_	_
28	liver	liver	NN	_	30	com	_	_
29	enzyme	enzyme	NN	_	30	com	_	_
30	elevations	elevation	NNS	_	11	conj	_	_
31	.	.	.	_	9	p	_	_

1	In	in	IN	_	2	case	_	_
2	comparison	comparison	NN	_	40	ppmod	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	40	p	_	_
6	the	the	DT	_	8	det	_	_
7	adverse	adverse	JJ	_	8	attr	_	_
8	events	event	NNS	_	40	dep	_	_
9	reported	report	VBN	_	8	acl	_	_
10	significantly	significantly	RB	_	12	com	_	_
11	more	more	RBR	_	12	com	_	_
12	frequently	frequently	RB	_	9	adv	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	9	ppmod	_	_
15	in	in	IN	_	19	case	_	_
16	>	>	JJ	_	19	attr	_	_
17	or	or	CC	_	16	cc	_	_
18	=	=	JJ	_	16	conj	_	_
19	3.5	0	CD	_	9	ppmod	_	_
20	%	%	NN	_	19	meta	_	_
21	of	of	IN	_	22	case	_	_
22	patients	patient	NNS	_	19	ppmod	_	_
23	were	be	VBD	_	22	acl	_	_
24	dry	dry	JJ	_	25	attr	_	_
25	mouth	mouth	NN	_	23	obj	_	_
26	,	,	,	_	25	p	_	_
27	bodyweight	bodyweight	NN	_	28	com	_	_
28	gain	gain	NN	_	25	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	increased	increase	VBN	_	31	attr	_	_
31	appetite	appetite	NN	_	25	conj	_	_
32	and	and	CC	_	9	cc	_	_
33	compared	compare	VBN	_	9	conj	_	_
34	with	with	IN	_	35	case	_	_
35	drug3	drug0	NN	_	33	ppmod	_	_
36	,	,	,	_	35	p	_	_
37	only	only	RB	_	35	adv	_	_
38	bodyweight	bodyweight	NN	_	39	com	_	_
39	gain	gain	NN	_	35	appo	_	_
40	occurred	occur	VBD	_	0	root	_	_
41	significantly	significantly	RB	_	43	com	_	_
42	more	more	RBR	_	43	com	_	_
43	frequently	frequently	RB	_	40	adv	_	_
44	with	with	IN	_	45	case	_	_
45	drug4	drug0	NN	_	40	ppmod	_	_
46	.	.	.	_	40	p	_	_

1	The	the	DT	_	4	det	_	_
2	high	high	JJ	_	4	attr	_	_
3	acquisition	acquisition	NN	_	4	com	_	_
4	cost	cost	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	is	be	VBZ	_	8	aux	_	_
8	offset	offset	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	reductions	reduction	NNS	_	8	ppmod	_	_
11	in	in	IN	_	14	case	_	_
12	other	other	JJ	_	14	attr	_	_
13	treatment	treatment	NN	_	14	com	_	_
14	costs	cost	NNS	_	10	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	inpatient	inpatient	NN	_	14	prn	_	_
17	and/or	and/or	CC	_	16	cc	_	_
18	outpatient	outpatient	JJ	_	19	attr	_	_
19	services	service	NNS	_	16	conj	_	_
20	)	-rrb-	-RRB-	_	16	p	_	_
21	of	of	IN	_	22	case	_	_
22	schizophrenia	schizophrenia	NN	_	14	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	Pharmacoeconomic	pharmacoeconomic	JJ	_	2	attr	_	_
2	analyses	analysis	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	drug1	drug0	NN	_	9	dep	_	_
6	does	do	VBZ	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	significantly	significantly	RB	_	9	adv	_	_
9	increase	increase	VB	_	3	comp	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	may	may	MD	_	14	modal	_	_
13	even	even	RB	_	14	adv	_	_
14	decrease	decrease	VB	_	9	conj	_	_
15	,	,	,	_	14	p	_	_
16	the	the	DT	_	20	det	_	_
17	overall	overall	JJ	_	20	attr	_	_
18	direct	direct	JJ	_	20	attr	_	_
19	treatment	treatment	NN	_	20	com	_	_
20	costs	cost	NNS	_	14	obj	_	_
21	of	of	IN	_	22	case	_	_
22	schizophrenia	schizophrenia	NN	_	20	ppmod	_	_
23	,	,	,	_	14	p	_	_
24	compared	compare	VBN	_	26	adv	_	_
25	with	with	IN	_	26	case	_	_
26	drug2	drug0	NN	_	14	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	Compared	compare	VBN	_	3	adv	_	_
2	with	with	IN	_	3	case	_	_
3	drug1	drug0	NN	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	drug2	drug0	NN	_	9	dep	_	_
6	has	have	VBZ	_	9	aux	_	_
7	also	also	RB	_	9	adv	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	decrease	decrease	VB	_	9	comp	_	_
12	overall	overall	JJ	_	14	attr	_	_
13	treatment	treatment	NN	_	14	com	_	_
14	costs	cost	NNS	_	11	obj	_	_
15	,	,	,	_	11	p	_	_
16	despite	despite	IN	_	22	case	_	_
17	the	the	DT	_	22	det	_	_
18	several-fold	several-fold	RB	_	19	adv	_	_
19	higher	high	JJR	_	22	attr	_	_
20	daily	daily	JJ	_	22	attr	_	_
21	acquisition	acquisition	NN	_	22	com	_	_
22	cost	cost	NN	_	11	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug	drug	NN	_	22	ppmod	_	_
26	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	treatment	treatment	NN	_	3	dep	_	_
3	improves	improve	VBZ	_	0	root	_	_
4	quality	quality	NN	_	3	obj	_	_
5	of	of	IN	_	6	case	_	_
6	life	life	NN	_	4	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	4	ppmod	_	_
9	with	with	IN	_	10	case	_	_
10	schizophrenia	schizophrenia	NN	_	8	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	related	related	JJ	_	13	attr	_	_
13	psychoses	psychosis	NNS	_	10	conj	_	_
14	to	to	TO	_	17	aux	_	_
15	a	a	DT	_	17	det	_	_
16	greater	great	JJR	_	17	attr	_	_
17	extent	extent	NN	_	3	ppmod	_	_
18	than	than	IN	_	19	case	_	_
19	drug2	drug0	NN	_	17	ppmod	_	_
20	,	,	,	_	17	p	_	_
21	and	and	CC	_	17	cc	_	_
22	to	to	TO	_	26	aux	_	_
23	broadly	broadly	RB	_	26	adv	_	_
24	the	the	DT	_	26	det	_	_
25	same	same	JJ	_	26	attr	_	_
26	extent	extent	NN	_	17	conj	_	_
27	as	as	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	demonstrated	demonstrate	VBD	_	1	acl	_	_
5	superior	superior	JJ	_	7	attr	_	_
6	antipsychotic	antipsychotic	JJ	_	7	attr	_	_
7	efficacy	efficacy	NN	_	4	obj	_	_
8	compared	compare	VBN	_	10	adv	_	_
9	with	with	IN	_	10	case	_	_
10	drug2	drug0	NN	_	4	ppmod	_	_
11	in	in	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	treatment	treatment	NN	_	4	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	acute	acute	JJ	_	17	attr	_	_
16	phase	phase	NN	_	17	com	_	_
17	schizophrenia	schizophrenia	NN	_	13	ppmod	_	_
18	,	,	,	_	13	p	_	_
19	and	and	CC	_	13	cc	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	treatment	treatment	NN	_	13	conj	_	_
23	of	of	IN	_	25	case	_	_
24	some	some	DT	_	25	det	_	_
25	patients	patient	NNS	_	22	ppmod	_	_
26	with	with	IN	_	27	case	_	_
27	first-episode	first-episode	NN	_	25	ppmod	_	_
28	or	or	CC	_	27	cc	_	_
29	treatment-resistant	treatment-resistant	JJ	_	30	attr	_	_
30	schizophrenia	schizophrenia	NN	_	27	conj	_	_
31	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	reduced	reduce	VBN	_	3	attr	_	_
3	risk	risk	NN	_	23	dep	_	_
4	of	of	IN	_	6	case	_	_
5	adverse	adverse	JJ	_	6	attr	_	_
6	events	event	NNS	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	therapeutic	therapeutic	JJ	_	9	attr	_	_
9	superiority	superiority	NN	_	6	conj	_	_
10	compared	compare	VBN	_	3	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	treatment	treatment	NN	_	10	ppmod	_	_
18	of	of	IN	_	22	case	_	_
19	negative	negative	JJ	_	22	attr	_	_
20	and	and	CC	_	22	cc	_	_
21	depressive	depressive	JJ	_	22	attr	_	_
22	symptoms	symptom	NNS	_	17	ppmod	_	_
23	support	support	VBP	_	0	root	_	_
24	the	the	DT	_	25	det	_	_
25	choice	choice	NN	_	23	obj	_	_
26	of	of	IN	_	27	case	_	_
27	drug3	drug0	NN	_	25	ppmod	_	_
28	as	as	IN	_	31	case	_	_
29	a	a	DT	_	31	det	_	_
30	first-line	first-line	JJ	_	31	attr	_	_
31	option	option	NN	_	23	ppmod	_	_
32	in	in	IN	_	34	case	_	_
33	the	the	DT	_	34	det	_	_
34	management	management	NN	_	31	ppmod	_	_
35	of	of	IN	_	36	case	_	_
36	schizophrenia	schizophrenia	NN	_	34	ppmod	_	_
37	in	in	IN	_	40	case	_	_
38	the	the	DT	_	40	det	_	_
39	acute	acute	JJ	_	40	attr	_	_
40	phase	phase	NN	_	34	ppmod	_	_
41	and	and	CC	_	40	cc	_	_
42	for	for	IN	_	44	case	_	_
43	the	the	DT	_	44	det	_	_
44	maintenance	maintenance	NN	_	40	conj	_	_
45	of	of	IN	_	47	case	_	_
46	treatment	treatment	NN	_	47	com	_	_
47	response	response	NN	_	44	ppmod	_	_
48	.	.	.	_	23	p	_	_

1	Antimicrobial	antimicrobial	JJ	_	2	attr	_	_
2	activity	activity	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	alone	alone	RB	_	2	adv	_	_
6	and	and	CC	_	5	cc	_	_
7	in	in	IN	_	8	case	_	_
8	combination	combination	NN	_	5	conj	_	_
9	with	with	IN	_	11	case	_	_
10	some	some	DT	_	11	det	_	_
11	drug2	drug0	NNS	_	8	ppmod	_	_
12	.	.	.	_	2	p	_	_

1	Antimicrobial	antimicrobial	JJ	_	2	attr	_	_
2	activity	activity	NN	_	21	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	the	the	DT	_	8	det	_	_
7	aqueous	aqueous	JJ	_	8	attr	_	_
8	extract	extract	NN	_	4	prn	_	_
9	from	from	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	carpophores	carpophore	NNS	_	8	ppmod	_	_
12	of	of	IN	_	18	case	_	_
13	Ganoderma	ganoderma	NN	_	14	com	_	_
14	lucidum	lucidum	NN	_	18	attr	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	FR	fr	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	KARST	karst	NN	_	11	ppmod	_	_
19	)	-rrb-	-RRB-	_	8	p	_	_
20	was	be	VBD	_	21	aux	_	_
21	tested	test	VBN	_	0	root	_	_
22	in	in	FW	_	23	adv	_	_
23	vitro	vitro	FW	_	21	adv	_	_
24	against	against	IN	_	30	case	_	_
25	Gram	gram	NN	_	26	advnp	_	_
26	positive	positive	JJ	_	30	attr	_	_
27	and	and	CC	_	26	cc	_	_
28	Gram	gram	NN	_	29	advnp	_	_
29	negative	negative	JJ	_	26	conj	_	_
30	bacteria	bacteria	NNS	_	21	ppmod	_	_
31	by	by	IN	_	35	case	_	_
32	serial	serial	JJ	_	35	attr	_	_
33	broth	broth	NN	_	35	com	_	_
34	dilution	dilution	NN	_	35	com	_	_
35	method	method	NN	_	21	ppmod	_	_
36	,	,	,	_	21	p	_	_
37	and	and	CC	_	21	cc	_	_
38	the	the	DT	_	40	det	_	_
39	antimicrobial	antimicrobial	JJ	_	40	attr	_	_
40	activity	activity	NN	_	42	dep	_	_
41	was	be	VBD	_	42	aux	_	_
42	expressed	express	VBN	_	21	conj	_	_
43	by	by	IN	_	46	case	_	_
44	minimal	minimal	JJ	_	46	attr	_	_
45	inhibitory	inhibitory	JJ	_	46	attr	_	_
46	concentration	concentration	NN	_	42	ppmod	_	_
47	(	-lrb-	-LRB-	_	48	p	_	_
48	MIC	mic	NN	_	46	prn	_	_
49	)	-rrb-	-RRB-	_	48	p	_	_
50	.	.	.	_	21	p	_	_

1	Among	among	IN	_	3	case	_	_
2	fifteen	#crd#	CD	_	3	num	_	_
3	species	species	NNS	_	13	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	bacteria	bacteria	NNS	_	3	ppmod	_	_
6	tested	test	VBN	_	3	acl	_	_
7	,	,	,	_	13	p	_	_
8	the	the	DT	_	10	det	_	_
9	antimicrobial	antimicrobial	JJ	_	10	attr	_	_
10	activity	activity	NN	_	13	dep	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	was	be	VBD	_	0	root	_	_
14	the	the	DT	_	16	det	_	_
15	most	most	RBS	_	16	adv	_	_
16	potent	potent	JJ	_	13	obj	_	_
17	against	against	IN	_	19	case	_	_
18	Micrococcus	micrococcus	JJ	_	19	attr	_	_
19	luteus	luteus	NNS	_	16	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	MIC	mic	NN	_	13	prn	_	_
22	,	,	,	_	21	p	_	_
23	0.75	0	CD	_	24	num	_	_
24	mg/ml	mg/ml	NN	_	21	appo	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	.	.	.	_	13	p	_	_

1	To	to	TO	_	2	aux	_	_
2	investigate	investigate	VB	_	34	advcl	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	antimicrobial	antimicrobial	JJ	_	7	attr	_	_
7	combinations	combination	NNS	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	with	with	IN	_	12	case	_	_
11	four	#crd#	CD	_	12	num	_	_
12	kinds	kind	NNS	_	4	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	drug3	drug0	NN	_	14	prn	_	_
17	,	,	,	_	16	p	_	_
18	drug4	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	drug5	drug0	NN	_	16	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	drug6	drug0	NN	_	16	conj	_	_
23	)	-rrb-	-RRB-	_	16	p	_	_
24	,	,	,	_	34	p	_	_
25	the	the	DT	_	29	det	_	_
26	fractional	fractional	JJ	_	29	attr	_	_
27	inhibitory	inhibitory	JJ	_	29	attr	_	_
28	concentration	concentration	NN	_	29	com	_	_
29	index	index	NN	_	34	dep	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	FICI	fici	NN	_	29	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	was	be	VBD	_	34	aux	_	_
34	determined	determine	VBN	_	0	root	_	_
35	by	by	IN	_	37	case	_	_
36	checkerboard	checkerboard	JJ	_	37	attr	_	_
37	assay	assay	NN	_	34	ppmod	_	_
38	for	for	IN	_	40	case	_	_
39	each	each	DT	_	40	det	_	_
40	strain	strain	NN	_	37	ppmod	_	_
41	.	.	.	_	34	p	_	_

1	The	the	DT	_	3	det	_	_
2	antimicrobial	antimicrobial	JJ	_	3	attr	_	_
3	combinations	combination	NNS	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	with	with	IN	_	8	case	_	_
7	four	#crd#	CD	_	8	num	_	_
8	drug2	drug0	NNS	_	3	ppmod	_	_
9	resulted	result	VBD	_	0	root	_	_
10	in	in	IN	_	12	case	_	_
11	additive	additive	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	most	most	JJS	_	15	attr	_	_
15	instances	instance	NNS	_	12	ppmod	_	_
16	,	,	,	_	9	p	_	_
17	synergism	synergism	NN	_	9	obj	_	_
18	in	in	IN	_	20	case	_	_
19	two	#crd#	CD	_	20	num	_	_
20	instances	instance	NNS	_	17	ppmod	_	_
21	,	,	,	_	17	p	_	_
22	and	and	CC	_	17	cc	_	_
23	antagonism	antagonism	NN	_	17	conj	_	_
24	in	in	IN	_	26	case	_	_
25	two	#crd#	CD	_	26	num	_	_
26	instances	instance	NNS	_	23	ppmod	_	_
27	.	.	.	_	9	p	_	_

1	Synergism	synergism	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	observed	observe	VBN	_	0	root	_	_
4	when	when	WRB	_	7	adv	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	combined	combine	VBN	_	3	comp	_	_
8	with	with	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	against	against	IN	_	12	case	_	_
11	Bacillus	bacillus	FW	_	12	attr	_	_
12	subtilis	subtilis	FW	_	7	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	Klebsiella	klebsiella	FW	_	15	attr	_	_
15	oxytoca	oxytoca	FW	_	12	conj	_	_
16	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	protects	protect	VBZ	_	0	root	_	_
3	mouse	mouse	NN	_	4	com	_	_
4	tumour	tumour	NN	_	2	obj	_	_
5	and	and	CC	_	4	cc	_	_
6	normal	normal	JJ	_	7	attr	_	_
7	tissues	tissue	NNS	_	4	conj	_	_
8	from	from	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	toxicity	toxicity	NN	_	2	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	drug2	drug0	NN	_	10	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	Because	because	IN	_	6	mark	_	_
2	the	the	DT	_	4	det	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	drug2	drug0	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	given	give	VBN	_	17	advcl	_	_
7	exclusively	exclusively	RB	_	6	adv	_	_
8	by	by	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	route	route	NN	_	6	ppmod	_	_
12	in	in	IN	_	13	case	_	_
13	man	man	NN	_	11	ppmod	_	_
14	,	,	,	_	17	p	_	_
15	we	we	PRP	_	17	dep	_	_
16	have	have	VBP	_	17	aux	_	_
17	carried	carry	VBN	_	0	root	_	_
18	out	out	RP	_	17	prt	_	_
19	studies	study	NNS	_	17	obj	_	_
20	in	in	IN	_	21	case	_	_
21	mice	mouse	NNS	_	19	ppmod	_	_
22	on	on	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	antitumour	antitumour	JJ	_	25	attr	_	_
25	activity	activity	NN	_	19	ppmod	_	_
26	,	,	,	_	25	p	_	_
27	acute	acute	JJ	_	28	attr	_	_
28	toxicity	toxicity	NN	_	25	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	pharmacokinetics	pharmacokinetics	NNS	_	25	conj	_	_
31	of	of	IN	_	33	case	_	_
32	oral	oral	JJ	_	33	attr	_	_
33	drug3	drug0	NN	_	25	ppmod	_	_
34	,	,	,	_	33	p	_	_
35	either	either	CC	_	36	cc	_	_
36	alone	alone	RB	_	33	adv	_	_
37	or	or	CC	_	36	cc	_	_
38	in	in	IN	_	39	case	_	_
39	combination	combination	NN	_	36	conj	_	_
40	with	with	IN	_	43	case	_	_
41	the	the	DT	_	43	det	_	_
42	chemosensitizer	chemosensitizer	NN	_	43	com	_	_
43	drug4	drug0	NN	_	39	ppmod	_	_
44	.	.	.	_	17	p	_	_

1	In	in	IN	_	3	case	_	_
2	both	both	CC	_	3	cc	_	_
3	plasma	plasma	NN	_	13	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	KHT	kht	JJ	_	6	attr	_	_
6	tumour	tumour	NN	_	3	conj	_	_
7	the	the	DT	_	9	det	_	_
8	peak	peak	JJ	_	9	attr	_	_
9	concentration	concentration	NN	_	13	dep	_	_
10	and	and	CC	_	9	cc	_	_
11	&quot	&quot	NN	_	9	conj	_	_
12	;	;	:	_	13	p	_	_
13	early&quot	early&quot	NN	_	0	root	_	_
14	;	;	:	_	13	p	_	_

1	AUC	auc	NN	_	5	dep	_	_
2	for	for	IN	_	4	case	_	_
3	total	total	JJ	_	4	attr	_	_
4	drug1	drug0	NN	_	1	ppmod	_	_
5	were	be	VBD	_	13	advcl	_	_
6	about	about	RB	_	7	adv	_	_
7	1.4-1.5	0	CD	_	8	num	_	_
8	fold	fold	NN	_	9	advnp	_	_
9	greater	great	JJR	_	5	dep	_	_
10	for	for	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	oral	oral	JJ	_	9	ppmod	_	_
13	compared	compare	VBN	_	0	root	_	_
14	to	to	TO	_	15	aux	_	_
15	the	the	DT	_	13	ppmod	_	_
16	i.p.	i.p.	RB	_	13	adv	_	_

1	route	route	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	These	these	DT	_	2	det	_	_
2	differences	difference	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	reflected	reflect	VBN	_	0	root	_	_
5	in	in	IN	_	11	case	_	_
6	the	the	DT	_	11	det	_	_
7	roughly	roughly	RB	_	9	adv	_	_
8	twofold	twofold	RB	_	9	adv	_	_
9	greater	great	JJR	_	11	attr	_	_
10	antitumour	antitumour	JJ	_	11	attr	_	_
11	activity	activity	NN	_	4	ppmod	_	_
12	for	for	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	route	route	NN	_	11	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	acute	acute	JJ	_	6	attr	_	_
5	toxicity	toxicity	NN	_	6	com	_	_
6	tests	test	NNS	_	7	dep	_	_
7	showed	show	VBD	_	0	root	_	_
8	that	that	IN	_	11	mark	_	_
9	oral	oral	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	11	dep	_	_
11	was	be	VBD	_	7	comp	_	_
12	1.45	0	CD	_	13	num	_	_
13	times	time	NNS	_	11	obj	_	_
14	less	less	RBR	_	15	adv	_	_
15	toxic	toxic	JJ	_	13	attr	_	_
16	to	to	TO	_	18	aux	_	_
17	normal	normal	JJ	_	18	attr	_	_
18	tissue	tissue	NN	_	15	ppmod	_	_
19	,	,	,	_	11	p	_	_
20	although	although	IN	_	25	mark	_	_
21	the	the	DT	_	23	det	_	_
22	dose-limiting	dose-limiting	JJ	_	23	attr	_	_
23	organ	organ	NN	_	25	dep	_	_
24	may	may	MD	_	25	modal	_	_
25	be	be	VB	_	11	comp	_	_
26	different	different	JJ	_	25	dep	_	_
27	for	for	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	two	#crd#	CD	_	30	num	_	_
30	routes	route	NNS	_	26	ppmod	_	_
31	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduced	reduce	VBD	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	antitumour	antitumour	JJ	_	5	attr	_	_
5	activity	activity	NN	_	2	obj	_	_
6	of	of	IN	_	8	case	_	_
7	oral	oral	JJ	_	8	attr	_	_
8	drug2	drug0	NN	_	5	ppmod	_	_
9	by	by	IN	_	12	case	_	_
10	dose	dose	NN	_	12	com	_	_
11	modifying	modifying	NN	_	12	com	_	_
12	factors	factor	NNS	_	2	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	DMF	dmf	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	of	of	IN	_	17	case	_	_
17	0.58-0.71	0	NN	_	12	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Similarly	similarly	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	the	the	DT	_	5	det	_	_
4	acute	acute	JJ	_	5	attr	_	_
5	toxicity	toxicity	NN	_	8	dep	_	_
6	was	be	VBD	_	8	aux	_	_
7	also	also	RB	_	8	adv	_	_
8	diminished	diminish	VBN	_	0	root	_	_
9	by	by	IN	_	11	case	_	_
10	a	a	DT	_	11	det	_	_
11	DMF	dmf	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	0.74	0	CD	_	11	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	has	have	VBZ	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	complex	complex	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	on	on	IN	_	9	case	_	_
7	oral	oral	JJ	_	9	attr	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	5	ppmod	_	_
10	.	.	.	_	2	p	_	_

1	The	the	DT	_	8	det	_	_
2	plasma	plasma	NN	_	8	attr	_	_
3	and	and	CC	_	2	cc	_	_
4	tumour	tumour	NN	_	2	conj	_	_
5	total	total	JJ	_	8	attr	_	_
6	drug1	drug0	NN	_	8	com	_	_
7	peak	peak	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	10	dep	_	_
9	were	be	VBD	_	10	aux	_	_
10	reduced	reduce	VBN	_	0	root	_	_
11	by	by	IN	_	15	case	_	_
12	1.5	0	CD	_	15	num	_	_
13	and	and	CC	_	12	cc	_	_
14	1.7	0	CD	_	12	conj	_	_
15	fold	fold	NN	_	10	ppmod	_	_
16	respectively	respectively	RB	_	15	adv	_	_
17	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	reduced	reduce	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	&quot	&quot	NN	_	3	obj	_	_
6	;	;	:	_	3	p	_	_
7	early&quot	early&quot	NN	_	3	dep	_	_
8	;	;	:	_	3	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	AUC	auc	NN	_	10	dep	_	_
3	,	,	,	_	2	p	_	_
4	with	with	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	extent	extent	NN	_	2	ppmod	_	_
7	of	of	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	reduction	reduction	NN	_	6	ppmod	_	_
10	depending	depend	VBG	_	0	root	_	_
11	on	on	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	minimum	minimum	JJ	_	15	attr	_	_
14	effective	effective	JJ	_	15	attr	_	_
15	concentration	concentration	NN	_	10	ppmod	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	MEC	mec	NN	_	15	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	chosen	choose	VBN	_	15	acl	_	_
20	.	.	.	_	10	p	_	_

1	For	for	IN	_	2	case	_	_
2	example	example	NN	_	9	ppmod	_	_
3	,	,	,	_	9	p	_	_
4	the	the	DT	_	7	det	_	_
5	plasma	plasma	NN	_	7	com	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	AUC	auc	NN	_	9	dep	_	_
8	was	be	VBD	_	9	aux	_	_
9	reduced	reduce	VBN	_	0	root	_	_
10	by	by	IN	_	11	case	_	_
11	factors	factor	NNS	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	1.05	0	CD	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	9.6	0	CD	_	13	conj	_	_
16	for	for	IN	_	18	case	_	_
17	MEC	mec	NN	_	18	com	_	_
18	values	value	NNS	_	9	ppmod	_	_
19	of	of	IN	_	24	case	_	_
20	1	0	CD	_	24	num	_	_
21	and	and	CC	_	20	cc	_	_
22	2	0	CD	_	20	conj	_	_
23	micrograms	microgram	NNS	_	24	com	_	_
24	ml-1	ml-0	NN	_	18	ppmod	_	_
25	respectively	respectively	RB	_	9	adv	_	_
26	.	.	.	_	9	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	propose	propose	VBP	_	0	root	_	_
3	these	these	DT	_	5	det	_	_
4	pharmacokinetic	pharmacokinetic	JJ	_	5	attr	_	_
5	changes	change	NNS	_	7	dep	_	_
6	to	to	TO	_	7	aux	_	_
7	be	be	VB	_	2	comp	_	_
8	the	the	DT	_	10	det	_	_
9	underlying	underlie	VBG	_	10	attr	_	_
10	mechanism	mechanism	NN	_	7	obj	_	_
11	for	for	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	reduction	reduction	NN	_	10	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	oral	oral	JJ	_	17	attr	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	cytotoxicity	cytotoxicity	NN	_	13	ppmod	_	_
18	by	by	IN	_	19	case	_	_
19	drug2	drug0	NN	_	13	ppmod	_	_
20	.	.	.	_	2	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	trials	trial	NNS	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	such	such	JJ	_	5	attr	_	_
5	combinations	combination	NNS	_	2	ppmod	_	_
6	should	should	MD	_	8	modal	_	_
7	be	be	VB	_	8	aux	_	_
8	accompanied	accompany	VBN	_	0	root	_	_
9	by	by	IN	_	12	case	_	_
10	detailed	detailed	JJ	_	12	attr	_	_
11	pharmacokinetic	pharmacokinetic	JJ	_	12	attr	_	_
12	evaluation	evaluation	NN	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	attr	_	_
2	interaction	interaction	NN	_	0	root	_	_
3	between	between	IN	_	6	case	_	_
4	single	single	JJ	_	6	attr	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	doses	dose	NNS	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	drug2	drug0	NN	_	8	conj	_	_
11	in	in	IN	_	13	case	_	_
12	healthy	healthy	JJ	_	13	attr	_	_
13	volunteers	volunteer	NNS	_	2	ppmod	_	_
14	.	.	.	_	2	p	_	_

1	AIM	aim	NN	_	0	root	_	_
2	AND	and	CC	_	1	cc	_	_
3	BACKGROUND	background	NN	_	1	conj	_	_
4	:	:	:	_	1	p	_	_
5	The	the	DT	_	7	det	_	_
6	pharmacokinetic	pharmacokinetic	JJ	_	7	attr	_	_
7	interaction	interaction	NN	_	22	dep	_	_
8	between	between	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	a	a	DT	_	12	det	_	_
12	drug2	drug0	NN	_	9	conj	_	_
13	metabolized	metabolize	VBN	_	12	acl	_	_
14	by	by	IN	_	15	case	_	_
15	CYP3A4	cyp0a0	NN	_	13	ppmod	_	_
16	,	,	,	_	12	p	_	_
17	and	and	CC	_	12	cc	_	_
18	the	the	DT	_	20	det	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	drug4	drug0	NN	_	9	conj	_	_
21	was	be	VBD	_	22	aux	_	_
22	studied	study	VBN	_	1	acl	_	_
23	in	in	IN	_	26	case	_	_
24	18	0	CD	_	26	num	_	_
25	healthy	healthy	JJ	_	26	attr	_	_
26	subjects	subject	NNS	_	22	ppmod	_	_
27	.	.	.	_	1	p	_	_

1	Several	several	JJ	_	4	attr	_	_
2	clinically	clinically	RB	_	3	adv	_	_
3	important	important	JJ	_	4	attr	_	_
4	interactions	interaction	NNS	_	8	dep	_	_
5	have	have	VBP	_	8	aux	_	_
6	previously	previously	RB	_	8	adv	_	_
7	been	be	VBN	_	8	aux	_	_
8	reported	report	VBN	_	0	root	_	_
9	for	for	IN	_	11	case	_	_
10	other	other	JJ	_	11	attr	_	_
11	drug1	drug0	NNS	_	8	ppmod	_	_
12	that	that	WDT	_	14	dep	_	_
13	are	be	VBP	_	14	aux	_	_
14	metabolized	metabolize	VBN	_	11	relcl	_	_
15	by	by	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	same	same	JJ	_	18	attr	_	_
18	enzyme	enzyme	NN	_	14	ppmod	_	_
19	and	and	CC	_	11	cc	_	_
20	for	for	IN	_	21	case	_	_
21	drug2	drug0	NN	_	11	conj	_	_
22	.	.	.	_	8	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Healthy	healthy	JJ	_	4	attr	_	_
4	subjects	subject	NNS	_	12	dep	_	_
5	who	who	WP	_	6	dep	_	_
6	were	be	VBD	_	4	relcl	_	_
7	20	0	CD	_	10	num	_	_
8	to	to	TO	_	7	cc	_	_
9	43	0	CD	_	7	conj	_	_
10	years	year	NNS	_	11	advnp	_	_
11	old	old	JJ	_	6	dep	_	_
12	participated	participate	VBD	_	1	acl	_	_
13	in	in	IN	_	22	case	_	_
14	an	an	DT	_	22	det	_	_
15	open	open	JJ	_	21	adv	_	_
16	,	,	,	_	21	p	_	_
17	three-period	three-period	JJ	_	21	adv	_	_
18	,	,	,	_	21	p	_	_
19	randomized	randomized	JJ	_	21	adv	_	_
20	,	,	,	_	21	p	_	_
21	crossover	crossover	JJ	_	22	attr	_	_
22	study	study	NN	_	12	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	pharmacokinetics	pharmacokinetics	NNS	_	22	ppmod	_	_
26	of	of	IN	_	31	case	_	_
27	a	a	DT	_	31	det	_	_
28	single	single	JJ	_	31	attr	_	_
29	10-mg	0-mg	JJ	_	31	attr	_	_
30	oral	oral	JJ	_	31	attr	_	_
31	dose	dose	NN	_	25	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	drug1	drug0	NN	_	31	ppmod	_	_
34	,	,	,	_	33	p	_	_
35	a	a	DT	_	39	det	_	_
36	single	single	JJ	_	39	attr	_	_
37	oral	oral	JJ	_	39	attr	_	_
38	120-mg	0-mg	NN	_	39	com	_	_
39	dose	dose	NN	_	33	appo	_	_
40	of	of	IN	_	41	case	_	_
41	drug2	drug0	NN	_	39	ppmod	_	_
42	,	,	,	_	12	p	_	_
43	and	and	CC	_	12	cc	_	_
44	the	the	DT	_	46	det	_	_
45	two	#crd#	CD	_	46	num	_	_
46	drugs	drug	NNS	_	47	dep	_	_
47	given	give	VBN	_	12	conj	_	_
48	together	together	RB	_	47	adv	_	_
49	.	.	.	_	1	p	_	_

1	The	the	DT	_	4	det	_	_
2	three	#crd#	CD	_	4	num	_	_
3	study	study	NN	_	4	com	_	_
4	periods	period	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	separated	separate	VBN	_	0	root	_	_
7	by	by	IN	_	11	case	_	_
8	a	a	DT	_	11	det	_	_
9	21-day	0-day	JJ	_	11	attr	_	_
10	washout	washout	NN	_	11	com	_	_
11	phase	phase	NN	_	6	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	5	det	_	_
4	geometric	geometric	JJ	_	5	attr	_	_
5	mean	mean	NN	_	21	dep	_	_
6	(	-lrb-	-LRB-	_	10	p	_	_
7	90	0	CD	_	10	num	_	_
8	%	%	NN	_	10	meta	_	_
9	confidence	confidence	NN	_	10	com	_	_
10	interval	interval	NN	_	5	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	whole	whole	JJ	_	15	attr	_	_
13	blood	blood	NN	_	15	com	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	area	area	NN	_	5	appo	_	_
16	under	under	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	plasma	plasma	NN	_	20	com	_	_
19	concentration	concentration	NN	_	20	com	_	_
20	time-curve	time-curve	NN	_	15	ppmod	_	_
21	increased	increase	VBD	_	1	acl	_	_
22	60	0	CD	_	21	obj	_	_
23	%	%	NN	_	22	meta	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	35	0	CD	_	27	num	_	_
26	%	%	NN	_	27	meta	_	_
27	-90	0	CD	_	22	num	_	_
28	%	%	NN	_	27	meta	_	_
29	)	-rrb-	-RRB-	_	27	p	_	_
30	,	,	,	_	21	p	_	_
31	from	from	IN	_	37	case	_	_
32	736	0	CD	_	37	num	_	_
33	to	to	TO	_	32	cc	_	_
34	1178	0	CD	_	32	conj	_	_
35	ng	ng	NN	_	37	com	_	_
36	x	x	NN	_	37	com	_	_
37	h/mL	h/ml	NN	_	21	ppmod	_	_
38	,	,	,	_	21	p	_	_
39	and	and	CC	_	21	cc	_	_
40	maximum	maximum	NN	_	41	com	_	_
41	concentration	concentration	NN	_	42	dep	_	_
42	increased	increase	VBD	_	21	conj	_	_
43	43	0	CD	_	42	obj	_	_
44	%	%	NN	_	43	meta	_	_
45	(	-lrb-	-LRB-	_	48	p	_	_
46	14	0	CD	_	48	num	_	_
47	%	%	NN	_	48	meta	_	_
48	-81	0	CD	_	43	num	_	_
49	%	%	NN	_	48	meta	_	_
50	)	-rrb-	-RRB-	_	48	p	_	_
51	,	,	,	_	42	p	_	_
52	from	from	IN	_	56	case	_	_
53	67	0	CD	_	56	num	_	_
54	to	to	TO	_	53	cc	_	_
55	96	0	CD	_	53	conj	_	_
56	ng/mL	ng/ml	NN	_	42	ppmod	_	_
57	,	,	,	_	42	p	_	_
58	with	with	IN	_	60	case	_	_
59	drug2	drug0	NN	_	60	com	_	_
60	coadministration	coadministration	NN	_	42	ppmod	_	_
61	,	,	,	_	42	p	_	_
62	whereas	whereas	IN	_	69	case	_	_
63	the	the	DT	_	66	det	_	_
64	mean	mean	JJ	_	66	attr	_	_
65	elimination	elimination	NN	_	66	com	_	_
66	half-life	half-life	NN	_	69	dep	_	_
67	of	of	IN	_	68	case	_	_
68	drug3	drug0	NN	_	66	ppmod	_	_
69	decreased	decrease	VBD	_	21	conj	_	_
70	slightly	slightly	RB	_	69	adv	_	_
71	,	,	,	_	69	p	_	_
72	from	from	IN	_	76	case	_	_
73	79	0	CD	_	76	num	_	_
74	to	to	TO	_	73	cc	_	_
75	67	0	CD	_	73	conj	_	_
76	hours	hour	NNS	_	69	ppmod	_	_
77	.	.	.	_	1	p	_	_

1	Apparent	apparent	JJ	_	3	attr	_	_
2	oral	oral	JJ	_	3	attr	_	_
3	clearance	clearance	NN	_	10	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	volume	volume	NN	_	3	conj	_	_
6	of	of	IN	_	7	case	_	_
7	distribution	distribution	NN	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	decreased	decrease	VBD	_	0	root	_	_
11	with	with	IN	_	12	case	_	_
12	38	0	CD	_	10	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	and	and	CC	_	12	cc	_	_
15	45	0	CD	_	12	conj	_	_
16	%	%	NN	_	15	meta	_	_
17	,	,	,	_	15	p	_	_
18	respectively	respectively	RB	_	12	conj	_	_
19	,	,	,	_	10	p	_	_
20	when	when	WRB	_	23	adv	_	_
21	drug2	drug0	NN	_	23	dep	_	_
22	was	be	VBD	_	23	aux	_	_
23	given	give	VBN	_	10	comp	_	_
24	with	with	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	10	p	_	_

1	The	the	DT	_	4	det	_	_
2	plasma	plasma	NN	_	4	com	_	_
3	maximum	maximum	NN	_	4	com	_	_
4	concentration	concentration	NN	_	19	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	area	area	NN	_	4	conj	_	_
7	under	under	IN	_	11	case	_	_
8	the	the	DT	_	11	det	_	_
9	plasma	plasma	NN	_	11	com	_	_
10	concentration-time	concentration-time	NN	_	11	com	_	_
11	curve	curve	NN	_	6	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	13	p	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	,	,	,	_	15	p	_	_
17	and	and	CC	_	15	cc	_	_
18	drug3	drug0	NN	_	13	conj	_	_
19	were	be	VBD	_	0	root	_	_
20	unchanged	unchanged	JJ	_	19	dep	_	_
21	after	after	IN	_	22	case	_	_
22	coadministration	coadministration	NN	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug4	drug0	NN	_	22	ppmod	_	_
25	,	,	,	_	19	p	_	_
26	and	and	CC	_	19	cc	_	_
27	no	no	DT	_	28	det	_	_
28	potentiation	potentiation	NN	_	46	dep	_	_
29	of	of	IN	_	31	case	_	_
30	the	the	DT	_	31	det	_	_
31	effects	effect	NNS	_	28	ppmod	_	_
32	of	of	IN	_	33	case	_	_
33	drug5	drug0	NN	_	31	ppmod	_	_
34	on	on	IN	_	39	case	_	_
35	diastolic	diastolic	JJ	_	39	attr	_	_
36	or	or	CC	_	35	cc	_	_
37	systolic	systolic	JJ	_	35	conj	_	_
38	blood	blood	NN	_	39	com	_	_
39	pressure	pressure	NN	_	31	ppmod	_	_
40	or	or	CC	_	39	cc	_	_
41	on	on	IN	_	44	case	_	_
42	the	the	DT	_	44	det	_	_
43	electrocardiographic	electrocardiographic	JJ	_	44	attr	_	_
44	parameters	parameter	NNS	_	39	conj	_	_
45	was	be	VBD	_	46	aux	_	_
46	seen	see	VBN	_	19	conj	_	_
47	.	.	.	_	19	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Single-dose	single-dose	JJ	_	5	attr	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	coadministration	coadministration	NN	_	6	dep	_	_
6	leads	lead	VBZ	_	1	acl	_	_
7	to	to	TO	_	10	aux	_	_
8	higher	high	JJR	_	10	attr	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	exposure	exposure	NN	_	6	ppmod	_	_
11	,	,	,	_	6	p	_	_
12	presumably	presumably	RB	_	6	adv	_	_
13	by	by	IN	_	14	case	_	_
14	inhibition	inhibition	NN	_	6	ppmod	_	_
15	of	of	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	first-pass	first-pass	NN	_	18	com	_	_
18	metabolism	metabolism	NN	_	14	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug3	drug0	NN	_	18	ppmod	_	_
21	.	.	.	_	1	p	_	_

1	Because	because	IN	_	6	case	_	_
2	of	of	IN	_	6	case	_	_
3	the	the	DT	_	6	det	_	_
4	pronounced	pronounced	JJ	_	6	attr	_	_
5	intersubject	intersubject	NN	_	6	com	_	_
6	variability	variability	NN	_	23	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	extent	extent	NN	_	6	ppmod	_	_
10	of	of	IN	_	15	case	_	_
11	the	the	DT	_	15	det	_	_
12	drug1	drug0	NN	_	15	attr	_	_
13	-	-	:	_	15	p	_	_
14	drug2	drug0	NN	_	15	com	_	_
15	interaction	interaction	NN	_	9	ppmod	_	_
16	,	,	,	_	23	p	_	_
17	whole	whole	JJ	_	20	attr	_	_
18	blood	blood	NN	_	20	com	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	concentrations	concentration	NNS	_	23	dep	_	_
21	should	should	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	monitored	monitor	VBN	_	0	root	_	_
24	closely	closely	RB	_	23	adv	_	_
25	in	in	IN	_	26	case	_	_
26	patients	patient	NNS	_	23	ppmod	_	_
27	treated	treat	VBN	_	26	acl	_	_
28	with	with	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	two	#crd#	CD	_	31	num	_	_
31	drugs	drug	NNS	_	27	ppmod	_	_
32	.	.	.	_	23	p	_	_

1	drug1	drug0	NN	_	10	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	8	det	_	_
4	trans-3,4-dimethyl-4-	trans-0-dimethyl-0-	NN	_	8	attr	_	_
5	(	-lrb-	-LRB-	_	8	p	_	_
6	3-hydroxyphenyl	0-hydroxyphenyl	NN	_	8	attr	_	_
7	)	-rrb-	-RRB-	_	8	p	_	_
8	piperidine	piperidine	NN	_	1	appo	_	_
9	,	,	,	_	1	p	_	_
10	prevents	prevent	VBZ	_	0	root	_	_
11	gastrointestinal	gastrointestinal	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	10	obj	_	_
13	of	of	IN	_	15	case	_	_
14	intravenous	intravenous	JJ	_	15	attr	_	_
15	drug2	drug0	NN	_	12	ppmod	_	_
16	without	without	IN	_	17	case	_	_
17	affecting	affect	VBG	_	10	ppmod	_	_
18	analgesia	analgesia	NN	_	17	obj	_	_
19	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	novel	novel	JJ	_	5	attr	_	_
5	drug2	drug0	NN	_	2	obj	_	_
6	that	that	WDT	_	9	dep	_	_
7	may	may	MD	_	9	modal	_	_
8	selectively	selectively	RB	_	9	adv	_	_
9	prevent	prevent	VB	_	5	relcl	_	_
10	drug3	drug0	NN	_	13	attr	_	_
11	-induced	-induced	JJ	_	13	attr	_	_
12	gastrointestinal	gastrointestinal	JJ	_	13	attr	_	_
13	effects	effect	NNS	_	9	obj	_	_
14	without	without	IN	_	15	case	_	_
15	reversing	reverse	VBG	_	9	ppmod	_	_
16	analgesia	analgesia	NN	_	15	obj	_	_
17	.	.	.	_	2	p	_	_

1	Gastrointestinal	gastrointestinal	JJ	_	3	attr	_	_
2	transit	transit	NN	_	3	com	_	_
3	time	time	NN	_	11	dep	_	_
4	(	-lrb-	-LRB-	_	8	p	_	_
5	lactulose	lactulose	NN	_	8	com	_	_
6	hydrogen	hydrogen	NN	_	8	com	_	_
7	breath	breath	NN	_	8	com	_	_
8	test	test	NN	_	3	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	was	be	VBD	_	11	aux	_	_
11	measured	measure	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	14	0	CD	_	14	num	_	_
14	volunteers	volunteer	NNS	_	11	ppmod	_	_
15	with	with	IN	_	19	case	_	_
16	oral	oral	JJ	_	19	attr	_	_
17	and	and	CC	_	16	cc	_	_
18	intravenous	intravenous	JJ	_	16	conj	_	_
19	placebo	placebo	NN	_	14	ppmod	_	_
20	,	,	,	_	19	p	_	_
21	oral	oral	JJ	_	22	attr	_	_
22	placebo	placebo	NN	_	19	conj	_	_
23	and	and	CC	_	22	cc	_	_
24	intravenous	intravenous	JJ	_	25	attr	_	_
25	drug1	drug0	NN	_	22	conj	_	_
26	(	-lrb-	-LRB-	_	28	p	_	_
27	0.05	0	CD	_	28	num	_	_
28	mg	mg	NN	_	22	prn	_	_
29	x	x	CC	_	28	cc	_	_
30	kg	kg	CD	_	28	conj	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	-1	0	CD	_	30	num	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	)	-rrb-	-RRB-	_	28	p	_	_
35	,	,	,	_	22	p	_	_
36	and	and	CC	_	22	cc	_	_
37	oral	oral	JJ	_	38	attr	_	_
38	drug2	drug0	NN	_	19	conj	_	_
39	(	-lrb-	-LRB-	_	41	p	_	_
40	4	0	CD	_	41	num	_	_
41	mg	mg	NN	_	38	prn	_	_
42	)	-rrb-	-RRB-	_	41	p	_	_
43	and	and	CC	_	38	cc	_	_
44	intravenous	intravenous	JJ	_	45	attr	_	_
45	drug3	drug0	NN	_	38	conj	_	_
46	(	-lrb-	-LRB-	_	48	p	_	_
47	0.05	0	CD	_	48	num	_	_
48	mg	mg	NN	_	38	prn	_	_
49	x	x	CC	_	48	cc	_	_
50	kg	kg	CD	_	48	conj	_	_
51	(	-lrb-	-LRB-	_	52	p	_	_
52	-1	0	CD	_	50	num	_	_
53	)	-rrb-	-RRB-	_	52	p	_	_
54	)	-rrb-	-RRB-	_	48	p	_	_
55	in	in	IN	_	58	case	_	_
56	a	a	DT	_	58	det	_	_
57	double	double	JJ	_	58	attr	_	_
58	blind	blind	NN	_	11	ppmod	_	_
59	,	,	,	_	58	p	_	_
60	cross-over	cross-over	JJ	_	61	attr	_	_
61	study	study	NN	_	58	appo	_	_
62	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	prolonged	prolong	VBD	_	0	root	_	_
3	gastrointestinal	gastrointestinal	JJ	_	5	attr	_	_
4	transit	transit	NN	_	5	com	_	_
5	time	time	NN	_	2	obj	_	_
6	from	from	IN	_	10	case	_	_
7	69	0	CD	_	10	num	_	_
8	to	to	TO	_	7	cc	_	_
9	103	0	CD	_	7	conj	_	_
10	minutes	minute	NNS	_	2	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	P	p	NN	_	14	attr	_	_
13	=	=	JJ	_	14	attr	_	_
14	.005	0	NN	_	10	num	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	;	;	:	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	prolonged	prolong	VBD	_	19	advcl	_	_
3	gastrointestinal	gastrointestinal	JJ	_	5	attr	_	_
4	transit	transit	NN	_	5	com	_	_
5	time	time	NN	_	2	obj	_	_
6	from	from	IN	_	10	case	_	_
7	69	0	CD	_	10	num	_	_
8	to	to	TO	_	7	cc	_	_
9	103	0	CD	_	7	conj	_	_
10	minutes	minute	NNS	_	2	ppmod	_	_
11	(	-lrb-	-LRB-	_	14	p	_	_
12	P	p	NN	_	14	attr	_	_
13	=	=	JJ	_	14	attr	_	_
14	.005	0	NN	_	10	num	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	;	;	:	_	19	p	_	_
17	this	this	DT	_	19	dep	_	_
18	was	be	VBD	_	19	aux	_	_
19	prevented	prevent	VBN	_	0	root	_	_
20	by	by	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	P	p	NN	_	21	prn	_	_
24	=	=	JJ	_	23	attr	_	_
25	.004	0	CD	_	23	num	_	_
26	)	-rrb-	-RRB-	_	23	p	_	_
27	.	.	.	_	19	p	_	_

1	Postoperatively	postoperatively	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	45	0	CD	_	4	num	_	_
4	patients	patient	NNS	_	7	dep	_	_
5	were	be	VBD	_	7	aux	_	_
6	randomly	randomly	RB	_	7	adv	_	_
7	assigned	assign	VBN	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	a	a	DT	_	11	det	_	_
10	double-blind	double-blind	JJ	_	11	attr	_	_
11	fashion	fashion	NN	_	7	ppmod	_	_
12	to	to	TO	_	13	aux	_	_
13	receive	receive	VBP	_	7	comp	_	_
14	drug1	drug0	NN	_	13	obj	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	4	0	CD	_	17	num	_	_
17	mg	mg	NN	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	or	or	CC	_	14	cc	_	_
20	placebo	placebo	NN	_	14	conj	_	_
21	and	and	CC	_	20	cc	_	_
22	intravenous	intravenous	JJ	_	23	attr	_	_
23	drug2	drug0	NN	_	20	conj	_	_
24	(	-lrb-	-LRB-	_	26	p	_	_
25	0.15	0	CD	_	26	num	_	_
26	mg/kg	mg/kg	NN	_	20	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	or	or	CC	_	13	cc	_	_
29	to	to	TO	_	30	aux	_	_
30	receive	receive	VBP	_	13	conj	_	_
31	oral	oral	JJ	_	34	attr	_	_
32	and	and	CC	_	31	cc	_	_
33	intravenous	intravenous	JJ	_	31	conj	_	_
34	placebo	placebo	NN	_	30	obj	_	_
35	.	.	.	_	7	p	_	_

1	Analgesia	analgesia	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	pupil	pupil	NN	_	4	com	_	_
4	constriction	constriction	NN	_	1	conj	_	_
5	were	be	VBD	_	6	aux	_	_
6	measured	measure	VBN	_	0	root	_	_
7	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	analgesia	analgesia	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	pupil	pupil	NN	_	5	com	_	_
5	constriction	constriction	NN	_	2	conj	_	_
6	were	be	VBD	_	7	aux	_	_
7	unaffected	unaffected	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	7	cc	_	_
11	differed	differ	VBD	_	7	conj	_	_
12	from	from	IN	_	13	case	_	_
13	placebo	placebo	NN	_	11	ppmod	_	_
14	(	-lrb-	-LRB-	_	18	p	_	_
15	P	p	NN	_	18	attr	_	_
16	&lt	&lt	NN	_	18	attr	_	_
17	;	;	:	_	18	p	_	_
18	.002	0	NN	_	13	num	_	_
19	)	-rrb-	-RRB-	_	18	p	_	_
20	.	.	.	_	7	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	conclude	conclude	VBP	_	0	root	_	_
3	that	that	IN	_	5	mark	_	_
4	drug1	drug0	NN	_	5	dep	_	_
5	prevents	prevent	VBZ	_	2	comp	_	_
6	drug2	drug0	NN	_	8	attr	_	_
7	-induced	-induced	JJ	_	8	attr	_	_
8	increases	increase	NNS	_	5	obj	_	_
9	in	in	IN	_	12	case	_	_
10	gastrointestinal	gastrointestinal	JJ	_	12	attr	_	_
11	transit	transit	NN	_	12	com	_	_
12	time	time	NN	_	8	ppmod	_	_
13	by	by	IN	_	14	case	_	_
14	means	mean	NNS	_	5	ppmod	_	_
15	of	of	IN	_	19	case	_	_
16	selective	selective	JJ	_	19	attr	_	_
17	peripheral	peripheral	JJ	_	19	attr	_	_
18	opioid	opioid	NN	_	19	com	_	_
19	anitagonism	anitagonism	NN	_	14	ppmod	_	_
20	without	without	IN	_	21	case	_	_
21	affecting	affect	VBG	_	5	ppmod	_	_
22	central	central	JJ	_	24	attr	_	_
23	opioid	opioid	NN	_	24	com	_	_
24	analgesia	analgesia	NN	_	21	obj	_	_
25	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	and	and	CC	_	6	cc	_	_
8	drug3	drug0	NN	_	4	conj	_	_
9	on	on	IN	_	11	case	_	_
10	bar-press	bar-press	JJ	_	11	attr	_	_
11	behavior	behavior	NN	_	2	ppmod	_	_
12	in	in	IN	_	17	case	_	_
13	normal	normal	JJ	_	17	attr	_	_
14	and	and	CC	_	13	cc	_	_
15	genetically	genetically	RB	_	16	adv	_	_
16	nervous	nervous	JJ	_	13	conj	_	_
17	dogs	dog	NNS	_	11	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Studies	study	NNS	_	9	dep	_	_
2	on	on	IN	_	4	case	_	_
3	two	#crd#	CD	_	4	num	_	_
4	strains	strain	NNS	_	1	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	pointer	pointer	JJ	_	7	attr	_	_
7	dogs	dog	NNS	_	4	ppmod	_	_
8	have	have	VBP	_	9	aux	_	_
9	demonstrated	demonstrate	VBN	_	0	root	_	_
10	that	that	IN	_	18	mark	_	_
11	administration	administration	NN	_	18	dep	_	_
12	of	of	IN	_	14	case	_	_
13	a	a	DT	_	14	det	_	_
14	drug1	drug0	NN	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	drug2	drug0	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	facilitates	facilitate	VBZ	_	9	comp	_	_
19	acquisition	acquisition	NN	_	18	obj	_	_
20	of	of	IN	_	22	case	_	_
21	goal-directed	goal-directed	JJ	_	22	attr	_	_
22	behavior	behavior	NN	_	19	ppmod	_	_
23	in	in	IN	_	24	case	_	_
24	&quot	&quot	NN	_	19	ppmod	_	_
25	;	;	:	_	9	p	_	_
26	genetically	genetically	RB	_	27	adv	_	_
27	nervous&quot	nervous&quot	NN	_	9	dep	_	_
28	;	;	:	_	27	p	_	_

1	subjects	subject	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Continued	continued	JJ	_	2	attr	_	_
2	admistration	admistration	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	drug	drug	NN	_	2	ppmod	_	_
6	is	be	VBZ	_	7	aux	_	_
7	required	require	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	maintain	maintain	VB	_	7	comp	_	_
10	barpress	barpress	NN	_	11	com	_	_
11	response	response	NN	_	9	obj	_	_
12	in	in	IN	_	14	case	_	_
13	this	this	DT	_	14	det	_	_
14	strain	strain	NN	_	9	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	dogs	dog	NNS	_	14	ppmod	_	_
17	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	18	dep	_	_
4	of	of	IN	_	6	case	_	_
5	either	either	CC	_	6	cc	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	compounds	compound	NNS	_	8	appo	_	_
11	which	which	WDT	_	12	dep	_	_
12	inhibit	inhibit	VBP	_	10	relcl	_	_
13	neuronal	neuronal	JJ	_	14	attr	_	_
14	reuptake	reuptake	NN	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	norepinephrine	norepinephrine	NN	_	14	ppmod	_	_
17	,	,	,	_	8	p	_	_
18	disrupts	disrupt	VBZ	_	0	root	_	_
19	the	the	DT	_	21	det	_	_
20	behavioral	behavioral	JJ	_	21	attr	_	_
21	response	response	NN	_	18	obj	_	_
22	of	of	IN	_	27	case	_	_
23	the	the	DT	_	27	det	_	_
24	genetically	genetically	RB	_	25	adv	_	_
25	nervous	nervous	JJ	_	27	attr	_	_
26	E-strain	e-strain	NN	_	27	com	_	_
27	subjects	subject	NNS	_	21	ppmod	_	_
28	to	to	TO	_	32	aux	_	_
29	a	a	DT	_	32	det	_	_
30	far	far	RB	_	31	adv	_	_
31	greater	great	JJR	_	32	attr	_	_
32	extent	extent	NN	_	21	ppmod	_	_
33	than	than	IN	_	37	case	_	_
34	the	the	DT	_	37	det	_	_
35	stable	stable	JJ	_	37	attr	_	_
36	A-strain	a-strain	NN	_	37	com	_	_
37	subjects	subject	NNS	_	32	ppmod	_	_
38	.	.	.	_	18	p	_	_

1	It	it	PRP	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	also	also	RB	_	4	adv	_	_
4	shown	show	VBN	_	0	root	_	_
5	that	that	IN	_	21	mark	_	_
6	after	after	IN	_	8	case	_	_
7	14	0	CD	_	8	num	_	_
8	days	day	NNS	_	21	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	daily	daily	JJ	_	11	attr	_	_
11	administration	administration	NN	_	8	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	,	,	,	_	21	p	_	_
15	withdrawal	withdrawal	NN	_	21	dep	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drug	drug	NN	_	15	ppmod	_	_
19	not	not	RB	_	20	com	_	_
20	only	only	RB	_	21	cc	_	_
21	re-results	re-results	VBZ	_	4	comp	_	_
22	in	in	IN	_	25	case	_	_
23	almost	almost	RB	_	24	adv	_	_
24	complete	complete	JJ	_	25	attr	_	_
25	loss	loss	NN	_	21	ppmod	_	_
26	of	of	IN	_	28	case	_	_
27	bar-press	bar-press	NN	_	28	com	_	_
28	response	response	NN	_	25	ppmod	_	_
29	in	in	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	E-strain	e-strain	JJ	_	32	attr	_	_
32	subjects	subject	NNS	_	25	ppmod	_	_
33	but	but	CC	_	21	cc	_	_
34	also	also	RB	_	33	com	_	_
35	results	result	VBZ	_	21	conj	_	_
36	in	in	IN	_	39	case	_	_
37	a	a	DT	_	39	det	_	_
38	temporary	temporary	JJ	_	39	attr	_	_
39	decrease	decrease	NN	_	35	ppmod	_	_
40	in	in	IN	_	44	case	_	_
41	the	the	DT	_	44	det	_	_
42	acquired	acquire	VBN	_	44	attr	_	_
43	behavioral	behavioral	JJ	_	44	attr	_	_
44	response	response	NN	_	39	ppmod	_	_
45	of	of	IN	_	49	case	_	_
46	the	the	DT	_	49	det	_	_
47	stable	stable	JJ	_	49	attr	_	_
48	A-strain	a-strain	NN	_	49	com	_	_
49	subjects	subject	NNS	_	44	ppmod	_	_
50	.	.	.	_	4	p	_	_

1	Therapeutic	therapeutic	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	monitoring	monitoring	NN	_	5	dep	_	_
4	can	can	MD	_	5	modal	_	_
5	avoid	avoid	VB	_	0	root	_	_
6	iatrogenic	iatrogenic	JJ	_	7	attr	_	_
7	alterations	alteration	NNS	_	5	obj	_	_
8	caused	cause	VBN	_	7	acl	_	_
9	by	by	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	MDP	mdp	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	-	-	CC	_	10	cc	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	interaction	interaction	NN	_	10	conj	_	_
17	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	an	an	DT	_	4	det	_	_
4	drug2	drug0	NN	_	2	obj	_	_
5	used	use	VBN	_	4	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	treat	treat	VB	_	5	comp	_	_
8	a	a	DT	_	10	det	_	_
9	wide	wide	JJ	_	10	attr	_	_
10	variety	variety	NN	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	infections	infection	NNS	_	10	ppmod	_	_
13	caused	cause	VBN	_	12	acl	_	_
14	by	by	IN	_	16	case	_	_
15	gram-negative	gram-negative	JJ	_	16	attr	_	_
16	organisms	organism	NNS	_	13	ppmod	_	_
17	,	,	,	_	2	p	_	_
18	but	but	CC	_	2	cc	_	_
19	it	it	PRP	_	20	dep	_	_
20	is	be	VBZ	_	2	conj	_	_
21	potentially	potentially	RB	_	22	adv	_	_
22	toxic	toxic	JJ	_	20	dep	_	_
23	to	to	TO	_	25	aux	_	_
24	the	the	DT	_	25	det	_	_
25	kidneys	kidney	NNS	_	22	ppmod	_	_
26	.	.	.	_	2	p	_	_

1	Due	due	IN	_	4	case	_	_
2	to	to	TO	_	4	aux	_	_
3	its	its	PRP$	_	4	poss	_	_
4	nephrotoxicity	nephrotoxicity	NN	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	may	may	MD	_	8	modal	_	_
8	cause	cause	VB	_	0	root	_	_
9	abnormal	abnormal	JJ	_	11	attr	_	_
10	renal	renal	JJ	_	11	attr	_	_
11	uptake	uptake	NN	_	8	obj	_	_
12	to	to	TO	_	14	aux	_	_
13	be	be	VB	_	14	aux	_	_
14	seen	see	VBN	_	8	comp	_	_
15	on	on	IN	_	18	case	_	_
16	drug2	drug0	NN	_	18	com	_	_
17	bone	bone	NN	_	18	com	_	_
18	scintigraphy	scintigraphy	NN	_	14	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	presence	presence	NN	_	18	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	kidneys	kidney	NNS	_	5	ppmod	_	_
9	,	,	,	_	18	p	_	_
10	along	along	IN	_	13	case	_	_
11	with	with	IN	_	13	case	_	_
12	an	an	DT	_	13	det	_	_
13	increase	increase	NN	_	18	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	renal	renal	JJ	_	16	attr	_	_
16	retention	retention	NN	_	13	ppmod	_	_
17	,	,	,	_	18	p	_	_
18	tend	tend	VBP	_	0	root	_	_
19	to	to	TO	_	20	aux	_	_
20	produce	produce	VB	_	18	comp	_	_
21	scintigraphic	scintigraphic	JJ	_	22	attr	_	_
22	results	result	NNS	_	20	obj	_	_
23	that	that	WDT	_	25	dep	_	_
24	falsely	falsely	RB	_	25	adv	_	_
25	identify	identify	VBP	_	22	relcl	_	_
26	characteristics	characteristic	NNS	_	25	obj	_	_
27	related	related	JJ	_	26	attr	_	_
28	to	to	TO	_	29	aux	_	_
29	diseases	disease	NNS	_	27	ppmod	_	_
30	such	such	JJ	_	33	adv	_	_
31	as	as	IN	_	33	case	_	_
32	renal	renal	JJ	_	33	attr	_	_
33	vascular	vascular	JJ	_	29	ppmod	_	_
34	,	,	,	_	29	p	_	_
35	or	or	CC	_	29	cc	_	_
36	urinary	urinary	JJ	_	38	attr	_	_
37	tract	tract	NN	_	38	com	_	_
38	obstruction	obstruction	NN	_	29	conj	_	_
39	,	,	,	_	38	p	_	_
40	and	and	CC	_	38	cc	_	_
41	even	even	JJ	_	43	attr	_	_
42	renal	renal	JJ	_	43	attr	_	_
43	cancer	cancer	NN	_	29	conj	_	_
44	.	.	.	_	18	p	_	_

1	An	an	DT	_	3	det	_	_
2	altered	altered	JJ	_	3	attr	_	_
3	biodistribution	biodistribution	NN	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	provide	provide	VB	_	0	root	_	_
6	misleading	misleading	JJ	_	7	attr	_	_
7	information	information	NN	_	5	obj	_	_
8	that	that	WDT	_	11	dep	_	_
9	can	can	MD	_	11	modal	_	_
10	either	either	CC	_	11	cc	_	_
11	mask	mask	VB	_	7	relcl	_	_
12	or	or	CC	_	11	cc	_	_
13	mimic	mimic	VB	_	11	conj	_	_
14	certain	certain	JJ	_	16	attr	_	_
15	disease	disease	NN	_	16	com	_	_
16	symptoms	symptom	NNS	_	13	obj	_	_
17	.	.	.	_	5	p	_	_

1	A	a	DT	_	2	det	_	_
2	method	method	NN	_	25	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	maximize	maximize	VB	_	2	acl	_	_
5	the	the	DT	_	7	det	_	_
6	therapeutic	therapeutic	JJ	_	7	attr	_	_
7	benefit	benefit	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	while	while	IN	_	11	mark	_	_
11	minimizing	minimize	VBG	_	4	comp	_	_
12	the	the	DT	_	13	det	_	_
13	risk	risk	NN	_	11	obj	_	_
14	of	of	IN	_	15	case	_	_
15	nephrotoxicity	nephrotoxicity	NN	_	13	ppmod	_	_
16	and	and	CC	_	13	cc	_	_
17	the	the	DT	_	18	det	_	_
18	appearance	appearance	NN	_	13	conj	_	_
19	of	of	IN	_	22	case	_	_
20	a	a	DT	_	22	det	_	_
21	hot	hot	JJ	_	22	attr	_	_
22	kidney	kidney	NN	_	18	ppmod	_	_
23	on	on	IN	_	24	case	_	_
24	scintigraphy	scintigraphy	NN	_	18	ppmod	_	_
25	is	be	VBZ	_	0	root	_	_
26	desirable	desirable	JJ	_	25	dep	_	_
27	.	.	.	_	25	p	_	_

1	Serial	serial	JJ	_	3	attr	_	_
2	pharmacokinetic	pharmacokinetic	JJ	_	3	attr	_	_
3	dosing	dosing	NN	_	6	dep	_	_
4	has	have	VBZ	_	6	aux	_	_
5	been	be	VBN	_	6	aux	_	_
6	proposed	propose	VBN	_	0	root	_	_
7	as	as	IN	_	9	case	_	_
8	a	a	DT	_	9	det	_	_
9	method	method	NN	_	6	ppmod	_	_
10	to	to	TO	_	11	aux	_	_
11	accomplish	accomplish	VB	_	9	acl	_	_
12	this	this	DT	_	13	det	_	_
13	goal	goal	NN	_	11	obj	_	_
14	.	.	.	_	6	p	_	_

1	Therapeutic	therapeutic	JJ	_	3	attr	_	_
2	drug	drug	NN	_	3	com	_	_
3	monitoring	monitoring	NN	_	20	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	TDM	tdm	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	of	of	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	therapy	therapy	NN	_	3	ppmod	_	_
10	,	,	,	_	3	p	_	_
11	and	and	CC	_	3	cc	_	_
12	bone	bone	NN	_	13	com	_	_
13	scintigraphy	scintigraphy	NN	_	3	conj	_	_
14	employing	employ	VBG	_	13	acl	_	_
15	drug2	drug0	NN	_	14	obj	_	_
16	as	as	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	drug3	drug0	NN	_	14	ppmod	_	_
19	was	be	VBD	_	20	aux	_	_
20	carried	carry	VBN	_	0	root	_	_
21	out	out	RP	_	20	prt	_	_
22	in	in	IN	_	24	case	_	_
23	22	0	CD	_	24	num	_	_
24	patients	patient	NNS	_	20	ppmod	_	_
25	.	.	.	_	20	p	_	_

1	The	the	DT	_	2	det	_	_
2	data	datum	NNS	_	5	dep	_	_
3	presented	present	VBN	_	2	acl	_	_
4	here	here	RB	_	3	adv	_	_
5	demonstrate	demonstrate	VBP	_	0	root	_	_
6	that	that	IN	_	23	mark	_	_
7	with	with	IN	_	10	case	_	_
8	serial	serial	JJ	_	10	attr	_	_
9	pharmacokinetic	pharmacokinetic	JJ	_	10	attr	_	_
10	dosing	dosing	NN	_	23	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	23	p	_	_
14	the	the	DT	_	16	det	_	_
15	iatrogenic	iatrogenic	JJ	_	16	attr	_	_
16	alteration	alteration	NN	_	23	dep	_	_
17	caused	cause	VBN	_	16	acl	_	_
18	by	by	IN	_	20	case	_	_
19	drug2	drug0	NN	_	20	com	_	_
20	therapy	therapy	NN	_	17	ppmod	_	_
21	can	can	MD	_	23	modal	_	_
22	be	be	VB	_	23	aux	_	_
23	avoided	avoid	VBN	_	5	comp	_	_
24	.	.	.	_	5	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	in	in	IN	_	8	case	_	_
7	anaesthetised	anaesthetised	JJ	_	8	attr	_	_
8	horses	horse	NNS	_	1	ppmod	_	_
9	.	.	.	_	1	p	_	_

1	Evoked	evoke	VBN	_	3	attr	_	_
2	hind	hind	NN	_	3	com	_	_
3	limb	limb	NN	_	12	dep	_	_
4	digital	digital	JJ	_	6	attr	_	_
5	extensor	extensor	NN	_	6	com	_	_
6	tension	tension	NN	_	3	appo	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	hoof	hoof	NN	_	9	com	_	_
9	twitch	twitch	NN	_	3	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	was	be	VBD	_	12	aux	_	_
12	maintained	maintain	VBN	_	0	root	_	_
13	at	at	IN	_	14	case	_	_
14	40	0	CD	_	12	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	of	of	IN	_	17	case	_	_
17	baseline	baseline	NN	_	14	ppmod	_	_
18	for	for	IN	_	20	case	_	_
19	1	0	CD	_	20	num	_	_
20	h	h	NN	_	12	ppmod	_	_
21	by	by	IN	_	23	case	_	_
22	drug1	drug0	NN	_	23	com	_	_
23	infusion	infusion	NN	_	12	ppmod	_	_
24	in	in	IN	_	26	case	_	_
25	7	0	CD	_	26	num	_	_
26	horses	horse	NNS	_	23	ppmod	_	_
27	anaesthetised	anaesthetised	JJ	_	26	attr	_	_
28	with	with	IN	_	29	case	_	_
29	drug2	drug0	NN	_	26	ppmod	_	_
30	.	.	.	_	12	p	_	_

1	After	after	IN	_	3	case	_	_
2	1	0	CD	_	3	num	_	_
3	h	h	NN	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	drug1	drug0	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	discontinued	discontinue	VBN	_	0	root	_	_
8	and	and	CC	_	7	cc	_	_
9	hoof	hoof	NN	_	10	com	_	_
10	twitch	twitch	NN	_	11	dep	_	_
11	allowed	allow	VBD	_	7	conj	_	_
12	to	to	TO	_	13	aux	_	_
13	recover	recover	VB	_	11	comp	_	_
14	to	to	TO	_	15	aux	_	_
15	75	0	CD	_	13	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	was	be	VBD	_	4	aux	_	_
3	again	again	RB	_	4	adv	_	_
4	given	give	VBN	_	24	advcl	_	_
5	by	by	IN	_	6	case	_	_
6	infusion	infusion	NN	_	4	ppmod	_	_
7	to	to	TO	_	8	aux	_	_
8	maintain	maintain	VB	_	24	advcl	_	_
9	40	0	CD	_	11	num	_	_
10	%	%	NN	_	9	meta	_	_
11	twitch	twitch	NN	_	8	obj	_	_
12	for	for	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	second	#ord#	JJ	_	15	attr	_	_
15	hour	hour	NN	_	11	ppmod	_	_
16	,	,	,	_	24	p	_	_
17	then	then	RB	_	18	adv	_	_
18	2	0	CD	_	19	num	_	_
19	mg	mg	NN	_	22	com	_	_
20	drug2	drug0	NN	_	22	com	_	_
21	/kg	/kg	NN	_	22	com	_	_
22	bwt	bwt	NN	_	24	dep	_	_
23	were	be	VBD	_	24	aux	_	_
24	given	give	VBN	_	0	root	_	_
25	i.v.	i.v.	NN	_	24	obj	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	infusion	infusion	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	continued	continue	VBN	_	0	root	_	_
5	for	for	IN	_	8	case	_	_
6	a	a	DT	_	8	det	_	_
7	third	#ord#	JJ	_	8	attr	_	_
8	hour	hour	NN	_	4	ppmod	_	_
9	,	,	,	_	4	p	_	_
10	and	and	CC	_	4	cc	_	_
11	then	then	RB	_	13	adv	_	_
12	hoof	hoof	NN	_	13	com	_	_
13	twitch	twitch	NN	_	16	dep	_	_
14	was	be	VBD	_	16	aux	_	_
15	again	again	RB	_	16	adv	_	_
16	allowed	allow	VBN	_	4	conj	_	_
17	to	to	TO	_	18	aux	_	_
18	recover	recover	VB	_	16	comp	_	_
19	spontaneously	spontaneously	RB	_	18	adv	_	_
20	to	to	TO	_	21	aux	_	_
21	75	0	CD	_	18	ppmod	_	_
22	%	%	NN	_	21	meta	_	_
23	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduced	reduce	VBD	_	0	root	_	_
3	twitch	twitch	NN	_	4	com	_	_
4	strength	strength	NN	_	2	obj	_	_
5	from	from	IN	_	6	case	_	_
6	40	0	CD	_	2	ppmod	_	_
7	+/-	+/-	CC	_	6	cc	_	_
8	1	0	CD	_	6	conj	_	_
9	%	%	NN	_	6	meta	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	mean	mean	NN	_	6	prn	_	_
12	+/-	+/-	CC	_	11	cc	_	_
13	sem	sem	NN	_	11	conj	_	_
14	)	-rrb-	-RRB-	_	11	p	_	_
15	to	to	TO	_	16	aux	_	_
16	29	0	CD	_	2	ppmod	_	_
17	+/-	+/-	CC	_	16	cc	_	_
18	4	0	CD	_	16	conj	_	_
19	%	%	NN	_	16	meta	_	_
20	within	within	IN	_	24	case	_	_
21	7.0	0	CD	_	24	num	_	_
22	+/-	+/-	CC	_	21	cc	_	_
23	1.5	0	CD	_	21	conj	_	_
24	min	min	NN	_	16	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	P	p	NN	_	24	prn	_	_
27	=	=	JJ	_	26	attr	_	_
28	0.02	0	CD	_	26	num	_	_
29	)	-rrb-	-RRB-	_	26	p	_	_
30	.	.	.	_	2	p	_	_

1	Twitch	twitch	NN	_	3	dep	_	_
2	gradually	gradually	RB	_	3	adv	_	_
3	returned	return	VBD	_	0	root	_	_
4	to	to	TO	_	7	aux	_	_
5	pre-	pre-	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	strength	strength	NN	_	3	ppmod	_	_
8	over	over	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	course	course	NN	_	3	ppmod	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	next	next	JJ	_	14	attr	_	_
14	hour	hour	NN	_	10	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Recovery	recovery	NN	_	11	dep	_	_
2	of	of	IN	_	4	case	_	_
3	hoof	hoof	NN	_	4	com	_	_
4	twitch	twitch	NN	_	1	ppmod	_	_
5	from	from	IN	_	6	case	_	_
6	50	0	CD	_	1	ppmod	_	_
7	%	%	NN	_	6	meta	_	_
8	to	to	TO	_	6	cc	_	_
9	75	0	CD	_	6	conj	_	_
10	%	%	NN	_	6	meta	_	_
11	took	take	VBD	_	0	root	_	_
12	7.7	0	CD	_	15	num	_	_
13	+/-	+/-	CC	_	12	cc	_	_
14	0.7	0	CD	_	12	conj	_	_
15	min	min	NN	_	11	obj	_	_
16	for	for	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	alone	alone	RB	_	17	adv	_	_
19	and	and	CC	_	15	cc	_	_
20	11.5	0	CD	_	23	num	_	_
21	+/-	+/-	CC	_	20	cc	_	_
22	2.7	0	CD	_	20	conj	_	_
23	min	min	NN	_	15	conj	_	_
24	for	for	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	plus	plus	CC	_	25	cc	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	(	-lrb-	-LRB-	_	29	p	_	_
29	P	p	NN	_	11	prn	_	_
30	=	=	JJ	_	29	attr	_	_
31	0.03	0	CD	_	29	num	_	_
32	)	-rrb-	-RRB-	_	29	p	_	_
33	.	.	.	_	11	p	_	_

1	Recovery	recovery	NN	_	11	dep	_	_
2	from	from	IN	_	5	case	_	_
3	50	0	CD	_	5	num	_	_
4	%	%	NN	_	3	meta	_	_
5	twitch	twitch	NN	_	1	ppmod	_	_
6	to	to	TO	_	5	attr	_	_
7	75	0	CD	_	5	num	_	_
8	%	%	NN	_	5	meta	_	_
9	fade	fade	VB	_	5	acl	_	_
10	recovery	recovery	NN	_	9	obj	_	_
11	took	take	VBD	_	0	root	_	_
12	13.8	0	CD	_	15	num	_	_
13	+/-	+/-	CC	_	12	cc	_	_
14	0.8	0	CD	_	12	conj	_	_
15	min	min	NN	_	11	obj	_	_
16	for	for	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	alone	alone	RB	_	17	adv	_	_
19	and	and	CC	_	15	cc	_	_
20	13.7	0	CD	_	23	num	_	_
21	+/-	+/-	CC	_	20	cc	_	_
22	1.2	0	CD	_	20	conj	_	_
23	min	min	NN	_	15	conj	_	_
24	for	for	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	plus	plus	CC	_	25	cc	_	_
27	drug3	drug0	NN	_	25	conj	_	_
28	.	.	.	_	11	p	_	_

1	At	at	IN	_	4	case	_	_
2	75	0	CD	_	4	num	_	_
3	%	%	NN	_	2	meta	_	_
4	recovery	recovery	NN	_	10	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	fade	fade	VB	_	4	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	hoof	hoof	NN	_	9	com	_	_
9	twitch	twitch	NN	_	10	dep	_	_
10	was	be	VBD	_	0	root	_	_
11	87	0	CD	_	10	obj	_	_
12	+/-	+/-	CC	_	11	cc	_	_
13	3	0	CD	_	11	conj	_	_
14	%	%	NN	_	11	meta	_	_
15	for	for	IN	_	16	case	_	_
16	drug1	drug0	NN	_	11	ppmod	_	_
17	alone	alone	RB	_	16	adv	_	_
18	and	and	CC	_	11	cc	_	_
19	82	0	CD	_	11	conj	_	_
20	+/-	+/-	CC	_	19	cc	_	_
21	4	0	CD	_	19	conj	_	_
22	%	%	NN	_	19	meta	_	_
23	for	for	IN	_	24	case	_	_
24	drug2	drug0	NN	_	19	ppmod	_	_
25	plus	plus	CC	_	24	cc	_	_
26	drug3	drug0	NN	_	24	conj	_	_
27	.	.	.	_	10	p	_	_

1	Reversal	reversal	NN	_	16	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	block	block	NN	_	1	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	1	cc	_	_
8	subsequent	subsequent	JJ	_	9	attr	_	_
9	recovery	recovery	NN	_	1	conj	_	_
10	of	of	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	horses	horse	NNS	_	9	ppmod	_	_
13	from	from	IN	_	14	case	_	_
14	anaesthesia	anaesthesia	NN	_	12	ppmod	_	_
15	were	be	VBD	_	16	aux	_	_
16	uneventful	uneventful	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	concluded	conclude	VBN	_	0	root	_	_
4	that	that	IN	_	18	mark	_	_
5	,	,	,	_	18	p	_	_
6	although	although	IN	_	9	mark	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	did	do	VBD	_	9	aux	_	_
9	augment	augment	VB	_	18	advcl	_	_
10	the	the	DT	_	12	det	_	_
11	neuromuscular	neuromuscular	JJ	_	12	attr	_	_
12	blockade	blockade	NN	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	,	,	,	_	18	p	_	_
16	the	the	DT	_	17	det	_	_
17	effect	effect	NN	_	18	dep	_	_
18	was	be	VBD	_	3	comp	_	_
19	minimal	minimal	JJ	_	18	dep	_	_
20	.	.	.	_	3	p	_	_

1	Diagnostic	diagnostic	JJ	_	6	dep	_	_
2	,	,	,	_	1	p	_	_
3	treatment	treatment	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	aftercare	aftercare	NN	_	1	conj	_	_
6	approaches	approach	NNS	_	0	root	_	_
7	to	to	TO	_	9	aux	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	abuse	abuse	NN	_	6	ppmod	_	_
10	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	general	general	JJ	_	3	attr	_	_
3	public	public	NN	_	4	dep	_	_
4	feels	feel	VBZ	_	0	root	_	_
5	that	that	IN	_	7	mark	_	_
6	drug1	drug0	NN	_	7	dep	_	_
7	is	be	VBZ	_	4	comp	_	_
8	not	not	RB	_	7	neg	_	_
9	particularly	particularly	RB	_	10	adv	_	_
10	dangerous	dangerous	JJ	_	7	dep	_	_
11	because	because	IN	_	15	mark	_	_
12	it	it	PRP	_	15	dep	_	_
13	does	do	VBZ	_	15	aux	_	_
14	not	not	RB	_	15	neg	_	_
15	produce	produce	VB	_	7	comp	_	_
16	a	a	DT	_	20	det	_	_
17	well	well	RB	_	18	adv	_	_
18	defined	define	VBN	_	20	attr	_	_
19	physical	physical	JJ	_	20	attr	_	_
20	dependency	dependency	NN	_	15	obj	_	_
21	and	and	CC	_	20	cc	_	_
22	abstinence	abstinence	NN	_	23	com	_	_
23	syndrome	syndrome	NN	_	20	conj	_	_
24	.	.	.	_	4	p	_	_

1	However	however	RB	_	27	adv	_	_
2	,	,	,	_	27	p	_	_
3	when	when	WRB	_	6	adv	_	_
4	addiction	addiction	NN	_	6	dep	_	_
5	is	be	VBZ	_	6	aux	_	_
6	defined	define	VBN	_	27	advcl	_	_
7	as	as	IN	_	8	case	_	_
8	compulsion	compulsion	NN	_	6	ppmod	_	_
9	,	,	,	_	8	p	_	_
10	loss	loss	NN	_	8	conj	_	_
11	of	of	IN	_	12	case	_	_
12	control	control	NN	_	10	ppmod	_	_
13	and	and	CC	_	10	cc	_	_
14	continued	continued	JJ	_	15	attr	_	_
15	use	use	NN	_	8	conj	_	_
16	in	in	IN	_	17	case	_	_
17	spite	spite	NN	_	15	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	adverse	adverse	JJ	_	20	attr	_	_
20	consequences	consequence	NNS	_	17	ppmod	_	_
21	,	,	,	_	27	p	_	_
22	drug1	drug0	NN	_	24	com	_	_
23	drug	drug	NN	_	24	com	_	_
24	hunger	hunger	NN	_	27	dep	_	_
25	can	can	MD	_	27	modal	_	_
26	be	be	VB	_	27	aux	_	_
27	seen	see	VBN	_	0	root	_	_
28	as	as	IN	_	30	case	_	_
29	an	an	DT	_	30	det	_	_
30	agent	agent	NN	_	27	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	addictive	addictive	JJ	_	33	attr	_	_
33	disease	disease	NN	_	30	ppmod	_	_
34	.	.	.	_	27	p	_	_

1	Withdrawal	withdrawal	NN	_	6	dep	_	_
2	from	from	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	dependence	dependence	NN	_	1	ppmod	_	_
5	usually	usually	RB	_	6	adv	_	_
6	involves	involve	VBZ	_	0	root	_	_
7	depression	depression	NN	_	6	obj	_	_
8	,	,	,	_	7	p	_	_
9	anxiety	anxiety	NN	_	7	conj	_	_
10	and	and	CC	_	9	cc	_	_
11	lethargy	lethargy	NN	_	7	conj	_	_
12	.	.	.	_	6	p	_	_

1	These	these	DT	_	3	dep	_	_
2	usually	usually	RB	_	3	adv	_	_
3	clear	clear	VB	_	0	root	_	_
4	within	within	IN	_	6	case	_	_
5	a	a	DT	_	6	det	_	_
6	week	week	NN	_	3	ppmod	_	_
7	,	,	,	_	3	p	_	_
8	leaving	leave	VBG	_	3	comp	_	_
9	only	only	RB	_	14	adv	_	_
10	the	the	DT	_	14	det	_	_
11	&quot	&quot	NN	_	14	attr	_	_
12	;	;	:	_	14	p	_	_
13	drug	drug	NN	_	14	com	_	_
14	hunger&quot	hunger&quot	NN	_	8	obj	_	_
15	;	;	:	_	3	p	_	_

1	to	to	TO	_	2	aux	_	_
2	contend	contend	VB	_	0	root	_	_
3	with	with	IN	_	2	case	_	_
4	.	.	.	_	2	p	_	_

1	Medication	medication	NN	_	4	dep	_	_
2	is	be	VBZ	_	4	aux	_	_
3	rarely	rarely	RB	_	4	adv	_	_
4	needed	need	VBN	_	0	root	_	_
5	.	.	.	_	4	p	_	_

1	When	when	WRB	_	3	adv	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	is	be	VBZ	_	14	advcl	_	_
4	the	the	DT	_	6	det	_	_
5	primary	primary	JJ	_	6	attr	_	_
6	addiction	addiction	NN	_	3	obj	_	_
7	,	,	,	_	14	p	_	_
8	after	after	IN	_	9	case	_	_
9	withdrawal	withdrawal	NN	_	14	ppmod	_	_
10	the	the	DT	_	13	det	_	_
11	most	most	RBS	_	12	adv	_	_
12	effective	effective	JJ	_	13	attr	_	_
13	treatment	treatment	NN	_	14	dep	_	_
14	is	be	VBZ	_	0	root	_	_
15	group	group	NN	_	16	com	_	_
16	therapy	therapy	NN	_	14	obj	_	_
17	with	with	IN	_	21	case	_	_
18	other	other	JJ	_	21	attr	_	_
19	recovering	recovering	JJ	_	21	attr	_	_
20	cocaine	cocaine	NN	_	21	com	_	_
21	abusers	abuser	NNS	_	16	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	incorporate	incorporate	VBP	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	principles	principle	NNS	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	recovery	recovery	NN	_	4	ppmod	_	_
7	and	and	CC	_	2	cc	_	_
8	define	define	VBP	_	2	conj	_	_
9	positive	positive	JJ	_	12	attr	_	_
10	and	and	CC	_	9	cc	_	_
11	constructive	constructive	JJ	_	9	conj	_	_
12	alternatives	alternative	NNS	_	8	obj	_	_
13	in	in	IN	_	14	case	_	_
14	dealing	deal	VBG	_	12	ppmod	_	_
15	with	with	IN	_	17	case	_	_
16	cocaine	cocaine	NN	_	17	com	_	_
17	hunger	hunger	NN	_	14	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	Recovery	recovery	NN	_	2	com	_	_
2	programs	program	NNS	_	4	dep	_	_
3	should	should	MD	_	4	modal	_	_
4	be	be	VB	_	0	root	_	_
5	flexible	flexible	JJ	_	4	dep	_	_
6	and	and	CC	_	4	cc	_	_
7	involve	involve	VB	_	4	conj	_	_
8	individual	individual	NN	_	7	obj	_	_
9	and	and	CC	_	8	cc	_	_
10	family	family	NN	_	11	com	_	_
11	education	education	NN	_	8	conj	_	_
12	on	on	IN	_	13	case	_	_
13	recovery	recovery	NN	_	7	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	the	the	DT	_	16	det	_	_
16	nature	nature	NN	_	13	conj	_	_
17	of	of	IN	_	19	case	_	_
18	addictive	addictive	JJ	_	19	attr	_	_
19	disease	disease	NN	_	16	ppmod	_	_
20	.	.	.	_	4	p	_	_

1	Exercise	exercise	NN	_	6	dep	_	_
2	that	that	WDT	_	3	dep	_	_
3	produces	produce	VBZ	_	1	relcl	_	_
4	cardiopulmonary	cardiopulmonary	JJ	_	5	attr	_	_
5	stimulation	stimulation	NN	_	3	obj	_	_
6	is	be	VBZ	_	0	root	_	_
7	a	a	DT	_	9	det	_	_
8	helpful	helpful	JJ	_	9	attr	_	_
9	means	means	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	reducing	reduce	VBG	_	9	ppmod	_	_
12	drug	drug	NN	_	13	com	_	_
13	hunger	hunger	NN	_	11	obj	_	_
14	and	and	CC	_	13	cc	_	_
15	anxiety	anxiety	NN	_	13	conj	_	_
16	during	during	IN	_	18	case	_	_
17	recovery	recovery	NN	_	18	com	_	_
18	therapy	therapy	NN	_	11	ppmod	_	_
19	.	.	.	_	6	p	_	_

1	Systemic	systemic	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	.	.	.	_	2	p	_	_

1	Understanding	understand	VBG	_	21	advcl	_	_
2	the	the	DT	_	3	det	_	_
3	breadth	breadth	NN	_	1	obj	_	_
4	of	of	IN	_	6	case	_	_
5	systemic	systemic	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	3	ppmod	_	_
7	available	available	JJ	_	6	attr	_	_
8	for	for	IN	_	9	case	_	_
9	use	use	NN	_	7	ppmod	_	_
10	by	by	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	dermatologist	dermatologist	NN	_	9	ppmod	_	_
13	and	and	CC	_	9	cc	_	_
14	their	their	PRP$	_	17	poss	_	_
15	associated	associated	JJ	_	17	attr	_	_
16	side-effect	side-effect	NN	_	17	com	_	_
17	profiles	profile	NNS	_	9	conj	_	_
18	and	and	CC	_	17	cc	_	_
19	drug	drug	NN	_	20	com	_	_
20	interactions	interaction	NNS	_	17	conj	_	_
21	allows	allow	VBZ	_	0	root	_	_
22	the	the	DT	_	23	det	_	_
23	clinician	clinician	NN	_	21	obj	_	_
24	to	to	TO	_	25	aux	_	_
25	offer	offer	VB	_	23	acl	_	_
26	patients	patient	NNS	_	28	attr	_	_
27	optimal	optimal	JJ	_	28	attr	_	_
28	care	care	NN	_	25	obj	_	_
29	in	in	IN	_	31	case	_	_
30	the	the	DT	_	31	det	_	_
31	management	management	NN	_	25	ppmod	_	_
32	of	of	IN	_	35	case	_	_
33	cutaneous	cutaneous	JJ	_	35	attr	_	_
34	infectious	infectious	JJ	_	35	attr	_	_
35	disease	disease	NN	_	31	ppmod	_	_
36	.	.	.	_	21	p	_	_

1	Altered	alter	VBN	_	0	root	_	_
2	responsiveness	responsiveness	NN	_	1	obj	_	_
3	to	to	TO	_	4	aux	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	after	after	IN	_	6	case	_	_
6	exposure	exposure	NN	_	1	ppmod	_	_
7	to	to	TO	_	9	aux	_	_
8	organic	organic	JJ	_	9	attr	_	_
9	lead	lead	NN	_	6	ppmod	_	_
10	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	known	know	VBN	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	effect	effect	VB	_	3	comp	_	_
6	the	the	DT	_	8	det	_	_
7	functional	functional	JJ	_	8	attr	_	_
8	integrity	integrity	NN	_	5	obj	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	limbic	limbic	JJ	_	12	attr	_	_
12	system	system	NN	_	8	ppmod	_	_
13	,	,	,	_	5	p	_	_
14	particularly	particularly	RB	_	16	adv	_	_
15	the	the	DT	_	16	det	_	_
16	hippocampus	hippocampus	NN	_	5	ppmod	_	_
17	,	,	,	_	5	p	_	_
18	and	and	CC	_	5	cc	_	_
19	to	to	TO	_	20	aux	_	_
20	alter	alter	VB	_	5	conj	_	_
21	behaviors	behavior	NNS	_	20	obj	_	_
22	which	which	WDT	_	24	dep	_	_
23	are	be	VBP	_	24	aux	_	_
24	thought	think	VBN	_	21	relcl	_	_
25	to	to	TO	_	27	aux	_	_
26	be	be	VB	_	27	aux	_	_
27	mediated	mediate	VBN	_	24	comp	_	_
28	through	through	IN	_	30	case	_	_
29	limbic	limbic	JJ	_	30	attr	_	_
30	function	function	NN	_	27	ppmod	_	_
31	.	.	.	_	3	p	_	_

1	Organometals	organometals	NNS	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	compromise	compromise	VB	_	0	root	_	_
4	the	the	DT	_	6	det	_	_
5	limbic	limbic	JJ	_	6	attr	_	_
6	system	system	NN	_	3	obj	_	_
7	and	and	CC	_	3	cc	_	_
8	result	result	VB	_	3	conj	_	_
9	in	in	IN	_	10	case	_	_
10	deficits	deficit	NNS	_	8	ppmod	_	_
11	in	in	IN	_	12	case	_	_
12	learning	learning	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	memory	memory	NN	_	12	conj	_	_
15	.	.	.	_	3	p	_	_

1	Since	since	IN	_	6	mark	_	_
2	both	both	CC	_	3	cc	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	and	and	CC	_	3	cc	_	_
5	organoleads	organoleads	NN	_	3	conj	_	_
6	are	be	VBP	_	25	advcl	_	_
7	present	present	JJ	_	6	dep	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	environment	environment	NN	_	7	ppmod	_	_
11	and	and	CC	_	6	cc	_	_
12	seem	seem	VBP	_	6	conj	_	_
13	to	to	TO	_	14	aux	_	_
14	influence	influence	VB	_	12	comp	_	_
15	limbic	limbic	JJ	_	16	attr	_	_
16	integration	integration	NN	_	14	obj	_	_
17	,	,	,	_	25	p	_	_
18	the	the	DT	_	19	det	_	_
19	interaction	interaction	NN	_	25	dep	_	_
20	of	of	IN	_	23	case	_	_
21	these	these	DT	_	23	det	_	_
22	two	#crd#	CD	_	23	num	_	_
23	compounds	compound	NNS	_	19	ppmod	_	_
24	was	be	VBD	_	25	aux	_	_
25	assessed	assess	VBN	_	0	root	_	_
26	in	in	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	present	present	JJ	_	29	attr	_	_
29	experiment	experiment	NN	_	25	ppmod	_	_
30	.	.	.	_	25	p	_	_

1	Thirty	#crd#	CD	_	3	num	_	_
2	male	male	JJ	_	3	attr	_	_
3	rats	rat	NNS	_	9	dep	_	_
4	of	of	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	Fischer-344	fischer-0	NN	_	7	com	_	_
7	strain	strain	NN	_	3	ppmod	_	_
8	were	be	VBD	_	9	aux	_	_
9	divided	divide	VBN	_	0	root	_	_
10	into	into	IN	_	13	case	_	_
11	three	#crd#	CD	_	13	num	_	_
12	equal	equal	JJ	_	13	attr	_	_
13	groups	group	NNS	_	9	ppmod	_	_
14	and	and	CC	_	9	cc	_	_
15	were	be	VBD	_	17	aux	_	_
16	given	give	VBN	_	17	lv	_	_
17	injections	injection	NNS	_	9	conj	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	drug2	drug0	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	(	-lrb-	-LRB-	_	28	p	_	_
24	8.0	0	CD	_	28	num	_	_
25	or	or	CC	_	24	cc	_	_
26	17.0	0	CD	_	24	conj	_	_
27	mg/kg/ml	mg/kg/ml	NN	_	28	com	_	_
28	SC	sc	NN	_	19	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	or	or	CC	_	19	cc	_	_
31	the	the	DT	_	33	det	_	_
32	saline	saline	NN	_	33	com	_	_
33	vehicle	vehicle	NN	_	19	conj	_	_
34	.	.	.	_	9	p	_	_

1	Fourteen	#crd#	CD	_	2	num	_	_
2	days	day	NNS	_	3	advnp	_	_
3	later	later	RB	_	8	adv	_	_
4	,	,	,	_	8	p	_	_
5	all	all	DT	_	6	det	_	_
6	animals	animal	NNS	_	8	dep	_	_
7	were	be	VBD	_	8	aux	_	_
8	challenged	challenge	VBN	_	0	root	_	_
9	with	with	IN	_	13	case	_	_
10	a	a	DT	_	13	det	_	_
11	single	single	JJ	_	13	attr	_	_
12	hypnotic	hypnotic	JJ	_	13	attr	_	_
13	dose	dose	NN	_	8	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	(	-lrb-	-LRB-	_	19	p	_	_
17	3.5	0	CD	_	19	num	_	_
18	g/kg	g/kg	NN	_	19	com	_	_
19	IP	ip	NN	_	13	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	.	.	.	_	8	p	_	_

1	The	the	DT	_	5	det	_	_
2	20	0	CD	_	5	num	_	_
3	%	%	NN	_	2	meta	_	_
4	v/v	v/v	NN	_	5	com	_	_
5	solution	solution	NN	_	9	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	prepared	prepare	VBN	_	0	root	_	_
10	in	in	IN	_	11	case	_	_
11	water	water	NN	_	9	ppmod	_	_
12	from	from	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	stock	stock	NN	_	15	com	_	_
15	solution	solution	NN	_	9	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	95	0	CD	_	19	num	_	_
18	%	%	NN	_	17	meta	_	_
19	drug2	drug0	NN	_	15	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	latency	latency	NN	_	15	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	loss	loss	NN	_	2	ppmod	_	_
5	of	of	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	righting	righting	JJ	_	8	attr	_	_
8	reflex	reflex	NN	_	4	ppmod	_	_
9	and	and	CC	_	4	cc	_	_
10	duration	duration	NN	_	4	conj	_	_
11	of	of	IN	_	13	case	_	_
12	sleep	sleep	JJ	_	13	attr	_	_
13	time	time	NN	_	10	ppmod	_	_
14	were	be	VBD	_	15	aux	_	_
15	recorded	record	VBN	_	0	root	_	_
16	while	while	IN	_	20	mark	_	_
17	the	the	DT	_	18	det	_	_
18	rats	rat	NNS	_	20	dep	_	_
19	were	be	VBD	_	20	aux	_	_
20	kept	keep	VBN	_	15	comp	_	_
21	in	in	IN	_	23	case	_	_
22	sound-attenuating	sound-attenuating	JJ	_	23	attr	_	_
23	chambers	chamber	NNS	_	20	ppmod	_	_
24	.	.	.	_	15	p	_	_

1	The	the	DT	_	2	det	_	_
2	rats	rat	NNS	_	10	dep	_	_
3	treated	treat	VBN	_	2	acl	_	_
4	with	with	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	highest	high	JJS	_	7	attr	_	_
7	dose	dose	NN	_	3	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	manifested	manifest	VBN	_	0	root	_	_
11	significantly	significantly	RB	_	12	adv	_	_
12	longer	long	JJR	_	13	attr	_	_
13	latencies	latency	NNS	_	10	obj	_	_
14	to	to	TO	_	15	aux	_	_
15	lose	lose	VB	_	10	comp	_	_
16	the	the	DT	_	18	det	_	_
17	righting	righting	NN	_	18	com	_	_
18	reflex	reflex	NN	_	15	obj	_	_
19	and	and	CC	_	18	cc	_	_
20	shorter	short	JJR	_	21	attr	_	_
21	durations	duration	NNS	_	18	conj	_	_
22	of	of	IN	_	23	case	_	_
23	sleep	sleep	NN	_	21	ppmod	_	_
24	than	than	IN	_	26	mark	_	_
25	did	do	VBD	_	26	lv	_	_
26	controls	control	NNS	_	15	comp	_	_
27	.	.	.	_	10	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	exposure	exposure	NN	_	10	dep	_	_
6	to	to	TO	_	8	aux	_	_
7	environmental	environmental	JJ	_	8	attr	_	_
8	drug1	drug0	NN	_	5	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	alter	alter	VBP	_	3	comp	_	_
11	the	the	DT	_	15	det	_	_
12	biological	biological	JJ	_	15	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	behavioral	behavioral	JJ	_	12	conj	_	_
15	responsiveness	responsiveness	NN	_	10	obj	_	_
16	of	of	IN	_	18	case	_	_
17	an	an	DT	_	18	det	_	_
18	animal	animal	NN	_	15	ppmod	_	_
19	to	to	TO	_	20	aux	_	_
20	drug2	drug0	NN	_	15	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	Evidence	evidence	NN	_	0	root	_	_
2	for	for	IN	_	3	case	_	_
3	reduction	reduction	NN	_	1	ppmod	_	_
4	of	of	IN	_	7	case	_	_
5	drug1	drug0	NN	_	7	com	_	_
6	uptake	uptake	NN	_	7	com	_	_
7	sites	site	NNS	_	3	ppmod	_	_
8	in	in	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	failing	failing	JJ	_	12	attr	_	_
11	human	human	JJ	_	12	attr	_	_
12	heart	heart	NN	_	3	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	OBJECTIVES	objective	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	investigated	investigate	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	role	role	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	neuronal	neuronal	JJ	_	8	attr	_	_
8	uptake	uptake	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	uptake-1	uptake-0	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	in	in	IN	_	17	case	_	_
15	human	human	JJ	_	17	attr	_	_
16	heart	heart	NN	_	17	com	_	_
17	failure	failure	NN	_	5	ppmod	_	_
18	as	as	IN	_	21	case	_	_
19	a	a	DT	_	21	det	_	_
20	local	local	JJ	_	21	attr	_	_
21	factor	factor	NN	_	3	ppmod	_	_
22	for	for	IN	_	23	case	_	_
23	altering	alter	VBG	_	21	ppmod	_	_
24	concentrations	concentration	NNS	_	23	obj	_	_
25	of	of	IN	_	26	case	_	_
26	norepinephrine	norepinephrine	NN	_	24	ppmod	_	_
27	at	at	IN	_	31	case	_	_
28	the	the	DT	_	31	det	_	_
29	cardiac	cardiac	JJ	_	31	attr	_	_
30	myocyte	myocyte	NN	_	31	com	_	_
31	membranes	membrane	NNS	_	23	ppmod	_	_
32	.	.	.	_	3	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Several	several	JJ	_	4	attr	_	_
2	beta-adrenergic	beta-adrenergic	JJ	_	4	attr	_	_
3	neuroeffector	neuroeffector	NN	_	4	com	_	_
4	defects	defect	NNS	_	5	dep	_	_
5	occur	occur	VBP	_	0	root	_	_
6	in	in	IN	_	8	case	_	_
7	heart	heart	NN	_	8	com	_	_
8	failure	failure	NN	_	5	ppmod	_	_
9	.	.	.	_	5	p	_	_

1	Whether	whether	IN	_	8	case	_	_
2	an	an	DT	_	3	det	_	_
3	alteration	alteration	NN	_	8	dep	_	_
4	in	in	IN	_	6	case	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	uptake-1	uptake-0	NN	_	3	ppmod	_	_
7	occurs	occur	VBZ	_	8	aux	_	_
8	is	be	VBZ	_	0	root	_	_
9	still	still	RB	_	10	adv	_	_
10	unresolved	unresolved	JJ	_	8	dep	_	_
11	.	.	.	_	8	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	role	role	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	uptake-1	uptake-0	NN	_	2	ppmod	_	_
6	was	be	VBD	_	7	aux	_	_
7	studied	study	VBN	_	0	root	_	_
8	in	in	IN	_	22	case	_	_
9	electrically	electrically	RB	_	10	adv	_	_
10	stimulated	stimulate	VBN	_	22	attr	_	_
11	(	-lrb-	-LRB-	_	17	p	_	_
12	1	0	CD	_	13	num	_	_
13	Hz	hz	NN	_	17	dep	_	_
14	,	,	,	_	17	p	_	_
15	37	0	CD	_	17	num	_	_
16	degrees	degree	NNS	_	17	com	_	_
17	C	c	NN	_	10	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	human	human	JJ	_	22	attr	_	_
20	ventricular	ventricular	JJ	_	22	attr	_	_
21	cardiac	cardiac	JJ	_	22	attr	_	_
22	preparations	preparation	NNS	_	7	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	isolated	isolate	VBN	_	26	attr	_	_
25	myocardial	myocardial	JJ	_	26	attr	_	_
26	membranes	membrane	NNS	_	22	conj	_	_
27	.	.	.	_	7	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effectiveness	effectiveness	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	increasing	increase	VBG	_	2	ppmod	_	_
7	the	the	DT	_	8	det	_	_
8	force	force	NN	_	6	obj	_	_
9	of	of	IN	_	10	case	_	_
10	contraction	contraction	NN	_	8	ppmod	_	_
11	was	be	VBD	_	12	aux	_	_
12	decreased	decrease	VBN	_	0	root	_	_
13	in	in	IN	_	14	case	_	_
14	relation	relation	NN	_	12	ppmod	_	_
15	to	to	TO	_	17	aux	_	_
16	the	the	DT	_	17	det	_	_
17	degree	degree	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	heart	heart	NN	_	20	com	_	_
20	failure	failure	NN	_	17	ppmod	_	_
21	.	.	.	_	12	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	9	ppmod	_	_
3	,	,	,	_	9	p	_	_
4	the	the	DT	_	5	det	_	_
5	potency	potency	NN	_	9	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	was	be	VBD	_	9	aux	_	_
9	increased	increase	VBN	_	0	root	_	_
10	in	in	IN	_	12	case	_	_
11	failing	failing	JJ	_	12	attr	_	_
12	hearts	heart	NNS	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	19	p	_	_
14	New	new	JJ	_	19	attr	_	_
15	York	york	NN	_	19	attr	_	_
16	Heart	heart	NN	_	19	attr	_	_
17	Association	association	NN	_	19	attr	_	_
18	functional	functional	JJ	_	19	attr	_	_
19	class	class	NN	_	9	prn	_	_
20	IV	iv	CD	_	19	num	_	_
21	)	-rrb-	-RRB-	_	19	p	_	_
22	in	in	IN	_	23	case	_	_
23	relation	relation	NN	_	9	ppmod	_	_
24	to	to	TO	_	26	aux	_	_
25	the	the	DT	_	26	det	_	_
26	concentrations	concentration	NNS	_	23	ppmod	_	_
27	producing	produce	VBG	_	26	acl	_	_
28	50	0	CD	_	27	obj	_	_
29	%	%	NN	_	28	meta	_	_
30	of	of	IN	_	33	case	_	_
31	the	the	DT	_	33	det	_	_
32	maximal	maximal	JJ	_	33	attr	_	_
33	effect	effect	NN	_	28	ppmod	_	_
34	(	-lrb-	-LRB-	_	35	p	_	_
35	EC50	ec0	NN	_	33	prn	_	_
36	)	-rrb-	-RRB-	_	35	p	_	_
37	.	.	.	_	9	p	_	_

1	The	the	DT	_	3	det	_	_
2	EC50	ec0	NN	_	3	com	_	_
3	values	value	NNS	_	17	dep	_	_
4	for	for	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	which	which	WDT	_	8	dep	_	_
8	is	be	VBZ	_	3	relcl	_	_
9	not	not	RB	_	8	neg	_	_
10	a	a	DT	_	11	det	_	_
11	substrate	substrate	NN	_	8	obj	_	_
12	for	for	IN	_	14	case	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	uptake-1	uptake-0	NN	_	11	ppmod	_	_
15	,	,	,	_	3	p	_	_
16	were	be	VBD	_	17	aux	_	_
17	reduced	reduce	VBN	_	0	root	_	_
18	in	in	IN	_	19	case	_	_
19	myocardium	myocardium	NN	_	17	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	functional	functional	JJ	_	22	attr	_	_
22	classes	class	NNS	_	19	ppmod	_	_
23	II	ii	CD	_	22	num	_	_
24	to	to	TO	_	23	attr	_	_
25	III	iii	CD	_	23	appo	_	_
26	and	and	CC	_	25	cc	_	_
27	IV	iv	CD	_	25	conj	_	_
28	compared	compare	VBN	_	30	adv	_	_
29	with	with	IN	_	30	case	_	_
30	those	those	DT	_	17	ppmod	_	_
31	in	in	IN	_	33	case	_	_
32	nonfailing	nonfailing	JJ	_	33	attr	_	_
33	myocardium	myocardium	NN	_	30	ppmod	_	_
34	.	.	.	_	17	p	_	_

1	The	the	DT	_	3	det	_	_
2	uptake	uptake	NN	_	3	com	_	_
3	inhibitors	inhibitor	NNS	_	11	dep	_	_
4	drug1	drug0	NN	_	3	appo	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	3	0	CD	_	9	num	_	_
9	mumol/liter	mumol/liter	NN	_	3	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	potentiated	potentiate	VBD	_	0	root	_	_
12	the	the	DT	_	15	det	_	_
13	positive	positive	JJ	_	15	attr	_	_
14	inotropic	inotropic	JJ	_	15	attr	_	_
15	effects	effect	NNS	_	11	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug3	drug0	NN	_	15	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	nonfailing	nonfailing	JJ	_	20	attr	_	_
20	myocardium	myocardium	NN	_	15	ppmod	_	_
21	(	-lrb-	-LRB-	_	25	p	_	_
22	p	p	NN	_	25	attr	_	_
23	&lt	&lt	CD	_	25	num	_	_
24	;	;	:	_	25	p	_	_
25	0.05	0	CD	_	20	num	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	but	but	CC	_	20	cc	_	_
28	not	not	RB	_	33	neg	_	_
29	in	in	IN	_	33	case	_	_
30	functional	functional	JJ	_	31	attr	_	_
31	class	class	NN	_	33	attr	_	_
32	IV	iv	CD	_	31	num	_	_
33	myocardium	myocardium	NN	_	20	conj	_	_
34	.	.	.	_	11	p	_	_

1	Radioligand	radioligand	NN	_	3	com	_	_
2	binding	binding	NN	_	3	com	_	_
3	experiments	experiment	NNS	_	10	dep	_	_
4	using	use	VBG	_	3	acl	_	_
5	the	the	DT	_	9	det	_	_
6	uptake	uptake	NN	_	9	com	_	_
7	inhibitor	inhibitor	NN	_	9	com	_	_
8	hydrogen-3	hydrogen-0	NN	_	9	com	_	_
9	drug1	drug0	NN	_	4	obj	_	_
10	revealed	reveal	VBD	_	0	root	_	_
11	a	a	DT	_	13	det	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	decrease	decrease	NN	_	10	obj	_	_
14	by	by	IN	_	16	case	_	_
15	approximately	approximately	RB	_	16	adv	_	_
16	30	0	CD	_	13	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	in	in	IN	_	22	case	_	_
19	drug2	drug0	NN	_	22	com	_	_
20	uptake-1	uptake-0	NN	_	22	com	_	_
21	carrier	carrier	NN	_	22	com	_	_
22	density	density	NN	_	13	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	functional	functional	JJ	_	25	attr	_	_
25	classes	class	NNS	_	13	ppmod	_	_
26	II	ii	CD	_	31	num	_	_
27	to	to	TO	_	26	cc	_	_
28	III	iii	CD	_	26	conj	_	_
29	and	and	CC	_	28	cc	_	_
30	IV	iv	CD	_	26	conj	_	_
31	myocardium	myocardium	NN	_	25	dep	_	_
32	versus	versus	CC	_	31	cc	_	_
33	nonfailing	nonfailing	JJ	_	34	attr	_	_
34	myocardium	myocardium	NN	_	31	conj	_	_
35	(	-lrb-	-LRB-	_	37	p	_	_
36	p	p	NN	_	37	com	_	_
37	&lt	&lt	NN	_	34	prn	_	_
38	;	;	:	_	37	p	_	_
39	0.05	0	CD	_	37	num	_	_
40	)	-rrb-	-RRB-	_	37	p	_	_
41	.	.	.	_	10	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	In	in	IN	_	4	case	_	_
2	human	human	JJ	_	4	attr	_	_
3	heart	heart	NN	_	4	com	_	_
4	failure	failure	NN	_	7	ppmod	_	_
5	,	,	,	_	7	p	_	_
6	there	there	EX	_	7	dep	_	_
7	is	be	VBZ	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	presynaptic	presynaptic	JJ	_	10	attr	_	_
10	defect	defect	NN	_	7	obj	_	_
11	in	in	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	sympathetic	sympathetic	JJ	_	15	attr	_	_
14	nervous	nervous	JJ	_	15	attr	_	_
15	system	system	NN	_	10	ppmod	_	_
16	,	,	,	_	10	p	_	_
17	leading	lead	VBG	_	10	acl	_	_
18	to	to	TO	_	21	aux	_	_
19	reduced	reduce	VBN	_	21	attr	_	_
20	uptake-1	uptake-0	NN	_	21	com	_	_
21	activity	activity	NN	_	17	ppmod	_	_
22	.	.	.	_	7	p	_	_

1	This	this	DT	_	2	det	_	_
2	defect	defect	NN	_	9	dep	_	_
3	in	in	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	failing	failing	JJ	_	6	attr	_	_
6	heart	heart	NN	_	2	ppmod	_	_
7	can	can	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	mimicked	mimic	VBN	_	0	root	_	_
10	by	by	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	effects	effect	NNS	_	9	ppmod	_	_
13	of	of	IN	_	16	case	_	_
14	uptake	uptake	NN	_	16	com	_	_
15	blocking	blocking	NN	_	16	com	_	_
16	agents	agent	NNS	_	12	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	such	such	JJ	_	20	adv	_	_
19	as	as	IN	_	20	case	_	_
20	drug1	drug0	NN	_	16	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug2	drug0	NN	_	20	conj	_	_
23	,	,	,	_	16	p	_	_
24	in	in	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	nonfailing	nonfailing	JJ	_	27	attr	_	_
27	heart	heart	NN	_	12	ppmod	_	_
28	only	only	RB	_	27	adv	_	_
29	.	.	.	_	9	p	_	_

1	Compromised	compromise	VBN	_	3	attr	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	uptake-1	uptake-0	NN	_	11	dep	_	_
4	in	in	IN	_	7	case	_	_
5	functional	functional	JJ	_	7	attr	_	_
6	class	class	NN	_	7	com	_	_
7	IV	iv	NN	_	3	ppmod	_	_
8	cannot	cannot	MD	_	11	modal	_	_
9	be	be	VB	_	11	aux	_	_
10	further	far	RB	_	11	adv	_	_
11	increased	increase	VBN	_	0	root	_	_
12	by	by	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	.	.	.	_	11	p	_	_

1	The	the	DT	_	3	det	_	_
2	pathophysiologic	pathophysiologic	JJ	_	3	attr	_	_
3	consequences	consequence	NNS	_	5	dep	_	_
4	could	could	MD	_	5	modal	_	_
5	be	be	VB	_	0	root	_	_
6	an	an	DT	_	9	det	_	_
7	increased	increase	VBN	_	9	attr	_	_
8	synaptic	synaptic	JJ	_	9	attr	_	_
9	concentration	concentration	NN	_	5	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	predisposing	predispose	VBG	_	9	acl	_	_
13	to	to	TO	_	16	aux	_	_
14	adenylyl	adenylyl	JJ	_	15	attr	_	_
15	cyclase	cyclase	NN	_	16	com	_	_
16	desensitization	desensitization	NN	_	12	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	mechanism	mechanism	NN	_	7	dep	_	_
3	of	of	IN	_	6	case	_	_
4	drug1	drug0	NN	_	6	attr	_	_
5	-induced	-induced	JJ	_	6	attr	_	_
6	vasorelaxation	vasorelaxation	NN	_	2	ppmod	_	_
7	differs	differ	VBZ	_	0	root	_	_
8	in	in	IN	_	12	case	_	_
9	the	the	DT	_	12	det	_	_
10	mesenteric	mesenteric	JJ	_	12	attr	_	_
11	resistance	resistance	NN	_	12	com	_	_
12	arteries	artery	NNS	_	7	ppmod	_	_
13	of	of	IN	_	17	case	_	_
14	lean	lean	JJ	_	17	attr	_	_
15	and	and	CC	_	14	cc	_	_
16	obese	obese	JJ	_	14	conj	_	_
17	rats	rat	NNS	_	12	ppmod	_	_
18	.	.	.	_	7	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	shown	show	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	induce	induce	VB	_	4	comp	_	_
7	vasorelaxation	vasorelaxation	NN	_	6	obj	_	_
8	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	study	study	NN	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	we	we	PRP	_	6	dep	_	_
6	investigated	investigate	VBD	_	0	root	_	_
7	the	the	DT	_	10	det	_	_
8	mechanism	mechanism	NN	_	10	attr	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	s	s	NNS	_	6	obj	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	of	of	IN	_	15	case	_	_
13	drug1	drug0	JJ	_	15	attr	_	_
14	-induced	-induced	JJ	_	15	attr	_	_
15	vasorelaxation	vasorelaxation	NN	_	10	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	resistance	resistance	NN	_	19	attr	_	_
18	mesenteric	mesenteric	JJ	_	19	attr	_	_
19	arteries	artery	NNS	_	15	ppmod	_	_
20	from	from	IN	_	26	case	_	_
21	male	male	JJ	_	26	attr	_	_
22	lean	lean	JJ	_	26	attr	_	_
23	and	and	CC	_	22	cc	_	_
24	dietary-induced	dietary-induced	JJ	_	22	conj	_	_
25	obese	obese	JJ	_	26	attr	_	_
26	rats	rat	NNS	_	19	ppmod	_	_
27	.	.	.	_	6	p	_	_

1	Compared	compare	VBN	_	4	adv	_	_
2	with	with	IN	_	4	case	_	_
3	lean	lean	JJ	_	4	attr	_	_
4	rats	rat	NNS	_	10	ppmod	_	_
5	,	,	,	_	10	p	_	_
6	arteries	artery	NNS	_	10	dep	_	_
7	from	from	IN	_	9	case	_	_
8	dietary-obese	dietary-obese	JJ	_	9	attr	_	_
9	rats	rat	NNS	_	6	ppmod	_	_
10	showed	show	VBD	_	0	root	_	_
11	significant	significant	JJ	_	18	attr	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	P&lt	p&lt	NN	_	11	prn	_	_
14	;	;	:	_	13	p	_	_
15	0.001	0	CD	_	13	appo	_	_
16	)	-rrb-	-RRB-	_	13	p	_	_
17	endothelial	endothelial	JJ	_	18	attr	_	_
18	dysfunction	dysfunction	NN	_	10	obj	_	_
19	,	,	,	_	10	p	_	_
20	as	as	IN	_	21	mark	_	_
21	indicated	indicate	VBN	_	10	comp	_	_
22	by	by	IN	_	24	case	_	_
23	a	a	DT	_	24	det	_	_
24	decrease	decrease	NN	_	21	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	>20	>0	CD	_	24	num	_	_
27	%	%	NN	_	26	meta	_	_
28	)	-rrb-	-RRB-	_	26	p	_	_
29	in	in	IN	_	32	case	_	_
30	maximal	maximal	JJ	_	32	attr	_	_
31	acetylcholine-induced	acetylcholine-induced	JJ	_	32	attr	_	_
32	vasorelaxation	vasorelaxation	NN	_	24	ppmod	_	_
33	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	6	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	5-35	0	CD	_	4	num	_	_
4	micromol/l	micromol/l	NN	_	1	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	induced	induce	VBD	_	0	root	_	_
7	concentration-dependent	concentration-dependent	JJ	_	8	attr	_	_
8	relaxation	relaxation	NN	_	6	obj	_	_
9	of	of	IN	_	11	case	_	_
10	mesenteric	mesenteric	JJ	_	11	attr	_	_
11	arteries	artery	NNS	_	8	ppmod	_	_
12	preconstricted	preconstricted	VBN	_	11	acl	_	_
13	with	with	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	8	0	CD	_	17	num	_	_
17	micromol/l	micromol/l	NN	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	or	or	CC	_	14	cc	_	_
20	drug3	drug0	NN	_	14	conj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	125	0	CD	_	23	num	_	_
23	mmol/l	mmol/l	NN	_	20	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	from	from	IN	_	30	case	_	_
26	both	both	CC	_	27	cc	_	_
27	lean	lean	JJ	_	30	attr	_	_
28	and	and	CC	_	27	cc	_	_
29	dietary-obese	dietary-obese	JJ	_	27	conj	_	_
30	rats	rat	NNS	_	6	ppmod	_	_
31	.	.	.	_	6	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	differences	difference	NNS	_	2	obj	_	_
6	between	between	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	two	#crd#	CD	_	9	num	_	_
9	groups	group	NNS	_	5	ppmod	_	_
10	,	,	,	_	2	p	_	_
11	achieving	achieve	VBG	_	2	comp	_	_
12	a	a	DT	_	14	det	_	_
13	maximum	maximum	JJ	_	14	attr	_	_
14	relaxation	relaxation	NN	_	11	obj	_	_
15	of	of	IN	_	16	case	_	_
16	>95	>0	CD	_	14	ppmod	_	_
17	%	%	NN	_	16	meta	_	_
18	at	at	IN	_	20	case	_	_
19	a	a	DT	_	20	det	_	_
20	concentration	concentration	NN	_	11	ppmod	_	_
21	of	of	IN	_	23	case	_	_
22	35	0	CD	_	23	num	_	_
23	micromol/l	micromol/l	NN	_	20	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	However	however	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	drug1	drug0	NN	_	12	dep	_	_
4	(	-lrb-	-LRB-	_	8	p	_	_
5	100	0	CD	_	8	num	_	_
6	and	and	CC	_	5	cc	_	_
7	300	0	CD	_	5	conj	_	_
8	micromol/l	micromol/l	NN	_	3	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	did	do	VBD	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	alter	alter	VB	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	effects	effect	NNS	_	12	obj	_	_
15	of	of	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	on	on	IN	_	18	case	_	_
18	arteries	artery	NNS	_	14	ppmod	_	_
19	from	from	IN	_	21	case	_	_
20	dietary-obese	dietary-obese	JJ	_	21	attr	_	_
21	rats	rat	NNS	_	18	ppmod	_	_
22	,	,	,	_	12	p	_	_
23	giving	give	VBG	_	12	comp	_	_
24	superimposed	superimposed	JJ	_	26	attr	_	_
25	concentration-responses	concentration-responses	JJ	_	26	attr	_	_
26	curves	curve	NNS	_	23	obj	_	_
27	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	also	also	RB	_	2	adv	_	_
4	ineffective	ineffective	JJ	_	2	dep	_	_
5	in	in	IN	_	6	case	_	_
6	altering	alter	VBG	_	2	ppmod	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	activity	activity	NN	_	6	obj	_	_
9	in	in	IN	_	10	case	_	_
10	arteries	artery	NNS	_	8	ppmod	_	_
11	from	from	IN	_	16	case	_	_
12	both	both	CC	_	13	cc	_	_
13	lean	lean	JJ	_	16	attr	_	_
14	and	and	CC	_	13	cc	_	_
15	dietary-obese	dietary-obese	JJ	_	13	conj	_	_
16	rats	rat	NNS	_	10	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	In	in	IN	_	4	case	_	_
2	drug1	drug0	JJ	_	4	attr	_	_
3	-precontracted	-precontracted	JJ	_	4	attr	_	_
4	arteries	artery	NNS	_	14	ppmod	_	_
5	from	from	IN	_	7	case	_	_
6	dietary-obese	dietary-obese	JJ	_	7	attr	_	_
7	rats	rat	NNS	_	4	ppmod	_	_
8	,	,	,	_	14	p	_	_
9	responses	response	NNS	_	14	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	were	be	VBD	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	attenuated	attenuate	VBN	_	0	root	_	_
15	by	by	IN	_	17	case	_	_
16	endothelial	endothelial	JJ	_	17	attr	_	_
17	denudation	denudation	NN	_	14	ppmod	_	_
18	,	,	,	_	14	p	_	_
19	indicating	indicate	VBG	_	14	comp	_	_
20	an	an	DT	_	21	det	_	_
21	action	action	NN	_	19	obj	_	_
22	independent	independent	JJ	_	21	attr	_	_
23	of	of	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	endothelium	endothelium	NN	_	22	ppmod	_	_
26	.	.	.	_	14	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	indicates	indicate	VBZ	_	0	root	_	_
4	that	that	IN	_	24	mark	_	_
5	:	:	:	_	11	p	_	_
6	(	-lrb-	-LRB-	_	7	p	_	_
7	a	a	LS	_	11	meta	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	the	the	DT	_	11	det	_	_
10	maximal	maximal	JJ	_	11	attr	_	_
11	effects	effect	NNS	_	24	dep	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	on	on	IN	_	16	case	_	_
15	resistance	resistance	NN	_	16	com	_	_
16	arteries	artery	NNS	_	11	ppmod	_	_
17	from	from	IN	_	21	case	_	_
18	lean	lean	JJ	_	21	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	dietary-obese	dietary-obese	JJ	_	18	conj	_	_
21	rats	rat	NNS	_	11	ppmod	_	_
22	are	be	VBP	_	24	aux	_	_
23	not	not	RB	_	24	neg	_	_
24	effected	effect	VBN	_	3	comp	_	_
25	by	by	IN	_	27	case	_	_
26	endothelial	endothelial	JJ	_	27	attr	_	_
27	dysfunction	dysfunction	NN	_	24	ppmod	_	_
28	,	,	,	_	24	p	_	_
29	and	and	CC	_	24	cc	_	_
30	(	-lrb-	-LRB-	_	31	p	_	_
31	b	b	LS	_	56	meta	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	the	the	DT	_	34	det	_	_
34	effects	effect	NNS	_	56	dep	_	_
35	of	of	IN	_	36	case	_	_
36	drug2	drug0	NN	_	34	ppmod	_	_
37	in	in	IN	_	39	case	_	_
38	lean	lean	JJ	_	39	attr	_	_
39	animals	animal	NNS	_	36	ppmod	_	_
40	(	-lrb-	-LRB-	_	39	p	_	_
41	where	where	WRB	_	44	adv	_	_
42	endothelial	endothelial	JJ	_	43	attr	_	_
43	function	function	NN	_	44	dep	_	_
44	is	be	VBZ	_	39	relcl	_	_
45	not	not	RB	_	46	neg	_	_
46	impaired	impaired	JJ	_	44	dep	_	_
47	)	-rrb-	-RRB-	_	39	p	_	_
48	,	,	,	_	39	p	_	_
49	but	but	CC	_	39	cc	_	_
50	not	not	RB	_	49	com	_	_
51	in	in	IN	_	53	case	_	_
52	dietary-obese	dietary-obese	JJ	_	53	attr	_	_
53	rats	rat	NNS	_	39	conj	_	_
54	,	,	,	_	53	p	_	_
55	are	be	VBP	_	56	aux	_	_
56	mediated	mediate	VBN	_	24	conj	_	_
57	via	via	IN	_	58	case	_	_
58	NO	no	NN	_	56	ppmod	_	_
59	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	:	:	:	_	5	p	_	_
3	an	an	DT	_	5	det	_	_
4	IgA-binding	iga-binding	NN	_	5	com	_	_
5	lectin	lectin	NN	_	0	root	_	_
6	.	.	.	_	5	p	_	_

1	We	we	PRP	_	3	dep	_	_
2	previously	previously	RB	_	3	adv	_	_
3	reported	report	VBD	_	0	root	_	_
4	that	that	IN	_	12	mark	_	_
5	seeds	seed	NNS	_	12	dep	_	_
6	of	of	IN	_	8	case	_	_
7	Artocarpus	artocarpus	FW	_	8	attr	_	_
8	integrifolia	integrifolia	FW	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	jackfruit	jackfruit	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	contain	contain	VBP	_	3	comp	_	_
13	a	a	DT	_	14	det	_	_
14	lectin	lectin	NN	_	12	obj	_	_
15	,	,	,	_	14	p	_	_
16	which	which	WDT	_	18	dep	_	_
17	we	we	PRP	_	18	dep	_	_
18	call	call	VBP	_	14	relcl	_	_
19	drug1	drug0	NN	_	18	obj	_	_
20	,	,	,	_	19	p	_	_
21	that	that	WDT	_	22	dep	_	_
22	is	be	VBZ	_	19	relcl	_	_
23	both	both	CC	_	28	cc	_	_
24	a	a	DT	_	28	det	_	_
25	potent	potent	JJ	_	28	attr	_	_
26	T	t	NN	_	28	com	_	_
27	cell	cell	NN	_	28	com	_	_
28	mitogen	mitogen	NN	_	22	obj	_	_
29	and	and	CC	_	28	cc	_	_
30	an	an	DT	_	34	det	_	_
31	apparently	apparently	RB	_	33	adv	_	_
32	T	t	NN	_	33	advnp	_	_
33	cell-independent	cell-independent	JJ	_	34	attr	_	_
34	activator	activator	NN	_	28	conj	_	_
35	of	of	IN	_	38	case	_	_
36	human	human	JJ	_	38	attr	_	_
37	B	b	NN	_	38	com	_	_
38	cells	cell	NNS	_	34	ppmod	_	_
39	for	for	IN	_	41	case	_	_
40	the	the	DT	_	41	det	_	_
41	secretion	secretion	NN	_	28	ppmod	_	_
42	of	of	IN	_	43	case	_	_
43	immunoglobulins	immunoglobulin	NNS	_	41	ppmod	_	_
44	.	.	.	_	3	p	_	_

1	During	during	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	above	above	JJ	_	4	attr	_	_
4	experiments	experiment	NNS	_	6	ppmod	_	_
5	we	we	PRP	_	6	dep	_	_
6	noted	note	VBN	_	0	root	_	_
7	a	a	DT	_	9	det	_	_
8	massive	massive	JJ	_	9	attr	_	_
9	precipitation	precipitation	NN	_	6	obj	_	_
10	in	in	IN	_	12	case	_	_
11	cell	cell	NN	_	12	com	_	_
12	cultures	culture	NNS	_	9	ppmod	_	_
13	stimulated	stimulate	VBN	_	12	acl	_	_
14	with	with	IN	_	21	case	_	_
15	greater	great	JJR	_	20	attr	_	_
16	than	than	IN	_	15	com	_	_
17	or	or	CC	_	20	cc	_	_
18	equal	equal	JJ	_	20	attr	_	_
19	to	to	TO	_	18	com	_	_
20	100	0	CD	_	21	num	_	_
21	micrograms	microgram	NNS	_	13	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	lectin	lectin	NN	_	21	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	paper	paper	NN	_	6	ppmod	_	_
4	,	,	,	_	6	p	_	_
5	we	we	PRP	_	6	dep	_	_
6	show	show	VBP	_	0	root	_	_
7	that	that	IN	_	11	mark	_	_
8	the	the	DT	_	9	det	_	_
9	precipitate	precipitate	NN	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	formed	form	VBN	_	6	comp	_	_
12	after	after	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	interaction	interaction	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	the	the	DT	_	20	det	_	_
19	serum	serum	NN	_	20	com	_	_
20	protein	protein	NN	_	16	conj	_	_
21	added	add	VBN	_	20	acl	_	_
22	to	to	TO	_	25	aux	_	_
23	the	the	DT	_	25	det	_	_
24	culture	culture	NN	_	25	com	_	_
25	medium	medium	NN	_	21	ppmod	_	_
26	.	.	.	_	6	p	_	_

1	More	more	RBR	_	2	com	_	_
2	importantly	importantly	RB	_	5	adv	_	_
3	,	,	,	_	5	p	_	_
4	we	we	PRP	_	5	dep	_	_
5	demonstrate	demonstrate	VBP	_	0	root	_	_
6	that	that	IN	_	8	mark	_	_
7	IgA	iga	NN	_	8	dep	_	_
8	is	be	VBZ	_	5	advcl	_	_
9	probably	probably	RB	_	8	adv	_	_
10	the	the	DT	_	13	det	_	_
11	major	major	JJ	_	13	attr	_	_
12	serum	serum	NN	_	13	com	_	_
13	constituent	constituent	NN	_	8	obj	_	_
14	precipitated	precipitate	VBD	_	13	acl	_	_
15	by	by	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	lectin	lectin	NN	_	14	ppmod	_	_
18	and	and	CC	_	8	cc	_	_
19	that	that	IN	_	26	mark	_	_
20	no	no	DT	_	21	det	_	_
21	IgG	igg	NN	_	26	dep	_	_
22	or	or	CC	_	21	cc	_	_
23	IgM	igm	NN	_	21	conj	_	_
24	can	can	MD	_	26	modal	_	_
25	be	be	VB	_	26	aux	_	_
26	detected	detect	VBN	_	8	conj	_	_
27	in	in	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	precipitates	precipitate	NNS	_	26	ppmod	_	_
30	.	.	.	_	5	p	_	_

1	In	in	IN	_	2	case	_	_
2	secretions	secretion	NNS	_	8	ppmod	_	_
3	such	such	JJ	_	5	adv	_	_
4	as	as	IN	_	5	case	_	_
5	colostrum	colostrum	NN	_	2	ppmod	_	_
6	,	,	,	_	8	p	_	_
7	IgA	iga	NN	_	8	dep	_	_
8	is	be	VBZ	_	0	root	_	_
9	the	the	DT	_	11	det	_	_
10	only	only	JJ	_	11	attr	_	_
11	protein	protein	NN	_	8	obj	_	_
12	precipitated	precipitate	VBD	_	11	acl	_	_
13	by	by	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	8	p	_	_

1	On	on	IN	_	6	case	_	_
2	the	the	DT	_	6	det	_	_
3	basis	basis	NN	_	6	advnp	_	_
4	of	of	IN	_	6	case	_	_
5	this	this	DT	_	6	det	_	_
6	specificity	specificity	NN	_	8	ppmod	_	_
7	we	we	PRP	_	8	dep	_	_
8	describe	describe	VBP	_	0	root	_	_
9	a	a	DT	_	15	det	_	_
10	simple	simple	JJ	_	15	attr	_	_
11	and	and	CC	_	10	cc	_	_
12	reliable	reliable	JJ	_	10	conj	_	_
13	affinity	affinity	NN	_	15	com	_	_
14	chromatography	chromatography	NN	_	15	com	_	_
15	procedure	procedure	NN	_	8	obj	_	_
16	for	for	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	purification	purification	NN	_	15	ppmod	_	_
19	of	of	IN	_	22	case	_	_
20	both	both	DT	_	22	det	_	_
21	human	human	JJ	_	22	attr	_	_
22	serum	serum	NN	_	18	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	colostrum	colostrum	NN	_	25	com	_	_
25	IgA	iga	NN	_	22	conj	_	_
26	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	6	det	_	_
4	D-Gal	d-gal	JJ	_	6	attr	_	_
5	binding	binding	NN	_	6	com	_	_
6	lectin	lectin	NN	_	2	obj	_	_
7	and	and	CC	_	2	cc	_	_
8	should	should	MD	_	9	modal	_	_
9	be	be	VB	_	2	conj	_	_
10	a	a	DT	_	12	det	_	_
11	useful	useful	JJ	_	12	attr	_	_
12	tool	tool	NN	_	9	obj	_	_
13	for	for	IN	_	14	case	_	_
14	studying	study	VBG	_	12	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	serum	serum	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	secretory	secretory	JJ	_	19	attr	_	_
19	IgA	iga	NN	_	16	conj	_	_
20	.	.	.	_	2	p	_	_

1	-LSB-2	-lsb-0	NN	_	2	com	_	_
2	epidemics	epidemics	NN	_	28	dep	_	_
3	of	of	IN	_	5	case	_	_
4	arsenical	arsenical	JJ	_	5	attr	_	_
5	encephalopathy	encephalopathy	NN	_	2	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	treatment	treatment	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	trypanosomiasis	trypanosomiasis	NN	_	8	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	Uganda	uganda	NNP	_	10	appo	_	_
13	,	,	,	_	14	p	_	_
14	1992-1993	0	CD	_	12	num	_	_
15	]	-rsb-	-RRB-	_	14	p	_	_
16	Since	since	IN	_	17	case	_	_
17	1988	0	CD	_	12	ppmod	_	_
18	,	,	,	_	10	p	_	_
19	the	the	DT	_	25	det	_	_
20	french	french	JJ	_	25	attr	_	_
21	non-governmental	non-governmental	JJ	_	25	attr	_	_
22	organisation	organisation	NN	_	25	com	_	_
23	M	m	NN	_	25	com	_	_
24	decins	decins	NN	_	25	com	_	_
25	Sans	sans	NN	_	10	appo	_	_
26	Fronti	fronti	NNP	_	27	com	_	_
27	res	res	NNP	_	25	appo	_	_
28	is	be	VBZ	_	0	root	_	_
29	running	run	VBG	_	28	comp	_	_
30	a	a	DT	_	32	det	_	_
31	control	control	JJ	_	32	attr	_	_
32	program	program	NN	_	29	obj	_	_
33	of	of	IN	_	36	case	_	_
34	human	human	JJ	_	36	attr	_	_
35	african	african	JJ	_	36	attr	_	_
36	trypanosomiasis	trypanosomiasis	NN	_	32	ppmod	_	_
37	in	in	IN	_	39	case	_	_
38	the	the	DT	_	39	det	_	_
39	district	district	NN	_	29	ppmod	_	_
40	of	of	IN	_	43	case	_	_
41	Moyo	moyo	NNP	_	43	attr	_	_
42	,	,	,	_	43	p	_	_
43	North-Uganda	north-uganda	NNP	_	39	ppmod	_	_
44	.	.	.	_	28	p	_	_

1	Between	between	IN	_	2	case	_	_
2	1988	0	CD	_	11	ppmod	_	_
3	and	and	CC	_	2	cc	_	_
4	1993	0	CD	_	2	conj	_	_
5	,	,	,	_	11	p	_	_
6	more	more	JJR	_	8	attr	_	_
7	than	than	IN	_	6	com	_	_
8	7,000	0	CD	_	9	num	_	_
9	patients	patient	NNS	_	11	dep	_	_
10	were	be	VBD	_	11	aux	_	_
11	diagnosed	diagnose	VBN	_	0	root	_	_
12	and	and	CC	_	11	cc	_	_
13	treated	treat	VBN	_	11	conj	_	_
14	.	.	.	_	11	p	_	_

1	Since	since	IN	_	2	case	_	_
2	1988	0	CD	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	it	it	PRP	_	7	dep	_	_
5	has	have	VBZ	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	noted	note	VBN	_	0	root	_	_
8	that	that	IN	_	14	mark	_	_
9	incidence	incidence	NN	_	14	dep	_	_
10	of	of	IN	_	12	case	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	reaction	reaction	NN	_	9	ppmod	_	_
13	had	have	VBD	_	14	aux	_	_
14	increased	increase	VBN	_	7	comp	_	_
15	systematically	systematically	RB	_	14	adv	_	_
16	between	between	IN	_	17	case	_	_
17	June	june	NNP	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	October	october	NN	_	17	conj	_	_
20	of	of	IN	_	22	case	_	_
21	each	each	DT	_	22	det	_	_
22	year	year	NN	_	19	ppmod	_	_
23	,	,	,	_	14	p	_	_
24	indicating	indicate	VBG	_	14	comp	_	_
25	strong	strong	JJ	_	27	attr	_	_
26	seasonal	seasonal	JJ	_	27	attr	_	_
27	variation	variation	NN	_	24	obj	_	_
28	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	1992	0	CD	_	15	ppmod	_	_
3	and	and	CC	_	2	cc	_	_
4	1993	0	CD	_	2	conj	_	_
5	,	,	,	_	15	p	_	_
6	two	#crd#	CD	_	7	num	_	_
7	outbreaks	outbreak	NNS	_	15	dep	_	_
8	of	of	IN	_	11	case	_	_
9	arsenical	arsenical	JJ	_	11	attr	_	_
10	reactive	reactive	JJ	_	11	attr	_	_
11	encephalopathy	encephalopathy	NN	_	7	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	ARE	be	VBP	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	occurred	occur	VBD	_	0	root	_	_
16	in	in	IN	_	20	case	_	_
17	the	the	DT	_	20	det	_	_
18	sleeping	sleeping	JJ	_	20	attr	_	_
19	sickness	sickness	NN	_	20	com	_	_
20	center	center	NN	_	15	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	Adjumani	adjumani	NNP	_	20	ppmod	_	_
23	.	.	.	_	15	p	_	_

1	The	the	DT	_	2	det	_	_
2	incidence	incidence	NN	_	6	dep	_	_
3	of	of	IN	_	2	case	_	_
4	ARE	be	VBP	_	6	aux	_	_
5	suddenly	suddenly	RB	_	6	adv	_	_
6	exceeded	exceed	VBD	_	0	root	_	_
7	10	0	CD	_	6	obj	_	_
8	%	%	NN	_	7	meta	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	patients	patient	NNS	_	7	ppmod	_	_
12	treated	treat	VBN	_	11	acl	_	_
13	by	by	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	during	during	IN	_	16	case	_	_
16	August	august	NNP	_	12	ppmod	_	_
17	1992	0	CD	_	16	num	_	_
18	and	and	CC	_	16	cc	_	_
19	September	september	NNP	_	16	conj	_	_
20	1993	0	CD	_	19	num	_	_
21	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	onset	onset	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	80	0	CD	_	2	ppmod	_	_
5	%	%	NN	_	4	meta	_	_
6	of	of	IN	_	8	case	_	_
7	those	those	DT	_	8	det	_	_
8	&quot	&quot	NN	_	4	ppmod	_	_
9	;	;	:	_	2	p	_	_
10	epidemic&quot	epidemic&quot	NN	_	2	appo	_	_
11	;	;	:	_	2	p	_	_

1	cases	case	NNS	_	3	dep	_	_
2	,	,	,	_	3	p	_	_
3	occurred	occur	VBD	_	0	root	_	_
4	between	between	IN	_	10	case	_	_
5	the	the	DT	_	10	det	_	_
6	5th	#ord#	JJ	_	10	attr	_	_
7	and	and	CC	_	10	cc	_	_
8	the	the	DT	_	10	det	_	_
9	11th	#ord#	JJ	_	10	attr	_	_
10	day	day	NN	_	3	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	treatment	treatment	NN	_	10	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Two	#crd#	CD	_	3	num	_	_
2	retrospective	retrospective	JJ	_	3	attr	_	_
3	studies	study	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	conducted	conduct	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	1992	0	CD	_	5	ppmod	_	_
8	(	-lrb-	-LRB-	_	10	p	_	_
9	75	0	CD	_	10	num	_	_
10	cases	case	NNS	_	7	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	and	and	CC	_	7	cc	_	_
13	in	in	IN	_	14	case	_	_
14	1993	0	CD	_	7	conj	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	51	0	CD	_	17	num	_	_
17	cases	case	NNS	_	14	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	.	.	.	_	5	p	_	_

1	Among	among	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	risk	risk	NN	_	4	com	_	_
4	factors	factor	NNS	_	8	ppmod	_	_
5	studied	study	VBN	_	4	acl	_	_
6	,	,	,	_	8	p	_	_
7	two	#crd#	CD	_	8	num	_	_
8	appear	appear	VBP	_	0	root	_	_
9	to	to	TO	_	10	aux	_	_
10	increase	increase	VB	_	8	comp	_	_
11	the	the	DT	_	12	det	_	_
12	risk	risk	NN	_	10	obj	_	_
13	of	of	IN	_	14	mark	_	_
14	ARE	be	VBP	_	12	acl	_	_
15	:	:	:	_	14	p	_	_
16	the	the	DT	_	17	det	_	_
17	prescription	prescription	NN	_	14	obj	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	to	to	TO	_	21	aux	_	_
21	treat	treat	VB	_	17	acl	_	_
22	strongyloidiasis	strongyloidiasis	NN	_	21	obj	_	_
23	during	during	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	drug2	drug0	NN	_	22	ppmod	_	_
26	cure	cure	NN	_	25	attr	_	_
27	and	and	CC	_	25	cc	_	_
28	the	the	DT	_	32	det	_	_
29	bad	bad	NN	_	32	attr	_	_
30	general	general	JJ	_	32	attr	_	_
31	clinical	clinical	JJ	_	32	attr	_	_
32	conditions	conditions	NN	_	25	conj	_	_
33	of	of	IN	_	34	case	_	_
34	patients	patient	NNS	_	25	ppmod	_	_
35	.	.	.	_	8	p	_	_

1	These	these	DT	_	2	det	_	_
2	observations	observation	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	exogenous	exogenous	JJ	_	6	attr	_	_
6	co-factors	co-factors	NNS	_	9	dep	_	_
7	could	could	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	involved	involve	VBN	_	3	comp	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	occurrence	occurrence	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	ARE	be	VBP	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	Recommendations	recommendation	NNS	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	avoid	avoid	VB	_	2	comp	_	_
5	administration	administration	NN	_	4	obj	_	_
6	of	of	IN	_	9	case	_	_
7	diffusible	diffusible	JJ	_	9	attr	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	treatment	treatment	NN	_	5	ppmod	_	_
10	during	during	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	cure	cure	NN	_	4	ppmod	_	_
13	,	,	,	_	4	p	_	_
14	and	and	CC	_	4	cc	_	_
15	to	to	TO	_	16	aux	_	_
16	improve	improve	VB	_	4	conj	_	_
17	the	the	DT	_	19	det	_	_
18	general	general	JJ	_	19	attr	_	_
19	conditions	condition	NNS	_	16	obj	_	_
20	of	of	IN	_	21	case	_	_
21	patients	patient	NNS	_	19	ppmod	_	_
22	before	before	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	cure	cure	NN	_	21	ppmod	_	_
25	of	of	IN	_	26	case	_	_
26	drug2	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	2	p	_	_

1	Behavioral	behavioral	JJ	_	2	attr	_	_
2	responses	response	NNS	_	10	dep	_	_
3	to	to	TO	_	6	aux	_	_
4	repeated	repeated	JJ	_	6	attr	_	_
5	drug1	drug0	NN	_	6	com	_	_
6	exposure	exposure	NN	_	2	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	mice	mouse	NNS	_	2	ppmod	_	_
9	selectively	selectively	RB	_	10	adv	_	_
10	bred	breed	VBN	_	0	root	_	_
11	for	for	IN	_	13	case	_	_
12	differential	differential	JJ	_	13	attr	_	_
13	sensitivity	sensitivity	NN	_	10	ppmod	_	_
14	to	to	TO	_	15	aux	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	10	p	_	_

1	Mice	mouse	NNS	_	40	dep	_	_
2	from	from	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	20th	#ord#	JJ	_	5	attr	_	_
5	generation	generation	NN	_	1	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	three	#crd#	CD	_	8	num	_	_
8	lines	line	NNS	_	5	ppmod	_	_
9	divergently	divergently	RB	_	10	adv	_	_
10	selected	select	VBN	_	8	acl	_	_
11	for	for	IN	_	12	case	_	_
12	response	response	NN	_	10	ppmod	_	_
13	to	to	TO	_	19	aux	_	_
14	drug1	drug0	NN	_	15	advnp	_	_
15	-induced	-induced	JJ	_	19	attr	_	_
16	sedation	sedation	NN	_	19	com	_	_
17	times	time	NNS	_	19	com	_	_
18	-LSB-long-sedation	-lsb-long-sedation	NN	_	19	com	_	_
19	time	time	NN	_	12	ppmod	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	LST	lst	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	,	,	,	_	19	p	_	_
24	short	short	JJ	_	26	attr	_	_
25	sedation	sedation	NN	_	26	com	_	_
26	time	time	NN	_	19	conj	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	SST	sst	NN	_	26	prn	_	_
29	)	-rrb-	-RRB-	_	28	p	_	_
30	,	,	,	_	26	p	_	_
31	and	and	CC	_	26	cc	_	_
32	randomly	randomly	RB	_	33	adv	_	_
33	bred	breed	VBN	_	36	attr	_	_
34	control	control	NN	_	36	attr	_	_
35	(	-lrb-	-LRB-	_	36	p	_	_
36	RBC	rbc	NNS	_	19	conj	_	_
37	)	-rrb-	-RRB-	_	36	p	_	_
38	]	-rsb-	-RRB-	_	36	p	_	_
39	were	be	VBD	_	40	aux	_	_
40	used	use	VBN	_	0	root	_	_
41	to	to	TO	_	42	aux	_	_
42	study	study	VB	_	40	comp	_	_
43	drug2	drug0	JJ	_	46	attr	_	_
44	-induced	-induced	JJ	_	46	attr	_	_
45	behavioral	behavioral	JJ	_	46	attr	_	_
46	sensitization	sensitization	NN	_	42	obj	_	_
47	.	.	.	_	40	p	_	_

1	These	these	DT	_	2	det	_	_
2	lines	line	NNS	_	3	dep	_	_
3	showed	show	VBD	_	0	root	_	_
4	variable	variable	JJ	_	5	attr	_	_
5	degrees	degree	NNS	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	locomotor	locomotor	JJ	_	8	attr	_	_
8	activities	activity	NNS	_	5	ppmod	_	_
9	in	in	IN	_	12	case	_	_
10	response	response	NN	_	12	advnp	_	_
11	to	to	TO	_	12	aux	_	_
12	drug1	drug0	NN	_	3	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	At	at	IN	_	5	case	_	_
2	a	a	DT	_	5	det	_	_
3	low	low	JJ	_	5	attr	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	dose	dose	NN	_	30	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	long	long	JJ	_	9	attr	_	_
8	withdrawal	withdrawal	NN	_	9	com	_	_
9	period	period	NN	_	5	conj	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	10	0	CD	_	12	num	_	_
12	mg/kg	mg/kg	NN	_	5	prn	_	_
13	,	,	,	_	12	p	_	_
14	twice	twice	RB	_	16	adv	_	_
15	a	a	DT	_	16	det	_	_
16	day	day	NN	_	12	appo	_	_
17	for	for	IN	_	19	case	_	_
18	5	0	CD	_	19	num	_	_
19	days	day	NNS	_	16	ppmod	_	_
20	followed	followed	VBN	_	19	acl	_	_
21	by	by	IN	_	24	case	_	_
22	a	a	DT	_	24	det	_	_
23	14-day	0-day	JJ	_	24	attr	_	_
24	withdrawal	withdrawal	NN	_	20	ppmod	_	_
25	)	-rrb-	-RRB-	_	12	p	_	_
26	,	,	,	_	30	p	_	_
27	the	the	DT	_	29	det	_	_
28	LST	lst	JJ	_	29	attr	_	_
29	mice	mouse	NNS	_	30	dep	_	_
30	showed	show	VBD	_	0	root	_	_
31	tolerance	tolerance	NN	_	32	com	_	_
32	development	development	NN	_	30	obj	_	_
33	.	.	.	_	30	p	_	_

1	In	in	IN	_	4	case	_	_
2	response	response	NN	_	4	advnp	_	_
3	to	to	TO	_	4	aux	_	_
4	drug1	drug0	NN	_	12	ppmod	_	_
5	,	,	,	_	12	p	_	_
6	the	the	DT	_	8	det	_	_
7	locomotor	locomotor	JJ	_	8	attr	_	_
8	activities	activity	NNS	_	12	dep	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	SST	sst	NN	_	8	ppmod	_	_
12	were	be	VBD	_	0	root	_	_
13	not	not	RB	_	12	neg	_	_
14	significantly	significantly	RB	_	15	adv	_	_
15	different	different	JJ	_	12	dep	_	_
16	from	from	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	RBC	rbc	NNS	_	19	com	_	_
19	group	group	NN	_	15	ppmod	_	_
20	.	.	.	_	12	p	_	_

1	At	at	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	higher	high	JJR	_	4	attr	_	_
4	dose	dose	NN	_	28	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	a	a	DT	_	9	det	_	_
7	shorter	short	JJR	_	9	attr	_	_
8	withdrawal	withdrawal	NN	_	9	com	_	_
9	period	period	NN	_	4	conj	_	_
10	(	-lrb-	-LRB-	_	12	p	_	_
11	20	0	CD	_	12	num	_	_
12	mg/kg	mg/kg	NN	_	9	prn	_	_
13	,	,	,	_	12	p	_	_
14	daily	daily	JJ	_	12	attr	_	_
15	for	for	IN	_	17	case	_	_
16	7	0	CD	_	17	num	_	_
17	days	day	NNS	_	14	ppmod	_	_
18	followed	followed	VBN	_	17	acl	_	_
19	by	by	IN	_	22	case	_	_
20	a	a	DT	_	22	det	_	_
21	3-day	0-day	JJ	_	22	attr	_	_
22	withdrawal	withdrawal	NN	_	18	ppmod	_	_
23	)	-rrb-	-RRB-	_	12	p	_	_
24	,	,	,	_	28	p	_	_
25	the	the	DT	_	27	det	_	_
26	SST	sst	NN	_	27	com	_	_
27	mice	mouse	NNS	_	28	dep	_	_
28	showed	show	VBD	_	0	root	_	_
29	behavioral	behavioral	JJ	_	30	attr	_	_
30	sensitization	sensitization	NN	_	28	obj	_	_
31	similar	similar	JJ	_	30	attr	_	_
32	to	to	TO	_	35	aux	_	_
33	the	the	DT	_	35	det	_	_
34	RBC	rbc	NNS	_	35	com	_	_
35	mice	mouse	NNS	_	31	ppmod	_	_
36	,	,	,	_	28	p	_	_
37	but	but	CC	_	28	cc	_	_
38	the	the	DT	_	40	det	_	_
39	LST	lst	JJ	_	40	attr	_	_
40	mice	mouse	NNS	_	43	dep	_	_
41	did	do	VBD	_	43	aux	_	_
42	not	not	RB	_	43	neg	_	_
43	develop	develop	VB	_	28	conj	_	_
44	sensitization	sensitization	NN	_	43	obj	_	_
45	.	.	.	_	28	p	_	_

1	The	the	DT	_	3	det	_	_
2	different	different	JJ	_	3	attr	_	_
3	responses	response	NNS	_	10	dep	_	_
4	in	in	IN	_	6	case	_	_
5	locomotor	locomotor	NN	_	6	com	_	_
6	activity	activity	NN	_	3	ppmod	_	_
7	induced	induce	VBN	_	6	acl	_	_
8	by	by	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	suggest	suggest	VBP	_	0	root	_	_
11	that	that	IN	_	15	mark	_	_
12	genetic	genetic	JJ	_	13	attr	_	_
13	factors	factor	NNS	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	play	play	VB	_	10	comp	_	_
16	a	a	DT	_	17	det	_	_
17	role	role	NN	_	15	obj	_	_
18	in	in	IN	_	19	case	_	_
19	determining	determine	VBG	_	15	ppmod	_	_
20	the	the	DT	_	21	det	_	_
21	magnitude	magnitude	NN	_	19	obj	_	_
22	of	of	IN	_	23	case	_	_
23	response	response	NN	_	21	ppmod	_	_
24	to	to	TO	_	26	aux	_	_
25	this	this	DT	_	26	det	_	_
26	drug	drug	NN	_	21	ppmod	_	_
27	.	.	.	_	10	p	_	_

1	Dopamine	dopamine	NN	_	5	attr	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	DA	da	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	levels	level	NNS	_	8	dep	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	differ	differ	VB	_	0	root	_	_
9	significantly	significantly	RB	_	8	adv	_	_
10	in	in	IN	_	12	case	_	_
11	either	either	CC	_	12	cc	_	_
12	striatum	striatum	NN	_	8	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	STR	str	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	or	or	CC	_	12	cc	_	_
17	nucleus	nucleus	NN	_	18	com	_	_
18	accumbens	accumbens	NNS	_	12	conj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	NAC	nac	NN	_	18	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	for	for	IN	_	26	case	_	_
23	the	the	DT	_	26	det	_	_
24	drug1	drug0	NN	_	26	attr	_	_
25	-treated	-treated	JJ	_	26	attr	_	_
26	animals	animal	NNS	_	8	ppmod	_	_
27	to	to	TO	_	31	aux	_	_
28	their	their	PRP$	_	31	poss	_	_
29	corresponding	corresponding	JJ	_	31	attr	_	_
30	saline-treated	saline-treated	JJ	_	31	attr	_	_
31	controls	control	NNS	_	8	ppmod	_	_
32	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	affinity	affinity	NN	_	11	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	Kd	kd	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	of	of	IN	_	7	case	_	_
7	D2	d0	NN	_	2	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	NAC	nac	NN	_	2	ppmod	_	_
11	decreased	decrease	VBD	_	0	root	_	_
12	significantly	significantly	RB	_	11	adv	_	_
13	,	,	,	_	11	p	_	_
14	without	without	IN	_	15	case	_	_
15	changes	change	NNS	_	11	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	density	density	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	Bmax	bmax	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	11	p	_	_
22	in	in	IN	_	26	case	_	_
23	the	the	DT	_	26	det	_	_
24	drug1	drug0	NN	_	26	attr	_	_
25	-treated	-treated	JJ	_	26	attr	_	_
26	SST	sst	NN	_	11	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	RBC	rbc	NN	_	29	com	_	_
29	mice	mouse	NNS	_	26	conj	_	_
30	.	.	.	_	11	p	_	_

1	On	on	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	other	other	JJ	_	4	attr	_	_
4	hand	hand	NN	_	24	ppmod	_	_
5	,	,	,	_	24	p	_	_
6	the	the	DT	_	7	det	_	_
7	density	density	NN	_	24	dep	_	_
8	of	of	IN	_	11	case	_	_
9	D2	d0	NN	_	11	com	_	_
10	binding	binding	NN	_	11	com	_	_
11	sites	site	NNS	_	7	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	SST	sst	NN	_	11	ppmod	_	_
15	and	and	CC	_	11	cc	_	_
16	the	the	DT	_	18	det	_	_
17	RBC	rbc	NNS	_	18	com	_	_
18	mice	mouse	NNS	_	11	conj	_	_
19	in	in	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	STR	str	NN	_	7	ppmod	_	_
22	was	be	VBD	_	24	aux	_	_
23	significantly	significantly	RB	_	24	adv	_	_
24	increased	increase	VBN	_	0	root	_	_
25	in	in	IN	_	28	case	_	_
26	drug1	drug0	JJ	_	28	attr	_	_
27	-treated	-treated	JJ	_	28	attr	_	_
28	groups	group	NNS	_	24	ppmod	_	_
29	without	without	IN	_	30	case	_	_
30	change	change	NN	_	28	ppmod	_	_
31	in	in	IN	_	32	case	_	_
32	Kd	kd	NN	_	30	ppmod	_	_
33	.	.	.	_	24	p	_	_

1	The	the	DT	_	3	det	_	_
2	LST	lst	JJ	_	3	attr	_	_
3	mice	mouse	NNS	_	6	dep	_	_
4	did	do	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	show	show	VB	_	0	root	_	_
7	any	any	DT	_	8	det	_	_
8	changes	change	NNS	_	6	obj	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	Kd	kd	NN	_	8	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	Bmax	bmax	NN	_	11	conj	_	_
14	in	in	IN	_	17	case	_	_
15	either	either	CC	_	17	cc	_	_
16	the	the	DT	_	17	det	_	_
17	STR	str	NN	_	11	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	the	the	DT	_	20	det	_	_
20	NAC	nac	NN	_	17	conj	_	_
21	.	.	.	_	6	p	_	_

1	Taken	take	VBN	_	6	advcl	_	_
2	together	together	RB	_	1	adv	_	_
3	,	,	,	_	6	p	_	_
4	these	these	DT	_	5	det	_	_
5	findings	finding	NNS	_	6	dep	_	_
6	suggest	suggest	VBP	_	0	root	_	_
7	that	that	IN	_	27	mark	_	_
8	the	the	DT	_	9	det	_	_
9	changes	change	NNS	_	27	dep	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	Kd	kd	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	D2	d0	NN	_	12	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	NAC	nac	NN	_	12	ppmod	_	_
18	and	and	CC	_	12	cc	_	_
19	the	the	DT	_	20	det	_	_
20	Bmax	bmax	NN	_	12	conj	_	_
21	of	of	IN	_	22	case	_	_
22	D2	d0	NN	_	20	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	the	the	DT	_	25	det	_	_
25	STR	str	NN	_	20	ppmod	_	_
26	may	may	MD	_	27	modal	_	_
27	contribute	contribute	VB	_	6	comp	_	_
28	to	to	TO	_	30	aux	_	_
29	the	the	DT	_	30	det	_	_
30	differences	difference	NNS	_	27	ppmod	_	_
31	in	in	IN	_	33	case	_	_
32	locomotor	locomotor	JJ	_	33	attr	_	_
33	responses	response	NNS	_	30	ppmod	_	_
34	to	to	TO	_	36	aux	_	_
35	drug1	drug0	NN	_	36	com	_	_
36	exposure	exposure	NN	_	33	ppmod	_	_
37	in	in	IN	_	40	case	_	_
38	these	these	DT	_	40	det	_	_
39	mouse	mouse	NN	_	40	com	_	_
40	lines	line	NNS	_	33	ppmod	_	_
41	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	inhibits	inhibit	VBZ	_	0	root	_	_
3	the	the	DT	_	6	det	_	_
4	CYP2C9	cyp0c0	RB	_	5	adv	_	_
5	catalyzed	catalyze	VBN	_	6	attr	_	_
6	biotransformation	biotransformation	NN	_	2	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Our	our	PRP$	_	4	poss	_	_
4	objective	objective	NN	_	5	dep	_	_
5	was	be	VBD	_	1	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	examine	examine	VB	_	5	comp	_	_
8	the	the	DT	_	9	det	_	_
9	interaction	interaction	NN	_	7	obj	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	to	to	TO	_	15	aux	_	_
15	confirm	confirm	VB	_	9	acl	_	_
16	that	that	IN	_	18	mark	_	_
17	drug3	drug0	NN	_	18	dep	_	_
18	inhibits	inhibit	VBZ	_	15	comp	_	_
19	CYP2C9	cyp0c0	NN	_	18	obj	_	_
20	.	.	.	_	1	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	study	study	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	carried	carry	VBN	_	1	acl	_	_
7	out	out	RP	_	6	prt	_	_
8	as	as	IN	_	15	case	_	_
9	an	an	DT	_	15	det	_	_
10	open	open	JJ	_	14	adv	_	_
11	,	,	,	_	14	p	_	_
12	randomized	randomized	JJ	_	14	adv	_	_
13	,	,	,	_	14	p	_	_
14	crossover	crossover	JJ	_	15	attr	_	_
15	design	design	NN	_	6	ppmod	_	_
16	with	with	IN	_	19	case	_	_
17	14	0	CD	_	19	num	_	_
18	healthy	healthy	JJ	_	19	attr	_	_
19	participants	participant	NNS	_	15	ppmod	_	_
20	.	.	.	_	1	p	_	_

1	In	in	IN	_	3	case	_	_
2	period	period	NN	_	3	com	_	_
3	A	a	NN	_	7	ppmod	_	_
4	,	,	,	_	7	p	_	_
5	all	all	DT	_	6	det	_	_
6	volunteers	volunteer	NNS	_	7	dep	_	_
7	took	take	VBD	_	0	root	_	_
8	500	0	CD	_	9	num	_	_
9	mg	mg	NN	_	7	obj	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	orally	orally	RB	_	7	adv	_	_
13	.	.	.	_	7	p	_	_

1	In	in	IN	_	3	case	_	_
2	period	period	NN	_	3	com	_	_
3	B	b	NN	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	the	the	DT	_	6	det	_	_
6	volunteers	volunteer	NNS	_	9	dep	_	_
7	were	be	VBD	_	9	aux	_	_
8	randomly	randomly	RB	_	9	adv	_	_
9	assigned	assign	VBN	_	0	root	_	_
10	to	to	TO	_	11	aux	_	_
11	one	#crd#	CD	_	9	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	two	#crd#	CD	_	14	num	_	_
14	groups	group	NNS	_	11	ppmod	_	_
15	.	.	.	_	9	p	_	_

1	Each	each	DT	_	2	det	_	_
2	group	group	NN	_	3	dep	_	_
3	took	take	VBD	_	0	root	_	_
4	either	either	CC	_	6	cc	_	_
5	150	0	CD	_	6	num	_	_
6	mg	mg	NN	_	3	obj	_	_
7	or	or	CC	_	6	cc	_	_
8	75	0	CD	_	9	num	_	_
9	mg	mg	NN	_	13	attr	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	a	a	DT	_	13	det	_	_
13	day	day	NN	_	6	conj	_	_
14	for	for	IN	_	16	case	_	_
15	5	0	CD	_	16	num	_	_
16	days	day	NNS	_	13	ppmod	_	_
17	(	-lrb-	-LRB-	_	18	p	_	_
18	day	day	NN	_	16	prn	_	_
19	-3	0	CD	_	18	num	_	_
20	to	to	TO	_	21	aux	_	_
21	day	day	NN	_	18	ppmod	_	_
22	2	0	CD	_	21	num	_	_
23	)	-rrb-	-RRB-	_	18	p	_	_
24	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	groups	group	NNS	_	4	dep	_	_
3	then	then	RB	_	4	adv	_	_
4	took	take	VBD	_	0	root	_	_
5	500	0	CD	_	6	num	_	_
6	mg	mg	NN	_	4	obj	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	as	as	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	single	single	JJ	_	12	attr	_	_
12	dose	dose	NN	_	4	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	day	day	NN	_	12	prn	_	_
15	0	0	CD	_	14	num	_	_
16	)	-rrb-	-RRB-	_	14	p	_	_
17	.	.	.	_	4	p	_	_

1	In	in	IN	_	3	case	_	_
2	both	both	DT	_	3	det	_	_
3	periods	period	NNS	_	9	ppmod	_	_
4	,	,	,	_	9	p	_	_
5	blood	blood	NN	_	9	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	urine	urine	NN	_	5	conj	_	_
8	were	be	VBD	_	9	aux	_	_
9	sampled	sample	VBN	_	0	root	_	_
10	at	at	IN	_	12	case	_	_
11	regular	regular	JJ	_	12	attr	_	_
12	intervals	interval	NNS	_	9	ppmod	_	_
13	.	.	.	_	9	p	_	_

1	Plasma	plasma	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	analyzed	analyze	VBN	_	0	root	_	_
4	for	for	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	3	p	_	_
7	and	and	CC	_	3	cc	_	_
8	urine	urine	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	analyzed	analyze	VBN	_	3	conj	_	_
11	for	for	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	its	its	PRP$	_	16	poss	_	_
15	two	#crd#	CD	_	16	num	_	_
16	metabolites	metabolite	NNS	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	appo	_	_
19	and	and	CC	_	18	cc	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	by	by	IN	_	22	case	_	_
22	means	mean	NNS	_	10	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	HPLC	hplc	NN	_	22	ppmod	_	_
25	.	.	.	_	3	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	During	during	IN	_	4	case	_	_
4	treatment	treatment	NN	_	9	ppmod	_	_
5	with	with	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	,	,	,	_	9	p	_	_
8	there	there	EX	_	9	dep	_	_
9	was	be	VBD	_	1	acl	_	_
10	a	a	DT	_	13	det	_	_
11	statistically	statistically	RB	_	12	adv	_	_
12	significant	significant	JJ	_	13	attr	_	_
13	decrease	decrease	NN	_	9	obj	_	_
14	in	in	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	median	median	NN	_	13	ppmod	_	_
17	of	of	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	total	total	JJ	_	20	attr	_	_
20	clearance	clearance	NN	_	16	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	,	,	,	_	9	p	_	_
24	from	from	IN	_	26	case	_	_
25	845	0	CD	_	26	num	_	_
26	mL/h	ml/h	NN	_	9	ppmod	_	_
27	to	to	TO	_	29	aux	_	_
28	688	0	CD	_	29	num	_	_
29	mL/h	ml/h	NN	_	26	ppmod	_	_
30	,	,	,	_	9	p	_	_
31	among	among	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	volunteers	volunteer	NNS	_	9	ppmod	_	_
34	who	who	WP	_	35	dep	_	_
35	received	receive	VBD	_	33	relcl	_	_
36	75	0	CD	_	37	num	_	_
37	mg/d	mg/d	NN	_	35	obj	_	_
38	.	.	.	_	1	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	a	a	DT	_	4	det	_	_
4	reduction	reduction	NN	_	2	obj	_	_
5	that	that	WDT	_	6	dep	_	_
6	reached	reach	VBD	_	4	relcl	_	_
7	borderline	borderline	NN	_	9	attr	_	_
8	statistical	statistical	JJ	_	9	attr	_	_
9	significance	significance	NN	_	6	obj	_	_
10	in	in	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	group	group	NN	_	6	ppmod	_	_
13	that	that	WDT	_	14	dep	_	_
14	received	receive	VBD	_	12	relcl	_	_
15	150	0	CD	_	16	num	_	_
16	mg/d	mg/d	NN	_	14	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	clearance	clearance	NN	_	11	dep	_	_
3	by	by	IN	_	4	case	_	_
4	means	mean	NNS	_	2	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	was	be	VBD	_	11	aux	_	_
10	significantly	significantly	RB	_	11	adv	_	_
11	reduced	reduce	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	both	both	DT	_	14	det	_	_
14	groups	group	NNS	_	11	ppmod	_	_
15	(	-lrb-	-LRB-	_	23	p	_	_
16	ie	ie	FW	_	23	ppmod	_	_
17	,	,	,	_	23	p	_	_
18	from	from	IN	_	20	case	_	_
19	901	0	CD	_	20	num	_	_
20	mL/h	ml/h	NN	_	23	ppmod	_	_
21	to	to	TO	_	23	aux	_	_
22	318	0	CD	_	23	num	_	_
23	mL/h	ml/h	NN	_	11	prn	_	_
24	in	in	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	group	group	NN	_	23	ppmod	_	_
27	that	that	WDT	_	28	dep	_	_
28	received	receive	VBD	_	26	relcl	_	_
29	150	0	CD	_	30	num	_	_
30	mg	mg	NN	_	28	obj	_	_
31	of	of	IN	_	32	case	_	_
32	drug3	drug0	NN	_	30	ppmod	_	_
33	per	per	IN	_	34	case	_	_
34	day	day	NN	_	30	ppmod	_	_
35	and	and	CC	_	23	cc	_	_
36	from	from	IN	_	38	case	_	_
37	723	0	CD	_	38	num	_	_
38	mL/h	ml/h	NN	_	23	conj	_	_
39	to	to	TO	_	41	aux	_	_
40	457	0	CD	_	41	num	_	_
41	mL/h	ml/h	NN	_	38	ppmod	_	_
42	in	in	IN	_	44	case	_	_
43	the	the	DT	_	44	det	_	_
44	group	group	NN	_	41	ppmod	_	_
45	that	that	WDT	_	46	dep	_	_
46	received	receive	VBD	_	44	relcl	_	_
47	75	0	CD	_	48	num	_	_
48	mg	mg	NN	_	46	obj	_	_
49	of	of	IN	_	50	case	_	_
50	drug4	drug0	NN	_	48	ppmod	_	_
51	per	per	IN	_	52	case	_	_
52	day	day	NN	_	48	ppmod	_	_
53	)	-rrb-	-RRB-	_	23	p	_	_
54	.	.	.	_	11	p	_	_

1	Thus	thus	RB	_	3	adv	_	_
2	there	there	EX	_	3	dep	_	_
3	was	be	VBD	_	0	root	_	_
4	a	a	DT	_	5	det	_	_
5	tendency	tendency	NN	_	3	obj	_	_
6	toward	toward	IN	_	10	case	_	_
7	a	a	DT	_	10	det	_	_
8	more	more	RBR	_	9	adv	_	_
9	pronounced	pronounced	JJ	_	10	attr	_	_
10	inhibition	inhibition	NN	_	5	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	4-hydroxylation	0-hydroxylation	NN	_	10	ppmod	_	_
14	during	during	IN	_	15	case	_	_
15	treatment	treatment	NN	_	3	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	150	0	CD	_	18	num	_	_
18	mg/d	mg/d	NN	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	drug1	drug0	NN	_	15	ppmod	_	_
21	compared	compare	VBN	_	24	adv	_	_
22	with	with	IN	_	24	case	_	_
23	75	0	CD	_	24	num	_	_
24	mg/d	mg/d	NN	_	3	ppmod	_	_
25	,	,	,	_	3	p	_	_
26	but	but	CC	_	3	cc	_	_
27	the	the	DT	_	28	det	_	_
28	difference	difference	NN	_	29	dep	_	_
29	was	be	VBD	_	3	conj	_	_
30	not	not	RB	_	29	neg	_	_
31	statistically	statistically	RB	_	32	adv	_	_
32	significant	significant	JJ	_	29	dep	_	_
33	.	.	.	_	3	p	_	_

1	CONCLUSION	conclusion	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	a	a	DT	_	7	det	_	_
6	moderate	moderate	JJ	_	7	attr	_	_
7	inhibitor	inhibitor	NN	_	4	obj	_	_
8	of	of	IN	_	9	case	_	_
9	CYP2C9	cyp0c0	NN	_	7	ppmod	_	_
10	in	in	FW	_	11	adv	_	_
11	vivo	vivo	FW	_	4	adv	_	_
12	.	.	.	_	1	p	_	_

1	Influence	influence	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	platelet	platelet	NN	_	6	com	_	_
6	function	function	NN	_	1	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	arachidonic	arachidonic	JJ	_	10	attr	_	_
9	acid	acid	NN	_	10	com	_	_
10	metabolism	metabolism	NN	_	6	conj	_	_
11	.	.	.	_	1	p	_	_

1	Available	available	JJ	_	2	attr	_	_
2	data	datum	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	that	that	IN	_	11	mark	_	_
5	platelet	platelet	NN	_	6	com	_	_
6	function	function	NN	_	11	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	arachidonic	arachidonic	JJ	_	10	attr	_	_
9	acid	acid	NN	_	10	com	_	_
10	metabolism	metabolism	NN	_	6	conj	_	_
11	are	be	VBP	_	3	comp	_	_
12	important	important	JJ	_	13	attr	_	_
13	factors	factor	NNS	_	11	obj	_	_
14	in	in	IN	_	15	case	_	_
15	hemostasis	hemostasis	NN	_	13	ppmod	_	_
16	and	and	CC	_	15	cc	_	_
17	regulation	regulation	NN	_	15	conj	_	_
18	of	of	IN	_	20	case	_	_
19	vascular	vascular	JJ	_	20	attr	_	_
20	tone	tone	NN	_	15	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	Plasma	plasma	NN	_	2	com	_	_
2	membrane	membrane	NN	_	9	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	intracellular	intracellular	JJ	_	5	attr	_	_
5	mobilization	mobilization	NN	_	2	conj	_	_
6	of	of	IN	_	8	case	_	_
7	calcium	calcium	NN	_	8	com	_	_
8	ions	ion	NNS	_	5	ppmod	_	_
9	are	be	VBP	_	0	root	_	_
10	intimately	intimately	RB	_	9	adv	_	_
11	related	related	JJ	_	9	dep	_	_
12	to	to	TO	_	14	aux	_	_
13	platelet	platelet	NN	_	14	com	_	_
14	activation	activation	NN	_	11	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	release	release	NN	_	14	conj	_	_
17	of	of	IN	_	19	case	_	_
18	platelet	platelet	NN	_	19	com	_	_
19	contents	content	NNS	_	14	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	Release	release	NN	_	21	dep	_	_
2	of	of	IN	_	4	case	_	_
3	arachidonic	arachidonic	JJ	_	4	attr	_	_
4	acid	acid	NN	_	1	ppmod	_	_
5	from	from	IN	_	7	case	_	_
6	membrane	membrane	NN	_	7	com	_	_
7	phospholipids	phospholipid	NNS	_	1	ppmod	_	_
8	as	as	RB	_	9	com	_	_
9	well	well	RB	_	1	cc	_	_
10	as	as	IN	_	9	com	_	_
11	subsequent	subsequent	JJ	_	12	attr	_	_
12	synthesis	synthesis	NN	_	1	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	release	release	NN	_	12	conj	_	_
15	of	of	IN	_	18	case	_	_
16	vasoconstrictor	vasoconstrictor	JJ	_	18	attr	_	_
17	thromboxane	thromboxane	NN	_	18	com	_	_
18	A2	a0	NN	_	12	ppmod	_	_
19	are	be	VBP	_	21	aux	_	_
20	also	also	RB	_	21	adv	_	_
21	regulated	regulate	VBN	_	0	root	_	_
22	by	by	IN	_	23	case	_	_
23	movement	movement	NN	_	21	ppmod	_	_
24	of	of	IN	_	26	case	_	_
25	calcium	calcium	NN	_	26	com	_	_
26	ions	ion	NNS	_	23	ppmod	_	_
27	.	.	.	_	21	p	_	_

1	Adenosine	adenosine	NN	_	9	dep	_	_
2	3	0	CD	_	1	num	_	_
3	'	'	POS	_	1	case	_	_
4	:	:	:	_	9	p	_	_
5	5'-cyclic	0'-cyclic	JJ	_	6	attr	_	_
6	phosphate	phosphate	NN	_	9	dep	_	_
7	in	in	IN	_	8	case	_	_
8	turn	turn	NN	_	6	ppmod	_	_
9	controls	control	VBZ	_	0	root	_	_
10	levels	level	NNS	_	9	obj	_	_
11	of	of	IN	_	14	case	_	_
12	free	free	JJ	_	14	attr	_	_
13	calcium	calcium	NN	_	14	com	_	_
14	ions	ion	NNS	_	10	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	platelets	platelet	NNS	_	14	ppmod	_	_
17	and	and	CC	_	9	cc	_	_
18	regulates	regulate	VBZ	_	9	conj	_	_
19	calcium-dependent	calcium-dependent	JJ	_	20	attr	_	_
20	reactions	reaction	NNS	_	18	obj	_	_
21	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	such	such	JJ	_	4	com	_	_
4	as	as	IN	_	1	cc	_	_
5	drug2	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	and	and	CC	_	7	cc	_	_
9	drug4	drug0	NN	_	5	conj	_	_
10	,	,	,	_	5	p	_	_
11	inhibit	inhibit	VBP	_	0	root	_	_
12	platelet	platelet	NN	_	13	com	_	_
13	activation	activation	NN	_	11	obj	_	_
14	in	in	FW	_	15	adv	_	_
15	vitro	vitro	FW	_	11	adv	_	_
16	,	,	,	_	11	p	_	_
17	and	and	CC	_	11	cc	_	_
18	decrease	decrease	VBP	_	11	conj	_	_
19	platelet	platelet	NN	_	20	com	_	_
20	adhesion	adhesion	NN	_	18	obj	_	_
21	intravascularly	intravascularly	RB	_	18	adv	_	_
22	.	.	.	_	11	p	_	_

1	These	these	DT	_	2	det	_	_
2	agents	agent	NNS	_	6	dep	_	_
3	have	have	VBP	_	6	aux	_	_
4	also	also	RB	_	6	adv	_	_
5	been	be	VBN	_	6	aux	_	_
6	shown	show	VBN	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	decrease	decrease	VB	_	6	comp	_	_
9	platelet	platelet	NN	_	11	com	_	_
10	nucleotide	nucleotide	NN	_	11	com	_	_
11	release	release	NN	_	8	obj	_	_
12	and	and	CC	_	11	cc	_	_
13	thromboxane	thromboxane	NN	_	15	com	_	_
14	A2	a0	NN	_	15	com	_	_
15	generation	generation	NN	_	11	conj	_	_
16	.	.	.	_	6	p	_	_

1	Some	some	DT	_	3	det	_	_
2	preliminary	preliminary	JJ	_	3	attr	_	_
3	data	datum	NNS	_	4	dep	_	_
4	suggest	suggest	VBP	_	0	root	_	_
5	that	that	IN	_	8	mark	_	_
6	drug1	drug0	NN	_	8	dep	_	_
7	also	also	RB	_	8	adv	_	_
8	increase	increase	VBP	_	4	comp	_	_
9	generation	generation	NN	_	8	obj	_	_
10	of	of	IN	_	15	case	_	_
11	vasodilator	vasodilator	JJ	_	15	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	platelet	platelet	NN	_	14	advnp	_	_
14	antiaggregant	antiaggregant	JJ	_	11	conj	_	_
15	prostacyclin	prostacyclin	NN	_	9	ppmod	_	_
16	,	,	,	_	9	p	_	_
17	which	which	WDT	_	19	dep	_	_
18	could	could	MD	_	19	modal	_	_
19	contribute	contribute	VB	_	9	relcl	_	_
20	to	to	TO	_	21	aux	_	_
21	decrease	decrease	NN	_	19	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	platelet	platelet	NN	_	24	com	_	_
24	function	function	NN	_	21	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	These	these	DT	_	2	det	_	_
2	effects	effect	NNS	_	13	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	platelet	platelet	NN	_	7	com	_	_
7	function	function	NN	_	2	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	arachidonic	arachidonic	JJ	_	11	attr	_	_
10	acid	acid	NN	_	11	com	_	_
11	metabolism	metabolism	NN	_	7	conj	_	_
12	could	could	MD	_	13	modal	_	_
13	contribute	contribute	VB	_	0	root	_	_
14	in	in	IN	_	15	case	_	_
15	part	part	NN	_	13	ppmod	_	_
16	to	to	TO	_	18	aux	_	_
17	their	their	PRP$	_	18	poss	_	_
18	efficacy	efficacy	NN	_	13	ppmod	_	_
19	in	in	IN	_	20	case	_	_
20	patients	patient	NNS	_	18	ppmod	_	_
21	with	with	IN	_	24	case	_	_
22	ischemic	ischemic	JJ	_	24	attr	_	_
23	heart	heart	NN	_	24	com	_	_
24	disease	disease	NN	_	20	ppmod	_	_
25	.	.	.	_	13	p	_	_

1	Pharmacology	pharmacology	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	pharmacotherapy	pharmacotherapy	NN	_	1	conj	_	_
4	of	of	IN	_	6	case	_	_
5	cardiovascular	cardiovascular	JJ	_	6	attr	_	_
6	drugs	drug	NNS	_	1	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	patients	patient	NNS	_	1	ppmod	_	_
9	with	with	IN	_	12	case	_	_
10	chronic	chronic	JJ	_	12	attr	_	_
11	renal	renal	JJ	_	12	attr	_	_
12	disease	disease	NN	_	8	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	Cardiovascular	cardiovascular	JJ	_	2	attr	_	_
2	disease	disease	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	a	a	DT	_	6	det	_	_
5	common	common	JJ	_	6	attr	_	_
6	comorbidity	comorbidity	NN	_	3	obj	_	_
7	and	and	CC	_	6	cc	_	_
8	a	a	DT	_	10	det	_	_
9	major	major	JJ	_	10	attr	_	_
10	cause	cause	NN	_	6	conj	_	_
11	of	of	IN	_	12	case	_	_
12	mortality	mortality	NN	_	10	ppmod	_	_
13	in	in	IN	_	14	case	_	_
14	patients	patient	NNS	_	10	ppmod	_	_
15	with	with	IN	_	18	case	_	_
16	chronic	chronic	JJ	_	18	attr	_	_
17	renal	renal	JJ	_	18	attr	_	_
18	disease	disease	NN	_	14	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	Drug	drug	NN	_	2	com	_	_
2	regimens	regimen	NNS	_	8	dep	_	_
3	in	in	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	cardiovascular	cardiovascular	JJ	_	7	attr	_	_
7	disease	disease	NN	_	4	ppmod	_	_
8	are	be	VBP	_	0	root	_	_
9	frequently	frequently	RB	_	8	adv	_	_
10	complex	complex	JJ	_	8	dep	_	_
11	and	and	CC	_	8	cc	_	_
12	can	can	MD	_	15	modal	_	_
13	be	be	VB	_	15	aux	_	_
14	significantly	significantly	RB	_	15	adv	_	_
15	affected	affect	VBN	_	8	conj	_	_
16	by	by	IN	_	17	case	_	_
17	alterations	alteration	NNS	_	15	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	renal	renal	JJ	_	20	attr	_	_
20	function	function	NN	_	17	ppmod	_	_
21	.	.	.	_	8	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	8	ppmod	_	_
3	,	,	,	_	8	p	_	_
4	several	several	JJ	_	6	attr	_	_
5	cardiovascular	cardiovascular	NN	_	6	com	_	_
6	drugs	drug	NNS	_	8	dep	_	_
7	directly	directly	RB	_	8	adv	_	_
8	affect	affect	VBP	_	0	root	_	_
9	renal	renal	JJ	_	10	attr	_	_
10	function	function	NN	_	8	obj	_	_
11	and	and	CC	_	10	cc	_	_
12	the	the	DT	_	13	det	_	_
13	management	management	NN	_	10	conj	_	_
14	of	of	IN	_	15	case	_	_
15	patients	patient	NNS	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	renal	renal	JJ	_	18	attr	_	_
18	disease	disease	NN	_	15	ppmod	_	_
19	.	.	.	_	8	p	_	_

1	This	this	DT	_	2	det	_	_
2	article	article	NN	_	3	dep	_	_
3	reviews	review	VBZ	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	impact	impact	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	renal	renal	JJ	_	8	attr	_	_
8	disease	disease	NN	_	5	ppmod	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	pharmacokinetics	pharmacokinetics	NNS	_	5	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	cardiovascular	cardiovascular	JJ	_	14	attr	_	_
14	drugs	drug	NNS	_	11	ppmod	_	_
15	and	and	CC	_	3	cc	_	_
16	identifies	identify	VBZ	_	3	conj	_	_
17	clinically	clinically	RB	_	18	adv	_	_
18	important	important	JJ	_	19	attr	_	_
19	interactions	interaction	NNS	_	16	obj	_	_
20	between	between	IN	_	21	case	_	_
21	these	these	DT	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	other	other	JJ	_	24	attr	_	_
24	drugs	drug	NNS	_	21	conj	_	_
25	commonly	commonly	RB	_	26	adv	_	_
26	used	use	VBN	_	24	acl	_	_
27	in	in	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	management	management	NN	_	26	ppmod	_	_
30	of	of	IN	_	33	case	_	_
31	chronic	chronic	JJ	_	33	attr	_	_
32	renal	renal	JJ	_	33	attr	_	_
33	disease	disease	NN	_	29	ppmod	_	_
34	.	.	.	_	3	p	_	_

1	Several	several	JJ	_	2	attr	_	_
2	classes	class	NNS	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	cardiovascular	cardiovascular	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	2	ppmod	_	_
6	are	be	VBP	_	8	aux	_	_
7	also	also	RB	_	8	adv	_	_
8	discussed	discuss	VBN	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	relationship	relationship	NN	_	8	ppmod	_	_
11	to	to	TO	_	14	aux	_	_
12	their	their	PRP$	_	14	poss	_	_
13	differential	differential	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	10	ppmod	_	_
15	on	on	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	management	management	NN	_	14	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	progression	progression	NN	_	17	conj	_	_
20	of	of	IN	_	22	case	_	_
21	renal	renal	JJ	_	22	attr	_	_
22	disease	disease	NN	_	17	ppmod	_	_
23	.	.	.	_	8	p	_	_

1	Influence	influence	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	sensitivity	sensitivity	NN	_	1	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	rat	rat	NN	_	12	attr	_	_
11	thoracic	thoracic	JJ	_	12	attr	_	_
12	aorta	aorta	NN	_	8	ppmod	_	_
13	to	to	TO	_	14	aux	_	_
14	drug3	drug0	NN	_	8	ppmod	_	_
15	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	aim	aim	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	study	study	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	investigate	investigate	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	effects	effect	NNS	_	8	obj	_	_
11	of	of	IN	_	15	case	_	_
12	low	low	JJ	_	15	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	high	high	JJ	_	12	conj	_	_
15	doses	dose	NNS	_	10	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	,	,	,	_	15	p	_	_
19	and	and	CC	_	15	cc	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	15	conj	_	_
22	on	on	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	response	response	NN	_	10	ppmod	_	_
25	to	to	TO	_	26	aux	_	_
26	drug3	drug0	NN	_	24	ppmod	_	_
27	in	in	IN	_	30	case	_	_
28	rat	rat	NN	_	30	attr	_	_
29	thoracic	thoracic	JJ	_	30	attr	_	_
30	aorta	aorta	NNS	_	26	ppmod	_	_
31	.	.	.	_	6	p	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	weeks	week	NNS	_	0	root	_	_
3	after	after	IN	_	5	case	_	_
4	bilateral	bilateral	JJ	_	5	attr	_	_
5	ovariectomy	ovariectomy	NN	_	2	ppmod	_	_
6	,	,	,	_	2	p	_	_
7	female	female	JJ	_	8	attr	_	_
8	rats	rat	NNS	_	2	appo	_	_
9	received	receive	VBD	_	8	acl	_	_
10	a	a	DT	_	11	det	_	_
11	s.c.	s.c.	NN	_	9	obj	_	_

1	injection	injection	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	vehicle	vehicle	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	6	p	_	_
5	corn	corn	NN	_	6	com	_	_
6	oil	oil	NN	_	3	prn	_	_
7	,	,	,	_	6	p	_	_
8	0.1	0	CD	_	9	num	_	_
9	mL/day	ml/day	NN	_	6	appo	_	_
10	)	-rrb-	-RRB-	_	6	p	_	_
11	,	,	,	_	3	p	_	_
12	drug1	drug0	NN	_	3	appo	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	10	0	CD	_	15	num	_	_
15	microg/kg/day	microg/kg/day	NN	_	12	prn	_	_
16	or	or	CC	_	15	cc	_	_
17	4	0	CD	_	18	num	_	_
18	mg/kg/day	mg/kg/day	NN	_	15	conj	_	_
19	)	-rrb-	-RRB-	_	15	p	_	_
20	and/or	and/or	CC	_	12	cc	_	_
21	drug2	drug0	NN	_	12	conj	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	20	0	CD	_	24	num	_	_
24	mg/kg/day	mg/kg/day	NN	_	21	prn	_	_
25	)	-rrb-	-RRB-	_	24	p	_	_
26	,	,	,	_	3	p	_	_
27	for	for	IN	_	29	case	_	_
28	eight	#crd#	CD	_	29	num	_	_
29	days	day	NNS	_	1	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	On	on	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	ninth	#ord#	JJ	_	4	attr	_	_
4	day	day	NN	_	9	ppmod	_	_
5	,	,	,	_	9	p	_	_
6	the	the	DT	_	7	det	_	_
7	rats	rat	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	sacrificed	sacrifice	VBN	_	0	root	_	_
10	and	and	CC	_	9	cc	_	_
11	aortic	aortic	JJ	_	12	attr	_	_
12	rings	ring	NNS	_	20	dep	_	_
13	,	,	,	_	12	p	_	_
14	with	with	IN	_	12	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	without	without	IN	_	17	case	_	_
17	endothelium	endothelium	NN	_	14	conj	_	_
18	,	,	,	_	12	p	_	_
19	were	be	VBD	_	20	aux	_	_
20	used	use	VBN	_	9	conj	_	_
21	to	to	TO	_	22	aux	_	_
22	generate	generate	VB	_	20	comp	_	_
23	concentration-response	concentration-response	JJ	_	24	attr	_	_
24	curves	curve	NNS	_	22	obj	_	_
25	to	to	TO	_	26	aux	_	_
26	drug1	drug0	NN	_	24	ppmod	_	_
27	.	.	.	_	9	p	_	_

1	Aortic	aortic	JJ	_	2	attr	_	_
2	rings	ring	NNS	_	15	dep	_	_
3	with	with	IN	_	5	case	_	_
4	intact	intact	JJ	_	5	attr	_	_
5	endothelium	endothelium	NN	_	2	ppmod	_	_
6	from	from	IN	_	14	case	_	_
7	the	the	DT	_	14	det	_	_
8	high-dose	high-dose	JJ	_	14	attr	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	4	0	CD	_	11	num	_	_
11	mg/kg/day	mg/kg/day	NN	_	14	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	group	group	NN	_	2	ppmod	_	_
15	were	be	VBD	_	0	root	_	_
16	supersensitive	supersensitive	JJ	_	15	dep	_	_
17	to	to	TO	_	18	aux	_	_
18	drug2	drug0	NN	_	16	ppmod	_	_
19	compared	compare	VBN	_	30	adv	_	_
20	to	to	TO	_	30	aux	_	_
21	the	the	DT	_	30	det	_	_
22	vehicle	vehicle	NN	_	30	attr	_	_
23	or	or	CC	_	22	cc	_	_
24	low-dose	low-dose	JJ	_	29	attr	_	_
25	(	-lrb-	-LRB-	_	27	p	_	_
26	10	0	CD	_	27	num	_	_
27	microg/kg/day	microg/kg/day	NNS	_	24	prn	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	estradiol	estradiol	NN	_	22	conj	_	_
30	groups	group	NNS	_	15	ppmod	_	_
31	(	-lrb-	-LRB-	_	34	p	_	_
32	pD2	pd0	NN	_	33	com	_	_
33	values	value	NNS	_	34	dep	_	_
34	=	=	JJ	_	15	prn	_	_
35	7.86+/-0.09	0+/-0	CD	_	34	obj	_	_
36	,	,	,	_	35	p	_	_
37	7.30+/-0.11	0+/-0	CD	_	35	conj	_	_
38	and	and	CC	_	37	cc	_	_
39	7.35+/-0.04	0+/-0	CD	_	35	conj	_	_
40	,	,	,	_	34	p	_	_
41	respectively	respectively	RB	_	34	adv	_	_
42	)	-rrb-	-RRB-	_	34	p	_	_
43	.	.	.	_	15	p	_	_

1	Endothelium-intact	endothelium-intact	NN	_	3	attr	_	_
2	aortic	aortic	JJ	_	3	attr	_	_
3	rings	ring	NNS	_	8	dep	_	_
4	from	from	IN	_	7	case	_	_
5	high-	high-	JJ	_	7	attr	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	rats	rat	NNS	_	3	ppmod	_	_
8	were	be	VBD	_	0	root	_	_
9	supersensitive	supersensitive	JJ	_	8	dep	_	_
10	to	to	TO	_	11	aux	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	when	when	WRB	_	13	adv	_	_
13	compared	compare	VBN	_	8	comp	_	_
14	to	to	TO	_	25	aux	_	_
15	vehicle-	vehicle-	JJ	_	24	adv	_	_
16	,	,	,	_	24	p	_	_
17	drug3	drug0	NN	_	24	advnp	_	_
18	-	-	CC	_	17	cc	_	_
19	and	and	CC	_	20	cc	_	_
20	drug4	drug0	JJ	_	23	attr	_	_
21	+	+	CC	_	20	cc	_	_
22	high-	high-	JJ	_	20	conj	_	_
23	drug5	drug0	NN	_	17	conj	_	_
24	-treated	-treated	JJ	_	25	attr	_	_
25	rats	rat	NNS	_	13	ppmod	_	_
26	(	-lrb-	-LRB-	_	29	p	_	_
27	pD2	pd0	NN	_	28	com	_	_
28	values	value	NNS	_	29	dep	_	_
29	=	=	JJ	_	25	prn	_	_
30	7.77+/-0.12	0+/-0	CD	_	29	obj	_	_
31	,	,	,	_	30	p	_	_
32	7.21+/-0.13	0+/-0	CD	_	30	conj	_	_
33	,	,	,	_	32	p	_	_
34	6.93+/-0.04	0+/-0	CD	_	30	conj	_	_
35	and	and	CC	_	34	cc	_	_
36	7.22+/-0.18	0+/-0	CD	_	30	conj	_	_
37	,	,	,	_	29	p	_	_
38	respectively	respectively	RB	_	29	adv	_	_
39	)	-rrb-	-RRB-	_	29	p	_	_
40	.	.	.	_	8	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	differences	difference	NNS	_	2	obj	_	_
6	among	among	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	pD2	pd0	NN	_	9	com	_	_
9	values	value	NNS	_	5	ppmod	_	_
10	for	for	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	in	in	IN	_	14	case	_	_
13	aortic	aortic	JJ	_	14	attr	_	_
14	rings	ring	NNS	_	9	ppmod	_	_
15	without	without	IN	_	16	case	_	_
16	endothelium	endothelium	NN	_	14	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	Both	both	DT	_	5	dep	_	_
2	of	of	IN	_	4	case	_	_
3	these	these	DT	_	4	det	_	_
4	effects	effect	NNS	_	1	ppmod	_	_
5	were	be	VBD	_	0	root	_	_
6	endothelium-dependent	endothelium-dependent	JJ	_	5	dep	_	_
7	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	therapeutics	therapeutic	NNS	_	1	conj	_	_
4	.	.	.	_	1	p	_	_

1	Two	#crd#	CD	_	3	num	_	_
2	different	different	JJ	_	3	attr	_	_
3	types	type	NNS	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	therapy	therapy	NN	_	3	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	are	be	VBP	_	9	aux	_	_
9	used	use	VBN	_	0	root	_	_
10	:	:	:	_	9	p	_	_
11	physiological	physiological	JJ	_	14	attr	_	_
12	oral	oral	JJ	_	14	attr	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	supplementation	supplementation	NN	_	9	obj	_	_
15	which	which	WDT	_	16	dep	_	_
16	is	be	VBZ	_	14	relcl	_	_
17	totally	totally	RB	_	18	adv	_	_
18	atoxic	atoxic	JJ	_	16	dep	_	_
19	since	since	IN	_	21	mark	_	_
20	it	it	PRP	_	21	dep	_	_
21	palliates	palliate	VBZ	_	16	comp	_	_
22	drug3	drug0	NN	_	23	com	_	_
23	deficiencies	deficiency	NNS	_	21	obj	_	_
24	by	by	IN	_	26	case	_	_
25	simply	simply	RB	_	26	adv	_	_
26	normalizing	normalize	VBG	_	21	ppmod	_	_
27	the	the	DT	_	29	det	_	_
28	drug4	drug0	NN	_	29	com	_	_
29	intake	intake	NN	_	26	obj	_	_
30	and	and	CC	_	29	cc	_	_
31	pharmacological	pharmacological	JJ	_	33	attr	_	_
32	drug5	drug0	NN	_	33	com	_	_
33	therapy	therapy	NN	_	29	conj	_	_
34	which	which	WDT	_	36	dep	_	_
35	may	may	MD	_	36	modal	_	_
36	induce	induce	VB	_	29	relcl	_	_
37	toxicity	toxicity	NN	_	36	obj	_	_
38	since	since	IN	_	40	mark	_	_
39	it	it	PRP	_	40	dep	_	_
40	creates	create	VBZ	_	36	comp	_	_
41	iatrogenic	iatrogenic	JJ	_	43	attr	_	_
42	drug6	drug0	NN	_	43	com	_	_
43	overload	overload	NN	_	40	obj	_	_
44	.	.	.	_	9	p	_	_

1	Primary	primary	JJ	_	5	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	secondary	secondary	JJ	_	1	conj	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	deficiencies	deficiency	NNS	_	6	dep	_	_
6	constitute	constitute	VBP	_	0	root	_	_
7	the	the	DT	_	9	det	_	_
8	sole	sole	JJ	_	9	attr	_	_
9	indication	indication	NN	_	6	obj	_	_
10	of	of	IN	_	14	case	_	_
11	physiological	physiological	JJ	_	14	attr	_	_
12	oral	oral	JJ	_	14	attr	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	therapy	therapy	NN	_	9	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	therefore	therefore	RB	_	2	adv	_	_
4	necessary	necessary	JJ	_	2	dep	_	_
5	to	to	TO	_	6	aux	_	_
6	be	be	VB	_	4	comp	_	_
7	well	well	RB	_	8	adv	_	_
8	acquainted	acquainted	JJ	_	6	dep	_	_
9	with	with	IN	_	14	case	_	_
10	the	the	DT	_	14	det	_	_
11	clinical	clinical	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	paraclinical	paraclinical	JJ	_	11	conj	_	_
14	pattern	pattern	NN	_	8	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	drug1	drug0	NN	_	17	com	_	_
17	deficit	deficit	NN	_	14	ppmod	_	_
18	and	and	CC	_	6	cc	_	_
19	to	to	TO	_	20	aux	_	_
20	discriminate	discriminate	VB	_	6	conj	_	_
21	between	between	IN	_	23	case	_	_
22	drug2	drug0	NN	_	23	com	_	_
23	deficiency	deficiency	NN	_	20	ppmod	_	_
24	due	due	JJ	_	23	attr	_	_
25	to	to	TO	_	29	aux	_	_
26	an	an	DT	_	29	det	_	_
27	insufficient	insufficient	JJ	_	29	attr	_	_
28	drug3	drug0	NN	_	29	com	_	_
29	intake	intake	NN	_	24	ppmod	_	_
30	which	which	WDT	_	32	dep	_	_
31	only	only	RB	_	32	adv	_	_
32	requires	require	VBZ	_	29	relcl	_	_
33	oral	oral	JJ	_	35	attr	_	_
34	physiological	physiological	JJ	_	35	attr	_	_
35	supplementation	supplementation	NN	_	32	obj	_	_
36	and	and	CC	_	35	cc	_	_
37	drug4	drug0	NN	_	38	com	_	_
38	depletion	depletion	NN	_	35	conj	_	_
39	related	related	JJ	_	35	attr	_	_
40	to	to	TO	_	42	aux	_	_
41	a	a	DT	_	42	det	_	_
42	dysregulation	dysregulation	NN	_	39	ppmod	_	_
43	of	of	IN	_	46	case	_	_
44	the	the	DT	_	46	det	_	_
45	control	control	JJ	_	46	attr	_	_
46	mechanisms	mechanism	NNS	_	42	ppmod	_	_
47	of	of	IN	_	49	case	_	_
48	drug5	drug0	NN	_	49	com	_	_
49	status	status	NN	_	46	ppmod	_	_
50	which	which	WDT	_	51	dep	_	_
51	requires	require	VBZ	_	42	relcl	_	_
52	more	more	JJR	_	56	attr	_	_
53	or	or	CC	_	52	cc	_	_
54	less	less	RBR	_	55	adv	_	_
55	specific	specific	JJ	_	52	conj	_	_
56	regulation	regulation	NN	_	51	obj	_	_
57	of	of	IN	_	60	case	_	_
58	its	its	PRP$	_	60	poss	_	_
59	causal	causal	JJ	_	60	attr	_	_
60	dysregulation	dysregulation	NN	_	56	ppmod	_	_
61	.	.	.	_	2	p	_	_

1	Physiological	physiological	JJ	_	4	attr	_	_
2	oral	oral	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	load	load	NN	_	5	dep	_	_
5	constitutes	constitute	VBZ	_	0	root	_	_
6	the	the	DT	_	8	det	_	_
7	best	good	JJS	_	8	attr	_	_
8	tool	tool	NN	_	5	obj	_	_
9	for	for	IN	_	10	case	_	_
10	diagnosis	diagnosis	NN	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	deficiency	deficiency	NN	_	10	ppmod	_	_
14	and	and	CC	_	8	cc	_	_
15	the	the	DT	_	17	det	_	_
16	first	#ord#	JJ	_	17	attr	_	_
17	step	step	NN	_	8	conj	_	_
18	of	of	IN	_	20	case	_	_
19	its	its	PRP$	_	20	poss	_	_
20	treatment	treatment	NN	_	17	ppmod	_	_
21	.	.	.	_	5	p	_	_

1	Physiological	physiological	JJ	_	4	attr	_	_
2	oral	oral	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	supplementation	supplementation	NN	_	9	dep	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	5	0	CD	_	7	num	_	_
7	mg/kg/day	mg/kg/day	NN	_	4	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	is	be	VBZ	_	0	root	_	_
10	easy	easy	JJ	_	9	dep	_	_
11	and	and	CC	_	9	cc	_	_
12	can	can	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	carried	carry	VBN	_	9	conj	_	_
15	out	out	RP	_	14	prt	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	diet	diet	NN	_	14	ppmod	_	_
19	or	or	CC	_	18	cc	_	_
20	with	with	IN	_	22	case	_	_
21	drug2	drug0	NN	_	22	com	_	_
22	s	s	NNS	_	18	conj	_	_
23	,	,	,	_	14	p	_	_
24	with	with	IN	_	28	case	_	_
25	practically	practically	RB	_	27	adv	_	_
26	only	only	RB	_	27	adv	_	_
27	one	#crd#	CD	_	28	num	_	_
28	contra-indication	contra-indication	NN	_	14	ppmod	_	_
29	:	:	:	_	9	p	_	_
30	overt	overt	JJ	_	32	attr	_	_
31	renal	renal	JJ	_	32	attr	_	_
32	failure	failure	NN	_	9	dep	_	_
33	.	.	.	_	9	p	_	_

1	Specific	specific	JJ	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	aspecific	aspecific	JJ	_	1	conj	_	_
4	treatments	treatment	NNS	_	8	dep	_	_
5	of	of	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	depletion	depletion	NN	_	4	ppmod	_	_
8	are	be	VBP	_	0	root	_	_
9	tricky	tricky	NN	_	10	advnp	_	_
10	using	use	VBG	_	13	attr	_	_
11	for	for	IN	_	12	case	_	_
12	example	example	NN	_	10	ppmod	_	_
13	drug2	drug0	NNS	_	8	obj	_	_
14	,	,	,	_	13	p	_	_
15	pharmacological	pharmacological	JJ	_	16	attr	_	_
16	doses	dose	NNS	_	13	appo	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	,	,	,	_	13	p	_	_
20	physiological	physiological	JJ	_	21	attr	_	_
21	doses	dose	NNS	_	13	appo	_	_
22	of	of	IN	_	23	case	_	_
23	drug4	drug0	NN	_	21	ppmod	_	_
24	and	and	CC	_	23	cc	_	_
25	of	of	IN	_	26	case	_	_
26	drug5	drug0	NN	_	23	conj	_	_
27	.	.	.	_	8	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	use	use	VB	_	23	advcl	_	_
5	the	the	DT	_	7	det	_	_
6	pharmacological	pharmacological	JJ	_	7	attr	_	_
7	properties	property	NNS	_	4	obj	_	_
8	of	of	IN	_	11	case	_	_
9	induced	induced	JJ	_	11	attr	_	_
10	therapeutic	therapeutic	JJ	_	11	attr	_	_
11	hypermagnesaemia	hypermagnesaemia	NN	_	7	ppmod	_	_
12	,	,	,	_	23	p	_	_
13	high	high	JJ	_	15	attr	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	doses	dose	NNS	_	23	dep	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	>	>	RB	_	20	adv	_	_
20	10	0	CD	_	21	num	_	_
21	mg/kg/day	mg/kg/day	NN	_	17	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	are	be	VBP	_	0	root	_	_
24	advisable	advisable	JJ	_	23	dep	_	_
25	for	for	IN	_	27	case	_	_
26	chronic	chronic	JJ	_	27	attr	_	_
27	indications	indication	NNS	_	24	ppmod	_	_
28	and	and	CC	_	23	cc	_	_
29	the	the	DT	_	31	det	_	_
30	parenteral	parenteral	JJ	_	31	attr	_	_
31	route	route	NN	_	32	dep	_	_
32	is	be	VBZ	_	23	conj	_	_
33	suitable	suitable	JJ	_	32	dep	_	_
34	for	for	IN	_	36	case	_	_
35	acute	acute	JJ	_	36	attr	_	_
36	indications	indication	NNS	_	33	ppmod	_	_
37	.	.	.	_	23	p	_	_

1	There	there	EX	_	2	dep	_	_
2	are	be	VBP	_	0	root	_	_
3	3	0	CD	_	4	num	_	_
4	types	type	NNS	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	indications	indication	NNS	_	4	ppmod	_	_
7	:	:	:	_	6	p	_	_
8	specific	specific	JJ	_	6	attr	_	_
9	(	-lrb-	-LRB-	_	20	p	_	_
10	for	for	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	treatment	treatment	NN	_	20	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	some	some	DT	_	15	det	_	_
15	forms	form	NNS	_	12	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	drug1	drug0	NN	_	18	com	_	_
18	deficit	deficit	NN	_	15	ppmod	_	_
19	i.e.	i.e.	FW	_	20	adv	_	_
20	acute	acute	JJ	_	8	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	,	,	,	_	8	p	_	_
23	pharmacological	pharmacological	JJ	_	8	conj	_	_
24	(	-lrb-	-LRB-	_	27	p	_	_
25	i.e.	i.e.	FW	_	27	ppmod	_	_
26	without	without	IN	_	27	case	_	_
27	alterations	alteration	NNS	_	23	prn	_	_
28	of	of	IN	_	30	case	_	_
29	drug2	drug0	NN	_	30	com	_	_
30	status	status	NN	_	27	ppmod	_	_
31	)	-rrb-	-RRB-	_	27	p	_	_
32	and	and	CC	_	23	cc	_	_
33	mixed--pharmacological	mixed--pharmacological	JJ	_	8	conj	_	_
34	and	and	CC	_	4	cc	_	_
35	aetiopathogenic--	aetiopathogenic--	CD	_	4	conj	_	_
36	(	-lrb-	-LRB-	_	39	p	_	_
37	for	for	IN	_	39	case	_	_
38	example	example	NN	_	39	com	_	_
39	complications	complication	NNS	_	35	prn	_	_
40	of	of	IN	_	42	case	_	_
41	chronic	chronic	JJ	_	42	attr	_	_
42	alcoholism	alcoholism	NN	_	39	ppmod	_	_
43	)	-rrb-	-RRB-	_	39	p	_	_
44	.	.	.	_	2	p	_	_

1	Today	today	JJ	_	4	attr	_	_
2	pharmacological	pharmacological	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	therapy	therapy	NN	_	6	dep	_	_
5	mainly	mainly	RB	_	6	adv	_	_
6	concerns	concern	VBZ	_	0	root	_	_
7	the	the	DT	_	13	det	_	_
8	obstetrical	obstetrical	JJ	_	13	attr	_	_
9	,	,	,	_	8	p	_	_
10	cardiological	cardiological	JJ	_	8	conj	_	_
11	and	and	CC	_	10	cc	_	_
12	anaesthesiological	anaesthesiological	JJ	_	8	conj	_	_
13	fields	field	NNS	_	6	obj	_	_
14	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	main	main	JJ	_	3	attr	_	_
3	indications	indication	NNS	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	eclampsia	eclampsia	NN	_	4	obj	_	_
6	,	,	,	_	5	p	_	_
7	some	some	DT	_	8	det	_	_
8	dysrhythmias	dysrhythmia	NNS	_	5	conj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	torsades	torsades	NNS	_	8	prn	_	_
11	de	de	NN	_	12	com	_	_
12	pointe	pointe	NN	_	10	attr	_	_
13	particularly	particularly	RB	_	10	adv	_	_
14	)	-rrb-	-RRB-	_	10	p	_	_
15	and	and	CC	_	8	cc	_	_
16	myocardial	myocardial	JJ	_	17	attr	_	_
17	ischaemias	ischaemias	NN	_	5	conj	_	_
18	.	.	.	_	4	p	_	_

1	But	but	CC	_	3	cc	_	_
2	it	it	PRP	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	now	now	RB	_	3	adv	_	_
5	difficult	difficult	JJ	_	3	dep	_	_
6	to	to	TO	_	7	aux	_	_
7	situate	situate	VB	_	5	comp	_	_
8	the	the	DT	_	10	det	_	_
9	exact	exact	JJ	_	10	attr	_	_
10	place	place	NN	_	7	obj	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	pharmacological	pharmacological	JJ	_	14	attr	_	_
14	indications	indication	NNS	_	10	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	infusions	infusion	NNS	_	6	dep	_	_
3	can	can	MD	_	6	modal	_	_
4	only	only	RB	_	6	adv	_	_
5	be	be	VB	_	6	aux	_	_
6	envisaged	envisage	VBN	_	0	root	_	_
7	in	in	IN	_	10	case	_	_
8	intensive	intensive	JJ	_	10	attr	_	_
9	care	care	NN	_	10	com	_	_
10	units	unit	NNS	_	6	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	careful	careful	JJ	_	13	attr	_	_
13	monitoring	monitoring	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	pulse	pulse	NN	_	13	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	arterial	arterial	JJ	_	18	attr	_	_
18	pressure	pressure	NN	_	15	conj	_	_
19	,	,	,	_	18	p	_	_
20	deep	deep	NN	_	22	com	_	_
21	tendon	tendon	NN	_	22	com	_	_
22	reflexes	reflex	NNS	_	15	conj	_	_
23	,	,	,	_	22	p	_	_
24	hourly	hourly	NN	_	25	com	_	_
25	diuresis	diuresis	NN	_	15	conj	_	_
26	,	,	,	_	25	p	_	_
27	electrocardiogram	electrocardiogram	NN	_	15	conj	_	_
28	and	and	CC	_	27	cc	_	_
29	respiratory	respiratory	JJ	_	30	attr	_	_
30	recordings	recording	NNS	_	15	conj	_	_
31	.	.	.	_	6	p	_	_

1	High	high	JJ	_	4	attr	_	_
2	oral	oral	JJ	_	4	attr	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	doses	dose	NNS	_	10	dep	_	_
5	besides	besides	IN	_	8	case	_	_
6	their	their	PRP$	_	8	poss	_	_
7	laxative	laxative	JJ	_	8	attr	_	_
8	action	action	NN	_	4	ppmod	_	_
9	may	may	MD	_	10	modal	_	_
10	bring	bring	VBP	_	0	root	_	_
11	latent	latent	JJ	_	12	attr	_	_
12	complications	complication	NNS	_	10	obj	_	_
13	which	which	WDT	_	15	dep	_	_
14	may	may	MD	_	15	modal	_	_
15	reduce	reduce	VB	_	12	relcl	_	_
16	lifespan	lifespan	NN	_	15	obj	_	_
17	.	.	.	_	10	p	_	_

1	There	there	EX	_	3	dep	_	_
2	may	may	MD	_	3	modal	_	_
3	remain	remain	VB	_	0	root	_	_
4	some	some	DT	_	5	det	_	_
5	indications	indication	NNS	_	3	obj	_	_
6	of	of	IN	_	11	case	_	_
7	the	the	DT	_	11	det	_	_
8	laxative	laxative	JJ	_	11	attr	_	_
9	and	and	CC	_	8	cc	_	_
10	antacid	antacid	JJ	_	8	conj	_	_
11	properties	property	NNS	_	5	ppmod	_	_
12	of	of	IN	_	15	case	_	_
13	non	non	JJ	_	15	attr	_	_
14	soluble	soluble	JJ	_	15	attr	_	_
15	drug1	drug0	NN	_	11	ppmod	_	_
16	,	,	,	_	3	p	_	_
17	particularly	particularly	RB	_	20	adv	_	_
18	during	during	IN	_	20	case	_	_
19	intermittent	intermittent	JJ	_	20	attr	_	_
20	haemodialysis	haemodialysis	NN	_	3	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	Lastly	lastly	RB	_	12	adv	_	_
2	local	local	JJ	_	3	attr	_	_
3	use	use	NN	_	12	dep	_	_
4	of	of	IN	_	9	case	_	_
5	the	the	DT	_	9	det	_	_
6	mucocutaneous	mucocutaneous	JJ	_	9	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	cytoprotective	cytoprotective	JJ	_	6	conj	_	_
9	properties	property	NNS	_	3	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	is	be	VBZ	_	0	root	_	_
13	still	still	RB	_	12	adv	_	_
14	valid	valid	JJ	_	12	dep	_	_
15	,	,	,	_	12	p	_	_
16	in	in	IN	_	17	case	_	_
17	drug2	drug0	NN	_	12	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	for	for	IN	_	20	case	_	_
20	preservation	preservation	NN	_	17	conj	_	_
21	of	of	IN	_	22	case	_	_
22	transplants	transplant	NNS	_	20	ppmod	_	_
23	particularly	particularly	RB	_	22	adv	_	_
24	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	upon	upon	IN	_	13	case	_	_
8	drug3	drug0	NN	_	12	advnp	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	drug4	drug0	NN	_	12	advnp	_	_
11	)	-rrb-	-RRB-	_	12	p	_	_
12	-induced	-induced	JJ	_	13	attr	_	_
13	locomotion	locomotion	NN	_	2	ppmod	_	_
14	and	and	CC	_	2	cc	_	_
15	behavioral	behavioral	JJ	_	16	attr	_	_
16	changes	change	NNS	_	2	conj	_	_
17	in	in	IN	_	18	case	_	_
18	mice	mouse	NNS	_	16	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	The	the	DT	_	3	det	_	_
2	behavioral	behavioral	JJ	_	3	attr	_	_
3	changes	change	NNS	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	mice	mouse	NNS	_	3	ppmod	_	_
6	induced	induce	VBN	_	3	acl	_	_
7	by	by	IN	_	8	case	_	_
8	acute	acute	JJ	_	6	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	repeated	repeated	JJ	_	8	conj	_	_
11	i.p.	i.p.	RB	_	6	adv	_	_

1	injection	injection	NN	_	8	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	drug2	drug0	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	were	be	VBD	_	8	aux	_	_
8	observed	observe	VBN	_	0	root	_	_
9	by	by	IN	_	10	case	_	_
10	measuring	measure	VBG	_	8	ppmod	_	_
11	locomotor	locomotor	JJ	_	12	attr	_	_
12	activity	activity	NN	_	10	obj	_	_
13	and	and	CC	_	12	cc	_	_
14	stereotyped	stereotyped	JJ	_	15	attr	_	_
15	behavior	behavior	NN	_	12	conj	_	_
16	.	.	.	_	8	p	_	_

1	Then	then	RB	_	27	adv	_	_
2	,	,	,	_	27	p	_	_
3	the	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	27	dep	_	_
5	of	of	IN	_	12	case	_	_
6	metabotropic	metabotropic	JJ	_	12	attr	_	_
7	glutamate	glutamate	NN	_	12	attr	_	_
8	receptor	receptor	NN	_	12	attr	_	_
9	(	-lrb-	-LRB-	_	12	p	_	_
10	mGluR	mglur	NN	_	12	attr	_	_
11	)	-rrb-	-RRB-	_	12	p	_	_
12	agonists	agonist	NNS	_	4	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug1	drug0	NN	_	12	appo	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	,	,	,	_	12	p	_	_
18	on	on	IN	_	22	case	_	_
19	the	the	DT	_	22	det	_	_
20	above	above	JJ	_	22	attr	_	_
21	behavioral	behavioral	JJ	_	22	attr	_	_
22	changes	change	NNS	_	4	ppmod	_	_
23	induced	induce	VBN	_	22	acl	_	_
24	by	by	IN	_	25	case	_	_
25	drug3	drug0	NN	_	23	ppmod	_	_
26	were	be	VBD	_	27	aux	_	_
27	found	find	VBN	_	0	root	_	_
28	.	.	.	_	27	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	0	root	_	_
6	very	very	RB	_	7	adv	_	_
7	strong	strong	JJ	_	5	dep	_	_
8	and	and	CC	_	5	cc	_	_
9	completely	completely	RB	_	10	adv	_	_
10	depressed	depress	VBD	_	5	conj	_	_
11	the	the	DT	_	14	det	_	_
12	drug2	drug0	JJ	_	14	attr	_	_
13	-induced	-induced	JJ	_	14	attr	_	_
14	hyperlocomotion	hyperlocomotion	NN	_	10	obj	_	_
15	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	were	be	VBD	_	0	root	_	_
6	not	not	RB	_	5	neg	_	_
7	so	so	RB	_	5	adv	_	_
8	strong	strong	JJ	_	5	dep	_	_
9	.	.	.	_	5	p	_	_

1	Repeated	repeated	JJ	_	2	attr	_	_
2	injection	injection	NN	_	10	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	for	for	IN	_	7	case	_	_
6	20	0	CD	_	7	num	_	_
7	days	day	NNS	_	2	ppmod	_	_
8	into	into	IN	_	9	case	_	_
9	mice	mouse	NNS	_	2	ppmod	_	_
10	induced	induce	VBD	_	0	root	_	_
11	lower	low	JJR	_	13	attr	_	_
12	locomotor	locomotor	NN	_	13	com	_	_
13	activity	activity	NN	_	10	obj	_	_
14	than	than	IN	_	15	case	_	_
15	that	that	DT	_	13	ppmod	_	_
16	in	in	IN	_	19	case	_	_
17	acutely	acutely	RB	_	18	adv	_	_
18	injected	inject	VBN	_	19	attr	_	_
19	mice	mouse	NNS	_	15	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	These	these	DT	_	3	det	_	_
2	behavioral	behavioral	JJ	_	3	attr	_	_
3	changes	change	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	be	be	VB	_	0	root	_	_
6	related	related	JJ	_	5	dep	_	_
7	with	with	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	negative	negative	JJ	_	10	attr	_	_
10	symptoms	symptom	NNS	_	6	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	schizophrenia	schizophrenia	NN	_	10	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	examine	examine	VB	_	35	advcl	_	_
5	some	some	DT	_	7	det	_	_
6	molecular	molecular	JJ	_	7	attr	_	_
7	mechanisms	mechanism	NNS	_	4	obj	_	_
8	of	of	IN	_	12	case	_	_
9	drug1	drug0	NN	_	12	attr	_	_
10	-induced	-induced	JJ	_	12	attr	_	_
11	behavioral	behavioral	NN	_	12	com	_	_
12	changes	change	NNS	_	7	ppmod	_	_
13	,	,	,	_	35	p	_	_
14	Northern	northern	NN	_	16	com	_	_
15	blot	blot	NN	_	16	com	_	_
16	analysis	analysis	NN	_	35	dep	_	_
17	of	of	IN	_	19	case	_	_
18	total	total	JJ	_	19	attr	_	_
19	RNA	rna	NN	_	16	ppmod	_	_
20	from	from	IN	_	23	case	_	_
21	prefrontal	prefrontal	JJ	_	23	attr	_	_
22	cortical	cortical	JJ	_	23	attr	_	_
23	tissues	tissue	NNS	_	19	ppmod	_	_
24	of	of	IN	_	25	case	_	_
25	mice	mouse	NNS	_	23	ppmod	_	_
26	treated	treat	VBN	_	25	acl	_	_
27	with	with	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	,	,	,	_	28	p	_	_
30	drug3	drug0	NN	_	28	conj	_	_
31	,	,	,	_	30	p	_	_
32	and	and	CC	_	30	cc	_	_
33	drug4	drug0	NN	_	28	conj	_	_
34	was	be	VBD	_	35	aux	_	_
35	carried	carry	VBN	_	0	root	_	_
36	out	out	RP	_	35	prt	_	_
37	.	.	.	_	35	p	_	_

1	Lack	lack	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	an	an	DT	_	4	det	_	_
4	effect	effect	NN	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	disposition	disposition	NN	_	4	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	11	conj	_	_
14	in	in	IN	_	16	case	_	_
15	HIV-infected	hiv-infected	JJ	_	16	attr	_	_
16	patients	patient	NNS	_	9	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	studies	study	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	conducted	conduct	VBN	_	0	root	_	_
5	in	in	IN	_	7	case	_	_
6	HIV-infected	hiv-infected	JJ	_	7	attr	_	_
7	subjects	subject	NNS	_	4	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	assess	assess	VB	_	4	comp	_	_
10	the	the	DT	_	11	det	_	_
11	potential	potential	NN	_	9	obj	_	_
12	for	for	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	to	to	TO	_	15	aux	_	_
15	interact	interact	VB	_	11	acl	_	_
16	with	with	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	and	and	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	17	conj	_	_
20	.	.	.	_	4	p	_	_

1	Both	both	DT	_	2	det	_	_
2	studies	study	NNS	_	3	dep	_	_
3	used	use	VBD	_	0	root	_	_
4	12	0	CD	_	5	num	_	_
5	subjects	subject	NNS	_	3	obj	_	_
6	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug1	drug0	JJ	_	3	attr	_	_
3	study	study	NN	_	4	dep	_	_
4	dosed	dose	VBD	_	0	root	_	_
5	subjects	subject	NNS	_	4	obj	_	_
6	with	with	IN	_	8	case	_	_
7	1200	0	CD	_	8	num	_	_
8	mg/day	mg/day	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	n	n	NN	_	10	prn	_	_
13	=	=	JJ	_	12	attr	_	_
14	7	0	CD	_	12	num	_	_
15	)	-rrb-	-RRB-	_	12	p	_	_
16	(	-lrb-	-LRB-	_	18	p	_	_
17	later	later	RB	_	18	adv	_	_
18	changed	change	VBN	_	10	prn	_	_
19	to	to	TO	_	22	aux	_	_
20	600	0	CD	_	21	num	_	_
21	mg/day	mg/day	NN	_	22	com	_	_
22	-LSB-n	-lsb-n	NN	_	18	ppmod	_	_
23	=	=	JJ	_	22	attr	_	_
24	5	0	CD	_	22	num	_	_
25	]	-rsb-	-RRB-	_	18	p	_	_
26	)	-rrb-	-RRB-	_	18	p	_	_
27	for	for	IN	_	28	case	_	_
28	Days	day	NNS	_	8	ppmod	_	_
29	8	0	CD	_	31	num	_	_
30	to	to	TO	_	31	attr	_	_
31	21	0	CD	_	28	num	_	_
32	of	of	IN	_	35	case	_	_
33	a	a	DT	_	35	det	_	_
34	21-day	0-day	JJ	_	35	attr	_	_
35	course	course	NN	_	28	ppmod	_	_
36	of	of	IN	_	38	case	_	_
37	100	0	CD	_	38	num	_	_
38	mg	mg	NN	_	35	ppmod	_	_
39	,	,	,	_	28	p	_	_
40	five	#crd#	CD	_	41	num	_	_
41	times/day	times/day	NNS	_	28	appo	_	_
42	of	of	IN	_	43	case	_	_
43	drug3	drug0	NN	_	41	ppmod	_	_
44	.	.	.	_	4	p	_	_

1	Subjects	subject	NNS	_	13	dep	_	_
2	treated	treat	VBN	_	1	acl	_	_
3	with	with	IN	_	5	case	_	_
4	200	0	CD	_	5	num	_	_
5	mg	mg	NN	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	twice	twice	RB	_	9	com	_	_
9	daily	daily	RB	_	2	adv	_	_
10	for	for	IN	_	12	case	_	_
11	21	0	CD	_	12	num	_	_
12	days	day	NNS	_	2	ppmod	_	_
13	received	receive	VBD	_	0	root	_	_
14	1200	0	CD	_	15	num	_	_
15	mg	mg	NN	_	13	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	or	or	CC	_	15	cc	_	_
19	an	an	DT	_	21	det	_	_
20	equivalent	equivalent	JJ	_	21	attr	_	_
21	amount	amount	NN	_	15	conj	_	_
22	of	of	IN	_	23	case	_	_
23	placebo/day	placebo/day	NN	_	21	ppmod	_	_
24	for	for	IN	_	25	case	_	_
25	Days	day	NNS	_	13	ppmod	_	_
26	8	0	CD	_	28	num	_	_
27	to	to	TO	_	28	attr	_	_
28	21	0	CD	_	25	num	_	_
29	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	plasma	plasma	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	urine	urine	NN	_	5	com	_	_
5	sampling	sampling	NN	_	2	conj	_	_
6	were	be	VBD	_	7	aux	_	_
7	conducted	conduct	VBN	_	0	root	_	_
8	on	on	IN	_	9	case	_	_
9	Days	day	NNS	_	7	ppmod	_	_
10	1	0	CD	_	9	num	_	_
11	,	,	,	_	10	p	_	_
12	7	0	CD	_	10	conj	_	_
13	,	,	,	_	12	p	_	_
14	and	and	CC	_	12	cc	_	_
15	21	0	CD	_	10	conj	_	_
16	for	for	IN	_	17	case	_	_
17	drug2	drug0	NN	_	9	ppmod	_	_
18	and	and	CC	_	9	cc	_	_
19	on	on	IN	_	20	case	_	_
20	Days	day	NNS	_	9	conj	_	_
21	7	0	CD	_	20	num	_	_
22	and	and	CC	_	20	cc	_	_
23	21	0	CD	_	20	conj	_	_
24	for	for	IN	_	25	case	_	_
25	drug3	drug0	NN	_	20	ppmod	_	_
26	.	.	.	_	7	p	_	_

1	Peripheral	peripheral	JJ	_	3	attr	_	_
2	mononuclear	mononuclear	JJ	_	3	attr	_	_
3	cells	cell	NNS	_	6	dep	_	_
4	were	be	VBD	_	6	aux	_	_
5	also	also	RB	_	6	adv	_	_
6	collected	collect	VBN	_	0	root	_	_
7	for	for	IN	_	8	case	_	_
8	quantitation	quantitation	NN	_	6	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	phosphorylated	phosphorylated	JJ	_	11	attr	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	impact	impact	NN	_	2	obj	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	Cmax	cmax	NN	_	2	ppmod	_	_
9	and	and	CC	_	8	cc	_	_
10	AUC	auc	NN	_	8	conj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	8	ppmod	_	_
13	,	,	,	_	2	p	_	_
14	although	although	IN	_	17	mark	_	_
15	it	it	PRP	_	17	dep	_	_
16	significantly	significantly	RB	_	17	adv	_	_
17	decreased	decrease	VBD	_	2	comp	_	_
18	the	the	DT	_	20	det	_	_
19	drug3	drug0	NN	_	20	com	_	_
20	tmax	tmax	NN	_	17	obj	_	_
21	by	by	IN	_	22	case	_	_
22	44	0	CD	_	17	ppmod	_	_
23	%	%	NN	_	22	meta	_	_
24	and	and	CC	_	17	cc	_	_
25	increased	increase	VBD	_	17	conj	_	_
26	the	the	DT	_	28	det	_	_
27	intracellular	intracellular	JJ	_	28	attr	_	_
28	exposure	exposure	NN	_	25	obj	_	_
29	to	to	TO	_	31	aux	_	_
30	phosphorylated	phosphorylated	VBN	_	31	attr	_	_
31	drug4	drug0	NN	_	28	ppmod	_	_
32	by	by	IN	_	33	case	_	_
33	110	0	CD	_	25	ppmod	_	_
34	%	%	NN	_	33	meta	_	_
35	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	had	have	VBD	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	effect	effect	NN	_	2	obj	_	_
6	on	on	IN	_	8	case	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
9	.	.	.	_	2	p	_	_

1	Based	base	VBN	_	4	adv	_	_
2	on	on	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	results	result	NNS	_	11	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	these	these	DT	_	7	det	_	_
7	studies	study	NNS	_	4	ppmod	_	_
8	,	,	,	_	11	p	_	_
9	it	it	PRP	_	11	dep	_	_
10	is	be	VBZ	_	11	aux	_	_
11	concluded	conclude	VBN	_	0	root	_	_
12	that	that	IN	_	17	mark	_	_
13	drug1	drug0	NN	_	17	dep	_	_
14	may	may	MD	_	17	modal	_	_
15	be	be	VB	_	17	aux	_	_
16	safely	safely	RB	_	17	adv	_	_
17	coadministered	coadministered	VBN	_	11	comp	_	_
18	with	with	IN	_	20	case	_	_
19	both	both	CC	_	20	cc	_	_
20	drug2	drug0	NN	_	17	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	drug3	drug0	NN	_	20	conj	_	_
23	.	.	.	_	11	p	_	_

1	Clinical	clinical	JJ	_	2	attr	_	_
2	implications	implication	NNS	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	JJ	_	5	attr	_	_
5	interactions	interaction	NNS	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	five	#crd#	CD	_	5	ppmod	_	_
8	drug2	drug0	VBP	_	0	root	_	_
9	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	intensity	intensity	NN	_	23	dep	_	_
3	,	,	,	_	2	p	_	_
4	uniformity	uniformity	NN	_	2	conj	_	_
5	and	and	CC	_	4	cc	_	_
6	time	time	NN	_	7	com	_	_
7	course	course	NN	_	2	conj	_	_
8	of	of	IN	_	10	case	_	_
9	drug1	drug0	NN	_	10	com	_	_
10	interference	interference	NN	_	2	ppmod	_	_
11	by	by	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	drug4	drug0	NN	_	12	conj	_	_
17	,	,	,	_	16	p	_	_
18	drug5	drug0	NN	_	12	conj	_	_
19	and	and	CC	_	18	cc	_	_
20	drug6	drug0	NN	_	12	conj	_	_
21	were	be	VBD	_	23	aux	_	_
22	systematically	systematically	RB	_	23	adv	_	_
23	investigated	investigate	VBN	_	0	root	_	_
24	in	in	IN	_	26	case	_	_
25	16	0	CD	_	26	num	_	_
26	patients	patient	NNS	_	23	ppmod	_	_
27	receiving	receive	VBG	_	26	acl	_	_
28	drug7	drug0	NN	_	29	com	_	_
29	therapy	therapy	NN	_	27	obj	_	_
30	.	.	.	_	23	p	_	_

1	Each	each	DT	_	2	det	_	_
2	subject	subject	NN	_	3	dep	_	_
3	received	receive	VBD	_	0	root	_	_
4	an	an	DT	_	8	det	_	_
5	individualized	individualized	JJ	_	8	attr	_	_
6	fixed	fixed	JJ	_	8	attr	_	_
7	daily	daily	JJ	_	8	attr	_	_
8	dose	dose	NN	_	3	obj	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	and	and	CC	_	3	cc	_	_
12	served	serve	VBD	_	3	conj	_	_
13	as	as	IN	_	20	case	_	_
14	his	his	PRP$	_	20	poss	_	_
15	own	own	JJ	_	20	attr	_	_
16	pre-	pre-	JJ	_	20	attr	_	_
17	and	and	CC	_	16	cc	_	_
18	postsedative	postsedative	JJ	_	16	conj	_	_
19	treatment	treatment	NN	_	20	com	_	_
20	control	control	NN	_	12	ppmod	_	_
21	.	.	.	_	3	p	_	_

1	Prothrombin	prothrombin	NN	_	2	com	_	_
2	times	time	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	measured	measure	VBN	_	0	root	_	_
5	four	#crd#	CD	_	6	num	_	_
6	times	time	NNS	_	4	obj	_	_
7	weekly	weekly	RB	_	4	adv	_	_
8	during	during	IN	_	11	case	_	_
9	five	#crd#	CD	_	11	num	_	_
10	long-term	long-term	JJ	_	11	attr	_	_
11	experiments	experiment	NNS	_	4	ppmod	_	_
12	.	.	.	_	4	p	_	_

1	Anticoagulant	anticoagulant	NN	_	2	com	_	_
2	inhibition	inhibition	NN	_	4	dep	_	_
3	was	be	VBD	_	4	aux	_	_
4	observed	observe	VBN	_	0	root	_	_
5	during	during	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	and	and	CC	_	11	cc	_	_
13	drug3	drug0	NN	_	9	conj	_	_
14	;	;	:	_	4	p	_	_

1	there	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	change	change	NN	_	2	obj	_	_
6	in	in	IN	_	9	case	_	_
7	prothrombin	prothrombin	NN	_	9	com	_	_
8	test	test	NN	_	9	com	_	_
9	results	result	NNS	_	5	ppmod	_	_
10	during	during	IN	_	12	case	_	_
11	the	the	DT	_	12	det	_	_
12	trials	trial	NNS	_	2	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	should	should	MD	_	7	modal	_	_
5	not	not	RB	_	7	neg	_	_
6	be	be	VB	_	7	aux	_	_
7	administered	administer	VBN	_	0	root	_	_
8	to	to	TO	_	9	aux	_	_
9	patients	patient	NNS	_	7	ppmod	_	_
10	receiving	receive	VBG	_	9	acl	_	_
11	drug3	drug0	NN	_	10	obj	_	_
12	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	concurrent	concurrent	JJ	_	3	attr	_	_
3	use	use	NN	_	10	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drugs	drug	NNS	_	3	ppmod	_	_
6	from	from	IN	_	8	case	_	_
7	these	these	DT	_	8	det	_	_
8	groups	group	NNS	_	5	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	decreasing	decrease	VBG	_	0	root	_	_
11	according	accord	VBG	_	14	adv	_	_
12	to	to	TO	_	14	aux	_	_
13	a	a	DT	_	14	det	_	_
14	survey	survey	NN	_	10	ppmod	_	_
15	of	of	IN	_	19	case	_	_
16	200	0	CD	_	19	num	_	_
17	hospital	hospital	NN	_	19	attr	_	_
18	medical	medical	JJ	_	19	attr	_	_
19	records	record	NNS	_	14	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	interact	interact	VBP	_	0	root	_	_
5	pharmacologically	pharmacologically	RB	_	4	adv	_	_
6	with	with	IN	_	9	case	_	_
7	orally	orally	RB	_	8	adv	_	_
8	administered	administer	VBN	_	9	attr	_	_
9	drug3	drug0	NN	_	4	ppmod	_	_
10	,	,	,	_	4	p	_	_
11	but	but	CC	_	4	cc	_	_
12	the	the	DT	_	13	det	_	_
13	effect	effect	NN	_	14	dep	_	_
14	is	be	VBZ	_	4	conj	_	_
15	not	not	RB	_	14	neg	_	_
16	clinically	clinically	RB	_	17	adv	_	_
17	significant	significant	JJ	_	14	dep	_	_
18	.	.	.	_	4	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	concluded	conclude	VBN	_	0	root	_	_
4	that	that	IN	_	10	mark	_	_
5	drug1	drug0	NN	_	10	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	may	may	MD	_	10	modal	_	_
9	be	be	VB	_	10	aux	_	_
10	administered	administer	VBN	_	3	comp	_	_
11	safely	safely	RB	_	10	adv	_	_
12	without	without	IN	_	14	case	_	_
13	additional	additional	JJ	_	14	attr	_	_
14	caution	caution	NN	_	10	ppmod	_	_
15	in	in	IN	_	18	case	_	_
16	prothrombin	prothrombin	NN	_	18	com	_	_
17	test	test	NN	_	18	com	_	_
18	monitoring	monitoring	NN	_	14	ppmod	_	_
19	during	during	IN	_	22	case	_	_
20	oral	oral	JJ	_	22	attr	_	_
21	drug3	drug0	NN	_	22	com	_	_
22	therapy	therapy	NN	_	10	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	constituents	constituent	NNS	_	1	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	alcoholic	alcoholic	JJ	_	7	attr	_	_
7	beverages	beverage	NNS	_	4	ppmod	_	_
8	in	in	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	promotion	promotion	NN	_	1	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	liver	liver	NN	_	13	com	_	_
13	damage	damage	NN	_	10	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	Little	little	JJ	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	studied	study	VBN	_	0	root	_	_
5	of	of	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	adverse	adverse	JJ	_	8	attr	_	_
8	effects	effect	NNS	_	4	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	exposure	exposure	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	liver	liver	NN	_	11	ppmod	_	_
15	to	to	TO	_	17	aux	_	_
16	the	the	DT	_	17	det	_	_
17	interaction	interaction	NN	_	11	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug1	drug0	NN	_	17	ppmod	_	_
20	with	with	IN	_	22	case	_	_
21	its	its	PRP$	_	22	poss	_	_
22	congeners	congener	NNS	_	17	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	drug2	drug0	NN	_	22	conj	_	_
25	,	,	,	_	4	p	_	_
26	coexisting	coexist	VBG	_	4	comp	_	_
27	in	in	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	contents	content	NNS	_	26	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	alcoholic	alcoholic	JJ	_	32	attr	_	_
32	beverages	beverage	NNS	_	29	ppmod	_	_
33	.	.	.	_	4	p	_	_

1	Twenty	#crd#	CD	_	5	num	_	_
2	four	#crd#	CD	_	5	num	_	_
3	male	male	JJ	_	5	attr	_	_
4	Wistar	wistar	NN	_	5	com	_	_
5	rats	rat	NNS	_	7	dep	_	_
6	were	be	VBD	_	7	aux	_	_
7	divided	divide	VBN	_	0	root	_	_
8	into	into	IN	_	10	case	_	_
9	four	#crd#	CD	_	10	num	_	_
10	groups	group	NNS	_	7	ppmod	_	_
11	.	.	.	_	7	p	_	_

1	Two	#crd#	CD	_	2	num	_	_
2	groups	group	NNS	_	9	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	SH/DA	sh/da	NNP	_	6	dep	_	_
5	;	;	:	_	6	p	_	_
6	SH/FA	sh/fa	NN	_	2	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	were	be	VBD	_	9	aux	_	_
9	submitted	submit	VBN	_	0	root	_	_
10	to	to	TO	_	12	aux	_	_
11	daily	daily	JJ	_	12	attr	_	_
12	treatment	treatment	NN	_	9	ppmod	_	_
13	with	with	IN	_	16	case	_	_
14	synthetic	synthetic	JJ	_	16	attr	_	_
15	hydroalcoholic	hydroalcoholic	JJ	_	16	attr	_	_
16	solutions	solution	NNS	_	12	ppmod	_	_
17	containing	contain	VBG	_	16	acl	_	_
18	drug1	drug0	NN	_	17	obj	_	_
19	,	,	,	_	18	p	_	_
20	drug2	drug0	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	higher	high	JJR	_	23	attr	_	_
23	drug3	drug0	NN	_	18	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	drug4	drug0	NN	_	18	conj	_	_
26	in	in	IN	_	29	case	_	_
27	the	the	DT	_	29	det	_	_
28	same	same	JJ	_	29	attr	_	_
29	proportions	proportion	NNS	_	18	ppmod	_	_
30	as	as	IN	_	31	case	_	_
31	those	those	DT	_	17	ppmod	_	_
32	found	find	VBN	_	31	acl	_	_
33	in	in	IN	_	40	case	_	_
34	most	most	RBS	_	35	adv	_	_
35	common	common	JJ	_	40	attr	_	_
36	distilled	distilled	JJ	_	40	attr	_	_
37	and	and	CC	_	36	cc	_	_
38	fermented	fermented	JJ	_	36	conj	_	_
39	alcoholic	alcoholic	JJ	_	40	attr	_	_
40	beverages	beverage	NNS	_	32	ppmod	_	_
41	;	;	:	_	9	p	_	_

1	the	the	DT	_	3	det	_	_
2	third	#ord#	JJ	_	3	attr	_	_
3	group	group	NN	_	8	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	SH/EA	sh/ea	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	was	be	VBD	_	8	aux	_	_
8	treated	treat	VBN	_	0	root	_	_
9	with	with	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	hydroalcoholic	hydroalcoholic	JJ	_	12	attr	_	_
12	solution	solution	NN	_	8	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	;	;	:	_	8	p	_	_

1	the	the	DT	_	3	det	_	_
2	fourth	#ord#	JJ	_	3	attr	_	_
3	group	group	NN	_	4	dep	_	_
4	served	serve	VBD	_	0	root	_	_
5	as	as	IN	_	6	case	_	_
6	control	control	NN	_	4	ppmod	_	_
7	and	and	CC	_	4	cc	_	_
8	received	receive	VBD	_	4	conj	_	_
9	an	an	DT	_	11	det	_	_
10	equivalent	equivalent	JJ	_	11	attr	_	_
11	volume	volume	NN	_	8	obj	_	_
12	of	of	IN	_	15	case	_	_
13	an	an	DT	_	15	det	_	_
14	isocaloric	isocaloric	JJ	_	15	attr	_	_
15	solution	solution	NN	_	11	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug1	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	All	all	PDT	_	3	det	_	_
2	the	the	DT	_	3	det	_	_
3	animals	animal	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	killed	kill	VBN	_	0	root	_	_
6	at	at	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	end	end	NN	_	5	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	9th	#ord#	JJ	_	12	attr	_	_
12	week	week	NN	_	8	ppmod	_	_
13	of	of	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	experiment	experiment	NN	_	12	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	ratio	ratio	NN	_	11	dep	_	_
3	between	between	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	liver	liver	NN	_	6	com	_	_
6	weight	weight	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	body	body	NN	_	9	com	_	_
9	weight	weight	NN	_	6	conj	_	_
10	was	be	VBD	_	11	aux	_	_
11	found	find	VBN	_	0	root	_	_
12	to	to	TO	_	13	aux	_	_
13	be	be	VB	_	11	comp	_	_
14	lower	low	JJR	_	13	dep	_	_
15	in	in	IN	_	18	case	_	_
16	the	the	DT	_	18	det	_	_
17	treated	treated	JJ	_	18	attr	_	_
18	animals	animal	NNS	_	14	ppmod	_	_
19	than	than	IN	_	23	case	_	_
20	in	in	IN	_	23	case	_	_
21	the	the	DT	_	23	det	_	_
22	control	control	JJ	_	23	attr	_	_
23	group	group	NN	_	14	ppmod	_	_
24	.	.	.	_	11	p	_	_

1	The	the	DT	_	2	det	_	_
2	histology	histology	NN	_	7	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	liver	liver	NN	_	2	ppmod	_	_
6	was	be	VBD	_	7	aux	_	_
7	altered	alter	VBN	_	0	root	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	three	#crd#	CD	_	11	num	_	_
11	groups	group	NNS	_	7	ppmod	_	_
12	which	which	WDT	_	14	dep	_	_
13	were	be	VBD	_	14	aux	_	_
14	submitted	submit	VBN	_	11	relcl	_	_
15	to	to	TO	_	16	aux	_	_
16	treatment	treatment	NN	_	14	ppmod	_	_
17	with	with	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	hydroalcoholic	hydroalcoholic	JJ	_	20	attr	_	_
20	solutions	solution	NNS	_	16	ppmod	_	_
21	,	,	,	_	7	p	_	_
22	with	with	IN	_	26	case	_	_
23	quantitative	quantitative	JJ	_	26	attr	_	_
24	and	and	CC	_	23	cc	_	_
25	qualitative	qualitative	JJ	_	23	conj	_	_
26	differences	difference	NNS	_	7	ppmod	_	_
27	between	between	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	groups	group	NNS	_	26	ppmod	_	_
30	.	.	.	_	7	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	13	mark	_	_
5	the	the	DT	_	6	det	_	_
6	hepatoxicity	hepatoxicity	NN	_	13	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	alcoholic	alcoholic	JJ	_	11	attr	_	_
11	beverages	beverage	NNS	_	6	ppmod	_	_
12	is	be	VBZ	_	13	aux	_	_
13	enhanced	enhance	VBN	_	3	comp	_	_
14	by	by	IN	_	15	case	_	_
15	interaction	interaction	NN	_	13	ppmod	_	_
16	with	with	IN	_	18	case	_	_
17	its	its	PRP$	_	18	poss	_	_
18	congeners	congener	NNS	_	15	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug2	drug0	NNS	_	18	conj	_	_
21	;	;	:	_	3	p	_	_

1	they	they	PRP	_	3	dep	_	_
2	also	also	RB	_	3	adv	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	7	mark	_	_
5	alcoholic	alcoholic	JJ	_	6	attr	_	_
6	beverages	beverage	NNS	_	7	dep	_	_
7	are	be	VBP	_	3	comp	_	_
8	not	not	RB	_	7	neg	_	_
9	equivalent	equivalent	JJ	_	7	dep	_	_
10	in	in	IN	_	12	case	_	_
11	their	their	PRP$	_	12	poss	_	_
12	potential	potential	NN	_	7	ppmod	_	_
13	to	to	TO	_	14	aux	_	_
14	cause	cause	VB	_	12	acl	_	_
15	liver	liver	NN	_	16	com	_	_
16	damage	damage	NN	_	14	obj	_	_
17	.	.	.	_	3	p	_	_

1	Administration	administration	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	prophylaxis	prophylaxis	NNS	_	1	ppmod	_	_
5	.	.	.	_	1	p	_	_

1	Successful	successful	JJ	_	2	attr	_	_
2	prophylaxis	prophylaxis	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	manic-depressive	manic-depressive	JJ	_	5	attr	_	_
5	disorder	disorder	NN	_	2	ppmod	_	_
6	requires	require	VBZ	_	0	root	_	_
7	more	more	RBR	_	6	adv	_	_
8	than	than	IN	_	7	case	_	_
9	the	the	DT	_	10	det	_	_
10	prescription	prescription	NN	_	6	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	.	.	.	_	6	p	_	_

1	The	the	DT	_	3	det	_	_
2	administrative	administrative	JJ	_	3	attr	_	_
3	arrangements	arrangement	NNS	_	10	dep	_	_
4	in	in	IN	_	6	case	_	_
5	an	an	DT	_	6	det	_	_
6	area	area	NN	_	3	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	Scotland	scotland	NNP	_	6	ppmod	_	_
9	were	be	VBD	_	10	aux	_	_
10	accompanied	accompany	VBN	_	0	root	_	_
11	by	by	IN	_	15	case	_	_
12	a	a	DT	_	15	det	_	_
13	300	0	CD	_	15	num	_	_
14	%	%	NN	_	15	meta	_	_
15	increase	increase	NN	_	10	ppmod	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	frequency	frequency	NN	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	admissions	admission	NNS	_	18	ppmod	_	_
21	for	for	IN	_	22	case	_	_
22	mania	mania	NN	_	20	ppmod	_	_
23	,	,	,	_	10	p	_	_
24	whereas	whereas	IN	_	37	mark	_	_
25	in	in	IN	_	27	case	_	_
26	an	an	DT	_	27	det	_	_
27	area	area	NN	_	37	ppmod	_	_
28	of	of	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	West	west	NNP	_	31	com	_	_
31	Midlands	midlands	NNP	_	27	ppmod	_	_
32	,	,	,	_	37	p	_	_
33	a	a	DT	_	35	det	_	_
34	large	large	JJ	_	35	attr	_	_
35	decrease	decrease	NN	_	37	dep	_	_
36	was	be	VBD	_	37	aux	_	_
37	achieved	achieve	VBN	_	10	comp	_	_
38	.	.	.	_	10	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	in	in	IN	_	11	case	_	_
10	healthy	healthy	JJ	_	11	attr	_	_
11	volunteers	volunteer	NNS	_	6	ppmod	_	_
12	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	authors	author	NNS	_	3	dep	_	_
3	examined	examine	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	effect	effect	NN	_	3	obj	_	_
6	of	of	IN	_	12	case	_	_
7	the	the	DT	_	12	det	_	_
8	cyclooxygenase-2	cyclooxygenase-0	NN	_	12	attr	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	COX-2	cox-0	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	inhibitor	inhibitor	NN	_	5	ppmod	_	_
13	,	,	,	_	12	p	_	_
14	drug1	drug0	NN	_	12	appo	_	_
15	,	,	,	_	12	p	_	_
16	at	at	IN	_	18	case	_	_
17	steady	steady	JJ	_	18	attr	_	_
18	state	state	NN	_	5	ppmod	_	_
19	on	on	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	pharmacokinetics	pharmacokinetics	NNS	_	5	ppmod	_	_
22	of	of	IN	_	23	case	_	_
23	drug2	drug0	NN	_	21	ppmod	_	_
24	following	follow	VBG	_	27	adv	_	_
25	a	a	DT	_	27	det	_	_
26	single	single	JJ	_	27	attr	_	_
27	dose	dose	NN	_	21	ppmod	_	_
28	in	in	IN	_	30	case	_	_
29	healthy	healthy	JJ	_	30	attr	_	_
30	subjects	subject	NNS	_	27	ppmod	_	_
31	.	.	.	_	3	p	_	_

1	Each	each	DT	_	3	det	_	_
2	healthy	healthy	JJ	_	3	attr	_	_
3	subject	subject	NN	_	9	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	N	n	NN	_	3	prn	_	_
6	=	=	JJ	_	5	attr	_	_
7	10	0	CD	_	5	num	_	_
8	)	-rrb-	-RRB-	_	5	p	_	_
9	received	receive	VBD	_	0	root	_	_
10	drug1	drug0	NN	_	9	obj	_	_
11	(	-lrb-	-LRB-	_	13	p	_	_
12	75	0	CD	_	13	num	_	_
13	mg	mg	NN	_	10	prn	_	_
14	once	once	RB	_	15	adv	_	_
15	daily	daily	JJ	_	13	attr	_	_
16	)	-rrb-	-RRB-	_	13	p	_	_
17	or	or	CC	_	10	cc	_	_
18	placebo	placebo	NN	_	10	conj	_	_
19	for	for	IN	_	21	case	_	_
20	11	0	CD	_	21	num	_	_
21	days	day	NNS	_	18	ppmod	_	_
22	in	in	IN	_	32	case	_	_
23	a	a	DT	_	32	det	_	_
24	double-blind	double-blind	JJ	_	30	adv	_	_
25	,	,	,	_	30	p	_	_
26	randomized	randomized	JJ	_	30	adv	_	_
27	,	,	,	_	30	p	_	_
28	balanced	balanced	JJ	_	30	adv	_	_
29	,	,	,	_	30	p	_	_
30	two-period	two-period	JJ	_	32	attr	_	_
31	crossover	crossover	NN	_	32	com	_	_
32	study	study	NN	_	21	ppmod	_	_
33	.	.	.	_	9	p	_	_

1	A	a	DT	_	6	det	_	_
2	single	single	JJ	_	6	attr	_	_
3	0.5	0	CD	_	6	num	_	_
4	mg	mg	NN	_	6	attr	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	dose	dose	NN	_	11	dep	_	_
7	of	of	IN	_	9	case	_	_
8	drug1	drug0	NN	_	9	com	_	_
9	elixir	elixir	NN	_	6	ppmod	_	_
10	was	be	VBD	_	11	aux	_	_
11	administered	administer	VBN	_	0	root	_	_
12	on	on	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	7th	#ord#	JJ	_	15	attr	_	_
15	day	day	NN	_	11	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	each	each	DT	_	19	det	_	_
18	11-day	0-day	JJ	_	19	attr	_	_
19	period	period	NN	_	15	ppmod	_	_
20	.	.	.	_	11	p	_	_

1	Each	each	DT	_	3	det	_	_
2	treatment	treatment	NN	_	3	com	_	_
3	period	period	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	separated	separate	VBN	_	0	root	_	_
6	by	by	IN	_	10	case	_	_
7	14	0	CD	_	10	num	_	_
8	to	to	TO	_	7	cc	_	_
9	21	0	CD	_	7	conj	_	_
10	days	day	NNS	_	5	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	Samples	sample	NNS	_	10	dep	_	_
2	for	for	IN	_	3	case	_	_
3	plasma	plasma	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	urine	urine	NN	_	8	attr	_	_
6	immunoreactive	immunoreactive	JJ	_	8	attr	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	3	conj	_	_
9	were	be	VBD	_	10	aux	_	_
10	collected	collect	VBN	_	0	root	_	_
11	through	through	IN	_	13	case	_	_
12	120	0	CD	_	13	num	_	_
13	hours	hour	NNS	_	10	ppmod	_	_
14	following	follow	VBG	_	17	adv	_	_
15	the	the	DT	_	17	det	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	dose	dose	NN	_	10	ppmod	_	_
18	.	.	.	_	10	p	_	_

1	No	no	DT	_	4	det	_	_
2	statistically	statistically	RB	_	3	adv	_	_
3	significant	significant	JJ	_	4	attr	_	_
4	differences	difference	NNS	_	9	dep	_	_
5	between	between	IN	_	7	case	_	_
6	treatment	treatment	NN	_	7	com	_	_
7	groups	group	NNS	_	4	ppmod	_	_
8	were	be	VBD	_	9	aux	_	_
9	observed	observe	VBN	_	0	root	_	_
10	for	for	IN	_	11	case	_	_
11	any	any	DT	_	9	ppmod	_	_
12	of	of	IN	_	17	case	_	_
13	the	the	DT	_	17	det	_	_
14	calculated	calculate	VBN	_	17	attr	_	_
15	drug1	drug0	NN	_	17	attr	_	_
16	pharmacokinetic	pharmacokinetic	JJ	_	17	attr	_	_
17	parameters	parameter	NNS	_	11	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	For	for	IN	_	3	case	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	AUC	auc	NN	_	35	ppmod	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	0-infinity	0-infinity	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	,	,	,	_	3	p	_	_
8	AUC	auc	NN	_	3	conj	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	0-24	0	NN	_	8	num	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	,	,	,	_	8	p	_	_
13	and	and	CC	_	8	cc	_	_
14	Cmax	cmax	NN	_	3	conj	_	_
15	,	,	,	_	35	p	_	_
16	the	the	DT	_	19	det	_	_
17	geometric	geometric	JJ	_	19	attr	_	_
18	mean	mean	NN	_	19	com	_	_
19	ratios	ratio	NNS	_	35	dep	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	90	0	CD	_	19	num	_	_
22	%	%	NN	_	21	meta	_	_
23	confidence	confidence	RB	_	24	adv	_	_
24	interval	interval	JJ	_	21	attr	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	for	for	IN	_	28	case	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	drug2	drug0	NN	_	19	prn	_	_
29	+	+	CC	_	28	cc	_	_
30	drug3	drug0	NN	_	31	com	_	_
31	/placebo	/placebo	NN	_	28	conj	_	_
32	+	+	CC	_	31	cc	_	_
33	drug4	drug0	NN	_	31	conj	_	_
34	)	-rrb-	-RRB-	_	28	p	_	_
35	were	be	VBD	_	0	root	_	_
36	1.04	0	CD	_	35	obj	_	_
37	(	-lrb-	-LRB-	_	40	p	_	_
38	0.94	0	CD	_	40	num	_	_
39	,	,	,	_	40	p	_	_
40	1.14	0	CD	_	36	num	_	_
41	)	-rrb-	-RRB-	_	40	p	_	_
42	,	,	,	_	36	p	_	_
43	1.02	0	CD	_	36	conj	_	_
44	(	-lrb-	-LRB-	_	47	p	_	_
45	0.94	0	CD	_	47	num	_	_
46	,	,	,	_	47	p	_	_
47	1.09	0	CD	_	43	num	_	_
48	)	-rrb-	-RRB-	_	47	p	_	_
49	,	,	,	_	43	p	_	_
50	and	and	CC	_	43	cc	_	_
51	1.00	0	CD	_	36	conj	_	_
52	(	-lrb-	-LRB-	_	55	p	_	_
53	0.91	0	CD	_	55	num	_	_
54	,	,	,	_	55	p	_	_
55	1.10	0	CD	_	51	num	_	_
56	)	-rrb-	-RRB-	_	55	p	_	_
57	,	,	,	_	35	p	_	_
58	respectively	respectively	RB	_	35	adv	_	_
59	.	.	.	_	35	p	_	_

1	The	the	DT	_	4	det	_	_
2	drug1	drug0	NN	_	4	com	_	_
3	median	median	NN	_	4	com	_	_
4	tmax	tmax	NN	_	5	dep	_	_
5	was	be	VBD	_	0	root	_	_
6	0.5	0	CD	_	7	num	_	_
7	hours	hour	NNS	_	5	obj	_	_
8	for	for	IN	_	10	case	_	_
9	both	both	DT	_	10	det	_	_
10	treatments	treatment	NNS	_	5	ppmod	_	_
11	.	.	.	_	5	p	_	_

1	The	the	DT	_	5	det	_	_
2	harmonic	harmonic	JJ	_	5	attr	_	_
3	mean	mean	NN	_	5	com	_	_
4	elimination	elimination	NN	_	5	com	_	_
5	half-life	half-life	NN	_	6	dep	_	_
6	was	be	VBD	_	0	root	_	_
7	45.7	0	CD	_	10	num	_	_
8	and	and	CC	_	7	cc	_	_
9	43.4	0	CD	_	7	conj	_	_
10	hours	hour	NNS	_	6	obj	_	_
11	for	for	IN	_	12	case	_	_
12	drug1	drug0	NN	_	6	ppmod	_	_
13	+	+	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	and	and	CC	_	12	cc	_	_
16	placebo	placebo	NN	_	19	attr	_	_
17	+	+	CC	_	16	cc	_	_
18	drug3	drug0	NN	_	16	conj	_	_
19	treatments	treatment	NNS	_	12	conj	_	_
20	,	,	,	_	6	p	_	_
21	respectively	respectively	RB	_	6	adv	_	_
22	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	eliminated	eliminate	VBN	_	0	root	_	_
4	renally	renally	RB	_	3	adv	_	_
5	.	.	.	_	3	p	_	_

1	The	the	DT	_	8	det	_	_
2	mean	mean	NN	_	8	attr	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	SD	sd	NN	_	2	prn	_	_
5	)	-rrb-	-RRB-	_	4	p	_	_
6	cumulative	cumulative	JJ	_	8	attr	_	_
7	urinary	urinary	JJ	_	8	attr	_	_
8	excretion	excretion	NN	_	19	dep	_	_
9	of	of	IN	_	11	case	_	_
10	immunoreactive	immunoreactive	JJ	_	11	attr	_	_
11	drug1	drug0	NN	_	8	ppmod	_	_
12	after	after	IN	_	14	case	_	_
13	concurrent	concurrent	JJ	_	14	attr	_	_
14	treatment	treatment	NN	_	8	ppmod	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	placebo	placebo	NN	_	16	conj	_	_
19	was	be	VBD	_	0	root	_	_
20	228.2	0	CD	_	19	obj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	+/-	+/-	CC	_	23	cc	_	_
23	30.8	0	CD	_	20	num	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	and	and	CC	_	20	cc	_	_
26	235.1	0	CD	_	32	num	_	_
27	(	-lrb-	-LRB-	_	29	p	_	_
28	+/-	+/-	CC	_	29	cc	_	_
29	39.1	0	CD	_	26	num	_	_
30	)	-rrb-	-RRB-	_	29	p	_	_
31	micrograms/120	micrograms/0	CD	_	32	num	_	_
32	hours	hour	NNS	_	20	conj	_	_
33	,	,	,	_	19	p	_	_
34	respectively	respectively	RB	_	19	adv	_	_
35	.	.	.	_	19	p	_	_

1	Transient	transient	JJ	_	5	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	minor	minor	JJ	_	1	conj	_	_
4	adverse	adverse	JJ	_	5	attr	_	_
5	events	event	NNS	_	6	dep	_	_
6	occurred	occur	VBD	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	similar	similar	JJ	_	9	attr	_	_
9	frequency	frequency	NN	_	6	ppmod	_	_
10	on	on	IN	_	11	case	_	_
11	placebo	placebo	NN	_	6	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug1	drug0	NN	_	14	com	_	_
14	treatments	treatment	NNS	_	11	conj	_	_
15	,	,	,	_	6	p	_	_
16	and	and	CC	_	6	cc	_	_
17	no	no	DT	_	19	det	_	_
18	treatment-related	treatment-related	JJ	_	19	attr	_	_
19	pattern	pattern	NN	_	20	dep	_	_
20	was	be	VBD	_	6	conj	_	_
21	apparent	apparent	JJ	_	20	dep	_	_
22	.	.	.	_	6	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	did	do	VBD	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	influence	influence	VB	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	4	obj	_	_
8	or	or	CC	_	7	cc	_	_
9	renal	renal	JJ	_	10	attr	_	_
10	elimination	elimination	NN	_	7	conj	_	_
11	of	of	IN	_	15	case	_	_
12	a	a	DT	_	15	det	_	_
13	single	single	JJ	_	15	attr	_	_
14	oral	oral	JJ	_	15	attr	_	_
15	dose	dose	NN	_	7	ppmod	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	and	and	CC	_	1	cc	_	_
6	drug3	drug0	NN	_	1	conj	_	_
7	:	:	:	_	1	p	_	_
8	comparison	comparison	NN	_	1	appo	_	_
9	of	of	IN	_	11	case	_	_
10	antiaddictive	antiaddictive	JJ	_	11	attr	_	_
11	efficacy	efficacy	NN	_	8	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	toxicity	toxicity	NN	_	11	conj	_	_
14	,	,	,	_	13	p	_	_
15	and	and	CC	_	13	cc	_	_
16	mechanisms	mechanism	NNS	_	11	conj	_	_
17	of	of	IN	_	18	case	_	_
18	action	action	NN	_	16	ppmod	_	_
19	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	11	dep	_	_
2	,	,	,	_	1	p	_	_
3	a	a	DT	_	7	det	_	_
4	novel	novel	JJ	_	7	attr	_	_
5	iboga	iboga	NN	_	7	com	_	_
6	alkaloid	alkaloid	NN	_	7	com	_	_
7	congener	congener	NN	_	1	appo	_	_
8	,	,	,	_	1	p	_	_
9	is	be	VBZ	_	11	aux	_	_
10	being	be	VBG	_	11	aux	_	_
11	developed	develop	VBN	_	0	root	_	_
12	as	as	IN	_	15	case	_	_
13	a	a	DT	_	15	det	_	_
14	potential	potential	JJ	_	15	attr	_	_
15	treatment	treatment	NN	_	11	ppmod	_	_
16	for	for	IN	_	18	case	_	_
17	multiple	multiple	JJ	_	18	attr	_	_
18	forms	form	NNS	_	15	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	drug	drug	NN	_	21	com	_	_
21	abuse	abuse	NN	_	18	ppmod	_	_
22	.	.	.	_	11	p	_	_

1	Like	like	IN	_	2	case	_	_
2	drug1	drug0	NN	_	13	ppmod	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	40	0	CD	_	5	num	_	_
5	mg/kg	mg/kg	NN	_	2	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	,	,	,	_	13	p	_	_
8	drug2	drug0	NN	_	13	dep	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	40	0	CD	_	11	num	_	_
11	mg/kg	mg/kg	NN	_	8	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	decreases	decrease	VBZ	_	0	root	_	_
14	the	the	DT	_	16	det	_	_
15	intravenous	intravenous	JJ	_	16	attr	_	_
16	self-administration	self-administration	NN	_	13	obj	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	and	and	CC	_	18	cc	_	_
20	drug4	drug0	NN	_	18	conj	_	_
21	and	and	CC	_	16	cc	_	_
22	the	the	DT	_	24	det	_	_
23	oral	oral	JJ	_	24	attr	_	_
24	self-administration	self-administration	NN	_	16	conj	_	_
25	of	of	IN	_	26	case	_	_
26	drug5	drug0	NN	_	24	ppmod	_	_
27	and	and	CC	_	26	cc	_	_
28	drug6	drug0	NN	_	26	conj	_	_
29	in	in	IN	_	30	case	_	_
30	rats	rat	NNS	_	26	ppmod	_	_
31	;	;	:	_	13	p	_	_

1	unlike	unlike	IN	_	2	case	_	_
2	drug1	drug0	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	drug2	drug0	NN	_	7	dep	_	_
5	does	do	VBZ	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	affect	affect	VB	_	0	root	_	_
8	responding	respond	VBG	_	7	obj	_	_
9	for	for	IN	_	12	case	_	_
10	a	a	DT	_	12	det	_	_
11	nondrug	nondrug	JJ	_	12	attr	_	_
12	reinforcer	reinforcer	NN	_	8	ppmod	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	water	water	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	.	.	.	_	7	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	ameliorate	ameliorate	VBP	_	0	root	_	_
6	drug3	drug0	NN	_	8	com	_	_
7	withdrawal	withdrawal	NN	_	8	com	_	_
8	signs	sign	NNS	_	5	obj	_	_
9	.	.	.	_	5	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	decrease	decrease	VBP	_	0	root	_	_
6	extracellular	extracellular	JJ	_	7	attr	_	_
7	levels	level	NNS	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	dopamine	dopamine	NN	_	7	ppmod	_	_
10	in	in	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	nucleus	nucleus	NN	_	13	com	_	_
13	accumbens	accumbens	NNS	_	5	ppmod	_	_
14	,	,	,	_	5	p	_	_
15	but	but	CC	_	5	cc	_	_
16	only	only	JJ	_	17	attr	_	_
17	drug3	drug0	NN	_	18	dep	_	_
18	increases	increase	VBZ	_	5	conj	_	_
19	extracellular	extracellular	JJ	_	20	attr	_	_
20	levels	level	NNS	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	serotonin	serotonin	NN	_	20	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	nucleus	nucleus	NN	_	26	com	_	_
26	accumbens	accumbens	NNS	_	18	ppmod	_	_
27	.	.	.	_	18	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	block	block	VBP	_	0	root	_	_
6	drug3	drug0	NN	_	5	obj	_	_
7	-induced	-induced	JJ	_	6	attr	_	_
8	and	and	CC	_	6	cc	_	_
9	drug4	drug0	JJ	_	12	attr	_	_
10	-induced	-induced	JJ	_	12	attr	_	_
11	dopamine	dopamine	NN	_	12	com	_	_
12	release	release	NN	_	6	conj	_	_
13	in	in	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	nucleus	nucleus	NN	_	16	com	_	_
16	accumbens	accumbens	NNS	_	6	ppmod	_	_
17	;	;	:	_	5	p	_	_

1	only	only	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	3	dep	_	_
3	enhances	enhance	VBZ	_	0	root	_	_
4	drug2	drug0	NN	_	6	attr	_	_
5	-induced	-induced	JJ	_	6	attr	_	_
6	increases	increase	NNS	_	3	obj	_	_
7	in	in	IN	_	9	case	_	_
8	accumbal	accumbal	JJ	_	9	attr	_	_
9	dopamine	dopamine	NN	_	6	ppmod	_	_
10	.	.	.	_	3	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	enhance	enhance	VBP	_	0	root	_	_
6	the	the	DT	_	10	det	_	_
7	locomotor	locomotor	JJ	_	10	attr	_	_
8	and/or	and/or	CC	_	7	cc	_	_
9	stereotypic	stereotypic	JJ	_	7	conj	_	_
10	effects	effect	NNS	_	5	obj	_	_
11	of	of	IN	_	12	case	_	_
12	stimulants	stimulant	NNS	_	10	ppmod	_	_
13	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	attenuates	attenuate	VBZ	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	but	but	CC	_	2	cc	_	_
5	drug2	drug0	NN	_	6	dep	_	_
6	potentiates	potentiate	VBZ	_	2	conj	_	_
7	,	,	,	_	6	p	_	_
8	the	the	DT	_	11	det	_	_
9	acute	acute	JJ	_	11	attr	_	_
10	locomotor	locomotor	NN	_	11	com	_	_
11	effects	effect	NNS	_	6	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drug3	drug0	NN	_	11	ppmod	_	_
14	;	;	:	_	6	p	_	_

1	both	both	DT	_	2	det	_	_
2	compounds	compound	NNS	_	3	dep	_	_
3	attenuate	attenuate	VBP	_	0	root	_	_
4	drug1	drug0	JJ	_	6	attr	_	_
5	-induced	-induced	JJ	_	6	attr	_	_
6	locomotion	locomotion	NN	_	3	obj	_	_
7	in	in	IN	_	10	case	_	_
8	drug2	drug0	JJ	_	10	attr	_	_
9	-experienced	-experienced	JJ	_	10	attr	_	_
10	rats	rat	NNS	_	6	ppmod	_	_
11	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	produces	produce	VBZ	_	0	root	_	_
3	whole	whole	JJ	_	5	attr	_	_
4	body	body	NN	_	5	com	_	_
5	tremors	tremors	NN	_	2	obj	_	_
6	and	and	CC	_	2	cc	_	_
7	,	,	,	_	20	p	_	_
8	at	at	IN	_	10	case	_	_
9	high	high	JJ	_	10	attr	_	_
10	doses	dose	NNS	_	20	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	>	>	JJ	_	10	prn	_	_
13	or	or	CC	_	12	cc	_	_
14	=	=	JJ	_	12	conj	_	_
15	100	0	CD	_	16	num	_	_
16	mg/kg	mg/kg	NN	_	14	advnp	_	_
17	)	-rrb-	-RRB-	_	12	p	_	_
18	,	,	,	_	20	p	_	_
19	cerebellar	cerebellar	JJ	_	20	attr	_	_
20	damage	damage	NN	_	2	conj	_	_
21	;	;	:	_	2	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	does	do	VBZ	_	4	aux	_	_
3	not	not	RB	_	4	neg	_	_
4	produce	produce	VB	_	0	root	_	_
5	these	these	DT	_	6	det	_	_
6	effects	effect	NNS	_	4	obj	_	_
7	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	but	but	CC	_	1	cc	_	_
4	not	not	RB	_	3	com	_	_
5	drug2	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	decreases	decrease	VBZ	_	0	root	_	_
8	heart	heart	NN	_	9	com	_	_
9	rate	rate	NN	_	7	obj	_	_
10	at	at	IN	_	12	case	_	_
11	high	high	JJ	_	12	attr	_	_
12	doses	dose	NNS	_	7	ppmod	_	_
13	.	.	.	_	7	p	_	_

1	While	while	IN	_	5	mark	_	_
2	drug1	drug0	NN	_	5	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	have	have	VBP	_	17	advcl	_	_
6	similar	similar	JJ	_	7	attr	_	_
7	affinities	affinity	NNS	_	5	obj	_	_
8	for	for	IN	_	10	case	_	_
9	kappa	kappa	NN	_	10	com	_	_
10	opioid	opioid	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	possibly	possibly	RB	_	14	adv	_	_
13	nicotinic	nicotinic	NN	_	14	com	_	_
14	receptors	receptor	NNS	_	10	conj	_	_
15	,	,	,	_	17	p	_	_
16	drug3	drug0	NN	_	17	dep	_	_
17	has	have	VBZ	_	0	root	_	_
18	much	much	RB	_	19	adv	_	_
19	lower	low	JJR	_	20	attr	_	_
20	affinities	affinity	NNS	_	17	obj	_	_
21	than	than	IN	_	22	case	_	_
22	drug4	drug0	NN	_	20	ppmod	_	_
23	for	for	IN	_	27	case	_	_
24	NMDA	nmda	NN	_	27	attr	_	_
25	and	and	CC	_	24	cc	_	_
26	sigma-2	sigma-0	NN	_	24	conj	_	_
27	receptors	receptor	NNS	_	20	ppmod	_	_
28	,	,	,	_	27	p	_	_
29	sodium	sodium	NN	_	30	com	_	_
30	channels	channel	NNS	_	27	conj	_	_
31	,	,	,	_	30	p	_	_
32	and	and	CC	_	30	cc	_	_
33	the	the	DT	_	35	det	_	_
34	5-HT	0-ht	JJ	_	35	attr	_	_
35	transporter	transporter	NN	_	27	conj	_	_
36	.	.	.	_	17	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	6	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	are	be	VBP	_	6	aux	_	_
6	sequestered	sequester	VBN	_	0	root	_	_
7	in	in	IN	_	8	case	_	_
8	fat	fat	NN	_	6	ppmod	_	_
9	and	and	CC	_	6	cc	_	_
10	,	,	,	_	16	p	_	_
11	like	like	IN	_	12	case	_	_
12	drug3	drug0	NN	_	16	ppmod	_	_
13	,	,	,	_	16	p	_	_
14	drug4	drug0	NN	_	16	dep	_	_
15	probably	probably	RB	_	16	adv	_	_
16	has	have	VBZ	_	6	conj	_	_
17	an	an	DT	_	19	det	_	_
18	active	active	JJ	_	19	attr	_	_
19	metabolite	metabolite	NN	_	16	obj	_	_
20	.	.	.	_	6	p	_	_

1	The	the	DT	_	2	det	_	_
2	data	datum	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	has	have	VBZ	_	3	comp	_	_
7	a	a	DT	_	9	det	_	_
8	narrower	narrower	JJ	_	9	attr	_	_
9	spectrum	spectrum	NN	_	6	obj	_	_
10	of	of	IN	_	11	case	_	_
11	actions	action	NNS	_	9	ppmod	_	_
12	and	and	CC	_	6	cc	_	_
13	will	will	MD	_	14	modal	_	_
14	have	have	VB	_	6	conj	_	_
15	a	a	DT	_	19	det	_	_
16	substantially	substantially	RB	_	17	adv	_	_
17	greater	great	JJR	_	19	attr	_	_
18	therapeutic	therapeutic	JJ	_	19	attr	_	_
19	index	index	NN	_	14	obj	_	_
20	than	than	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	4	case	_	_
3	coadministered	coadministered	JJ	_	4	attr	_	_
4	drugs	drug	NNS	_	1	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug1	drug0	NN	_	4	conj	_	_
7	on	on	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	binding	binding	NN	_	1	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	therapeutic	therapeutic	JJ	_	12	attr	_	_
12	drugs	drug	NNS	_	9	ppmod	_	_
13	to	to	TO	_	15	aux	_	_
14	human	human	JJ	_	15	attr	_	_
15	serum	serum	NN	_	9	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	vitro	vitro	FW	_	9	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	20	dep	_	_
3	of	of	IN	_	5	case	_	_
4	coadministered	coadministered	JJ	_	5	attr	_	_
5	drugs	drug	NNS	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug1	drug0	NN	_	5	conj	_	_
8	on	on	IN	_	10	case	_	_
9	the	the	DT	_	10	det	_	_
10	binding	binding	NN	_	2	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	therapeutic	therapeutic	JJ	_	13	attr	_	_
13	drugs	drug	NNS	_	10	ppmod	_	_
14	to	to	TO	_	16	aux	_	_
15	human	human	JJ	_	16	attr	_	_
16	serum	serum	NN	_	10	ppmod	_	_
17	in	in	FW	_	18	adv	_	_
18	vitro	vitro	FW	_	10	adv	_	_
19	was	be	VBD	_	20	aux	_	_
20	investigated	investigate	VBN	_	0	root	_	_
21	.	.	.	_	20	p	_	_

1	drug1	drug0	NN	_	14	dep	_	_
2	,	,	,	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	,	,	,	_	5	p	_	_
7	drug4	drug0	NN	_	1	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug5	drug0	NN	_	1	conj	_	_
10	,	,	,	_	9	p	_	_
11	and	and	CC	_	9	cc	_	_
12	drug6	drug0	NN	_	1	conj	_	_
13	were	be	VBD	_	14	aux	_	_
14	added	add	VBN	_	0	root	_	_
15	to	to	TO	_	18	aux	_	_
16	pooled	pooled	JJ	_	18	attr	_	_
17	human	human	JJ	_	18	attr	_	_
18	serum	serum	NN	_	14	ppmod	_	_
19	at	at	IN	_	21	case	_	_
20	therapeutic	therapeutic	JJ	_	21	attr	_	_
21	concentrations	concentration	NNS	_	14	ppmod	_	_
22	.	.	.	_	14	p	_	_

1	To	to	TO	_	3	aux	_	_
2	each	each	DT	_	3	det	_	_
3	preparation	preparation	NN	_	5	ppmod	_	_
4	was	be	VBD	_	5	aux	_	_
5	added	add	VBN	_	0	root	_	_
6	one	#crd#	CD	_	8	num	_	_
7	additional	additional	JJ	_	8	attr	_	_
8	drug	drug	NN	_	5	obj	_	_
9	at	at	IN	_	11	case	_	_
10	three	#crd#	CD	_	11	num	_	_
11	concentrations	concentration	NNS	_	5	ppmod	_	_
12	ranging	range	VBG	_	11	acl	_	_
13	from	from	IN	_	16	case	_	_
14	therapeutic	therapeutic	JJ	_	16	adv	_	_
15	to	to	TO	_	16	adv	_	_
16	toxic	toxic	JJ	_	12	ppmod	_	_
17	.	.	.	_	5	p	_	_

1	The	the	DT	_	7	det	_	_
2	following	following	JJ	_	7	attr	_	_
3	eight	#crd#	CD	_	7	num	_	_
4	target	target	NN	_	7	attr	_	_
5	drug/added	drug/added	JJ	_	7	attr	_	_
6	drug	drug	NN	_	7	com	_	_
7	combinations	combination	NNS	_	9	dep	_	_
8	were	be	VBD	_	9	aux	_	_
9	studied	study	VBN	_	0	root	_	_
10	:	:	:	_	9	p	_	_
11	drug1	drug0	NN	_	9	obj	_	_
12	/	/	:	_	11	p	_	_
13	drug2	drug0	NN	_	11	appo	_	_
14	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	/	/	:	_	1	p	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	,	,	,	_	3	p	_	_
5	drug3	drug0	NN	_	1	conj	_	_
6	/	/	:	_	5	p	_	_
7	drug4	drug0	NN	_	1	conj	_	_
8	,	,	,	_	7	p	_	_
9	drug5	drug0	NN	_	1	conj	_	_
10	/	/	:	_	9	p	_	_
11	drug6	drug0	NN	_	1	conj	_	_
12	,	,	,	_	11	p	_	_
13	drug7	drug0	NN	_	1	conj	_	_
14	/	/	:	_	13	p	_	_
15	drug8	drug0	NN	_	1	conj	_	_
16	,	,	,	_	15	p	_	_
17	drug9	drug0	NN	_	1	conj	_	_
18	/	/	:	_	17	p	_	_
19	drug10	drug0	CD	_	1	conj	_	_
20	,	,	,	_	19	p	_	_
21	drug11	drug0	CD	_	23	num	_	_
22	/	/	:	_	23	p	_	_
23	drug12	drug0	CD	_	1	conj	_	_
24	,	,	,	_	23	p	_	_
25	and	and	CC	_	23	cc	_	_
26	drug13	drug0	NN	_	1	conj	_	_
27	/	/	:	_	1	p	_	_
28	drug14	drug0	NN	_	1	appo	_	_
29	.	.	.	_	1	p	_	_

1	Each	each	DT	_	2	det	_	_
2	serum	serum	NN	_	23	dep	_	_
3	without	without	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	other	other	JJ	_	7	attr	_	_
6	added	add	VBN	_	7	attr	_	_
7	drug	drug	NN	_	2	ppmod	_	_
8	as	as	RB	_	9	com	_	_
9	well	well	RB	_	2	cc	_	_
10	as	as	IN	_	9	com	_	_
11	the	the	DT	_	12	det	_	_
12	serum	serum	NN	_	2	conj	_	_
13	supplemented	supplement	VBN	_	12	acl	_	_
14	with	with	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	other	other	JJ	_	17	attr	_	_
17	drug	drug	NN	_	13	ppmod	_	_
18	at	at	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	three	#crd#	CD	_	21	num	_	_
21	concentrations	concentration	NNS	_	13	ppmod	_	_
22	was	be	VBD	_	23	aux	_	_
23	dialyzed	dialyze	VBN	_	0	root	_	_
24	against	against	IN	_	26	case	_	_
25	phosphate	phosphate	NN	_	26	com	_	_
26	buffer	buffer	NN	_	23	ppmod	_	_
27	.	.	.	_	23	p	_	_

1	Similarly	similarly	RB	_	2	adv	_	_
2	dialyzed	dialyze	VBN	_	3	dep	_	_
3	were	be	VBD	_	0	root	_	_
4	drug1	drug0	NN	_	3	obj	_	_
5	,	,	,	_	4	p	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug3	drug0	NN	_	4	conj	_	_
10	,	,	,	_	9	p	_	_
11	both	both	CC	_	12	cc	_	_
12	alone	alone	RB	_	4	conj	_	_
13	at	at	IN	_	15	case	_	_
14	therapeutic	therapeutic	JJ	_	15	attr	_	_
15	concentrations	concentration	NNS	_	3	ppmod	_	_
16	in	in	IN	_	17	case	_	_
17	serum	serum	NN	_	15	ppmod	_	_
18	and	and	CC	_	15	cc	_	_
19	with	with	IN	_	20	case	_	_
20	drug4	drug0	NN	_	24	ppmod	_	_
21	at	at	IN	_	24	case	_	_
22	three	#crd#	CD	_	24	num	_	_
23	different	different	JJ	_	24	attr	_	_
24	concentrations	concentration	NNS	_	15	conj	_	_
25	in	in	IN	_	26	case	_	_
26	serum	serum	NN	_	24	ppmod	_	_
27	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	percentage	percentage	NN	_	10	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug	drug	NN	_	5	com	_	_
5	binding	binding	NN	_	2	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	each	each	DT	_	8	det	_	_
8	preparation	preparation	NN	_	2	ppmod	_	_
9	was	be	VBD	_	10	aux	_	_
10	calculated	calculate	VBN	_	0	root	_	_
11	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	diminished	diminish	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	binding	binding	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	to	to	TO	_	9	aux	_	_
8	human	human	JJ	_	9	attr	_	_
9	serum	serum	NN	_	4	ppmod	_	_
10	by	by	IN	_	13	case	_	_
11	a	a	DT	_	13	det	_	_
12	net	net	JJ	_	13	attr	_	_
13	change	change	NN	_	2	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	5.7	0	CD	_	13	ppmod	_	_
16	%	%	NN	_	15	meta	_	_
17	(	-lrb-	-LRB-	_	27	p	_	_
18	percentage	percentage	NN	_	19	com	_	_
19	increase	increase	NN	_	27	dep	_	_
20	in	in	IN	_	24	case	_	_
21	free	free	JJ	_	24	attr	_	_
22	drug	drug	NN	_	24	com	_	_
23	fraction	fraction	NN	_	24	com	_	_
24	-LSB-FDF	-lsb-fdf	NN	_	19	ppmod	_	_
25	]	-rsb-	-RRB-	_	27	p	_	_
26	,	,	,	_	27	p	_	_
27	11.0	0	CD	_	15	num	_	_
28	%	%	NN	_	27	meta	_	_
29	)	-rrb-	-RRB-	_	27	p	_	_
30	at	at	IN	_	32	case	_	_
31	662	0	CD	_	32	num	_	_
32	micromol/L	micromol/l	NN	_	15	ppmod	_	_
33	and	and	CC	_	13	cc	_	_
34	by	by	IN	_	37	case	_	_
35	a	a	DT	_	37	det	_	_
36	net	net	JJ	_	37	attr	_	_
37	change	change	NN	_	13	conj	_	_
38	of	of	IN	_	39	case	_	_
39	7.1	0	CD	_	37	ppmod	_	_
40	%	%	NN	_	39	meta	_	_
41	(	-lrb-	-LRB-	_	47	p	_	_
42	percentage	percentage	NN	_	43	com	_	_
43	increase	increase	NN	_	47	dep	_	_
44	in	in	IN	_	45	case	_	_
45	FDF	fdf	NN	_	43	ppmod	_	_
46	,	,	,	_	47	p	_	_
47	13.7	0	CD	_	39	num	_	_
48	%	%	NN	_	47	meta	_	_
49	)	-rrb-	-RRB-	_	47	p	_	_
50	at	at	IN	_	52	case	_	_
51	1324	0	NN	_	52	num	_	_
52	micromol/L	micromol/l	NN	_	39	ppmod	_	_
53	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	decreased	decrease	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	binding	binding	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	by	by	IN	_	10	case	_	_
8	a	a	DT	_	10	det	_	_
9	net	net	JJ	_	10	attr	_	_
10	change	change	NN	_	2	ppmod	_	_
11	of	of	IN	_	12	case	_	_
12	6.8	0	CD	_	10	ppmod	_	_
13	%	%	NN	_	12	meta	_	_
14	(	-lrb-	-LRB-	_	20	p	_	_
15	percentage	percentage	NN	_	16	com	_	_
16	increase	increase	NN	_	20	dep	_	_
17	in	in	IN	_	18	case	_	_
18	FDF	fdf	NN	_	16	ppmod	_	_
19	,	,	,	_	20	p	_	_
20	8.8	0	CD	_	2	num	_	_
21	%	%	NN	_	20	meta	_	_
22	)	-rrb-	-RRB-	_	20	p	_	_
23	at	at	IN	_	25	case	_	_
24	277.5	0	CD	_	25	num	_	_
25	micromol/L	micromol/l	NN	_	2	ppmod	_	_
26	;	;	:	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	reduced	reduce	VBD	_	0	root	_	_
3	it	it	PRP	_	2	obj	_	_
4	by	by	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	net	net	JJ	_	7	attr	_	_
7	change	change	NN	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	6.6	0	CD	_	7	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	(	-lrb-	-LRB-	_	17	p	_	_
12	percentage	percentage	NN	_	13	com	_	_
13	increase	increase	NN	_	17	dep	_	_
14	in	in	IN	_	15	case	_	_
15	FDF	fdf	NN	_	13	ppmod	_	_
16	,	,	,	_	17	p	_	_
17	8.5	0	CD	_	2	num	_	_
18	%	%	NN	_	17	meta	_	_
19	)	-rrb-	-RRB-	_	17	p	_	_
20	at	at	IN	_	22	case	_	_
21	431	0	CD	_	22	num	_	_
22	micromol/L	micromol/l	NN	_	2	ppmod	_	_
23	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	diminished	diminish	VBD	_	0	root	_	_
3	binding	binding	NN	_	2	obj	_	_
4	of	of	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	by	by	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	net	net	JJ	_	9	attr	_	_
9	change	change	NN	_	3	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	9.9	0	CD	_	9	ppmod	_	_
12	%	%	NN	_	11	meta	_	_
13	(	-lrb-	-LRB-	_	19	p	_	_
14	percentage	percentage	NN	_	15	com	_	_
15	increase	increase	NN	_	19	dep	_	_
16	in	in	IN	_	17	case	_	_
17	FDF	fdf	NN	_	15	ppmod	_	_
18	,	,	,	_	19	p	_	_
19	21.2	0	CD	_	11	num	_	_
20	%	%	NN	_	19	meta	_	_
21	)	-rrb-	-RRB-	_	19	p	_	_
22	at	at	IN	_	24	case	_	_
23	1732	0	CD	_	24	num	_	_
24	micromol/L	micromol/l	NN	_	11	ppmod	_	_
25	.	.	.	_	2	p	_	_

1	No	no	DT	_	3	det	_	_
2	significant	significant	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	noted	note	VBN	_	0	root	_	_
6	with	with	IN	_	9	case	_	_
7	other	other	JJ	_	9	attr	_	_
8	drug	drug	NN	_	9	com	_	_
9	combinations	combination	NNS	_	5	ppmod	_	_
10	or	or	CC	_	9	cc	_	_
11	with	with	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	addition	addition	NN	_	9	conj	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	.	.	.	_	5	p	_	_

1	Coingestion	coingestion	NN	_	20	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	drug3	drug0	NN	_	5	conj	_	_
8	with	with	IN	_	9	case	_	_
9	drug4	drug0	NN	_	7	ppmod	_	_
10	,	,	,	_	7	p	_	_
11	and	and	CC	_	7	cc	_	_
12	drug5	drug0	NN	_	5	conj	_	_
13	with	with	IN	_	14	case	_	_
14	drug6	drug0	NN	_	3	ppmod	_	_
15	at	at	IN	_	19	case	_	_
16	high	high	JJ	_	18	adv	_	_
17	to	to	TO	_	18	adv	_	_
18	toxic	toxic	JJ	_	19	attr	_	_
19	concentrations	concentration	NNS	_	1	ppmod	_	_
20	decreases	decrease	VBZ	_	0	root	_	_
21	the	the	DT	_	22	det	_	_
22	binding	binding	NN	_	20	obj	_	_
23	of	of	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	target	target	NN	_	26	com	_	_
26	drug	drug	NN	_	22	ppmod	_	_
27	.	.	.	_	20	p	_	_

1	The	the	DT	_	3	det	_	_
2	resulting	result	VBG	_	3	attr	_	_
3	increase	increase	NN	_	9	dep	_	_
4	in	in	IN	_	7	case	_	_
5	free	free	JJ	_	7	attr	_	_
6	drug	drug	NN	_	7	com	_	_
7	concentration	concentration	NN	_	3	ppmod	_	_
8	may	may	MD	_	9	modal	_	_
9	lead	lead	VB	_	0	root	_	_
10	to	to	TO	_	13	aux	_	_
11	enhanced	enhance	VBN	_	13	attr	_	_
12	drug	drug	NN	_	13	com	_	_
13	effect	effect	NN	_	9	ppmod	_	_
14	in	in	FW	_	15	adv	_	_
15	vivo	vivo	FW	_	9	adv	_	_
16	.	.	.	_	9	p	_	_

1	Effect	effect	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	on	on	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug2	drug0	NN	_	6	ppmod	_	_
9	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	steady-state	steady-state	JJ	_	8	attr	_	_
8	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug2	drug0	NN	_	8	ppmod	_	_
11	was	be	VBD	_	12	aux	_	_
12	evaluated	evaluate	VBN	_	0	root	_	_
13	in	in	IN	_	18	case	_	_
14	a	a	DT	_	18	det	_	_
15	randomized	randomized	JJ	_	17	adv	_	_
16	,	,	,	_	17	p	_	_
17	double-blind	double-blind	JJ	_	18	attr	_	_
18	study	study	NN	_	12	ppmod	_	_
19	.	.	.	_	12	p	_	_

1	Five	#crd#	CD	_	2	num	_	_
2	days	day	NNS	_	9	dep	_	_
3	of	of	IN	_	5	case	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	treatment	treatment	NN	_	2	ppmod	_	_
6	did	do	VBD	_	9	aux	_	_
7	not	not	RB	_	9	neg	_	_
8	significantly	significantly	RB	_	9	adv	_	_
9	affect	affect	VB	_	0	root	_	_
10	steady-state	steady-state	JJ	_	12	attr	_	_
11	pharmacokinetic	pharmacokinetic	JJ	_	12	attr	_	_
12	variables	variable	NNS	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	compared	compare	VBN	_	17	adv	_	_
16	with	with	IN	_	17	case	_	_
17	placebo	placebo	NN	_	12	ppmod	_	_
18	;	;	:	_	9	p	_	_

1	therefore	therefore	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	the	the	DT	_	4	det	_	_
4	use	use	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	does	do	VBZ	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	necessitate	necessitate	VBP	_	0	root	_	_
10	an	an	DT	_	11	det	_	_
11	adjustment	adjustment	NN	_	9	obj	_	_
12	in	in	IN	_	14	case	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	dose	dose	NN	_	9	ppmod	_	_
15	to	to	TO	_	16	aux	_	_
16	maintain	maintain	VB	_	9	comp	_	_
17	therapeutic	therapeutic	JJ	_	19	attr	_	_
18	digoxin	digoxin	NN	_	19	com	_	_
19	levels	level	NNS	_	16	obj	_	_
20	.	.	.	_	9	p	_	_

1	Acid-catalyzed	acid-catalyzed	JJ	_	2	attr	_	_
2	ethanolysis	ethanolysis	NN	_	0	root	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	anhydrous	anhydrous	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	aqueous	aqueous	JJ	_	10	attr	_	_
9	drug2	drug0	NN	_	10	com	_	_
10	solutions	solution	NNS	_	6	conj	_	_
11	.	.	.	_	2	p	_	_

1	The	the	DT	_	2	det	_	_
2	drug1	drug0	NNS	_	3	dep	_	_
3	are	be	VBP	_	0	root	_	_
4	a	a	DT	_	5	det	_	_
5	family	family	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug3	drug0	NN	_	7	conj	_	_
10	.	.	.	_	3	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	taken	take	VBN	_	11	advcl	_	_
3	concurrently	concurrently	RB	_	2	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	2	ppmod	_	_
6	,	,	,	_	11	p	_	_
7	a	a	DT	_	9	det	_	_
8	pharmacological	pharmacological	JJ	_	9	attr	_	_
9	interaction	interaction	NN	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	occur	occur	VB	_	0	root	_	_
12	,	,	,	_	11	p	_	_
13	potentiating	potentiate	VBG	_	11	comp	_	_
14	the	the	DT	_	17	det	_	_
15	central	central	JJ	_	17	attr	_	_
16	nervous	nervous	JJ	_	17	attr	_	_
17	system	system	NN	_	18	com	_	_
18	depression	depression	NN	_	13	obj	_	_
19	produced	produce	VBN	_	18	acl	_	_
20	by	by	IN	_	22	case	_	_
21	either	either	DT	_	22	det	_	_
22	drug	drug	NN	_	19	ppmod	_	_
23	.	.	.	_	11	p	_	_

1	In	in	IN	_	6	case	_	_
2	addition	addition	NN	_	6	advnp	_	_
3	to	to	TO	_	6	aux	_	_
4	this	this	DT	_	6	det	_	_
5	pharmacological	pharmacological	JJ	_	6	attr	_	_
6	interaction	interaction	NN	_	10	ppmod	_	_
7	,	,	,	_	10	p	_	_
8	this	this	DT	_	9	det	_	_
9	report	report	NN	_	10	dep	_	_
10	describes	describe	VBZ	_	0	root	_	_
11	a	a	DT	_	14	det	_	_
12	novel	novel	JJ	_	14	attr	_	_
13	chemical	chemical	JJ	_	14	attr	_	_
14	reaction	reaction	NN	_	10	obj	_	_
15	between	between	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	(	-lrb-	-LRB-	_	19	p	_	_
18	a	a	DT	_	19	det	_	_
19	drug2	drug0	NN	_	16	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	and	and	CC	_	16	cc	_	_
22	drug3	drug0	NN	_	16	conj	_	_
23	under	under	IN	_	25	case	_	_
24	acidic	acidic	JJ	_	25	attr	_	_
25	conditions	condition	NNS	_	10	ppmod	_	_
26	similar	similar	JJ	_	25	attr	_	_
27	to	to	TO	_	28	aux	_	_
28	those	those	DT	_	26	ppmod	_	_
29	found	find	VBN	_	28	acl	_	_
30	in	in	IN	_	31	case	_	_
31	vivo	vivo	FW	_	29	ppmod	_	_
32	,	,	,	_	10	p	_	_
33	resulting	result	VBG	_	10	comp	_	_
34	in	in	IN	_	37	case	_	_
35	a	a	DT	_	37	det	_	_
36	3-ethoxylated	0-ethoxylated	JJ	_	37	attr	_	_
37	product	product	NN	_	33	ppmod	_	_
38	.	.	.	_	10	p	_	_

1	Optimal	optimal	JJ	_	2	attr	_	_
2	conditions	condition	NNS	_	16	dep	_	_
3	,	,	,	_	16	p	_	_
4	kinetics	kinetics	NN	_	16	dep	_	_
5	,	,	,	_	4	p	_	_
6	equilibrium	equilibrium	NN	_	4	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	the	the	DT	_	10	det	_	_
10	mechanism	mechanism	NN	_	4	conj	_	_
11	of	of	IN	_	14	case	_	_
12	this	this	DT	_	14	det	_	_
13	acid-catalyzed	acid-catalyzed	JJ	_	14	attr	_	_
14	ethanolysis	ethanolysis	NN	_	10	ppmod	_	_
15	are	be	VBP	_	16	aux	_	_
16	reported	report	VBN	_	0	root	_	_
17	.	.	.	_	16	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	raise	raise	VBP	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	possibility	possibility	NN	_	3	obj	_	_
6	that	that	IN	_	11	mark	_	_
7	the	the	DT	_	9	det	_	_
8	ethanolysis	ethanolysis	NN	_	9	com	_	_
9	reaction	reaction	NN	_	11	dep	_	_
10	may	may	MD	_	11	modal	_	_
11	occur	occur	VB	_	5	acl	_	_
12	in	in	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	stomach	stomach	NN	_	11	ppmod	_	_
15	of	of	IN	_	16	case	_	_
16	people	people	NN	_	14	ppmod	_	_
17	who	who	WP	_	18	dep	_	_
18	consume	consume	VBD	_	16	relcl	_	_
19	drug1	drug0	NN	_	18	obj	_	_
20	and	and	CC	_	19	cc	_	_
21	drug2	drug0	NN	_	19	conj	_	_
22	on	on	IN	_	25	case	_	_
23	a	a	DT	_	25	det	_	_
24	regular	regular	JJ	_	25	attr	_	_
25	basis	basis	NN	_	18	ppmod	_	_
26	.	.	.	_	3	p	_	_

1	The	the	DT	_	5	det	_	_
2	acid-catalyzed	acid-catalyzed	JJ	_	5	attr	_	_
3	drug1	drug0	NN	_	5	com	_	_
4	-drug	-drug	NN	_	5	com	_	_
5	reaction	reaction	NN	_	6	dep	_	_
6	is	be	VBZ	_	0	root	_	_
7	a	a	DT	_	10	det	_	_
8	relatively	relatively	RB	_	9	adv	_	_
9	unexplored	unexplored	JJ	_	10	attr	_	_
10	area	area	NN	_	6	obj	_	_
11	and	and	CC	_	6	cc	_	_
12	may	may	MD	_	13	modal	_	_
13	alter	alter	VB	_	6	conj	_	_
14	the	the	DT	_	16	det	_	_
15	pharmacological	pharmacological	JJ	_	16	attr	_	_
16	action	action	NN	_	13	obj	_	_
17	of	of	IN	_	19	case	_	_
18	some	some	DT	_	19	det	_	_
19	drugs	drug	NNS	_	16	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	Inhibitory	inhibitory	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	7	case	_	_
6	inositol	inositol	NN	_	7	com	_	_
7	1,4	0	NN	_	2	ppmod	_	_
8	,	,	,	_	2	p	_	_
9	5-trisphosphate-induced	0-trisphosphate-induced	VBD	_	0	root	_	_
10	responses	response	NNS	_	9	obj	_	_
11	in	in	IN	_	13	case	_	_
12	rat	rat	NN	_	13	com	_	_
13	megakaryocytes	megakaryocyte	NNS	_	10	ppmod	_	_
14	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	effects	effect	NNS	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	6	p	_	_
6	drug2	drug0	NN	_	4	prn	_	_
7	)	-rrb-	-RRB-	_	6	p	_	_
8	on	on	IN	_	14	case	_	_
9	drug3	drug0	NN	_	13	advnp	_	_
10	(	-lrb-	-LRB-	_	13	p	_	_
11	drug4	drug0	NN	_	13	advnp	_	_
12	)	-rrb-	-RRB-	_	13	p	_	_
13	-induced	-induced	JJ	_	14	attr	_	_
14	responses	response	NNS	_	2	ppmod	_	_
15	were	be	VBD	_	16	aux	_	_
16	studied	study	VBN	_	0	root	_	_
17	in	in	IN	_	21	case	_	_
18	rat	rat	NN	_	21	com	_	_
19	bone	bone	NN	_	21	com	_	_
20	marrow	marrow	NN	_	21	com	_	_
21	megakaryocytes	megakaryocyte	NNS	_	16	ppmod	_	_
22	with	with	IN	_	27	case	_	_
23	the	the	DT	_	27	det	_	_
24	patch-clamp	patch-clamp	NN	_	27	attr	_	_
25	whole-cell	whole-cell	JJ	_	27	attr	_	_
26	recording	recording	NN	_	27	com	_	_
27	technique	technique	NN	_	16	ppmod	_	_
28	in	in	IN	_	29	case	_	_
29	combination	combination	NN	_	16	ppmod	_	_
30	with	with	IN	_	32	case	_	_
31	fura-2	fura-0	NN	_	32	com	_	_
32	microfluorometry	microfluorometry	NN	_	29	ppmod	_	_
33	.	.	.	_	16	p	_	_

1	Internal	internal	JJ	_	2	attr	_	_
2	application	application	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	100	0	CD	_	7	num	_	_
7	microM	microm	NN	_	4	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	increased	increase	VBD	_	0	root	_	_
10	intracellular	intracellular	JJ	_	15	attr	_	_
11	Ca	ca	NN	_	15	attr	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	2+	0+	NN	_	15	attr	_	_
14	)	-rrb-	-RRB-	_	15	p	_	_
15	concentration	concentration	NN	_	9	obj	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	-LSB-Ca	-lsb-ca	NN	_	15	prn	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	2+	0+	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	]	-rsb-	-RRB-	_	19	p	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	i	i	NN	_	17	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	)	-rrb-	-RRB-	_	17	p	_	_
26	and	and	CC	_	9	cc	_	_
27	activated	activate	VBD	_	9	conj	_	_
28	the	the	DT	_	34	det	_	_
29	Ca	ca	NN	_	33	advnp	_	_
30	(	-lrb-	-LRB-	_	33	p	_	_
31	2+	0+	NN	_	33	advnp	_	_
32	)	-rrb-	-RRB-	_	33	p	_	_
33	-dependent	-dependent	JJ	_	34	attr	_	_
34	K	k	NN	_	38	attr	_	_
35	(	-lrb-	-LRB-	_	34	p	_	_
36	+	+	CC	_	34	cc	_	_
37	)	-rrb-	-RRB-	_	34	p	_	_
38	current	current	NN	_	27	obj	_	_
39	.	.	.	_	9	p	_	_

1	Administering	administer	VBG	_	10	advcl	_	_
2	drug1	drug0	NN	_	1	obj	_	_
3	together	together	RB	_	5	adv	_	_
4	with	with	IN	_	5	case	_	_
5	drug2	drug0	NN	_	1	ppmod	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	100-500	0	CD	_	8	num	_	_
8	microM	microm	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	inhibited	inhibit	VBD	_	0	root	_	_
11	InsP	insp	NN	_	15	advnp	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	3	0	CD	_	15	num	_	_
14	)	-rrb-	-RRB-	_	15	p	_	_
15	-induced	-induced	JJ	_	16	attr	_	_
16	responses	response	NNS	_	10	obj	_	_
17	(	-lrb-	-LRB-	_	19	p	_	_
18	both	both	CC	_	19	cc	_	_
19	Ca	ca	NN	_	16	prn	_	_
20	(	-lrb-	-LRB-	_	21	p	_	_
21	2+	0+	NN	_	19	prn	_	_
22	)	-rrb-	-RRB-	_	21	p	_	_
23	and	and	CC	_	19	cc	_	_
24	current	current	JJ	_	25	attr	_	_
25	responses	response	NNS	_	19	conj	_	_
26	)	-rrb-	-RRB-	_	19	p	_	_
27	in	in	IN	_	30	case	_	_
28	a	a	DT	_	30	det	_	_
29	dose-dependent	dose-dependent	JJ	_	30	attr	_	_
30	fashion	fashion	NN	_	10	ppmod	_	_
31	.	.	.	_	10	p	_	_

1	Pretreatment	pretreatment	NN	_	12	dep	_	_
2	of	of	IN	_	3	case	_	_
3	megakaryocytes	megakaryocyte	NNS	_	1	ppmod	_	_
4	with	with	IN	_	6	case	_	_
5	extracellular	extracellular	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	1	ppmod	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	50	0	CD	_	9	num	_	_
9	microM	microm	NN	_	6	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	also	also	RB	_	12	adv	_	_
12	inhibited	inhibit	VBD	_	0	root	_	_
13	drug2	drug0	NN	_	15	attr	_	_
14	-induced	-induced	JJ	_	15	attr	_	_
15	responses	response	NNS	_	12	obj	_	_
16	.	.	.	_	12	p	_	_

1	Intracellular	intracellular	JJ	_	4	attr	_	_
2	and	and	CC	_	1	cc	_	_
3	extracellular	extracellular	JJ	_	1	conj	_	_
4	application	application	NN	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	reduced	reduce	VBD	_	0	root	_	_
8	ADP-induced	adp-induced	JJ	_	9	attr	_	_
9	increases	increase	NNS	_	7	obj	_	_
10	in	in	IN	_	11	case	_	_
11	-LSB-Ca	-lsb-ca	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	2+	0+	NN	_	11	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	]	-rsb-	-RRB-	_	13	p	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	i	i	NN	_	11	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	.	.	.	_	7	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	12	ppmod	_	_
3	,	,	,	_	12	p	_	_
4	in	in	IN	_	9	case	_	_
5	isolated	isolate	VBN	_	9	attr	_	_
6	single	single	JJ	_	9	attr	_	_
7	pancreatic	pancreatic	JJ	_	9	attr	_	_
8	acinar	acinar	JJ	_	9	attr	_	_
9	cells	cell	NNS	_	12	ppmod	_	_
10	,	,	,	_	12	p	_	_
11	drug1	drug0	NN	_	12	dep	_	_
12	had	have	VBD	_	0	root	_	_
13	no	no	DT	_	14	det	_	_
14	effect	effect	NN	_	12	obj	_	_
15	on	on	IN	_	18	case	_	_
16	drug2	drug0	JJ	_	18	attr	_	_
17	-induced	-induced	JJ	_	18	attr	_	_
18	responses	response	NNS	_	12	ppmod	_	_
19	.	.	.	_	12	p	_	_

1	Taken	take	VBN	_	6	advcl	_	_
2	together	together	RB	_	1	adv	_	_
3	,	,	,	_	6	p	_	_
4	these	these	DT	_	5	det	_	_
5	results	result	NNS	_	6	dep	_	_
6	suggest	suggest	VBP	_	0	root	_	_
7	that	that	IN	_	16	mark	_	_
8	the	the	DT	_	9	det	_	_
9	site	site	NN	_	16	dep	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	inhibitory	inhibitory	JJ	_	13	attr	_	_
13	action	action	NN	_	9	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	drug1	drug0	NN	_	13	ppmod	_	_
16	is	be	VBZ	_	6	comp	_	_
17	at	at	IN	_	23	case	_	_
18	the	the	DT	_	23	det	_	_
19	InsP	insp	NN	_	23	attr	_	_
20	(	-lrb-	-LRB-	_	23	p	_	_
21	3	0	CD	_	23	num	_	_
22	)	-rrb-	-RRB-	_	23	p	_	_
23	receptor	receptor	NN	_	16	ppmod	_	_
24	,	,	,	_	23	p	_	_
25	or	or	CC	_	23	cc	_	_
26	its	its	PRP$	_	29	poss	_	_
27	closely	closely	RB	_	28	adv	_	_
28	associated	associate	VBN	_	29	attr	_	_
29	proteins	protein	NNS	_	23	conj	_	_
30	.	.	.	_	6	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	6	ppmod	_	_
3	,	,	,	_	6	p	_	_
4	we	we	PRP	_	6	dep	_	_
5	have	have	VBP	_	6	aux	_	_
6	shown	show	VBN	_	0	root	_	_
7	that	that	IN	_	9	mark	_	_
8	drug1	drug0	NN	_	9	dep	_	_
9	is	be	VBZ	_	6	comp	_	_
10	a	a	DT	_	13	det	_	_
11	useful	useful	JJ	_	13	attr	_	_
12	pharmacological	pharmacological	JJ	_	13	attr	_	_
13	tool	tool	NN	_	9	obj	_	_
14	with	with	IN	_	15	case	_	_
15	which	which	WDT	_	17	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	examine	examine	VB	_	13	relcl	_	_
18	the	the	DT	_	21	det	_	_
19	drug2	drug0	NN	_	21	attr	_	_
20	-mediated	-mediated	JJ	_	21	attr	_	_
21	responses	response	NNS	_	17	obj	_	_
22	of	of	IN	_	23	case	_	_
23	megakaryocytes	megakaryocyte	NNS	_	21	ppmod	_	_
24	.	.	.	_	6	p	_	_

1	Concomitant	concomitant	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	,	,	,	_	4	p	_	_
6	drug3	drug0	NN	_	2	conj	_	_
7	,	,	,	_	6	p	_	_
8	and	and	CC	_	6	cc	_	_
9	drug4	drug0	NN	_	10	com	_	_
10	chemotherapy	chemotherapy	NN	_	2	conj	_	_
11	plus	plus	CC	_	10	cc	_	_
12	drug5	drug0	NN	_	13	com	_	_
13	therapy	therapy	NN	_	10	conj	_	_
14	in	in	IN	_	15	case	_	_
15	patients	patient	NNS	_	10	ppmod	_	_
16	with	with	IN	_	22	case	_	_
17	human	human	JJ	_	22	attr	_	_
18	immunodeficiency	immunodeficiency	NN	_	22	attr	_	_
19	virus-related	virus-related	JJ	_	22	attr	_	_
20	,	,	,	_	22	p	_	_
21	non-Hodgkin	non-hodgkin	JJ	_	22	attr	_	_
22	lymphoma	lymphoma	NN	_	15	ppmod	_	_
23	.	.	.	_	10	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	feasibility	feasibility	NN	_	16	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	efficacy	efficacy	NN	_	4	conj	_	_
7	of	of	IN	_	9	case	_	_
8	concomitant	concomitant	JJ	_	9	attr	_	_
9	chemotherapy	chemotherapy	NN	_	4	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	therapy	therapy	NN	_	9	conj	_	_
13	(	-lrb-	-LRB-	_	14	p	_	_
14	HAART	haart	NN	_	12	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	is	be	VBZ	_	1	acl	_	_
17	still	still	RB	_	16	adv	_	_
18	unknown	unknown	JJ	_	16	dep	_	_
19	in	in	IN	_	20	case	_	_
20	patients	patient	NNS	_	18	ppmod	_	_
21	with	with	IN	_	29	case	_	_
22	human	human	JJ	_	24	attr	_	_
23	immunodeficiency	immunodeficiency	NN	_	24	com	_	_
24	virus	virus	NN	_	29	attr	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	HIV	hiv	NN	_	24	prn	_	_
27	)	-rrb-	-RRB-	_	26	p	_	_
28	-related	-related	JJ	_	29	attr	_	_
29	malignancies	malignancy	NNS	_	20	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	To	to	TO	_	2	aux	_	_
2	evaluate	evaluate	VB	_	28	advcl	_	_
3	the	the	DT	_	4	det	_	_
4	impact	impact	NN	_	2	obj	_	_
5	of	of	IN	_	6	case	_	_
6	chemotherapy	chemotherapy	NN	_	4	ppmod	_	_
7	plus	plus	CC	_	6	cc	_	_
8	HAART	haart	NN	_	6	conj	_	_
9	on	on	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	clinical	clinical	JJ	_	12	attr	_	_
12	course	course	NN	_	6	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	patients	patient	NNS	_	12	ppmod	_	_
15	with	with	IN	_	21	case	_	_
16	HIV-related	hiv-related	JJ	_	18	adv	_	_
17	,	,	,	_	18	p	_	_
18	systemic	systemic	JJ	_	21	attr	_	_
19	,	,	,	_	21	p	_	_
20	non-Hodgkin	non-hodgkin	JJ	_	21	attr	_	_
21	lymphoma	lymphoma	NN	_	14	ppmod	_	_
22	(	-lrb-	-LRB-	_	23	p	_	_
23	HIV-NHL	hiv-nhl	NN	_	21	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	,	,	,	_	28	p	_	_
26	the	the	DT	_	27	det	_	_
27	authors	author	NNS	_	28	dep	_	_
28	compared	compare	VBD	_	0	root	_	_
29	retrospectively	retrospectively	RB	_	28	adv	_	_
30	a	a	DT	_	31	det	_	_
31	group	group	NN	_	28	obj	_	_
32	of	of	IN	_	34	case	_	_
33	24	0	CD	_	34	num	_	_
34	patients	patient	NNS	_	31	ppmod	_	_
35	with	with	IN	_	36	case	_	_
36	HIV-NHL	hiv-nhl	NN	_	34	ppmod	_	_
37	who	who	WP	_	39	dep	_	_
38	were	be	VBD	_	39	aux	_	_
39	treated	treat	VBN	_	34	relcl	_	_
40	with	with	IN	_	42	case	_	_
41	the	the	DT	_	42	det	_	_
42	drug1	drug0	NN	_	39	ppmod	_	_
43	,	,	,	_	42	p	_	_
44	drug2	drug0	NN	_	42	conj	_	_
45	,	,	,	_	44	p	_	_
46	drug3	drug0	NN	_	42	conj	_	_
47	,	,	,	_	46	p	_	_
48	and	and	CC	_	46	cc	_	_
49	drug4	drug0	NN	_	54	attr	_	_
50	(	-lrb-	-LRB-	_	54	p	_	_
51	CHOP	chop	NN	_	54	attr	_	_
52	)	-rrb-	-RRB-	_	54	p	_	_
53	chemotherapy	chemotherapy	NN	_	54	com	_	_
54	regimen	regimen	NN	_	42	conj	_	_
55	plus	plus	CC	_	54	cc	_	_
56	HAART	haart	NN	_	54	conj	_	_
57	with	with	IN	_	59	case	_	_
58	a	a	DT	_	59	det	_	_
59	group	group	NN	_	39	ppmod	_	_
60	of	of	IN	_	62	case	_	_
61	80	0	CD	_	62	num	_	_
62	patients	patient	NNS	_	59	ppmod	_	_
63	who	who	WP	_	65	dep	_	_
64	were	be	VBD	_	65	aux	_	_
65	treated	treat	VBN	_	62	relcl	_	_
66	with	with	IN	_	68	case	_	_
67	CHOP	chop	NN	_	68	com	_	_
68	chemotherapy	chemotherapy	NN	_	65	ppmod	_	_
69	or	or	CC	_	68	cc	_	_
70	a	a	DT	_	72	det	_	_
71	CHOP-like	chop-like	JJ	_	72	attr	_	_
72	regimen	regimen	NN	_	68	conj	_	_
73	(	-lrb-	-LRB-	_	76	p	_	_
74	i.e.	i.e.	FW	_	76	adv	_	_
75	,	,	,	_	76	p	_	_
76	drug5	drug0	NN	_	72	prn	_	_
77	,	,	,	_	76	p	_	_
78	drug6	drug0	NN	_	76	conj	_	_
79	,	,	,	_	78	p	_	_
80	drug7	drug0	NN	_	76	conj	_	_
81	,	,	,	_	80	p	_	_
82	and	and	CC	_	80	cc	_	_
83	drug8	drug0	NN	_	76	conj	_	_
84	with	with	IN	_	85	case	_	_
85	drug9	drug0	NN	_	76	ppmod	_	_
86	plus	plus	CC	_	85	cc	_	_
87	drug10	drug0	NN	_	85	conj	_	_
88	)	-rrb-	-RRB-	_	76	p	_	_
89	without	without	IN	_	90	case	_	_
90	receiving	receive	VBG	_	65	ppmod	_	_
91	drug11	drug0	NN	_	92	com	_	_
92	therapy	therapy	NN	_	90	obj	_	_
93	.	.	.	_	28	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	All	all	DT	_	4	det	_	_
4	patients	patient	NNS	_	6	dep	_	_
5	were	be	VBD	_	6	aux	_	_
6	enrolled	enrol	VBN	_	1	acl	_	_
7	in	in	IN	_	10	case	_	_
8	two	#crd#	CD	_	10	num	_	_
9	sequential	sequential	JJ	_	10	attr	_	_
10	trials	trial	NNS	_	6	ppmod	_	_
11	performed	performed	VBN	_	10	acl	_	_
12	at	at	IN	_	16	case	_	_
13	the	the	DT	_	16	det	_	_
14	Aviano	aviano	JJ	_	16	attr	_	_
15	Cancer	cancer	NN	_	16	com	_	_
16	Center	center	NN	_	11	ppmod	_	_
17	,	,	,	_	16	p	_	_
18	Italy	italy	NN	_	16	appo	_	_
19	,	,	,	_	6	p	_	_
20	from	from	IN	_	21	case	_	_
21	April	april	NNP	_	6	ppmod	_	_
22	1988	0	CD	_	21	num	_	_
23	to	to	TO	_	21	attr	_	_
24	December	december	NNP	_	21	appo	_	_
25	1998	0	CD	_	24	num	_	_
26	.	.	.	_	1	p	_	_

1	HAART	haart	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	included	include	VBN	_	0	root	_	_
4	with	with	IN	_	6	case	_	_
5	combination	combination	NN	_	6	com	_	_
6	therapy	therapy	NN	_	3	ppmod	_	_
7	from	from	IN	_	8	case	_	_
8	January	january	NNP	_	6	ppmod	_	_
9	1997	0	CD	_	8	num	_	_
10	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	regimens	regimen	NNS	_	3	dep	_	_
3	consisted	consist	VBD	_	0	root	_	_
4	of	of	IN	_	6	case	_	_
5	two	#crd#	CD	_	6	num	_	_
6	drug2	drug0	NN	_	3	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	one	#crd#	CD	_	9	num	_	_
9	drug3	drug0	NN	_	6	conj	_	_
10	.	.	.	_	3	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	6	det	_	_
4	two	#crd#	CD	_	6	num	_	_
5	treatment	treatment	NN	_	6	com	_	_
6	groups	group	NNS	_	9	dep	_	_
7	were	be	VBD	_	9	aux	_	_
8	well	well	RB	_	9	adv	_	_
9	matched	match	VBN	_	1	acl	_	_
10	with	with	IN	_	11	case	_	_
11	regard	regard	NN	_	9	ppmod	_	_
12	to	to	TO	_	14	aux	_	_
13	patient	patient	NN	_	14	com	_	_
14	demographics	demographics	NNS	_	11	ppmod	_	_
15	,	,	,	_	14	p	_	_
16	NHL	nhl	NN	_	17	com	_	_
17	characteristics	characteristic	NNS	_	14	conj	_	_
18	,	,	,	_	17	p	_	_
19	HIV	hiv	NN	_	20	com	_	_
20	status	status	NN	_	14	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	treatment	treatment	NN	_	14	conj	_	_
24	,	,	,	_	14	p	_	_
25	i.e.	i.e.	FW	_	28	adv	_	_
26	,	,	,	_	28	p	_	_
27	the	the	DT	_	28	det	_	_
28	number	number	NN	_	14	ppmod	_	_
29	of	of	IN	_	30	case	_	_
30	cycles	cycle	NNS	_	28	ppmod	_	_
31	and	and	CC	_	30	cc	_	_
32	chemotherapy	chemotherapy	NN	_	33	com	_	_
33	dose	dose	NN	_	30	conj	_	_
34	.	.	.	_	1	p	_	_

1	The	the	DT	_	3	det	_	_
2	response	response	NN	_	3	com	_	_
3	rates	rate	NNS	_	4	dep	_	_
4	were	be	VBD	_	0	root	_	_
5	similar	similar	JJ	_	4	dep	_	_
6	between	between	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	two	#crd#	CD	_	9	num	_	_
9	groups	group	NNS	_	5	ppmod	_	_
10	.	.	.	_	4	p	_	_

1	Severe	severe	JJ	_	2	attr	_	_
2	anemia	anemia	NN	_	14	dep	_	_
3	(	-lrb-	-LRB-	_	4	p	_	_
4	Grade	grade	NN	_	2	prn	_	_
5	3-4	0	JJ	_	4	num	_	_
6	according	accord	VBG	_	12	adv	_	_
7	to	to	TO	_	12	aux	_	_
8	the	the	DT	_	12	det	_	_
9	World	world	NN	_	12	com	_	_
10	Health	health	NN	_	12	com	_	_
11	Organization	organization	NN	_	12	com	_	_
12	criteria	criterion	NNS	_	4	ppmod	_	_
13	)	-rrb-	-RRB-	_	4	p	_	_
14	was	be	VBD	_	0	root	_	_
15	significantly	significantly	RB	_	16	adv	_	_
16	greater	great	JJR	_	14	dep	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	patients	patient	NNS	_	16	ppmod	_	_
20	who	who	WP	_	21	dep	_	_
21	received	receive	VBD	_	19	relcl	_	_
22	CHOP-HAART	chop-haart	NN	_	21	obj	_	_
23	compared	compare	VBN	_	26	adv	_	_
24	with	with	IN	_	26	case	_	_
25	the	the	DT	_	26	det	_	_
26	patients	patient	NNS	_	21	ppmod	_	_
27	who	who	WP	_	28	dep	_	_
28	received	receive	VBD	_	26	relcl	_	_
29	CHOP	chop	NN	_	28	obj	_	_
30	alone	alone	RB	_	29	adv	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	33	0	CD	_	28	num	_	_
33	%	%	NN	_	32	meta	_	_
34	vs.	vs.	CC	_	32	cc	_	_
35	7	0	CD	_	32	conj	_	_
36	%	%	NN	_	35	meta	_	_
37	,	,	,	_	35	p	_	_
38	respectively	respectively	RB	_	32	conj	_	_
39	;	;	:	_	32	p	_	_
40	P	p	NN	_	41	dep	_	_
41	=	=	JJ	_	32	advcl	_	_
42	0.001	0	CD	_	41	obj	_	_
43	)	-rrb-	-RRB-	_	32	p	_	_
44	.	.	.	_	14	p	_	_

1	Leukopenia	leukopenia	NN	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	similar	similar	JJ	_	2	dep	_	_
4	between	between	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	two	#crd#	CD	_	7	num	_	_
7	groups	group	NNS	_	3	ppmod	_	_
8	,	,	,	_	2	p	_	_
9	but	but	CC	_	2	cc	_	_
10	colony	colony	NN	_	12	com	_	_
11	stimulating	stimulating	NN	_	12	com	_	_
12	factor	factor	NN	_	13	com	_	_
13	support	support	NN	_	14	dep	_	_
14	was	be	VBD	_	2	conj	_	_
15	significantly	significantly	RB	_	16	adv	_	_
16	greater	great	JJR	_	14	dep	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	CHOP-HAART	chop-haart	JJ	_	20	attr	_	_
20	group	group	NN	_	16	ppmod	_	_
21	than	than	IN	_	25	case	_	_
22	in	in	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	control	control	JJ	_	25	attr	_	_
25	group	group	NN	_	16	ppmod	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	92	0	CD	_	16	num	_	_
28	%	%	NN	_	27	meta	_	_
29	vs.	vs.	CC	_	27	cc	_	_
30	66	0	CD	_	27	conj	_	_
31	%	%	NN	_	30	meta	_	_
32	,	,	,	_	30	p	_	_
33	respectively	respectively	RB	_	27	conj	_	_
34	;	;	:	_	27	p	_	_
35	P	p	NN	_	36	dep	_	_
36	=	=	JJ	_	27	advcl	_	_
37	0.03	0	CD	_	36	obj	_	_
38	)	-rrb-	-RRB-	_	27	p	_	_
39	.	.	.	_	2	p	_	_

1	Seventeen	#crd#	CD	_	2	num	_	_
2	percent	percent	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	CHOP-HAART	chop-haart	JJ	_	5	attr	_	_
5	patients	patient	NNS	_	2	ppmod	_	_
6	developed	develop	VBD	_	17	advcl	_	_
7	severe	severe	JJ	_	9	attr	_	_
8	autonomic	autonomic	JJ	_	9	attr	_	_
9	neurotoxicity	neurotoxicity	NN	_	6	obj	_	_
10	,	,	,	_	17	p	_	_
11	whereas	whereas	IN	_	17	case	_	_
12	none	none	NN	_	17	dep	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	CHOP	chop	NN	_	16	com	_	_
16	patients	patient	NNS	_	12	ppmod	_	_
17	developed	develop	VBD	_	0	root	_	_
18	neurotoxicity	neurotoxicity	NN	_	17	obj	_	_
19	(	-lrb-	-LRB-	_	20	p	_	_
20	P	p	NN	_	18	prn	_	_
21	=	=	JJ	_	20	attr	_	_
22	0.002	0	CD	_	20	num	_	_
23	)	-rrb-	-RRB-	_	20	p	_	_
24	.	.	.	_	17	p	_	_

1	At	at	IN	_	4	case	_	_
2	similar	similar	JJ	_	4	attr	_	_
3	median	median	NN	_	4	com	_	_
4	follow-up	follow-up	NN	_	14	ppmod	_	_
5	,	,	,	_	14	p	_	_
6	opportunistic	opportunistic	JJ	_	7	attr	_	_
7	infection	infection	NN	_	11	attr	_	_
8	(	-lrb-	-LRB-	_	9	p	_	_
9	OI	oi	NN	_	7	prn	_	_
10	)	-rrb-	-RRB-	_	9	p	_	_
11	rates	rate	NNS	_	14	dep	_	_
12	and	and	CC	_	11	cc	_	_
13	mortality	mortality	NN	_	11	conj	_	_
14	were	be	VBD	_	0	root	_	_
15	significantly	significantly	RB	_	16	adv	_	_
16	lower	low	JJR	_	14	dep	_	_
17	in	in	IN	_	20	case	_	_
18	the	the	DT	_	20	det	_	_
19	CHOP-HAART	chop-haart	JJ	_	20	attr	_	_
20	patients	patient	NNS	_	16	ppmod	_	_
21	than	than	IN	_	25	case	_	_
22	in	in	IN	_	25	case	_	_
23	the	the	DT	_	25	det	_	_
24	CHOP	chop	NN	_	25	com	_	_
25	patients	patient	NNS	_	16	ppmod	_	_
26	(	-lrb-	-LRB-	_	40	p	_	_
27	18	0	CD	_	40	num	_	_
28	%	%	NN	_	27	meta	_	_
29	vs.	vs.	CC	_	27	cc	_	_
30	52	0	CD	_	27	conj	_	_
31	%	%	NN	_	30	meta	_	_
32	,	,	,	_	27	p	_	_
33	respectively	respectively	RB	_	27	adv	_	_
34	;	;	:	_	40	p	_	_
35	P	p	NN	_	40	dep	_	_
36	=	=	JJ	_	35	attr	_	_
37	0.05	0	CD	_	36	num	_	_
38	;	;	:	_	40	p	_	_
39	and	and	CC	_	40	cc	_	_
40	38	0	CD	_	16	num	_	_
41	%	%	NN	_	40	meta	_	_
42	vs.	vs.	CC	_	40	cc	_	_
43	85	0	CD	_	40	conj	_	_
44	%	%	NN	_	43	meta	_	_
45	,	,	,	_	40	p	_	_
46	respectively	respectively	RB	_	40	adv	_	_
47	;	;	:	_	40	p	_	_
48	P	p	NN	_	49	dep	_	_
49	=	=	JJ	_	40	advcl	_	_
50	0.001	0	CD	_	49	obj	_	_
51	)	-rrb-	-RRB-	_	40	p	_	_
52	.	.	.	_	14	p	_	_

1	The	the	DT	_	3	det	_	_
2	median	median	JJ	_	3	attr	_	_
3	survival	survival	NN	_	9	dep	_	_
4	for	for	IN	_	6	case	_	_
5	CHOP-HAART	chop-haart	JJ	_	6	attr	_	_
6	patients	patient	NNS	_	3	ppmod	_	_
7	was	be	VBD	_	9	aux	_	_
8	not	not	RB	_	9	neg	_	_
9	reached	reach	VBN	_	18	advcl	_	_
10	,	,	,	_	18	p	_	_
11	whereas	whereas	IN	_	18	case	_	_
12	the	the	DT	_	14	det	_	_
13	medial	medial	JJ	_	14	attr	_	_
14	survival	survival	NN	_	18	dep	_	_
15	of	of	IN	_	17	case	_	_
16	CHOP	chop	NN	_	17	com	_	_
17	patients	patient	NNS	_	14	ppmod	_	_
18	was	be	VBD	_	0	root	_	_
19	7	0	CD	_	20	num	_	_
20	months	month	NNS	_	18	obj	_	_
21	(	-lrb-	-LRB-	_	23	p	_	_
22	P	p	NN	_	23	dep	_	_
23	=	=	JJ	_	18	prn	_	_
24	0.03	0	CD	_	23	obj	_	_
25	)	-rrb-	-RRB-	_	23	p	_	_
26	.	.	.	_	18	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	combination	combination	NN	_	9	dep	_	_
5	of	of	IN	_	6	case	_	_
6	CHOP	chop	NN	_	4	ppmod	_	_
7	plus	plus	CC	_	6	cc	_	_
8	HAART	haart	NN	_	6	conj	_	_
9	is	be	VBZ	_	1	acl	_	_
10	feasible	feasible	JJ	_	9	dep	_	_
11	and	and	CC	_	9	cc	_	_
12	may	may	MD	_	13	modal	_	_
13	reduce	reduce	VB	_	9	conj	_	_
14	the	the	DT	_	15	det	_	_
15	morbidity	morbidity	NN	_	13	obj	_	_
16	from	from	IN	_	17	case	_	_
17	OIs	ois	NN	_	15	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	HIV-NHL	hiv-nhl	JJ	_	20	attr	_	_
20	patients	patient	NNS	_	15	ppmod	_	_
21	.	.	.	_	1	p	_	_

1	However	however	RB	_	7	adv	_	_
2	,	,	,	_	7	p	_	_
3	careful	careful	JJ	_	4	attr	_	_
4	attention	attention	NN	_	7	dep	_	_
5	must	must	MD	_	7	modal	_	_
6	be	be	VB	_	7	aux	_	_
7	directed	direct	VBN	_	0	root	_	_
8	to	to	TO	_	10	aux	_	_
9	cross	cross	NN	_	10	com	_	_
10	toxicity	toxicity	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	possible	possible	JJ	_	14	attr	_	_
13	pharmacokinetic	pharmacokinetic	JJ	_	14	attr	_	_
14	interactions	interaction	NNS	_	10	conj	_	_
15	between	between	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	.	.	.	_	7	p	_	_

1	The	the	DT	_	2	det	_	_
2	impact	impact	NN	_	13	dep	_	_
3	of	of	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	combined	combined	JJ	_	6	attr	_	_
6	chemotherapy	chemotherapy	NN	_	2	ppmod	_	_
7	plus	plus	CC	_	6	cc	_	_
8	HAART	haart	NN	_	9	com	_	_
9	treatment	treatment	NN	_	6	conj	_	_
10	on	on	IN	_	12	case	_	_
11	patient	patient	NN	_	12	com	_	_
12	survival	survival	NN	_	2	ppmod	_	_
13	needs	need	VBZ	_	0	root	_	_
14	urgently	urgently	RB	_	17	adv	_	_
15	to	to	TO	_	17	aux	_	_
16	be	be	VB	_	17	aux	_	_
17	evaluated	evaluate	VBN	_	13	comp	_	_
18	in	in	IN	_	20	case	_	_
19	prospective	prospective	JJ	_	20	attr	_	_
20	studies	study	NNS	_	17	ppmod	_	_
21	.	.	.	_	13	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	:	:	:	_	7	p	_	_
5	a	a	DT	_	7	det	_	_
6	drug	drug	NN	_	7	com	_	_
7	interaction	interaction	NN	_	0	root	_	_
8	.	.	.	_	7	p	_	_

1	The	the	DT	_	3	det	_	_
2	drug	drug	NN	_	3	com	_	_
3	interaction	interaction	NN	_	11	dep	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	is	be	VBZ	_	11	aux	_	_
9	not	not	RB	_	11	neg	_	_
10	well	well	RB	_	11	adv	_	_
11	known	know	VBN	_	0	root	_	_
12	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	has	have	VBZ	_	4	aux	_	_
3	been	be	VBN	_	4	aux	_	_
4	reported	report	VBN	_	0	root	_	_
5	to	to	TO	_	6	aux	_	_
6	increase	increase	VB	_	4	comp	_	_
7	the	the	DT	_	9	det	_	_
8	drug2	drug0	NN	_	9	com	_	_
9	requirements	requirement	NNS	_	6	obj	_	_
10	in	in	IN	_	12	case	_	_
11	human	human	JJ	_	12	attr	_	_
12	subjects	subject	NNS	_	9	ppmod	_	_
13	ingesting	ingest	VBG	_	12	acl	_	_
14	these	these	DT	_	15	det	_	_
15	agents	agent	NNS	_	13	obj	_	_
16	simultaneously	simultaneously	RB	_	6	adv	_	_
17	.	.	.	_	4	p	_	_

1	The	the	DT	_	3	det	_	_
2	concomitant	concomitant	JJ	_	3	attr	_	_
3	administration	administration	NN	_	8	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	resulted	result	VBD	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	need	need	NN	_	8	ppmod	_	_
12	for	for	IN	_	17	case	_	_
13	an	an	DT	_	17	det	_	_
14	unusually	unusually	RB	_	15	adv	_	_
15	high	high	JJ	_	17	attr	_	_
16	maintenance	maintenance	NN	_	17	com	_	_
17	dose	dose	NN	_	11	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	drug3	drug0	NN	_	17	ppmod	_	_
20	(	-lrb-	-LRB-	_	22	p	_	_
21	20	0	CD	_	22	num	_	_
22	mg	mg	NN	_	17	prn	_	_
23	per	per	IN	_	24	case	_	_
24	day	day	NN	_	22	ppmod	_	_
25	)	-rrb-	-RRB-	_	22	p	_	_
26	in	in	IN	_	29	mark	_	_
27	order	order	NN	_	29	dep	_	_
28	to	to	TO	_	29	aux	_	_
29	produce	produce	VB	_	8	comp	_	_
30	a	a	DT	_	32	det	_	_
31	therapeutic	therapeutic	JJ	_	32	attr	_	_
32	effect	effect	NN	_	29	obj	_	_
33	.	.	.	_	8	p	_	_

1	Withdrawal	withdrawal	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	decreased	decrease	VBD	_	0	root	_	_
5	the	the	DT	_	7	det	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	requirement	requirement	NN	_	4	obj	_	_
8	by	by	IN	_	9	case	_	_
9	50	0	CD	_	4	ppmod	_	_
10	%	%	NN	_	9	meta	_	_
11	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	effect	effect	NN	_	5	dep	_	_
3	may	may	MD	_	5	modal	_	_
4	be	be	VB	_	5	aux	_	_
5	mediated	mediate	VBN	_	0	root	_	_
6	by	by	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	ability	ability	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	to	to	TO	_	12	aux	_	_
12	induce	induce	VB	_	8	acl	_	_
13	microsomal	microsomal	JJ	_	14	attr	_	_
14	enzymes	enzyme	NNS	_	12	obj	_	_
15	and	and	CC	_	5	cc	_	_
16	,	,	,	_	5	p	_	_
17	thus	thus	RB	_	5	adv	_	_
18	,	,	,	_	5	p	_	_
19	the	the	DT	_	20	det	_	_
20	catabolism	catabolism	NN	_	5	conj	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	12	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	on	on	IN	_	8	case	_	_
6	the	the	DT	_	8	det	_	_
7	drug2	drug0	JJ	_	8	attr	_	_
8	requirement	requirement	NN	_	2	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	our	our	PRP$	_	11	poss	_	_
11	patient	patient	NN	_	8	ppmod	_	_
12	appeared	appear	VBD	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	be	be	VB	_	12	comp	_	_
15	maximal	maximal	JJ	_	14	dep	_	_
16	5	0	CD	_	19	num	_	_
17	to	to	TO	_	16	cc	_	_
18	7	0	CD	_	16	conj	_	_
19	days	day	NNS	_	22	dat	_	_
20	after	after	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	initiation	initiation	NN	_	15	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	drug3	drug0	NN	_	22	ppmod	_	_
25	and	and	CC	_	12	cc	_	_
26	extended	extend	VBD	_	12	conj	_	_
27	a	a	DT	_	29	det	_	_
28	similar	similar	JJ	_	29	attr	_	_
29	length	length	NN	_	26	obj	_	_
30	of	of	IN	_	31	case	_	_
31	time	time	NN	_	29	ppmod	_	_
32	after	after	IN	_	34	case	_	_
33	drug4	drug0	NN	_	34	com	_	_
34	withdrawal	withdrawal	NN	_	26	ppmod	_	_
35	.	.	.	_	12	p	_	_

1	This	this	DT	_	2	det	_	_
2	interaction	interaction	NN	_	3	dep	_	_
3	appears	appear	VBZ	_	0	root	_	_
4	to	to	TO	_	5	aux	_	_
5	be	be	VB	_	3	comp	_	_
6	clinically	clinically	RB	_	7	adv	_	_
7	significant	significant	JJ	_	5	dep	_	_
8	.	.	.	_	3	p	_	_

1	Increased	increase	VBN	_	0	root	_	_
2	stability	stability	NN	_	1	obj	_	_
3	of	of	IN	_	4	case	_	_
4	nucleophosmin/B23	nucleophosmin/b0	NN	_	2	ppmod	_	_
5	in	in	IN	_	7	case	_	_
6	anti-apoptotic	anti-apoptotic	JJ	_	7	attr	_	_
7	effect	effect	NN	_	1	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	ras	ras	NN	_	7	ppmod	_	_
10	during	during	IN	_	12	case	_	_
11	serum	serum	NN	_	12	com	_	_
12	deprivation	deprivation	NN	_	7	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	obtained	obtain	VBD	_	0	root	_	_
3	evidence	evidence	NN	_	2	obj	_	_
4	that	that	IN	_	10	mark	_	_
5	increased	increase	VBN	_	6	attr	_	_
6	stability	stability	NN	_	10	dep	_	_
7	of	of	IN	_	8	case	_	_
8	nucleophosmin/B23	nucleophosmin/b0	NN	_	6	ppmod	_	_
9	is	be	VBZ	_	10	aux	_	_
10	involved	involve	VBN	_	3	acl	_	_
11	in	in	IN	_	13	case	_	_
12	antiapoptotic	antiapoptotic	JJ	_	13	attr	_	_
13	effect	effect	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	ras	ras	NN	_	13	ppmod	_	_
16	during	during	IN	_	18	case	_	_
17	serum	serum	NN	_	18	com	_	_
18	deprivation	deprivation	NN	_	13	ppmod	_	_
19	.	.	.	_	2	p	_	_

1	Nucleophosmin/B23	nucleophosmin/b0	NN	_	12	dep	_	_
2	in	in	IN	_	10	case	_	_
3	serum-deprived	serum-deprived	JJ	_	10	attr	_	_
4	(	-lrb-	-LRB-	_	7	p	_	_
5	0	0	CD	_	7	num	_	_
6	%	%	NN	_	5	meta	_	_
7	serum	serum	NN	_	3	prn	_	_
8	)	-rrb-	-RRB-	_	7	p	_	_
9	NIH-3T3	nih-0t0	NN	_	10	com	_	_
10	cells	cell	NNS	_	1	ppmod	_	_
11	was	be	VBD	_	12	aux	_	_
12	found	find	VBN	_	0	root	_	_
13	to	to	TO	_	14	aux	_	_
14	be	be	VB	_	12	comp	_	_
15	highly	highly	RB	_	16	adv	_	_
16	unstable	unstable	JJ	_	14	dep	_	_
17	with	with	IN	_	19	case	_	_
18	a	a	DT	_	19	det	_	_
19	half-life	half-life	NN	_	16	ppmod	_	_
20	less	less	JJR	_	19	attr	_	_
21	than	than	IN	_	23	case	_	_
22	4	0	CD	_	23	num	_	_
23	h	h	NN	_	20	ppmod	_	_
24	.	.	.	_	12	p	_	_

1	In	in	IN	_	2	case	_	_
2	contrast	contrast	NN	_	12	ppmod	_	_
3	,	,	,	_	12	p	_	_
4	nucleophosmin/B23	nucleophosmin/b0	NN	_	12	dep	_	_
5	in	in	IN	_	11	case	_	_
6	serum-deprived	serum-deprived	JJ	_	11	attr	_	_
7	ras-transformed	ras-transformed	JJ	_	11	attr	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	RAS-3T3	ras-0t0	NN	_	11	attr	_	_
10	)	-rrb-	-RRB-	_	11	p	_	_
11	cells	cell	NNS	_	4	ppmod	_	_
12	was	be	VBD	_	0	root	_	_
13	as	as	RB	_	14	adv	_	_
14	stable	stable	JJ	_	12	dep	_	_
15	as	as	IN	_	16	case	_	_
16	that	that	DT	_	14	ppmod	_	_
17	in	in	IN	_	19	case	_	_
18	serum-supplemented	serum-supplemented	JJ	_	19	attr	_	_
19	NIH-3T3	nih-0t0	NN	_	16	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	RAS-3T3	ras-0t0	NN	_	22	com	_	_
22	cells	cell	NNS	_	19	conj	_	_
23	.	.	.	_	12	p	_	_

1	Treatment	treatment	NN	_	10	dep	_	_
2	of	of	IN	_	4	case	_	_
3	RAS-3T3	ras-0t0	NN	_	4	com	_	_
4	cells	cell	NNS	_	1	ppmod	_	_
5	with	with	IN	_	8	case	_	_
6	nucleophosmin/B23	nucleophosmin/b0	NN	_	8	attr	_	_
7	antisense	antisense	JJ	_	8	attr	_	_
8	oligomer	oligomer	NN	_	1	ppmod	_	_
9	significantly	significantly	RB	_	10	adv	_	_
10	potentiated	potentiate	VBD	_	0	root	_	_
11	the	the	DT	_	12	det	_	_
12	apoptosis	apoptosis	NN	_	10	obj	_	_
13	induced	induce	VBN	_	12	acl	_	_
14	by	by	IN	_	16	case	_	_
15	serum	serum	NN	_	16	com	_	_
16	deprivation	deprivation	NN	_	13	ppmod	_	_
17	.	.	.	_	10	p	_	_

1	Much	much	RB	_	2	adv	_	_
2	less	less	JJR	_	4	attr	_	_
3	caspase-3	caspase-0	NN	_	4	com	_	_
4	activity	activity	NN	_	6	dep	_	_
5	was	be	VBD	_	6	aux	_	_
6	noted	note	VBN	_	0	root	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	lysate	lysate	NN	_	6	ppmod	_	_
10	derived	derive	VBN	_	9	acl	_	_
11	from	from	IN	_	14	case	_	_
12	serum-deprived	serum-deprived	JJ	_	14	attr	_	_
13	RAS-3T3	ras-0t0	NN	_	14	com	_	_
14	cells	cell	NNS	_	10	ppmod	_	_
15	compared	compare	VBN	_	17	adv	_	_
16	with	with	IN	_	17	case	_	_
17	that	that	DT	_	6	ppmod	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	lysate	lysate	NN	_	17	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	serum-deprived	serum-deprived	JJ	_	24	attr	_	_
23	NIH-3T3	nih-0t0	NN	_	24	com	_	_
24	cells	cell	NNS	_	20	ppmod	_	_
25	.	.	.	_	6	p	_	_

1	Cell	cell	NN	_	4	attr	_	_
2	permeable	permeable	JJ	_	4	attr	_	_
3	caspase-3	caspase-0	NN	_	4	com	_	_
4	inhibitor	inhibitor	NN	_	9	dep	_	_
5	added	add	VBN	_	4	acl	_	_
6	in	in	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	medium	medium	NN	_	5	ppmod	_	_
9	blocked	block	VBD	_	0	root	_	_
10	the	the	DT	_	11	det	_	_
11	decrease	decrease	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	nucleophosmin/B23	nucleophosmin/b0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	apoptosis	apoptosis	NN	_	13	conj	_	_
16	induced	induce	VBN	_	13	acl	_	_
17	by	by	IN	_	19	case	_	_
18	serum	serum	NN	_	19	com	_	_
19	deprivation	deprivation	NN	_	16	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	NIH-3T3	nih-0t0	NN	_	22	com	_	_
22	cells	cell	NNS	_	19	ppmod	_	_
23	.	.	.	_	9	p	_	_

1	The	the	DT	_	2	det	_	_
2	inhibitor	inhibitor	NN	_	9	dep	_	_
3	,	,	,	_	9	p	_	_
4	on	on	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	other	other	JJ	_	7	attr	_	_
7	hand	hand	NN	_	9	ppmod	_	_
8	,	,	,	_	9	p	_	_
9	promoted	promote	VBD	_	0	root	_	_
10	significant	significant	JJ	_	11	attr	_	_
11	decrease	decrease	NN	_	9	obj	_	_
12	of	of	IN	_	13	case	_	_
13	nucleolin/C23	nucleolin/c0	NN	_	11	ppmod	_	_
14	in	in	IN	_	16	case	_	_
15	NIH-3T3	nih-0t0	NN	_	16	com	_	_
16	cells	cell	NNS	_	11	ppmod	_	_
17	during	during	IN	_	19	case	_	_
18	serum	serum	NN	_	19	com	_	_
19	deprivation	deprivation	NN	_	9	ppmod	_	_
20	.	.	.	_	9	p	_	_

1	Unlike	unlike	IN	_	2	case	_	_
2	nucleolin/C23	nucleolin/c0	NN	_	7	ppmod	_	_
3	,	,	,	_	7	p	_	_
4	down-regulation	down-regulation	NN	_	7	dep	_	_
5	of	of	IN	_	6	case	_	_
6	nucleophosmin/B23	nucleophosmin/b0	NN	_	4	ppmod	_	_
7	was	be	VBD	_	0	root	_	_
8	thus	thus	RB	_	7	adv	_	_
9	not	not	RB	_	7	neg	_	_
10	proliferation-dependent	proliferation-dependent	JJ	_	7	dep	_	_
11	but	but	CC	_	10	cc	_	_
12	caspase-3-	caspase-0-	JJ	_	10	conj	_	_
13	and	and	CC	_	12	cc	_	_
14	apoptosis-dependent	apoptosis-dependent	JJ	_	12	conj	_	_
15	.	.	.	_	7	p	_	_

1	Our	our	PRP$	_	2	poss	_	_
2	results	result	NNS	_	3	dep	_	_
3	indicate	indicate	VBP	_	0	root	_	_
4	important	important	JJ	_	5	attr	_	_
5	relationships	relationship	NNS	_	3	obj	_	_
6	among	among	IN	_	7	case	_	_
7	ras	ras	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	nucleophosmin/B23	nucleophosmin/b0	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	activation	activation	NN	_	7	conj	_	_
12	of	of	IN	_	13	case	_	_
13	caspase-3	caspase-0	NN	_	11	ppmod	_	_
14	,	,	,	_	11	p	_	_
15	and	and	CC	_	11	cc	_	_
16	induction	induction	NN	_	7	conj	_	_
17	of	of	IN	_	18	case	_	_
18	apoptosis	apoptosis	NN	_	16	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	mammalian	mammalian	JJ	_	4	attr	_	_
4	target	target	NN	_	9	dep	_	_
5	of	of	IN	_	7	case	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	inhibitor	inhibitor	NN	_	4	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	prevent	prevent	VB	_	1	acl	_	_
10	kidney	kidney	NN	_	11	com	_	_
11	rejection	rejection	NN	_	9	obj	_	_
12	.	.	.	_	1	p	_	_

1	Current	current	JJ	_	3	attr	_	_
2	immunosuppressive	immunosuppressive	JJ	_	3	attr	_	_
3	therapies	therapy	NNS	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	effective	effective	JJ	_	4	dep	_	_
6	but	but	CC	_	4	cc	_	_
7	can	can	MD	_	9	modal	_	_
8	be	be	VB	_	9	aux	_	_
9	associated	associate	VBN	_	4	conj	_	_
10	with	with	IN	_	13	case	_	_
11	significant	significant	JJ	_	13	attr	_	_
12	adverse	adverse	JJ	_	13	attr	_	_
13	reactions	reaction	NNS	_	9	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	works	work	VBZ	_	0	root	_	_
3	differently	differently	RB	_	2	adv	_	_
4	from	from	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	drug2	drug0	NNS	_	2	ppmod	_	_
7	currently	currently	RB	_	8	adv	_	_
8	available	available	JJ	_	6	attr	_	_
9	,	,	,	_	2	p	_	_
10	and	and	CC	_	2	cc	_	_
11	except	except	IN	_	15	case	_	_
12	for	for	IN	_	15	case	_	_
13	increased	increase	VBN	_	15	attr	_	_
14	lipid	lipid	NN	_	15	com	_	_
15	levels	level	NNS	_	25	ppmod	_	_
16	,	,	,	_	25	p	_	_
17	the	the	DT	_	20	det	_	_
18	adverse	adverse	JJ	_	20	attr	_	_
19	reaction	reaction	NN	_	20	com	_	_
20	profile	profile	NN	_	25	dep	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	does	do	VBZ	_	25	aux	_	_
24	not	not	RB	_	25	neg	_	_
25	appear	appear	VB	_	2	conj	_	_
26	to	to	TO	_	27	aux	_	_
27	overlap	overlap	VB	_	25	comp	_	_
28	to	to	TO	_	31	aux	_	_
29	any	any	DT	_	31	det	_	_
30	great	great	JJ	_	31	attr	_	_
31	extent	extent	NN	_	27	ppmod	_	_
32	with	with	IN	_	33	case	_	_
33	that	that	DT	_	27	ppmod	_	_
34	associated	associate	VBN	_	33	acl	_	_
35	with	with	IN	_	36	case	_	_
36	drug4	drug0	NN	_	34	ppmod	_	_
37	or	or	CC	_	36	cc	_	_
38	drug5	drug0	NN	_	36	conj	_	_
39	.	.	.	_	2	p	_	_

1	While	while	IN	_	5	mark	_	_
2	additional	additional	JJ	_	3	attr	_	_
3	research	research	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	needed	need	VBN	_	14	advcl	_	_
6	,	,	,	_	14	p	_	_
7	the	the	DT	_	10	det	_	_
8	initial	initial	JJ	_	10	attr	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	data	datum	NNS	_	14	dep	_	_
11	in	in	IN	_	13	case	_	_
12	kidney	kidney	NN	_	13	com	_	_
13	recipients	recipient	NNS	_	10	ppmod	_	_
14	suggest	suggest	VBP	_	0	root	_	_
15	that	that	IN	_	26	mark	_	_
16	drug1	drug0	NN	_	26	dep	_	_
17	,	,	,	_	26	p	_	_
18	in	in	IN	_	19	case	_	_
19	combination	combination	NN	_	26	ppmod	_	_
20	with	with	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	or	or	CC	_	21	cc	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	,	,	,	_	26	p	_	_
25	might	might	MD	_	26	modal	_	_
26	have	have	VB	_	14	comp	_	_
27	the	the	DT	_	28	det	_	_
28	potential	potential	NN	_	26	obj	_	_
29	to	to	TO	_	30	aux	_	_
30	reduce	reduce	VB	_	28	acl	_	_
31	the	the	DT	_	32	det	_	_
32	frequency	frequency	NN	_	30	obj	_	_
33	of	of	IN	_	35	case	_	_
34	rejection	rejection	NN	_	35	com	_	_
35	episodes	episode	NNS	_	32	ppmod	_	_
36	,	,	,	_	30	p	_	_
37	permit	permit	VB	_	30	conj	_	_
38	reductions	reduction	NNS	_	37	obj	_	_
39	in	in	IN	_	40	case	_	_
40	drug4	drug0	NN	_	38	ppmod	_	_
41	or	or	CC	_	40	cc	_	_
42	drug5	drug0	NN	_	43	com	_	_
43	dosage	dosage	NN	_	40	conj	_	_
44	,	,	,	_	37	p	_	_
45	and	and	CC	_	37	cc	_	_
46	permit	permit	VB	_	30	conj	_	_
47	steroid	steroid	NN	_	48	com	_	_
48	withdrawal	withdrawal	NN	_	46	obj	_	_
49	(	-lrb-	-LRB-	_	50	p	_	_
50	Kelly	kelly	NNP	_	26	prn	_	_
51	,	,	,	_	50	p	_	_
52	1999	0	CD	_	50	appo	_	_
53	)	-rrb-	-RRB-	_	50	p	_	_
54	.	.	.	_	14	p	_	_

1	Development	development	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	pharmacology	pharmacology	NN	_	1	conj	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	the	the	DT	_	5	det	_	_
4	first	#ord#	JJ	_	5	attr	_	_
5	drug2	drug0	NN	_	2	obj	_	_
6	to	to	TO	_	7	aux	_	_
7	be	be	VB	_	5	acl	_	_
8	approved	approved	JJ	_	7	dep	_	_
9	for	for	IN	_	11	case	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	use	use	NN	_	8	ppmod	_	_
12	,	,	,	_	2	p	_	_
13	and	and	CC	_	2	cc	_	_
14	has	have	VBZ	_	16	aux	_	_
15	been	be	VBN	_	16	aux	_	_
16	studied	study	VBN	_	2	conj	_	_
17	extensively	extensively	RB	_	16	adv	_	_
18	in	in	IN	_	19	case	_	_
19	humans	human	NNS	_	16	ppmod	_	_
20	since	since	IN	_	21	case	_	_
21	1986	0	CD	_	19	ppmod	_	_
22	.	.	.	_	2	p	_	_

1	It	it	PRP	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	structurally	structurally	RB	_	4	adv	_	_
4	distinct	distinct	JJ	_	2	dep	_	_
5	from	from	IN	_	10	case	_	_
6	the	the	DT	_	10	det	_	_
7	other	other	JJ	_	10	attr	_	_
8	currently	currently	RB	_	9	adv	_	_
9	available	available	JJ	_	10	attr	_	_
10	drug1	drug0	NN	_	4	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	drug2	drug0	NN	_	10	prn	_	_
13	,	,	,	_	12	p	_	_
14	drug3	drug0	NN	_	12	conj	_	_
15	,	,	,	_	14	p	_	_
16	and	and	CC	_	14	cc	_	_
17	drug4	drug0	NN	_	12	conj	_	_
18	)	-rrb-	-RRB-	_	12	p	_	_
19	,	,	,	_	2	p	_	_
20	leading	lead	VBG	_	2	comp	_	_
21	to	to	TO	_	24	aux	_	_
22	unique	unique	JJ	_	24	attr	_	_
23	biopharmaceutical	biopharmaceutical	JJ	_	24	attr	_	_
24	properties	property	NNS	_	20	ppmod	_	_
25	relative	relative	JJ	_	24	attr	_	_
26	to	to	TO	_	29	aux	_	_
27	the	the	DT	_	29	det	_	_
28	other	other	JJ	_	29	attr	_	_
29	agents	agent	NNS	_	25	ppmod	_	_
30	of	of	IN	_	32	case	_	_
31	this	this	DT	_	32	det	_	_
32	class	class	NN	_	29	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	Absorption	absorption	NN	_	4	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	is	be	VBZ	_	0	root	_	_
5	virtually	virtually	RB	_	6	adv	_	_
6	complete	complete	JJ	_	4	dep	_	_
7	across	across	IN	_	9	case	_	_
8	all	all	DT	_	9	det	_	_
9	species	species	NNS	_	6	ppmod	_	_
10	,	,	,	_	9	p	_	_
11	including	include	VBG	_	12	adv	_	_
12	man	man	NN	_	9	ppmod	_	_
13	,	,	,	_	9	p	_	_
14	and	and	CC	_	4	cc	_	_
15	is	be	VBZ	_	17	aux	_	_
16	not	not	RB	_	17	neg	_	_
17	affected	affect	VBN	_	4	conj	_	_
18	by	by	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	presence	presence	NN	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	food	food	NN	_	20	ppmod	_	_
23	.	.	.	_	4	p	_	_

1	Systemic	systemic	JJ	_	2	attr	_	_
2	exposure	exposure	NN	_	3	dep	_	_
3	is	be	VBZ	_	0	root	_	_
4	limited	limited	JJ	_	3	dep	_	_
5	,	,	,	_	3	p	_	_
6	as	as	IN	_	8	mark	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	is	be	VBZ	_	3	comp	_	_
9	subject	subject	JJ	_	8	dep	_	_
10	to	to	TO	_	12	aux	_	_
11	first-pass	first-pass	NN	_	12	com	_	_
12	metabolism	metabolism	NN	_	9	ppmod	_	_
13	,	,	,	_	8	p	_	_
14	and	and	CC	_	8	cc	_	_
15	the	the	DT	_	17	det	_	_
16	plasma	plasma	NN	_	17	com	_	_
17	half-life	half-life	NN	_	21	dep	_	_
18	of	of	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	drug	drug	NN	_	17	ppmod	_	_
21	is	be	VBZ	_	8	conj	_	_
22	approximately	approximately	RB	_	23	adv	_	_
23	30	0	CD	_	24	num	_	_
24	minutes	minute	NNS	_	21	obj	_	_
25	.	.	.	_	3	p	_	_

1	Some	some	DT	_	2	det	_	_
2	95	0	CD	_	11	num	_	_
3	%	%	NN	_	2	meta	_	_
4	of	of	IN	_	7	case	_	_
5	a	a	DT	_	7	det	_	_
6	single	single	JJ	_	7	attr	_	_
7	dosage	dosage	NN	_	2	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	is	be	VBZ	_	11	aux	_	_
11	excreted	excrete	VBN	_	0	root	_	_
12	via	via	IN	_	15	case	_	_
13	the	the	DT	_	15	det	_	_
14	biliary	biliary	JJ	_	15	attr	_	_
15	route	route	NN	_	11	ppmod	_	_
16	,	,	,	_	11	p	_	_
17	with	with	IN	_	24	case	_	_
18	less	less	JJR	_	20	attr	_	_
19	than	than	IN	_	18	com	_	_
20	2	0	CD	_	24	num	_	_
21	%	%	NN	_	20	meta	_	_
22	of	of	IN	_	23	case	_	_
23	this	this	DT	_	20	ppmod	_	_
24	being	be	VBG	_	11	ppmod	_	_
25	the	the	DT	_	27	det	_	_
26	parent	parent	NN	_	27	com	_	_
27	compound	compound	NN	_	24	obj	_	_
28	.	.	.	_	11	p	_	_

1	Additionally	additionally	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	no	no	DT	_	6	det	_	_
6	evidence	evidence	NN	_	4	obj	_	_
7	of	of	IN	_	10	case	_	_
8	circulating	circulating	JJ	_	10	attr	_	_
9	active	active	JJ	_	10	attr	_	_
10	metabolites	metabolite	NNS	_	6	ppmod	_	_
11	or	or	CC	_	10	cc	_	_
12	accumulation	accumulation	NN	_	10	conj	_	_
13	during	during	IN	_	15	case	_	_
14	chronic	chronic	JJ	_	15	attr	_	_
15	dosing	dosing	NN	_	12	ppmod	_	_
16	.	.	.	_	4	p	_	_

1	Studies	study	NNS	_	13	dep	_	_
2	of	of	IN	_	4	case	_	_
3	the	the	DT	_	4	det	_	_
4	effect	effect	NN	_	1	ppmod	_	_
5	of	of	IN	_	6	case	_	_
6	food	food	NN	_	4	ppmod	_	_
7	on	on	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	4	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	have	have	VBP	_	13	aux	_	_
13	demonstrated	demonstrate	VBN	_	0	root	_	_
14	marked	marked	JJ	_	15	attr	_	_
15	reductions	reduction	NNS	_	13	obj	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	rate	rate	NN	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	bioavailability--from	bioavailability--from	NN	_	18	ppmod	_	_
21	40	0	CD	_	20	num	_	_
22	%	%	NN	_	20	meta	_	_
23	to	to	TO	_	20	attr	_	_
24	60	0	CD	_	20	num	_	_
25	%	%	NN	_	20	meta	_	_
26	;	;	:	_	13	p	_	_

1	however	however	RB	_	16	adv	_	_
2	,	,	,	_	16	p	_	_
3	a	a	DT	_	4	det	_	_
4	comparison	comparison	NN	_	16	dep	_	_
5	of	of	IN	_	7	case	_	_
6	drug1	drug0	NN	_	7	com	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	with	with	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	evening	evening	NN	_	11	com	_	_
11	meal	meal	NN	_	4	ppmod	_	_
12	or	or	CC	_	11	cc	_	_
13	at	at	IN	_	14	case	_	_
14	bedtime	bedtime	NN	_	11	conj	_	_
15	has	have	VBZ	_	16	aux	_	_
16	revealed	reveal	VBN	_	0	root	_	_
17	no	no	DT	_	19	det	_	_
18	significant	significant	JJ	_	19	attr	_	_
19	differences	difference	NNS	_	16	obj	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	extent	extent	NN	_	19	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	bioavailability	bioavailability	NN	_	22	ppmod	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	area	area	NN	_	24	prn	_	_
27	under	under	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	curve	curve	NN	_	26	ppmod	_	_
30	)	-rrb-	-RRB-	_	26	p	_	_
31	of	of	IN	_	34	case	_	_
32	these	these	DT	_	34	det	_	_
33	two	#crd#	CD	_	34	num	_	_
34	regimens	regimen	NNS	_	24	ppmod	_	_
35	.	.	.	_	16	p	_	_

1	Furthermore	furthermore	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	no	no	DT	_	5	det	_	_
4	significant	significant	JJ	_	5	attr	_	_
5	difference	difference	NN	_	19	dep	_	_
6	in	in	IN	_	8	case	_	_
7	pharmacodynamic	pharmacodynamic	JJ	_	8	attr	_	_
8	effect	effect	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	reduction	reduction	NN	_	8	prn	_	_
11	in	in	IN	_	15	case	_	_
12	low-density	low-density	JJ	_	14	attr	_	_
13	lipoprotein	lipoprotein	NN	_	14	com	_	_
14	cholesterol	cholesterol	NN	_	15	com	_	_
15	levels	level	NNS	_	10	ppmod	_	_
16	)	-rrb-	-RRB-	_	10	p	_	_
17	could	could	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	ascertained	ascertain	VBN	_	0	root	_	_
20	between	between	IN	_	22	case	_	_
21	mealtime	mealtime	NN	_	22	com	_	_
22	dosing	dosing	NN	_	19	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	bedtime	bedtime	NN	_	25	com	_	_
25	dosing	dosing	NN	_	22	conj	_	_
26	.	.	.	_	19	p	_	_

1	The	the	DT	_	2	det	_	_
2	pharmacokinetics	pharmacokinetics	NNS	_	8	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	have	have	VBP	_	8	aux	_	_
6	also	also	RB	_	8	adv	_	_
7	been	be	VBN	_	8	aux	_	_
8	assessed	assess	VBN	_	0	root	_	_
9	in	in	IN	_	12	case	_	_
10	various	various	JJ	_	12	attr	_	_
11	demographic	demographic	JJ	_	12	attr	_	_
12	groups	group	NNS	_	8	ppmod	_	_
13	.	.	.	_	8	p	_	_

1	Relative	relative	JJ	_	5	adv	_	_
2	to	to	TO	_	5	aux	_	_
3	the	the	DT	_	5	det	_	_
4	general	general	JJ	_	5	attr	_	_
5	population	population	NN	_	13	ppmod	_	_
6	,	,	,	_	13	p	_	_
7	plasma	plasma	NN	_	8	com	_	_
8	concentrations	concentration	NNS	_	13	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	do	do	VBP	_	13	aux	_	_
12	not	not	RB	_	13	neg	_	_
13	vary	vary	VB	_	0	root	_	_
14	as	as	IN	_	16	case	_	_
15	a	a	DT	_	16	det	_	_
16	function	function	NN	_	13	ppmod	_	_
17	of	of	IN	_	19	case	_	_
18	either	either	CC	_	19	cc	_	_
19	age	age	NN	_	16	ppmod	_	_
20	or	or	CC	_	19	cc	_	_
21	gender	gender	NN	_	19	conj	_	_
22	.	.	.	_	13	p	_	_

1	In	in	IN	_	2	case	_	_
2	addition	addition	NN	_	12	ppmod	_	_
3	,	,	,	_	12	p	_	_
4	administration	administration	NN	_	12	dep	_	_
5	to	to	TO	_	8	aux	_	_
6	a	a	DT	_	8	det	_	_
7	patient	patient	NN	_	8	com	_	_
8	population	population	NN	_	4	ppmod	_	_
9	with	with	IN	_	11	case	_	_
10	hepatic	hepatic	JJ	_	11	attr	_	_
11	insufficiency	insufficiency	NN	_	4	ppmod	_	_
12	resulted	result	VBD	_	0	root	_	_
13	in	in	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	2.5-fold	0-fold	JJ	_	16	attr	_	_
16	increase	increase	NN	_	12	ppmod	_	_
17	in	in	IN	_	20	case	_	_
18	both	both	CC	_	20	cc	_	_
19	the	the	DT	_	20	det	_	_
20	rate	rate	NN	_	16	ppmod	_	_
21	and	and	CC	_	20	cc	_	_
22	extent	extent	NN	_	20	conj	_	_
23	of	of	IN	_	24	case	_	_
24	bioavailability	bioavailability	NN	_	20	ppmod	_	_
25	relative	relative	JJ	_	24	attr	_	_
26	to	to	TO	_	27	aux	_	_
27	controls	control	NNS	_	25	ppmod	_	_
28	.	.	.	_	12	p	_	_

1	Also	also	RB	_	34	adv	_	_
2	,	,	,	_	34	p	_	_
3	although	although	IN	_	15	mark	_	_
4	minimal	minimal	JJ	_	5	attr	_	_
5	alterations	alteration	NNS	_	15	dep	_	_
6	of	of	IN	_	8	case	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	clearance	clearance	NN	_	5	ppmod	_	_
9	in	in	IN	_	10	case	_	_
10	patients	patient	NNS	_	5	ppmod	_	_
11	with	with	IN	_	13	case	_	_
12	renal	renal	JJ	_	13	attr	_	_
13	insufficiency	insufficiency	NN	_	10	ppmod	_	_
14	are	be	VBP	_	15	aux	_	_
15	anticipated	anticipate	VBN	_	34	advcl	_	_
16	due	due	JJ	_	20	adv	_	_
17	to	to	TO	_	20	aux	_	_
18	limited	limited	JJ	_	20	attr	_	_
19	renal	renal	JJ	_	20	attr	_	_
20	excretion	excretion	NN	_	15	ppmod	_	_
21	(	-lrb-	-LRB-	_	22	p	_	_
22	5	0	CD	_	20	num	_	_
23	%	%	NN	_	22	meta	_	_
24	)	-rrb-	-RRB-	_	22	p	_	_
25	,	,	,	_	34	p	_	_
26	a	a	DT	_	27	det	_	_
27	study	study	NN	_	34	dep	_	_
28	in	in	IN	_	31	case	_	_
29	this	this	DT	_	31	det	_	_
30	patient	patient	NN	_	31	com	_	_
31	group	group	NN	_	27	ppmod	_	_
32	is	be	VBZ	_	34	aux	_	_
33	currently	currently	RB	_	34	adv	_	_
34	underway	underway	VBN	_	0	root	_	_
35	to	to	TO	_	36	aux	_	_
36	examine	examine	VB	_	34	comp	_	_
37	this	this	DT	_	38	det	_	_
38	further	far	JJ	_	36	obj	_	_
39	.	.	.	_	34	p	_	_

1	Interaction	interaction	NN	_	2	com	_	_
2	studies	study	NNS	_	5	dep	_	_
3	have	have	VBP	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	performed	performed	VBN	_	0	root	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	several	several	JJ	_	10	attr	_	_
10	drugs	drug	NNS	_	7	conj	_	_
11	with	with	IN	_	12	case	_	_
12	which	which	WDT	_	16	ppmod	_	_
13	it	it	PRP	_	16	dep	_	_
14	might	might	MD	_	16	modal	_	_
15	be	be	VB	_	16	aux	_	_
16	coadministered	coadministered	VBN	_	7	relcl	_	_
17	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	7	dep	_	_
2	,	,	,	_	1	p	_	_
3	an	an	DT	_	5	det	_	_
4	anionic-binding	anionic-binding	JJ	_	5	attr	_	_
5	resin	resin	NN	_	1	appo	_	_
6	,	,	,	_	1	p	_	_
7	has	have	VBZ	_	0	root	_	_
8	a	a	DT	_	10	det	_	_
9	considerable	considerable	JJ	_	10	attr	_	_
10	effect	effect	NN	_	7	obj	_	_
11	in	in	IN	_	12	case	_	_
12	lowering	lower	VBG	_	7	ppmod	_	_
13	the	the	DT	_	14	det	_	_
14	rate	rate	NN	_	12	obj	_	_
15	and	and	CC	_	14	cc	_	_
16	extent	extent	NN	_	14	conj	_	_
17	of	of	IN	_	19	case	_	_
18	drug2	drug0	NN	_	19	com	_	_
19	bioavailability	bioavailability	NN	_	14	ppmod	_	_
20	.	.	.	_	7	p	_	_

1	Although	although	IN	_	5	mark	_	_
2	this	this	DT	_	3	det	_	_
3	effect	effect	NN	_	5	dep	_	_
4	was	be	VBD	_	5	aux	_	_
5	noted	note	VBN	_	21	advcl	_	_
6	even	even	RB	_	7	com	_	_
7	when	when	WRB	_	10	adv	_	_
8	drug1	drug0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	given	give	VBN	_	5	comp	_	_
11	4	0	CD	_	12	num	_	_
12	hours	hour	NNS	_	13	advnp	_	_
13	prior	prior	RB	_	10	adv	_	_
14	to	to	TO	_	15	aux	_	_
15	drug2	drug0	NN	_	13	ppmod	_	_
16	,	,	,	_	21	p	_	_
17	this	this	DT	_	18	det	_	_
18	regimen	regimen	NN	_	21	dep	_	_
19	did	do	VBD	_	21	aux	_	_
20	not	not	RB	_	21	neg	_	_
21	result	result	VB	_	0	root	_	_
22	in	in	IN	_	24	case	_	_
23	diminished	diminish	VBN	_	24	attr	_	_
24	efficacy	efficacy	NN	_	21	ppmod	_	_
25	.	.	.	_	21	p	_	_

1	Further	far	RB	_	13	adv	_	_
2	,	,	,	_	13	p	_	_
3	no	no	DT	_	4	det	_	_
4	effects	effect	NNS	_	13	dep	_	_
5	on	on	IN	_	8	case	_	_
6	either	either	CC	_	8	cc	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	levels	level	NNS	_	4	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	prothrombin	prothrombin	NN	_	11	com	_	_
11	times	time	NNS	_	8	conj	_	_
12	were	be	VBD	_	13	aux	_	_
13	observed	observe	VBN	_	0	root	_	_
14	in	in	IN	_	16	case	_	_
15	a	a	DT	_	16	det	_	_
16	study	study	NN	_	13	ppmod	_	_
17	involving	involve	VBG	_	16	acl	_	_
18	concomitant	concomitant	JJ	_	19	attr	_	_
19	administration	administration	NN	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	drug3	drug0	NN	_	21	conj	_	_
24	.	.	.	_	13	p	_	_

1	Moreover	moreover	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	additional	additional	JJ	_	5	attr	_	_
4	interaction	interaction	NN	_	5	com	_	_
5	studies	study	NNS	_	12	dep	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	have	have	VBP	_	12	aux	_	_
11	not	not	RB	_	12	neg	_	_
12	demonstrated	demonstrate	VBN	_	0	root	_	_
13	any	any	DT	_	14	det	_	_
14	effect	effect	NN	_	12	obj	_	_
15	on	on	IN	_	18	case	_	_
16	drug3	drug0	NN	_	18	com	_	_
17	plasma	plasma	NN	_	18	com	_	_
18	levels	level	NNS	_	14	ppmod	_	_
19	,	,	,	_	12	p	_	_
20	and	and	CC	_	12	cc	_	_
21	administration	administration	NN	_	29	dep	_	_
22	to	to	TO	_	25	aux	_	_
23	a	a	DT	_	25	det	_	_
24	patient	patient	NN	_	25	com	_	_
25	population	population	NN	_	21	ppmod	_	_
26	chronically	chronically	RB	_	27	adv	_	_
27	receiving	receive	VBG	_	25	acl	_	_
28	drug4	drug0	NN	_	27	obj	_	_
29	resulted	result	VBD	_	12	conj	_	_
30	in	in	IN	_	32	case	_	_
31	no	no	DT	_	32	det	_	_
32	difference	difference	NN	_	29	ppmod	_	_
33	in	in	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	extent	extent	NN	_	32	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	bioavailability	bioavailability	NN	_	35	ppmod	_	_
38	of	of	IN	_	39	case	_	_
39	drug5	drug0	NN	_	37	ppmod	_	_
40	relative	relative	JJ	_	39	attr	_	_
41	to	to	TO	_	43	aux	_	_
42	control	control	JJ	_	43	attr	_	_
43	data	datum	NNS	_	40	ppmod	_	_
44	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	results	result	NNS	_	13	dep	_	_
3	generated	generate	VBN	_	2	acl	_	_
4	to	to	TO	_	5	aux	_	_
5	date	date	NN	_	3	ppmod	_	_
6	in	in	IN	_	9	case	_	_
7	clinical	clinical	JJ	_	9	attr	_	_
8	pharmacokinetic	pharmacokinetic	JJ	_	9	attr	_	_
9	studies	study	NNS	_	3	ppmod	_	_
10	with	with	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	thus	thus	RB	_	13	adv	_	_
13	support	support	VBP	_	0	root	_	_
14	its	its	PRP$	_	15	poss	_	_
15	use	use	NN	_	13	obj	_	_
16	in	in	IN	_	19	case	_	_
17	a	a	DT	_	19	det	_	_
18	broad	broad	JJ	_	19	attr	_	_
19	population	population	NN	_	15	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	hypercholesterolaemic	hypercholesterolaemic	JJ	_	22	attr	_	_
22	patients	patient	NNS	_	19	ppmod	_	_
23	.	.	.	_	13	p	_	_

1	Molecular	molecular	JJ	_	2	attr	_	_
2	basis	basis	NN	_	0	root	_	_
3	for	for	IN	_	6	case	_	_
4	the	the	DT	_	6	det	_	_
5	selective	selective	JJ	_	6	attr	_	_
6	toxicity	toxicity	NN	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	for	for	IN	_	10	case	_	_
10	yeast	yeast	NN	_	2	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	for	for	IN	_	15	case	_	_
14	animal	animal	NN	_	15	com	_	_
15	cells	cell	NNS	_	2	ppmod	_	_
16	.	.	.	_	2	p	_	_

1	Among	among	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	drug1	drug0	NN	_	12	ppmod	_	_
4	,	,	,	_	12	p	_	_
5	many	many	JJ	_	12	dep	_	_
6	,	,	,	_	12	p	_	_
7	like	like	IN	_	8	case	_	_
8	drug2	drug0	NN	_	12	ppmod	_	_
9	,	,	,	_	12	p	_	_
10	cannot	cannot	NN	_	12	dep	_	_
11	be	be	VB	_	12	aux	_	_
12	used	use	VBN	_	0	root	_	_
13	clinically	clinically	RB	_	12	adv	_	_
14	because	because	IN	_	16	mark	_	_
15	they	they	PRP	_	16	dep	_	_
16	are	be	VBP	_	12	comp	_	_
17	toxic	toxic	JJ	_	16	dep	_	_
18	;	;	:	_	12	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	,	,	,	_	5	p	_	_
3	however	however	RB	_	5	adv	_	_
4	,	,	,	_	5	p	_	_
5	is	be	VBZ	_	0	root	_	_
6	useful	useful	JJ	_	5	dep	_	_
7	in	in	IN	_	8	case	_	_
8	therapy	therapy	NN	_	6	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	human	human	JJ	_	12	attr	_	_
11	fungal	fungal	JJ	_	12	attr	_	_
12	infections	infection	NNS	_	8	ppmod	_	_
13	because	because	IN	_	15	mark	_	_
14	it	it	PRP	_	15	dep	_	_
15	is	be	VBZ	_	5	comp	_	_
16	less	less	RBR	_	17	adv	_	_
17	toxic	toxic	JJ	_	15	dep	_	_
18	.	.	.	_	5	p	_	_

1	Both	both	CC	_	3	cc	_	_
2	the	the	DT	_	3	det	_	_
3	toxicity	toxicity	NN	_	14	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	and	and	CC	_	3	cc	_	_
7	the	the	DT	_	9	det	_	_
8	therapeutic	therapeutic	JJ	_	9	attr	_	_
9	value	value	NN	_	3	conj	_	_
10	of	of	IN	_	11	case	_	_
11	drug2	drug0	NN	_	9	ppmod	_	_
12	can	can	MD	_	14	modal	_	_
13	be	be	VB	_	14	aux	_	_
14	rationalized	rationalize	VBN	_	31	advcl	_	_
15	at	at	IN	_	20	case	_	_
16	the	the	DT	_	20	det	_	_
17	cellular	cellular	JJ	_	20	attr	_	_
18	and	and	CC	_	17	cc	_	_
19	molecular	molecular	JJ	_	17	conj	_	_
20	level	level	NN	_	14	ppmod	_	_
21	by	by	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	following	following	JJ	_	24	attr	_	_
24	observations	observation	NNS	_	14	ppmod	_	_
25	:	:	:	_	31	p	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	i	i	LS	_	31	meta	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	these	these	DT	_	30	det	_	_
30	drug3	drug0	NNS	_	31	dep	_	_
31	showed	show	VBD	_	0	root	_	_
32	differential	differential	JJ	_	33	attr	_	_
33	effects	effect	NNS	_	31	obj	_	_
34	on	on	IN	_	35	case	_	_
35	cells	cell	NNS	_	33	ppmod	_	_
36	;	;	:	_	31	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	more	more	RBR	_	4	adv	_	_
4	potent	potent	JJ	_	2	dep	_	_
5	in	in	IN	_	10	case	_	_
6	lysing	lysing	VBG	_	10	attr	_	_
7	human	human	JJ	_	10	attr	_	_
8	red	red	JJ	_	10	attr	_	_
9	blood	blood	NN	_	10	com	_	_
10	cells	cell	NNS	_	2	ppmod	_	_
11	,	,	,	_	2	p	_	_
12	whereas	whereas	IN	_	14	mark	_	_
13	drug2	drug0	NN	_	14	dep	_	_
14	was	be	VBD	_	2	comp	_	_
15	more	more	RBR	_	16	adv	_	_
16	potent	potent	JJ	_	14	dep	_	_
17	in	in	IN	_	18	case	_	_
18	inhibiting	inhibit	VBG	_	14	ppmod	_	_
19	yeast	yeast	NN	_	21	com	_	_
20	cell	cell	NN	_	21	com	_	_
21	growth	growth	NN	_	18	obj	_	_
22	;	;	:	_	2	p	_	_

1	and	and	CC	_	12	cc	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	ii	ii	LS	_	12	meta	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	the	the	DT	_	6	det	_	_
6	effects	effect	NNS	_	12	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	were	be	VBD	_	12	aux	_	_
10	more	more	RBR	_	11	com	_	_
11	efficiently	efficiently	RB	_	12	adv	_	_
12	inhibited	inhibit	VBN	_	33	advcl	_	_
13	by	by	IN	_	15	case	_	_
14	added	add	VBN	_	15	attr	_	_
15	cholesterol	cholesterol	NN	_	12	ppmod	_	_
16	,	,	,	_	15	p	_	_
17	the	the	DT	_	20	det	_	_
18	major	major	JJ	_	20	attr	_	_
19	membrane	membrane	NN	_	20	com	_	_
20	sterol	sterol	NN	_	15	appo	_	_
21	in	in	IN	_	23	case	_	_
22	human	human	JJ	_	23	attr	_	_
23	cells	cell	NNS	_	20	ppmod	_	_
24	,	,	,	_	33	p	_	_
25	whereas	whereas	IN	_	33	case	_	_
26	the	the	DT	_	27	det	_	_
27	effects	effect	NNS	_	33	dep	_	_
28	of	of	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	were	be	VBD	_	33	aux	_	_
31	more	more	RBR	_	32	com	_	_
32	efficiently	efficiently	RB	_	33	adv	_	_
33	inhibited	inhibit	VBN	_	0	root	_	_
34	by	by	IN	_	35	case	_	_
35	ergosterol	ergosterol	NN	_	33	ppmod	_	_
36	,	,	,	_	35	p	_	_
37	the	the	DT	_	40	det	_	_
38	major	major	JJ	_	40	attr	_	_
39	membrane	membrane	NN	_	40	com	_	_
40	sterol	sterol	NN	_	35	appo	_	_
41	in	in	IN	_	42	case	_	_
42	yeast	yeast	NN	_	40	ppmod	_	_
43	.	.	.	_	33	p	_	_

1	The	the	DT	_	3	det	_	_
2	simplest	simple	JJS	_	3	attr	_	_
3	inference	inference	NN	_	4	dep	_	_
4	is	be	VBZ	_	0	root	_	_
5	that	that	IN	_	13	mark	_	_
6	the	the	DT	_	7	det	_	_
7	toxicity	toxicity	NN	_	13	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	effectiveness	effectiveness	NN	_	7	conj	_	_
10	of	of	IN	_	11	case	_	_
11	polyenes	polyenes	NNS	_	7	ppmod	_	_
12	are	be	VBP	_	13	aux	_	_
13	determined	determine	VBN	_	4	comp	_	_
14	by	by	IN	_	17	case	_	_
15	their	their	PRP$	_	17	poss	_	_
16	relative	relative	JJ	_	17	attr	_	_
17	avidities	avidity	NNS	_	13	ppmod	_	_
18	for	for	IN	_	21	case	_	_
19	the	the	DT	_	21	det	_	_
20	predominant	predominant	JJ	_	21	attr	_	_
21	sterol	sterol	NN	_	17	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	cell	cell	NN	_	24	com	_	_
24	membranes	membrane	NNS	_	21	ppmod	_	_
25	.	.	.	_	4	p	_	_

1	-LSB-Hippocampus	-lsb-hippocampus	NNS	_	15	dep	_	_
2	as	as	IN	_	4	case	_	_
3	interaction	interaction	NN	_	4	com	_	_
4	sites	site	NNS	_	1	ppmod	_	_
5	between	between	IN	_	8	case	_	_
6	cerebral	cerebral	JJ	_	8	attr	_	_
7	memory	memory	NN	_	8	com	_	_
8	systems	system	NNS	_	1	ppmod	_	_
9	]	-rsb-	-RRB-	_	1	p	_	_
10	Most	most	JJ	_	14	adv	_	_
11	of	of	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	current	current	JJ	_	14	attr	_	_
14	theories	theory	NNS	_	1	ppmod	_	_
15	assume	assume	VB	_	0	root	_	_
16	that	that	IN	_	18	mark	_	_
17	there	there	EX	_	18	dep	_	_
18	are	be	VBP	_	15	comp	_	_
19	multiple	multiple	JJ	_	20	attr	_	_
20	forms	form	NNS	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	memory	memory	NN	_	20	ppmod	_	_
23	that	that	WDT	_	25	dep	_	_
24	are	be	VBP	_	25	aux	_	_
25	supported	support	VBN	_	20	relcl	_	_
26	by	by	IN	_	29	case	_	_
27	separate	separate	JJ	_	29	attr	_	_
28	brain	brain	NN	_	29	com	_	_
29	systems	system	NNS	_	25	ppmod	_	_
30	and	and	CC	_	25	cc	_	_
31	have	have	VBP	_	25	conj	_	_
32	different	different	JJ	_	33	attr	_	_
33	characteristics	characteristic	NNS	_	31	obj	_	_
34	.	.	.	_	15	p	_	_

1	Animals	animal	NNS	_	2	com	_	_
2	studies	study	NNS	_	10	dep	_	_
3	on	on	IN	_	7	case	_	_
4	the	the	DT	_	7	det	_	_
5	various	various	JJ	_	7	attr	_	_
6	dual-memory	dual-memory	NN	_	7	com	_	_
7	theories	theory	NNS	_	2	ppmod	_	_
8	have	have	VBP	_	10	aux	_	_
9	been	be	VBN	_	10	aux	_	_
10	carried	carry	VBN	_	0	root	_	_
11	out	out	RP	_	10	prt	_	_
12	mainly	mainly	RB	_	19	adv	_	_
13	on	on	IN	_	19	case	_	_
14	the	the	DT	_	19	det	_	_
15	basis	basis	NN	_	19	advnp	_	_
16	of	of	IN	_	19	case	_	_
17	hippocampal	hippocampal	JJ	_	19	attr	_	_
18	system	system	NN	_	19	com	_	_
19	function	function	NN	_	10	ppmod	_	_
20	.	.	.	_	10	p	_	_

1	Specifically	specifically	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	they	they	PRP	_	5	dep	_	_
4	have	have	VBP	_	5	aux	_	_
5	focused	focus	VBN	_	0	root	_	_
6	on	on	IN	_	7	case	_	_
7	aspects	aspect	NNS	_	5	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	learning	learning	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	memory	memory	NN	_	9	conj	_	_
12	that	that	WDT	_	13	dep	_	_
13	are	be	VBP	_	9	relcl	_	_
14	impaired	impaired	JJ	_	13	dep	_	_
15	(	-lrb-	-LRB-	_	14	p	_	_
16	vs.	vs.	CC	_	14	cc	_	_
17	spared	spare	VBN	_	14	conj	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	by	by	IN	_	20	case	_	_
20	lesions	lesion	NNS	_	13	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	hippocampal	hippocampal	JJ	_	24	attr	_	_
24	formation	formation	NN	_	20	ppmod	_	_
25	.	.	.	_	5	p	_	_

1	However	however	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	there	there	EX	_	4	dep	_	_
4	are	be	VBP	_	0	root	_	_
5	several	several	JJ	_	6	attr	_	_
6	instances	instance	NNS	_	4	obj	_	_
7	in	in	IN	_	10	case	_	_
8	the	the	DT	_	10	det	_	_
9	animal	animal	JJ	_	10	attr	_	_
10	literature	literature	NN	_	6	ppmod	_	_
11	showing	show	VBG	_	10	acl	_	_
12	that	that	IN	_	16	mark	_	_
13	hippocampal	hippocampal	JJ	_	14	attr	_	_
14	lesions	lesion	NNS	_	16	dep	_	_
15	actually	actually	RB	_	16	adv	_	_
16	produced	produce	VBD	_	11	comp	_	_
17	enhanced	enhance	VBN	_	21	attr	_	_
18	learning	learning	NN	_	21	attr	_	_
19	and	and	CC	_	18	cc	_	_
20	memory	memory	NN	_	18	conj	_	_
21	function	function	NN	_	16	obj	_	_
22	.	.	.	_	4	p	_	_

1	Moreover	moreover	RB	_	19	adv	_	_
2	,	,	,	_	19	p	_	_
3	the	the	DT	_	4	det	_	_
4	acquisition	acquisition	NN	_	19	dep	_	_
5	of	of	IN	_	6	case	_	_
6	tasks	task	NNS	_	4	ppmod	_	_
7	that	that	WDT	_	9	dep	_	_
8	are	be	VBP	_	9	aux	_	_
9	facilitated	facilitate	VBN	_	6	relcl	_	_
10	by	by	IN	_	12	case	_	_
11	hippocampal	hippocampal	JJ	_	12	attr	_	_
12	lesions	lesion	NNS	_	9	ppmod	_	_
13	(	-lrb-	-LRB-	_	15	p	_	_
14	or	or	CC	_	15	cc	_	_
15	dysfunction	dysfunction	NN	_	12	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	is	be	VBZ	_	19	aux	_	_
18	nevertheless	nevertheless	RB	_	19	adv	_	_
19	associated	associate	VBN	_	0	root	_	_
20	,	,	,	_	19	p	_	_
21	in	in	IN	_	23	case	_	_
22	intact	intact	JJ	_	23	attr	_	_
23	subjects	subject	NNS	_	19	ppmod	_	_
24	,	,	,	_	19	p	_	_
25	with	with	IN	_	28	case	_	_
26	specific	specific	JJ	_	28	attr	_	_
27	neurobiological	neurobiological	JJ	_	28	attr	_	_
28	alterations	alteration	NNS	_	19	ppmod	_	_
29	in	in	IN	_	31	case	_	_
30	the	the	DT	_	31	det	_	_
31	hippocampus	hippocampus	NN	_	28	ppmod	_	_
32	.	.	.	_	19	p	_	_

1	This	this	DT	_	2	det	_	_
2	problem	problem	NN	_	5	dep	_	_
3	has	have	VBZ	_	5	aux	_	_
4	been	be	VBN	_	5	aux	_	_
5	analysed	analyse	VBN	_	0	root	_	_
6	using	use	VBG	_	5	comp	_	_
7	two	#crd#	CD	_	9	num	_	_
8	different	different	JJ	_	9	attr	_	_
9	tasks	task	NNS	_	6	obj	_	_
10	in	in	IN	_	11	case	_	_
11	mice	mouse	NNS	_	9	ppmod	_	_
12	:	:	:	_	9	p	_	_
13	a	a	DT	_	15	det	_	_
14	bar-press	bar-press	JJ	_	15	attr	_	_
15	conditioning	conditioning	NN	_	9	appo	_	_
16	and	and	CC	_	15	cc	_	_
17	a	a	DT	_	20	det	_	_
18	spatial	spatial	JJ	_	20	attr	_	_
19	discrimination	discrimination	NN	_	20	com	_	_
20	task	task	NN	_	15	conj	_	_
21	.	.	.	_	5	p	_	_

1	Results	result	NNS	_	2	dep	_	_
2	showed	show	VBD	_	0	root	_	_
3	that	that	IN	_	15	mark	_	_
4	,	,	,	_	15	p	_	_
5	depending	depend	VBG	_	8	adv	_	_
6	on	on	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	task	task	NN	_	15	ppmod	_	_
9	considered	consider	VBN	_	8	acl	_	_
10	,	,	,	_	15	p	_	_
11	the	the	DT	_	14	det	_	_
12	same	same	JJ	_	14	attr	_	_
13	pharmacological	pharmacological	JJ	_	14	attr	_	_
14	treatment	treatment	NN	_	15	dep	_	_
15	produced	produce	VBD	_	2	comp	_	_
16	either	either	CC	_	18	cc	_	_
17	a	a	DT	_	18	det	_	_
18	facilitation	facilitation	NN	_	15	obj	_	_
19	or	or	CC	_	18	cc	_	_
20	an	an	DT	_	21	det	_	_
21	impairment	impairment	NN	_	18	conj	_	_
22	of	of	IN	_	23	case	_	_
23	acquisition	acquisition	NN	_	21	ppmod	_	_
24	.	.	.	_	2	p	_	_

1	Moreover	moreover	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	each	each	DT	_	4	det	_	_
4	task	task	NN	_	5	dep	_	_
5	induced	induce	VBD	_	0	root	_	_
6	significant	significant	JJ	_	7	attr	_	_
7	alterations	alteration	NNS	_	5	obj	_	_
8	in	in	IN	_	12	case	_	_
9	hippocampal	hippocampal	JJ	_	11	attr	_	_
10	adenylate	adenylate	NN	_	11	com	_	_
11	cyclase	cyclase	NN	_	12	com	_	_
12	activity	activity	NN	_	5	ppmod	_	_
13	but	but	CC	_	12	cc	_	_
14	in	in	IN	_	16	case	_	_
15	opposite	opposite	JJ	_	16	attr	_	_
16	directions	direction	NNS	_	12	conj	_	_
17	.	.	.	_	5	p	_	_

1	Together	together	RB	_	4	adv	_	_
2	with	with	IN	_	4	case	_	_
3	previous	previous	JJ	_	4	attr	_	_
4	findings	finding	NNS	_	8	ppmod	_	_
5	,	,	,	_	8	p	_	_
6	these	these	DT	_	7	det	_	_
7	results	result	NNS	_	8	dep	_	_
8	suggest	suggest	VBP	_	0	root	_	_
9	that	that	IN	_	13	mark	_	_
10	the	the	DT	_	11	det	_	_
11	hippocampus	hippocampus	NN	_	13	dep	_	_
12	is	be	VBZ	_	13	aux	_	_
13	involved	involve	VBN	_	8	comp	_	_
14	in	in	IN	_	20	case	_	_
15	both	both	CC	_	20	cc	_	_
16	the	the	DT	_	20	det	_	_
17	so-called	so-called	JJ	_	20	attr	_	_
18	&quot	&quot	NN	_	20	attr	_	_
19	;	;	:	_	20	p	_	_
20	hippocampal-dependent&quot	hippocampal-dependent&quot	NN	_	13	ppmod	_	_
21	;	;	:	_	8	p	_	_

1	&quot	&quot	NN	_	0	root	_	_
2	;	;	:	_	1	p	_	_
3	hippocampal-independent&quot	hippocampal-independent&quot	NN	_	1	appo	_	_
4	;	;	:	_	1	p	_	_

1	forms	form	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	memory	memory	NN	_	1	ppmod	_	_
4	.	.	.	_	1	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	postulated	postulate	VBN	_	0	root	_	_
4	that	that	IN	_	13	mark	_	_
5	some	some	DT	_	13	dep	_	_
6	of	of	IN	_	11	case	_	_
7	the	the	DT	_	11	det	_	_
8	observed	observe	VBN	_	11	attr	_	_
9	training-induced	training-induced	JJ	_	11	attr	_	_
10	neurobiological	neurobiological	JJ	_	11	attr	_	_
11	alterations	alteration	NNS	_	5	ppmod	_	_
12	might	might	MD	_	13	modal	_	_
13	reflect	reflect	VB	_	3	comp	_	_
14	the	the	DT	_	15	det	_	_
15	interaction	interaction	NN	_	13	obj	_	_
16	between	between	IN	_	24	case	_	_
17	two	#crd#	CD	_	24	num	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	or	or	CC	_	20	cc	_	_
20	more	more	JJR	_	24	prn	_	_
21	)	-rrb-	-RRB-	_	20	p	_	_
22	competing	compete	VBG	_	24	attr	_	_
23	memory	memory	NN	_	24	com	_	_
24	systems	system	NNS	_	15	ppmod	_	_
25	at	at	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	hippocampal	hippocampal	JJ	_	28	attr	_	_
28	level	level	NN	_	15	ppmod	_	_
29	.	.	.	_	3	p	_	_

1	Thus	thus	RB	_	21	adv	_	_
2	,	,	,	_	21	p	_	_
3	in	in	IN	_	11	case	_	_
4	addition	addition	NN	_	11	advnp	_	_
5	to	to	TO	_	11	aux	_	_
6	its	its	PRP$	_	11	poss	_	_
7	proposed	proposed	JJ	_	11	attr	_	_
8	specific	specific	JJ	_	11	attr	_	_
9	information	information	NN	_	11	com	_	_
10	processing	processing	NN	_	11	com	_	_
11	functions	function	NNS	_	21	ppmod	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	i.e.	i.e.	FW	_	15	adv	_	_
14	,	,	,	_	15	p	_	_
15	relational	relational	NN	_	11	prn	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	,	,	,	_	21	p	_	_
18	the	the	DT	_	19	det	_	_
19	hippocampus	hippocampus	NN	_	21	dep	_	_
20	would	would	MD	_	21	modal	_	_
21	play	play	VB	_	0	root	_	_
22	a	a	DT	_	23	det	_	_
23	role	role	NN	_	21	obj	_	_
24	in	in	IN	_	25	case	_	_
25	addressing	address	VBG	_	21	ppmod	_	_
26	information	information	NN	_	25	obj	_	_
27	to	to	TO	_	31	aux	_	_
28	the	the	DT	_	31	det	_	_
29	brain	brain	NN	_	31	com	_	_
30	memory	memory	NN	_	31	com	_	_
31	system	system	NN	_	26	ppmod	_	_
32	that	that	WDT	_	39	dep	_	_
33	,	,	,	_	39	p	_	_
34	in	in	IN	_	37	case	_	_
35	a	a	DT	_	37	det	_	_
36	given	given	JJ	_	37	attr	_	_
37	situation	situation	NN	_	39	ppmod	_	_
38	,	,	,	_	39	p	_	_
39	has	have	VBZ	_	31	relcl	_	_
40	the	the	DT	_	43	det	_	_
41	best	good	JJS	_	43	attr	_	_
42	adaptive	adaptive	JJ	_	43	attr	_	_
43	value.	value.	NN	_	39	obj	_	_
44	(	-lrb-	-LRB-	_	45	p	_	_
45	ABSTRACT	abstract	NN	_	43	prn	_	_
46	TRUNCATED	truncate	VBN	_	45	acl	_	_
47	AT	at	IN	_	49	case	_	_
48	250	0	CD	_	49	num	_	_
49	WORDS	word	NNS	_	46	ppmod	_	_
50	)	-rrb-	-RRB-	_	45	p	_	_

1	Behavioral	behavioral	JJ	_	2	attr	_	_
2	mechanisms	mechanism	NNS	_	3	dep	_	_
3	underlying	underlie	VBG	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	link	link	NN	_	3	obj	_	_
6	between	between	IN	_	7	case	_	_
7	smoking	smoking	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drinking	drinking	NN	_	7	conj	_	_
10	.	.	.	_	3	p	_	_

1	Many	many	JJ	_	2	attr	_	_
2	people	people	NN	_	3	dep	_	_
3	use	use	VBP	_	0	root	_	_
4	both	both	CC	_	5	cc	_	_
5	drug1	drug0	NN	_	3	obj	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	(	-lrb-	-LRB-	_	11	p	_	_
9	i.e.	i.e.	FW	_	11	ppmod	_	_
10	,	,	,	_	11	p	_	_
11	cigarettes	cigarette	NNS	_	3	prn	_	_
12	and	and	CC	_	11	cc	_	_
13	other	other	JJ	_	15	attr	_	_
14	tobacco	tobacco	NN	_	15	com	_	_
15	products	product	NNS	_	11	conj	_	_
16	)	-rrb-	-RRB-	_	11	p	_	_
17	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	behavioral	behavioral	JJ	_	3	attr	_	_
3	effects	effect	NNS	_	8	dep	_	_
4	of	of	IN	_	7	case	_	_
5	these	these	DT	_	7	det	_	_
6	two	#crd#	CD	_	7	num	_	_
7	drugs	drug	NNS	_	3	ppmod	_	_
8	differ	differ	VBP	_	0	root	_	_
9	,	,	,	_	8	p	_	_
10	and	and	CC	_	8	cc	_	_
11	they	they	PRP	_	14	dep	_	_
12	do	do	VBP	_	14	aux	_	_
13	not	not	RB	_	14	neg	_	_
14	act	act	VB	_	8	conj	_	_
15	on	on	IN	_	19	case	_	_
16	the	the	DT	_	19	det	_	_
17	same	same	JJ	_	19	attr	_	_
18	target	target	NN	_	19	com	_	_
19	sites	site	NNS	_	14	ppmod	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	brain	brain	NN	_	19	ppmod	_	_
23	,	,	,	_	14	p	_	_
24	although	although	IN	_	27	mark	_	_
25	they	they	PRP	_	27	dep	_	_
26	may	may	MD	_	27	modal	_	_
27	share	share	VB	_	14	comp	_	_
28	,	,	,	_	27	p	_	_
29	or	or	CC	_	27	cc	_	_
30	partly	partly	RB	_	31	adv	_	_
31	share	share	VBP	_	27	conj	_	_
32	,	,	,	_	34	p	_	_
33	certain	certain	JJ	_	34	attr	_	_
34	properties	property	NNS	_	31	obj	_	_
35	.	.	.	_	8	p	_	_

1	The	the	DT	_	2	det	_	_
2	initiation	initiation	NN	_	9	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	or	or	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	7	com	_	_
7	use	use	NN	_	4	conj	_	_
8	may	may	MD	_	9	modal	_	_
9	be	be	VB	_	0	root	_	_
10	precipitated	precipitated	JJ	_	9	dep	_	_
11	by	by	IN	_	14	case	_	_
12	similar	similar	JJ	_	14	attr	_	_
13	personality	personality	NN	_	14	com	_	_
14	characteristics	characteristic	NNS	_	10	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	user	user	NN	_	14	ppmod	_	_
18	,	,	,	_	14	p	_	_
19	such	such	JJ	_	21	adv	_	_
20	as	as	IN	_	21	case	_	_
21	impulsivity	impulsivity	NN	_	14	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	sensation	sensation	NN	_	24	com	_	_
24	seeking	seeking	NN	_	21	conj	_	_
25	.	.	.	_	9	p	_	_

1	Moreover	moreover	RB	_	11	adv	_	_
2	,	,	,	_	11	p	_	_
3	the	the	DT	_	4	det	_	_
4	mechanisms	mechanism	NNS	_	11	dep	_	_
5	underlying	underlie	VBG	_	4	acl	_	_
6	the	the	DT	_	7	det	_	_
7	development	development	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	dependence	dependence	NN	_	7	ppmod	_	_
10	may	may	MD	_	11	modal	_	_
11	be	be	VB	_	0	root	_	_
12	similar	similar	JJ	_	11	dep	_	_
13	for	for	IN	_	14	case	_	_
14	drug1	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	drug2	drug0	NN	_	14	conj	_	_
17	.	.	.	_	11	p	_	_

1	Thus	thus	RB	_	22	adv	_	_
2	,	,	,	_	22	p	_	_
3	certain	certain	JJ	_	4	attr	_	_
4	factors	factor	NNS	_	22	dep	_	_
5	,	,	,	_	4	p	_	_
6	such	such	JJ	_	10	adv	_	_
7	as	as	IN	_	10	case	_	_
8	reinforcing	reinforce	VBG	_	10	attr	_	_
9	drug	drug	NN	_	10	com	_	_
10	effects	effect	NNS	_	4	ppmod	_	_
11	,	,	,	_	10	p	_	_
12	conditioning	conditioning	JJ	_	13	attr	_	_
13	processes	process	NNS	_	10	conj	_	_
14	,	,	,	_	13	p	_	_
15	automatic	automatic	JJ	_	16	attr	_	_
16	behavior	behavior	NN	_	10	conj	_	_
17	,	,	,	_	16	p	_	_
18	and	and	CC	_	16	cc	_	_
19	stress	stress	NN	_	10	conj	_	_
20	,	,	,	_	4	p	_	_
21	may	may	MD	_	22	modal	_	_
22	influence	influence	VB	_	0	root	_	_
23	the	the	DT	_	24	det	_	_
24	development	development	NN	_	22	obj	_	_
25	of	of	IN	_	26	case	_	_
26	dependence	dependence	NN	_	24	ppmod	_	_
27	on	on	IN	_	29	case	_	_
28	both	both	DT	_	29	det	_	_
29	drugs	drug	NNS	_	26	ppmod	_	_
30	.	.	.	_	22	p	_	_

1	Other	other	JJ	_	2	attr	_	_
2	factors	factor	NNS	_	23	dep	_	_
3	,	,	,	_	2	p	_	_
4	such	such	JJ	_	6	adv	_	_
5	as	as	IN	_	6	case	_	_
6	tolerance	tolerance	NN	_	2	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	sensitization	sensitization	NN	_	6	conj	_	_
9	to	to	TO	_	13	aux	_	_
10	the	the	DT	_	11	det	_	_
11	drugs	drug	NNS	_	13	poss	_	_
12	'	'	POS	_	11	case	_	_
13	actions	action	NNS	_	6	ppmod	_	_
14	and	and	CC	_	6	cc	_	_
15	the	the	DT	_	16	det	_	_
16	development	development	NN	_	6	conj	_	_
17	of	of	IN	_	19	case	_	_
18	withdrawal	withdrawal	NN	_	19	com	_	_
19	symptoms	symptom	NNS	_	16	ppmod	_	_
20	,	,	,	_	2	p	_	_
21	may	may	MD	_	23	modal	_	_
22	also	also	RB	_	23	adv	_	_
23	contribute	contribute	VB	_	0	root	_	_
24	to	to	TO	_	25	aux	_	_
25	dependence	dependence	NN	_	23	ppmod	_	_
26	.	.	.	_	23	p	_	_

1	This	this	DT	_	2	det	_	_
2	review	review	NN	_	3	dep	_	_
3	discusses	discuss	VBZ	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	actions	action	NNS	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	two	#crd#	CD	_	9	num	_	_
9	drugs	drug	NNS	_	5	ppmod	_	_
10	on	on	IN	_	19	case	_	_
11	certain	certain	JJ	_	19	attr	_	_
12	brain	brain	NN	_	19	attr	_	_
13	chemical	chemical	JJ	_	19	attr	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	i.e.	i.e.	FW	_	17	adv	_	_
16	,	,	,	_	17	p	_	_
17	neurotransmitter	neurotransmitter	NN	_	19	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	systems	system	NNS	_	5	ppmod	_	_
20	and	and	CC	_	19	cc	_	_
21	the	the	DT	_	22	det	_	_
22	extent	extent	NN	_	19	conj	_	_
23	to	to	TO	_	24	aux	_	_
24	which	which	WDT	_	32	ppmod	_	_
25	the	the	DT	_	26	det	_	_
26	effects	effect	NNS	_	32	dep	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	two	#crd#	CD	_	30	num	_	_
30	drugs	drug	NNS	_	26	ppmod	_	_
31	may	may	MD	_	32	modal	_	_
32	interact	interact	VB	_	22	relcl	_	_
33	.	.	.	_	3	p	_	_

1	Vancomycin	vancomycin	NN	_	3	com	_	_
2	resistance	resistance	NN	_	3	com	_	_
3	reversal	reversal	NN	_	0	root	_	_
4	in	in	IN	_	5	case	_	_
5	enterococci	enterococci	NN	_	3	ppmod	_	_
6	by	by	IN	_	7	case	_	_
7	flavonoids	flavonoid	NNS	_	3	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	development	development	NN	_	12	dep	_	_
3	of	of	IN	_	6	case	_	_
4	clinical	clinical	JJ	_	6	attr	_	_
5	vancomycin-resistant	vancomycin-resistant	JJ	_	6	attr	_	_
6	strains	strain	NNS	_	2	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	enterococci	enterococci	NNS	_	6	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	VRE	vre	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	is	be	VBZ	_	0	root	_	_
13	a	a	DT	_	15	det	_	_
14	major	major	JJ	_	15	attr	_	_
15	cause	cause	NN	_	12	obj	_	_
16	for	for	IN	_	17	case	_	_
17	concern	concern	NN	_	15	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	Here	here	RB	_	3	adv	_	_
2	we	we	PRP	_	3	dep	_	_
3	show	show	VBP	_	0	root	_	_
4	that	that	IN	_	15	mark	_	_
5	a	a	DT	_	6	det	_	_
6	combination	combination	NN	_	15	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	3,7-dihydroxyflavone	0-dihydroxyflavone	NN	_	8	conj	_	_
11	with	with	IN	_	12	case	_	_
12	drug2	drug0	NN	_	6	ppmod	_	_
13	may	may	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	used	use	VBN	_	3	comp	_	_
16	to	to	TO	_	17	aux	_	_
17	sensitize	sensitize	VB	_	15	comp	_	_
18	resistant	resistant	JJ	_	19	attr	_	_
19	strains	strain	NNS	_	17	obj	_	_
20	of	of	IN	_	22	case	_	_
21	Enterococcus	enterococcus	FW	_	22	attr	_	_
22	faecalis	faecalis	FW	_	19	ppmod	_	_
23	and	and	CC	_	22	cc	_	_
24	Enterococcus	enterococcus	FW	_	25	attr	_	_
25	faecium	faecium	FW	_	22	conj	_	_
26	to	to	TO	_	28	aux	_	_
27	the	the	DT	_	28	det	_	_
28	level	level	NN	_	17	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	vancomycin-sensitive	vancomycin-sensitive	JJ	_	31	attr	_	_
31	strains	strain	NNS	_	28	ppmod	_	_
32	.	.	.	_	3	p	_	_

1	Minimum	minimum	JJ	_	3	attr	_	_
2	inhibitory	inhibitory	JJ	_	3	attr	_	_
3	concentrations	concentration	NNS	_	11	dep	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	MICs	mics	NN	_	3	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	and	and	CC	_	3	cc	_	_
8	viable	viable	JJ	_	9	attr	_	_
9	counts	count	NNS	_	3	conj	_	_
10	were	be	VBD	_	11	aux	_	_
11	determined	determine	VBN	_	0	root	_	_
12	in	in	IN	_	13	case	_	_
13	Iso-sensitest	iso-sensitest	NN	_	11	ppmod	_	_
14	broth	broth	CD	_	13	num	_	_
15	using	use	VBG	_	11	comp	_	_
16	a	a	DT	_	18	det	_	_
17	microtitre	microtitre	NN	_	18	com	_	_
18	method	method	NN	_	15	obj	_	_
19	.	.	.	_	11	p	_	_

1	MICs	mic	NNS	_	18	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	against	against	IN	_	5	case	_	_
5	67	0	CD	_	1	ppmod	_	_
6	%	%	NN	_	5	meta	_	_
7	of	of	IN	_	10	case	_	_
8	resistant	resistant	JJ	_	10	attr	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	isolates	isolate	NNS	_	5	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	a	a	DT	_	14	det	_	_
13	type	type	NN	_	14	com	_	_
14	strain	strain	NN	_	10	conj	_	_
15	of	of	IN	_	16	case	_	_
16	enterococci	enterococci	NN	_	14	ppmod	_	_
17	were	be	VBD	_	18	aux	_	_
18	lowered	lower	VBN	_	0	root	_	_
19	from	from	IN	_	23	case	_	_
20	>	>	NN	_	23	attr	_	_
21	250	0	CD	_	23	num	_	_
22	microg	microg	NN	_	23	com	_	_
23	mL	ml	NN	_	18	ppmod	_	_
24	(	-lrb-	-LRB-	_	25	p	_	_
25	-1	0	CD	_	23	num	_	_
26	)	-rrb-	-RRB-	_	25	p	_	_
27	to	to	TO	_	28	aux	_	_
28	1	0	CD	_	18	ppmod	_	_

1	4	0	CD	_	3	num	_	_
2	microg	microg	NN	_	3	com	_	_
3	mL	ml	NN	_	0	root	_	_
4	(	-lrb-	-LRB-	_	5	p	_	_
5	-1	0	CD	_	3	num	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	in	in	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	presence	presence	NN	_	3	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	(	-lrb-	-LRB-	_	15	p	_	_
13	12.5	0	CD	_	15	num	_	_
14	microg	microg	NN	_	15	com	_	_
15	mL	ml	NN	_	11	prn	_	_
16	(	-lrb-	-LRB-	_	17	p	_	_
17	-1	0	CD	_	15	num	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	)	-rrb-	-RRB-	_	15	p	_	_
20	or	or	CC	_	11	cc	_	_
21	3,7-dihydroxyflavone	0-dihydroxyflavone	NN	_	11	conj	_	_
22	(	-lrb-	-LRB-	_	25	p	_	_
23	6.25	0	CD	_	25	num	_	_
24	microg	microg	NN	_	25	com	_	_
25	mL	ml	NN	_	21	prn	_	_
26	(	-lrb-	-LRB-	_	27	p	_	_
27	-1	0	CD	_	25	num	_	_
28	)	-rrb-	-RRB-	_	27	p	_	_
29	)	-rrb-	-RRB-	_	25	p	_	_
30	.	.	.	_	3	p	_	_

1	Viable	viable	JJ	_	2	attr	_	_
2	counts	count	NNS	_	0	root	_	_
3	for	for	IN	_	6	case	_	_
4	type	type	NN	_	6	com	_	_
5	culture	culture	NN	_	6	com	_	_
6	E	e	NN	_	2	ppmod	_	_
7	.	.	.	_	2	p	_	_

1	faecalis	faecalis	NN	_	2	com	_	_
2	ATCC	atcc	NN	_	4	dep	_	_
3	51299	0	CD	_	2	num	_	_
4	showed	show	VBD	_	0	root	_	_
5	the	the	DT	_	10	det	_	_
6	flavonoids	flavonoid	NNS	_	10	attr	_	_
7	alone	alone	RB	_	10	adv	_	_
8	significantly	significantly	RB	_	10	adv	_	_
9	lowered	lowered	JJ	_	10	attr	_	_
10	numbers	number	NNS	_	4	obj	_	_
11	of	of	IN	_	14	case	_	_
12	colony	colony	NN	_	14	attr	_	_
13	forming	form	VBG	_	14	attr	_	_
14	units	unit	NNS	_	10	ppmod	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	CFUs	cfus	NN	_	14	prn	_	_
17	)	-rrb-	-RRB-	_	16	p	_	_
18	.	.	.	_	4	p	_	_

1	CFUs	cfus	NN	_	3	dep	_	_
2	were	be	VBD	_	3	aux	_	_
3	maintained	maintain	VBN	_	0	root	_	_
4	at	at	IN	_	6	case	_	_
5	low	low	JJ	_	6	attr	_	_
6	levels	level	NNS	_	3	ppmod	_	_
7	(	-lrb-	-LRB-	_	13	p	_	_
8	10	0	CD	_	13	num	_	_
9	(	-lrb-	-LRB-	_	13	p	_	_
10	3	0	CD	_	13	num	_	_
11	)	-rrb-	-RRB-	_	13	p	_	_
12	CFU	cfu	NN	_	13	com	_	_
13	mL	ml	NN	_	6	prn	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	-1	0	CD	_	13	num	_	_
16	)	-rrb-	-RRB-	_	15	p	_	_
17	)	-rrb-	-RRB-	_	13	p	_	_
18	for	for	IN	_	20	case	_	_
19	24	0	CD	_	20	num	_	_
20	h	h	NN	_	3	ppmod	_	_
21	by	by	IN	_	24	case	_	_
22	drug1	drug0	NN	_	24	com	_	_
23	/flavone	/flavone	NN	_	24	com	_	_
24	combinations	combination	NNS	_	3	ppmod	_	_
25	.	.	.	_	3	p	_	_

1	This	this	DT	_	3	det	_	_
2	combinational	combinational	JJ	_	3	attr	_	_
3	action	action	NN	_	10	dep	_	_
4	in	in	IN	_	5	case	_	_
5	reversing	reverse	VBG	_	3	ppmod	_	_
6	vancomycin	vancomycin	NN	_	7	com	_	_
7	resistance	resistance	NN	_	5	obj	_	_
8	of	of	IN	_	9	case	_	_
9	enterococci	enterococci	NN	_	7	ppmod	_	_
10	highlights	highlight	VBZ	_	0	root	_	_
11	novel	novel	JJ	_	13	attr	_	_
12	drug	drug	NN	_	13	com	_	_
13	targets	target	NNS	_	10	obj	_	_
14	and	and	CC	_	10	cc	_	_
15	has	have	VBZ	_	10	conj	_	_
16	importance	importance	NN	_	15	obj	_	_
17	in	in	IN	_	19	case	_	_
18	the	the	DT	_	19	det	_	_
19	design	design	NN	_	16	ppmod	_	_
20	of	of	IN	_	23	case	_	_
21	new	new	JJ	_	23	attr	_	_
22	therapeutic	therapeutic	JJ	_	23	attr	_	_
23	regimes	regime	NNS	_	19	ppmod	_	_
24	against	against	IN	_	26	case	_	_
25	resistant	resistant	JJ	_	26	attr	_	_
26	pathogens	pathogen	NNS	_	23	ppmod	_	_
27	.	.	.	_	10	p	_	_

1	Lack	lack	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	interaction	interaction	NN	_	1	ppmod	_	_
4	between	between	IN	_	5	case	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	:	:	:	_	1	p	_	_
9	pharmacokinetics	pharmacokinetics	NNS	_	1	appo	_	_
10	and	and	CC	_	9	cc	_	_
11	drug	drug	NN	_	12	com	_	_
12	disposition	disposition	NN	_	9	conj	_	_
13	.	.	.	_	1	p	_	_

1	Previous	previous	JJ	_	2	attr	_	_
2	studies	study	NNS	_	4	dep	_	_
3	have	have	VBP	_	4	aux	_	_
4	demonstrated	demonstrate	VBN	_	0	root	_	_
5	a	a	DT	_	7	det	_	_
6	significant	significant	JJ	_	7	attr	_	_
7	reduction	reduction	NN	_	4	obj	_	_
8	in	in	IN	_	11	case	_	_
9	the	the	DT	_	11	det	_	_
10	oral	oral	JJ	_	11	attr	_	_
11	bioavailability	bioavailability	NN	_	7	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	and	and	CC	_	13	cc	_	_
15	drug2	drug0	NN	_	13	conj	_	_
16	when	when	WRB	_	17	adv	_	_
17	administered	administer	VBN	_	7	relcl	_	_
18	concomitantly	concomitantly	RB	_	17	adv	_	_
19	with	with	IN	_	22	case	_	_
20	an	an	DT	_	22	det	_	_
21	intravenous	intravenous	JJ	_	22	attr	_	_
22	drug3	drug0	NN	_	17	ppmod	_	_
23	such	such	JJ	_	25	adv	_	_
24	as	as	IN	_	25	case	_	_
25	drug4	drug0	NN	_	22	ppmod	_	_
26	.	.	.	_	4	p	_	_

1	This	this	DT	_	2	det	_	_
2	decrease	decrease	NN	_	5	dep	_	_
3	in	in	IN	_	4	case	_	_
4	absorption	absorption	NN	_	2	ppmod	_	_
5	results	result	VBZ	_	0	root	_	_
6	in	in	IN	_	14	case	_	_
7	a	a	DT	_	14	det	_	_
8	36	0	CD	_	13	num	_	_
9	%	%	NN	_	8	meta	_	_
10	and	and	CC	_	8	cc	_	_
11	50	0	CD	_	8	conj	_	_
12	%	%	NN	_	11	meta	_	_
13	lower	low	JJR	_	14	attr	_	_
14	AUC	auc	NN	_	5	ppmod	_	_
15	for	for	IN	_	16	case	_	_
16	drug1	drug0	NN	_	14	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	drug2	drug0	NN	_	16	conj	_	_
19	,	,	,	_	18	p	_	_
20	respectively	respectively	RB	_	16	conj	_	_
21	,	,	,	_	14	p	_	_
22	which	which	WDT	_	24	dep	_	_
23	could	could	MD	_	24	modal	_	_
24	cause	cause	VB	_	14	relcl	_	_
25	clinical	clinical	JJ	_	26	attr	_	_
26	failures	failure	NNS	_	24	obj	_	_
27	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	authors	author	NNS	_	3	dep	_	_
3	investigated	investigate	VBD	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	possibility	possibility	NN	_	3	obj	_	_
6	of	of	IN	_	9	case	_	_
7	a	a	DT	_	9	det	_	_
8	similar	similar	JJ	_	9	attr	_	_
9	interaction	interaction	NN	_	5	ppmod	_	_
10	between	between	IN	_	11	case	_	_
11	drug1	drug0	NN	_	9	ppmod	_	_
12	and	and	CC	_	11	cc	_	_
13	drug2	drug0	NN	_	11	conj	_	_
14	.	.	.	_	3	p	_	_

1	Eight	#crd#	CD	_	3	num	_	_
2	healthy	healthy	JJ	_	3	attr	_	_
3	volunteers	volunteer	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	randomized	randomize	VBN	_	0	root	_	_
6	in	in	IN	_	12	case	_	_
7	an	an	DT	_	12	det	_	_
8	open-label	open-label	JJ	_	10	adv	_	_
9	,	,	,	_	10	p	_	_
10	two-way	two-way	JJ	_	12	attr	_	_
11	crossover	crossover	NN	_	12	com	_	_
12	study	study	NN	_	5	ppmod	_	_
13	to	to	TO	_	14	aux	_	_
14	receive	receive	VBP	_	5	comp	_	_
15	drug1	drug0	NN	_	14	obj	_	_
16	,	,	,	_	15	p	_	_
17	5	0	CD	_	18	num	_	_
18	mg	mg	NN	_	19	com	_	_
19	p.o.	p.o.	NN	_	15	appo	_	_

1	Q4H	q0h	NN	_	0	root	_	_
2	,	,	,	_	1	p	_	_
3	and	and	CC	_	1	cc	_	_
4	drug1	drug0	NN	_	1	conj	_	_
5	,	,	,	_	4	p	_	_
6	500	0	CD	_	7	num	_	_
7	mg	mg	NN	_	8	com	_	_
8	p.o.	p.o.	NN	_	1	conj	_	_

1	1	0	CD	_	2	num	_	_
2	hour	hour	NN	_	0	root	_	_
3	after	after	IN	_	4	case	_	_
4	starting	start	VBG	_	2	ppmod	_	_
5	the	the	DT	_	6	det	_	_
6	drug1	drug0	NN	_	4	obj	_	_
7	or	or	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	11	attr	_	_
9	500	0	CD	_	11	num	_	_
10	mg	mg	NN	_	11	com	_	_
11	p.o.	p.o.	NN	_	6	conj	_	_

1	alone	alone	RB	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Blood	blood	NN	_	2	com	_	_
2	samples	sample	NNS	_	4	dep	_	_
3	were	be	VBD	_	4	aux	_	_
4	drawn	draw	VBN	_	0	root	_	_
5	at	at	IN	_	30	case	_	_
6	0	0	CD	_	30	num	_	_
7	,	,	,	_	6	p	_	_
8	0.5	0	CD	_	6	conj	_	_
9	,	,	,	_	8	p	_	_
10	1	0	CD	_	6	conj	_	_
11	,	,	,	_	10	p	_	_
12	1.5	0	CD	_	6	conj	_	_
13	,	,	,	_	12	p	_	_
14	2	0	CD	_	6	conj	_	_
15	,	,	,	_	14	p	_	_
16	3	0	CD	_	6	conj	_	_
17	,	,	,	_	16	p	_	_
18	4	0	CD	_	6	conj	_	_
19	,	,	,	_	18	p	_	_
20	6	0	CD	_	6	conj	_	_
21	,	,	,	_	20	p	_	_
22	8	0	CD	_	6	conj	_	_
23	,	,	,	_	22	p	_	_
24	12	0	CD	_	6	conj	_	_
25	,	,	,	_	24	p	_	_
26	18	0	CD	_	6	conj	_	_
27	,	,	,	_	26	p	_	_
28	and	and	CC	_	26	cc	_	_
29	24	0	CD	_	6	conj	_	_
30	hours	hour	NNS	_	4	ppmod	_	_
31	for	for	IN	_	32	case	_	_
32	Cmax	cmax	NN	_	4	ppmod	_	_
33	,	,	,	_	32	p	_	_
34	tmax	tmax	NN	_	32	conj	_	_
35	,	,	,	_	34	p	_	_
36	and	and	CC	_	34	cc	_	_
37	AUC	auc	NN	_	38	com	_	_
38	determinations	determination	NNS	_	32	conj	_	_
39	.	.	.	_	4	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	not	not	RB	_	2	neg	_	_
4	a	a	DT	_	6	det	_	_
5	significant	significant	JJ	_	6	attr	_	_
6	difference	difference	NN	_	2	obj	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	p	p	NN	_	9	com	_	_
9	>	>	NN	_	6	prn	_	_
10	0.05	0	CD	_	9	num	_	_
11	)	-rrb-	-RRB-	_	9	p	_	_
12	in	in	IN	_	13	case	_	_
13	AUC	auc	NN	_	6	ppmod	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	48.59	0	CD	_	13	num	_	_
16	+/-	+/-	CC	_	15	cc	_	_
17	8.52	0	CD	_	15	conj	_	_
18	vs.	vs.	CC	_	17	cc	_	_
19	49.9	0	CD	_	15	conj	_	_
20	+/-	+/-	CC	_	15	cc	_	_
21	9.93	0	NN	_	15	conj	_	_
22	)	-rrb-	-RRB-	_	15	p	_	_
23	,	,	,	_	13	p	_	_
24	Cmax	cmax	NN	_	13	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	7.73	0	CD	_	24	num	_	_
27	+/-	+/-	CC	_	26	cc	_	_
28	2.6	0	CD	_	26	conj	_	_
29	vs.	vs.	CC	_	28	cc	_	_
30	6.6	0	CD	_	26	conj	_	_
31	+/-	+/-	CC	_	30	cc	_	_
32	2.0	0	CD	_	26	conj	_	_
33	)	-rrb-	-RRB-	_	26	p	_	_
34	,	,	,	_	24	p	_	_
35	and	and	CC	_	24	cc	_	_
36	tmax	tmax	NN	_	13	conj	_	_
37	(	-lrb-	-LRB-	_	38	p	_	_
38	1.1	0	CD	_	36	num	_	_
39	+/-	+/-	CC	_	38	cc	_	_
40	0.6	0	CD	_	38	conj	_	_
41	vs.	vs.	CC	_	40	cc	_	_
42	1.6	0	CD	_	38	conj	_	_
43	+/-	+/-	CC	_	42	cc	_	_
44	1.1	0	CD	_	38	conj	_	_
45	)	-rrb-	-RRB-	_	38	p	_	_
46	for	for	IN	_	47	case	_	_
47	drug1	drug0	NN	_	6	ppmod	_	_
48	versus	versus	CC	_	47	cc	_	_
49	drug2	drug0	NN	_	47	conj	_	_
50	/	/	:	_	47	p	_	_
51	drug3	drug0	NN	_	52	com	_	_
52	regimens	regimen	NNS	_	47	appo	_	_
53	.	.	.	_	2	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	concluded	conclude	VBN	_	0	root	_	_
4	that	that	IN	_	11	mark	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	drug1	drug0	NN	_	11	dep	_	_
7	and	and	CC	_	6	cc	_	_
8	drug2	drug0	NN	_	6	conj	_	_
9	can	can	MD	_	11	modal	_	_
10	be	be	VB	_	11	aux	_	_
11	administered	administer	VBN	_	3	comp	_	_
12	concomitantly	concomitantly	RB	_	11	adv	_	_
13	without	without	IN	_	16	case	_	_
14	a	a	DT	_	16	det	_	_
15	significant	significant	JJ	_	16	attr	_	_
16	decrease	decrease	NN	_	11	ppmod	_	_
17	in	in	IN	_	18	case	_	_
18	AUC	auc	NN	_	16	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	Cmax	cmax	NN	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	or	or	CC	_	20	cc	_	_
23	tmax	tmax	NN	_	18	conj	_	_
24	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	mode	mode	NN	_	12	dep	_	_
3	of	of	IN	_	5	case	_	_
4	toxic	toxic	JJ	_	5	attr	_	_
5	action	action	NN	_	2	ppmod	_	_
6	of	of	IN	_	9	case	_	_
7	the	the	DT	_	9	det	_	_
8	pesticide	pesticide	NN	_	9	com	_	_
9	drug1	drug0	NN	_	5	ppmod	_	_
10	:	:	:	_	12	p	_	_
11	the	the	DT	_	12	det	_	_
12	metabolism	metabolism	NN	_	0	root	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	to	to	TO	_	16	aux	_	_
16	drug3	drug0	NN	_	12	ppmod	_	_
17	.	.	.	_	12	p	_	_

1	The	the	DT	_	3	det	_	_
2	biochemical	biochemical	JJ	_	3	attr	_	_
3	toxicology	toxicology	NN	_	23	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	,	,	,	_	5	p	_	_
7	a	a	DT	_	9	det	_	_
8	known	known	JJ	_	9	attr	_	_
9	metabolite	metabolite	NN	_	5	appo	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	major	major	JJ	_	13	attr	_	_
13	ingredient	ingredient	NN	_	9	ppmod	_	_
14	of	of	IN	_	17	case	_	_
15	the	the	DT	_	17	det	_	_
16	pesticide	pesticide	JJ	_	17	attr	_	_
17	drug2	drug0	NN	_	13	ppmod	_	_
18	(	-lrb-	-LRB-	_	19	p	_	_
19	drug3	drug0	NN	_	17	prn	_	_
20	)	-rrb-	-RRB-	_	19	p	_	_
21	,	,	,	_	5	p	_	_
22	was	be	VBD	_	23	aux	_	_
23	investigated	investigate	VBN	_	0	root	_	_
24	in	in	FW	_	25	adv	_	_
25	vivo	vivo	FW	_	23	adv	_	_
26	and	and	CC	_	25	cc	_	_
27	in	in	FW	_	28	adv	_	_
28	vitro	vitro	FW	_	25	conj	_	_
29	.	.	.	_	23	p	_	_

1	Rat	rat	NN	_	3	com	_	_
2	kidney	kidney	NN	_	3	com	_	_
3	homogenates	homogenate	NNS	_	15	dep	_	_
4	supplemented	supplement	VBN	_	3	acl	_	_
5	with	with	IN	_	7	case	_	_
6	coenzyme	coenzyme	NN	_	7	com	_	_
7	A	a	NN	_	4	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	ATP	atp	NN	_	7	conj	_	_
10	,	,	,	_	9	p	_	_
11	oxaloacetate	oxaloacetate	NN	_	7	conj	_	_
12	,	,	,	_	11	p	_	_
13	and	and	CC	_	11	cc	_	_
14	Mg2+	mg0+	NN	_	7	conj	_	_
15	converted	convert	VBD	_	0	root	_	_
16	drug1	drug0	NN	_	15	obj	_	_
17	to	to	TO	_	18	aux	_	_
18	drug2	drug0	NN	_	15	ppmod	_	_
19	in	in	FW	_	20	adv	_	_
20	vitro	vitro	FW	_	15	adv	_	_
21	.	.	.	_	15	p	_	_

1	Administration	administration	NN	_	18	dep	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	(	-lrb-	-LRB-	_	12	p	_	_
5	100	0	CD	_	12	num	_	_
6	mg	mg	NN	_	12	attr	_	_
7	kg	kg	CD	_	12	num	_	_
8	(	-lrb-	-LRB-	_	12	p	_	_
9	-1	0	CD	_	12	num	_	_
10	)	-rrb-	-RRB-	_	12	p	_	_
11	body	body	NN	_	12	com	_	_
12	weight	weight	NN	_	3	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	to	to	TO	_	15	aux	_	_
15	rats	rat	NNS	_	1	ppmod	_	_
16	in	in	FW	_	17	adv	_	_
17	vivo	vivo	FW	_	1	adv	_	_
18	resulted	result	VBD	_	0	root	_	_
19	in	in	IN	_	21	case	_	_
20	drug2	drug0	NN	_	21	com	_	_
21	synthesis	synthesis	NN	_	18	ppmod	_	_
22	in	in	IN	_	24	case	_	_
23	the	the	DT	_	24	det	_	_
24	kidney	kidney	NN	_	21	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	which	which	WDT	_	28	dep	_	_
27	was	be	VBD	_	28	aux	_	_
28	preceded	precede	VBN	_	24	relcl	_	_
29	by	by	IN	_	31	case	_	_
30	an	an	DT	_	31	det	_	_
31	elevation	elevation	NN	_	28	ppmod	_	_
32	in	in	IN	_	34	case	_	_
33	fluoride	fluoride	JJ	_	34	attr	_	_
34	levels	level	NNS	_	31	ppmod	_	_
35	and	and	CC	_	28	cc	_	_
36	followed	followed	VBN	_	28	conj	_	_
37	by	by	IN	_	39	case	_	_
38	citrate	citrate	NN	_	39	com	_	_
39	accumulation	accumulation	NN	_	36	ppmod	_	_
40	.	.	.	_	18	p	_	_

1	Animals	animal	NNS	_	7	dep	_	_
2	dosed	dose	VBN	_	1	acl	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	did	do	VBD	_	7	aux	_	_
6	not	not	RB	_	7	neg	_	_
7	display	display	VB	_	0	root	_	_
8	the	the	DT	_	12	det	_	_
9	2-3	0	CD	_	10	num	_	_
10	hour	hour	NN	_	12	com	_	_
11	lag	lag	NN	_	12	com	_	_
12	phase	phase	NN	_	7	obj	_	_
13	in	in	IN	_	16	case	_	_
14	either	either	DT	_	16	det	_	_
15	drug2	drug0	NN	_	16	com	_	_
16	synthesis	synthesis	NN	_	12	ppmod	_	_
17	or	or	CC	_	16	cc	_	_
18	in	in	IN	_	22	case	_	_
19	citrate	citrate	NN	_	22	attr	_	_
20	and	and	CC	_	19	cc	_	_
21	fluoride	fluoride	NN	_	19	conj	_	_
22	accumulation	accumulation	NN	_	16	conj	_	_
23	characteristic	characteristic	JJ	_	22	attr	_	_
24	of	of	IN	_	25	case	_	_
25	animals	animal	NNS	_	23	ppmod	_	_
26	dosed	dose	VBN	_	25	acl	_	_
27	with	with	IN	_	28	case	_	_
28	drug3	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	7	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	demonstrate	demonstrate	VBP	_	0	root	_	_
3	that	that	IN	_	14	mark	_	_
4	the	the	DT	_	5	det	_	_
5	conversion	conversion	NN	_	14	dep	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	to	to	TO	_	9	aux	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	by	by	IN	_	13	case	_	_
11	an	an	DT	_	13	det	_	_
12	NAD+-dependent	nad+-dependent	JJ	_	13	attr	_	_
13	oxidation	oxidation	NN	_	9	ppmod	_	_
14	is	be	VBZ	_	2	comp	_	_
15	the	the	DT	_	17	det	_	_
16	rate-limiting	rate-limiting	JJ	_	17	attr	_	_
17	step	step	NN	_	14	obj	_	_
18	in	in	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	synthesis	synthesis	NN	_	17	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	toxic	toxic	JJ	_	24	attr	_	_
24	product	product	NN	_	20	ppmod	_	_
25	,	,	,	_	24	p	_	_
26	drug3	drug0	NN	_	24	appo	_	_
27	from	from	IN	_	28	case	_	_
28	drug4	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	2	p	_	_

1	Prior	prior	JJ	_	2	attr	_	_
2	administration	administration	NN	_	16	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	(	-lrb-	-LRB-	_	7	p	_	_
6	90	0	CD	_	7	num	_	_
7	mg	mg	NN	_	4	prn	_	_
8	kg	kg	CD	_	7	num	_	_
9	(	-lrb-	-LRB-	_	7	p	_	_
10	-1	0	CD	_	7	num	_	_
11	)	-rrb-	-RRB-	_	7	p	_	_
12	body	body	NN	_	13	com	_	_
13	weight	weight	NN	_	7	appo	_	_
14	)	-rrb-	-RRB-	_	7	p	_	_
15	was	be	VBD	_	16	aux	_	_
16	shown	show	VBN	_	0	root	_	_
17	to	to	TO	_	18	aux	_	_
18	prevent	prevent	VB	_	16	comp	_	_
19	the	the	DT	_	20	det	_	_
20	conversion	conversion	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	31	p	_	_
24	100	0	CD	_	31	num	_	_
25	mg	mg	NN	_	31	attr	_	_
26	kg	kg	CD	_	31	num	_	_
27	(	-lrb-	-LRB-	_	31	p	_	_
28	-1	0	CD	_	31	num	_	_
29	)	-rrb-	-RRB-	_	31	p	_	_
30	body	body	NN	_	31	com	_	_
31	weight	weight	NN	_	22	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	to	to	TO	_	34	aux	_	_
34	drug3	drug0	NN	_	20	ppmod	_	_
35	in	in	FW	_	36	adv	_	_
36	vivo	vivo	FW	_	18	adv	_	_
37	and	and	CC	_	18	cc	_	_
38	to	to	TO	_	39	aux	_	_
39	eliminate	eliminate	VB	_	18	conj	_	_
40	the	the	DT	_	41	det	_	_
41	fluoride	fluoride	NN	_	39	obj	_	_
42	and	and	CC	_	41	cc	_	_
43	citrate	citrate	NN	_	44	com	_	_
44	elevations	elevation	NNS	_	41	conj	_	_
45	seen	see	VBN	_	41	acl	_	_
46	in	in	IN	_	49	case	_	_
47	drug4	drug0	JJ	_	49	attr	_	_
48	-intoxicated	-intoxicated	JJ	_	49	attr	_	_
49	animals	animal	NNS	_	45	ppmod	_	_
50	.	.	.	_	16	p	_	_

1	However	however	RB	_	33	adv	_	_
2	,	,	,	_	33	p	_	_
3	administration	administration	NN	_	33	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	(	-lrb-	-LRB-	_	14	p	_	_
7	90	0	CD	_	14	num	_	_
8	mg	mg	NN	_	14	attr	_	_
9	kg	kg	CD	_	14	num	_	_
10	(	-lrb-	-LRB-	_	14	p	_	_
11	-1	0	CD	_	14	num	_	_
12	)	-rrb-	-RRB-	_	14	p	_	_
13	body	body	NN	_	14	com	_	_
14	weight	weight	NN	_	5	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	to	to	TO	_	17	aux	_	_
17	rats	rat	NNS	_	3	ppmod	_	_
18	2	0	CD	_	19	num	_	_
19	hours	hour	NNS	_	20	advnp	_	_
20	prior	prior	RB	_	17	adv	_	_
21	to	to	TO	_	22	aux	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	(	-lrb-	-LRB-	_	31	p	_	_
24	100	0	CD	_	31	num	_	_
25	mg	mg	NN	_	31	attr	_	_
26	kg	kg	CD	_	31	num	_	_
27	(	-lrb-	-LRB-	_	31	p	_	_
28	-1	0	CD	_	31	num	_	_
29	)	-rrb-	-RRB-	_	31	p	_	_
30	body	body	NN	_	31	com	_	_
31	weight	weight	NN	_	20	prn	_	_
32	)	-rrb-	-RRB-	_	31	p	_	_
33	was	be	VBD	_	0	root	_	_
34	ineffective	ineffective	JJ	_	33	dep	_	_
35	in	in	IN	_	36	case	_	_
36	preventing	prevent	VBG	_	34	ppmod	_	_
37	drug3	drug0	NN	_	38	com	_	_
38	synthesis	synthesis	NN	_	36	obj	_	_
39	and	and	CC	_	33	cc	_	_
40	did	do	VBD	_	42	aux	_	_
41	not	not	RB	_	42	neg	_	_
42	diminish	diminish	VB	_	33	conj	_	_
43	fluoride	fluoride	NN	_	42	obj	_	_
44	or	or	CC	_	43	cc	_	_
45	citrate	citrate	NN	_	46	com	_	_
46	accumulation	accumulation	NN	_	43	conj	_	_
47	in	in	FW	_	48	adv	_	_
48	vivo	vivo	FW	_	42	adv	_	_
49	.	.	.	_	33	p	_	_

1	We	we	PRP	_	2	dep	_	_
2	conclude	conclude	VBP	_	0	root	_	_
3	that	that	IN	_	17	mark	_	_
4	the	the	DT	_	8	det	_	_
5	prophylactic	prophylactic	JJ	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	antidotal	antidotal	JJ	_	5	conj	_	_
8	properties	property	NNS	_	17	dep	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	seen	see	VBN	_	10	acl	_	_
12	in	in	IN	_	13	case	_	_
13	animals	animal	NNS	_	11	ppmod	_	_
14	treated	treat	VBN	_	13	acl	_	_
15	with	with	IN	_	16	case	_	_
16	drug2	drug0	NN	_	14	ppmod	_	_
17	derive	derive	VBP	_	2	comp	_	_
18	from	from	IN	_	20	case	_	_
19	its	its	PRP$	_	20	poss	_	_
20	capacity	capacity	NN	_	17	ppmod	_	_
21	to	to	TO	_	22	aux	_	_
22	inhibit	inhibit	VB	_	20	acl	_	_
23	the	the	DT	_	25	det	_	_
24	NAD+-dependent	nad+-dependent	JJ	_	25	attr	_	_
25	oxidation	oxidation	NN	_	22	obj	_	_
26	responsible	responsible	JJ	_	25	attr	_	_
27	for	for	IN	_	28	case	_	_
28	converting	convert	VBG	_	26	ppmod	_	_
29	drug3	drug0	NN	_	28	obj	_	_
30	to	to	TO	_	31	aux	_	_
31	drug4	drug0	NN	_	29	ppmod	_	_
32	in	in	IN	_	35	case	_	_
33	the	the	DT	_	35	det	_	_
34	committed	commit	VBN	_	35	attr	_	_
35	step	step	NN	_	28	ppmod	_	_
36	of	of	IN	_	39	case	_	_
37	the	the	DT	_	39	det	_	_
38	toxic	toxic	JJ	_	39	attr	_	_
39	pathway	pathway	NN	_	35	ppmod	_	_
40	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	advnp	_	_
2	-induced	-induced	JJ	_	4	attr	_	_
3	oxidative	oxidative	JJ	_	4	attr	_	_
4	stress	stress	NN	_	11	dep	_	_
5	in	in	IN	_	7	case	_	_
6	rat	rat	NN	_	7	com	_	_
7	brain	brain	NN	_	4	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	liver	liver	NN	_	7	conj	_	_
10	is	be	VBZ	_	11	aux	_	_
11	prevented	prevent	VBN	_	0	root	_	_
12	by	by	IN	_	13	case	_	_
13	drug2	drug0	NN	_	11	ppmod	_	_
14	or	or	CC	_	13	cc	_	_
15	drug3	drug0	NN	_	13	conj	_	_
16	.	.	.	_	11	p	_	_

1	Considering	consider	VBG	_	25	advcl	_	_
2	that	that	IN	_	14	mark	_	_
3	the	the	DT	_	4	det	_	_
4	involvement	involvement	NN	_	14	dep	_	_
5	of	of	IN	_	8	case	_	_
6	reactive	reactive	JJ	_	8	attr	_	_
7	oxygen	oxygen	NN	_	8	com	_	_
8	species	species	NNS	_	4	ppmod	_	_
9	(	-lrb-	-LRB-	_	10	p	_	_
10	ROS	ros	NN	_	8	prn	_	_
11	)	-rrb-	-RRB-	_	10	p	_	_
12	has	have	VBZ	_	14	aux	_	_
13	been	be	VBN	_	14	aux	_	_
14	implicated	implicate	VBN	_	1	comp	_	_
15	in	in	IN	_	17	case	_	_
16	the	the	DT	_	17	det	_	_
17	toxicity	toxicity	NN	_	14	ppmod	_	_
18	of	of	IN	_	20	case	_	_
19	various	various	JJ	_	20	attr	_	_
20	pesticides	pesticide	NNS	_	17	ppmod	_	_
21	,	,	,	_	25	p	_	_
22	this	this	DT	_	23	det	_	_
23	study	study	NN	_	25	dep	_	_
24	was	be	VBD	_	25	aux	_	_
25	designed	design	VBN	_	0	root	_	_
26	to	to	TO	_	27	aux	_	_
27	investigate	investigate	VB	_	25	comp	_	_
28	the	the	DT	_	29	det	_	_
29	possibility	possibility	NN	_	27	obj	_	_
30	of	of	IN	_	33	case	_	_
31	oxidative	oxidative	JJ	_	32	attr	_	_
32	stress	stress	NN	_	33	com	_	_
33	induction	induction	NN	_	29	ppmod	_	_
34	by	by	IN	_	35	case	_	_
35	drug1	drug0	NN	_	33	ppmod	_	_
36	,	,	,	_	35	p	_	_
37	a	a	DT	_	38	det	_	_
38	drug2	drug0	NN	_	35	appo	_	_
39	.	.	.	_	25	p	_	_

1	Either	either	CC	_	2	cc	_	_
2	single	single	JJ	_	19	attr	_	_
3	(	-lrb-	-LRB-	_	5	p	_	_
4	170	0	CD	_	5	num	_	_
5	mg/kg	mg/kg	NN	_	2	prn	_	_
6	)	-rrb-	-RRB-	_	5	p	_	_
7	or	or	CC	_	2	cc	_	_
8	repeated	repeated	JJ	_	2	conj	_	_
9	(	-lrb-	-LRB-	_	11	p	_	_
10	75	0	CD	_	11	num	_	_
11	mg/kg	mg/kg	NN	_	19	prn	_	_
12	per	per	IN	_	13	case	_	_
13	day	day	NN	_	11	ppmod	_	_
14	for	for	IN	_	16	case	_	_
15	5	0	CD	_	16	num	_	_
16	days	day	NNS	_	11	ppmod	_	_
17	)	-rrb-	-RRB-	_	11	p	_	_
18	oral	oral	JJ	_	19	attr	_	_
19	administration	administration	NN	_	23	dep	_	_
20	of	of	IN	_	21	case	_	_
21	drug1	drug0	NN	_	19	ppmod	_	_
22	was	be	VBD	_	23	aux	_	_
23	found	find	VBN	_	0	root	_	_
24	to	to	TO	_	25	aux	_	_
25	produce	produce	VB	_	23	comp	_	_
26	significant	significant	JJ	_	28	attr	_	_
27	oxidative	oxidative	JJ	_	28	attr	_	_
28	stress	stress	NN	_	25	obj	_	_
29	in	in	IN	_	33	case	_	_
30	cerebral	cerebral	JJ	_	33	attr	_	_
31	and	and	CC	_	30	cc	_	_
32	hepatic	hepatic	JJ	_	30	conj	_	_
33	tissues	tissue	NNS	_	25	ppmod	_	_
34	of	of	IN	_	35	case	_	_
35	rats	rat	NNS	_	33	ppmod	_	_
36	,	,	,	_	25	p	_	_
37	as	as	IN	_	38	mark	_	_
38	was	be	VBD	_	25	comp	_	_
39	evident	evident	JJ	_	38	dep	_	_
40	by	by	IN	_	42	case	_	_
41	the	the	DT	_	42	det	_	_
42	elevation	elevation	NN	_	39	ppmod	_	_
43	of	of	IN	_	45	case	_	_
44	the	the	DT	_	45	det	_	_
45	level	level	NN	_	42	ppmod	_	_
46	of	of	IN	_	50	case	_	_
47	thiobarbituric	thiobarbituric	JJ	_	50	attr	_	_
48	acid	acid	NN	_	50	attr	_	_
49	reactive	reactive	JJ	_	50	attr	_	_
50	substances	substance	NNS	_	45	ppmod	_	_
51	(	-lrb-	-LRB-	_	52	p	_	_
52	TBARS	tbars	NNS	_	50	prn	_	_
53	)	-rrb-	-RRB-	_	52	p	_	_
54	in	in	IN	_	56	case	_	_
55	both	both	DT	_	56	det	_	_
56	tissues	tissue	NNS	_	45	ppmod	_	_
57	,	,	,	_	42	p	_	_
58	either	either	CC	_	42	cc	_	_
59	4	0	CD	_	62	num	_	_
60	or	or	CC	_	59	cc	_	_
61	24	0	CD	_	59	conj	_	_
62	h	h	NN	_	42	conj	_	_
63	after	after	IN	_	64	case	_	_
64	treatment	treatment	NN	_	62	ppmod	_	_
65	.	.	.	_	23	p	_	_

1	Much	much	RB	_	2	adv	_	_
2	higher	high	JJR	_	3	attr	_	_
3	changes	change	NNS	_	5	dep	_	_
4	were	be	VBD	_	5	aux	_	_
5	observed	observe	VBN	_	0	root	_	_
6	in	in	IN	_	7	case	_	_
7	liver	liver	NN	_	5	ppmod	_	_
8	,	,	,	_	7	p	_	_
9	increasing	increase	VBG	_	7	acl	_	_
10	from	from	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	level	level	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	60	0	CD	_	12	ppmod	_	_
15	%	%	NN	_	14	meta	_	_
16	at	at	IN	_	18	case	_	_
17	4	0	CD	_	18	num	_	_
18	h	h	NN	_	9	ppmod	_	_
19	up	up	IN	_	23	case	_	_
20	to	to	TO	_	23	aux	_	_
21	nearly	nearly	RB	_	22	adv	_	_
22	4	0	CD	_	23	num	_	_
23	times	time	NNS	_	9	ppmod	_	_
24	the	the	DT	_	25	det	_	_
25	control	control	NN	_	23	appo	_	_
26	at	at	IN	_	28	case	_	_
27	24	0	CD	_	28	num	_	_
28	h	h	NN	_	25	ppmod	_	_
29	for	for	IN	_	31	case	_	_
30	single	single	JJ	_	31	attr	_	_
31	dose	dose	NN	_	25	ppmod	_	_
32	.	.	.	_	5	p	_	_

1	Reduced	reduce	VBN	_	2	attr	_	_
2	levels	level	NNS	_	36	dep	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	up	up	RB	_	6	adv	_	_
5	to	to	TO	_	6	attr	_	_
6	20	0	CD	_	2	num	_	_
7	%	%	NN	_	6	meta	_	_
8	)	-rrb-	-RRB-	_	6	p	_	_
9	of	of	IN	_	11	case	_	_
10	total	total	JJ	_	11	attr	_	_
11	glutathione	glutathione	NN	_	2	ppmod	_	_
12	(	-lrb-	-LRB-	_	14	p	_	_
13	total	total	JJ	_	14	attr	_	_
14	GSH	gsh	NN	_	11	prn	_	_
15	)	-rrb-	-RRB-	_	14	p	_	_
16	,	,	,	_	2	p	_	_
17	and	and	CC	_	2	cc	_	_
18	elevation	elevation	NN	_	2	conj	_	_
19	of	of	IN	_	21	case	_	_
20	conjugated	conjugate	VBN	_	21	attr	_	_
21	dienes	dienes	NNS	_	18	ppmod	_	_
22	(	-lrb-	-LRB-	_	24	p	_	_
23	approximately	approximately	RB	_	24	adv	_	_
24	60	0	CD	_	21	num	_	_
25	%	%	NN	_	24	meta	_	_
26	in	in	IN	_	27	case	_	_
27	liver	liver	NN	_	24	ppmod	_	_
28	by	by	IN	_	30	case	_	_
29	single	single	JJ	_	30	attr	_	_
30	dose	dose	NN	_	24	ppmod	_	_
31	at	at	IN	_	33	case	_	_
32	4	0	CD	_	33	num	_	_
33	h	h	NN	_	30	ppmod	_	_
34	)	-rrb-	-RRB-	_	24	p	_	_
35	also	also	RB	_	36	adv	_	_
36	indicated	indicate	VBD	_	0	root	_	_
37	the	the	DT	_	38	det	_	_
38	presence	presence	NN	_	36	obj	_	_
39	of	of	IN	_	42	case	_	_
40	an	an	DT	_	42	det	_	_
41	oxidative	oxidative	JJ	_	42	attr	_	_
42	insult	insult	NN	_	38	ppmod	_	_
43	.	.	.	_	36	p	_	_

1	Glutathione-S-transferase	glutathione-s-transferase	NN	_	5	attr	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	GST	gst	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	activity	activity	NN	_	11	dep	_	_
6	,	,	,	_	11	p	_	_
7	however	however	RB	_	11	adv	_	_
8	,	,	,	_	11	p	_	_
9	did	do	VBD	_	11	aux	_	_
10	not	not	RB	_	11	neg	_	_
11	differ	differ	VB	_	0	root	_	_
12	from	from	IN	_	14	case	_	_
13	control	control	NN	_	14	com	_	_
14	values	value	NNS	_	11	ppmod	_	_
15	for	for	IN	_	17	case	_	_
16	any	any	DT	_	17	det	_	_
17	dose	dose	NN	_	14	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	at	at	IN	_	22	case	_	_
20	any	any	DT	_	22	det	_	_
21	time	time	NN	_	22	com	_	_
22	point	point	NN	_	17	conj	_	_
23	in	in	IN	_	27	case	_	_
24	cerebral	cerebral	JJ	_	27	attr	_	_
25	and	and	CC	_	24	cc	_	_
26	hepatic	hepatic	JJ	_	24	conj	_	_
27	tissues	tissue	NNS	_	22	ppmod	_	_
28	.	.	.	_	11	p	_	_

1	Pretreatment	pretreatment	NN	_	36	dep	_	_
2	of	of	IN	_	3	case	_	_
3	rats	rat	NNS	_	1	ppmod	_	_
4	with	with	IN	_	5	case	_	_
5	drug1	drug0	NN	_	1	ppmod	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	100	0	CD	_	8	num	_	_
8	mg/kg	mg/kg	NN	_	5	prn	_	_
9	,	,	,	_	8	p	_	_
10	ip	ip	NN	_	8	appo	_	_
11	)	-rrb-	-RRB-	_	8	p	_	_
12	or	or	CC	_	5	cc	_	_
13	drug2	drug0	NN	_	5	conj	_	_
14	(	-lrb-	-LRB-	_	16	p	_	_
15	100	0	CD	_	16	num	_	_
16	mg/kg	mg/kg	NN	_	13	prn	_	_
17	per	per	IN	_	18	case	_	_
18	day	day	NN	_	16	ppmod	_	_
19	,	,	,	_	18	p	_	_
20	ig	ig	NN	_	18	appo	_	_
21	,	,	,	_	18	p	_	_
22	for	for	IN	_	24	case	_	_
23	3	0	CD	_	24	num	_	_
24	days	day	NNS	_	16	ppmod	_	_
25	and	and	CC	_	16	cc	_	_
26	a	a	DT	_	30	det	_	_
27	dose	dose	NN	_	30	attr	_	_
28	of	of	IN	_	30	case	_	_
29	40	0	CD	_	30	num	_	_
30	mg/kg	mg/kg	NN	_	16	conj	_	_
31	on	on	IN	_	34	case	_	_
32	the	the	DT	_	34	det	_	_
33	4th	#ord#	JJ	_	34	attr	_	_
34	day	day	NN	_	30	ppmod	_	_
35	)	-rrb-	-RRB-	_	16	p	_	_
36	provided	provided	VBD	_	0	root	_	_
37	significant	significant	JJ	_	38	attr	_	_
38	protection	protection	NN	_	36	obj	_	_
39	against	against	IN	_	41	case	_	_
40	the	the	DT	_	41	det	_	_
41	elevation	elevation	NN	_	38	ppmod	_	_
42	of	of	IN	_	44	case	_	_
43	TBARS	tbars	NNS	_	44	com	_	_
44	levels	level	NNS	_	41	ppmod	_	_
45	in	in	IN	_	49	case	_	_
46	cerebral	cerebral	JJ	_	49	attr	_	_
47	and	and	CC	_	46	cc	_	_
48	hepatic	hepatic	JJ	_	46	conj	_	_
49	tissues	tissue	NNS	_	44	ppmod	_	_
50	,	,	,	_	41	p	_	_
51	induced	induce	VBN	_	41	acl	_	_
52	by	by	IN	_	55	case	_	_
53	single	single	JJ	_	55	attr	_	_
54	high	high	JJ	_	55	attr	_	_
55	dose	dose	NN	_	51	ppmod	_	_
56	of	of	IN	_	59	case	_	_
57	oral	oral	JJ	_	59	attr	_	_
58	drug3	drug0	NN	_	59	com	_	_
59	administration	administration	NN	_	55	ppmod	_	_
60	within	within	IN	_	62	case	_	_
61	4	0	CD	_	62	num	_	_
62	h	h	NN	_	51	ppmod	_	_
63	.	.	.	_	36	p	_	_

1	Thus	thus	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	the	the	DT	_	4	det	_	_
4	results	result	NNS	_	5	dep	_	_
5	suggest	suggest	VBP	_	0	root	_	_
6	that	that	IN	_	11	mark	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	exposure	exposure	NN	_	11	dep	_	_
9	of	of	IN	_	10	case	_	_
10	rats	rat	NNS	_	8	ppmod	_	_
11	results	result	VBZ	_	5	comp	_	_
12	in	in	IN	_	16	case	_	_
13	free	free	JJ	_	16	attr	_	_
14	radical-mediated	radical-mediated	JJ	_	16	attr	_	_
15	tissue	tissue	NN	_	16	com	_	_
16	damage	damage	NN	_	11	ppmod	_	_
17	,	,	,	_	11	p	_	_
18	as	as	IN	_	19	mark	_	_
19	indicated	indicate	VBN	_	11	comp	_	_
20	by	by	IN	_	26	case	_	_
21	elevated	elevated	JJ	_	26	attr	_	_
22	cerebral	cerebral	JJ	_	26	attr	_	_
23	and	and	CC	_	22	cc	_	_
24	hepatic	hepatic	JJ	_	22	conj	_	_
25	lipid	lipid	NN	_	26	com	_	_
26	peroxidation	peroxidation	NN	_	19	ppmod	_	_
27	,	,	,	_	26	p	_	_
28	which	which	WDT	_	30	dep	_	_
29	was	be	VBD	_	30	aux	_	_
30	prevented	prevent	VBN	_	26	relcl	_	_
31	by	by	IN	_	32	case	_	_
32	drug2	drug0	NN	_	30	ppmod	_	_
33	and	and	CC	_	32	cc	_	_
34	drug3	drug0	NN	_	32	conj	_	_
35	.	.	.	_	5	p	_	_

1	Serum	serum	NN	_	3	com	_	_
2	drug1	drug0	NN	_	3	com	_	_
3	levels	level	NNS	_	9	dep	_	_
4	using	use	VBG	_	3	acl	_	_
5	an	an	DT	_	7	det	_	_
6	125I-labelled	0i-labelled	JJ	_	7	attr	_	_
7	antigen	antigen	NN	_	4	obj	_	_
8	:	:	:	_	9	p	_	_
9	Validation	validation	NN	_	0	root	_	_
10	of	of	IN	_	11	case	_	_
11	method	method	NN	_	9	ppmod	_	_
12	and	and	CC	_	9	cc	_	_
13	observations	observation	NNS	_	9	conj	_	_
14	on	on	IN	_	16	case	_	_
15	cardiac	cardiac	JJ	_	16	attr	_	_
16	patients	patient	NNS	_	13	ppmod	_	_
17	.	.	.	_	9	p	_	_

1	1	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Determinations	determination	NNS	_	14	dep	_	_
2	of	of	IN	_	5	case	_	_
3	serum	serum	NN	_	5	com	_	_
4	drug1	drug0	NN	_	5	com	_	_
5	levels	level	NNS	_	1	ppmod	_	_
6	utilizing	utilize	VBG	_	5	acl	_	_
7	commercially	commercially	RB	_	8	adv	_	_
8	available	available	JJ	_	9	attr	_	_
9	kits	kit	NNS	_	6	obj	_	_
10	with	with	IN	_	13	case	_	_
11	an	an	DT	_	13	det	_	_
12	125I-labelled	0i-labelled	JJ	_	13	attr	_	_
13	antigen	antigen	NN	_	6	ppmod	_	_
14	were	be	VBD	_	0	root	_	_
15	precise	precise	JJ	_	14	dep	_	_
16	and	and	CC	_	15	cc	_	_
17	not	not	RB	_	19	neg	_	_
18	materially	materially	RB	_	19	adv	_	_
19	different	different	JJ	_	15	conj	_	_
20	from	from	IN	_	21	case	_	_
21	results	result	NNS	_	19	ppmod	_	_
22	obtained	obtain	VBN	_	21	acl	_	_
23	with	with	IN	_	26	case	_	_
24	a	a	DT	_	26	det	_	_
25	3H-labelled	0h-labelled	JJ	_	26	attr	_	_
26	antigen	antigen	NN	_	22	ppmod	_	_
27	.	.	.	_	14	p	_	_

1	2	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	In	in	IN	_	4	mark	_	_
2	order	order	NN	_	4	dep	_	_
3	to	to	TO	_	4	aux	_	_
4	approximate	approximate	JJ	_	15	advcl	_	_
5	the	the	DT	_	8	det	_	_
6	steady	steady	JJ	_	8	attr	_	_
7	state	state	NN	_	8	com	_	_
8	level	level	NN	_	4	obj	_	_
9	,	,	,	_	15	p	_	_
10	serum	serum	NN	_	12	com	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	levels	level	NNS	_	15	dep	_	_
13	should	should	MD	_	15	modal	_	_
14	be	be	VB	_	15	aux	_	_
15	drawn	draw	VBN	_	0	root	_	_
16	either	either	CC	_	17	cc	_	_
17	before	before	IN	_	15	ppmod	_	_
18	or	or	CC	_	17	cc	_	_
19	at	at	IN	_	22	case	_	_
20	least	least	JJS	_	21	attr	_	_
21	six	#crd#	CD	_	22	num	_	_
22	hours	hour	NNS	_	17	conj	_	_
23	following	follow	VBG	_	25	adv	_	_
24	the	the	DT	_	25	det	_	_
25	administration	administration	NN	_	15	ppmod	_	_
26	of	of	IN	_	29	case	_	_
27	an	an	DT	_	29	det	_	_
28	oral	oral	JJ	_	29	attr	_	_
29	tablet	tablet	NN	_	25	ppmod	_	_
30	.	.	.	_	15	p	_	_

1	3	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Concomitantly	concomitantly	RB	_	2	adv	_	_
2	given	give	VBN	_	3	attr	_	_
3	drug1	drug0	NN	_	6	dep	_	_
4	did	do	VBD	_	6	aux	_	_
5	not	not	RB	_	6	neg	_	_
6	interfere	interfere	VB	_	0	root	_	_
7	with	with	IN	_	9	case	_	_
8	the	the	DT	_	9	det	_	_
9	absorption	absorption	NN	_	6	ppmod	_	_
10	of	of	IN	_	12	case	_	_
11	a	a	DT	_	12	det	_	_
12	tablet	tablet	NN	_	9	ppmod	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	4	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	digitalized	digitalized	JJ	_	4	attr	_	_
4	patient	patient	NN	_	16	ppmod	_	_
5	,	,	,	_	16	p	_	_
6	slow	slow	JJ	_	7	attr	_	_
7	alterations	alteration	NNS	_	16	dep	_	_
8	in	in	IN	_	10	case	_	_
9	serum	serum	NN	_	10	com	_	_
10	levels	level	NNS	_	7	ppmod	_	_
11	after	after	IN	_	13	case	_	_
12	oral	oral	JJ	_	13	attr	_	_
13	administration	administration	NN	_	10	ppmod	_	_
14	appeared	appear	VBD	_	16	aux	_	_
15	well	well	RB	_	16	adv	_	_
16	correlated	correlate	VBN	_	0	root	_	_
17	with	with	IN	_	16	case	_	_
18	,	,	,	_	16	p	_	_
19	at	at	IN	_	20	case	_	_
20	least	least	JJS	_	16	adv	_	_
21	,	,	,	_	16	p	_	_
22	the	the	DT	_	25	det	_	_
23	negative	negative	JJ	_	25	attr	_	_
24	chronotropic	chronotropic	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	16	obj	_	_
26	of	of	IN	_	28	case	_	_
27	the	the	DT	_	28	det	_	_
28	drug	drug	NN	_	25	ppmod	_	_
29	.	.	.	_	16	p	_	_

1	5	0	CD	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	Maximal	maximal	JJ	_	3	attr	_	_
2	exercise	exercise	NN	_	3	com	_	_
3	testing	testing	NN	_	16	dep	_	_
4	,	,	,	_	3	p	_	_
5	a	a	DT	_	6	det	_	_
6	maneuver	maneuver	NN	_	3	appo	_	_
7	often	often	RB	_	8	adv	_	_
8	applied	apply	VBN	_	6	acl	_	_
9	to	to	TO	_	11	aux	_	_
10	cardiac	cardiac	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	,	,	,	_	3	p	_	_
13	does	do	VBZ	_	16	aux	_	_
14	not	not	RB	_	16	neg	_	_
15	significantly	significantly	RB	_	16	adv	_	_
16	alter	alter	VB	_	0	root	_	_
17	the	the	DT	_	20	det	_	_
18	serum	serum	NN	_	20	com	_	_
19	drug1	drug0	NN	_	20	com	_	_
20	level	level	NN	_	16	obj	_	_
21	.	.	.	_	16	p	_	_

1	Analysis	analysis	NN	_	0	root	_	_
2	of	of	IN	_	5	case	_	_
3	drug1	drug0	JJ	_	5	attr	_	_
4	-induced	-induced	JJ	_	5	attr	_	_
5	diarrhea	diarrhea	NN	_	1	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	cecectomized	cecectomized	JJ	_	8	attr	_	_
8	rats	rat	NNS	_	5	ppmod	_	_
9	.	.	.	_	1	p	_	_

1	The	the	DT	_	7	det	_	_
2	drug1	drug0	NN	_	6	advnp	_	_
3	(	-lrb-	-LRB-	_	6	p	_	_
4	drug2	drug0	NN	_	6	advnp	_	_
5	)	-rrb-	-RRB-	_	6	p	_	_
6	-induced	-induced	JJ	_	7	attr	_	_
7	diarrhea	diarrhea	NN	_	9	dep	_	_
8	was	be	VBD	_	9	aux	_	_
9	analyzed	analyze	VBN	_	0	root	_	_
10	in	in	IN	_	12	case	_	_
11	cecectomized	cecectomized	JJ	_	12	attr	_	_
12	rats	rat	NNS	_	9	ppmod	_	_
13	prepared	prepare	VBN	_	12	acl	_	_
14	by	by	IN	_	15	case	_	_
15	resecting	resect	VBG	_	13	ppmod	_	_
16	the	the	DT	_	17	det	_	_
17	cecum	cecum	NN	_	15	obj	_	_
18	and	and	CC	_	17	cc	_	_
19	its	its	PRP$	_	20	poss	_	_
20	vasculature	vasculature	NN	_	17	conj	_	_
21	without	without	IN	_	22	case	_	_
22	disturbing	disturb	VBG	_	15	ppmod	_	_
23	the	the	DT	_	25	det	_	_
24	ileocecal	ileocecal	JJ	_	25	attr	_	_
25	junction	junction	NN	_	22	obj	_	_
26	.	.	.	_	9	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	0.1-1.0	0	CD	_	4	num	_	_
4	mg/kg	mg/kg	NN	_	1	prn	_	_
5	,	,	,	_	4	p	_	_
6	p.o.	p.o.	NN	_	4	appo	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_

1	dose-dependently	dose-dependently	RB	_	2	adv	_	_
2	increased	increase	VBD	_	0	root	_	_
3	the	the	DT	_	4	det	_	_
4	number	number	NN	_	2	obj	_	_
5	of	of	IN	_	7	case	_	_
6	defecation	defecation	NN	_	7	com	_	_
7	episodes	episode	NNS	_	4	ppmod	_	_
8	and	and	CC	_	2	cc	_	_
9	induced	induce	VBD	_	2	conj	_	_
10	a	a	DT	_	14	det	_	_
11	soft	soft	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	watery	watery	JJ	_	11	conj	_	_
14	stool	stool	NN	_	9	obj	_	_
15	in	in	IN	_	17	case	_	_
16	cecectomized	cecectomized	JJ	_	17	attr	_	_
17	rats	rat	NNS	_	14	ppmod	_	_
18	.	.	.	_	2	p	_	_

1	At	at	IN	_	3	case	_	_
2	0.3	0	CD	_	3	num	_	_
3	mg/kg	mg/kg	NN	_	10	ppmod	_	_
4	,	,	,	_	10	p	_	_
5	the	the	DT	_	7	det	_	_
6	diarrhea-inducing	diarrhea-inducing	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	10	dep	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	were	be	VBD	_	0	root	_	_
11	more	more	RBR	_	12	adv	_	_
12	pronounced	pronounced	JJ	_	10	dep	_	_
13	in	in	IN	_	14	case	_	_
14	cecectomized	cecectomized	NN	_	10	ppmod	_	_
15	than	than	IN	_	18	case	_	_
16	in	in	IN	_	18	case	_	_
17	control	control	JJ	_	18	attr	_	_
18	rats	rat	NNS	_	10	ppmod	_	_
19	.	.	.	_	10	p	_	_

1	When	when	WRB	_	2	adv	_	_
2	given	give	VBN	_	10	advcl	_	_
3	i.p.	i.p.	RB	_	2	adv	_	_
4	,	,	,	_	10	p	_	_
5	drug1	drug0	NN	_	10	dep	_	_
6	(	-lrb-	-LRB-	_	8	p	_	_
7	0.3	0	CD	_	8	num	_	_
8	mg/kg	mg/kg	NN	_	5	prn	_	_
9	)	-rrb-	-RRB-	_	8	p	_	_
10	induced	induce	VBD	_	0	root	_	_
11	a	a	DT	_	13	det	_	_
12	watery	watery	JJ	_	13	attr	_	_
13	stool	stool	NN	_	10	obj	_	_
14	in	in	IN	_	18	case	_	_
15	cecectomized	cecectomized	JJ	_	18	attr	_	_
16	and	and	CC	_	15	cc	_	_
17	control	control	NN	_	15	conj	_	_
18	rats	rat	NNS	_	10	ppmod	_	_
19	with	with	IN	_	22	case	_	_
20	the	the	DT	_	22	det	_	_
21	same	same	JJ	_	22	attr	_	_
22	efficacy	efficacy	NN	_	18	ppmod	_	_
23	,	,	,	_	10	p	_	_
24	although	although	IN	_	27	mark	_	_
25	these	these	DT	_	26	det	_	_
26	effects	effect	NNS	_	27	dep	_	_
27	were	be	VBD	_	10	comp	_	_
28	short-lasting	short-lasting	JJ	_	27	dep	_	_
29	as	as	IN	_	30	mark	_	_
30	compared	compare	VBN	_	27	comp	_	_
31	to	to	TO	_	33	aux	_	_
32	oral	oral	JJ	_	33	attr	_	_
33	administration	administration	NN	_	30	ppmod	_	_
34	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	4	0	CD	_	4	num	_	_
4	ml/kg	ml/kg	NN	_	1	prn	_	_
5	,	,	,	_	4	p	_	_
6	p.o.	p.o.	NN	_	4	appo	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_

1	also	also	RB	_	2	adv	_	_
2	induced	induce	VBD	_	0	root	_	_
3	diarrhea	diarrhea	NN	_	2	obj	_	_
4	,	,	,	_	2	p	_	_
5	but	but	CC	_	2	cc	_	_
6	did	do	VBD	_	8	aux	_	_
7	not	not	RB	_	8	neg	_	_
8	produce	produce	VB	_	2	conj	_	_
9	a	a	DT	_	11	det	_	_
10	watery	watery	JJ	_	11	attr	_	_
11	stool	stool	NN	_	8	obj	_	_
12	in	in	IN	_	14	case	_	_
13	cecectomized	cecectomized	JJ	_	14	attr	_	_
14	rats	rat	NNS	_	11	ppmod	_	_
15	.	.	.	_	2	p	_	_

1	There	there	EX	_	2	dep	_	_
2	were	be	VBD	_	0	root	_	_
3	no	no	DT	_	4	det	_	_
4	differences	difference	NNS	_	2	obj	_	_
5	between	between	IN	_	6	case	_	_
6	cecectomized	cecectomized	JJ	_	4	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	control	control	JJ	_	9	attr	_	_
9	rats	rat	NNS	_	6	conj	_	_
10	in	in	IN	_	14	case	_	_
11	basal	basal	JJ	_	14	attr	_	_
12	small	small	JJ	_	14	attr	_	_
13	intestinal	intestinal	JJ	_	14	attr	_	_
14	transits	transit	NNS	_	4	ppmod	_	_
15	or	or	CC	_	14	cc	_	_
16	in	in	IN	_	25	case	_	_
17	drug1	drug0	NN	_	24	advnp	_	_
18	(	-lrb-	-LRB-	_	20	p	_	_
19	0.3	0	CD	_	20	num	_	_
20	mg/kg	mg/kg	NN	_	17	prn	_	_
21	,	,	,	_	20	p	_	_
22	p.o.	p.o.	NN	_	20	appo	_	_
23	)	-rrb-	-RRB-	_	20	p	_	_
24	-induced	-induced	JJ	_	25	attr	_	_
25	enhancements	enhancement	NNS	_	14	conj	_	_
26	.	.	.	_	2	p	_	_

1	Moreover	moreover	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	the	the	DT	_	11	det	_	_
4	basal	basal	JJ	_	11	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	drug1	drug0	NN	_	7	advnp	_	_
7	-induced	-induced	JJ	_	4	conj	_	_
8	jejunal	jejunal	JJ	_	11	attr	_	_
9	net	net	JJ	_	11	attr	_	_
10	fluid	fluid	NN	_	11	com	_	_
11	transfers	transfer	NNS	_	12	dep	_	_
12	were	be	VBD	_	0	root	_	_
13	the	the	DT	_	14	det	_	_
14	same	same	JJ	_	12	obj	_	_
15	in	in	IN	_	16	case	_	_
16	cecectomized	cecectomized	JJ	_	12	ppmod	_	_
17	and	and	CC	_	16	cc	_	_
18	in	in	IN	_	20	case	_	_
19	control	control	NN	_	20	com	_	_
20	rats	rat	NNS	_	16	conj	_	_
21	.	.	.	_	12	p	_	_

1	On	on	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	other	other	JJ	_	4	attr	_	_
4	hand	hand	NN	_	18	ppmod	_	_
5	,	,	,	_	18	p	_	_
6	the	the	DT	_	8	det	_	_
7	enhanced	enhance	VBN	_	8	attr	_	_
8	secretion	secretion	NN	_	18	dep	_	_
9	of	of	IN	_	11	case	_	_
10	colonic	colonic	JJ	_	11	attr	_	_
11	fluid	fluid	NN	_	8	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	drug1	drug0	NN	_	8	ppmod	_	_
14	,	,	,	_	8	p	_	_
15	given	give	VBN	_	8	acl	_	_
16	intraluminally	intraluminally	RB	_	15	adv	_	_
17	,	,	,	_	8	p	_	_
18	was	be	VBD	_	0	root	_	_
19	only	only	RB	_	20	adv	_	_
20	half	half	NN	_	18	obj	_	_
21	of	of	IN	_	22	case	_	_
22	that	that	DT	_	20	ppmod	_	_
23	in	in	IN	_	25	case	_	_
24	control	control	NN	_	25	com	_	_
25	rats	rat	NNS	_	22	ppmod	_	_
26	,	,	,	_	18	p	_	_
27	whereas	whereas	IN	_	37	mark	_	_
28	the	the	DT	_	31	det	_	_
29	colonic	colonic	JJ	_	31	attr	_	_
30	transit-enhancing	transit-enhancing	JJ	_	31	attr	_	_
31	effect	effect	NN	_	37	dep	_	_
32	of	of	IN	_	33	case	_	_
33	drug2	drug0	NN	_	31	ppmod	_	_
34	in	in	IN	_	36	case	_	_
35	cecectomized	cecectomized	JJ	_	36	attr	_	_
36	rats	rat	NNS	_	31	ppmod	_	_
37	was	be	VBD	_	18	comp	_	_
38	more	more	RBR	_	39	adv	_	_
39	pronounced	pronounced	JJ	_	37	dep	_	_
40	than	than	IN	_	43	case	_	_
41	in	in	IN	_	43	case	_	_
42	control	control	JJ	_	43	attr	_	_
43	rats	rat	NNS	_	37	ppmod	_	_
44	at	at	IN	_	45	case	_	_
45	15	0	CD	_	37	ppmod	_	_
46	but	but	CC	_	45	cc	_	_
47	not	not	RB	_	50	neg	_	_
48	at	at	IN	_	50	case	_	_
49	30	0	CD	_	50	num	_	_
50	min	min	NN	_	45	conj	_	_
51	after	after	IN	_	53	case	_	_
52	its	its	PRP$	_	53	poss	_	_
53	administration	administration	NN	_	50	ppmod	_	_
54	.	.	.	_	18	p	_	_

1	The	the	DT	_	5	det	_	_
2	basal	basal	JJ	_	5	attr	_	_
3	colonic	colonic	JJ	_	5	attr	_	_
4	fluid	fluid	NN	_	5	com	_	_
5	contents	content	NNS	_	8	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	transits	transit	NNS	_	5	conj	_	_
8	were	be	VBD	_	0	root	_	_
9	the	the	DT	_	10	det	_	_
10	same	same	JJ	_	8	obj	_	_
11	in	in	IN	_	12	case	_	_
12	cecectomized	cecectomized	JJ	_	8	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	in	in	IN	_	16	case	_	_
15	control	control	NN	_	16	com	_	_
16	rats	rat	NNS	_	12	conj	_	_
17	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	8	p	_	_
5	0.1	0	CD	_	8	num	_	_
6	and	and	CC	_	5	cc	_	_
7	1.0	0	CD	_	5	conj	_	_
8	mg/kg	mg/kg	NN	_	1	prn	_	_
9	,	,	,	_	8	p	_	_
10	s.c.	s.c.	NN	_	8	appo	_	_
11	)	-rrb-	-RRB-	_	8	p	_	_

1	drug1	drug0	NN	_	12	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	(	-lrb-	-LRB-	_	8	p	_	_
5	0.1	0	CD	_	8	num	_	_
6	and	and	CC	_	5	cc	_	_
7	1.0	0	CD	_	5	conj	_	_
8	mg/kg	mg/kg	NN	_	1	prn	_	_
9	,	,	,	_	8	p	_	_
10	s.c.	s.c.	NN	_	8	appo	_	_
11	)	-rrb-	-RRB-	_	8	p	_	_
12	inhibited	inhibit	VBD	_	0	root	_	_
13	the	the	DT	_	22	det	_	_
14	drug3	drug0	NN	_	21	advnp	_	_
15	(	-lrb-	-LRB-	_	17	p	_	_
16	0.3	0	CD	_	17	num	_	_
17	mg/kg	mg/kg	NN	_	14	prn	_	_
18	,	,	,	_	17	p	_	_
19	p.o.	p.o.	NN	_	17	appo	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	-induced	-induced	JJ	_	22	attr	_	_
22	diarrhea	diarrhea	NN	_	12	obj	_	_
23	in	in	IN	_	25	case	_	_
24	cecectomized	cecectomized	JJ	_	25	attr	_	_
25	rats	rat	NNS	_	22	ppmod	_	_
26	.	.	.	_	12	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	5	0	CD	_	4	num	_	_
4	mg/kg	mg/kg	NN	_	1	prn	_	_
5	,	,	,	_	4	p	_	_
6	s.c.	s.c.	NN	_	4	appo	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_

1	drug1	drug0	NN	_	9	dep	_	_
2	(	-lrb-	-LRB-	_	4	p	_	_
3	5	0	CD	_	4	num	_	_
4	mg/kg	mg/kg	NN	_	1	prn	_	_
5	,	,	,	_	4	p	_	_
6	s.c.	s.c.	NN	_	4	appo	_	_
7	)	-rrb-	-RRB-	_	4	p	_	_
8	completely	completely	RB	_	9	adv	_	_
9	antagonized	antagonize	VBD	_	0	root	_	_
10	the	the	DT	_	12	det	_	_
11	inhibitory	inhibitory	JJ	_	12	attr	_	_
12	effect	effect	NN	_	9	obj	_	_
13	of	of	IN	_	14	case	_	_
14	drug2	drug0	NN	_	12	ppmod	_	_
15	and	and	CC	_	9	cc	_	_
16	partly	partly	RB	_	17	adv	_	_
17	antagonized	antagonize	VBD	_	9	conj	_	_
18	the	the	DT	_	19	det	_	_
19	effect	effect	NN	_	17	obj	_	_
20	of	of	IN	_	21	case	_	_
21	drug3	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	9	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	oral	oral	JJ	_	6	attr	_	_
6	administration	administration	NN	_	9	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	induces	induce	VBZ	_	3	comp	_	_
10	a	a	DT	_	14	det	_	_
11	more	more	RBR	_	12	adv	_	_
12	pronounced	pronounced	JJ	_	14	attr	_	_
13	secretory	secretory	JJ	_	14	attr	_	_
14	diarrhea	diarrhea	NN	_	9	obj	_	_
15	in	in	IN	_	16	case	_	_
16	cecectomized	cecectomized	VBN	_	9	ppmod	_	_
17	than	than	IN	_	16	case	_	_
18	in	in	IN	_	20	case	_	_
19	control	control	NN	_	20	com	_	_
20	rats	rat	NNS	_	16	ppmod	_	_
21	,	,	,	_	9	p	_	_
22	probably	probably	RB	_	9	adv	_	_
23	due	due	JJ	_	26	adv	_	_
24	to	to	TO	_	26	aux	_	_
25	the	the	DT	_	26	det	_	_
26	lack	lack	NN	_	9	ppmod	_	_
27	of	of	IN	_	30	case	_	_
28	the	the	DT	_	30	det	_	_
29	reservoir	reservoir	NN	_	30	com	_	_
30	function	function	NN	_	26	ppmod	_	_
31	of	of	IN	_	33	case	_	_
32	the	the	DT	_	33	det	_	_
33	cecum	cecum	NN	_	30	ppmod	_	_
34	in	in	IN	_	37	case	_	_
35	the	the	DT	_	37	det	_	_
36	operated	operated	JJ	_	37	attr	_	_
37	animals	animal	NNS	_	30	ppmod	_	_
38	.	.	.	_	3	p	_	_

1	This	this	DT	_	4	det	_	_
2	secretory	secretory	JJ	_	4	attr	_	_
3	diarrhea	diarrhea	NN	_	4	com	_	_
4	model	model	NN	_	5	dep	_	_
5	is	be	VBZ	_	0	root	_	_
6	suitable	suitable	JJ	_	5	dep	_	_
7	for	for	IN	_	8	case	_	_
8	evaluating	evaluate	VBG	_	6	ppmod	_	_
9	the	the	DT	_	11	det	_	_
10	antidiarrheal	antidiarrheal	JJ	_	11	attr	_	_
11	activity	activity	NN	_	8	obj	_	_
12	of	of	IN	_	13	case	_	_
13	drugs	drug	NNS	_	11	ppmod	_	_
14	.	.	.	_	5	p	_	_

1	drug1	drug0	NN	_	0	root	_	_
2	as	as	IN	_	4	case	_	_
3	potent	potent	JJ	_	4	attr	_	_
4	drug2	drug0	NN	_	1	ppmod	_	_
5	of	of	IN	_	12	case	_	_
6	glucocorticoid-induced	glucocorticoid-induced	JJ	_	12	attr	_	_
7	mouse	mouse	NN	_	10	attr	_	_
8	mammary	mammary	JJ	_	10	attr	_	_
9	tumor	tumor	NN	_	10	com	_	_
10	virus	virus	NN	_	12	com	_	_
11	gene	gene	NN	_	12	com	_	_
12	expression	expression	NN	_	4	ppmod	_	_
13	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	effect	effect	NN	_	14	dep	_	_
3	of	of	IN	_	8	case	_	_
4	natural	natural	JJ	_	8	attr	_	_
5	and	and	CC	_	4	cc	_	_
6	synthetic	synthetic	JJ	_	4	conj	_	_
7	galloyl	galloyl	NN	_	8	com	_	_
8	esters	ester	NNS	_	2	ppmod	_	_
9	on	on	IN	_	12	case	_	_
10	glucocorticoid-induced	glucocorticoid-induced	JJ	_	12	attr	_	_
11	gene	gene	NN	_	12	com	_	_
12	expression	expression	NN	_	2	ppmod	_	_
13	was	be	VBD	_	14	aux	_	_
14	evaluated	evaluate	VBN	_	0	root	_	_
15	by	by	IN	_	16	case	_	_
16	using	use	VBG	_	14	ppmod	_	_
17	rat	rat	NN	_	20	com	_	_
18	fibroblast	fibroblast	NN	_	20	com	_	_
19	3Y1	0y0	NN	_	20	com	_	_
20	cells	cell	NNS	_	16	obj	_	_
21	stably	stably	RB	_	22	adv	_	_
22	transfected	transfected	VBN	_	20	acl	_	_
23	with	with	IN	_	27	case	_	_
24	a	a	DT	_	27	det	_	_
25	luciferase	luciferase	NN	_	27	com	_	_
26	reporter	reporter	NN	_	27	com	_	_
27	gene	gene	NN	_	22	ppmod	_	_
28	under	under	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	transcriptional	transcriptional	JJ	_	31	attr	_	_
31	regulation	regulation	NN	_	27	ppmod	_	_
32	of	of	IN	_	37	case	_	_
33	the	the	DT	_	37	det	_	_
34	mouse	mouse	NN	_	37	attr	_	_
35	mammary	mammary	JJ	_	37	attr	_	_
36	tumor	tumor	NN	_	37	com	_	_
37	virus	virus	NN	_	31	ppmod	_	_
38	drug1	drug0	CD	_	37	num	_	_
39	.	.	.	_	14	p	_	_

1	The	the	DT	_	4	det	_	_
2	glucocorticoid-induced	glucocorticoid-induced	JJ	_	4	attr	_	_
3	gene	gene	NN	_	4	com	_	_
4	transcription	transcription	NN	_	7	dep	_	_
5	was	be	VBD	_	7	aux	_	_
6	strongly	strongly	RB	_	7	adv	_	_
7	suppressed	suppress	VBN	_	0	root	_	_
8	by	by	IN	_	11	case	_	_
9	synthetic	synthetic	JJ	_	11	attr	_	_
10	alkyl	alkyl	NN	_	11	com	_	_
11	esters	ester	NNS	_	7	ppmod	_	_
12	;	;	:	_	7	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	showed	show	VBD	_	0	root	_	_
3	the	the	DT	_	6	det	_	_
4	most	most	RBS	_	5	adv	_	_
5	potent	potent	JJ	_	6	attr	_	_
6	inhibition	inhibition	NN	_	2	obj	_	_
7	(	-lrb-	-LRB-	_	8	p	_	_
8	66	0	CD	_	6	num	_	_
9	%	%	NN	_	8	meta	_	_
10	inhibition	inhibition	NN	_	8	appo	_	_
11	at	at	IN	_	13	case	_	_
12	10	0	CD	_	13	num	_	_
13	microM	microm	NN	_	8	ppmod	_	_
14	)	-rrb-	-RRB-	_	8	p	_	_
15	,	,	,	_	6	p	_	_
16	which	which	WDT	_	17	dep	_	_
17	was	be	VBD	_	6	relcl	_	_
18	far	far	RB	_	19	com	_	_
19	more	more	RBR	_	20	adv	_	_
20	potent	potent	JJ	_	17	dep	_	_
21	than	than	IN	_	22	case	_	_
22	that	that	DT	_	20	ppmod	_	_
23	of	of	IN	_	25	case	_	_
24	crude	crude	JJ	_	25	attr	_	_
25	drug2	drug0	NNS	_	22	ppmod	_	_
26	.	.	.	_	2	p	_	_

1	n-Octyl	n-octyl	NN	_	6	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	n-cetyl	n-cetyl	NN	_	4	com	_	_
4	gallate	gallate	NN	_	1	conj	_	_
5	also	also	RB	_	6	adv	_	_
6	showed	show	VBD	_	0	root	_	_
7	good	good	JJ	_	8	attr	_	_
8	inhibition	inhibition	NN	_	6	obj	_	_
9	,	,	,	_	6	p	_	_
10	while	while	IN	_	14	mark	_	_
11	gallic	gallic	JJ	_	12	attr	_	_
12	acid	acid	NN	_	14	dep	_	_
13	itself	itself	PRP	_	12	appo	_	_
14	was	be	VBD	_	6	comp	_	_
15	not	not	RB	_	14	neg	_	_
16	so	so	RB	_	14	adv	_	_
17	active	active	JJ	_	14	dep	_	_
18	,	,	,	_	6	p	_	_
19	suggesting	suggest	VBG	_	6	comp	_	_
20	that	that	IN	_	27	mark	_	_
21	the	the	DT	_	22	det	_	_
22	presence	presence	NN	_	27	dep	_	_
23	of	of	IN	_	26	case	_	_
24	hydrophobic	hydrophobic	JJ	_	26	attr	_	_
25	side	side	JJ	_	26	attr	_	_
26	chain	chain	NN	_	22	ppmod	_	_
27	is	be	VBZ	_	19	comp	_	_
28	important	important	JJ	_	27	dep	_	_
29	for	for	IN	_	32	case	_	_
30	the	the	DT	_	32	det	_	_
31	suppressive	suppressive	JJ	_	32	attr	_	_
32	effect	effect	NN	_	28	ppmod	_	_
33	.	.	.	_	6	p	_	_

1	On	on	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	other	other	JJ	_	4	attr	_	_
4	hand	hand	NN	_	19	ppmod	_	_
5	,	,	,	_	19	p	_	_
6	surprisingly	surprisingly	RB	_	19	adv	_	_
7	,	,	,	_	19	p	_	_
8	drug1	drug0	NN	_	19	dep	_	_
9	,	,	,	_	8	p	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	-	-	CC	_	13	prn	_	_
12	)	-rrb-	-RRB-	_	11	p	_	_
13	-epigallocatechin-3-O-gallate	-epigallocatechin-0-o-gallate	NN	_	8	appo	_	_
14	and	and	CC	_	13	cc	_	_
15	theasinensin	theasinensin	NN	_	16	com	_	_
16	A	a	NN	_	13	conj	_	_
17	,	,	,	_	8	p	_	_
18	potently	potently	RB	_	19	adv	_	_
19	enhanced	enhance	VBD	_	0	root	_	_
20	the	the	DT	_	22	det	_	_
21	promoter	promoter	NN	_	22	com	_	_
22	activity	activity	NN	_	19	obj	_	_
23	(	-lrb-	-LRB-	_	28	p	_	_
24	182	0	CD	_	28	num	_	_
25	and	and	CC	_	24	cc	_	_
26	247	0	CD	_	24	conj	_	_
27	%	%	NN	_	24	meta	_	_
28	activity	activity	NN	_	22	prn	_	_
29	at	at	IN	_	31	case	_	_
30	1	0	CD	_	31	num	_	_
31	microM	microm	NN	_	28	ppmod	_	_
32	,	,	,	_	31	p	_	_
33	respectively	respectively	RB	_	31	adv	_	_
34	)	-rrb-	-RRB-	_	28	p	_	_
35	.	.	.	_	19	p	_	_

1	The	the	DT	_	2	det	_	_
2	regulation	regulation	NN	_	15	dep	_	_
3	of	of	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	level	level	NN	_	2	ppmod	_	_
6	of	of	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	glucocorticoid-induced	glucocorticoid-induced	JJ	_	10	attr	_	_
9	gene	gene	NN	_	10	com	_	_
10	expression	expression	NN	_	5	ppmod	_	_
11	by	by	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	antioxidative	antioxidative	JJ	_	14	attr	_	_
14	gallates	gallates	NNS	_	2	ppmod	_	_
15	is	be	VBZ	_	0	root	_	_
16	of	of	IN	_	18	case	_	_
17	great	great	JJ	_	18	attr	_	_
18	interest	interest	NN	_	15	ppmod	_	_
19	from	from	IN	_	22	case	_	_
20	a	a	DT	_	22	det	_	_
21	therapeutic	therapeutic	JJ	_	22	attr	_	_
22	point	point	NN	_	15	ppmod	_	_
23	of	of	IN	_	24	case	_	_
24	view	view	NN	_	22	ppmod	_	_
25	.	.	.	_	15	p	_	_

1	High-dose	high-dose	JJ	_	2	attr	_	_
2	drug1	drug0	NN	_	0	root	_	_
3	with	with	IN	_	5	case	_	_
4	drug2	drug0	NN	_	5	com	_	_
5	protection	protection	NN	_	2	ppmod	_	_
6	.	.	.	_	2	p	_	_

1	Nephrotoxicity	nephrotoxicity	NN	_	3	dep	_	_
2	frequently	frequently	RB	_	3	adv	_	_
3	limits	limit	VBZ	_	0	root	_	_
4	the	the	DT	_	5	det	_	_
5	dose	dose	NN	_	3	obj	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	to	to	TO	_	12	aux	_	_
9	less	less	JJR	_	11	attr	_	_
10	than	than	IN	_	9	com	_	_
11	120	0	CD	_	12	num	_	_
12	mg/m2	mg/m0	NNS	_	3	ppmod	_	_
13	per	per	IN	_	14	case	_	_
14	injection	injection	NN	_	12	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	a	a	DT	_	5	det	_	_
4	neutralizing	neutralizing	NN	_	5	com	_	_
5	agent	agent	NN	_	2	obj	_	_
6	for	for	IN	_	7	case	_	_
7	drug2	drug0	NN	_	5	ppmod	_	_
8	that	that	WDT	_	9	dep	_	_
9	protects	protect	VBZ	_	5	relcl	_	_
10	against	against	IN	_	12	case	_	_
11	renal	renal	JJ	_	12	attr	_	_
12	damage	damage	NN	_	9	ppmod	_	_
13	.	.	.	_	2	p	_	_

1	To	to	TO	_	2	aux	_	_
2	determine	determine	VB	_	24	advcl	_	_
3	whether	whether	IN	_	8	mark	_	_
4	injection	injection	NN	_	8	dep	_	_
5	of	of	IN	_	6	case	_	_
6	drug1	drug0	NN	_	4	ppmod	_	_
7	would	would	MD	_	8	modal	_	_
8	permit	permit	VB	_	2	comp	_	_
9	larger	large	JJR	_	10	attr	_	_
10	doses	dose	NNS	_	8	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	to	to	TO	_	15	aux	_	_
14	be	be	VB	_	15	aux	_	_
15	administered	administer	VBN	_	8	comp	_	_
16	,	,	,	_	24	p	_	_
17	a	a	DT	_	20	det	_	_
18	fixed	fixed	JJ	_	20	attr	_	_
19	9.9-g/m2	0-g/m0	NN	_	20	com	_	_
20	dose	dose	NN	_	24	dep	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	was	be	VBD	_	24	aux	_	_
24	given	give	VBN	_	0	root	_	_
25	intravenously	intravenously	RB	_	24	adv	_	_
26	over	over	IN	_	28	case	_	_
27	three	#crd#	CD	_	28	num	_	_
28	hours	hour	NNS	_	24	ppmod	_	_
29	concurrently	concurrently	RB	_	32	adv	_	_
30	with	with	IN	_	32	case	_	_
31	escalating	escalating	JJ	_	32	attr	_	_
32	doses	dose	NNS	_	24	ppmod	_	_
33	of	of	IN	_	34	case	_	_
34	drug4	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	24	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	administered	administer	VBN	_	0	root	_	_
4	over	over	IN	_	8	case	_	_
5	the	the	DT	_	8	det	_	_
6	last	last	JJ	_	8	attr	_	_
7	two	#crd#	CD	_	8	num	_	_
8	hours	hour	NNS	_	3	ppmod	_	_
9	of	of	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	drug2	drug0	NN	_	12	com	_	_
12	infusion	infusion	NN	_	8	ppmod	_	_
13	.	.	.	_	3	p	_	_

1	Using	use	VBG	_	6	advcl	_	_
2	this	this	DT	_	3	det	_	_
3	technique	technique	NN	_	1	obj	_	_
4	,	,	,	_	6	p	_	_
5	it	it	PRP	_	6	dep	_	_
6	was	be	VBD	_	0	root	_	_
7	possible	possible	JJ	_	6	dep	_	_
8	to	to	TO	_	9	aux	_	_
9	escalate	escalate	VB	_	7	comp	_	_
10	the	the	DT	_	12	det	_	_
11	drug1	drug0	NN	_	12	com	_	_
12	dose	dose	NN	_	9	obj	_	_
13	to	to	TO	_	15	aux	_	_
14	225	0	NN	_	15	num	_	_
15	mg/m2	mg/m0	NNS	_	9	ppmod	_	_
16	before	before	IN	_	20	mark	_	_
17	dose-limiting	dose-limiting	JJ	_	18	attr	_	_
18	toxicities	toxicity	NNS	_	20	dep	_	_
19	were	be	VBD	_	20	aux	_	_
20	encountered	encounter	VBN	_	6	comp	_	_
21	.	.	.	_	6	p	_	_

1	Comparison	comparison	NN	_	23	dep	_	_
2	of	of	IN	_	4	case	_	_
3	drug1	drug0	NN	_	4	com	_	_
4	pharmacokinetics	pharmacokinetics	NNS	_	1	ppmod	_	_
5	in	in	IN	_	6	case	_	_
6	patients	patient	NNS	_	4	ppmod	_	_
7	treated	treat	VBN	_	6	acl	_	_
8	with	with	IN	_	10	case	_	_
9	202.5	0	CD	_	10	num	_	_
10	mg/m2	mg/m0	NNS	_	7	ppmod	_	_
11	plus	plus	CC	_	10	cc	_	_
12	drug2	drug0	NN	_	10	conj	_	_
13	to	to	TO	_	14	aux	_	_
14	those	those	DT	_	1	ppmod	_	_
15	in	in	IN	_	16	case	_	_
16	patients	patient	NNS	_	14	ppmod	_	_
17	treated	treat	VBN	_	16	acl	_	_
18	with	with	IN	_	20	case	_	_
19	100	0	CD	_	20	num	_	_
20	mg/m2	mg/m0	NNS	_	17	ppmod	_	_
21	without	without	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	indicated	indicate	VBD	_	0	root	_	_
24	that	that	IN	_	26	mark	_	_
25	there	there	EX	_	26	dep	_	_
26	were	be	VBD	_	23	comp	_	_
27	no	no	DT	_	28	det	_	_
28	changes	change	NNS	_	26	obj	_	_
29	in	in	IN	_	33	case	_	_
30	the	the	DT	_	32	det	_	_
31	elimination	elimination	NN	_	32	com	_	_
32	rate	rate	NN	_	33	com	_	_
33	constant	constant	NN	_	28	ppmod	_	_
34	,	,	,	_	28	p	_	_
35	volume	volume	NN	_	28	conj	_	_
36	of	of	IN	_	37	case	_	_
37	distribution	distribution	NN	_	35	ppmod	_	_
38	,	,	,	_	35	p	_	_
39	or	or	CC	_	35	cc	_	_
40	total	total	JJ	_	42	attr	_	_
41	body	body	NN	_	42	com	_	_
42	clearance	clearance	NN	_	28	conj	_	_
43	of	of	IN	_	44	case	_	_
44	drug4	drug0	NN	_	42	ppmod	_	_
45	.	.	.	_	23	p	_	_

1	The	the	DT	_	4	det	_	_
2	total	total	JJ	_	4	attr	_	_
3	drug	drug	NN	_	4	com	_	_
4	exposure	exposure	NN	_	8	dep	_	_
5	for	for	IN	_	7	case	_	_
6	the	the	DT	_	7	det	_	_
7	plasma	plasma	NN	_	4	ppmod	_	_
8	was	be	VBD	_	0	root	_	_
9	approximately	approximately	RB	_	10	adv	_	_
10	twofold	twofold	JJ	_	8	dep	_	_
11	at	at	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	higher	high	JJR	_	15	attr	_	_
14	drug1	drug0	NN	_	15	com	_	_
15	dose	dose	NN	_	8	ppmod	_	_
16	.	.	.	_	8	p	_	_

1	This	this	DT	_	2	det	_	_
2	study	study	NN	_	3	dep	_	_
3	demonstrates	demonstrate	VBZ	_	0	root	_	_
4	that	that	IN	_	9	mark	_	_
5	concurrent	concurrent	JJ	_	6	attr	_	_
6	administration	administration	NN	_	9	dep	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	permits	permit	VBZ	_	3	comp	_	_
10	at	at	IN	_	11	case	_	_
11	least	least	JJS	_	9	adv	_	_
12	a	a	DT	_	14	det	_	_
13	twofold	twofold	JJ	_	14	attr	_	_
14	increase	increase	NN	_	9	obj	_	_
15	in	in	IN	_	16	case	_	_
16	dose	dose	NN	_	14	ppmod	_	_
17	and	and	CC	_	14	cc	_	_
18	total	total	JJ	_	19	attr	_	_
19	exposure	exposure	NN	_	14	conj	_	_
20	to	to	TO	_	21	aux	_	_
21	drug2	drug0	NN	_	19	ppmod	_	_
22	.	.	.	_	3	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	on	on	IN	_	5	case	_	_
3	the	the	DT	_	5	det	_	_
4	antinociceptive	antinociceptive	JJ	_	5	attr	_	_
5	effect	effect	NN	_	1	ppmod	_	_
6	between	between	IN	_	7	case	_	_
7	drug1	drug0	NN	_	1	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	or	or	CC	_	9	cc	_	_
11	drug3	drug0	NN	_	7	conj	_	_
12	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	aim	aim	NN	_	6	dep	_	_
3	of	of	IN	_	5	case	_	_
4	this	this	DT	_	5	det	_	_
5	paper	paper	NN	_	2	ppmod	_	_
6	was	be	VBD	_	0	root	_	_
7	to	to	TO	_	8	aux	_	_
8	study	study	VB	_	6	comp	_	_
9	the	the	DT	_	10	det	_	_
10	interaction	interaction	NN	_	8	obj	_	_
11	between	between	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	both	both	CC	_	15	cc	_	_
15	drug2	drug0	NN	_	12	conj	_	_
16	or	or	CC	_	15	cc	_	_
17	its	its	PRP$	_	20	poss	_	_
18	synthetic	synthetic	JJ	_	20	attr	_	_
19	analogue	analogue	NN	_	20	com	_	_
20	drug3	drug0	NN	_	15	conj	_	_
21	,	,	,	_	15	p	_	_
22	or	or	CC	_	15	cc	_	_
23	drug4	drug0	NN	_	12	conj	_	_
24	,	,	,	_	8	p	_	_
25	on	on	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	antinonciceptive	antinonciceptive	JJ	_	28	attr	_	_
28	effect	effect	NN	_	8	ppmod	_	_
29	of	of	IN	_	31	case	_	_
30	these	these	DT	_	31	det	_	_
31	peptides	peptide	NNS	_	28	ppmod	_	_
32	in	in	IN	_	33	case	_	_
33	mice	mouse	NNS	_	28	ppmod	_	_
34	after	after	IN	_	36	case	_	_
35	intracisternal	intracisternal	JJ	_	36	attr	_	_
36	injection	injection	NN	_	33	ppmod	_	_
37	.	.	.	_	6	p	_	_

1	Antinociception	antinociception	NN	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	measured	measure	VBN	_	0	root	_	_
4	by	by	IN	_	7	case	_	_
5	the	the	DT	_	7	det	_	_
6	hot-plate	hot-plate	JJ	_	7	attr	_	_
7	method	method	NN	_	3	ppmod	_	_
8	.	.	.	_	3	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	was	be	VBD	_	3	aux	_	_
3	shown	show	VBN	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	antagonized	antagonize	VBD	_	3	comp	_	_
7	evidently	evidently	RB	_	6	adv	_	_
8	the	the	DT	_	10	det	_	_
9	antinociceptive	antinociceptive	JJ	_	10	attr	_	_
10	effect	effect	NN	_	6	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	their	their	PRP$	_	15	poss	_	_
15	analogue	analogue	NN	_	12	conj	_	_
16	.	.	.	_	3	p	_	_

1	On	on	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	contrary	contrary	NN	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	drug1	drug0	NN	_	8	dep	_	_
6	and	and	CC	_	5	cc	_	_
7	drug2	drug0	NN	_	5	conj	_	_
8	were	be	VBD	_	0	root	_	_
9	agonists	agonist	NNS	_	8	obj	_	_
10	in	in	IN	_	11	case	_	_
11	induction	induction	NN	_	9	ppmod	_	_
12	of	of	IN	_	13	case	_	_
13	analgesia	analgesia	NN	_	11	ppmod	_	_
14	.	.	.	_	8	p	_	_

1	It	it	PRP	_	3	dep	_	_
2	is	be	VBZ	_	3	aux	_	_
3	concluded	conclude	VBN	_	0	root	_	_
4	that	that	IN	_	6	mark	_	_
5	drug1	drug0	NN	_	6	dep	_	_
6	modulates	modulate	VBZ	_	3	comp	_	_
7	in	in	IN	_	10	case	_	_
8	an	an	DT	_	10	det	_	_
9	opposite	opposite	JJ	_	10	attr	_	_
10	way	way	NN	_	6	ppmod	_	_
11	the	the	DT	_	12	det	_	_
12	function	function	NN	_	6	obj	_	_
13	of	of	IN	_	16	case	_	_
14	the	the	DT	_	16	det	_	_
15	enkephalinergic	enkephalinergic	JJ	_	16	attr	_	_
16	neurons	neuron	NNS	_	12	ppmod	_	_
17	and	and	CC	_	12	cc	_	_
18	the	the	DT	_	20	det	_	_
19	central	central	JJ	_	20	attr	_	_
20	action	action	NN	_	12	conj	_	_
21	of	of	IN	_	22	case	_	_
22	drug2	drug0	NN	_	20	ppmod	_	_
23	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	emerging	emerge	VBG	_	3	attr	_	_
3	roles	role	NNS	_	0	root	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	in	in	IN	_	8	case	_	_
7	drug2	drug0	NN	_	8	com	_	_
8	therapy	therapy	NN	_	3	ppmod	_	_
9	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	availability	availability	NN	_	15	dep	_	_
3	of	of	IN	_	10	case	_	_
4	potent	potent	JJ	_	10	attr	_	_
5	drug1	drug0	NN	_	10	attr	_	_
6	(	-lrb-	-LRB-	_	10	p	_	_
7	drug2	drug0	NN	_	10	attr	_	_
8	)	-rrb-	-RRB-	_	10	p	_	_
9	-based	-based	JJ	_	10	attr	_	_
10	regimens	regimen	NNS	_	2	ppmod	_	_
11	for	for	IN	_	13	case	_	_
12	drug3	drug0	NN	_	13	com	_	_
13	therapy	therapy	NN	_	10	ppmod	_	_
14	and	and	CC	_	15	cc	_	_
15	concerns	concern	VBZ	_	0	root	_	_
16	regarding	regard	VBG	_	15	comp	_	_
17	drug4	drug0	NN	_	21	advnp	_	_
18	(	-lrb-	-LRB-	_	21	p	_	_
19	drug5	drug0	NN	_	21	advnp	_	_
20	)	-rrb-	-RRB-	_	21	p	_	_
21	-related	-related	JJ	_	23	attr	_	_
22	metabolic	metabolic	JJ	_	23	attr	_	_
23	disturbances	disturbance	NNS	_	16	obj	_	_
24	have	have	VBP	_	25	aux	_	_
25	led	lead	VBN	_	23	acl	_	_
26	to	to	TO	_	28	aux	_	_
27	significant	significant	JJ	_	28	attr	_	_
28	shifts	shift	NNS	_	25	ppmod	_	_
29	in	in	IN	_	31	case	_	_
30	treatment	treatment	NN	_	31	com	_	_
31	practices	practice	NNS	_	28	ppmod	_	_
32	in	in	IN	_	34	case	_	_
33	HIV	hiv	NN	_	34	com	_	_
34	infection	infection	NN	_	31	ppmod	_	_
35	.	.	.	_	15	p	_	_

1	drug1	drug0	NN	_	3	attr	_	_
2	-based	-based	JJ	_	3	attr	_	_
3	regimens	regimen	NNS	_	5	dep	_	_
4	may	may	MD	_	5	modal	_	_
5	have	have	VB	_	0	root	_	_
6	several	several	JJ	_	7	attr	_	_
7	advantages	advantage	NNS	_	5	obj	_	_
8	over	over	IN	_	11	case	_	_
9	drug2	drug0	JJ	_	11	attr	_	_
10	-based	-based	JJ	_	11	attr	_	_
11	therapy	therapy	NN	_	7	ppmod	_	_
12	for	for	IN	_	16	case	_	_
13	initial	initial	JJ	_	16	attr	_	_
14	or	or	CC	_	16	cc	_	_
15	prolonged	prolonged	JJ	_	16	attr	_	_
16	therapy	therapy	NN	_	11	ppmod	_	_
17	,	,	,	_	7	p	_	_
18	including	include	VBG	_	22	adv	_	_
19	more	more	RBR	_	20	adv	_	_
20	convenient	convenient	JJ	_	22	attr	_	_
21	administration	administration	NN	_	22	com	_	_
22	regimens	regimen	NNS	_	7	ppmod	_	_
23	,	,	,	_	22	p	_	_
24	lower	low	JJR	_	26	attr	_	_
25	tablet	tablet	NN	_	26	com	_	_
26	volume	volume	NN	_	22	conj	_	_
27	,	,	,	_	26	p	_	_
28	fewer	few	JJR	_	30	attr	_	_
29	drug	drug	NN	_	30	com	_	_
30	interactions	interaction	NNS	_	22	conj	_	_
31	,	,	,	_	30	p	_	_
32	and	and	CC	_	30	cc	_	_
33	central	central	JJ	_	35	attr	_	_
34	nervous	nervous	JJ	_	35	attr	_	_
35	system	system	NN	_	36	com	_	_
36	penetration	penetration	NN	_	22	conj	_	_
37	.	.	.	_	5	p	_	_

1	No	no	DT	_	2	det	_	_
2	data	datum	NNS	_	8	dep	_	_
3	from	from	IN	_	6	case	_	_
4	prospective	prospective	JJ	_	6	attr	_	_
5	clinical	clinical	JJ	_	6	attr	_	_
6	trials	trial	NNS	_	2	ppmod	_	_
7	currently	currently	RB	_	8	adv	_	_
8	exist	exist	VBP	_	0	root	_	_
9	comparing	compare	VBG	_	8	comp	_	_
10	the	the	DT	_	13	det	_	_
11	3	0	CD	_	13	num	_	_
12	approved	approved	JJ	_	13	attr	_	_
13	agents	agent	NNS	_	9	obj	_	_
14	(	-lrb-	-LRB-	_	15	p	_	_
15	drug1	drug0	NN	_	13	prn	_	_
16	,	,	,	_	15	p	_	_
17	drug2	drug0	NN	_	15	conj	_	_
18	or	or	CC	_	17	cc	_	_
19	drug3	drug0	NN	_	15	conj	_	_
20	)	-rrb-	-RRB-	_	15	p	_	_
21	.	.	.	_	8	p	_	_

1	Both	both	CC	_	2	cc	_	_
2	drug1	drug0	NN	_	7	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	drug2	drug0	NN	_	2	conj	_	_
5	have	have	VBP	_	7	aux	_	_
6	been	be	VBN	_	7	aux	_	_
7	compared	compare	VBN	_	0	root	_	_
8	to	to	TO	_	10	aux	_	_
9	triple	triple	JJ	_	10	attr	_	_
10	therapy	therapy	NN	_	7	ppmod	_	_
11	with	with	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	drug3	drug0	NN	_	14	com	_	_
14	drug4	drug0	NN	_	10	ppmod	_	_
15	over	over	IN	_	17	case	_	_
16	48	0	CD	_	17	num	_	_
17	weeks	week	NNS	_	14	ppmod	_	_
18	as	as	IN	_	20	case	_	_
19	initial	initial	JJ	_	20	attr	_	_
20	therapy	therapy	NN	_	14	ppmod	_	_
21	,	,	,	_	7	p	_	_
22	with	with	IN	_	26	case	_	_
23	similar	similar	JJ	_	24	attr	_	_
24	responses	response	NNS	_	26	dep	_	_
25	being	be	VBG	_	26	aux	_	_
26	observed	observe	VBN	_	7	ppmod	_	_
27	with	with	IN	_	29	case	_	_
28	drug5	drug0	NN	_	29	com	_	_
29	regimens	regimen	NNS	_	26	ppmod	_	_
30	and	and	CC	_	29	cc	_	_
31	superiority	superiority	NN	_	29	conj	_	_
32	observed	observe	VBN	_	29	acl	_	_
33	with	with	IN	_	34	case	_	_
34	drug6	drug0	NN	_	32	ppmod	_	_
35	.	.	.	_	7	p	_	_

1	A	a	DT	_	4	det	_	_
2	smaller	small	JJR	_	4	attr	_	_
3	24-week	0-week	JJ	_	4	attr	_	_
4	study	study	NN	_	6	dep	_	_
5	has	have	VBZ	_	6	aux	_	_
6	suggested	suggest	VBN	_	0	root	_	_
7	drug1	drug0	NN	_	9	dep	_	_
8	may	may	MD	_	9	modal	_	_
9	be	be	VB	_	6	comp	_	_
10	superior	superior	JJ	_	9	dep	_	_
11	to	to	TO	_	14	aux	_	_
12	the	the	DT	_	14	det	_	_
13	drug2	drug0	NN	_	14	com	_	_
14	drug3	drug0	NN	_	10	ppmod	_	_
15	.	.	.	_	6	p	_	_

1	Limited	limited	JJ	_	3	attr	_	_
2	comparative	comparative	JJ	_	3	attr	_	_
3	data	datum	NNS	_	19	dep	_	_
4	in	in	IN	_	5	case	_	_
5	patients	patient	NNS	_	3	ppmod	_	_
6	with	with	IN	_	9	case	_	_
7	high	high	JJ	_	9	attr	_	_
8	viral	viral	JJ	_	9	attr	_	_
9	loads	load	NNS	_	5	ppmod	_	_
10	treated	treat	VBN	_	5	acl	_	_
11	with	with	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	-	-	:	_	12	p	_	_
14	or	or	CC	_	12	cc	_	_
15	drug2	drug0	NN	_	17	attr	_	_
16	-based	-based	JJ	_	17	attr	_	_
17	regimens	regimen	NNS	_	12	conj	_	_
18	currently	currently	RB	_	19	adv	_	_
19	exist	exist	VBP	_	0	root	_	_
20	.	.	.	_	19	p	_	_

1	However	however	RB	_	12	adv	_	_
2	,	,	,	_	12	p	_	_
3	cohort	cohort	NN	_	4	com	_	_
4	data	datum	NNS	_	12	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	selected	select	VBN	_	8	attr	_	_
7	patient	patient	NN	_	8	com	_	_
8	data	datum	NNS	_	4	conj	_	_
9	from	from	IN	_	11	case	_	_
10	clinical	clinical	JJ	_	11	attr	_	_
11	trials	trial	NNS	_	4	ppmod	_	_
12	suggest	suggest	VBP	_	0	root	_	_
13	comparable	comparable	JJ	_	14	attr	_	_
14	activity	activity	NN	_	12	obj	_	_
15	to	to	TO	_	18	aux	_	_
16	drug1	drug0	JJ	_	18	attr	_	_
17	-based	-based	JJ	_	18	attr	_	_
18	regimens	regimen	NNS	_	14	ppmod	_	_
19	in	in	IN	_	21	case	_	_
20	these	these	DT	_	21	det	_	_
21	patients	patient	NNS	_	14	ppmod	_	_
22	.	.	.	_	12	p	_	_

1	The	the	DT	_	2	det	_	_
2	superiority	superiority	NN	_	11	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	over	over	IN	_	8	case	_	_
6	drug2	drug0	NN	_	8	attr	_	_
7	-based	-based	JJ	_	8	attr	_	_
8	regimens	regimen	NNS	_	2	ppmod	_	_
9	has	have	VBZ	_	11	aux	_	_
10	been	be	VBN	_	11	aux	_	_
11	observed	observe	VBN	_	0	root	_	_
12	in	in	IN	_	14	case	_	_
13	comparative	comparative	JJ	_	14	attr	_	_
14	data	datum	NNS	_	11	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	subset	subset	NN	_	11	ppmod	_	_
18	of	of	IN	_	19	case	_	_
19	patients	patient	NNS	_	17	ppmod	_	_
20	with	with	IN	_	23	case	_	_
21	high	high	JJ	_	23	attr	_	_
22	viral	viral	JJ	_	23	attr	_	_
23	loads	load	NNS	_	19	ppmod	_	_
24	.	.	.	_	11	p	_	_

1	In	in	IN	_	3	case	_	_
2	treatment-experienced	treatment-experienced	JJ	_	3	attr	_	_
3	patients	patient	NNS	_	8	ppmod	_	_
4	,	,	,	_	8	p	_	_
5	available	available	JJ	_	7	attr	_	_
6	uncontrolled	uncontrolled	JJ	_	7	attr	_	_
7	data	datum	NNS	_	8	dep	_	_
8	suggest	suggest	VBP	_	0	root	_	_
9	these	these	DT	_	10	det	_	_
10	agents	agent	NNS	_	11	dep	_	_
11	contribute	contribute	VBP	_	8	comp	_	_
12	to	to	TO	_	14	aux	_	_
13	regimen	regimen	NN	_	14	com	_	_
14	efficacy	efficacy	NN	_	11	ppmod	_	_
15	in	in	IN	_	21	case	_	_
16	drug1	drug0	NN	_	21	attr	_	_
17	-na	-na	NN	_	21	attr	_	_
18	ve	ve	NN	_	21	attr	_	_
19	,	,	,	_	21	p	_	_
20	treatment-experienced	treatment-experienced	JJ	_	21	attr	_	_
21	patients	patient	NNS	_	14	ppmod	_	_
22	.	.	.	_	8	p	_	_

1	drug1	drug0	NN	_	3	dep	_	_
2	has	have	VBZ	_	3	aux	_	_
3	demonstrated	demonstrate	VBN	_	0	root	_	_
4	superiority	superiority	NN	_	3	obj	_	_
5	over	over	IN	_	6	case	_	_
6	drug2	drug0	NN	_	4	ppmod	_	_
7	in	in	IN	_	9	case	_	_
8	nucleoside-experienced	nucleoside-experienced	JJ	_	9	attr	_	_
9	patients	patient	NNS	_	4	ppmod	_	_
10	,	,	,	_	3	p	_	_
11	although	although	IN	_	12	mark	_	_
12	combining	combine	VBG	_	3	comp	_	_
13	these	these	DT	_	15	det	_	_
14	2	0	CD	_	15	num	_	_
15	agents	agent	NNS	_	17	dep	_	_
16	may	may	MD	_	17	modal	_	_
17	represent	represent	VB	_	12	comp	_	_
18	the	the	DT	_	20	det	_	_
19	best	good	JJS	_	20	attr	_	_
20	approach	approach	NN	_	17	obj	_	_
21	in	in	IN	_	23	case	_	_
22	these	these	DT	_	23	det	_	_
23	circumstances	circumstance	NNS	_	20	ppmod	_	_
24	.	.	.	_	3	p	_	_

1	The	the	DT	_	2	det	_	_
2	tolerability	tolerability	NN	_	5	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	appears	appear	VBZ	_	0	root	_	_
6	generally	generally	RB	_	7	adv	_	_
7	good	good	JJ	_	5	dep	_	_
8	with	with	IN	_	10	case	_	_
9	few	few	JJ	_	10	attr	_	_
10	individuals	individual	NNS	_	7	ppmod	_	_
11	discontinuing	discontinue	VBG	_	10	acl	_	_
12	in	in	IN	_	14	case	_	_
13	clinical	clinical	JJ	_	14	attr	_	_
14	studies	study	NNS	_	11	ppmod	_	_
15	as	as	IN	_	17	case	_	_
16	a	a	DT	_	17	det	_	_
17	result	result	NN	_	11	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	adverse	adverse	JJ	_	21	attr	_	_
20	drug	drug	NN	_	21	com	_	_
21	events	event	NNS	_	17	ppmod	_	_
22	.	.	.	_	5	p	_	_

1	The	the	DT	_	2	det	_	_
2	majority	majority	NN	_	8	dep	_	_
3	of	of	IN	_	5	case	_	_
4	adverse	adverse	JJ	_	5	attr	_	_
5	events	event	NNS	_	2	ppmod	_	_
6	with	with	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	occur	occur	VBP	_	0	root	_	_
9	within	within	IN	_	12	case	_	_
10	the	the	DT	_	12	det	_	_
11	first	#ord#	JJ	_	12	attr	_	_
12	month	month	NN	_	8	ppmod	_	_
13	,	,	,	_	8	p	_	_
14	and	and	CC	_	8	cc	_	_
15	are	be	VBP	_	8	conj	_	_
16	predictable	predictable	JJ	_	15	dep	_	_
17	and	and	CC	_	16	cc	_	_
18	manageable	manageable	JJ	_	16	conj	_	_
19	without	without	IN	_	21	case	_	_
20	therapy	therapy	NN	_	21	com	_	_
21	interruption	interruption	NN	_	15	ppmod	_	_
22	.	.	.	_	8	p	_	_

1	Suppression	suppression	NN	_	0	root	_	_
2	by	by	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	of	of	IN	_	8	case	_	_
5	drug2	drug0	NN	_	8	attr	_	_
6	-enhanced	-enhanced	JJ	_	8	attr	_	_
7	peritoneal	peritoneal	JJ	_	8	attr	_	_
8	metastasis	metastasis	NN	_	1	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	intestinal	intestinal	JJ	_	11	attr	_	_
11	adenocarcinomas	adenocarcinoma	NNS	_	8	ppmod	_	_
12	induced	induce	VBN	_	11	acl	_	_
13	by	by	IN	_	14	case	_	_
14	drug3	drug0	NN	_	12	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	wistar	wistar	JJ	_	17	attr	_	_
17	rats	rat	NNS	_	12	ppmod	_	_
18	.	.	.	_	1	p	_	_

1	BACKGROUND	background	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	The	the	DT	_	4	det	_	_
4	effects	effect	NNS	_	42	dep	_	_
5	of	of	IN	_	7	case	_	_
6	combined	combined	JJ	_	7	attr	_	_
7	administration	administration	NN	_	4	ppmod	_	_
8	of	of	IN	_	9	case	_	_
9	drug1	drug0	NN	_	7	ppmod	_	_
10	and	and	CC	_	9	cc	_	_
11	drug2	drug0	NN	_	9	conj	_	_
12	(	-lrb-	-LRB-	_	13	p	_	_
13	drug3	drug0	NN	_	9	prn	_	_
14	)	-rrb-	-RRB-	_	13	p	_	_
15	,	,	,	_	9	p	_	_
16	a	a	DT	_	17	det	_	_
17	drug4	drug0	NN	_	9	appo	_	_
18	,	,	,	_	9	p	_	_
19	on	on	IN	_	21	case	_	_
20	the	the	DT	_	21	det	_	_
21	incidence	incidence	NN	_	4	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	peritoneal	peritoneal	JJ	_	24	attr	_	_
24	metastasis	metastasis	NN	_	21	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	intestinal	intestinal	JJ	_	27	attr	_	_
27	adenocarcinomas	adenocarcinoma	NNS	_	24	ppmod	_	_
28	induced	induce	VBN	_	27	acl	_	_
29	by	by	IN	_	30	case	_	_
30	drug5	drug0	NN	_	28	ppmod	_	_
31	(	-lrb-	-LRB-	_	32	p	_	_
32	drug6	drug0	NN	_	30	prn	_	_
33	)	-rrb-	-RRB-	_	32	p	_	_
34	and	and	CC	_	21	cc	_	_
35	the	the	DT	_	37	det	_	_
36	labeling	labeling	NN	_	37	com	_	_
37	index	index	NN	_	21	conj	_	_
38	of	of	IN	_	40	case	_	_
39	intestinal	intestinal	JJ	_	40	attr	_	_
40	cancers	cancer	NNS	_	37	ppmod	_	_
41	were	be	VBD	_	42	aux	_	_
42	investigated	investigate	VBN	_	1	acl	_	_
43	in	in	IN	_	46	case	_	_
44	male	male	JJ	_	46	attr	_	_
45	Wistar	wistar	NN	_	46	com	_	_
46	rats	rat	NNS	_	42	ppmod	_	_
47	.	.	.	_	1	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	From	from	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	beginning	beginning	NN	_	16	ppmod	_	_
6	of	of	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	experiment	experiment	NN	_	5	ppmod	_	_
9	,	,	,	_	16	p	_	_
10	rats	rat	NNS	_	16	dep	_	_
11	were	be	VBD	_	16	aux	_	_
12	given	give	VBN	_	16	lv	_	_
13	10	0	CD	_	16	num	_	_
14	weekly	weekly	JJ	_	16	attr	_	_
15	subcutaneous	subcutaneous	JJ	_	16	attr	_	_
16	injections	injection	NNS	_	1	acl	_	_
17	of	of	IN	_	18	case	_	_
18	drug1	drug0	NN	_	16	ppmod	_	_
19	(	-lrb-	-LRB-	_	23	p	_	_
20	7.4	0	CD	_	23	num	_	_
21	mg/kg	mg/kg	NN	_	23	com	_	_
22	body	body	NN	_	23	com	_	_
23	weight	weight	NN	_	18	prn	_	_
24	)	-rrb-	-RRB-	_	23	p	_	_
25	and	and	CC	_	18	cc	_	_
26	subcutaneous	subcutaneous	JJ	_	27	attr	_	_
27	injections	injection	NNS	_	38	attr	_	_
28	of	of	IN	_	29	case	_	_
29	drug2	drug0	NN	_	27	ppmod	_	_
30	(	-lrb-	-LRB-	_	34	p	_	_
31	40	0	CD	_	34	num	_	_
32	microg/kg	microg/kg	NN	_	34	com	_	_
33	body	body	NN	_	34	com	_	_
34	weight	weight	NN	_	29	prn	_	_
35	)	-rrb-	-RRB-	_	34	p	_	_
36	every	every	DT	_	38	det	_	_
37	other	other	JJ	_	38	attr	_	_
38	day	day	NN	_	18	conj	_	_
39	,	,	,	_	18	p	_	_
40	and	and	CC	_	18	cc	_	_
41	from	from	IN	_	42	case	_	_
42	week	week	NN	_	18	conj	_	_
43	16	0	CD	_	42	num	_	_
44	,	,	,	_	16	p	_	_
45	intraperitoneal	intraperitoneal	JJ	_	46	attr	_	_
46	injections	injection	NNS	_	16	appo	_	_
47	of	of	IN	_	48	case	_	_
48	drug3	drug0	NN	_	46	ppmod	_	_
49	(	-lrb-	-LRB-	_	55	p	_	_
50	10	0	CD	_	55	num	_	_
51	or	or	CC	_	50	cc	_	_
52	20	0	CD	_	50	conj	_	_
53	mg/kg	mg/kg	NN	_	55	com	_	_
54	body	body	NN	_	55	com	_	_
55	weight	weight	NN	_	48	prn	_	_
56	)	-rrb-	-RRB-	_	55	p	_	_
57	every	every	DT	_	59	det	_	_
58	other	other	JJ	_	59	attr	_	_
59	day	day	NN	_	16	appo	_	_
60	until	until	IN	_	63	case	_	_
61	the	the	DT	_	63	det	_	_
62	end	end	NN	_	63	com	_	_
63	fo	fo	NN	_	16	ppmod	_	_
64	the	the	DT	_	65	det	_	_
65	experiment	experiment	NN	_	63	appo	_	_
66	in	in	IN	_	67	case	_	_
67	week	week	NN	_	65	ppmod	_	_
68	45	0	CD	_	67	num	_	_
69	.	.	.	_	1	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	5	dep	_	_
4	significantly	significantly	RB	_	5	adv	_	_
5	increased	increase	VBD	_	1	acl	_	_
6	the	the	DT	_	7	det	_	_
7	incidence	incidence	NN	_	5	obj	_	_
8	of	of	IN	_	10	case	_	_
9	intestinal	intestinal	JJ	_	10	attr	_	_
10	tumors	tumor	NNS	_	7	ppmod	_	_
11	and	and	CC	_	7	cc	_	_
12	cancer	cancer	NN	_	13	com	_	_
13	metastasis	metastasis	NN	_	7	conj	_	_
14	to	to	TO	_	16	aux	_	_
15	the	the	DT	_	16	det	_	_
16	peritoneum	peritoneum	NN	_	13	ppmod	_	_
17	.	.	.	_	1	p	_	_

1	Although	although	IN	_	7	mark	_	_
2	drug1	drug0	NN	_	7	dep	_	_
3	administered	administer	VBN	_	2	acl	_	_
4	at	at	IN	_	6	case	_	_
5	either	either	DT	_	6	det	_	_
6	dose	dose	NN	_	3	ppmod	_	_
7	had	have	VBD	_	46	advcl	_	_
8	little	little	JJ	_	7	obj	_	_
9	or	or	CC	_	8	cc	_	_
10	no	no	DT	_	11	det	_	_
11	effect	effect	NN	_	8	conj	_	_
12	on	on	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	enhancement	enhancement	NN	_	7	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	intestinal	intestinal	JJ	_	17	attr	_	_
17	carcinogenesis	carcinogenesis	NN	_	14	ppmod	_	_
18	by	by	IN	_	19	case	_	_
19	drug2	drug0	NN	_	14	ppmod	_	_
20	or	or	CC	_	14	cc	_	_
21	on	on	IN	_	23	case	_	_
22	the	the	DT	_	23	det	_	_
23	location	location	NN	_	14	conj	_	_
24	,	,	,	_	23	p	_	_
25	histologic	histologic	JJ	_	26	attr	_	_
26	type	type	NN	_	23	appo	_	_
27	,	,	,	_	23	p	_	_
28	depth	depth	NN	_	23	appo	_	_
29	of	of	IN	_	30	case	_	_
30	involvement	involvement	NN	_	28	ppmod	_	_
31	,	,	,	_	30	p	_	_
32	labeling	labeling	NN	_	33	com	_	_
33	index	index	NN	_	30	conj	_	_
34	,	,	,	_	33	p	_	_
35	apoptotic	apoptotic	JJ	_	36	attr	_	_
36	index	index	NN	_	30	conj	_	_
37	or	or	CC	_	36	cc	_	_
38	tumor	tumor	NN	_	39	com	_	_
39	vascularity	vascularity	NN	_	30	conj	_	_
40	of	of	IN	_	42	case	_	_
41	intestinal	intestinal	JJ	_	42	attr	_	_
42	cancers	cancer	NNS	_	28	ppmod	_	_
43	,	,	,	_	46	p	_	_
44	it	it	PRP	_	46	dep	_	_
45	significantly	significantly	RB	_	46	adv	_	_
46	decreased	decrease	VBD	_	0	root	_	_
47	the	the	DT	_	48	det	_	_
48	incidence	incidence	NN	_	46	obj	_	_
49	of	of	IN	_	51	case	_	_
50	cancer	cancer	NN	_	51	com	_	_
51	metastasis	metastasis	NN	_	48	ppmod	_	_
52	.	.	.	_	46	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	also	also	RB	_	4	adv	_	_
3	significantly	significantly	RB	_	4	adv	_	_
4	decreased	decrease	VBD	_	0	root	_	_
5	the	the	DT	_	6	det	_	_
6	incidence	incidence	NN	_	4	obj	_	_
7	of	of	IN	_	9	case	_	_
8	lymphatic	lymphatic	JJ	_	9	attr	_	_
9	invasion	invasion	NN	_	6	ppmod	_	_
10	of	of	IN	_	11	case	_	_
11	adenocarcinomas	adenocarcinomas	NN	_	9	ppmod	_	_
12	,	,	,	_	11	p	_	_
13	which	which	WDT	_	15	dep	_	_
14	was	be	VBD	_	15	aux	_	_
15	enhanced	enhance	VBN	_	11	relcl	_	_
16	by	by	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	.	.	.	_	4	p	_	_

1	CONCLUSION	conclusion	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	These	these	DT	_	4	det	_	_
4	findings	finding	NNS	_	5	dep	_	_
5	indicate	indicate	VBP	_	1	acl	_	_
6	that	that	IN	_	8	mark	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	inhibits	inhibit	VBZ	_	5	comp	_	_
9	cancer	cancer	NN	_	10	com	_	_
10	metastasis	metastasis	NN	_	8	obj	_	_
11	through	through	IN	_	12	case	_	_
12	actions	action	NNS	_	8	ppmod	_	_
13	that	that	WDT	_	16	dep	_	_
14	do	do	VBP	_	16	aux	_	_
15	not	not	RB	_	16	neg	_	_
16	affect	affect	VB	_	12	relcl	_	_
17	the	the	DT	_	18	det	_	_
18	growth	growth	NN	_	16	obj	_	_
19	of	of	IN	_	21	case	_	_
20	intestinal	intestinal	JJ	_	21	attr	_	_
21	cancers	cancer	NNS	_	18	ppmod	_	_
22	.	.	.	_	1	p	_	_

1	-LSB-Dose-time	-lsb-dose-time	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	17	attr	_	_
3	of	of	IN	_	5	case	_	_
4	competitive	competitive	JJ	_	5	attr	_	_
5	displacement	displacement	NN	_	17	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	by	by	IN	_	9	case	_	_
9	drug2	drug0	NN	_	5	ppmod	_	_
10	following	follow	VBG	_	14	adv	_	_
11	oral	oral	JJ	_	14	attr	_	_
12	and	and	CC	_	14	cc	_	_
13	intravenous	intravenous	JJ	_	14	attr	_	_
14	administration	administration	NN	_	17	ppmod	_	_
15	]	-rsb-	-RRB-	_	17	p	_	_
16	The	the	DT	_	17	det	_	_
17	effect	effect	NN	_	46	dep	_	_
18	of	of	IN	_	20	case	_	_
19	various	various	JJ	_	20	attr	_	_
20	doses	dose	NNS	_	17	ppmod	_	_
21	of	of	IN	_	22	case	_	_
22	drug3	drug0	NN	_	20	ppmod	_	_
23	in	in	IN	_	26	case	_	_
24	several	several	JJ	_	26	attr	_	_
25	dose	dose	NN	_	26	com	_	_
26	fractions	fraction	NNS	_	22	ppmod	_	_
27	on	on	IN	_	29	case	_	_
28	the	the	DT	_	29	det	_	_
29	extent	extent	NN	_	17	ppmod	_	_
30	and	and	CC	_	17	cc	_	_
31	the	the	DT	_	33	det	_	_
32	time	time	NN	_	33	com	_	_
33	scale	scale	NN	_	17	conj	_	_
34	of	of	IN	_	35	case	_	_
35	displacement	displacement	NN	_	33	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug4	drug0	NNS	_	35	ppmod	_	_
38	,	,	,	_	37	p	_	_
39	in	in	IN	_	40	case	_	_
40	dependence	dependence	NN	_	37	ppmod	_	_
41	on	on	IN	_	43	case	_	_
42	application	application	NN	_	43	com	_	_
43	mode	mode	NN	_	40	ppmod	_	_
44	,	,	,	_	37	p	_	_
45	was	be	VBD	_	46	aux	_	_
46	studied	study	VBN	_	0	root	_	_
47	.	.	.	_	46	p	_	_

1	An	an	DT	_	3	det	_	_
2	intravenous	intravenous	JJ	_	3	attr	_	_
3	dose	dose	NN	_	8	dep	_	_
4	of	of	IN	_	7	case	_	_
5	50	0	CD	_	6	num	_	_
6	mg	mg	NN	_	7	com	_	_
7	drug1	drug0	NN	_	3	ppmod	_	_
8	was	be	VBD	_	0	root	_	_
9	in	in	IN	_	10	case	_	_
10	respect	respect	NN	_	8	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	competitive	competitive	JJ	_	13	attr	_	_
13	suppression	suppression	NN	_	10	ppmod	_	_
14	of	of	IN	_	15	case	_	_
15	organs	organ	NNS	_	13	ppmod	_	_
16	actively	actively	RB	_	17	adv	_	_
17	concentrating	concentrate	VBG	_	15	acl	_	_
18	drug2	drug0	NN	_	17	obj	_	_
19	as	as	RB	_	20	adv	_	_
20	effective	effective	JJ	_	8	dep	_	_
21	as	as	IN	_	32	case	_	_
22	intravenous	intravenous	JJ	_	32	attr	_	_
23	1000	0	CD	_	24	num	_	_
24	mg	mg	NN	_	32	attr	_	_
25	ClO-4-	clo-0-	JJ	_	24	attr	_	_
26	simultaneously	simultaneously	RB	_	24	adv	_	_
27	or	or	CC	_	24	cc	_	_
28	1000	0	CD	_	29	num	_	_
29	mg	mg	NN	_	24	conj	_	_
30	orally	orally	RB	_	31	adv	_	_
31	30	0	CD	_	29	num	_	_
32	min	min	NN	_	20	ppmod	_	_
33	before	before	IN	_	35	case	_	_
34	the	the	DT	_	35	det	_	_
35	injection	injection	NN	_	32	ppmod	_	_
36	of	of	IN	_	37	case	_	_
37	drug3	drug0	NN	_	35	ppmod	_	_
38	.	.	.	_	8	p	_	_

1	An	an	DT	_	3	det	_	_
2	intravenous	intravenous	JJ	_	3	attr	_	_
3	injection	injection	NN	_	9	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	given	give	VBN	_	3	acl	_	_
7	later	later	RB	_	6	adv	_	_
8	also	also	RB	_	9	adv	_	_
9	produces	produce	VBZ	_	0	root	_	_
10	a	a	DT	_	15	det	_	_
11	complete	complete	JJ	_	15	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	immediately	immediately	RB	_	14	adv	_	_
14	beginning	begin	VBG	_	11	conj	_	_
15	depletion	depletion	NN	_	9	obj	_	_
16	of	of	IN	_	17	case	_	_
17	drug2	drug0	NN	_	15	ppmod	_	_
18	already	already	RB	_	19	adv	_	_
19	accumulated	accumulate	VBN	_	17	acl	_	_
20	in	in	IN	_	22	case	_	_
21	the	the	DT	_	22	det	_	_
22	thyroid	thyroid	NN	_	19	ppmod	_	_
23	,	,	,	_	9	p	_	_
24	within	within	IN	_	26	case	_	_
25	a	a	DT	_	26	det	_	_
26	period	period	NN	_	9	ppmod	_	_
27	of	of	IN	_	29	case	_	_
28	195	0	CD	_	29	num	_	_
29	min	min	NN	_	26	ppmod	_	_
30	after	after	IN	_	31	case	_	_
31	99m-TcO-4-injection	0m-tco-0-injection	NN	_	29	ppmod	_	_
32	with	with	IN	_	35	case	_	_
33	a	a	DT	_	35	det	_	_
34	corresponding	corresponding	JJ	_	35	attr	_	_
35	increase	increase	NN	_	31	ppmod	_	_
36	in	in	IN	_	38	case	_	_
37	blood	blood	NN	_	38	com	_	_
38	levels	level	NNS	_	35	ppmod	_	_
39	.	.	.	_	9	p	_	_

1	20	0	CD	_	2	num	_	_
2	mg	mg	NN	_	3	dep	_	_
3	result	result	VBP	_	0	root	_	_
4	in	in	IN	_	6	case	_	_
5	incomplete	incomplete	JJ	_	6	attr	_	_
6	depletion	depletion	NN	_	3	ppmod	_	_
7	which	which	WDT	_	8	dep	_	_
8	becomes	become	VBZ	_	6	relcl	_	_
9	complete	complete	JJ	_	8	dep	_	_
10	after	after	IN	_	14	case	_	_
11	a	a	DT	_	14	det	_	_
12	second	#ord#	JJ	_	14	attr	_	_
13	additional	additional	JJ	_	14	attr	_	_
14	dose	dose	NN	_	8	ppmod	_	_
15	.	.	.	_	3	p	_	_

1	The	the	DT	_	3	det	_	_
2	intravenous	intravenous	JJ	_	3	attr	_	_
3	application	application	NN	_	6	dep	_	_
4	of	of	IN	_	5	case	_	_
5	drug1	drug0	NN	_	3	ppmod	_	_
6	offers	offer	VBZ	_	0	root	_	_
7	advantages	advantages	RB	_	6	adv	_	_
8	in	in	IN	_	10	case	_	_
9	clinical	clinical	JJ	_	10	attr	_	_
10	use	use	NN	_	6	ppmod	_	_
11	.	.	.	_	6	p	_	_

1	Combinations	combination	NNS	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	3	conj	_	_
6	:	:	:	_	1	p	_	_
7	effects	effect	NNS	_	1	appo	_	_
8	on	on	IN	_	10	case	_	_
9	drug	drug	NN	_	10	com	_	_
10	discrimination	discrimination	NN	_	7	ppmod	_	_
11	and	and	CC	_	10	cc	_	_
12	behavioral	behavioral	NN	_	13	com	_	_
13	inhibition	inhibition	NN	_	10	conj	_	_
14	in	in	IN	_	15	case	_	_
15	rats	rat	NNS	_	7	ppmod	_	_
16	.	.	.	_	1	p	_	_

1	drug1	drug0	NN	_	5	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	drug2	drug0	NN	_	1	prn	_	_
4	)	-rrb-	-RRB-	_	3	p	_	_
5	produces	produce	VBZ	_	0	root	_	_
6	psychotomimetic	psychotomimetic	JJ	_	7	attr	_	_
7	effects	effect	NNS	_	5	obj	_	_
8	in	in	IN	_	9	case	_	_
9	humans	human	NNS	_	5	ppmod	_	_
10	that	that	WDT	_	11	dep	_	_
11	resemble	resemble	VBP	_	9	relcl	_	_
12	schizophrenia	schizophrenia	NN	_	13	com	_	_
13	symptoms	symptom	NNS	_	11	obj	_	_
14	.	.	.	_	5	p	_	_

1	In	in	IN	_	3	case	_	_
2	an	an	DT	_	3	det	_	_
3	effort	effort	NN	_	14	ppmod	_	_
4	to	to	TO	_	5	aux	_	_
5	screen	screen	VB	_	3	acl	_	_
6	compounds	compound	NNS	_	5	obj	_	_
7	for	for	IN	_	9	case	_	_
8	antipsychotic	antipsychotic	JJ	_	9	attr	_	_
9	activity	activity	NN	_	6	ppmod	_	_
10	,	,	,	_	14	p	_	_
11	preclinical	preclinical	JJ	_	12	attr	_	_
12	researchers	researcher	NNS	_	14	dep	_	_
13	have	have	VBP	_	14	aux	_	_
14	investigated	investigate	VBN	_	0	root	_	_
15	whether	whether	IN	_	18	mark	_	_
16	these	these	DT	_	17	det	_	_
17	compounds	compound	NNS	_	18	dep	_	_
18	block	block	VBP	_	14	comp	_	_
19	drug1	drug0	JJ	_	21	attr	_	_
20	-induced	-induced	JJ	_	21	attr	_	_
21	behaviors	behavior	NNS	_	18	obj	_	_
22	in	in	IN	_	23	case	_	_
23	animals	animal	NNS	_	21	ppmod	_	_
24	.	.	.	_	14	p	_	_

1	In	in	IN	_	4	case	_	_
2	the	the	DT	_	4	det	_	_
3	present	present	JJ	_	4	attr	_	_
4	study	study	NN	_	10	ppmod	_	_
5	,	,	,	_	10	p	_	_
6	the	the	DT	_	8	det	_	_
7	drug1	drug0	NN	_	8	com	_	_
8	drug2	drug0	NN	_	10	dep	_	_
9	was	be	VBD	_	10	aux	_	_
10	tested	test	VBN	_	0	root	_	_
11	in	in	IN	_	12	case	_	_
12	combination	combination	NN	_	10	ppmod	_	_
13	with	with	IN	_	16	case	_	_
14	an	an	DT	_	16	det	_	_
15	active	active	JJ	_	16	attr	_	_
16	dose	dose	NN	_	12	ppmod	_	_
17	of	of	IN	_	18	case	_	_
18	drug3	drug0	NN	_	16	ppmod	_	_
19	in	in	IN	_	22	case	_	_
20	two-lever	two-lever	JJ	_	22	attr	_	_
21	drug	drug	NN	_	22	com	_	_
22	discrimination	discrimination	NN	_	18	ppmod	_	_
23	and	and	CC	_	18	cc	_	_
24	mixed	mixed	JJ	_	30	attr	_	_
25	signalled-unsignalled	signalled-unsignalled	JJ	_	30	attr	_	_
26	differential-reinforcement-of-low-rates	differential-reinforcement-of-low-rates	NN	_	30	attr	_	_
27	(	-lrb-	-LRB-	_	30	p	_	_
28	DRL	drl	NN	_	30	attr	_	_
29	)	-rrb-	-RRB-	_	30	p	_	_
30	procedures	procedure	NNS	_	18	conj	_	_
31	.	.	.	_	10	p	_	_

1	drug1	drug0	NN	_	2	dep	_	_
2	produced	produce	VBD	_	0	root	_	_
3	distinctive	distinctive	JJ	_	4	attr	_	_
4	effects	effect	NNS	_	2	obj	_	_
5	in	in	IN	_	7	case	_	_
6	each	each	DT	_	7	det	_	_
7	task	task	NN	_	2	ppmod	_	_
8	:	:	:	_	2	p	_	_
9	it	it	PRP	_	10	dep	_	_
10	substituted	substitute	VBN	_	2	conj	_	_
11	for	for	IN	_	14	case	_	_
12	the	the	DT	_	14	det	_	_
13	training	training	JJ	_	14	attr	_	_
14	dose	dose	NN	_	10	ppmod	_	_
15	in	in	IN	_	17	case	_	_
16	drug2	drug0	NN	_	17	com	_	_
17	discrimination	discrimination	NN	_	14	ppmod	_	_
18	and	and	CC	_	10	cc	_	_
19	it	it	PRP	_	20	dep	_	_
20	increased	increase	VBD	_	2	conj	_	_
21	the	the	DT	_	22	det	_	_
22	number	number	NN	_	20	obj	_	_
23	of	of	IN	_	24	case	_	_
24	responses	response	NNS	_	22	ppmod	_	_
25	with	with	IN	_	34	case	_	_
26	short	short	JJ	_	34	attr	_	_
27	(	-lrb-	-LRB-	_	28	p	_	_
28	&lt	&lt	NN	_	26	prn	_	_
29	;	;	:	_	28	p	_	_
30	3	0	CD	_	31	num	_	_
31	s	s	NN	_	28	appo	_	_
32	)	-rrb-	-RRB-	_	28	p	_	_
33	interresponse	interresponse	NN	_	34	com	_	_
34	times	time	NNS	_	20	ppmod	_	_
35	as	as	RB	_	36	com	_	_
36	well	well	RB	_	34	cc	_	_
37	as	as	IN	_	36	com	_	_
38	increasing	increase	VBG	_	41	attr	_	_
39	overall	overall	JJ	_	41	attr	_	_
40	response	response	NN	_	41	com	_	_
41	rates	rate	NNS	_	34	conj	_	_
42	in	in	IN	_	45	case	_	_
43	the	the	DT	_	45	det	_	_
44	DRL	drl	NN	_	45	com	_	_
45	schedule	schedule	NN	_	41	ppmod	_	_
46	.	.	.	_	20	p	_	_

1	Acute	acute	JJ	_	2	attr	_	_
2	dosing	dosing	NN	_	5	dep	_	_
3	with	with	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	failed	fail	VBD	_	0	root	_	_
6	to	to	TO	_	7	aux	_	_
7	alter	alter	VB	_	5	comp	_	_
8	the	the	DT	_	10	det	_	_
9	behavioral	behavioral	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug2	drug0	NN	_	10	ppmod	_	_
13	in	in	IN	_	15	case	_	_
14	either	either	DT	_	15	det	_	_
15	procedure	procedure	NN	_	10	ppmod	_	_
16	even	even	RB	_	17	com	_	_
17	when	when	WRB	_	18	adv	_	_
18	tested	test	VBN	_	7	comp	_	_
19	up	up	RP	_	21	prt	_	_
20	to	to	TO	_	21	aux	_	_
21	doses	dose	NNS	_	18	ppmod	_	_
22	that	that	WDT	_	23	dep	_	_
23	produced	produce	VBD	_	21	relcl	_	_
24	pharmacological	pharmacological	JJ	_	25	attr	_	_
25	effects	effect	NNS	_	23	obj	_	_
26	alone	alone	RB	_	25	adv	_	_
27	.	.	.	_	5	p	_	_

1	These	these	DT	_	2	det	_	_
2	results	result	NNS	_	3	dep	_	_
3	suggest	suggest	VBP	_	0	root	_	_
4	that	that	IN	_	11	mark	_	_
5	acute	acute	JJ	_	6	attr	_	_
6	dosing	dosing	NN	_	11	dep	_	_
7	with	with	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	would	would	MD	_	11	modal	_	_
10	not	not	RB	_	11	neg	_	_
11	affect	affect	VB	_	3	comp	_	_
12	behaviors	behavior	NNS	_	11	obj	_	_
13	most	most	RBS	_	14	com	_	_
14	closely	closely	RB	_	15	adv	_	_
15	associated	associate	VBN	_	12	acl	_	_
16	with	with	IN	_	18	case	_	_
17	drug2	drug0	NN	_	18	com	_	_
18	intoxication	intoxication	NN	_	15	ppmod	_	_
19	.	.	.	_	3	p	_	_

1	Further	far	RB	_	4	adv	_	_
2	,	,	,	_	4	p	_	_
3	they	they	PRP	_	4	dep	_	_
4	bring	bring	VBP	_	0	root	_	_
5	into	into	IN	_	6	case	_	_
6	question	question	NN	_	4	ppmod	_	_
7	the	the	DT	_	8	det	_	_
8	utility	utility	NN	_	4	obj	_	_
9	of	of	IN	_	10	case	_	_
10	using	use	VBG	_	8	ppmod	_	_
11	drug1	drug0	NN	_	13	com	_	_
12	combination	combination	NN	_	13	com	_	_
13	procedures	procedure	NNS	_	10	obj	_	_
14	in	in	IN	_	15	case	_	_
15	animals	animal	NNS	_	13	ppmod	_	_
16	to	to	TO	_	17	aux	_	_
17	screen	screen	VB	_	10	comp	_	_
18	for	for	IN	_	20	case	_	_
19	antipsychotic	antipsychotic	JJ	_	20	attr	_	_
20	potential	potential	NN	_	17	ppmod	_	_
21	.	.	.	_	4	p	_	_

1	Since	since	IN	_	5	mark	_	_
2	chronic	chronic	JJ	_	3	attr	_	_
3	dosing	dosing	NN	_	5	dep	_	_
4	is	be	VBZ	_	5	aux	_	_
5	required	require	VBN	_	15	advcl	_	_
6	for	for	IN	_	8	case	_	_
7	therapeutic	therapeutic	JJ	_	8	attr	_	_
8	efficacy	efficacy	NN	_	5	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	,	,	,	_	15	p	_	_
12	future	future	JJ	_	13	attr	_	_
13	studies	study	NNS	_	15	dep	_	_
14	should	should	MD	_	15	modal	_	_
15	focus	focus	VB	_	0	root	_	_
16	on	on	IN	_	17	case	_	_
17	investigation	investigation	NN	_	15	ppmod	_	_
18	of	of	IN	_	21	case	_	_
19	chronic	chronic	JJ	_	21	attr	_	_
20	dosing	dosing	NN	_	21	com	_	_
21	effects	effect	NNS	_	17	ppmod	_	_
22	of	of	IN	_	24	case	_	_
23	these	these	DT	_	24	det	_	_
24	drugs	drug	NNS	_	21	ppmod	_	_
25	in	in	IN	_	26	case	_	_
26	combination	combination	NN	_	21	ppmod	_	_
27	with	with	IN	_	28	case	_	_
28	drug2	drug0	NN	_	26	ppmod	_	_
29	.	.	.	_	15	p	_	_

1	-LSB-Multiple	-lsb-multiple	JJ	_	9	advcl	_	_
2	occupational	occupational	JJ	_	3	attr	_	_
3	exposure	exposure	NN	_	1	obj	_	_
4	to	to	TO	_	5	aux	_	_
5	solvents	solvent	NNS	_	3	ppmod	_	_
6	]	-rsb-	-RRB-	_	1	p	_	_
7	This	this	DT	_	8	det	_	_
8	article	article	NN	_	9	dep	_	_
9	review	review	VBP	_	0	root	_	_
10	papers	paper	NNS	_	9	obj	_	_
11	published	publish	VBN	_	10	acl	_	_
12	over	over	IN	_	16	case	_	_
13	the	the	DT	_	16	det	_	_
14	last	last	JJ	_	16	attr	_	_
15	20	0	CD	_	16	num	_	_
16	years	year	NNS	_	11	ppmod	_	_
17	on	on	IN	_	20	case	_	_
18	multiple	multiple	JJ	_	20	attr	_	_
19	occupational	occupational	JJ	_	20	attr	_	_
20	exposure	exposure	NN	_	16	ppmod	_	_
21	to	to	TO	_	22	aux	_	_
22	solvents	solvent	NNS	_	20	ppmod	_	_
23	.	.	.	_	9	p	_	_

1	At	at	IN	_	2	case	_	_
2	low-levels	low-levels	NNS	_	14	ppmod	_	_
3	of	of	IN	_	4	case	_	_
4	exposure	exposure	NN	_	2	ppmod	_	_
5	the	the	DT	_	7	det	_	_
6	toxicokinetic	toxicokinetic	JJ	_	7	attr	_	_
7	interferences	interference	NNS	_	14	dep	_	_
8	between	between	IN	_	9	case	_	_
9	solvents	solvent	NNS	_	7	ppmod	_	_
10	have	have	VBP	_	14	aux	_	_
11	generally	generally	RB	_	14	adv	_	_
12	not	not	RB	_	14	neg	_	_
13	been	be	VBN	_	14	aux	_	_
14	observed	observe	VBN	_	0	root	_	_
15	in	in	IN	_	16	case	_	_
16	man	man	NN	_	14	ppmod	_	_
17	and	and	CC	_	14	cc	_	_
18	presumably	presumably	RB	_	22	adv	_	_
19	a	a	DT	_	21	det	_	_
20	threshold	threshold	NN	_	21	com	_	_
21	limit	limit	NN	_	22	dep	_	_
22	exists	exist	VBZ	_	14	conj	_	_
23	.	.	.	_	14	p	_	_

1	Conversely	conversely	RB	_	5	adv	_	_
2	,	,	,	_	5	p	_	_
3	at	at	IN	_	5	case	_	_
4	exposure	exposure	NN	_	5	com	_	_
5	levels	level	NNS	_	0	root	_	_
6	close	close	JJ	_	5	attr	_	_
7	to	to	TO	_	9	aux	_	_
8	the	the	DT	_	9	det	_	_
9	&quot	&quot	NN	_	6	ppmod	_	_
10	;	;	:	_	5	p	_	_
11	limit	limit	NN	_	12	com	_	_
12	values&quot	values&quot	NN	_	5	dep	_	_
13	;	;	:	_	5	p	_	_

1	metabolic	metabolic	JJ	_	2	attr	_	_
2	interference	interference	NN	_	6	dep	_	_
3	has	have	VBZ	_	6	aux	_	_
4	sometimes	sometimes	RB	_	6	adv	_	_
5	been	be	VBN	_	6	aux	_	_
6	observed	observe	VBN	_	0	root	_	_
7	and	and	CC	_	6	cc	_	_
8	the	the	DT	_	9	det	_	_
9	behaviour	behaviour	NN	_	14	dep	_	_
10	of	of	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	biological	biological	JJ	_	13	attr	_	_
13	indicators	indicator	NNS	_	9	ppmod	_	_
14	differs	differ	VBZ	_	6	conj	_	_
15	from	from	IN	_	19	case	_	_
16	what	what	WP	_	19	dep	_	_
17	would	would	MD	_	19	modal	_	_
18	be	be	VB	_	19	aux	_	_
19	expected	expect	VBN	_	14	ppmod	_	_
20	.	.	.	_	6	p	_	_

1	Toxicodynamic	toxicodynamic	JJ	_	2	attr	_	_
2	interference	interference	NN	_	6	dep	_	_
3	between	between	IN	_	4	case	_	_
4	solvents	solvent	NNS	_	2	ppmod	_	_
5	can	can	MD	_	6	modal	_	_
6	give	give	VBP	_	0	root	_	_
7	rise	rise	NN	_	6	obj	_	_
8	to	to	TO	_	16	aux	_	_
9	additive	additive	JJ	_	15	adv	_	_
10	,	,	,	_	15	p	_	_
11	potentiation	potentiation	NN	_	15	adv	_	_
12	,	,	,	_	15	p	_	_
13	synergistic	synergistic	JJ	_	15	adv	_	_
14	,	,	,	_	15	p	_	_
15	antagonistic	antagonistic	JJ	_	16	attr	_	_
16	effects	effect	NNS	_	6	ppmod	_	_
17	.	.	.	_	6	p	_	_

1	For	for	IN	_	3	case	_	_
2	the	the	DT	_	3	det	_	_
3	identification	identification	NN	_	15	ppmod	_	_
4	of	of	IN	_	5	case	_	_
5	&quot	&quot	NN	_	3	ppmod	_	_
6	;	;	:	_	5	p	_	_
7	limit	limit	NN	_	8	com	_	_
8	values&quot	values&quot	NN	_	5	appo	_	_
9	;	;	:	_	5	p	_	_
10	,	,	,	_	15	p	_	_
11	it	it	PRP	_	15	dep	_	_
12	has	have	VBZ	_	15	aux	_	_
13	generally	generally	RB	_	15	adv	_	_
14	been	be	VBN	_	15	aux	_	_
15	suggested	suggest	VBN	_	0	root	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	literature	literature	NN	_	15	ppmod	_	_
19	that	that	IN	_	28	mark	_	_
20	the	the	DT	_	22	det	_	_
21	possible	possible	JJ	_	22	attr	_	_
22	effects	effect	NNS	_	28	dep	_	_
23	deriving	derive	VBG	_	22	acl	_	_
24	from	from	IN	_	26	case	_	_
25	multiple	multiple	JJ	_	26	attr	_	_
26	exposure	exposure	NN	_	23	ppmod	_	_
27	be	be	VB	_	28	aux	_	_
28	considered	consider	VBN	_	15	comp	_	_
29	as	as	IN	_	30	case	_	_
30	additive	additive	JJ	_	28	ppmod	_	_
31	.	.	.	_	15	p	_	_

1	However	however	RB	_	9	adv	_	_
2	,	,	,	_	9	p	_	_
3	numerous	numerous	JJ	_	5	attr	_	_
4	potentiation	potentiation	NN	_	5	com	_	_
5	effects	effect	NNS	_	9	dep	_	_
6	have	have	VBP	_	9	aux	_	_
7	frequently	frequently	RB	_	9	adv	_	_
8	been	be	VBN	_	9	aux	_	_
9	reported	report	VBN	_	0	root	_	_
10	for	for	IN	_	12	case	_	_
11	combined	combined	JJ	_	12	attr	_	_
12	exposure	exposure	NN	_	9	ppmod	_	_
13	to	to	TO	_	14	aux	_	_
14	substances	substance	NNS	_	12	ppmod	_	_
15	of	of	IN	_	17	case	_	_
16	widespread	widespread	JJ	_	17	attr	_	_
17	use	use	NN	_	14	ppmod	_	_
18	.	.	.	_	9	p	_	_

1	In	in	IN	_	3	case	_	_
2	this	this	DT	_	3	det	_	_
3	paper	paper	NN	_	4	ppmod	_	_
4	lists	list	VBZ	_	0	root	_	_
5	of	of	IN	_	7	case	_	_
6	multiple	multiple	JJ	_	7	attr	_	_
7	exposure	exposure	NN	_	4	ppmod	_	_
8	in	in	IN	_	9	case	_	_
9	which	which	WDT	_	32	ppmod	_	_
10	the	the	DT	_	11	det	_	_
11	doses	dose	NNS	_	32	dep	_	_
12	of	of	IN	_	14	case	_	_
13	the	the	DT	_	14	det	_	_
14	substances	substance	NNS	_	11	ppmod	_	_
15	,	,	,	_	11	p	_	_
16	the	the	DT	_	17	det	_	_
17	types	type	NNS	_	11	conj	_	_
18	of	of	IN	_	19	case	_	_
19	interferences	interference	NNS	_	17	ppmod	_	_
20	and	and	CC	_	17	cc	_	_
21	the	the	DT	_	22	det	_	_
22	behaviour	behaviour	NN	_	11	conj	_	_
23	of	of	IN	_	26	case	_	_
24	the	the	DT	_	26	det	_	_
25	biological	biological	JJ	_	26	attr	_	_
26	levels	level	NNS	_	22	ppmod	_	_
27	have	have	VBP	_	32	aux	_	_
28	been	be	VBN	_	32	aux	_	_
29	drawn	draw	VBN	_	32	aux	_	_
30	up	up	RP	_	32	prt	_	_
31	and	and	CC	_	32	cc	_	_
32	proposed	propose	VBN	_	7	relcl	_	_
33	as	as	IN	_	35	case	_	_
34	a	a	DT	_	35	det	_	_
35	tool	tool	NN	_	32	ppmod	_	_
36	for	for	IN	_	38	case	_	_
37	easy	easy	JJ	_	38	attr	_	_
38	consultation	consultation	NN	_	35	ppmod	_	_
39	.	.	.	_	4	p	_	_

1	drug1	drug0	NN	_	4	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	drug2	drug0	NN	_	1	conj	_	_
4	exert	exert	VBP	_	0	root	_	_
5	additive	additive	JJ	_	10	attr	_	_
6	ocular	ocular	JJ	_	10	attr	_	_
7	and	and	CC	_	6	cc	_	_
8	renal	renal	JJ	_	6	conj	_	_
9	vasodilator	vasodilator	JJ	_	10	attr	_	_
10	effects	effect	NNS	_	4	obj	_	_
11	on	on	IN	_	13	case	_	_
12	healthy	healthy	JJ	_	13	attr	_	_
13	humans	human	NNS	_	4	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	AIMS/HYPOTHESIS	aims/hypothesis	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	There	there	EX	_	4	dep	_	_
4	is	be	VBZ	_	1	acl	_	_
5	evidence	evidence	NN	_	4	obj	_	_
6	that	that	IN	_	10	mark	_	_
7	drug1	drug0	NN	_	10	dep	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	cause	cause	VBP	_	5	acl	_	_
11	renal	renal	JJ	_	14	attr	_	_
12	and	and	CC	_	11	cc	_	_
13	ocular	ocular	JJ	_	11	conj	_	_
14	vasodilation	vasodilation	NN	_	10	obj	_	_
15	.	.	.	_	1	p	_	_

1	There	there	EX	_	2	dep	_	_
2	is	be	VBZ	_	0	root	_	_
3	,	,	,	_	2	p	_	_
4	however	however	RB	_	2	adv	_	_
5	,	,	,	_	2	p	_	_
6	currently	currently	RB	_	2	adv	_	_
7	no	no	DT	_	8	det	_	_
8	data	datum	NNS	_	2	obj	_	_
9	on	on	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	effect	effect	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	combined	combined	JJ	_	14	attr	_	_
14	hyperglycaemia	hyperglycaemia	NN	_	11	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	hyper	hyper	NN	_	18	com	_	_
17	drug1	drug0	NN	_	18	com	_	_
18	aemia	aemia	NN	_	14	conj	_	_
19	on	on	IN	_	25	case	_	_
20	the	the	DT	_	25	det	_	_
21	renal	renal	JJ	_	25	attr	_	_
22	and	and	CC	_	21	cc	_	_
23	ocular	ocular	JJ	_	21	conj	_	_
24	blood	blood	NN	_	25	com	_	_
25	flow	flow	NN	_	11	ppmod	_	_
26	seen	see	VBN	_	25	acl	_	_
27	in	in	IN	_	29	case	_	_
28	diabetic	diabetic	JJ	_	29	attr	_	_
29	patients	patient	NNS	_	26	ppmod	_	_
30	on	on	IN	_	32	case	_	_
31	insulin	insulin	NN	_	32	com	_	_
32	therapy	therapy	NN	_	29	ppmod	_	_
33	.	.	.	_	2	p	_	_

1	METHODS	method	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	We	we	PRP	_	4	dep	_	_
4	carried	carry	VBD	_	1	acl	_	_
5	out	out	RP	_	4	prt	_	_
6	two	#crd#	CD	_	10	num	_	_
7	different	different	JJ	_	10	attr	_	_
8	3-way	0-way	NN	_	10	com	_	_
9	crossover	crossover	NN	_	10	com	_	_
10	studies	study	NNS	_	4	obj	_	_
11	in	in	IN	_	13	case	_	_
12	healthy	healthy	JJ	_	13	attr	_	_
13	subjects	subject	NNS	_	4	ppmod	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	each	each	DT	_	17	dep	_	_
16	,	,	,	_	17	p	_	_
17	n	n	NN	_	13	prn	_	_
18	=	=	JJ	_	17	attr	_	_
19	9	0	CD	_	17	num	_	_
20	)	-rrb-	-RRB-	_	17	p	_	_
21	.	.	.	_	1	p	_	_

1	In	in	IN	_	2	case	_	_
2	study	study	NN	_	19	ppmod	_	_
3	one	#crd#	CD	_	2	num	_	_
4	,	,	,	_	19	p	_	_
5	hyperglycaemic	hyperglycaemic	JJ	_	6	attr	_	_
6	clamps	clamp	NNS	_	19	dep	_	_
7	(	-lrb-	-LRB-	_	9	p	_	_
8	5.6	0	CD	_	9	num	_	_
9	mmol/l	mmol/l	NN	_	6	prn	_	_
10	,	,	,	_	9	p	_	_
11	11.1	0	CD	_	12	num	_	_
12	mmol/	mmol/	NN	_	9	appo	_	_
13	1	0	CD	_	12	num	_	_
14	,	,	,	_	9	p	_	_
15	16.7	0	CD	_	16	num	_	_
16	mmol/l	mmol/l	NN	_	9	appo	_	_
17	)	-rrb-	-RRB-	_	9	p	_	_
18	were	be	VBD	_	19	aux	_	_
19	carried	carry	VBN	_	0	root	_	_
20	out	out	RP	_	19	prt	_	_
21	during	during	IN	_	38	case	_	_
22	placebo	placebo	NN	_	38	attr	_	_
23	or	or	CC	_	22	cc	_	_
24	drug1	drug0	NN	_	22	conj	_	_
25	(	-lrb-	-LRB-	_	26	p	_	_
26	dose	dose	NN	_	22	prn	_	_
27	1	0	CD	_	26	num	_	_
28	:	:	:	_	26	p	_	_
29	1	0	CD	_	30	num	_	_
30	mU/kg/min	mu/kg/min	NN	_	26	appo	_	_
31	;	;	:	_	26	p	_	_
32	dose	dose	NN	_	26	appo	_	_
33	2	0	CD	_	32	num	_	_
34	:	:	:	_	26	p	_	_
35	2	0	CD	_	36	num	_	_
36	mU/kg/min	mu/kg/min	NN	_	26	appo	_	_
37	)	-rrb-	-RRB-	_	26	p	_	_
38	infusion	infusion	NN	_	19	ppmod	_	_
39	.	.	.	_	19	p	_	_

1	The	the	DT	_	3	det	_	_
2	second	#ord#	JJ	_	3	attr	_	_
3	study	study	NN	_	4	dep	_	_
4	was	be	VBD	_	0	root	_	_
5	identical	identical	JJ	_	4	dep	_	_
6	but	but	CC	_	4	cc	_	_
7	endogenous	endogenous	JJ	_	9	attr	_	_
8	insulin	insulin	NN	_	9	com	_	_
9	secretion	secretion	NN	_	11	dep	_	_
10	was	be	VBD	_	11	aux	_	_
11	blocked	block	VBN	_	4	conj	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	11	ppmod	_	_
14	.	.	.	_	4	p	_	_

1	The	the	DT	_	4	det	_	_
2	renal	renal	JJ	_	4	attr	_	_
3	plasma	plasma	NN	_	4	com	_	_
4	flow	flow	NN	_	15	dep	_	_
5	,	,	,	_	4	p	_	_
6	glomerular	glomerular	JJ	_	8	attr	_	_
7	filtration	filtration	NN	_	8	com	_	_
8	rate	rate	NN	_	4	conj	_	_
9	and	and	CC	_	8	cc	_	_
10	pulsatile	pulsatile	JJ	_	13	attr	_	_
11	choroidal	choroidal	JJ	_	13	attr	_	_
12	blood	blood	NN	_	13	com	_	_
13	flow	flow	NN	_	4	conj	_	_
14	were	be	VBD	_	15	aux	_	_
15	measured	measure	VBN	_	0	root	_	_
16	using	use	VBG	_	15	comp	_	_
17	the	the	DT	_	19	det	_	_
18	paraaminohippurate	paraaminohippurate	NN	_	19	com	_	_
19	method	method	NN	_	16	obj	_	_
20	,	,	,	_	19	p	_	_
21	the	the	DT	_	23	det	_	_
22	inulin	inulin	NN	_	23	com	_	_
23	method	method	NN	_	19	conj	_	_
24	and	and	CC	_	23	cc	_	_
25	a	a	DT	_	28	det	_	_
26	laser	laser	NN	_	28	attr	_	_
27	interferometric	interferometric	JJ	_	28	attr	_	_
28	measurement	measurement	NN	_	19	conj	_	_
29	of	of	IN	_	32	case	_	_
30	fundus	fundus	NN	_	31	com	_	_
31	pulsation	pulsation	NN	_	32	com	_	_
32	amplitude	amplitude	NN	_	28	ppmod	_	_
33	,	,	,	_	16	p	_	_
34	respectively	respectively	RB	_	16	adv	_	_
35	.	.	.	_	15	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	increased	increase	VBD	_	1	acl	_	_
5	renal	renal	JJ	_	7	attr	_	_
6	plasma	plasma	NN	_	7	com	_	_
7	flow	flow	NN	_	4	obj	_	_
8	and	and	CC	_	7	cc	_	_
9	fundus	fundus	NN	_	10	com	_	_
10	pulsation	pulsation	NN	_	11	com	_	_
11	amplitude	amplitude	NN	_	7	conj	_	_
12	but	but	CC	_	11	cc	_	_
13	not	not	RB	_	12	com	_	_
14	the	the	DT	_	17	det	_	_
15	glomerular	glomerular	JJ	_	17	attr	_	_
16	filtration	filtration	NN	_	17	com	_	_
17	rate	rate	NN	_	7	conj	_	_
18	.	.	.	_	1	p	_	_

1	Hyperglycaemia	hyperglycaemia	NN	_	2	dep	_	_
2	increased	increase	VBD	_	0	root	_	_
3	all	all	PDT	_	8	det	_	_
4	the	the	DT	_	8	det	_	_
5	renal	renal	JJ	_	8	attr	_	_
6	and	and	CC	_	5	cc	_	_
7	ocular	ocular	JJ	_	5	conj	_	_
8	parameters	parameter	NNS	_	2	obj	_	_
9	studied	study	VBN	_	8	acl	_	_
10	.	.	.	_	2	p	_	_

1	Haemodynamic	haemodynamic	JJ	_	2	attr	_	_
2	effects	effect	NNS	_	7	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	and	and	CC	_	4	cc	_	_
6	drug2	drug0	NN	_	4	conj	_	_
7	were	be	VBD	_	0	root	_	_
8	additive	additive	JJ	_	7	dep	_	_
9	when	when	WRB	_	12	adv	_	_
10	drug3	drug0	NN	_	12	dep	_	_
11	was	be	VBD	_	12	aux	_	_
12	co-administered	co-administered	VBN	_	7	comp	_	_
13	but	but	CC	_	12	cc	_	_
14	not	not	RB	_	12	conj	_	_
15	under	under	IN	_	17	case	_	_
16	basal	basal	JJ	_	17	attr	_	_
17	conditions	condition	NNS	_	14	ppmod	_	_
18	.	.	.	_	7	p	_	_

1	CONCLUSIONS/INTERPRETATION	conclusions/interpretation	NN	_	7	dep	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	1	conj	_	_
4	and	and	CC	_	3	cc	_	_
5	drug2	drug0	NN	_	1	conj	_	_
6	can	can	MD	_	7	modal	_	_
7	exert	exert	VB	_	0	root	_	_
8	additive	additive	JJ	_	10	attr	_	_
9	vasodilator	vasodilator	NN	_	10	com	_	_
10	properties	property	NNS	_	7	obj	_	_
11	on	on	IN	_	15	case	_	_
12	renal	renal	JJ	_	15	attr	_	_
13	and	and	CC	_	12	cc	_	_
14	ocular	ocular	JJ	_	12	conj	_	_
15	circulation	circulation	NN	_	7	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	To	to	TO	_	2	aux	_	_
2	find	find	VB	_	0	root	_	_
3	out	out	RP	_	2	prt	_	_
4	whether	whether	IN	_	7	mark	_	_
5	this	this	DT	_	6	det	_	_
6	observation	observation	NN	_	7	dep	_	_
7	is	be	VBZ	_	2	comp	_	_
8	related	related	JJ	_	7	dep	_	_
9	to	to	TO	_	13	aux	_	_
10	the	the	DT	_	13	det	_	_
11	increased	increase	VBN	_	13	attr	_	_
12	regional	regional	JJ	_	13	attr	_	_
13	perfusion	perfusion	NN	_	8	ppmod	_	_
14	in	in	IN	_	17	case	_	_
15	diabetes	diabetes	NN	_	17	attr	_	_
16	longitudinal	longitudinal	JJ	_	17	attr	_	_
17	studies	study	NNS	_	13	ppmod	_	_
18	on	on	IN	_	29	mark	_	_
19	patients	patient	NNS	_	29	dep	_	_
20	with	with	IN	_	27	case	_	_
21	Type	type	NN	_	27	attr	_	_
22	I	i	NN	_	27	attr	_	_
23	(	-lrb-	-LRB-	_	27	p	_	_
24	insulin-dependent	insulin-dependent	JJ	_	27	attr	_	_
25	)	-rrb-	-RRB-	_	27	p	_	_
26	diabetes	diabetes	NN	_	27	com	_	_
27	mellitus	mellitus	NN	_	19	ppmod	_	_
28	are	be	VBP	_	29	aux	_	_
29	needed	need	VBN	_	17	acl	_	_
30	.	.	.	_	2	p	_	_

1	Interaction	interaction	NN	_	0	root	_	_
2	between	between	IN	_	3	case	_	_
3	drug1	drug0	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	antidiuretic	antidiuretic	JJ	_	6	attr	_	_
6	hormone	hormone	NN	_	3	conj	_	_
7	and	and	CC	_	1	cc	_	_
8	its	its	PRP$	_	9	poss	_	_
9	effect	effect	NN	_	1	conj	_	_
10	on	on	IN	_	13	case	_	_
11	the	the	DT	_	13	det	_	_
12	milk	milk	NN	_	13	com	_	_
13	secretion	secretion	NN	_	9	ppmod	_	_
14	by	by	IN	_	15	case	_	_
15	alveoli	alveolus	NNS	_	13	ppmod	_	_
16	of	of	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	mammary	mammary	JJ	_	19	attr	_	_
19	gland	gland	NN	_	15	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	lactating	lactating	JJ	_	22	attr	_	_
22	rats	rat	NNS	_	19	ppmod	_	_
23	.	.	.	_	9	p	_	_

1	Interaction	interaction	NN	_	10	dep	_	_
2	between	between	IN	_	6	case	_	_
3	exogenous	exogenous	JJ	_	6	attr	_	_
4	and	and	CC	_	3	cc	_	_
5	endogenous	endogenous	JJ	_	3	conj	_	_
6	drug1	drug0	NN	_	1	ppmod	_	_
7	and	and	CC	_	6	cc	_	_
8	vasopressin	vasopressin	NN	_	6	conj	_	_
9	was	be	VBD	_	10	aux	_	_
10	found	find	VBN	_	0	root	_	_
11	to	to	TO	_	12	aux	_	_
12	affect	affect	VB	_	10	comp	_	_
13	the	the	DT	_	14	det	_	_
14	mechanism	mechanism	NN	_	12	obj	_	_
15	of	of	IN	_	17	case	_	_
16	milk	milk	NN	_	17	com	_	_
17	ejection	ejection	NN	_	14	ppmod	_	_
18	by	by	IN	_	20	case	_	_
19	the	the	DT	_	20	det	_	_
20	alveoli	alveolus	NNS	_	12	ppmod	_	_
21	of	of	IN	_	24	case	_	_
22	the	the	DT	_	24	det	_	_
23	mammary	mammary	JJ	_	24	attr	_	_
24	gland	gland	NN	_	20	ppmod	_	_
25	in	in	IN	_	27	case	_	_
26	lactating	lactating	JJ	_	27	attr	_	_
27	rats	rat	NNS	_	20	ppmod	_	_
28	.	.	.	_	10	p	_	_

1	Inhibition	inhibition	NN	_	15	dep	_	_
2	and	and	CC	_	1	cc	_	_
3	stimulation	stimulation	NN	_	1	conj	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	effect	effect	NN	_	1	ppmod	_	_
7	of	of	IN	_	8	case	_	_
8	drug1	drug0	NN	_	6	ppmod	_	_
9	on	on	IN	_	11	case	_	_
10	milk	milk	NN	_	11	com	_	_
11	ejection	ejection	NN	_	6	ppmod	_	_
12	by	by	IN	_	13	case	_	_
13	vasopressin	vasopressin	NN	_	1	ppmod	_	_
14	was	be	VBD	_	15	aux	_	_
15	demonstrated	demonstrate	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	On	on	IN	_	6	case	_	_
2	the	the	DT	_	6	det	_	_
3	basis	basis	NN	_	6	advnp	_	_
4	of	of	IN	_	6	case	_	_
5	the	the	DT	_	6	det	_	_
6	principles	principle	NNS	_	14	ppmod	_	_
7	observed	observe	VBD	_	14	dep	_	_
8	the	the	DT	_	9	det	_	_
9	concentrations	concentration	NNS	_	14	dep	_	_
10	fo	fo	NN	_	9	acl	_	_
11	these	these	DT	_	12	det	_	_
12	hormones	hormone	NNS	_	10	obj	_	_
13	were	be	VBD	_	14	aux	_	_
14	investigated	investigate	VBN	_	0	root	_	_
15	in	in	IN	_	19	case	_	_
16	the	the	DT	_	19	det	_	_
17	plasma	plasma	NN	_	19	advnp	_	_
18	of	of	IN	_	19	case	_	_
19	dogs	dog	NNS	_	14	ppmod	_	_
20	deprived	deprive	VBN	_	19	acl	_	_
21	of	of	IN	_	22	case	_	_
22	water	water	NN	_	20	ppmod	_	_
23	for	for	IN	_	25	case	_	_
24	3	0	CD	_	25	num	_	_
25	days	day	NNS	_	20	ppmod	_	_
26	and	and	CC	_	14	cc	_	_
27	then	then	RB	_	28	adv	_	_
28	allowed	allow	VBN	_	14	conj	_	_
29	to	to	TO	_	30	aux	_	_
30	drink	drink	NN	_	28	ppmod	_	_
31	.	.	.	_	14	p	_	_

1	-LSB-Quantitative	-lsb-quantitative	JJ	_	2	attr	_	_
2	approach	approach	NN	_	0	root	_	_
3	to	to	TO	_	4	aux	_	_
4	treatment	treatment	NN	_	2	ppmod	_	_
5	with	with	IN	_	7	case	_	_
6	incisive	incisive	JJ	_	7	attr	_	_
7	drug1	drug0	NN	_	4	ppmod	_	_
8	by	by	IN	_	10	case	_	_
9	therapeutic	therapeutic	JJ	_	10	attr	_	_
10	monitoring	monitoring	NN	_	2	ppmod	_	_
11	]	-rsb-	-RRB-	_	2	p	_	_
12	;	;	:	_	2	p	_	_
13	The	the	DT	_	14	det	_	_
14	problems	problem	NNS	_	26	dep	_	_
15	encountered	encounter	VBN	_	14	acl	_	_
16	during	during	IN	_	19	case	_	_
17	the	the	DT	_	19	det	_	_
18	longterm	longterm	JJ	_	19	attr	_	_
19	treatment	treatment	NN	_	15	ppmod	_	_
20	of	of	IN	_	22	case	_	_
21	psychotic	psychotic	JJ	_	22	attr	_	_
22	patients	patient	NNS	_	19	ppmod	_	_
23	with	with	IN	_	24	case	_	_
24	drug2	drug0	NN	_	22	ppmod	_	_
25	are	be	VBP	_	26	aux	_	_
26	illustrated	illustrate	VBN	_	2	acl	_	_
27	by	by	IN	_	31	case	_	_
28	six	#crd#	CD	_	31	num	_	_
29	typical	typical	JJ	_	31	attr	_	_
30	case	case	NN	_	31	com	_	_
31	reports	report	NNS	_	26	ppmod	_	_
32	.	.	.	_	2	p	_	_

1	A	a	DT	_	2	det	_	_
2	group	group	NN	_	17	dep	_	_
3	of	of	IN	_	4	case	_	_
4	patients	patient	NNS	_	2	ppmod	_	_
5	who	who	WP	_	7	dep	_	_
6	had	have	VBD	_	7	aux	_	_
7	had	have	VBD	_	4	relcl	_	_
8	a	a	DT	_	11	det	_	_
9	new	new	JJ	_	11	attr	_	_
10	acute	acute	JJ	_	11	attr	_	_
11	episode	episode	NN	_	7	obj	_	_
12	despite	despite	IN	_	15	case	_	_
13	seemingly	seemingly	RB	_	14	adv	_	_
14	adequate	adequate	JJ	_	15	attr	_	_
15	treatment	treatment	NN	_	7	ppmod	_	_
16	were	be	VBD	_	17	aux	_	_
17	selected	select	VBN	_	0	root	_	_
18	.	.	.	_	17	p	_	_

1	In	in	IN	_	4	case	_	_
2	these	these	DT	_	4	det	_	_
3	six	#crd#	CD	_	4	num	_	_
4	cases	case	NNS	_	7	ppmod	_	_
5	it	it	PRP	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	demonstrated	demonstrate	VBN	_	0	root	_	_
8	that	that	IN	_	12	mark	_	_
9	the	the	DT	_	11	det	_	_
10	drug1	drug0	NN	_	11	com	_	_
11	dosage	dosage	NN	_	12	dep	_	_
12	was	be	VBD	_	7	comp	_	_
13	inappropriate	inappropriate	JJ	_	12	dep	_	_
14	,	,	,	_	12	p	_	_
15	being	be	VBG	_	12	comp	_	_
16	either	either	CC	_	18	cc	_	_
17	too	too	RB	_	18	adv	_	_
18	high	high	JJ	_	15	dep	_	_
19	or	or	CC	_	18	cc	_	_
20	too	too	RB	_	21	adv	_	_
21	low	low	JJ	_	18	conj	_	_
22	as	as	IN	_	23	mark	_	_
23	judged	judge	VBN	_	15	comp	_	_
24	from	from	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	plasma	plasma	NN	_	27	com	_	_
27	concentrations	concentration	NNS	_	23	ppmod	_	_
28	.	.	.	_	7	p	_	_

1	Ways	way	NNS	_	15	dep	_	_
2	of	of	IN	_	3	case	_	_
3	improving	improve	VBG	_	1	ppmod	_	_
4	the	the	DT	_	5	det	_	_
5	adequacy	adequacy	NN	_	3	obj	_	_
6	of	of	IN	_	8	case	_	_
7	the	the	DT	_	8	det	_	_
8	treatment	treatment	NN	_	5	ppmod	_	_
9	of	of	IN	_	11	case	_	_
10	psychotic	psychotic	JJ	_	11	attr	_	_
11	patients	patient	NNS	_	8	ppmod	_	_
12	with	with	IN	_	13	case	_	_
13	drug1	drug0	NN	_	8	ppmod	_	_
14	are	be	VBP	_	15	aux	_	_
15	discussed	discuss	VBN	_	0	root	_	_
16	.	.	.	_	15	p	_	_

1	Longitudinal	longitudinal	JJ	_	2	attr	_	_
2	assessment	assessment	NN	_	17	dep	_	_
3	of	of	IN	_	4	case	_	_
4	drug1	drug0	NN	_	2	ppmod	_	_
5	in	in	IN	_	10	case	_	_
6	de	de	FW	_	7	adv	_	_
7	novo	novo	FW	_	10	attr	_	_
8	renal	renal	JJ	_	10	attr	_	_
9	transplant	transplant	NN	_	10	com	_	_
10	recipients	recipient	NNS	_	2	ppmod	_	_
11	over	over	IN	_	15	case	_	_
12	the	the	DT	_	15	det	_	_
13	first	#ord#	JJ	_	15	attr	_	_
14	post-transplant	post-transplant	JJ	_	15	attr	_	_
15	year	year	NN	_	10	ppmod	_	_
16	:	:	:	_	17	p	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	0	root	_	_
18	,	,	,	_	17	p	_	_
19	exposure-response	exposure-response	JJ	_	20	attr	_	_
20	relationships	relationship	NNS	_	17	conj	_	_
21	,	,	,	_	20	p	_	_
22	and	and	CC	_	20	cc	_	_
23	influence	influence	NN	_	17	conj	_	_
24	on	on	IN	_	25	case	_	_
25	drug2	drug0	NN	_	23	ppmod	_	_
26	.	.	.	_	17	p	_	_

1	OBJECTIVE	objective	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	Our	our	PRP$	_	4	poss	_	_
4	objective	objective	NN	_	5	dep	_	_
5	was	be	VBD	_	1	acl	_	_
6	to	to	TO	_	7	aux	_	_
7	characterize	characterize	VB	_	5	comp	_	_
8	the	the	DT	_	10	det	_	_
9	steady-state	steady-state	JJ	_	10	attr	_	_
10	pharmacokinetics	pharmacokinetics	NNS	_	7	obj	_	_
11	of	of	IN	_	12	case	_	_
12	drug1	drug0	NN	_	10	ppmod	_	_
13	and	and	CC	_	12	cc	_	_
14	drug2	drug0	NN	_	12	conj	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	INN	inn	NNP	_	7	prn	_	_
17	,	,	,	_	16	p	_	_
18	drug3	drug0	NN	_	16	appo	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	when	when	WRB	_	21	adv	_	_
21	coadministered	coadministered	VBN	_	5	comp	_	_
22	in	in	IN	_	27	case	_	_
23	de	de	FW	_	24	adv	_	_
24	novo	novo	FW	_	27	attr	_	_
25	kidney	kidney	NN	_	27	com	_	_
26	allograft	allograft	NN	_	27	com	_	_
27	recipients	recipient	NNS	_	21	ppmod	_	_
28	during	during	IN	_	31	case	_	_
29	the	the	DT	_	31	det	_	_
30	first	#ord#	JJ	_	31	attr	_	_
31	year	year	NN	_	27	ppmod	_	_
32	after	after	IN	_	33	case	_	_
33	transplantation	transplantation	NN	_	31	ppmod	_	_
34	.	.	.	_	1	p	_	_

1	METHOD	method	NN	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	This	this	DT	_	4	det	_	_
4	study	study	NN	_	5	dep	_	_
5	was	be	VBD	_	1	acl	_	_
6	a	a	DT	_	10	det	_	_
7	multicenter	multicenter	JJ	_	10	attr	_	_
8	randomized	randomized	JJ	_	10	attr	_	_
9	double-blind	double-blind	JJ	_	10	attr	_	_
10	study	study	NN	_	5	obj	_	_
11	of	of	IN	_	13	case	_	_
12	101	0	CD	_	13	num	_	_
13	patients	patient	NNS	_	10	ppmod	_	_
14	who	who	WP	_	18	dep	_	_
15	were	be	VBD	_	18	aux	_	_
16	randomly	randomly	RB	_	18	adv	_	_
17	assigned	assign	VBN	_	18	aux	_	_
18	1:1:1	0	VBN	_	13	relcl	_	_
19	to	to	TO	_	20	aux	_	_
20	receive	receive	VBP	_	18	comp	_	_
21	drug1	drug0	NN	_	22	com	_	_
22	tablets	tablet	NNS	_	20	obj	_	_
23	at	at	IN	_	24	case	_	_
24	doses	dose	NNS	_	20	ppmod	_	_
25	of	of	IN	_	27	case	_	_
26	0.5	0	CD	_	27	num	_	_
27	mg	mg	NN	_	24	ppmod	_	_
28	,	,	,	_	27	p	_	_
29	1	0	CD	_	30	num	_	_
30	mg	mg	NN	_	27	conj	_	_
31	,	,	,	_	30	p	_	_
32	or	or	CC	_	30	cc	_	_
33	2	0	CD	_	34	num	_	_
34	mg	mg	NN	_	27	conj	_	_
35	twice	twice	RB	_	36	adv	_	_
36	daily	daily	JJ	_	34	attr	_	_
37	with	with	IN	_	38	case	_	_
38	drug2	drug0	NN	_	36	ppmod	_	_
39	and	and	CC	_	38	cc	_	_
40	drug3	drug0	NN	_	38	conj	_	_
41	.	.	.	_	1	p	_	_

1	Blood	blood	NN	_	2	com	_	_
2	sampling	sampling	NN	_	11	dep	_	_
3	for	for	IN	_	5	case	_	_
4	the	the	DT	_	5	det	_	_
5	pharmacokinetics	pharmacokinetics	NNS	_	2	ppmod	_	_
6	of	of	IN	_	7	case	_	_
7	drug1	drug0	NN	_	5	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	drug2	drug0	NN	_	7	conj	_	_
10	was	be	VBD	_	11	aux	_	_
11	performed	performed	VBN	_	0	root	_	_
12	on	on	IN	_	13	case	_	_
13	day	day	NN	_	11	ppmod	_	_
14	1	0	CD	_	13	num	_	_
15	,	,	,	_	11	p	_	_
16	on	on	IN	_	17	case	_	_
17	weeks	week	NNS	_	11	ppmod	_	_
18	1	0	CD	_	17	num	_	_
19	,	,	,	_	18	p	_	_
20	2	0	CD	_	18	conj	_	_
21	,	,	,	_	20	p	_	_
22	3	0	CD	_	18	conj	_	_
23	,	,	,	_	22	p	_	_
24	and	and	CC	_	22	cc	_	_
25	4	0	CD	_	18	conj	_	_
26	,	,	,	_	17	p	_	_
27	and	and	CC	_	17	cc	_	_
28	on	on	IN	_	29	case	_	_
29	months	month	NNS	_	17	conj	_	_
30	2	0	CD	_	29	num	_	_
31	,	,	,	_	30	p	_	_
32	3	0	CD	_	30	conj	_	_
33	,	,	,	_	32	p	_	_
34	6	0	CD	_	30	conj	_	_
35	,	,	,	_	34	p	_	_
36	9	0	CD	_	30	conj	_	_
37	,	,	,	_	36	p	_	_
38	and	and	CC	_	36	cc	_	_
39	12	0	CD	_	30	conj	_	_
40	.	.	.	_	11	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	dose-proportionality	dose-proportionality	NN	_	8	dep	_	_
3	and	and	CC	_	2	cc	_	_
4	stability	stability	NN	_	2	conj	_	_
5	over	over	IN	_	6	case	_	_
6	time	time	NN	_	2	ppmod	_	_
7	were	be	VBD	_	8	aux	_	_
8	assessed	assess	VBN	_	0	root	_	_
9	in	in	IN	_	11	case	_	_
10	the	the	DT	_	11	det	_	_
11	context	context	NN	_	8	ppmod	_	_
12	of	of	IN	_	14	case	_	_
13	linear	linear	JJ	_	14	attr	_	_
14	regression	regression	NN	_	11	ppmod	_	_
15	and	and	CC	_	14	cc	_	_
16	ANOVA	anova	NN	_	17	com	_	_
17	models	model	NNS	_	14	conj	_	_
18	.	.	.	_	8	p	_	_

1	drug1	drug0	JJ	_	3	attr	_	_
2	exposure-response	exposure-response	JJ	_	3	attr	_	_
3	relationships	relationship	NNS	_	24	dep	_	_
4	between	between	IN	_	5	case	_	_
5	area	area	NN	_	3	ppmod	_	_
6	under	under	IN	_	10	case	_	_
7	the	the	DT	_	10	det	_	_
8	blood	blood	NN	_	10	com	_	_
9	concentration-time	concentration-time	NN	_	10	com	_	_
10	curve	curve	NN	_	5	ppmod	_	_
11	(	-lrb-	-LRB-	_	12	p	_	_
12	AUC	auc	NN	_	10	prn	_	_
13	)	-rrb-	-RRB-	_	12	p	_	_
14	and	and	CC	_	5	cc	_	_
15	changes	change	NNS	_	5	conj	_	_
16	in	in	IN	_	17	case	_	_
17	platelets	platelet	NNS	_	15	ppmod	_	_
18	,	,	,	_	17	p	_	_
19	leukocytes	leukocyte	NNS	_	17	conj	_	_
20	,	,	,	_	19	p	_	_
21	and	and	CC	_	19	cc	_	_
22	lipids	lipid	NNS	_	17	conj	_	_
23	were	be	VBD	_	24	aux	_	_
24	explored	explore	VBN	_	0	root	_	_
25	with	with	IN	_	28	case	_	_
26	the	the	DT	_	28	det	_	_
27	median-effect	median-effect	JJ	_	28	attr	_	_
28	model	model	NN	_	24	ppmod	_	_
29	.	.	.	_	24	p	_	_

1	Potential	potential	JJ	_	2	attr	_	_
2	differences	difference	NNS	_	15	dep	_	_
3	in	in	IN	_	5	case	_	_
4	drug1	drug0	JJ	_	5	attr	_	_
5	dosing	dosing	NN	_	2	ppmod	_	_
6	and	and	CC	_	5	cc	_	_
7	pharmacokinetics	pharmacokinetics	NNS	_	5	conj	_	_
8	at	at	IN	_	10	case	_	_
9	different	different	JJ	_	10	attr	_	_
10	levels	level	NNS	_	5	ppmod	_	_
11	of	of	IN	_	13	case	_	_
12	drug2	drug0	NN	_	13	com	_	_
13	exposure	exposure	NN	_	10	ppmod	_	_
14	were	be	VBD	_	15	aux	_	_
15	assessed	assess	VBN	_	0	root	_	_
16	in	in	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	context	context	NN	_	15	ppmod	_	_
19	of	of	IN	_	20	case	_	_
20	ANOVA	anova	NN	_	18	ppmod	_	_
21	.	.	.	_	15	p	_	_

1	RESULTS	result	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	5	attr	_	_
4	steady	steady	JJ	_	5	attr	_	_
5	state	state	NN	_	7	dep	_	_
6	was	be	VBD	_	7	aux	_	_
7	reached	reach	VBN	_	1	acl	_	_
8	on	on	IN	_	7	ppmod	_	_
9	or	or	CC	_	8	cc	_	_
10	before	before	IN	_	11	case	_	_
11	day	day	NN	_	8	conj	_	_
12	7	0	CD	_	11	num	_	_
13	,	,	,	_	7	p	_	_
14	with	with	IN	_	18	case	_	_
15	a	a	DT	_	18	det	_	_
16	median	median	JJ	_	18	attr	_	_
17	3-fold	0-fold	JJ	_	18	attr	_	_
18	accumulation	accumulation	NN	_	7	ppmod	_	_
19	of	of	IN	_	21	case	_	_
20	drug	drug	NN	_	21	com	_	_
21	exposure	exposure	NN	_	18	ppmod	_	_
22	compared	compare	VBN	_	24	adv	_	_
23	with	with	IN	_	24	case	_	_
24	that	that	DT	_	18	ppmod	_	_
25	after	after	IN	_	29	case	_	_
26	the	the	DT	_	29	det	_	_
27	first	#ord#	JJ	_	29	attr	_	_
28	postoperative	postoperative	JJ	_	29	attr	_	_
29	dose	dose	NN	_	24	ppmod	_	_
30	.	.	.	_	1	p	_	_

1	Both	both	CC	_	4	cc	_	_
2	steady-state	steady-state	JJ	_	4	attr	_	_
3	maximum	maximum	NN	_	4	com	_	_
4	concentration	concentration	NN	_	7	dep	_	_
5	and	and	CC	_	4	cc	_	_
6	AUC	auc	NN	_	4	conj	_	_
7	were	be	VBD	_	0	root	_	_
8	dose	dose	NN	_	9	advnp	_	_
9	proportional	proportional	JJ	_	7	dep	_	_
10	over	over	IN	_	14	case	_	_
11	the	the	DT	_	14	det	_	_
12	full	full	JJ	_	14	attr	_	_
13	dose	dose	NN	_	14	com	_	_
14	range	range	NN	_	7	ppmod	_	_
15	when	when	WRB	_	16	adv	_	_
16	assessed	assess	VBN	_	7	comp	_	_
17	on	on	IN	_	18	case	_	_
18	day	day	NN	_	16	ppmod	_	_
19	1	0	CD	_	18	num	_	_
20	,	,	,	_	18	p	_	_
21	as	as	RB	_	22	com	_	_
22	well	well	RB	_	18	cc	_	_
23	as	as	IN	_	22	com	_	_
24	for	for	IN	_	27	case	_	_
25	the	the	DT	_	27	det	_	_
26	full	full	JJ	_	27	attr	_	_
27	duration	duration	NN	_	18	conj	_	_
28	of	of	IN	_	30	case	_	_
29	the	the	DT	_	30	det	_	_
30	study	study	NN	_	27	ppmod	_	_
31	at	at	IN	_	33	case	_	_
32	steady	steady	JJ	_	33	attr	_	_
33	state	state	NN	_	27	ppmod	_	_
34	.	.	.	_	7	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	evidence	evidence	NN	_	2	obj	_	_
4	for	for	IN	_	6	case	_	_
5	longitudinal	longitudinal	JJ	_	6	attr	_	_
6	stability	stability	NN	_	3	ppmod	_	_
7	in	in	IN	_	8	case	_	_
8	AUC	auc	NN	_	2	ppmod	_	_
9	of	of	IN	_	10	case	_	_
10	drug1	drug0	NN	_	8	ppmod	_	_
11	during	during	IN	_	13	case	_	_
12	the	the	DT	_	13	det	_	_
13	course	course	NN	_	2	ppmod	_	_
14	of	of	IN	_	16	case	_	_
15	the	the	DT	_	16	det	_	_
16	study	study	NN	_	13	ppmod	_	_
17	.	.	.	_	2	p	_	_

1	The	the	DT	_	4	det	_	_
2	interindividual	interindividual	JJ	_	4	attr	_	_
3	pharmacokinetic	pharmacokinetic	JJ	_	4	attr	_	_
4	variability	variability	NN	_	7	dep	_	_
5	for	for	IN	_	6	case	_	_
6	AUC	auc	NN	_	4	ppmod	_	_
7	was	be	VBD	_	15	advcl	_	_
8	85.4	0	CD	_	11	num	_	_
9	%	%	NN	_	8	meta	_	_
10	and	and	CC	_	11	cc	_	_
11	intraindividual	intraindividual	JJ	_	7	dep	_	_
12	,	,	,	_	15	p	_	_
13	interoccasion	interoccasion	NN	_	14	com	_	_
14	variability	variability	NN	_	15	dep	_	_
15	was	be	VBD	_	0	root	_	_
16	40.8	0	CD	_	15	obj	_	_
17	%	%	NN	_	16	meta	_	_
18	.	.	.	_	15	p	_	_

1	Age	age	NN	_	26	dep	_	_
2	(	-lrb-	-LRB-	_	3	p	_	_
3	range	range	NN	_	1	prn	_	_
4	,	,	,	_	3	p	_	_
5	17-69	0	CD	_	6	num	_	_
6	years	year	NNS	_	3	appo	_	_
7	)	-rrb-	-RRB-	_	3	p	_	_
8	,	,	,	_	1	p	_	_
9	weight	weight	NN	_	1	conj	_	_
10	(	-lrb-	-LRB-	_	11	p	_	_
11	range	range	NN	_	9	prn	_	_
12	,	,	,	_	11	p	_	_
13	49-106	0	CD	_	14	num	_	_
14	kg	kg	NN	_	11	appo	_	_
15	)	-rrb-	-RRB-	_	11	p	_	_
16	,	,	,	_	9	p	_	_
17	and	and	CC	_	9	cc	_	_
18	sex	sex	NN	_	1	conj	_	_
19	(	-lrb-	-LRB-	_	21	p	_	_
20	65	0	CD	_	21	num	_	_
21	men	man	NNS	_	18	prn	_	_
22	and	and	CC	_	21	cc	_	_
23	36	0	CD	_	24	num	_	_
24	women	woman	NNS	_	21	conj	_	_
25	)	-rrb-	-RRB-	_	21	p	_	_
26	were	be	VBD	_	0	root	_	_
27	not	not	RB	_	26	neg	_	_
28	significant	significant	JJ	_	29	attr	_	_
29	contributors	contributor	NNS	_	26	obj	_	_
30	to	to	TO	_	31	aux	_	_
31	variability	variability	NN	_	29	ppmod	_	_
32	.	.	.	_	26	p	_	_

1	There	there	EX	_	2	dep	_	_
2	was	be	VBD	_	0	root	_	_
3	an	an	DT	_	5	det	_	_
4	increasing	increase	VBG	_	5	attr	_	_
5	incidence	incidence	NN	_	2	obj	_	_
6	of	of	IN	_	8	case	_	_
7	transient	transient	JJ	_	8	attr	_	_
8	thrombocytopenia	thrombocytopenia	NN	_	5	ppmod	_	_
9	(	-lrb-	-LRB-	_	17	p	_	_
10	or	or	CC	_	17	cc	_	_
11	=100	0	CD	_	17	num	_	_
12	x	x	NN	_	17	attr	_	_
13	10	0	CD	_	17	num	_	_
14	(	-lrb-	-LRB-	_	17	p	_	_
15	9	0	CD	_	17	num	_	_
16	)	-rrb-	-RRB-	_	17	p	_	_
17	/L	/l	NN	_	8	prn	_	_
18	)	-rrb-	-RRB-	_	17	p	_	_
19	with	with	IN	_	20	case	_	_
20	increasing	increase	VBG	_	2	ppmod	_	_
21	drug1	drug0	NN	_	22	com	_	_
22	AUC	auc	NN	_	20	obj	_	_
23	(	-lrb-	-LRB-	_	25	p	_	_
24	P	p	NN	_	25	dep	_	_
25	=	=	JJ	_	2	prn	_	_
26	.03	0	CD	_	25	obj	_	_
27	)	-rrb-	-RRB-	_	25	p	_	_
28	.	.	.	_	2	p	_	_

1	drug1	drug0	NN	_	2	com	_	_
2	doses	dose	NNS	_	9	dep	_	_
3	,	,	,	_	2	p	_	_
4	trough	trough	NN	_	5	com	_	_
5	concentrations	concentration	NNS	_	2	conj	_	_
6	,	,	,	_	5	p	_	_
7	and	and	CC	_	5	cc	_	_
8	AUC	auc	NN	_	2	conj	_	_
9	exhibited	exhibit	VBD	_	0	root	_	_
10	similar	similar	JJ	_	12	attr	_	_
11	temporal	temporal	JJ	_	12	attr	_	_
12	patterns	pattern	NNS	_	9	obj	_	_
13	during	during	IN	_	15	case	_	_
14	the	the	DT	_	15	det	_	_
15	course	course	NN	_	9	ppmod	_	_
16	of	of	IN	_	18	case	_	_
17	the	the	DT	_	18	det	_	_
18	study	study	NN	_	15	ppmod	_	_
19	regardless	regardless	RB	_	9	adv	_	_
20	of	of	IN	_	25	case	_	_
21	the	the	DT	_	25	det	_	_
22	co-administered	co-administered	VBN	_	25	attr	_	_
23	drug2	drug0	NN	_	25	com	_	_
24	dose	dose	NN	_	25	com	_	_
25	level	level	NN	_	19	ppmod	_	_
26	(	-lrb-	-LRB-	_	28	p	_	_
27	P	p	NN	_	28	dep	_	_
28	=	=	JJ	_	25	prn	_	_
29	.13	0	CD	_	28	obj	_	_
30	,	,	,	_	29	p	_	_
31	.82	0	CD	_	29	conj	_	_
32	,	,	,	_	31	p	_	_
33	and	and	CC	_	31	cc	_	_
34	.76	0	CD	_	29	conj	_	_
35	,	,	,	_	28	p	_	_
36	respectively	respectively	RB	_	28	adv	_	_
37	)	-rrb-	-RRB-	_	28	p	_	_
38	.	.	.	_	9	p	_	_

1	CONCLUSIONS	conclusion	NNS	_	0	root	_	_
2	:	:	:	_	1	p	_	_
3	drug1	drug0	NN	_	4	dep	_	_
4	exhibited	exhibit	VBD	_	1	acl	_	_
5	dose-proportional	dose-proportional	JJ	_	7	adv	_	_
6	,	,	,	_	7	p	_	_
7	stable	stable	JJ	_	8	attr	_	_
8	exposure	exposure	NN	_	4	obj	_	_
9	during	during	IN	_	13	case	_	_
10	the	the	DT	_	13	det	_	_
11	first	#ord#	JJ	_	13	attr	_	_
12	post-transplant	post-transplant	JJ	_	13	attr	_	_
13	year	year	NN	_	4	ppmod	_	_
14	.	.	.	_	1	p	_	_

1	For	for	IN	_	4	case	_	_
2	a	a	DT	_	4	det	_	_
3	4-fold	0-fold	JJ	_	4	attr	_	_
4	range	range	NN	_	9	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	drug1	drug0	JJ	_	7	attr	_	_
7	doses	dose	NNS	_	4	ppmod	_	_
8	there	there	EX	_	9	dep	_	_
9	were	be	VBD	_	0	root	_	_
10	no	no	DT	_	12	det	_	_
11	differential	differential	JJ	_	12	attr	_	_
12	effects	effect	NNS	_	9	obj	_	_
13	on	on	IN	_	15	case	_	_
14	drug2	drug0	JJ	_	15	attr	_	_
15	dosing	dosing	NN	_	12	ppmod	_	_
16	or	or	CC	_	15	cc	_	_
17	pharmacokinetics	pharmacokinetics	NNS	_	15	conj	_	_
18	.	.	.	_	9	p	_	_

1	Toxicity	toxicity	NN	_	0	root	_	_
2	of	of	IN	_	3	case	_	_
3	cadmium	cadmium	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug1	drug0	NN	_	3	conj	_	_
6	to	to	TO	_	7	aux	_	_
7	encystment	encystment	NN	_	1	ppmod	_	_
8	and	and	CC	_	7	cc	_	_
9	in	in	FW	_	10	adv	_	_
10	vitro	vitro	FW	_	11	attr	_	_
11	excystment	excystment	NN	_	7	conj	_	_
12	of	of	IN	_	13	case	_	_
13	Parorchis	parorchis	NNP	_	7	ppmod	_	_
14	acanthus	acanthus	FW	_	13	attr	_	_
15	(	-lrb-	-LRB-	_	16	p	_	_
16	Digenea	digenea	NNP	_	13	prn	_	_
17	:	:	:	_	16	p	_	_
18	Philophthalmidae	philophthalmidae	NNP	_	16	appo	_	_
19	)	-rrb-	-RRB-	_	16	p	_	_
20	.	.	.	_	1	p	_	_

1	The	the	DT	_	2	det	_	_
2	toxicity	toxicity	NN	_	19	dep	_	_
3	of	of	IN	_	4	case	_	_
4	cadmium	cadmium	NN	_	2	ppmod	_	_
5	,	,	,	_	4	p	_	_
6	drug1	drug0	NN	_	4	conj	_	_
7	and	and	CC	_	6	cc	_	_
8	cadmium/zinc	cadmium/zinc	NN	_	9	com	_	_
9	mixtures	mixture	NNS	_	4	conj	_	_
10	at	at	IN	_	11	case	_	_
11	concentrations	concentration	NNS	_	2	ppmod	_	_
12	ranging	range	VBG	_	11	acl	_	_
13	from	from	IN	_	17	case	_	_
14	1000	0	CD	_	17	num	_	_
15	to	to	TO	_	14	cc	_	_
16	50000	0	CD	_	14	conj	_	_
17	microg/l	microg/l	NN	_	12	ppmod	_	_
18	were	be	VBD	_	19	aux	_	_
19	investigated	investigate	VBN	_	0	root	_	_
20	against	against	IN	_	21	case	_	_
21	cercariae	cercariae	NN	_	19	ppmod	_	_
22	and	and	CC	_	21	cc	_	_
23	metacercariae	metacercariae	NN	_	21	conj	_	_
24	of	of	IN	_	26	case	_	_
25	Parorchis	parorchis	FW	_	26	attr	_	_
26	acanthus	acanthus	FW	_	21	ppmod	_	_
27	obtained	obtain	VBN	_	26	acl	_	_
28	from	from	IN	_	33	case	_	_
29	the	the	DT	_	33	det	_	_
30	dog	dog	NN	_	33	com	_	_
31	whelk	whelk	NN	_	33	com	_	_
32	Nucella	nucella	NN	_	33	com	_	_
33	lapillus	lapillus	NN	_	27	ppmod	_	_
34	.	.	.	_	19	p	_	_

1	Cercarial	cercarial	JJ	_	2	attr	_	_
2	encystment	encystment	NN	_	12	dep	_	_
3	at	at	IN	_	4	case	_	_
4	concentrations	concentration	NNS	_	2	ppmod	_	_
5	of	of	IN	_	7	case	_	_
6	25000	0	CD	_	7	num	_	_
7	microg/l	microg/l	NN	_	4	ppmod	_	_
8	or	or	CC	_	9	cc	_	_
9	higher	high	JJR	_	7	num	_	_
10	was	be	VBD	_	12	aux	_	_
11	significantly	significantly	RB	_	12	adv	_	_
12	impaired	impair	VBN	_	0	root	_	_
13	by	by	IN	_	16	case	_	_
14	all	all	DT	_	16	det	_	_
15	test	test	NN	_	16	com	_	_
16	metals	metal	NNS	_	12	ppmod	_	_
17	;	;	:	_	12	p	_	_

1	however	however	RB	_	8	adv	_	_
2	,	,	,	_	8	p	_	_
3	at	at	IN	_	5	case	_	_
4	lower	low	JJR	_	5	attr	_	_
5	concentrations	concentration	NNS	_	8	ppmod	_	_
6	only	only	RB	_	7	adv	_	_
7	drug1	drug0	NN	_	8	dep	_	_
8	demonstrated	demonstrate	VBD	_	0	root	_	_
9	toxicity	toxicity	NN	_	8	obj	_	_
10	.	.	.	_	8	p	_	_

1	Mixtures	mixture	NNS	_	6	dep	_	_
2	of	of	IN	_	3	case	_	_
3	cadmium	cadmium	NN	_	1	ppmod	_	_
4	and	and	CC	_	3	cc	_	_
5	drug1	drug0	NN	_	3	conj	_	_
6	had	have	VBD	_	0	root	_	_
7	a	a	DT	_	9	det	_	_
8	synergistic	synergistic	JJ	_	9	attr	_	_
9	effect	effect	NN	_	6	obj	_	_
10	compared	compare	VBN	_	14	adv	_	_
11	with	with	IN	_	14	case	_	_
12	single	single	JJ	_	14	attr	_	_
13	metal	metal	JJ	_	14	attr	_	_
14	toxicity	toxicity	NN	_	6	ppmod	_	_
15	but	but	CC	_	14	cc	_	_
16	only	only	RB	_	19	adv	_	_
17	at	at	IN	_	19	case	_	_
18	50000	0	CD	_	19	num	_	_
19	microg/l	microg/l	NN	_	14	conj	_	_
20	.	.	.	_	6	p	_	_

1	Excystment	excystment	NN	_	7	dep	_	_
2	in	in	FW	_	3	adv	_	_
3	vitro	vitro	FW	_	1	adv	_	_
4	was	be	VBD	_	7	aux	_	_
5	only	only	RB	_	6	com	_	_
6	significantly	significantly	RB	_	7	adv	_	_
7	affected	affect	VBN	_	0	root	_	_
8	by	by	IN	_	9	case	_	_
9	cercariae	cercariae	NN	_	7	ppmod	_	_
10	exposed	expose	VBN	_	9	acl	_	_
11	to	to	TO	_	13	aux	_	_
12	cadmium/zinc	cadmium/zinc	NN	_	13	com	_	_
13	mixtures	mixture	NNS	_	10	ppmod	_	_
14	whilst	whilst	IN	_	15	case	_	_
15	encysting	encysting	NN	_	10	ppmod	_	_
16	.	.	.	_	7	p	_	_

1	Twenty-four	twenty-four	CD	_	3	num	_	_
2	h	h	NN	_	3	com	_	_
3	exposures	exposure	NNS	_	8	dep	_	_
4	of	of	IN	_	7	case	_	_
5	fully	fully	RB	_	6	adv	_	_
6	formed	form	VBN	_	7	attr	_	_
7	cysts	cyst	NNS	_	3	ppmod	_	_
8	had	have	VBD	_	0	root	_	_
9	no	no	DT	_	10	det	_	_
10	effect	effect	NN	_	8	obj	_	_
11	on	on	IN	_	12	case	_	_
12	excystment	excystment	NN	_	8	ppmod	_	_
13	in	in	FW	_	14	adv	_	_
14	vitro	vitro	FW	_	8	adv	_	_
15	.	.	.	_	8	p	_	_

1	Effects	effect	NNS	_	12	dep	_	_
2	on	on	IN	_	6	case	_	_
3	in	in	FW	_	4	adv	_	_
4	vitro	vitro	FW	_	6	attr	_	_
5	excystment	excystment	NN	_	6	com	_	_
6	rates	rate	NNS	_	1	ppmod	_	_
7	over	over	IN	_	11	case	_	_
8	a	a	DT	_	11	det	_	_
9	2	0	CD	_	10	num	_	_
10	h	h	NN	_	11	com	_	_
11	period	period	NN	_	6	ppmod	_	_
12	demonstrated	demonstrate	VBD	_	0	root	_	_
13	widespread	widespread	JJ	_	14	attr	_	_
14	effects	effect	NNS	_	12	obj	_	_
15	for	for	IN	_	17	case	_	_
16	cercariae-exposed	cercariae-exposed	JJ	_	17	attr	_	_
17	P	p	NN	_	12	ppmod	_	_
18	.	.	.	_	12	p	_	_

1	acanthus	acanthus	NN	_	0	root	_	_
2	.	.	.	_	1	p	_	_

1	No	no	DT	_	2	det	_	_
2	effects	effect	NNS	_	3	dep	_	_
3	were	be	VBD	_	0	root	_	_
4	evident	evident	JJ	_	3	dep	_	_
5	on	on	IN	_	7	case	_	_
6	excystment	excystment	JJ	_	7	attr	_	_
7	rates	rate	NNS	_	3	ppmod	_	_
8	of	of	IN	_	10	case	_	_
9	cyst-exposed	cyst-exposed	JJ	_	10	attr	_	_
10	parasites	parasite	NNS	_	7	ppmod	_	_
11	.	.	.	_	3	p	_	_

